
<html lang="en"     class="pb-page"  data-request-id="f4fd4058-4ac8-4465-9c4b-353a45fedce1"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2015.58.issue-10;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/jm5013227;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends" /></meta><meta name="dc.Creator" content="Paolo  Montuschi" /></meta><meta name="dc.Creator" content="Giovanni  Ciabattoni" /></meta><meta name="dc.Description" content="Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological treatment of stable chro..." /></meta><meta name="Description" content="Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological treatment of stable chro..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 9, 2015" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm5013227" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm5013227" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm5013227" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm5013227" /></link>
        
    
    

<title>Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm5013227" /></meta><meta property="og:title" content="Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0017.jpeg" /></meta><meta property="og:description" content="Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological treatment of stable chronic obstructive pulmonary disease (COPD). Among approved LAMA, tiotropium bromide, glycopyrronium bromide, and umeclidinium bromide are administered once daily, whereas aclidinium bromide is administered every 12 h. New LAMA are under development for COPD. Among the approved LABA, indacaterol has a 24 h duration of action, whereas salmeterol and formoterol require twice-daily administration. New once-daily LABA, including vilanterol, olodaterol, milveterol, carmoterol, and abediterol, are in development. LAMA/LABA fixed dose combinations (FDCs) provide the convenience of two bronchodilators with different mechanism of action in a single inhaler. Indacaterol/glycopyrronium, umeclidinium/vilanterol, and olodaterol/tiotropium FDCs have been approved or are under approval and are likely to become a standard pharmacological strategy for COPD. Inhaled dual-pharmacology compounds, combining muscarinic antagonism and β2-agonism (MABA) in a single molecule, potentially provide additive or synergistic bronchodilation over either inhaled antimuscarinic or β2-agonist monotherapy." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological treatment of stable chronic obstructive pulmonary disease (COPD). Among approved LAMA, tiotropium bromide, glycopyrronium bromide, and umeclidinium bromide are administered once daily, whereas aclidinium bromide is administered every 12 h. New LAMA are under development for COPD. Among the approved LABA, indacaterol has a 24 h duration of action, whereas salmeterol and formoterol require twice-daily administration. New once-daily LABA, including vilanterol, olodaterol, milveterol, carmoterol, and abediterol, are in development. LAMA/LABA fixed dose combinations (FDCs) provide the convenience of two bronchodilators with different mechanism of action in a single inhaler. Indacaterol/glycopyrronium, umeclidinium/vilanterol, and olodaterol/tiotropium FDCs have been approved or are under approval and are likely to become a standard pharmacological strategy for COPD. Inhaled dual-pharmacology compounds, combining muscarinic antagonism and β2-agonism (MABA) in a single molecule, potentially provide additive or synergistic bronchodilation over either inhaled antimuscarinic or β2-agonist monotherapy." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0017.jpeg" /></meta><meta name="twitter:title" content="Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm5013227"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm5013227">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm5013227&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm5013227&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm5013227&amp;href=/doi/10.1021/jm5013227" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 4131-4164</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm500330k" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.5b00067" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends<a class="ref internalNav" href="#notes-2" aria-label=""></a></span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paolo++Montuschi">Paolo Montuschi</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"> and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Giovanni++Ciabattoni">Giovanni Ciabattoni</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Department of Pharmacology, Faculty of Medicine, Catholic University of the Sacred Heart, Largo Francesco Vito, 1, Rome, 00168, Italy</span></div><div class="corresp-info"><strong>*</strong>Phone: 39-06-30156092. Fax: 39-06-30506292. E-mail: <a href="/cdn-cgi/l/email-protection#2454494b4a505157474c4d6456490a514a4d474550500a4d50"><span class="__cf_email__" data-cfemail="3b4b5654554f4e485853527b4956154e5552585a4f4f15524f">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm5013227&amp;href=/doi/10.1021%2Fjm5013227" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 4131–4164</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 14, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>28 August 2014</li><li><span class="item_label"><b>Published</b> online</span>9 February 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 May 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm5013227" title="DOI URL">https://doi.org/10.1021/jm5013227</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4131%26pageCount%3D34%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DPaolo%2BMontuschi%252C%2BGiovanni%2BCiabattoni%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D10%26contentID%3Djm5013227%26title%3DBronchodilating%2BDrugs%2Bfor%2BChronic%2BObstructive%2BPulmonary%2BDisease%253A%2BCurrent%2BStatus%2Band%2BFuture%2BTrends%26numPages%3D34%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4164%26publicationDate%3DMay%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm5013227"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3989</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">48</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm5013227" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Paolo&quot;,&quot;last_name&quot;:&quot;Montuschi&quot;},{&quot;first_name&quot;:&quot;Giovanni&quot;,&quot;last_name&quot;:&quot;Ciabattoni&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;4131-4164&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm5013227&quot;},&quot;abstract&quot;:&quot;Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological treatment of stable chronic obstructive pulmonary disease (COPD). Among approved LAMA, tiotropium bromide, glycopyrronium bromide, and umeclidinium bromide are administered once daily, whereas aclidinium bromide is administered every 12 h. New LAMA are under development for COPD. Among the approved LABA, indacaterol has a 24 h duration of action, whereas salmeterol and formoterol require twice-daily administration. New once-daily LABA, including vilanterol, olodaterol, milveterol, carmoterol, and abediterol, are in development. LAMA/LABA fixed dose combinations (FDCs) provide the convenience of two bronchodilators with different mechanism of action in a single inhaler. Indacaterol/glycopyrronium, umeclidinium/vilanterol, and olodaterol/tiotropium FDCs have been approved or are under approval and are likely to become a standard pharmacologi&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm5013227&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5013227" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm5013227&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5013227" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm5013227&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5013227" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm5013227&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm5013227&amp;href=/doi/10.1021/jm5013227" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm5013227" /></input><a href="/doi/pdf/10.1021/jm5013227" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm5013227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm5013227%26sid%3Dliteratum%253Aachs%26pmid%3D25587755%26genre%3Darticle%26aulast%3DMontuschi%26date%3D2015%26atitle%3DBronchodilating%2BDrugs%2Bfor%2BChronic%2BObstructive%2BPulmonary%2BDisease%253A%2BCurrent%2BStatus%2Band%2BFuture%2BTrends%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D10%26spage%3D4131%26epage%3D4164%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291651" title="Anions">Anions</a>,</li><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=291697" title="Safety">Safety</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/10" title="Go to Volume 58, Issue 10"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jmcmar.2015.58.issue-10/20150528/jmcmar.2015.58.issue-10.largecover.jpg" alt="Go to Volume 58, Issue 10"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0017.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and long-acting β<sub>2</sub>-adrenoreceptor agonists (LABA), are the mainstay of pharmacological treatment of stable chronic obstructive pulmonary disease (COPD). Among approved LAMA, tiotropium bromide, glycopyrronium bromide, and umeclidinium bromide are administered once daily, whereas aclidinium bromide is administered every 12 h. New LAMA are under development for COPD. Among the approved LABA, indacaterol has a 24 h duration of action, whereas salmeterol and formoterol require twice-daily administration. New once-daily LABA, including vilanterol, olodaterol, milveterol, carmoterol, and abediterol, are in development. LAMA/LABA fixed dose combinations (FDCs) provide the convenience of two bronchodilators with different mechanism of action in a single inhaler. Indacaterol/glycopyrronium, umeclidinium/vilanterol, and olodaterol/tiotropium FDCs have been approved or are under approval and are likely to become a standard pharmacological strategy for COPD. Inhaled dual-pharmacology compounds, combining muscarinic antagonism and β<sub>2</sub>-agonism (MABA) in a single molecule, potentially provide additive or synergistic bronchodilation over either inhaled antimuscarinic or β<sub>2</sub>-agonist monotherapy.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67722" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67722" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Chronic obstructive pulmonary disease (COPD), the fourth leading cause of death in the world, is characterized by persistent airflow limitation that is generally progressive and associated with increased chronic inflammation in the airways and the lung caused by noxious particles or gases.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The persistent airflow limitation is due to peripheral airways disease (obstructive bronchiolitis) and/or parenchymal destruction (emphysema).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Pharmacological treatment of COPD can prevent and decrease symptoms (especially dyspnoea), reduce the frequency and severity of exacerbations, improve health status, and improve exercise capacity.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">Drugs for maintenance treatment of stable COPD are shown in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>. Bronchodilators administered by inhalation, which maximizes their direct effect on the airways while minimizing their systemic effects, are the mainstay of pharmacological treatment of COPD.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Bronchodilator drug devices include pressurized metered dose inhalers (pMDIs), dry powder inhalers (DPIs), or nebulizers.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> pMDIs and DPIs simplify therapy, improve pharmacological compliance, and may reduce extra medication requirement and patient cost. When used correctly, the bronchodilator response is equivalent to that achieved with a nebulizer.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> However, for some patients, a nebulizer may be easier to use and may be necessary when proper pMDI technique is not possible.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0019.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Drugs for pharmacological maintenance treatment of stable chronic obstructive pulmonary disease (COPD). Drugs currently approved for COPD are signed with an asterisk. Abbreviations: FDC, fixed dose combination; FF, fluticasone furoate; FP, fluticasone propionate; ICS, inhaled corticosteroids; LABA, long-acting β<sub>2</sub>-adrenoreceptor agonists; LAMA, long-acting muscarinic receptor antagonists; MABA, dual muscarinic antagonist-β<sub>2</sub>-agonist compounds; PDE<sub>4</sub>, phosphodiesterase 4; SABA, short-acting β<sub>2</sub>-adrenoreceptor agonists; SAMA, short-acting muscarinic receptor antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Bronchodilators include inhaled muscarinic acethylcholine receptor (mAcChR) antagonists and selective β<sub>2</sub>-adrenoreceptor agonists.<a onclick="showRef(event, 'ref1 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref3 ref4">(1, 3, 4)</a> They are both available in short-acting and long-acting inhaled formulations.<a onclick="showRef(event, 'ref1 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref3 ref4">(1, 3, 4)</a></div><div class="NLM_p">Inhaled mAcChR antagonists approved for the pharmacological maintenance treatment of stable COPD include ipratropium bromide [(1<i>S</i>,5<i>R</i>)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate bromide; C<sub>20</sub>H<sub>30</sub>BrNO<sub>3</sub>] (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A),<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> oxitropium bromide (1<i>R</i>,2<i>R</i>,4<i>S</i>,5<i>S</i>,7<i>s</i>,9<i>s</i>)-9-ethyl-7-{[(2<i>S</i>)-3-hydroxy-2-phenylpropanoyl]oxy}-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.0<sup>2,4</sup>]nonane bromide; C<sub>19</sub>H<sub>26</sub>BrNO<sub>4</sub>] (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B),<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> tiotropium bromide [1<i>a</i>,2<i>b</i>,4<i>b</i>,5a,7<i>b</i>)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0<sup>2,4</sup>]nonane bromide; C<sub>19</sub>H<sub>22</sub>BrNO<sub>4</sub>S<sub>2</sub>] (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>C),<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> aclidinium bromide [(3<i>R</i>)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide; C<sub>26</sub>H<sub>30</sub>BrNO<sub>4</sub>S<sub>2</sub>] (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A),<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and glycopyrronium bromide (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate bromide; C<sub>19</sub>H<sub>28</sub>BrNO<sub>3</sub>) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>B).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Ipratropium bromide, the prototype of anticholinergic bronchodilators, is short-acting.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Tiotropium bromide and glycopyrronium bromide, which are long-acting muscarinic receptor antagonists (LAMA), are administered once a day,<a onclick="showRef(event, 'ref3 ref6'); return false;" href="javascript:void(0);" class="ref ref3 ref6">(3, 6)</a> whereas aclidinium bromide is administered every 12 h.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Umeclidinium bromide (4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>C) has recently been approved for the maintenance treatment of COPD.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> New LAMA are in development for pharmacological treatment of COPD.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of ipratropium bromide (A), oxitropium bromide (B), and tiotropium bromide (C).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of aclidinium bromide (A), glycopyrronium bromide (B), and umeclidinium bromide (C).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The short-acting β<sub>2</sub>-adrenoreceptor agonists (SABAs), including salbutamol 4-[2-(<i>tert</i>-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; C<sub>13</sub>H<sub>21</sub>NO<sub>3</sub>] (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A), terbutaline 5-[2-(<i>tert</i>-butylamino)-1-hydroxyethyl]benzene-1,3-diol; C<sub>12</sub>H<sub>19</sub>NO<sub>3</sub>] (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>B), and fenoterol 5-[1-hydroxy-2-[1-(4-hydroxyphenyl)propan-2-ylamino]ethyl]benzene-1,3-diol; C<sub>17</sub>H<sub>21</sub>NO<sub>4</sub>] (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>C), have a rapid onset of action and a bronchodilating effect which lasts 3–6 h.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Twice daily long-acting β<sub>2</sub>-adrenoreceptor agonists (LABA) licensed for COPD include salmeterol [2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol; C<sub>25</sub>H<sub>37</sub>NO<sub>4</sub>] (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>A) and formoterol <i>N</i>-[2-hydroxy-5-[(1<i>S</i>)-1-hydroxy-2-[[(2<i>S</i>)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide; C<sub>19</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>] (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>B).<a onclick="showRef(event, 'ref1 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref4">(1, 4)</a> Salmeterol, which is available as a racemic mixture of salmeterol xinafoate, has lower intrinsic activity than salbutamol and delayed onset of action, but its bronchodilating effect persist for 12 h and is dose-independent.<a onclick="showRef(event, 'ref1 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref4">(1, 4)</a> Formoterol, which is available as formoterol fumarate in a single racemic diastereoisomer (<i>RR</i>, <i>SS</i>), has high intrinsic activity with rapid onset of action (similar to salbutamol), but its duration of action is dose-dependent.<a onclick="showRef(event, 'ref1 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref4">(1, 4)</a> Because of their 12 h duration of action, formoterol and salmeterol are used with a twice-daily dosing regimen.<a onclick="showRef(event, 'ref1 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref4">(1, 4)</a> Arformoterol [<i>N</i>-[2-hydroxy-5-[(1<i>R</i>)-1-hydroxy-2-[[(2<i>R</i>)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide; C<sub>19</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>] (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>C), the active (<i>R</i>,<i>R</i>)-enantiomer of formoterol, is another LABA approved by the United States Food and Drug Administration (FDA) for treatment of COPD.<a onclick="showRef(event, 'ref1 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref4">(1, 4)</a> Indacaterol [5-[(1<i>R</i>)-2-[(5,6-diethyl-2,3-dihydro-1<i>H</i>-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1<i>H</i>-quinolin-2-one; C<sub>24</sub>H<sub>28</sub>N<sub>2</sub>O<sub>3</sub>] (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>D), a once-daily third generation LABA, has been approved for long-term treatment of COPD in Europe and in the USA.<a onclick="showRef(event, 'ref4 ref8'); return false;" href="javascript:void(0);" class="ref ref4 ref8">(4, 8)</a> Indacaterol is administered as inhalation powder through a DPI and has a 24 h duration of action and a once-daily dosing regimen.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Newer ultra-LABA, including vilanterol [4-[(1<i>R</i>)-2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1 hydroxyethyl]-2-(hydroxymethyl)phenol; C<sub>24</sub>H<sub>33</sub>Cl<sub>2</sub>NO<sub>5</sub>] (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>A), olodaterol [6-hydroxy-8-[(1<i>R</i>)-1-hydroxy-2-[[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino]ethyl]-4<i>H</i>-1,4-benzoxazin-3-one; C<sub>21</sub>H<sub>26</sub>N<sub>2</sub>O<sub>5</sub>] (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>B), abediterol [5-[(1<i>R</i>)-2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl]-8-hydroxyquinolin-2(1<i>H</i>)-one; C<sub>25</sub>H<sub>30</sub>F<sub>2</sub>N<sub>2</sub>O<sub>4</sub>] (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>C), milveterol [<i>N</i>-[2-hydroxy-5-[(1<i>R</i>)-1-hydroxy-2-[2-[4-[[(2<i>R</i>)-2-hydroxy-2-phenylethyl]amino]phenyl]ethylamino]ethyl]phenyl]formamide hydrochloride; C<sub>25</sub>H<sub>30</sub>ClN<sub>3</sub>O<sub>4</sub>] (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>D), and carmoterol [8-hydroxy-5-[(1<i>R</i>)-1-hydroxy-2-[[(2<i>R</i>)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1<i>H</i>-quinolin-2-one; C<sub>21</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>] (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>E), are in development.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of the short-acting β<sub>2</sub>-adrenoreceptor agonists (SABA) salbutamol (A), terbutaline (B), and fenoterol (C).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structures of the long-acting β<sub>2</sub>-adrenoreceptor agonists (LABA) salmeterol (A), formoterol (B), arformoterol (C), and indacaterol (D).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical structures of new once-daily long-acting β<sub>2</sub>-adrenoreceptor agonists (LABA) vilanterol (A), olodaterol (B), abediterol (C), milveterol (D), and carmoterol (E).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Classification of COPD severity according to global obstructive lung disease (GOLD) guidelines includes four classes (A–D), based on intensity of symptoms, as measured by the modified Medical Research Council (mMRC) dyspnoea scale and/or the COPD Assessment Test, and risk of poor outcomes [identified by the degree of airflow limitation (classes I–IV) and/or the frequency of exacerbations] in a three-dimensional evaluation.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">As regular long-term treatment with bronchodilators does not modify the natural history of COPD, no treatment is required in asymptomatic patients. In symptomatic patients, relief of dyspnoea and improvement in exercise tolerance and quality of life are the main achievable outcomes of therapy.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Current guidelines suggest that all symptomatic patients with COPD should be prescribed a short-acting bronchodilator to be used on an as-needed basis.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> If symptoms are not adequately controlled with short-acting bronchodilator therapy, particularly in patients who have more advanced disease (GOLD stage II and higher), regular treatment with LAMA and/or LABA should be started.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">Inhaled LAMA or LABA, the principal drugs used in the chronic treatment of COPD, are the first choice in COPD patients with low risk for exacerbations, more symptoms, and forced expiratory volume in 1 s (FEV<sub>1</sub>) of ≥50% predicted value (GOLD class B).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In patients with severe lung function impairment (FEV<sub>1</sub> ≤ 50% predicted value) and high risk for exacerbations, independent of symptom severity (GOLD patient categories C and D), either treatment with a fixed dose combination (FDC) of LABA/inhaled corticosteroids (ICSs) or tiotropium alone, a LAMA, is considered first choice.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> However, long-term treatment with ICSs, as required by patients with severe COPD, is associated with adverse effects including increased risk of fractures and pneumonia.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> For this reason, the risk/benefit ratio for combinations containing ICSs should be carefully evaluated in patients with COPD. Anticholinergics act as competitive mAcChR antagonists, play an important role in the management of COPD, and are frequently preferred over β<sub>2</sub>-agonists for their minimal cardiac stimulatory effects and greater efficacy in most studies.<a onclick="showRef(event, 'ref1 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref4">(1, 4)</a> Their therapeutic efficacy is based on the fact that vagally mediated bronchoconstriction is the major reversible component of airflow limitation in patients with COPD,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> which by definition is limited, as COPD is characterized by a fixed or poorly reversible airflow limitation.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> However, a mixed phenotype, known as asthma–COPD overlap syndrome (ACOS), which can be characterized by a higher response to bronchodilators, has been recently identified.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> This COPD phenotype is defined by the presence of two major diagnostic criteria (history of asthma, sputum eosinophilia, very positive response to bronchodilators) or one major criterion and two minor criteria (high serum total IgE concentrations, history of atopy, positive response to bronchodilators).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p last">This review presents the current status of COPD treatment with mAcChR antagonists and β<sub>2</sub>-adrenegic receptor agonists, the most used bronchodilators in COPD, particularly focusing on the recently approved medicines, and new therapeutic perspectives for these drugs.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Pharmacological Modulation of Airway Receptors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07223" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07223" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Pharmacological modulation of the airway smooth muscle cell and mechanism of action of bronchodilators are shown in Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Pharmacological modulation of airway smooth muscle cell and mechanism of action of bronchodilators. Abbreviations: AC, adenylyl cyclase; Ach, acetylcholine; ATP, adenosine triphosphate; β<sub>2</sub>, β<sub>2</sub>-adrenergic receptor; Ca<sup>2+</sup>, calcium ion; cAMP, cyclic adenosine monophosphate; DAG, diacylglycerol; ER, endoplasmic reticulum; G<sub>i</sub>, inhibitory G protein; G<sub>q</sub>, G<sub>q</sub> protein, G<sub>s</sub>, stimulatory G protein; IP3, inositol 1,4,5-trisphosphate; LABA, long-acting β<sub>2</sub>-adrenenoreceptor agonists; LAMA, long-acting muscarinic receptor antagonists; M, muscarinic acetylcholine receptor; N, nicotinic acetylcholine receptor; PIP2, phosphatidylinositol 4,5-bisphosphate; PLC, phospholipase C; PKA, protein kinase A; SABA, short-acting β<sub>2</sub>-adrenoreceptor agonists; SAMA, short-acting muscarinic receptor antagonists; +, receptor activation; −, receptor antagonism.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Muscarinic Acethylcholine Receptors</h3><div class="NLM_p">At least five subtypes of mAcChR, which belong to the superfamily of G-protein-coupled seven-transmembrane receptors, have been identified.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Three receptor subtypes are expressed in the lung.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> M<sub>1</sub> receptors, which are present on peribronchial ganglion cells, are responsible for “tonic” or slow response of these cells.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Presynaptic M<sub>2</sub> receptors on the postganglionic vagal nerve endings are inhibitory autoreceptors, and their activation leads to reduction in acethylcholine release from the nerve ending.<a onclick="showRef(event, 'ref9 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref11">(9, 11)</a> M<sub>2</sub> receptors are also expressed on airway smooth muscle cells.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Activation of postsynaptic M<sub>2</sub> mAcChR, through interaction with an inhibitory G protein (G<sub>i</sub>), reduces β<sub>2</sub> receptor-induced stimulation of adenylyl cyclase activity and the resulting airway smooth muscle relaxant effect (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> M<sub>3</sub> receptors are expressed on effector cells including airway smooth muscle cells and submucosal gland cells.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> M<sub>3</sub> receptor activation by acetylcholine and mAcChR agonists on airway smooth muscle and gland cells causes bronchoconstriction and increased tracheobronchial gland secretion, respectively.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">The parasympathetic bronchoconstrictor effect of the vagus nerve is directly mediated by M<sub>3</sub> receptor activation on effector cells and indirectly mediated by activation of M<sub>1</sub> mAcChR subtypes on ganglion cells (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Vagal fibers synapse and activate nicotinic and M<sub>1</sub> mAcChR in parasympathetic ganglion cells within the airway wall.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p">Acetylcholine released from parasympathetic vagal nerve endings causes airway smooth muscle contraction by activating postsynaptic M<sub>3</sub> mAcChR (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>).<a onclick="showRef(event, 'ref9 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref11">(9, 11)</a> Agonist/receptor complex activates a G<sub>q</sub> protein, which in turn enhances phospholipase C (PLC) β activity. This enzyme catalyzes the production of the second messengers inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) from the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>).<a onclick="showRef(event, 'ref9 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref11">(9, 11)</a> DAG activates protein kinase C, whereas IP3, by interacting with specific receptors on the endoplasmic reticulum, mobilizes calcium ions (Ca<sup>2+</sup>) from intracellular stores into the cytoplasm (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>).<a onclick="showRef(event, 'ref9 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref11">(9, 11)</a> Both events ultimately facilitate actin–myosin interaction with consequent airway smooth muscle contraction (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>).<a onclick="showRef(event, 'ref9 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref11">(9, 11)</a></div><div class="NLM_p">Short-acting muscarinic receptor antagonists (SAMA) and LAMA cause bronchodilation principally by blocking postsynaptic M<sub>3</sub> mAcChR (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> M<sub>3</sub> mAcChR antagonists, competing with acetylcholine released from postganglionic vagal efferent nerves, which make synapse with airway smooth muscle cells in central airways or from non-neuronal sources in the distal airways, inhibit bronchomotor tone, thus causing airway relaxation.<a onclick="showRef(event, 'ref4 ref9'); return false;" href="javascript:void(0);" class="ref ref4 ref9">(4, 9)</a> Blockade of M<sub>3</sub> mAcChR on airway gland cells inhibits airway secretions, an effect that contributes to reduction in airflow limitation induced by SAMA and LAMA.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p last">As activation of M<sub>2</sub> receptors has a presynaptic inhibitory effect that limits further release of acetylcholine and protects against parasympathetic-mediated bronchoconstriction,<a onclick="showRef(event, 'ref9 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref11">(9, 11)</a> an ideal mAcChR antagonist would selectively block M<sub>1</sub> and M<sub>3</sub> receptors sparing M<sub>2</sub> receptors (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). More selective inhaled muscarinic M<sub>3</sub> mAcChR antagonists (e.g., aclidinium bromide and glycopyrronium bromide) might avoid increase in acetylcholine released due to presynaptic M<sub>2</sub> blockade, but the lack of postsynaptic M<sub>2</sub> antagonism might increase the M<sub>2</sub>-mediated inhibitory effect on β<sub>2</sub>-induced bronchodilation (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Whether selective inhaled M<sub>3</sub> receptor antagonists are preferable over nonselective antimuscarinic brochodilators is controversial.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> M<sub>2</sub> receptor antagonism enhances β<sub>2</sub>-induced airway relaxation in in vitro human airways.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> By inhibition of cyclic adenosine monophosphate (cAMP) production, activation of postsynaptic M<sub>2</sub> receptor subtypes, which are more numerous than M<sub>3</sub> receptors on airway smooth muscle cells, might reduce β<sub>2</sub> receptor-induced airway relaxation (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>), an effect that would limit the therapeutic efficacy of inhaled selective M<sub>3</sub> receptor antagonists as brochodilators in patients with COPD.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> On the other hand, with nonselective antimuscarinic bronchodilators, the increased acethylcholine release from vagal fibers caused by M<sub>2</sub> inhibitory presynaptic receptor blockade would be counteracted by concomitant M<sub>3</sub> receptor antagonism (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> However, the implications of M<sub>2</sub> receptor modulation for the bronchodilatating effect in patients with COPD are mostly unknown, as data on the functional role of M<sub>2</sub> receptors have been principally obtained in in vitro and in vivo animal studies.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> β<sub>2</sub>-Adrenergic Receptors</h3><div class="NLM_p">SABA and LABA induce bronchodilation by activating β<sub>2</sub>-adrenergic receptors on airway smooth muscle cells (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Binding of endogenous agonists (e.g., cathecolamines), SABA, or LABA to the β<sub>2</sub>-adrenergic receptor causes a conformational receptor change, stimulatory G-protein (G<sub>s</sub>) activation, and subsequent enhanced adenylyl cyclase activity which catalyzes the production of cAMP from adenosine triphosphate (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Increased intracellular cAMP concentrations activate protein kinase A, triggering a cascade of intracellular events, including myosin light chain kinase inhibition, which ultimately leads to airway smooth muscle relaxation.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">Formoterol and salmeterol have a different pharmacodynamic profile, the main differences being their rate of onset of action and efficacy.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Formoterol is much faster, as about 70% of maximum bronchodilation is observed within 5 min of inhalation compared with nearly an hour for salmeterol.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> In vitro efficacy of LABA is expressed as intrinsic activity which is the maximal response of the test compound relative to the maximum effect of the high efficacy agonist isoprenaline whose intrinsic activity, by definition, is 1.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Salmeterol is a partial agonist, while formoterol is a full agonist.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> A partial agonist has a lower intrinsic activity than a full agonist and requires greater receptor occupancy for a maximal response. Formoterol is significantly more effective than salmeterol.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14, 15)</a> Intrinsic activity for formoterol is 0.97, and that of salmeterol is 0.37.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a><i>E</i><sub>max</sub> (the maximal relaxant effect expressed as a percentage of the maximal relaxant effect induced by theophylline) of salmeterol on isolated human bronchus at resting tone is 70 ± 4% versus 93 ± 1% for formoterol.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><div class="NLM_p">Indacaterol, a third-generation once-daily LABA approved by the European Medicines Association in December 2009 and by the U.S. FDA in July 2011 for maintenance bronchodilator treatment in patients with COPD,<a onclick="showRef(event, 'ref4 ref8'); return false;" href="javascript:void(0);" class="ref ref4 ref8">(4, 8)</a> has fast onset of action, and its bronchodilation effect is clinically significant over 24 h.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div class="NLM_p">The debate on the mechanism for the long clinical bronchodilating effect exhibited by inhaled β<sub>2</sub>-adrenoreceptor agonists has been ongoing since the discovery and clinical use of salmeterol and formoterol in the early 1990s.</div><div class="NLM_p">Persistent airway smooth muscle relaxation by LABA after washout, the rapid disappearance of this effect following exposure to β-receptor antagonists and its recovery after antagonist removal (“reassertion”), has been demonstrated in in vitro experiments.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The microkinetic model, the exosite model, and the rebinding model have been proposed for explaining the persistent bronchodilating effect of LABA.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> In the diffusion microkinetic model, which implies that LABA are constantly partitioned between the membrane and the surrounding aqueous phase depending on their degree of lipophilicity,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> the plasma membrane would act as a depot/reservoir for the LABA rather than merely providing an inert structural substratum for the receptor. Formoterol is continuously released from the lipid bilayer depot into the aqueous phase to interact with the active site of the β<sub>2</sub>-adrenergic receptor.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The concentration of formoterol determines the initial size of the depot,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> which in turn determines the duration of action, that is the time lag during which a sufficient amount of this agonist can be released in the aqueous phase to cause effective airway smooth muscle relaxation in vitro.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p last">Because of its very high partitioning in synthetic plasma membranes and slow release from such membranes [half-life (<i>t</i><sub>1/2</sub>) of 25 min],<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> salmeterol is thought to reach the receptor by lateral diffusion through the membrane and reach the central core of the receptor by lateral diffusion between the receptor’s membrane spanning hydrophobic α helices.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Consistent with the microkinetic model, an even slower release of salmeterol from tracheal strips (<i>t</i><sub>1/2</sub> of 3 h) has been reported.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The diffusion microkinetic model is sufficient to explain the persistent β<sub>2</sub>-activation and reassertion observed at high concentrations of salmeterol.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> However, at lower concentrations of salmeterol, “exosite” binding and “rebinding” might be the most important mechanisms.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The exosite model implies that the lipophilic phenylalkoxyalkyl side chain of salmeterol would be tightly bound to an accessory site (the exosite), located either close to the β<sub>2</sub>-adrenergic receptor or even within the receptor molecule itself.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> This would keep the agonist in the immediate vicinity of the active site of the β<sub>2</sub>-adrenergic receptor and cause its persistent activation. However, the existence of an exosite at the β<sub>2</sub>-adrenergic receptor has not been demonstrated. The “rebinding” model assumes that dissociated salmeterol can reassociate to the same or other receptor molecules. The continuous shuffling of salmeterol between nearby β<sub>2</sub>-adrenergic receptors would delay its escape from the membrane, thus maintaining the pharmacological effect.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Structure–Activity Relationships</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04533" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04533" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Muscarinic Receptor Antagonists</h3><div class="NLM_p">Inhaled mAcChR antagonists used as bronchodilators are generally quaternary ammonium synthetic derivatives of the natural tertiary ammonium compounds such as atropine, the prototype of mAcChR antagonists.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Nevertheless, a novel tertiary amine series of potent M<sub>3</sub> mAcChR antagonists have been described as potential inhaled long-acting bronchodilators for the pharmacological treatment of COPD.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p">Quaternary ammonium compounds include ipratropium bromide, obtained by the introduction of an isopropyl group to the N atom of atropine (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A),<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> oxitropium bromide (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B), a derivative of scopolamine formed by the introduction of an ethyl group, and tiotropium bromide (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>C).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The structures of quaternary ammonium compounds (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) make them water-soluble but lipid-insoluble. Therefore, unlike the lipid-soluble tertiary ammonium compounds, these compounds do not easily cross biological barriers. Most of the pharmacological characteristics that distinguish quaternary ammonium compounds from atropine are due to lipid solubility.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Being lipid-soluble, tertiary ammonium compounds are easily absorbed and can cause significant systemic side effects, including effects on the central nervous system.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In contrast, quaternary ammonium compounds are poorly absorbed after oral administration, do not cross blood–brain barrier, and for these reasons are better tolerated.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> As quaternary mAcChR antagonist bronchodilators are administered topically by inhalation, the possible interference with neuromuscular transmission due to their greater nicotinic receptor selectivity, at doses that more closely approximate to those that cause muscarinic antagonism, has little, if any, relevance.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><div class="NLM_p">From the structural point of view, mAcChR antagonist bronchodilators are characterized by an aromatic group attached to an ester moiety (like in atropine and scopolamine) and a positively charged center, generally a protonated or quaternized nitrogen (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a> and Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The optimal distance between the nitrogen and the carbonyl oxygen of 2,2-diphenylpropionate mAcChR antagonists is estimated to be 4.4–5.9 Å.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><div class="NLM_p">The long half-life of tiotropium (more than 24 h) is potentially due to interactions in the binding site; in particular, a highly directed interaction of the ligands’ hydroxy group with an asparagine (N508(6.52)) prevents rapid dissociation via a snap–lock mechanism.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_p">In the search for novel antagonist bronchodilators, structures incorporating nitrogen containing rings (e.g., piperidine, pyrrolodine, or tropane) and an aromatic moiety (e.g., phenyl, thiophene, or biphenyl) separated by four to six carbon–carbon bonds have been identified.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26, 27)</a></div><div class="NLM_p">Lainé et al. at GlaxoSmithKline characterized a novel series of tropane derivatives starting from compound <b>1a</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>A) which has a hydroxyethyl group linking the tropane and the aromatic region.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Initial results, leading to compound <b>1h</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>B), showed that the C-3 endo configuration, a quaternary ammonium salt, and a two-carbon linker were preferred features around the tropane template.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Structure–activity relationship (SAR) studies, undertaken by preparing a series of quaternary ammonium salts derived from compound <b>1h</b>, suggest that the nature of the linker between the tropane ring and the aromatic rings is important for potency and in vivo efficacy.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> On this basis, the effect of substituting the linker at the C-20 position was explored.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> SAR optimization around the tropane scaffold leads to the identification of the quaternary ammonium salt <b>34</b> as a very potent M<sub>3</sub> mAcChR antagonist (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>C). This compound is functionally active and displays a duration of action greater than 24 h in a mouse model of bronchoconstriction.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Chemical structures of compound <b>1a</b> (A), compound <b>1h</b> (B), compound <b>34</b> (C), and revatropate (D).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In another study, Lainé et al. discovered novel 1-azoniabicyclo[2.2.2]octane mAcChR antagonists from structural changes of the [2.2.2]quinuclidine ring which has a positive center and two aromatic groups.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The general strategy was based on the exploration of the linker length and connectivity point, substitution of the phenyl ring and nitrogen substituents, the ring size, and the replacement of the hydroxyl group.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> SARs of the various compounds were explained by computational docking studies using a homology model of the M<sub>3</sub> mAcChR.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p">Among the identified compounds, compound <b>14o</b> (GSK573719)<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> (umeclidinium bromide) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>C) is a very potent, slow reversible M<sub>3</sub> mAcChR antagonist with a very long in vivo duration of action (greater than 50% of bronchoprotection observed at 48 h) in a mouse bronchoconstriction model.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p">3-Quinuclidinol esters are potent mAcChR antagonists.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29, 30)</a> Quaternarization of the tertiary amino function, a common chemical manipulation of 3-quinuclidinol esters, minimizes absorption, resulting in low oral bioavailability and blood–brain barrier permeability.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Revatropate, a (3<i>R</i>)-quinuclidinol ester with a M<sub>3</sub> and M<sub>1</sub> selective antagonist activity (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>D), entered phase II clinical trials for COPD, but its development was stopped likely because of its short duration of action.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Quaternary ammonium derivatives of quinuclidinyl benzylate with aliphatic chains of different length on the N<sup>+</sup> of the azoniabicyclo ring have antagonist activity at mAcChR.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Prat et al. at Almirall discovered a series of novel quaternary ammonium derivatives of (3<i>R</i>)-quinuclidinol esters.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Among these compounds, aclidinium bromide was initially developed as once-daily maintenance treatment of COPD (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Two 2-thienyl substituents at R<sup>1</sup> and a phenethyl chain or phenoxypropyl chain at R<sup>2</sup> provide the highest affinity for the M<sub>3</sub> mAcChR (0.18–1.62 nM).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Quaternarization maintains or even improves the duration of action of these compounds.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The presence of two 2-thienyl substituents on the R<sup>1</sup> group and quaternarization of the (3<i>R</i>)-quinuclidinol ester (aclidinium bromide) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A) decrease compound stability in human plasma.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Compounds with a hydroxyl substituent were less stable in human plasma than compounds with a methyl substituent.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Aclidinium bromide is approved for pharmacological treatment of COPD. This potent mAcChR antagonist is rapidly hydrolyzed in human plasma, with minimal potential risks for class-related systemic side effects.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> In guinea pigs in vivo, its duration of action [defined as the time taken to reduce the maximal inhibition of acethylcholine-induced bronchoconstriction achieved at 1 h by 50% (<i>t</i><sub>1/2</sub>)] is 29 h.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> This duration of action is considerably longer than that of ipratropium (<i>t</i><sub>1/2</sub> of 8 h) and shorter than that of tiotropium (<i>t</i><sub>1/2</sub> of 64 h).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> However, as a single dose of aclidinium does not have a clinically significant brochodilating effect over 24 h, twice daily administration is required in patients with COPD.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Interestingly, airway antiremodeling effects of aclidinium bromide have been reported in in vitro and in vivo experimental models.<a onclick="showRef(event, 'ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38">(36-38)</a> In vitro studies show that aclidinium bromide inhibits carbachol, transforming growth factor β and cigarette smoke-induced human lung fibroblast-to-myofibroblast transition,<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> a key step in peribronchiolar fibrosis formation which is part of lung remodeling in asthma and COPD and contributes to airflow limitation.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Airway antiremodeling effects of aclidinium have also been observed in vivo, as this drug inhibits smooth muscle enlargement in small airways and, to a lesser extent, airspace enlargement in guinea pigs chronically exposed to cigarette smoke, an experimental model of COPD.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><div class="NLM_p">Glossop et al. at Pfizer identified compound <b>47</b> (PF-3635659)<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>A) as a phase II clinical candidate from a novel tertiary amine series.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Compound <b>47</b> is characterized by geminal dimethyl functionality which confers very long dissociative half-life from the M<sub>3</sub> mAcChR in vitro.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In vivo studies have confirmed that compound <b>47</b> has slow off-rate binding kinetics from M<sub>3</sub> mAcChR, making it potentially suitable for inhaled once-daily treatment of COPD.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Combination of rapid oxidative clearance with targeted introduction of a phenolic moiety to enable rapid glucuronidation minimizes systemic exposure after inhalation and the consequent side effects.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Chemical structures of compound <b>47</b> (A), darotropium (B), compound <b>24</b> (C), compound <b>43a</b> (D), and compound <b>50</b> (E).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Searching for novel inhaled LAMA, Lainé et al. identified a new series of N-substituted tropane derivatives which were characterized as potent M<sub>3</sub> mAcChR antagonists.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> SARs at the M<sub>3</sub> mAcChR of a N-substituted series of analogs of compound <b>1</b> (darotropium) (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>B) have been studied.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Quaternary salts <b>3</b>–<b>15</b> derived from darotropium were obtained as a mixture of two isomers.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The N-endo derivatives possessing the pending chain on the same side as the C-3 substituent were more potent than N-exo isomers having the chain on the opposite side as the C-3 substituent.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Initial results, indicating the importance of the stereochemistry at the tropan nitrogen, suggested that testing of the compounds as diasteroisomeric mixtures was not the best strategy.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Therefore, subsequent SAR studies were focused on N-endo derivatives with linear alkyl chains of up to seven carbon atoms that can be tolerated at the receptor pocket.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Among the N-endo derivatives, compound <b>24</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>C) was selected for further evaluation based on its ability to form a stable crystalline form with a high melting point (>200 °C), a desirable characteristic for a DPI drug, as it can increase compound stability during the manufacturing processes.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> In kinetic washout studies at the human M<sub>3</sub> cloned receptor and in human airway kinetic studies, the N-endo-substituted analog <b>24</b> displayed a very long off rate at the M<sub>3</sub> mAcChR (off <i>t</i><sub>50</sub> > 600 min) that was considerably longer than the methyl-substituted parent molecule <b>1</b> darotropium (85 min).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> This profile translated into a much more persistent in vivo duration of action of compound <b>24</b> (>96 h) compared with darotropium (about 48 h) as shown in a mouse plethysmography model.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Longer duration of bronchoprotection observed with compound <b>24</b> is most likely due to its slower target off-rate.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> From a pharmacokinetic standpoint, compound <b>24</b> has a very high systemic clearance and low bioavailability. These properties are required for a drug delivered by inhalation. Therefore, the introduction of alkyl chains on the tropane nitrogen of darotropium has enabled the identification of a novel class of mAcChR antagonists with a better potential for long-lasting duration of bronchodilation in humans.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><div class="NLM_p">Nagashima et al. at Astella Pharma have recently described the synthesis and pharmacological profiles of novel quinuclidinyl heteroarylcarbamate derivatives.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Among them, the quinuclidin-4-yl thiazolylcarbamate derivative compound <b>43a</b> (ASP9133)<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>D) was identified as a promising LAMA showing more selective inhibition of bronchoconstriction versus salivation and more rapid onset of action than tiotropium bromide in a rat model.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><div class="NLM_p last">Peretto et al. at Chiesi Farmaceutici reported the synthesis of diaryl imidazolidin-2-one derivatives.<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41, 42)</a> The novel quaternary ammonium salt (3<i>R</i>)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide, compound <b>50</b> (CHF5407)<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>E), which initiated clinical development in 2007, shows a prolonged antibronchospastic activity, both in vitro and in vivo, caused by a very slow dissociation from M<sub>3</sub> receptors, whereas it is markedly short-acting at M<sub>2</sub> receptors, a behavior not shared by tiotropium.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> This compound is being developed both as a single agent and in combination with compounds of other classes for the treatment of COPD.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> β<sub>2</sub>-Adrenergic Receptor Agonists</h3><div class="NLM_p">Development of once daily bronchodilators is a priority in the LABA research programs, as these drugs would likely improve patient outcomes and compliance with pharmacological treatment.</div><div class="NLM_p">Unlike salbutamol, which is hydrophilic and has a rapid onset and short duration of action, salmeterol has an arylalkyl group with a chain length of 11 atoms from the amine (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A). This bulkiness makes the compound more lipophilic and selective at the β<sub>2</sub>-receptor. Similarly, formoterol is highly selective for the β<sub>2</sub> receptor and its lipophilicity contributes to its long duration of action. Because of their lipophilic properties, both formoterol and salmeterol remain in the airway tissues as a depot in close vicinity of the β<sub>2</sub>-receptors and is postulated for their long duration of action (diffusion microkinetic model).<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a></div><div class="NLM_p">From the structural point of view, salmeterol is about 25 Å long and preferentially accumulates in the outer monolayer of synthetic membranes wherein it assumes a highly specific orientation similar to the phospholipids.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> Salmeterol has a saligenin (arylethanolamine) head that is responsible for β<sub>2</sub>-adrenergic receptor activation and an extended lipophilic phenylalkoxyalkyl side chain (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>) that is not generally present in most LABA. SAR studies show that the position of the oxygen atom in the side chain does not affect the lipophilicity of salmeterol but that it is essential for its long duration of action.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> These findings are consistent with the exosite model in which phenylalkoxyalkyl side chain of salmeterol would anchor the drug to an accessory site (the exosite) located either close to or even within the β<sub>2</sub>-adrenergic receptor itself. The exosite’s ability to keep the phenylalkoxyalkyl side chain in place would enable the active saligenin head of salmeterol to continuously sneak in and out of the active receptor site. The position of the oxygen atom in the alkyloxalkyl side chain would not affect the average depth of penetration of the whole salmeterol molecule in the membrane, but it could determine the depth of the “hinge” and, therefore, the efficiency of the docking process.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0009.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structure of salmeterol. The saligenin head, the hydrophobic phenylalkoxyalkyl chain, and the oxygen “hinge” are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Pharmacological characteristics required by novel inhaled LABA include 24 h bronchodilator effect in vivo which would make them suitable for once daily administration, high potency and selectivity for β<sub>2</sub>-adrenoceptors, low oral bioavailability (<5%) after inhalation, high systemic clearance, and lipophilicity as compounds with a log <i>D</i> > 2 generally have a longer duration of action.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> From a pharmacokinetic point of view, increased lipophilicity could result in increased cell permability and subsequent increased oral absorption following inhalation but also in high first pass metabolism, which would decrease oral bioavailability after inhalation.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><div class="NLM_p">A homology model was built to facilitate the understanding of the SAR for LABA. Computational docking of compounds to the homology model was undertaken by identifying “interacting” residues by receptor mutagenesis and molecular modeling studies.<a onclick="showRef(event, 'ref15 ref46'); return false;" href="javascript:void(0);" class="ref ref15 ref46">(15, 46)</a> On the basis of this model, catechol mimic interacts with the serine residues 204 and 207 on the fifth transmembrane spanning domain (TM5), the benzyl alcohol interacts with the chirally discriminating Asn-293 on TM6 and the protonated amine with Asp-113 on TM3.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Interaction between the methylene groups near the protonated amine of salmeterol and Tyr-308 on TM7 would be responsible for salmeterol β<sub>2</sub> selectivity.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Moreover, Tyr-308 is the residue which defines the interactions of the amine substituents of carmoterol and formoterol.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The ether oxygen in the phenylalkoxyalkyl side chain of salmeterol interacts with Tyr-316,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> and consequently, its 4-phenylbutyl ether group would interact with the exosite binding pocket which is defined by the amino acids at positions 149–158 on TM4.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><div class="NLM_p">Baur et al. at Novartis Pharma synthesized an 8-hydroxyquinolinone 2-aminoindan derived series of β<sub>2</sub>-adrenergic receptor agonists which were assessed as inhaled once-daily long-acting bronchodilators.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Determination of their activities at the human β<sub>2</sub>-adrenergic receptor showed that symmetrical substitution of the 2-aminoindan moiety at the 5- and 6-positions delivered the targeted intermediate potency and intrinsic-efficacy profiles relative to a series of clinical reference β<sub>2</sub>-agonists.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The 5,6-diethylindan analogue indacaterol (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>D) possesses a unique profile which combines a rapid onset of action with a long duration of action in vitro.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Further in vivo studies of indacaterol confirmed the sustained duration of action and showed a wide therapeutic index following pulmonary administration. For these reasons, this compound was selected as a development candidate.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Indacaterol is synthesized by combining the dihydroindeneamine region and the quinolinol region of the molecule.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div><div class="NLM_p">Beattie et al. at Novartis Pharma described the synthesis of a series of indacaterol analogues, in which each of the three structural regions of indacaterol is modified in a systematic manner.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Evaluation of the affinity of these analogues for the β<sub>2</sub>-adrenoceptor identified the 3,4-dihydroquinolinone and 5-<i>n</i>-butylindanyl analogues to demonstrate the most similar profiles to indacaterol.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> An α-methylaminoindane analogue was discovered to be 25-fold more potent than indacaterol.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Functional studies revealed an atypical β<sub>2</sub>-adrenoceptor activation profile for this compound consistent with that of a slowly dissociating “superagonist”.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div><div class="NLM_p">By incorporation of the arylsulfonamide groups on the right-hand side phenyl ring of (<i>R</i>)-salmeterol, Procopiou et al. at GlaxoSmithKline obtained a series of very potent saligenin alkoxyalkylphenylsulfonamide β<sub>2</sub>-adrenoceptor agonists.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The (<i>S</i>)-enantiomer of meta-substituted primary sulfonamide was more potent than the para and the ortho-analogues. Primary sulfonamides were more potent than the secondary and tertiary analogues.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The onset and duration of action of selected compounds in vitro was assessed on isolated superfused guinea pig trachea. The primary sulfonamide at the meta-position (<b>29b</b>) (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>) was identified as the analogue that fulfilled all the criteria of high potency and selectivity, rapid onset, and long duration of action in vivo, low oral bioavailability, and higher therapeutic index than salmeterol.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The cinnamate salt of <b>29b</b>, which was found to have suitable properties for inhaled administration, was selected as a candidate for further development.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0010.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Chemical structure of compound <b>29b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The following interactions between sulfonamide <b>29b</b> groups and β<sub>2</sub>-adrenoceptor amino acid residues were found when sulfonamide <b>29b</b> was docked in the model described previously: phenolic hydroxyl with Ser-207, benzylic hydroxyl with Ser-204 and Ser-203, asymmetric benzylic hydroxyl and Asn-293, ether oxygen in the side chain with Asn-318 (TM7), <i>m</i>-sulfamido group with Ser-120 (TM3) and Asn-322 (TM7) (Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The sulfonamide tail was found to project down toward the exosite binding pocket, but no direct interaction was described.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Postulated interactions of the <i>m</i>-sulfonamide <b>29b</b> with the β<sub>2</sub>-receptor derived from modeling studies were confirmed by crystal structure studies.<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52, 53)</a></div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0011.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Postulated interactions of the <i>m</i>-sulfonamide <b>29b</b> with the β<sub>2</sub> receptor. Portions of TM6 are omitted (from <contrib-group>Procopiou, P. A.</contrib-group>;  <cite>J. Med. Chem.</cite> <span class="NLM_year">2009</span>, <em>52</em>, 2280–2288).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Procopiou et al. identified a series of saligenin β<sub>2</sub>-adrenoceptor agonist antedrugs which possess high metabolic clearance by incorporation of an oxygen atom at the homobenzylic position of the right-hand-side phenyl ring of (<i>R</i>)-salmeterol.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Antedrugs act locally at the site of application but once absorbed into the systemic circulation are transformed into inactive metabolites.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> This approach reduces potential systemic side effects while maintaining efficacy. The compounds were screened for β<sub>2</sub>, β<sub>1</sub>, and β<sub>3</sub> agonist activity in CHO cells.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The onset and duration of action of selected compounds in vitro were assessed on isolated superfused guinea pig trachea.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The 2,6-dichlorobenzyl analogue <b>13f</b>, vilanterol (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>A), fulfilled all the criteria of potency, selectivity, rapid onset of action on guinea pig trachea, long duration of action, rapid metabolism, and in vivo long-lasting efficacy that increased with increasing dose.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The <i>R</i>-phenylcinnamate and triphenylacetate salts of vilanterol were found to have suitable properties for inhaled administration. For this reason, they were selected as candidates for further development.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> As they have never been used in marketed inhaled products, these salts underwent further toxicological investigation.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Vilanterol trifenatate (compound <b>13f</b> triphenylacetate) is currently undergoing clinical trials for the maintenance treatment of COPD and asthma, as a combination with umeclidinium bromide (approved for COPD) or fluticasone furoate or both.<a onclick="showRef(event, 'ref7 ref54'); return false;" href="javascript:void(0);" class="ref ref7 ref54">(7, 54)</a> Because of its bronchodilating effect which lasts over 24 h in patients with asthma, vilanterol is potentially suitable for once daily administration.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> All interactions between vilanterol groups and β<sub>2</sub>-receptor amino acid residues, derived from modeling studies and confirmed by crystal structure studies, were similar to those reported for compound <b>29b</b>.<a onclick="showRef(event, 'ref15 ref54'); return false;" href="javascript:void(0);" class="ref ref15 ref54">(15, 54)</a> The benzylic ether oxygen on vilanterol, which is not present on <b>29b</b>, shows the same interaction with Ser-120 (TM3) and Asn-322 (TM7) as the <i>m</i>-sulfonamido group on <b>29b</b>.<a onclick="showRef(event, 'ref15 ref54'); return false;" href="javascript:void(0);" class="ref ref15 ref54">(15, 54)</a> The hypothesis for the persistence and reassertion profile of vilanterol is more than likely based on the microkinetic model<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a> as the calculated log <i>P</i> value for vilanterol (3.2) is similar to that of salmeterol (3.1).<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> However, dissociation kinetics in a recombinant expression system is not sufficiently slow to explain the duration of action of vilanterol.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Further studies combining radioligand binding, mutagenesis/receptor modeling (based on the crystal structure determined for the β<sub>2</sub>-adrenoceptor–G protein α<sub>s</sub> complex exposed to a range of structurally distinct LABA), and functional studies in basic and more complex physiological systems are required to clarify the mechanism(s) of action which explain the long-lasting bronchodilating effect of vilanterol and other LABA.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></div><div class="NLM_p">Searching for new ultra-LABA, Brown et al. at Pfizer synthesized and characterized a novel series of saligenin analogues.<a onclick="showRef(event, 'ref45 ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref45 ref57 ref58">(45, 57, 58)</a> Compound <b>5</b> belongs to a series of indole compounds (Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>A).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> In compounds <b>11</b>, the indole linker has been replaced by a phenyl acetic group (Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>B),<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> whereas in compound <b>7</b>, an adamantyl group has replaced the dichlorophenyl group of compound <b>11</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>C).<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Compound <b>5</b> has equivalent, whereas compounds <b>7</b> and <b>11</b> have greater, potency and duration of action than salmeterol in guinea pig trachea in vitro.<a onclick="showRef(event, 'ref45 ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref45 ref57 ref58">(45, 57, 58)</a> All compounds are potentially safer than salmeterol because of their lower oral bioavailability after inhalation.<a onclick="showRef(event, 'ref45 ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref45 ref57 ref58">(45, 57, 58)</a> This was achieved by introducing amide functionality with high hydrogen bonding potential to reduce oral absorption while maintaining high hepatic metabolism through phase I cytochrome P450 enzymes.<a onclick="showRef(event, 'ref45 ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref45 ref57 ref58">(45, 57, 58)</a> For optimum potency the saligenin template required <i>R</i>,<i>R</i>-stereochemistry, α-methyl substitution, and N–H indole bearing amide substitution at the 2-position.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> As these compounds are isolipophilic with salmeterol, their long duration of action could be explained by the diffusion microkinetic hypothesis.<a onclick="showRef(event, 'ref45 ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref45 ref57 ref58">(45, 57, 58)</a> Although indole derivatives have less conformational flexibility, their structural similarity to salmeterol would also be compatibile with the exosite hypothesis.<a onclick="showRef(event, 'ref45 ref58'); return false;" href="javascript:void(0);" class="ref ref45 ref58">(45, 58)</a></div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0012.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Chemical structures of compound <b>5</b> (A), compound <b>11</b> (B), compound <b>7</b> (C), and compound <b>38</b> (D).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of “inhalation by design” strategy, which includes searching for compounds combining once-daily LABA (ultra-LABA) characteristics with the solid form attributes required by delivery in a DPI device, Glossop et al. at Pfizer identified of a novel series of selective and potent sulfonamide derived β<sub>2</sub>-adrenergic receptor agonists.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> The key design feature is the incorporation of a sulfonamide group in the headgroup of target compounds structurally similar to a previous saligenin series.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> The identified compounds elicit very long-lasting smooth muscle relaxation in guinea pig trachea strips.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> From this series, compound <b>38</b> (PF-610355) was identified as a clinical candidate (Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>D). As compound <b>38</b> is isolipophilic with salmeterol, its long duration of action could be explained, at least partially, by the diffusion microkinetic model.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Compound <b>38</b> might also access the proposed β<sub>2</sub>-receptor exosite, and this might explain its long lasting effect on airway smooth muscle. Although the sulfonamide template has less conformational flexibility than salmeterol, when the β<sub>2</sub>-adrenergic receptor agonist headgroups are superimposed, the aromatic tail residues occupy similar regions of space (Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>).<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> From a SAR point of view, the position of the amide group in compound <b>38</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>D) could have a similar significance to the ether oxygen atom in the salmeterol tail (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>).<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Introduction of a phenolic moiety optimizes the pharmacokinetic profile, including a rapid phase II clearance through glucuronidation,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> which minimizes systemic exposure after inhalation, thus reducing systemic adverse effects. In vivo studies confirm that compound <b>38</b> has long duration of action which makes it potentially suitable for once-daily administration.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> In phase Ib clinical trials, compound <b>38</b> provides a 24 h bronchodilating effect in healthy subjects, confirming compound <b>38</b> as a once-daily LABA.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Compound <b>38</b> has achieved positive proof-of-concept for the treatment of asthma and COPD and is currently in phase II clinical studies.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0013.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structural overlays of compound <b>38</b> (orange) with salmeterol (purple) (from <contrib-group>Glossop, P. A.</contrib-group>;  <cite>J. Med. Chem.</cite> <span class="NLM_year">2010</span>, <em>53</em>, 6640–6652).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Bouyssou et al. and Hoencke et al. at Boehringer Ingelheim Pharma identified novel β<sub>2</sub>-agonists with a 5-hydroxy-4<i>H</i>-benzo[1,4]oxazin-3-one moiety as headgroup (Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>).<a onclick="showRef(event, 'ref60 ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref60 ref61 ref62">(60-62)</a> The template compound <b>1</b> has a 5-hydroxy-4<i>H</i>-benzo[1,4]oxazin-3-one moiety at its left-hand side and a phenethylamine residue with two geminal methyl groups at the carbon atom next to the amine at its right-hand side (Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>A).<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> This structure is similar to the amine portion of formoterol.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0014.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Chemical structures of compound <b>1</b> (A) and compound <b>6m</b> (B). Chemical structure of 6-hydroxy-4<i>H</i>-benzo[1,4]oxazin-3-ones from which olodaterol is derived (C).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Systematic chemical variations at the phenethylamine group of these compounds led to the discovery of compound <b>6m</b>, a potent, β<sub>2</sub>-adrenoceptor full agonist with a high β<sub>2</sub>/β<sub>1</sub>-selectivity (Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>B).<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Molecular modeling revealed an interaction between the carboxylic acid group of <b>6m</b> and a lysine residue (K305) at the extracellular end of the β<sub>2</sub>-receptor TM7 as putative explanation for its high selectivity.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> In a guinea pig in vivo model, compound <b>6m</b> demonstrated a bronchodilating effect lasting over the complete study period of 5 h.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> However, a significant increase in heart rate (>10%) was observed at doses of 10 μg/kg, required for achieving maximal bronchodilation. By contrast, the first dose required for reaching the maximal effect observed with formoterol was 10-fold lower (≥1 μg/kg) than that required to cause tachycardia (10 μg/kg).<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Development of compound <b>6m</b> was stopped because of its inferior safety margin compared with formoterol.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></div><div class="NLM_p">Shifting the phenolic hydroxyl group of the β<sub>2</sub>-agonist from the para- to the meta-position with respect to the ethanolamine substituent provides a series of 6-hydroxy-4<i>H</i>-benzo[1,4]oxazin-3-ones with a considerably optimized profile.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div><div class="NLM_p">Compound (<i>R</i>)-<b>4p</b> (olodaterol) (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>B), which was identified from a series of 6-hydroxy-4<i>H</i>-benzo[1,4]oxazin-3-ones (Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>C), is a highly potent and selective β<sub>2</sub>-agonist.<a onclick="showRef(event, 'ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref62 ref63">(62, 63)</a> Olodaterol causes dose-dependent bronchodilation in a guinea pig in vivo model.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Up to 10-fold above the first dose required for reaching maximal bronchodilation, no cardiovascular side effects are observed.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Olodaterol and formoterol have a similar therapeutic index.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> The (<i>R</i>) enantiomer of olodaterol has a duration of action over 24 h in dog and guinea pig in vivo models of bronchoprotection with no systemic effects including decrease in serum potassium concentrations and increase in serum glucose and lactate concentrations.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Despite a log <i>D</i> value of 1.2 (at pH 7.4), olodaterol has a long lasting bronchodilating effect,<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> indicating that lipophilicity is not necessarily a requirement for inhaled once-daily LABA.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> In a model of bronchoprotection in dogs, olodaterol showed a superior safety margin compared with formoterol, as equally effective doses of olodaterol were not associated with systemic metabolic effects and tachycardia was less pronounced than that observed with formoterol.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div><div class="NLM_p">Olodaterol has favorable pharmacokinetic properties. Olodaterol systemic availability is low as suggested by the lack of metabolic side effects after inhalation. This was confirmed by pharmacokinetic data showing low permeability in vitro and low oral bioavailability (3 ± 2%) after oral administration in rats.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> The physical–chemical properties of a crystalline hydrocholride salt of (<i>R</i>)-olodaterol are compatible with a formulation in a DPI and in a Soft Mist inhaler as an aqueous solution.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Olodaterol is currently approved for the once-daily maintenance treatment of COPD in Canada and Russia and under approval evaluation in other countries including EU and USA.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><div class="NLM_p">Connelly et al. at AstraZeneca synthesized and characterized a new potential once-daily LABA by modifying the dual DA<sub>2</sub>/β<sub>2</sub>-agonist sibenadet structure (Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a>A).<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Addition of a benzylic hydroxyl group increases selectivity at the dopamine receptor, potency, and intrinsic activity.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Incorporation of a second base along the chain improves pharmacokinetic profile.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Plasma half-life was optimized by modifying lipophilicity.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Because of its bronchoprotection effect in guinea pig in vivo which lasts 24 h, compound <b>16</b> is potentially suitable for once daily administration (Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a>B).<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> A dihydrobromide salt of compound <b>16</b>, which has acceptable inhaled characteristics, is currently in development.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Compound <b>31</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a>C), a potent, effective, and selective β<sub>2</sub>-adrenoreceptor agonist, has been identified from a similar series of novel dibasic compounds.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Compound <b>31</b> has a duration of action longer than that of salmeterol and formoterol and similar to that of indacaterol in a bronchoconstriction guinea pig model.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> On the basis of these results, compound <b>31</b> was progressed into development for further studies as the bis-malonate salt.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0015.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Chemical structures of sibenadet (A), compound <b>16</b> (B), and compound <b>31</b> (C).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Developing New Bronchodilators: “Inhalation by Design” Strategies</h3><div class="NLM_p">“Inhalation by design” has been implemented in the development of new bronchodilators in order to improve their pharmacokinetic/pharmacodynamics profile.<a onclick="showRef(event, 'ref22 ref54 ref59 ref66'); return false;" href="javascript:void(0);" class="ref ref22 ref54 ref59 ref66">(22, 54, 59, 66)</a> This drug discovery strategy aims at identifying molecules with high potency to achieve a low inhaled drug dose (≤1 mg), a clinically significant duration of bronchodilating effect, high clearance and low oral absorption to minimize systemic exposure and consequently potential side effects, multiple routes of clearance to minimize the effect of drug interactions, and characteristics of physical form suitable for a DPI including high crystallinity and compatibility with lactose, the commonly used excipient,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> and good long-term stability and high degree of delivered dose reproducibility.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Complying with the last two features is technically more challenging for low-dose highly potent compounds including formoterol.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> For this reason, β<sub>2</sub>-agonists with intermediate potency facilitate manufacturing of formulations suitable for a final drug product.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> This is particularly relevant as β<sub>2</sub>-agonists are frequently coformulated in FDC with other drug classes (e.g., LAMA and/or ICS).<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div><div class="NLM_p">Inhalation by design has been used for developing novel tertiary amine muscarinic M<sub>3</sub> receptor antagonists with slow off-rate binding kinetics<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and novel ultralong-acting β<sub>2</sub>-adrenoreceptor agonists which utilize a sulfonamide agonist headgroup.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Introduction of alkyl chains on the tropane nitrogen led to the discovery of a novel class of mAChR antagonists with a better likelihood to achieve long-lasting bronchodilation in humans.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><div class="NLM_p">Moving from the lipophilicity and metabolism based hypotheses, which are part of the inhalation by design strategy, Beattie et al. first described the chiral synthesis of a 4-hydroxybenzothiazolone based series of β<sub>2</sub>-adrenoceptor agonists which were used for preparing a library of N-substituted analogues.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> This approach led to the identification of β-phenethyl, α-substituted cyclopentyl and monoterpene N-substituents with the potential to be fast onset and long-acting β<sub>2</sub>-agonist inhaled bronchodilators with improved therapeutic margins.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div><div class="NLM_p last">Development of new bronchodilators relying on antedrugs which are active in the airways, but once absorbed are inactivated, has been proposed to synthesize a series of β<sub>2</sub>-adrenoceptor agonists prepared by reacting a protected saligenin oxazolidinone with protected hydroxyethoxyalkoxyalkyl bromides, followed by removal of hydroxyl-protecting group, alkylation, and final deprotection.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Approved Muscarinic Receptor Antagonists for COPD: Pharmacological and Clinical Aspects</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45775" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45775" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Short-Acting Muscarinic Antagonists (SAMA)</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> Ipratropium Bromide</h4><div class="NLM_p">Ipratropium bromide is a polar nonlipophilic quaternary ammonium SAMA (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A). Unlike atropine, which is a nonpolar lipophilic tertiary amine, ipratropium bromide is poorly absorbed from the lungs or the gastrointestinal tract and does not inhibit mucociliary clearance.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> For this reason, treatment with ipratropium bromide in patients with COPD avoids the increased accumulation of lower airway secretions and the antagonism of β-agonist-induced enhancement of mucociliary clearance that occurs with atropine.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Even at doses much higher than those recommended, ipratropium bromide causes little or no change in heart rate, blood pressure, bladder function, intraocular pressure, or pupillary diameter.<a onclick="showRef(event, 'ref3 ref23'); return false;" href="javascript:void(0);" class="ref ref3 ref23">(3, 23)</a> This selectivity reflects the very low absorption of the drug from airway or gastrointestinal mucosa.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><div class="NLM_p">Ipratropium bromide was first introduced in a pMDI form and then in a solution for nebulized administration.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Each puff of the pMDI with hydrofluoroalkane as a propellent provides 21 μg of ipratropium bromide (delivered dose from the valve equivalent to 17 μg of ipratropium bromide from the mouthpiece). The recommended dose from the pMDI is 2 puffs 4 times a day, but the medication is well tolerated at much higher doses.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Each 2.5 mL unit dose of the nebulized solution contains 500 μg of ipratropium, the recommended dose to be given 3–4 times per day.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Ipratropium bromide does not seem to induce tachyphylaxis, and therefore, its efficacy is not blunted over years of regular use.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">Ipratropium bromide improves dyspnoea, increases exercise tolerance, and improves pulmonary function and gas exchange in patients with COPD.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> However, ipratropium bromide does not possess anti-inflammatory properties and does not modify the natural history of COPD in terms of lung function or mortality.<a onclick="showRef(event, 'ref3 ref67'); return false;" href="javascript:void(0);" class="ref ref3 ref67">(3, 67)</a></div><div class="NLM_p">The Lung Health Study prospectively evaluated the effect of smoking cessation with or without ipratropium bromide treatment on the decline of lung function in 5887 smokers with COPD.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> In this study, ipratropium bromide was the bronchodilator of choice due to its low frequency of side effects, relatively long duration of action, and demonstrated bronchodilator efficacy in patients with COPD.<a onclick="showRef(event, 'ref3 ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref3 ref68 ref69">(3, 68, 69)</a> Regular treatment with inhaled ipratropium bromide produced increased FEV<sub>1</sub>, an effect that was evident at the end of the first year and maintained for the succeeding 4 years. However, improvement in lung function did not increase over time and appeared to reverse within a few weeks of suspension of treatment with ipratropium bromide.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> These results reflect the relatively short-term, pharmacologically mediated change in lung function attributable to the ipratropium bromide. As this effect is presumably available at any time during the course of COPD, these results support the treatment with bronchodilators for symptomatic benefit, including improvement in dyspnoea and exercise tolerance.</div><div class="NLM_p">Ipratropium bromide was found to be superior to a β-agonist in a randomized, double-blind, multicenter study in 260 patients with COPD which showed that ipratropium bromide had higher efficacy and longer duration of action than metaproterenol.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Moreover, ipratropium bromide can produce significant bronchodilation in patients who do not respond to inhaled β<sub>2</sub>-agonists.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> In a randomized, double-blind trial conducted in 183 patients with moderate to severe COPD who received either ipratropium (80 μg, 3 times per day through pMDI), formoterol (18 μg, delivered dose, twice daily through DPI), or placebo for 12 weeks, ipratropium bromide improved pulmonary function, increased exercise capacity, and decreased dyspnoea and cough compared to placebo.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></div><div class="NLM_p">Treatment with ipratropium bromide may also improve the quality of life in patients with COPD. In a multicenter, double-blind, randomized study conducted in 223 patients with COPD, the efficacy of nebulized ipratropium bromide (500 μg) was compared with nebulized salbutamol (2.5 mg) (each taken 3 times daily for up to 85 days).<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Clinical improvement was noted in both groups, but treatment with ipratropium bromide was associated with a greater symptomatic benefit and higher score on quality of life questionnaires.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></div><div class="NLM_p last">The rationale of combination therapy with ipratropium and β<sub>2</sub>-agonists relies on the fact that the degree of bronchodilation achieved with SABA and anticholinergics is additive. In fact, mAcChR antagonists act predominantly on the proximal large airways, whereas β<sub>2</sub>-agonists act on the more distal small airways. Moreover, the two classes of drugs cause bronchodilation via complementary mechanisms. β<sub>2</sub>-Agonists cause bronchodilation by activating β<sub>2</sub>-adrenergic receptors on airway smooth muscle cells with subsequent binding to G<sub>s</sub> protein, increased adenylyl cyclase activity, and increased intracellular cAMP concentrations. Ipratropium bromide causes bronchodilation principally by antagonizing the effects of acethylcholine released by vagal fibers on M<sub>3</sub> mAcChR on airway smooth muscle cells with subsequent binding to G<sub>q</sub> protein, PLC activation, increased synthesis of IP3 and DAG, and increased intracellular calcium concentrations and PKC activation.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> Combination Treatment with Ipratropium Bromide and Salbutamol</h4><div class="NLM_p">Concomitant treatment with ipratropium bromide and SABA provides the relatively persistent effect of the former and the rapid onset of action of the latter. The efficacy of their combined effect is exploited at intermediate times. When bronchodilators with different mechanisms of action are used at the recommended doses in patients with COPD, combination treatment generally provides more pronounced bronchodilation than does the administration of single drugs.<a onclick="showRef(event, 'ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref73 ref74">(73, 74)</a></div><div class="NLM_p last">In one crossover trial conducted in 863 patients, combination treatment with ipratropium bromide and salbutamol resulted in peak FEV<sub>1</sub> that was 24% higher than that achieved by salbutamol monotherapy and 37% greater than that achieved with ipratropium bromide monotherapy.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> In a 12-week prospective, randomized, double-blind, parallel-group trial conducted in 534 patients with COPD who were assigned to receive either salbutamol alone, ipratropium bromide alone, or salbutamol plus ipratropium, combination treatment resulted in mean peak FEV<sub>1</sub> increase greater than that obtained with either drug alone but did not change the frequency of COPD exacerbations.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> In contrast, a similar study reported that ipratropium bromide plus salbutamol decreased the frequency of COPD exacerbation compared with salbutamol alone but not ipratropium bromide alone.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Because of availability of LAMA such as tiotropium bromide and glycopyrronium bromide which provide 24 h bronchodilation,<a onclick="showRef(event, 'ref3 ref6'); return false;" href="javascript:void(0);" class="ref ref3 ref6">(3, 6)</a> regular use of ipratropium bromide alone for long-term maintenance treatment of stable COPD is not common and not recommended by GOLD guidelines.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> However, pMDIs containing a FDC of ipratropium bromide and salbutamol are commercially available and are the short-acting bronchodilator standard of care for COPD treatment.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Once Daily Long-Acting Muscarinic Antagonists (LAMA)</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> Tiotropium</h4><div class="NLM_p">Tiotropium bromide is about 15-fold more potent [dissociation constant (<i>K</i><sub>D</sub>) = 0.014 nM) than ipratropium bromide (<i>K</i><sub>D</sub> = 0.204) at the human M<sub>3</sub> mAcChR and dissociates more slowly from the M<sub>3</sub> receptor (<i>t</i><sub>1/2</sub> = 34.7 h) than from the M<sub>2</sub> (<i>t</i><sub>1/2</sub> = 3.6 h) and the M<sub>1</sub> receptor (<i>t</i><sub>1/2</sub> = 15 h), resulting in a “kinetic” selectivity.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> This mechanism explains the much more prolonged duration of action of tiotropium bromide, which produces sustained bronchodilation for as long as 24 h with once-daily dosing,<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> as opposed to 6–8 h after each dose of ipratropium bromide.</div><div class="NLM_p">Tiotropium bromide is a LAMA that was initially introduced in a dry powder formulation (delivered in single doses via the Handihaler, one puff once daily, single capsules each containing 18 μg of tiotropium) and, more recently, in a novel, multidose micronebulizer device for delivering drug as a soft mist in single doses of 3.124 μg, equivalent to 2.5 μg of tiotropium, two puffs once daily (Respimat).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Efficacy and safety of tiotropium bromide in patients with COPD have been shown in a systematic review and meta-analysis of nine trials of at least 12 weeks duration including 8002 patients.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Tiotropium bromide has a longer duration of action than ipratropium bromide and enables a more convenient dosing schedule for patients with COPD.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> In a 15-week, multicentre, double blind, double dummy, parallel group study including 288 patients with severe COPD who received either tiotropium bromide once daily or ipratropium bromide four times per day, significantly greater bronchodilation was achieved and significantly less rescue salbutamol was used in the tiotropium bromide group.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Continuous treatment with tiotropium bromide seems to be well tolerated and is associated with fewer acute COPD exacerbations and hospitalizations,<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> decreased dyspnoea,<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> reduction in lung hyperinflation at rest and during exercise,<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> and improved overnight arterial oxygen saturation compared with placebo.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a></div><div class="NLM_p">The lack of an immediate bronchodilator response does not correlate with long-term outcome measures as reported in a large 1-year randomized placebo-controlled trial with tiotropium bromide,<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> in which patients with COPD who were treated with tiotropium bromide had improved pulmonary function and less dyspnoea than patients who received placebo.</div><div class="NLM_p">Understanding Potential Long-Term Impacts of Function with Tiotropium (UPLIFT) study, the largest and longest randomized placebo controlled trial with tiotropium bromide, included 5993 patients with moderate to severe COPD who were followed for up to 4 years.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Patients were allowed to use concomitant respiratory medication, including LABA, ICSs and theophylline, throughout the trial but not SAMA.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> The trial primary end points, which are annual rates of decline in prebronchodilator and postbronchodilator FEV<sub>1</sub>, were not achieved.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> However, sustained improvement in prebronchodilator and postbronchodilator trough FEV<sub>1</sub> (87–103 and 47–65 mL, respectively) and trough forced vital capacity (170–204 and 32–65 mL, respectively) over placebo was observed with tiotropium bromide at each time point (30 days and every 6 months thereafter) throughout the 4 year-trial.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Importantly, whereas treatment with tiotropium bromide did not modify the rate of decline in FEV<sub>1</sub>, it did result in persistent improvement in pulmonary function so that mean prebronchodilator FEV<sub>1</sub> at the end of the 4 years of the study was not inferior to that observed at baseline.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> These beneficial effects on pulmonary function tests were achieved in spite of the fact that more 70% of the patients with COPD were being treated with a LABA and an ICS and 35% used theophylline concomitantly during the trial.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> These results imply that tiotropium bromide provides additional benefits to these commonly used maintenance respiratory pharmacological treatments.</div><div class="NLM_p">A subgroup analysis conducted in the 2739 patients with GOLD stage II (moderate) COPD included in the UPLIFT study showed persistent tiotropium-minus-placebo improvements over the 4-year trial in pre- and postbronchodilator FEV<sub>1</sub> (100–118 and 52–81 mL, respectively; <i>p</i> < 0.0001 at all time points) which were numerically greater than those achieved in those patients with more severe COPD.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> These results provide a strong rationale for treating GOLD stage II COPD patients with tiotropium bromide. The same subgroup analysis reported a modest, but significant, lower rate of decline in the postbronchodilator FEV<sub>1</sub> in the tiotropium bromide group than in the placebo group (43 ± 2 mL vs 49 ± 2 mL, respectively; <i>p</i> = 0.02).<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> A further analysis of the UPLIFT study showed that, compared with placebo, the benefits of tiotropium bromide in terms of pre- and postbronchodilator FEV<sub>1</sub>, COPD exacerbation risk, and quality of life were present irrespective of smoking status.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> However, the effect size varied among current smokers, intermittent smokers, and continuing ex-smokers.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> In another post hoc analysis of the UPLIFT study, a lower risk of mortality was observed in the tiotropium group [hazard ratio (HR), 0.84; 95% confidence interval (CI), 0.73–0.97] at the end of the protocol-defined treatment period (<i>p</i> = 0.034) but not 30 days thereafter (<i>p</i> = 0.086).<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></div><div class="NLM_p">Treatment with tiotropium bromide reduces COPD exacerbation rate as reported in several studies. In a 12-month multicenter trial including more than 1000 COPD patients, tiotropium bromide increased the time to the first exacerbation expressed in months by approximately 100 days, reduced the proportion of patients with at least one COPD exacerbation by 17%, and decreased the number of exacerbations by 35% compared with placebo.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> In the UPLIFT study, compared with placebo (median 12.5 months, 95% CI, 11.5–13.8), treatment with inhaled tiotropium bromide [18 μg once daily through a DPI] for 4 years delayed the time to the first exacerbation (median 16.7, 95% CI, 14.9–17.9) (HR 0.86, 95% CI, 0.81–0.91).<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Tiotropium bromide also caused a significant delay in the time to the first hospitalization for a COPD exacerbation (HR 0.86, 95% CI, 0.78–0.95) and a reduction in the mean number of exacerbations of 14% (<i>p</i> < 0.001).<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> In a study assessing the effect of a 12-month treatment with tiotropium bromide vs placebo on exacerbations and sputum and serum inflammatory markers in 142 patients with COPD, tiotropium bromide was associated with a 52% reduction in the rate of exacerbations per patient per year (1.17 ± 2.25) compared with placebo (2.46 ± 3.82; <i>p</i> = 0.007).<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Treatment with tiotropium bromide also caused a significant delay in the time to the first COPD exacerbation (236 ± 143 days) compared with placebo (157 ± 124 days; <i>p</i> = 0.009).<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> There were no differences in sputum interleukin (IL)-6, IL-8, and myeloperoxydase, or serum IL-6 and C-reactive protein measured as inflammatory markers between the two treatment arms.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> These findings suggest that the decreased exacerbation rate does not seem to be related to a reduction in airway or systemic inflammation as reflected by the inflammatory markers included in this study.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a></div><div class="NLM_p">Data from 13 randomized controlled trials including 6078 subjects showed that treatment with tiotropium bromide reduced COPD-related exacerbations [odds ratio (OR) 0.76, 95% CI, 0.68–0.87] and hospital admissions (OR 0.59, 95% CI, 0.47–0.73) compared with placebo.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> In a randomized, controlled, multicenter, international trial, 7376 patients with moderate to very severe COPD who had experienced at least 1 exacerbation in the previous year were treated with either tiotropium bromide or salmeterol for 12 months.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Tiotropium bromide was more effective than salmeterol in increasing the time to first COPD exacerbation (trial primary outcome measure) (tiotropium, 187 days; salmeterol, 145 days, corresponding to a 17% reduction in risk with tiotropium (HR, 0.83; 95% CI, 0.77–0.90; <i>p</i> < 0.001), in increasing the time to first severe exacerbation, and in reducing the number of moderate or severe exacerbations during the 12-month study period.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> No significant differences in mortality or adverse events were observed between the treatment groups.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Data on pulmonary function were not provided in this study.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a></div><div class="NLM_p">In the INSPIRE study, the relative efficacy of tiotropium bromide [18 μg once daily trough a DPI] vs a LABA/ICS FDC [salmeterol/fluticasone propionate, 50/500 μg twice daily through a DPI (Diskus)] in preventing exacerbations and related outcomes in severe and very severe patients with COPD was compared.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Tiotropium bromide monotherapy was as effective as salmeterol/fluticasone FDC on the exacerbation rate, as the modeled annual exacerbation rate was not significantly different between the salmeterol/fluticasone group and the tiotropium group (1.28 vs 1.32, respectively; <i>p</i> = 0.656).<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> On the other hand, treatment with salmeterol/fluticasone FDC was associated with significantly lower mortality (<i>p</i> = 0.032), but a higher number of pneumonias relative to tiotropium (<i>p</i> = 0.008).<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> These results reinforce data derived from the UPLIFT study in which treatment with tiotropium bromide was not associated with an increased incidence of pneumonia.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></div><div class="NLM_p">Tiotropium bromide improves health-related quality of life as assessed by the St. George’s Respiratory Questionnaire (SGRQ). In a meta-analysis, a higher proportion of patients with COPD exhibiting an improvement of at least 4 units (which is considered clinically significant) has been reported with tiotropium bromide compared with placebo and ipratropium bromide, but not salmeterol.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> A 1-year study including 913 patients with COPD confirmed these results as treatment with tiotropium bromide significantly improved the SGRQ total score compared with placebo (40.9 units vs 43.7 units, respectively; <i>p</i> < 0.01).<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> The difference in the proportion of tiotropium bromide vs placebo patients with COPD who had at least 4-unit improvement in SGRQ total score (53% vs 44%, respectively) approached statistical significance (<i>p</i> = 0.052).<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> In another study, more tiotropium-treated (59.1%) than placebo-treated patients with moderate to severe COPD (48.2%, <i>p</i> = 0.029) achieved a reduction of at least 4 units in the SGRQ total score after 9 months of treatment.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> In the UPLIFT study, the proportion of COPD patients with at least 4 units improvement in the SGRQ total score at 4 years was 45% with tiotropium bromide and 36% with placebo (<i>p</i> < 0.001).<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></div><div class="NLM_p">In a 12-week study evaluating the effect of tiotropium bromide on dyspnoea in a small sample of patients with moderate to severe COPD, tiotropium resulted in a clinically meaningful numeric improvement in transition dyspnoea index (TDI) compared with placebo, but statistical significance was not achieved because of the small sample size.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Treatment with tiotropium bromide also improved exercise tolerance measured by the incremental shuttle walking test (36 ± 14 m increased walking distance compared with placebo; <i>p</i> < 0.05).<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a></div><div class="NLM_p">In patients with stable COPD, tiotropium bromide as well ipratropium bromide seems to provide greater bronchodilation and improvement in dyspnoea than LABA.<a onclick="showRef(event, 'ref98 ref99'); return false;" href="javascript:void(0);" class="ref ref98 ref99">(98, 99)</a> In two 6-month randomized, placebo controlled, double blind, double dummy studies comparing tiotropium bromide, salmeterol, and placebo in 1207 patients with COPD, tiotropium treatment resulted in a significant delay in the time to first exacerbation and fewer exacebations per year than treatment with placebo, but exacerbation rate in tiotropium and salmeterol groups was similar.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> However, the effect of tiotropium on other health outcomes was superior than that of salmeterol.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></div><div class="NLM_p last">Although further studies are required for verifying these results and extending the observations of the above-mentioned trials to all the subgroups of COPD patients, the available evidence provides important information to clinicians regarding the choice of an initial inhaled long-acting bronchodilator for patients with moderate to very severe COPD.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Glycopyrronium Bromide</h4><div class="NLM_p">Glycopyrronium bromide (NVA237) (Seebri) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>B) is a once daily, fast-acting LAMA which is approved in several countries, including the EU, as a maintenance bronchodilator for the symptomatic pharmacological treatment of patients with COPD.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> It is delivered as capsules for inhalation through a single-dose dry powder inhaler (SDDPI) (Breezehaler).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Each capsule contains 63 μg of glycopyrronium bromide, equivalent to 50 μg of glycopyrronium, the active principle, and each delivered dose, which is the amount of drug that leaves the inhaler, contains 55 μg of glycopyrronium bromide, equivalent to 44 μg of glycopyrronium.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The pharmacological profile of glycopyrronium bromide has been recently reviewed.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Glycopyrronium bromide is a competitive mAcChR antagonist which has higher affinity for human M<sub>1</sub> and M<sub>3</sub> receptors than for the human M<sub>2</sub> receptor under in vitro physiological conditions (equilibrium binding affinity constants of 9.60 and 9.59 vs 8.70, respectively).<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Its M<sub>3</sub> selectivity ratio, which is ratio of the affinity constant for the M<sub>3</sub> receptor vs that for the M<sub>2</sub> receptor, is 7.76-fold, which is higher than that reported for tiotropium bromide (2.09-fold).<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> However, selectivity ratios lower than 10 are generally of limited pharmacological significance and may have little, if any, clinical relevance. Dissociation half-life of glycopyrronium bromide from the M<sub>3</sub> (11.4 min; kinetic off rate 0.061 per min) and M<sub>1</sub> receptors (13.9 min; kinetic off rate 0.05 per min) is slower that that from the M<sub>2</sub> receptor (1.07 min; kinetic off rate 0.646).<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> M<sub>3</sub> kinetic selectivity ratio, which is the ratio of the area under the simulated association and dissociation curves for the M<sub>3</sub> receptor vs that for the M<sub>2</sub> receptor, reported for glycopyrronium bromide is 11.41-fold, whereas that reported for tiotropium bromide is 4.30-fold.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a></div><div class="NLM_p">Onset of action of glycopyrronium bromide in vitro is 2.5- to 4.8-fold faster than that of tiotropium.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> The fast bronchodilating action of glycopyrronium bromide was confirmed in a phase II study in which patients with moderate to severe COPD who were treated with glycopyrronium bromide (50 μg) had postdose FEV<sub>1</sub> values from 5 min to 2 h on the first day of treatment significantly higher than those observed in patients who were receiving tiotropium bromide [18 μg through a DPI].<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> However, no between group difference was observed after 7 days of treatment.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> In one in vivo experimental animal study, tiotropium bromide provided more effective inhibition of acetylcholine-induced bronchospasm than aclidinium bromide and glycopyrronium bromide 24 h after administration of each drug at equivalent doses.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Bronchoprotection was 35% with tiotropium bromide, 21% with aclidinium bromide, whereas no bronchoprotection was observed with glycopyrronium bromide at 24 h.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> In another preclinical study, tiotropium bromide caused 70.6% inhibition of acetylcholine-induced bronchospasm 24 after drug administration, whereas the inhibitory effect of glycopyrronium bromide was 29.7%.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div><div class="NLM_p">The clinically significant bronchodilating effect of glycopyrronium bromide and tiotropium bromide has been attributed to their long residency time at the M<sub>3</sub> mAcChR.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> However, recent in vitro experiments performed under more physiological conditions reported much shorter dissociation half-lives for glycopyrronium bromide (11.4 min) and tiotropium bromide (46.2 min)<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> than those previously reported under nonphysiological conditions (at room temperature, in the absence of sodium ions) (glycopyrronium bromide, 173 min; tiotropium bromide, 462 min).<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> These results are in contrast with the hypothesis that the clinically observed 24 h bronchodilating action of LAMA is directly related to the residency time at the receptor, pointing out that in vitro receptor binding kinetics are only one variable in the complex pulmonary pharmacology and cannot reliably predict the duration of effect of inhaled drugs.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> The “rebinding” model, based on restricted diffusion of free drug molecules away from the airway vagal cholinergic neuroeffector junction, which would allow freshly dissociated ligands to “rebind” to the same receptor and/or receptors nearby,<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> might explain how glycopyrronium bromide and tiotropium bromide maintain their 24 h duration of bronchodilating effect, despite their rapid kinetic off rates.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a></div><div class="NLM_p">Phase II studies showed that inhaled glycopyrronium bromide administered via DPI at doses of 100 and 200 μg once daily provides clinically significant 24 h bronchodilation with a rapid onset of action and a favorable safety and tolerability profile.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Phase III clinical trials using a SDDPI showed that glycopyrronium bromide has low systemic absorption resulting in a low potential for systemic side effects, including inhibition of salivary secretion,<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> and confirmed its long duration of action, which makes it suitable for once daily dosing, as well as a rapid onset of bronchodilation.<a onclick="showRef(event, 'ref101 ref104 ref106'); return false;" href="javascript:void(0);" class="ref ref101 ref104 ref106">(101, 104, 106)</a> Effects of glycopyrronium bromide on pulmonary function seem to be similar to those of tiotropium bromide.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> In a randomized, double-blind, placebo-controlled, two-period, crossover, multicenter trial, 33 patients with COPD received glycopyrronium bromide 50 μg once daily followed by placebo or placebo followed by glycopyrronium bromide 50 μg for 14 days.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Treatment with glycopyrronium bromide was well tolerated and resulted in significant and sustained 24 h bronchodilation.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Efficacy and safety of glycopyrronium bromide were also assessed in a randomized, double-blind, placebo-controlled, four-period, incomplete block crossover study, with open-label tiotropium bromide as active comparator, conducted in 83 patients with stable moderate-to-severe COPD.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Patients received glycopyrronium bromide at a dose of 12.5, 25, 50, or 100 μg, placebo, or tiotropium bromide at a dose of 18 μg once daily for 7 days.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> The primary end point was mean trough (23–24 h postdose) FEV<sub>1</sub> on day 7. Mean trough FEV<sub>1</sub> on day 7 and day 1 was significantly higher with all active treatments compared with placebo (<i>p</i> < 0.05).<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Glycopyrronium bromide 50 μg, 100 μg, and tiotropium bromide provided clinically relevant improvements over placebo on day 7 and day 1.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> On day 1, but not day 7, FEV<sub>1</sub> was significantly higher (<i>p</i> < 0.05) with glycopyrronium 50 μg and 100 μg vs tiotropium from 5 min up to 2 and 4 h postdose, respectively.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> All doses of glycopyrronium bromide and tiotropium bromide were well tolerated. These results confirm that glycopyrronium once-daily is effective and well tolerated versus placebo and has a rapid and sustained 24 h bronchodilator effect.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a></div><div class="NLM_p last">In the randomized, controlled, phase III GLOW-1 (glycopyrronium bromide in chronic obstructive pulmonary disease airways clinical study 1) and GLOW-2 studies, including 822 and 1066 patients, respectively, treatment with inhaled glycopyrronium bromide at a dose of 50 μg once daily was associated with a significant improvement in pulmonary function over placebo in patients with moderate to severe COPD as reflected by increased trough FEV<sub>1</sub> at 12 weeks (primary end point).<a onclick="showRef(event, 'ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref107 ref108">(107, 108)</a> This effect was maintained for up to 52 weeks.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Secondary outcome measures including dyspnoea scores, health status, and exacerbation rates were also improved to a greater extent in the inhaled glycopyrronium bromide group than in the placebo group.<a onclick="showRef(event, 'ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref107 ref108">(107, 108)</a> In the randomized, controlled, phase III GLOW3 trial, treatment with inhaled glycopyrronium bromide induced a significantly longer exercise endurance time than placebo after 3 weeks’ treatment in patients with moderate to severe COPD.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> The drug was generally well tolerated over the 26-week (GLOW1) or 52-week (GLOW2) study duration<a onclick="showRef(event, 'ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref107 ref108">(107, 108)</a> and had a tolerability profile that was similar to that of tiotropium bromide.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Serious adverse events were consistent with those expected in patients with moderate to severe COPD.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Twice Daily LAMA</h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Aclidinium Bromide</h4><div class="NLM_p last">A novel series of (3<i>R</i>)-quinuclidinol esters were synthesized and characterized as mAcChR antagonists.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Aclidinium bromide, a potent and selective mAcChR antagonist, interacts rapidly with muscarinic receptors,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and its association rate for the M<sub>3</sub> mAcChR is similar to that of ipratropium bromide and 2.6 times faster than that of tiotropium bromide.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Aclidinium bromide dissociates slightly faster from M<sub>2</sub> and M<sub>3</sub> mAcChR than tiotropium but much more slowly than ipratropium bromide.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Residence half-life of [<sup>3</sup>H]aclidinium at the M<sub>2</sub> mAcChR was shorter than that at the M<sub>3</sub> mAcChR, indicating kinetic selectivity for the M<sub>3</sub> receptor.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> A potent bronchodilatory effect has been observed after inhalation of aclidinium bromide.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Clinical trials have demonstrated that aclidinium bromide provides a sustained bronchodilation similar to that observed with tiotropium bromide and confirmed the positive safety profile of aclidinium bromide, particularly in terms of a very low propensity to cause antimuscarinic adverse events.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Aclidinium bromide, administered in a multidose DPI (Genuair), is rapidly hydrolyzed once absorbed into the plasma,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> which enhances its safety profile.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(111)</a> However, as its duration of action at the doses employed in phase III clinical trials does not provide a clinically significant bronchodilation over 24 h, inhaled aclidinium bromide has been proposed for registration and approved with a twice daily regimen.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The predetermined dose of aclidinium bromide is 400 μg (equivalent to 343 μg of aclidinium), whereas each delivered dose, which is the amount of drug that leaves the inhaler, contains 375 μg of aclidinium bromide, equivalent to 322 μg of aclidinium.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The long-term efficacy and safety of aclidinium bromide were recently investigated in patients with moderate to severe COPD in two double-blind, placebo-controlled 52-week studies.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(112)</a> At 12 and 28 weeks, aclidinium bromide significantly improved trough FEV<sub>1</sub> compared with placebo, an effect which was maintained over the 52-week study period.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(112)</a> A higher number of patients with COPD in the aclidinium group than in the placebo group had a SGRQ improvement (greater than or equal to 4 units) at 52 weeks.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(112)</a> The time to first COPD exacerbation was significantly delayed by aclidinium bromide. Adverse events were minor in both studies, more frequently nasopharyngitis and headache.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(112)</a> In another randomized, placebo-controlled study aclidinium bromide significantly improved exercise tolerance, airflow obstruction, and lung hyperinflation and was safe and well tolerated.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(113)</a></div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Safety and Potential Risks</h3><div class="NLM_p">In spite of the minimal impact of ipratropium bromide and tiotropium bromide on heart rate and blood pressure, possible adverse cardiovascular effects of inhaled antimuscarinic drugs in patients with COPD have raised concern. Conflicting results have been reported in multiple studies and meta-analyses.<a onclick="showRef(event, 'ref86 ref115 ref116 ref117'); return false;" href="javascript:void(0);" class="ref ref86 ref115 ref116 ref117">(86, 114-116)</a></div><div class="NLM_p">The UPLIFT study randomized patients to either tiotropium bromide delivered through a DPI or placebo in addition to other, unrestricted respiratory medications for 4 years.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> In this study, treatment with tiotropium bromide was associated with a significantly lower rate of cardiac adverse events (risk ratio (RR) 0.84; 95% CI, 0.73–0.98)<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> and reduced cardiac mortality (relative risk 0.81; 95% CI, 0.60–1.10 as established by a mortality adjudication committee; relative risk 0.80; 95% CI, 0.76–0.99 as established by site investigator).<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(117)</a> The risk of cardiovascular events was further examined using the clinical trial safety database for tiotropium, which monitored 19545 patients with moderate to severe patients with COPD (including the UPLIFT data).<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(116)</a> Patients were randomly assigned to tiotropium or placebo group in a total of 30 trials.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(116)</a> No increase in all-cause mortality, cardiovascular mortality, or cardiovascular events was observed in the tiotropium group.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(116)</a> Data from two cohorts of patients with COPD, a cohort including patients prescribed tiotropium bromide and a historic cohort including patients seen before the introduction of tiotropium, suggested that treatment with tiotropium was associated with a reduced all-cause mortality risk when combined with ICS plus LABA versus a medication regimen of ICS plus LABA (HR 0.60; 95% CI, 0.45–0.79) but with an increased all-cause mortality risk when tiotropium was combined with other medication regimens, including ipratropium bromide and theophylline (HR, 1.38; 95% CI, 1.06–1.81).<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(118)</a> Nevertheless, data from this observational study must be considered with caution, as they could be confounded by differences in COPD severity and smoking status.</div><div class="NLM_p">In contrast, in a prior meta-analysis of 17 randomized trials (12 tiotropium and 5 ipratropium trials) including nearly 15 000 patients with COPD, but not those enrolled in the UPLIFT trial, treatment with ipratropium bromide or tiotropium for more than 30 days significantly increased the risk of myocardial infarction (RR 1.53; 95% CI, 1.05–2.23) and cardiovascular death (RR 1.80; 95% CI, 1.17–2.77).<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(114)</a> However, the possibility that ipratropium bromide and tiotropium bromide have different effects on cardiovascular events should be considered. The potential effect of ipratropium bromide on cardiovascular events was examined in a cohort study of 82 717 United States veterans with COPD who were followed from 1999 to 2002.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(115)</a> The HR for cardiovascular events among patients with COPD who had 4 or fewer 30-day prescriptions for ipratropium bromide was 1.40 (95% CI, 1.30–1.51), and the HR among those with more than 4 30-day prescriptions for ipratropium bromide was 1.23 (95% CI, 1.13–1.36).<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(115)</a> However, the case cohort design results in several limitations on data interpretation. Further data on the safety of ipratropium bromide are needed to draw definitive conclusions. Randomized trials in which cardiovascular end points are specifically sought and predefined are required. In the meantime, any potential for cardiovascular risk should be balanced against the known benefits of inhaled mAcChR antagonists, which include reduction in frequency of exacerbations and hospitalizations for COPD and improvement in dyspnoea.</div><div class="NLM_p">In a systematic review and mixed treatment comparison meta-analysis of 42 randomized controlled trials including 52 516 patients with COPD, tiotropium bromide soft mist inhaler was associated with increased risk of overall death compared with placebo (OR 1.51; 95% CI, 1.06–2.19), tiotropium DPI (OR 1.65; 95% CI, 1.13–2.43), LABA (OR 1.63; 95% CI, 1.10–2.44), and LABA/ICS (OR 1.90; 95% CI, 1.28–2.86).<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(119)</a> The risk was more pronounced for cardiovascular death, in patients with severe COPD, and at a higher tiotropium soft mist inhaler daily dose.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(119)</a> Treatment with LABA/ICS was associated with the lowest risk of death among all treatments.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(119)</a> No excess risk was observed with tiotropium DPI or LABA.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(119)</a> In a systematic review and meta-analysis of five randomized clinical trials, treatment with tiotropium soft mist inhaler was associated with increased risk of mortality (RR 1.52; 95% CI, 1.06–2.16; <i>p</i> = 0.02). Both 10 μg (RR 2.15; 95% CI, 1.03–4.51; <i>p</i> = 0.04) and 5 μg (RR 1.46; 95% CI, 1.01–2.10; <i>p</i> = 0.04) doses of tiotropium bromide mist inhaler were associated with an increased risk of mortality.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(120)</a> To formally address this safety issue, a randomized, double-blind, parallel-group trial (Tiotropium Safety and Performance in Respimat, TIOSPIR) involving 17 135 patients with COPD was undertaken to evaluate the risk of death of tiotropium soft mist inhaler at a once-daily dose of 2.5 or 5 μg, as compared with tiotropium DPI at a once-daily dose of 18 μg.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(121)</a> During a mean follow-up of 2.3 years, tiotropium soft mist inhaler was noninferior to tiotropium DPI with respect to the risk of death (tiotropium soft mist inhaler at a dose of 5 μg vs tiotropium DPI, HR, 0.96, 95% CI, 0.84–1.09; tiotropium soft mist inhaler at a dose of 2.5 μg vs tiotropium DPI, HR, 1.00, 95% CI, 0.87–1.14).<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(121)</a> Causes of death and incidences of major cardiovascular adverse events were similar in the three groups.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(121)</a> This study shows that tiotropium soft mist inhaler at a dose of 5 or 2.5 μg has a safety profile similar to that of tiotropium DPI at a dose of 18 μg in patients with COPD.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(121)</a> However, considering overall mortality or composite cardiovascular end points might mask differences in cause-specific mortality.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(122)</a> The significant association between the use of tiotropium soft mist inhaler at a dose of 5 μg once daily and fatal myocardial infarction among patients with COPD in the TIOSPIR trial, as reported by a recent post hoc analysis,<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(122)</a> raised further concerns about the cardiac safety of tiotropium soft mist inhaler. However, analysis of nonfatal and fatal myocardial infarction did not yield definitive evidence for an elevated risk among patients in each tiotropium soft mist inhaler group in isolation.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(122)</a> Reasons for apparent increased risk of mortality associated with tiotropium soft mist inhaler as compared with tiotropium DPI are unknown.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(121)</a> Lung deposition of tiotropium delivered through soft mist inhaler is likely higher than that of tiotropium delivered through DPI as shown by the fact that a daily dose of the former (5 μg) is more than 3 times lower than that of the latter (18 μg). The potential increased risk of mortality, particularly cardiovascular,<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(122)</a> with tiotropium soft mist inhaler compared with tiotropium DPI<a onclick="showRef(event, 'ref120 ref121'); return false;" href="javascript:void(0);" class="ref ref120 ref121">(119, 120)</a> might suggest that a daily dose of tiotropium soft mist inhaler of 5 μg once daily might be too high and/or that COPD patients with cardiovascular comorbidities (e.g., ischemic heart disease, arrhythmias) might be more susceptible to tiotropium soft mist inhaler.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(122)</a></div><div class="NLM_p last">Adverse events other than cardiovascular effects are reported in some studies. A pooled clinical trial analysis of tiotropium safety, including 4435 patients who were treated with tiotropium bromide and 3384 patients who received placebo, revealed dry mouth (RR 3.60; 95% CI, 2.56–5.05) as one of the most commonly reported adverse events.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(123)</a> Urinary retention was a rare event (incidence rate of 0.78 per 100-patient years in tiotropium-treated patients), but the RR for this event was 10.93 (95% CI, 1.26–94.8).<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(123)</a> Other known side effects of muscarinic receptor antagonists, including constipation and visual blurring, occurred infrequently.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(123)</a> The type and frequency of adverse events reported in the UPLIFT trial<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> are similar to those reported in the pooled analysis of previous clinical trials.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(123)</a></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Approved β<sub>2</sub>-Adrenoceptor Agonists for COPD: Pharmacological and Clinical Aspects</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28301" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28301" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Short-Acting β<sub>2</sub>-Agonists (SABA)</h3><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Salbutamol</h4><div class="NLM_p last">Salbutamol, the prototype of SABA, has a rapid onset of bronchodilating effect (within 5 min) which generally peaks within 30 min and starts decreasing after 2 h. Duration of action of salbutamol is 3–6 h.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Salbutamol is a partial agonist with a mean <i>E</i><sub>max</sub> of 47% of the maximal effect of isoprenaline at human β<sub>2</sub>-adrenoceptors in vitro.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Twice Daily LABA</h3><div class="NLM_p">LABA alone or in combination with LAMA are effective drugs in patients with stable COPD (see ref <a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">1</a> for individual studies).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Efficacy of LABA has been assessed principally through the impact of these drugs on pulmonary function, although the bronchodilating response in patients with COPD is limited by definition.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> As spirometry is currently recognized as a poor predictor of disability and quality of life, therapeutic efficacy should also be assessed by other variables and outcomes of importance to the patient including symptoms, quality of life, frequency of exacerbations, COPD progression, and mortality.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In most of the randomized clinical trials, LABA monotherapy has been compared with LABA/ICS combination.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">All LABA approved for COPD (salmeterol, formoterol, indacaterol) improve pulmonary function.<a onclick="showRef(event, 'ref1 ref125 ref126 ref127 ref128 ref129 ref130 ref131 ref132'); return false;" href="javascript:void(0);" class="ref ref1 ref125 ref126 ref127 ref128 ref129 ref130 ref131 ref132">(1, 124-131)</a> LABA improve prebronchodilator FEV<sub>1</sub> compared with placebo, with an effect size that ranges from 50 to 90 mL.<a onclick="showRef(event, 'ref130 ref131'); return false;" href="javascript:void(0);" class="ref ref130 ref131">(129, 130)</a></div><div class="NLM_p">In patients with COPD, formoterol and salmeterol improve symptom control as assessed by a reduction in diary card symptom scores and requirement for rescue bronchodilator treatment.<a onclick="showRef(event, 'ref1 ref125 ref130 ref131'); return false;" href="javascript:void(0);" class="ref ref1 ref125 ref130 ref131">(1, 124, 129, 130)</a> However, less consistent results are reported when validated scales of dyspnoea are used.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Studies evaluating the effect of LABA on exercise tolerance are relatively few. However, both formoterol and salmeterol significantly improve exercise tolerance through amelioration of dynamic hyperinflation,<a onclick="showRef(event, 'ref133 ref134'); return false;" href="javascript:void(0);" class="ref ref133 ref134">(132, 133)</a> an exercise-induced air trapping which significantly contributes to exercise limitation caused by intolerable dyspnoea. LABA improve peripheral airway patency and, as a consequence, the rate of lung emptying, thus reducing the functional residual capacity (FRC). Breathing at a lower FRC, in turn, decreases the work of breathing while placing the respiratory muscle in a more favorable geometric arrangement for their pressure generating capacity. The combination of the reduced work of breathing with improved respiratory muscle performance results in increase of exercise tolerance and reduction of dyspnoea. LABA-induced bronchodilation, independent of the FEV<sub>1</sub> changes, is associated with a significant reduction in FRC resulting in increased inspiratory capacity (IC).<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(133)</a> IC is inversely correlated with dyspnoea as assessed by the visual analog scale or the Borg scale and positively correlated with exercise capacity.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(134)</a> Therefore, the improvement in the exercise capacity in patients with COPD does not seem to depend principally on changes in FEV<sub>1</sub> but on improvement in IC as a consequence of decreased FRC.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(134)</a></div><div class="NLM_p">As it may reflect COPD severity more accurately than FEV<sub>1</sub>, general health status is an important summary end point. Treatment with inhaled formoterol<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(129)</a> or salmeterol<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(130)</a> has been reported to significantly improve health-related quality of life, as assessed by the SGRQ, compared with placebo.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> On the contrary, other studies have not shown a significant effect of formoterol and salmeterol on quality of life.<a onclick="showRef(event, 'ref1 ref136'); return false;" href="javascript:void(0);" class="ref ref1 ref136">(1, 135)</a></div><div class="NLM_p">In a meta-analysis comprising 14 randomized clinical trials including 6453 patients with COPD, salmeterol or formoterol significantly reduced exacerbations requiring study withdrawal or hospitalization compared with placebo [relative risk 0.78; 95% CI, 0.67–0.91; number needed to treat, which is the average number of patients who need to be treated to prevent one additional exacerbation: 30 (95% CI, 20–52)].<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(136)</a> Combination with ICS was not associated with a further risk reduction.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(136)</a> In another meta-analysis including 23 randomized controlled trials of twice-daily LABA (16 trials comparing salmeterol vs placebo, 4 formoterol vs placebo, 3 salmeterol vs tiotropium, and 1 formoterol vs tiotropium), treatment with a LABA was associated with a significant reduction in the risk of a COPD exacerbation compared with placebo (odds ratio [OR] 0.84; 95% CI, 0.76–0.92), whereas tiotropium bromide significantly reduced the exacerbation risk compared with a LABA (OR 0.82; 95% CI, 0.72–0.93).<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(137)</a> There was no difference between LABA/ICS combination and LABA monotherapy in reducing the risk of a COPD exacerbation (OR 0.90; 95% CI, 0.80–1.01).<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(137)</a></div><div class="NLM_p">In a systematic review and meta-analysis of 27 trials including 30 495 patients with COPD, treatment with ICS/LABA combination was associated with reduced total mortality compared with placebo (RR, 0.80; <i>p</i> = 0.005).<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(138)</a> Neither tiotropium (RR, 1.08; <i>p</i> = 0.61) nor LABA monotherapy (RR, 0.90; <i>p</i> = 0.21) was associated with reduced mortality.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(138)</a> On the basis of these results, the authors conclude that, unlike LABA and tiotropium monotherapy, ICS/LABA combination seems to be effective in reducing mortality by approximately 20% and prolong survival in patients with COPD.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(138)</a> However, definitive conclusions on the effect of ICS/LABA combination on mortality in patients with COPD cannot be drawn because of high heterogeneity of drugs and doses used in the various trials, lack of assessment of COPD-related mortality, and lack of access to individual data. In a Cochrane systematic review, which examined 10 randomized, double-blind controlled trials including 10 680 patients with severe COPD, treatment with ICS/LABA combination or LABA monotherapy was reported to have similar effects on mortality for COPD (OR 0.92; 95% CI, 0.76–1.11) with a moderate quality evidence.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(139)</a></div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Salmeterol</h4><div class="NLM_p">Treatment with inhaled salmeterol at a dose of 50 μg twice daily significantly increases FEV<sub>1</sub> as compared to baseline values but limited to an average effect size of 51 mL.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(140)</a> In the Toward a Revolution in COPD Health (TORCH) study, the largest trial with salmeterol, a randomized, double blind, parallel group, placebo controlled study, 6112 patients, mostly with severe COPD (mean FEV<sub>1</sub> of 44% predicted), were assigned to one of four groups: salmeterol alone [50 μg twice daily delivered through a DPI], fluticasone alone [500 μg twice daily delivered through a DPI], salmeterol/fluticasone FDC [50/500 μg twice daily delivered through a DPI], or placebo.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(141)</a> Study duration was 3 years.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(141)</a> Salmeterol and, to a greater extent, salmeterol/fluticasone FDC significantly reduced the decline in pulmonary function, reduced COPD exacerbation rate, and improved health-related quality of life compared with placebo.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(141)</a> In a post hoc analysis of TORCH data, FEV<sub>1</sub> declined at a similar rate in all active treatment groups (salmeterol/fluticasone, 39 mL/year; salmeterol, 42 mL/year; fluticasone, 42 mL/year) but at a significantly slower rate than placebo (55 mL/year).<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(142)</a> Either salmeterol or fluticasone was effective, but there was no additional effect of the salmeterol/fluticasone FDC over salmeterol alone.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(142)</a></div><div class="NLM_p">In the INSPIRE trial, salmeterol/fluticasone and tiotropium bromide had a similar effect on the mean number of COPD exacerbations/year (1.28 and 1.32, respectively).<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> In the TORCH study, salmeterol, fluticasone, and salmeterol/fluticasone FDC were all superior to placebo in reducing the rate of moderate and severe COPD exacerbations.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(141)</a> However, the mean number of such exacerbations was small (0.85–0.97 per patient per year in the active treatment groups and 1.13 per patient per year in the placebo group).<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(141)</a> A Cochrane meta-analysis including trials of duration ranging from 12 to 52 weeks showed that COPD exacerbation rate was significantly reduced with salmeterol (50 μg twice daily) compared with placebo.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(140)</a></div><div class="NLM_p">The TORCH study failed to demonstrate reduction in all cause mortality, the primary study end-point, following treatment with salmeterol/fluticasone FDC for 3 years (HR = 0.825, 95% CI, 0.681–1.002; <i>p</i> = 0.052).<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(141)</a> In the same study, monotherapy with either salmeterol or fluticasone had no effect on all cause mortality in patients with COPD.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(141)</a></div><div class="NLM_p">In the INSPIRE study, salmeterol/fluticasone FDC provided a 52% reduction in risk of mortality vs tiotropium at all time points during treatment (HR = 0.476; 95% CI, 0.267–0.848; <i>p</i> = 0.012).<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a></div><div class="NLM_p last">In a meta-analysis, a significant reduction in mortality with salmeterol/fluticasone FDC vs placebo (OR, 0.79; 95% CI, 0.65–0.98),<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(143)</a> but not vs LABA alone, was reported.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(139)</a></div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Formoterol</h4><div class="NLM_p">In a 6-month double blind placebo-controlled study, formoterol improved FEV<sub>1</sub> compared with placebo, showing that this drug is an effective maintenance treatment for patients with COPD.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(144)</a> In a 12-month randomized, double blind, placebo-controlled trial, treatment with formoterol/budesonide FDC (two puffs of 4.5/160 μg twice daily), budesonide alone (two puffs of 200 μg twice daily) and formoterol alone (two puffs of 4.5 μg twice daily) increased FEV<sub>1</sub> compared with placebo in patients with moderate to severe COPD.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(145)</a> In terms of changes in postbronchodilator FEV<sub>1</sub>, efficacy of formoterol/budesonide FDC (15% increase compared with placebo, <i>p</i> < 0.001) and formoterol alone (14% increase compared with placebo, <i>p</i> < 0.001) was similar.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(145)</a> In contrast, formoterol/budesonide FDC was more effective than individual treatments (formoterol or budesonide alone) in another randomized, multicenter study in which patients with COPD were enrolled on the basis of FEV<sub>1</sub> ≤ 50% of predicted values, smoking history of ≥10 pack years and ≥1 COPD exacerbation in the previous 2–12 months.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(129)</a></div><div class="NLM_p last">In two studies, formoterol monotherapy was not associated with reduced frequency or delayed time to the first severe COPD exacerbation.<a onclick="showRef(event, 'ref130 ref146'); return false;" href="javascript:void(0);" class="ref ref130 ref146">(129, 145)</a> However, combined pharmacological treatment with formoterol and budesonide reduced COPD exacerbation rate compared with formoterol monotherapy and placebo.<a onclick="showRef(event, 'ref130 ref140 ref144 ref146'); return false;" href="javascript:void(0);" class="ref ref130 ref140 ref144 ref146">(129, 139, 143, 145)</a></div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Once Daily LABA</h3><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Indacaterol</h4><div class="NLM_p">Indacaterol (Onbrez), a novel, inhaled, once-daily LABA approved in the EU at doses of 150 or 300 μg and in the USA at a dose of 75 μg for the maintenance treatment of COPD,<a onclick="showRef(event, 'ref8 ref147'); return false;" href="javascript:void(0);" class="ref ref8 ref147">(8, 146)</a> is administered once daily by means of a SDDPI.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Indacaterol is a partial agonist with higher intrinsic activity than salmeterol and salbutamol.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(146)</a> Reported mean <i>E</i><sub>max</sub> for indacaterol at human β<sub>2</sub>-adrenoceptors in vitro is 73% of the maximal effect of isoprenaline, whereas mean <i>E</i><sub>max</sub> values for formoterol, salmeterol, and salbutamol are 90%, 38%, and 47%, respectively.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(146)</a> Like formoterol, indacaterol is a very weak agonist at the β<sub>1</sub>-adrenoceptor (mean <i>E</i><sub>max</sub> of 16%).<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(146)</a> Indacaterol has β<sub>2</sub>-adrenoceptor agonist activity which causes airway smooth muscle relaxation and bronchodilation, a long duration of action, and a fast onset of action in both in vitro and in vivo animal models.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The faster onset of action and longer duration of action of indacaterol compared with some other β<sub>2</sub>-adrenoceptor agonists may be due to its intrinsic efficacy and lipid membrane interactions.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p">In randomized controlled trials including more than 400 patients, indacaterol at a dose of 150 or 300 μg once-daily improved pulmonary function compared with placebo after 12 weeks of treatment.<a onclick="showRef(event, 'ref126 ref127 ref128 ref129'); return false;" href="javascript:void(0);" class="ref ref126 ref127 ref128 ref129">(125-128)</a> In the INHANCE trial, indacaterol improved trough FEV<sub>1</sub> values compared with placebo more effectively than open label tiotropium.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(127)</a> Moreover, indacaterol had a greater effect on trough FEV<sub>1</sub> values at 12 weeks than formoterol or salmeterol.<a onclick="showRef(event, 'ref126 ref129'); return false;" href="javascript:void(0);" class="ref ref126 ref129">(125, 128)</a> Inhaled indacaterol at a dose of 150 μg<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(127)</a> and 300 μg<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(125)</a> once daily significantly reduces exacerbations and improves COPD symptom control and health-related quality of life assessed using the SGRQ compared with placebo.<a onclick="showRef(event, 'ref126 ref128 ref129'); return false;" href="javascript:void(0);" class="ref ref126 ref128 ref129">(125, 127, 128)</a></div><div class="NLM_p">In a randomized, double blind, placebo-controlled study (INLIGHT-2) comparing once-daily indacaterol (150 μg) and twice-daily salmeterol (50 μg) in 838 patients with moderate-to-severe COPD, indacaterol improved FEV<sub>1</sub> compared with placebo (<i>p</i> < 0.001) and salmeterol (<i>p</i> < 0.001) after 6 months of treatment.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(128)</a> Both indacaterol and salmeterol improved health status, as assessed by the SGRQ, and dyspnoea compared with placebo, with differences between them favoring indacaterol.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(128)</a></div><div class="NLM_p">In patients with COPD, indacaterol improves exercise tolerance, dyspnoea, and dynamic lung hyperinflation.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p">In studies up to 1 year, indacaterol was well tolerated showing a safety profile, including cardiovascular safety, similar to placebo, and comparable to tiotropium bromide, salmerterol, and formoterol.<a onclick="showRef(event, 'ref126 ref128 ref129'); return false;" href="javascript:void(0);" class="ref ref126 ref128 ref129">(125, 127, 128)</a> Among COPD patients who received indacaterol at a dose of 150 and 300 μg in the INVOLVE and INHANCE studies, the incidence of adverse events that are typically associated with β<sub>2</sub>-adrenoceptor activation, such as tremor (0.2–0.5%) and tachycardia (0.2–1.2%), was low (where reported).<a onclick="showRef(event, 'ref126 ref128'); return false;" href="javascript:void(0);" class="ref ref126 ref128">(125, 127)</a></div><div class="NLM_p last">In summary, clinical studies suggest that indacaterol provides a rapid (within 5 min) and long-lasting (at least 24 h) bronchodilation in patients with COPD. Exposure to a maximum of 28 days’ treatment with different doses of indacaterol confirmed that this drug is suitable for once daily dosing, with a favorable overall safety profile, and maintained efficacy without evidence of tolerance development.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Open-label studies indicate that indacaterol may be at least as effective as tiotropium bromide in providing long-lasting bronchodilation.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Safety</h3><div class="NLM_p">The most common class effects of LABA include tremor and tachycardia that may limit the maximal tolerated dose, particularly in some older patients.<a onclick="showRef(event, 'ref1 ref14'); return false;" href="javascript:void(0);" class="ref ref1 ref14">(1, 14)</a> β<sub>1</sub>- and β<sub>2</sub>-adrenoceptors are both expressed in the heart, but β<sub>1</sub>-adrenoceptor density is 3-fold higher than that of β<sub>2</sub>-adrenoceptors. Heart β<sub>2</sub>-adrenoceptors activation could explain, at least partially, cardiac adverse effects induced by LABA.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Cardiovascular side effects are more likely in susceptible patients. There is some risk associated with β<sub>2</sub>-agonist treatment in patients with COPD and concomitant cardiac diseases, particularly chronic heart failure,<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(147)</a> a frequent comorbidity in these patients. Nevertheless, salmeterol and formoterol are considered generally safe<a onclick="showRef(event, 'ref1 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref4">(1, 4)</a> and well tolerated over periods of at least 1 year.<a onclick="showRef(event, 'ref130 ref131 ref142 ref146'); return false;" href="javascript:void(0);" class="ref ref130 ref131 ref142 ref146">(129, 130, 141, 145)</a></div><div class="NLM_p">Proarrhythmic effects of LABA in patients with COPD were evaluated in two double blind randomized clinical trials in which patients were assigned to one of the following five treatment groups for 12 weeks: arformoterol 15 μg twice daily; arformoterol 25 μg twice daily; arformoterol 50 μg twice daily; salmeterol 42 μg twice daily; placebo.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(148)</a> The percentage of patients with treatment emergent atrial tachycardia, which is not present at baseline, ranged from 27% to 32% and was similar in the LABA groups (2–5%) and in the placebo group.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(148)</a> More serious arrhythmias were not frequent, and their frequency was not increase with inhaled LABA treatment. The safety profile of the two long-acting bronchodiltators used in these studies, arformoterol and salmeterol, was similar.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(148)</a></div><div class="NLM_p last">In contrast to asthma,<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(149)</a> LABA monotherapy in patients with COPD is not associated with increased risk of mortality for respiratory causes. In a meta-analysis including 27 studies, no significant difference between LABA and placebo in terms of risk of respiratory death was observed (relative risk 1.09, 95% CI, 0.45–2.64).<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(136)</a> These results were confirmed in a more recent meta-analysis including 23 trials which reported a similar risk of mortality comparing a LABA with placebo (OR 0.95, 95% CI, 0.71–1.27).<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(137)</a></div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Combination Therapy</h3><div class="NLM_p">Pharmacological therapy combining classes of bronchodilators with different mechanism(s) of action improves efficacy and reduces the risk of adverse events compared with increasing the dose of a single bronchodilator.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">Combination treatment with tiotropium bromide and formoterol is more effective than monotherapy in inducing bronchodilation and improvement of symptoms in patients with COPD.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Compared with monotherapy, combination of tiotropium bromide (18 μg once daily) and formoterol (10 μg twice daily) was superior to monotherapy for FEV<sub>1</sub> 2 h postdose at 24 weeks (primary outcome measure) (<i>p</i> = 0.044 vs formoterol), FEV<sub>1</sub> 5 min after the first dose (<i>p</i> < 0.001) and at 12 weeks (<i>p</i> < 0.05 vs tiotropium) and mean morning peak expiratory flow rate over the first 6 weeks of treatment (<i>p</i> < 0.001 for both).<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(150)</a> The addition of nebulized arformoterol to tiotropium bromide was more effective than tiotropium alone in improving pulmonary function and dyspnoea index.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(151)</a> A 6-week randomized clinical trial comparing tiotropium plus formoterol vs salmeterol plus fluticasone showed that the double-bronchodilator combination resulted in greater bronchodilation over the course of 12 h than salmeterol plus fluticasone.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(152)</a> However, the short treatment period precludes definitive conclusions about the relative benefits of the two different combinations, including their effects on patient-reported outcomes.</div><div class="NLM_p">In a randomized double-blind placebo-controlled trial, 449 patients with moderate to severe COPD were assigned to one of the following treatment group: tiotropium plus placebo, tiotropium plus salmeterol, or tiotropium plus fluticasone/salmeterol FDC.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(153)</a> The duration of pharmacological treatment was 1 year. The percentage of patients who experienced a COPD exacerbation that required treatment with systemic steroids or antibiotics, the primary study end point, was similar in the tiotropium plus placebo group (62.8%), in the tiotropium plus salmeterol group (64.8%), and in the tiotropium plus fluticasone/salmeterol FDC group (60.0%).<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(153)</a> Regarding secondary end points, treatment with tiotropium plus fluticasone/salmeterol FDC was more effective than tiotropium plus placebo in improving pulmonary function (<i>p</i> = 0.049) and disease-specific quality of life (<i>p</i> = 0.01) and reducing the number of hospitalizations for COPD exacerbation and all-cause hospitalizations.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(153)</a> In contrast, treatment with tiotropium plus salmeterol and tiotropium plus placebo had a similar effect on lung function or hospitalization rates in patients with COPD.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(153)</a></div><div class="NLM_p">In small-scale, double-blind, double-dummy, 2-week crossover study comparing combination treatment with salmeterol/fluticasone FDC plus tiotropium bromide (triple therapy) with its two major individual component (salmeterol/fluticasone FDC and tiotropium) in symptomatic patients with moderate to severe COPD, triple therapy was more effective than salmeterol/fluticasone FDC alone or tiotropium alone in improving lung function and dyspnoea score and reducing rescue medication.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(154)</a></div><div class="NLM_p">In a retrospective study including two cohorts of patients with COPD, one treated with a combination of inhaled tiotropium plus LABA plus ICS, the other, a historic, matched COPD population, treated with an inhaled LABA plus ICS, triple therapy was associated with a reduced risk of mortality, COPD exacerbations, and hospitalizations, whereas tiotropium plus other medications was not associated with these effects.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(118)</a></div><div class="NLM_p">A 12-week randomized clinical trial including 660 patients with moderate to severe COPD showed that triple inhaler therapy consisting of budesonide/formoterol FDC at a dose of 320/9 μg twice daily plus tiotropium bromide at a dose of 18 μg once daily (<i>n</i> = 329) was more effective than inhaled tiotropium alone (<i>n</i> = 331) in improving prebronchodilator FEV<sub>1</sub> (primary outcome), postbronchodilator FEV<sub>1</sub>, and morning symptoms, and reducing the number of severe exacerbations.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(155)</a></div><div class="NLM_p">The efficacy of the triple inhaler therapy is also supported by data obtained in the UPLIFT trial.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> In this study, patients were randomized to receive usual standard care for COPD either with or without tiotropium bromide.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> In those two-thirds of the patients who were on a LABA/ICS combination as their usual treatment, the addition of tiotropium significantly reduced COPD exacerbation rate and improved pulmonary function and health-related quality of life.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></div><div class="NLM_p last">Taken together, this evidence supports an additional benefit of combining tiotropium bromide with either a LABA (double inhaler therapy) or a LABA/ICS combination (triple inhaler therapy) which seems to be particularly useful in patients with severe COPD. Nevertheless, the role of ICS in the treatment of COPD is not clearly defined.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Pharmacological response to these drugs is likely dependent on the COPD phenotype. To formally address this issue, future prospective randomized controlled trials should focus on phenotypes of patients with COPD more likely to respond to ICS [e.g., patients with ACOS or frequent exacerbators].</div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">New Bronchodilators and Pharmacological Strategies for COPD</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12832" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12832" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> New LAMA</h3><div class="NLM_p">In patients with stable COPD in whom regular treatment with a single bronchodilator is not sufficient for disease control, the trend is moving toward combining medications in double inhaler therapy (LAMA/LABA) to achieve “maximal” bronchodilation or, limited to responders, triple inhaler therapy (LAMA/LABA/ICS) which, in addition to that, provides the potential benefits of ICS anti-inflammatory effects. In patients with COPD who require a single bronchodilator, new LAMA will have to face a tough competion with tiotropium which is well tolerated and considered the gold standard.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> As tiotropium bromide is going to be available as a generic, pharmacoeconomic considerations could also favor this drug among the various LAMA. New LAMA will only likely to be competitive if they are developed as FDC. However, apart from their development in FDC, glycopyrronium bromide<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>B) and aclidinium bromide<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A), which are both well tolerated, as well as umeclidinium bromide<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>C) have been approved for COPD as single bronchodilators in various countries. Several novel M<sub>3</sub> mAcChR antagonists are in various stages of development for COPD treatment.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div id="sec6_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Umeclidinium</h4><div class="NLM_p">Umeclidinium (Incruse) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>C), a potent new inhaled once-daily LAMA, has been approved for pharmacological maintenance treatment of stable COPD in several countries including Europe, USA, Australia, and Canada.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> It is delivered as powder (contained in blisters) for oral inhalation through a DPI (Ellipta).<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Each blister contains 74.5 μg of umeclidinium bromide, equivalent to 62.5 μg of umeclidinium. Under standardized in vitro conditions, this device delivers 55 μg of umeclidinium per dose when tested at a flow rate of 60 L/min for 4 s. Umeclidinium affinity of the human M<sub>1</sub>–M<sub>5</sub> mAcChR ranges from 0.05 to 0.16 nM.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(156)</a> Dissociation of umeclidinium bromide from the M<sub>3</sub> receptor in vitro is slower than that for the M<sub>2</sub> receptor [half-life (<i>t</i><sub>1/2</sub>) values: 82 and 9 min, respectively].<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(156)</a> Umeclidinium bromide is a potent mAcChR antagonist with slow functional reversibility at the human M<sub>3</sub> receptor and long duration of action in animal models, a pharmacological profile which translates into a 24 h duration of bronchidilation in vivo.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(156)</a> In a 14-day dose ranging efficacy study in patients with COPD, inhaled umeclidinium bromide provided clinically significant and persistent improvements in pulmonary function over 24 h with similar efficacy to twice-daily dosing.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(157)</a> Similar results were obtained in a 28-day randomized, double-blind, placebo-controlled, parallel group study, including 285 patients with COPD, in which three once-daily doses of umeclinidium (125, 250, and 500 μg) were tested.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(158)</a> All drug doses significantly increased morning trough FEV<sub>1</sub> on day 29 (primary end-point) over placebo.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(158)</a> Effect size ranged from 150 to 168 mL with a clinically significant bronchodilating effect lasting over 24 h.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(158)</a> Umeclidinium bromide was well tolerated with no apparent treatment-related changes in vital signs.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(158)</a></div><div class="NLM_p">Two recent trials provided initial assessment of safety, tolerability, bronchodilatory effect, and pharmacokinetics following single and repeat doses of inhaled umeclidinium in patients with COPD.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(159)</a> In the single-dose trial (NCT00515502), a randomized, double-blind, placebo-controlled, double-dummy, dose-ascending, crossover study, 24 patients with COPD were randomized to receive four of the following five treatments: umeclidinium bromide (250, 500, and 1000 μg), tiotropium bromide 18 μg (as a positive control), or placebo. All active treatments significantly improved lung function over placebo, as reflected by increased specific airway conductance and FEV<sub>1</sub> for up to 24 h.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(159)</a> The repeat dose study (NCT700732472) assessing safety, tolerability, and pharmacokinetics of inhaled umeclidinium at a dose of 250 or 1000 μg administered once-daily for 7 days in 31 patients with COPD showed that most adverse events were mild-to-moderate and transient.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(159)</a> No clinically significant effect on heart rate, QT interval, blood pressure, and laboratory assessments was reported.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(159)</a> After single and repeat doses, maximum observed plasma umeclidinium concentration (<i>C</i><sub>max</sub>) was reached in 5–15 min and 1.5- to 1.9-fold accumulation was observed after repeat-dosing.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(159)</a></div><div class="NLM_p last">Although relatively limited, this evidence suggests that umeclidinium bromide can be a well-tolerated and effective LAMA bronchodilator which is suitable for once-daily pharmacological maintenance treatment of COPD. However, larger clinical studies are required for assessing its efficacy and tolerability in patients with COPD. Umeclidinium bromide<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>C) has been approved in various countries for maintenance treatment of COPD both as a single bronchodilator and in a FDC with vilanterol.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div></div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> New LABA</h3><div id="sec6_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Vilanterol</h4><div class="NLM_p">Vilanterol (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>A) is a novel, potent, and selective β<sub>2</sub>-adrenoceptor agonist with 24 h activity. It displays subnanomolar affinity for β<sub>2</sub>-adrenergic receptors similar to that of salmeterol, but higher affinity than olodaterol, formoterol, or indacaterol.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> In cAMP functional activity studies, selectivity of vilanterol for β<sub>2</sub>-adrenoreceptors was about 1000-fold higher than that for β<sub>1</sub>- or β<sub>3</sub>-adrenoreceptors, with a selectivity profile that was significantly superior to that of formoterol, indacaterol, and salbutamol, but not to that of salmeterol.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> On the basis of in vitro studies, vilanterol intrinsic efficacy was similar to that of indacaterol, but significantly greater than that of salmeterol and lower than that of formoterol and isoprenaline.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> In isolated human small airways, vilanterol had a faster onset of action than salmeterol (dissociation half-life of 3.1 min vs 8.3 min, respectively; <i>p</i> < 0.0001) and longer duration of action (only vilanterol exhibited significantly bronchodilation at 22 h; <i>p</i> < 0.01).<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Dissociation half-life (<i>t</i><sub>1/2</sub>) was calculated from dissociation rate (<i>k</i><sub>off</sub>) using the equation dissociation <i>t</i><sub>1/2</sub> = 0.693/<i>k</i><sub>off</sub>.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Pharmacological profile of vilanterol is consistent with its once-daily dosing in the treatment of asthma and COPD.</div><div class="NLM_p last">In COPD, vilanterol trifenatate has been approved in FDC with umeclidinium (double inhaler therapy) and is being developed in FDC with umeclidinium bromide and fluticasone furoate (triple inhaler therapy).<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div></div><div id="sec6_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Olodaterol</h4><div class="NLM_p">Olodaterol (Striverdi) (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>B) received its first global approval for the once-daily maintenance treatment of COPD in Canada (Health Canada) in 2013 and was then approved in Russia.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Submissions for regulatory approval have also been made in the USA, the EU, and elsewhere.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><div class="NLM_p">Preclinical studies suggest potential for once-daily dosing of olodaterol in humans, along with rapid onset of action and a favorable safety profile.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(160)</a> Like formoterol, olodaterol reduces in vitro profibrotic cellular activity in human lung fibroblasts,<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(161)</a> but causes less in vitro desensitization than formoterol after repeated exposure.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><div class="NLM_p">Phase III studies are based on doses of 5 and 10 μg once daily. However, only the 5 μg dose, administered as two 2.5 μg puffs through the soft mist inhaler, was approved, as the 10 μg dose was not more effective in phase III or phase II trials likely because the bronchodilating effect of olodaterol reaches a plateau at 5 μg once daily.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><div class="NLM_p">Olodaterol is a fast-acting LABA as shown by improved lung function 5 min after the first dose in patients with COPD.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Single doses of olodaterol improved FEV<sub>1</sub> for 24 h in patients with COPD, making this bronchodilator suitable for once-daily administration.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> This long-lasting bronchodilator effect is likely due to a dissociation half-life of 17.8 h of the stable drug/receptor complex.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(162)</a></div><div class="NLM_p">In four pivotal, 48-week, phase III trials in patients with moderate to very severe COPD (trials 1222.11–14), olodaterol at a dose of 5 μg once daily on top of the usual maintenance treatment improved lung function and the secondary end point of the SGRQ score, which assesses symptoms, activity and impact, compared with placebo.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><div class="NLM_p">From the safety standpoint, like other LABA, olodaterol prolongs the QT interval in a dose-dependent manner.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> However, in healthy subjects at the highest olodeterol therapeutic dose (10 μg daily), increase in QT interval was below 10 ms, the threshold of concern.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> In a pooled analysis, the incidence of any adverse events (69–71%), serious adverse events (15–16.4%), fatal adverse events (1.5–2.2%), and treatment-related cardiac adverse events (1.4–1.7%) seems to be similar to formoterol and placebo.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> The most common serious adverse events associated with olodaterol treatment are COPD exacerbation (4.7%) and pneumonia (1.6%) which are not different from placebo (6% and 1.5%, respectively).<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><div class="NLM_p last">On the basis of the information available at <a href="http://www.clinicaltrials.gov" class="extLink">http://www.clinicaltrials.gov</a>, all phase II and III trials of olodaterol in patients with COPD have been completed.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div></div><div id="sec6_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Abediterol</h4><div class="NLM_p last">Abediterol (LAS100977)<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(163)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>C) has a preclinical profile which is suitable for once-daily dosing in humans, a fast onset of action, and a favorable cardiovascular safety profile.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(163)</a> Abediterol is a full agonist with a subnanomolar affinity for the human β<sub>2</sub>-adrenoceptor and a duration of action up to 48 h which is similar to that of indacaterol.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(163)</a> In dogs, abediterol has a greater safety margin (defined as the ratio of dose increasing heart rate by 5% and dose inhibiting bronchospasm by 50%) (5.6) than indacaterol (0.3), formoterol (2.2), and salmeterol (3.3).<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(163)</a> The first-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of abediterol at once daily doses of 5, 10, 25, or 50 μg shows a potent, rapid, and sustained bronchodilatory effect of this drug in healthy male subjects.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(164)</a> At the time of writing, September 2014, lower doses of abediterol are under investigation in patients with asthma and in patients with COPD.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(164)</a> In a phase IIa study, abediterol at single doses of 2.5, 5, and 10 μg was superior to indacaterol at a dose of 150 μg in improving trough FEV<sub>1</sub> over baseline values. Phase IIb studies with a once-daily FDC of abediterol and ICS in patients with asthma and COPD are ongoing [information available at: <a href="http://www.epgonline.org/news/2012/Jun/Abediterol-Almirall-Forest-superior-to.cfm" class="extLink">http://www.epgonline.org/news/2012/Jun/Abediterol-Almirall-Forest-superior-to.cfm</a>].</div></div><div id="sec6_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Carmoterol</h4><div class="NLM_p last">Carmoterol (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>E) is a non-catechol β<sub>2</sub>-adrenoceptor agonist with a <i>p</i>-methoxyphenyl group on the amine side chain and an 8-hydroxyl group on the carbostyril aromatic ring.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(165)</a> Most of the pharmacological information on carmoterol has been published in abstract form (see ref <a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">4</a> for individual studies). Compared with other β<sub>1</sub>- and β<sub>2</sub>-adrenoceptor agonists, carmoterol has a high selectivity and affinity for the β<sub>2</sub>-adrenoceptor.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Carmoterol has a fast onset and long duration of action (30 h) in vitro and a long-lasting bronchodilating effect in patients with COPD.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Development of pharmacological tolerance was not observed over 2 weeks of treatment.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In a phase II study in patients with COPD, treatment with carmoterol at both doses of 2 and 4 μg once daily resulted in significantly higher bronchodilation over 24 h compared with placebo and similar to that obtained with salmeterol at a dose of 50 μg twice daily.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Preliminary data in patients with COPD suggest that carmoterol is well tolerated and has a good safety profile.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div></div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Dual Bronchodilator Therapy for COPD</h3><div id="sec6_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> LAMA/LABA Fixed Dose Combinations</h4><div class="NLM_p">When dual bronchodilation is indicated, new LAMA/LABA FDCs provide the convenience of two bronchodilators in a single inhaler and, at the same time, a simple, once-daily dosing regimen that may improve compliance with pharmacological treatment. Combining different mechanisms of actions, LAMA/LABA FDCs at full doses provide additive effects, thus increasing efficacy (maximal broncodilatation) as compared with monotherapy. On the other hand, reducing the dose of individual components with consequent reduced risk for side effects can improve drug safety and tolerability profiles while maintaining therapeutic efficacy. Therefore, LAMA/LABA FDCs are a valuable pharmacological strategy in the treatment of COPD.</div><div class="NLM_p last">Three LAMA/LABA FDCs including indacaterol/glycopyrronium bromide, umeclidinium bromide/vilanterol, and olodaterol/tiotropium bromide have been approved or are under approval in various countries.</div></div><div id="sec6_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Indacaterol/Glycopyrronium Bromide</h4><div class="NLM_p">Indacaterol/glycopyrronium bromide (QVA149)<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(166)</a> (Ultibro), a once daily FDC of indacaterol (inhalation powder hard capsule containing 143 μg of indacaterol maleate equivalent to 110 μg of indacaterol) and glycopyrronium bromide (inhalation powder hard capsule containing 63 μg of glycopyrronium bromide equivalent to 50 μg of glycopyrronium) in a single DPI, was approved in the EU and Japan in 2013 as a maintenance bronchodilator treatment of COPD.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(166)</a> Each delivered dose contains 110 μg of indacaterol maleate equivalent to 85 μg of indacaterol and 54 μg of glycopyrronium bromide equivalent to 43 μg of glycopyrronium.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(166)</a></div><div class="NLM_p">Efficacy and safety/tolerability of indacaterol/glycopyrronium bromide FDC are being assessed in the IGNITE phase III clinical trial program including more than 10 000 patients worldwide in 11 trials.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(166)</a></div><div class="NLM_p">In patients with moderate-to-severe COPD, indacaterol/glycopyrronium bromide FDC significantly improved lung function compared with placebo.<a onclick="showRef(event, 'ref168 ref169 ref170'); return false;" href="javascript:void(0);" class="ref ref168 ref169 ref170">(167-169)</a> Bronchodilation appeared 5 min after the first drug dose, was clinically significant (FEV<sub>1</sub> ≥ 100 mL, minimal clinical important difference [MCID]) at all time points, including day 1, and was maintained during treatment for up to 52 weeks.<a onclick="showRef(event, 'ref168 ref169 ref170'); return false;" href="javascript:void(0);" class="ref ref168 ref169 ref170">(167-169)</a></div><div class="NLM_p">Lung function improvement induced by indacaterol/glycopyrronium bromide FDC treatment was associated with amelioration in dyspnoea,<a onclick="showRef(event, 'ref168 ref169'); return false;" href="javascript:void(0);" class="ref ref168 ref169">(167, 168)</a> health status,<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(167)</a> symptoms,<a onclick="showRef(event, 'ref168 ref170'); return false;" href="javascript:void(0);" class="ref ref168 ref170">(167, 169)</a> rescue medication use,<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(167)</a> and exercise tolerance.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(170)</a></div><div class="NLM_p">In the SHINE study, indacaterol/glycopyrronium bromide FDC treatment reduced moderate-to-severe COPD exacerbation rate by 43% compared with placebo, although the primary study end point was trough FEV<sub>1</sub> at week 26 for indacaterol/glycopyrronium bromide FDC versus its monocomponents.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(167)</a></div><div class="NLM_p">Compared with active treatment, indacaterol/glycopyrronium bromide FDC was more effective than monotherapy with indacaterol, glycopyrronium bromide, and tiotropium bromide in improving pulmonary function in patients with COPD<a onclick="showRef(event, 'ref168 ref169 ref171 ref172'); return false;" href="javascript:void(0);" class="ref ref168 ref169 ref171 ref172">(167, 168, 170, 171)</a> and not inferior to its active monocomponents administered concurrently.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(172)</a> A recent metanalysis including 4842 patients enrolled in five trials (only one trial including patients with very severe COPD)<a onclick="showRef(event, 'ref167 ref168 ref169 ref170 ref172'); return false;" href="javascript:void(0);" class="ref ref167 ref168 ref169 ref170 ref172">(166-169, 171)</a> suggests that indacaterol/glycopyrronium bromide FDC has higher efficacy than glycopyrronium bromide and the current standard of care tiotropium bromide in patients with COPD.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(173)</a> Compared with tiotropium, indacaterol/glycopyrronium bromide FDC significantly increases trough FEV<sub>1</sub> (effect size ranges from 60 to 100 mL) from day 1 to week 64, reduces COPD exacerbation rate (number needed to treat for benefit is 19)<a onclick="showRef(event, 'ref168 ref172'); return false;" href="javascript:void(0);" class="ref ref168 ref172">(167, 171)</a> and the use of rescue medication (−0.63 puffs/day) with a higher likelihood of achieving a minimal clinically important difference in TDI (19%) (number needed to treat for benefit is 11) and in health status as assessed by SGRQ score (16%) (number needed to treat for benefit is 11).<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(173)</a> Compared with glycopyrronium bromide, indacaterol/glycopyrronium bromide FDC significantly increases trough FEV<sub>1</sub> (70 mL) up to 26 weeks,<a onclick="showRef(event, 'ref168 ref169'); return false;" href="javascript:void(0);" class="ref ref168 ref169">(167, 168)</a> increases the percentage of patients who achieved a minimal clinically important difference in the SGRQ score (number needed to treat for benefit is 12), reduces COPD exacerbation rate<a onclick="showRef(event, 'ref168 ref172'); return false;" href="javascript:void(0);" class="ref ref168 ref172">(167, 171)</a> (number needed to treat for benefit is 25), and reduces rescue medication use (−0.59 puffs/day).<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(173)</a> Regarding comparison between indacaterol/glycopyrronium bromide FDC and indacaterol, pooled analysis of data was not possible, as only one study reported this comparison.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(173)</a> Mean improvements in trough FEV<sub>1</sub> vs tiotropium, glycopyrronium, and indacaterol were similar (70 mL) and close to those observed comparing a LABA (salmeterol, formoterol, or indacaterol) and tiotropium combination vs tiotropium alone (60 mL).<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(174)</a></div><div class="NLM_p">Improvement in pulmonary function with indacaterol/glycopyrronium bromide FDC treatment compared with LAMA or LABA monotherapy was rapid in onset<a onclick="showRef(event, 'ref168 ref169'); return false;" href="javascript:void(0);" class="ref ref168 ref169">(167, 168)</a> and maintained up to 64 weeks.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(171)</a> Compared with monotherapies, treatment with indacaterol/glycopyrronium FDC achieved or approched the minimal clinically significant difference in trough FEV<sub>1</sub> of 100 mL.<a onclick="showRef(event, 'ref168 ref169 ref172'); return false;" href="javascript:void(0);" class="ref ref168 ref169 ref172">(167, 168, 171)</a> However, this threshold is used for comparisons vs placebo and a similar thershold for comparisons vs active treatments has not yet been established.</div><div class="NLM_p">Significant differences in health status and dyspnoea following indacaterol/glycopyrronium bromide FDC treatment as compared with its monocomponents,<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(167)</a> but not with tiotropium bromide,<a onclick="showRef(event, 'ref168 ref169'); return false;" href="javascript:void(0);" class="ref ref168 ref169">(167, 168)</a> were not generally observed in patients with moderate to severe COPD at low risk for exacerbation. In contrast, treatment with glycopyrronium/indacaterol FDC was associated with improvement in health status in severe or very severe COPD patients at high exacerbation risk.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(171)</a> The clinical relevance of these differences is unknown as the minimal clinically important difference in health status and dyspnoea between active treatments is not established.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(166)</a></div><div class="NLM_p">In patients with severe to very severe COPD at high risk for exacerbation, treatment with glycopyrronium/indacaterol FDC for 64 weeks was more effetive than glycopyrronium bromide alone, but not than tiotropium bromide, in reducing the annualized rate (−12%) of moderate to severe exacerbations (primary outcome).<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(171)</a> Annualized rate of all exacerbations (mild, moderate, and severe) was reduced by 15% compared with glycopyrronium and 14% compared with tiotropium.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(171)</a></div><div class="NLM_p">In patients with moderate to severe COPD without exacerbations in the previous year, once daily treatment with glycopyrronium/indacaterol FDC was more effective than salmeterol/fluticasone FDC at a dose of 50/500 μg b.i.d. in improving pulmonary function, an effect that was rapid in onset and persistent throughout the 26-week study period.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(175)</a> The increase of 138 mL in the standardized area under the curve from 0 to 12 h postdose for FEV<sub>1</sub> [FEV<sub>1</sub> area under the curve (AUC)<sub>0–12h</sub>) over salmeterol/fluticasone FDC after 26 week treatment with indacaterol/glycopyrronium bromide FDC (primary outcome) is considered clinically meaningful.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(175)</a> Improved dyspnoea and reduced rescue medication over salmeterol/fluticasone FDC were reported with indacaterol/glycopyrronium bromide FDC.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(175)</a></div><div class="NLM_p">Indacaterol/glycopyrronium bromide FDC was generally well tolerated in patients with moderate to very severe COPD.<a onclick="showRef(event, 'ref167 ref168 ref170 ref172 ref176'); return false;" href="javascript:void(0);" class="ref ref167 ref168 ref170 ref172 ref176">(166, 167, 169, 171, 175)</a> COPD worsening was the most common treatment-emergent adverse event and serious adverse event.<a onclick="showRef(event, 'ref168 ref170 ref172'); return false;" href="javascript:void(0);" class="ref ref168 ref170 ref172">(167, 169, 171)</a> Other common adverse events (incidence of ≥2%) include nasopharyngitis, cough, upper and lower respiratory tract infections, headache, oropharyngeal pain.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(166)</a> Compared with placebo, adverse events in patients with moderate to severe COPD who were being treated with indacaterol/glycopyrronium bromide FDC up to 52 weeks were generally similar.<a onclick="showRef(event, 'ref168 ref170'); return false;" href="javascript:void(0);" class="ref ref168 ref170">(167, 169)</a> Likewise, indacaterol/glycopyrronium bromide FDC was well tolerated with no potential safety signals reported compared with tiotropium, glycopyrronium, and indacaterol.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(173)</a> Its overall profile of cardiovascular safety was similar to tiotropium, glycopyrronium, and indacaterol.<a onclick="showRef(event, 'ref168 ref174'); return false;" href="javascript:void(0);" class="ref ref168 ref174">(167, 173)</a></div><div class="NLM_p last">The FLAME study, a 52-week treatment, multicenter, randomized, double-blind, double dummy, parallel-group, active controlled study to compare the effect of indacaterol/glycopyrronium bromide FDC with salmeterol/fluticasone FDC on the rate of exacerbations in subjects with moderate to very severe COPD, is ongoing as well as other phase III studies with indacaterol/glycopyrronium bromide FDC.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(166)</a></div></div><div id="sec6_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Umeclidinium Bromide/Vilanterol</h4><div class="NLM_p">Inhaled umeclidinium bromide/vilanterol received its first global approval in the USA in 2013 for the long-term, once-daily maintenance treatment of airflow limitation in patients with COPD.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Umeclidinium bromide/vilanterol was then approved in Canada for the same indication, and regulatory applications have been filed in the EU, Japan, and elsewhere.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> In the USA, umeclidinium bromide/vilanterol FDC (Anoro) has been approved at a dose of 62.5 μg/25 μg taken once-daily through a DPI.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p">Umeclidinium bromide and vilanterol are principally absorbed in the lungs with minimal oral absorption.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Following inhalation, <i>C</i><sub>max</sub> occurs in 5–15 min.</div><div class="NLM_p">The once daily dose of umeclidinium/vilanterol FDC used in phase III registration trials was 62.5 or 125 μg of umeclidinium and 25 μg of vilanterol as determined in phase II dose finding studies.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Two pivotal 24-week, randomized, double-blind, parallel group, placebo-controlled<a onclick="showRef(event, 'ref7 ref177 ref178'); return false;" href="javascript:void(0);" class="ref ref7 ref177 ref178">(7, 176, 177)</a> and two pivotal 24-week, multicenter, randomized, blinded, double-dummy, parallel-group, active comparator-controlled studies were performed to test the efficacy and safety of once-daily 125/25 μg and 62.5/25 μg doses of umeclidinium/vilanterol FDC.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(178)</a> A total of 5353 patients with moderate to very severe COPD (GOLD stages II–IV) were included in the pivotal trials. Supportive evidence was provided by two 12-week, double-blind, crossover, multicenter, exercise endurance trials (NCT01328444 and NCT01323660) including a total of 657 patients with COPD.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> In the pivotal trials, the primary efficacy end point was the predose trough FEV<sub>1</sub> on treatment day 169 (study end), defined as the mean of the FEV<sub>1</sub> values obtained at 23 and 24 h after dosing on treatment day 168.<a onclick="showRef(event, 'ref177 ref178 ref179'); return false;" href="javascript:void(0);" class="ref ref177 ref178 ref179">(176-178)</a> In the exercise endurance trials, the coprimary end points were the change from baseline to study end in exercise endurance time measured during the shuttle walk test and the trough FEV<sub>1</sub> at study end.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p">In the placebo-controlled pivotal trials, all active treatments improved trough FEV<sub>1</sub> as compared with placebo at 24 weeks (umeclidinium/vilanterol 62.5/25 μg vs placebo: mean difference 0.167 L [95% CI, 0.128−0.207], <i>p</i> < 0.001;<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(176)</a> umeclidinium/vilanterol 125/25 μg vs placebo: mean difference 0.238 L [95% CI, 0.200−0.276], <i>p</i> < 0.001<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(177)</a>). Improvements with both 125/25 μg (ClinicalTrials.gov identifier: NCT01313637) (0.079 L vs umeclidinium alone; 0.114 L vs vilanterol alone; both <i>p</i> ≤ 0.001)<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(177)</a> and 62.5/25 μg (ClinicalTrials.gov identifier: NCT01313637) (0.052 L vs umeclidinium alone, <i>p</i> = 0.004; 0.095 L vs vilanterol alone, <i>p</i> ≤ 0.001)<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(176)</a> umeclidinium/vilanterol were significantly greater than those observed with the individual drugs at the same respective doses.<a onclick="showRef(event, 'ref177 ref178'); return false;" href="javascript:void(0);" class="ref ref177 ref178">(176, 177)</a> Additional lung function and symptomatic and health-related quality of life end points were also improved after treatment with umeclidinium/vilanterol as compared with placebo.<a onclick="showRef(event, 'ref177 ref178'); return false;" href="javascript:void(0);" class="ref ref177 ref178">(176, 177)</a></div><div class="NLM_p">In the two pivotal active-controlled trials, increases in trough FEV<sub>1</sub> on day 169 for both doses of umeclidinium/vilanterol compared with tiotropium monotherapy (administered at once-daily dose of 18 μg via DPI as active control) were observed (study 1, umeclidinium/vilanterol 125/25 μg, 0.088 L [95% CI, 0.036–0.140; <i>p</i> = 0.0010]; study 1, umeclidinium/vilanterol 62.5/25 μg, 0.090 L [95% CI, 0.039–0.141; <i>p</i> = 0.0006]; study 2, umeclidinium/vilanterol 125/25 μg, 0.074 L [95% CI, 0.025–0.123; <i>p</i> = 0.0031]; study 2, umeclidinium/vilanterol 62.5/25 μg, 0.060 L [95% CI, 0.010–0.109; nominal <i>p</i> = 0.0182]).<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(178)</a> Both doses of umeclidinium/vilanterol improved trough FEV<sub>1</sub> compared with vilanterol monotherapy (umeclidinium/vilanterol 125/25 μg, 0.088 L [95% CI, 0.036–0.140; <i>p</i> = 0.0010]; umeclidinium/vilanterol 62.5/25 μg, 0.090 L [95% CI, 0.039–0.142; <i>p</i> = 0.0006]) but not compared with umeclidinium 125 μg monotherapy (umeclidinium/vilanterol 125/25 μg, 0.037 L [95% CI, −0.012 to 0.087; <i>p</i> = 0.14]; umeclidinium/vilanterol 62.5/25 μg, 0.022 L [95% CI, −0.027 to 0.072; <i>p</i> = 0. 38]).<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(178)</a> There was no statistically significant difference between the two doses of umeclidinium/vilanterol.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(178)</a> All treatments improved dyspnoea and health-related quality of life. No significant differences in symptoms, health status, or risk of COPD exacerbation between umeclidinium/vilanterol FDC and tiotropium were observed.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(178)</a></div><div class="NLM_p">The most common on-treatment, severe-intensity adverse event in both studies was acute COPD exacerbation (1–4 [<1–2%] patients across treatment groups in study 1 and 1–6 [<1–3%] patients in study 2).<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(178)</a> Five to 15 (2–7%) on-treatment serious adverse events across treatment groups in study 1, and nine to 22 (4–10%) in study 2 were reported.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(178)</a></div><div class="NLM_p">No clinically significant changes from baseline in vital signs, electrocardiography, or laboratory parameters were observed in any of the treatment groups in the pivotal trials, indicating that both doses of umeclidinium/vilanterol are well tolerated.<a onclick="showRef(event, 'ref177 ref178 ref179'); return false;" href="javascript:void(0);" class="ref ref177 ref178 ref179">(176-178)</a></div><div class="NLM_p">In the exercise endurance trials, treatment with both once-daily 125/25 μg and 62.5/25 μg doses of umeclidinium/vilanterol FDC increased trough FEV<sub>1</sub> at 12 weeks compared with placebo and with the respective individual drug doses (coprimary end point).<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> At study end, increase in 3 h postdose exercise endurance time over placebo (coprimary end point) was observed with both doses of umeclidinium/vilanterol FDC in the NCT01323660 trial but not in the NCT01328444 trial.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> There was no difference between the two doses of umeclidinium/vilanterol FDC or between combination and monotherapy groups for changes from baseline to study end.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p">Three 12-week multicenter, randomized, double-blind, double-dummy, parallel group studies comparing the efficacy and safety of umeclidinium/vilanterol FDC (62.5/25 μg once daily) and fluticasone propionate/salmeterol FDC (250/50 μg twice daily, NCT01817764 and NCT01879410; 500/50 μg twice daily, NCT01822899) (treatments administered via Accuhaler/Diskus DPIs) in COPD subjects have recently been completed, and results are awaiting to be published (<a href="http://clinicaltrials.gov" class="extLink">http://clinicaltrials.gov</a>). The 24-h weighted-mean serial FEV<sub>1</sub> on treatment day 84 (time frame, day 84) was the primary outcome measure (information available at: <a href="http://clinicaltrials.gov" class="extLink">http://clinicaltrials.gov</a>).</div><div class="NLM_p last">Two clinical trials with umeclidinium/vilanterol FDC are currently ongoing (information available at <a href="http://clinicaltrials.gov" class="extLink">http://clinicaltrials.gov</a>). One 12-week randomized, double blind, double dummy, parallel group study will assess the efficacy of umeclidinium/vilanterol 62.5/25 μg vs tiotropium monotherapy at a dose of 18 μg once daily via a DPI in COPD patients not adequately controlled with tiotropium alone (NCT01899742). The primary efficacy end point is trough FEV<sub>1</sub> on day 85. Another 4-week randomized, double-blind, crossover study will assess the effect of umeclidinium/vilanterol FDC 62.5/25 μg vs umeclidinium 125 μg alone on exertional dyspnoea, exercise endurance, and neuromechanical coupling in patients with GOLD stage II COPD (NCT01491802) (information available at: <a href="http://clinicaltrials.gov" class="extLink">http://clinicaltrials.gov</a>).</div></div><div id="sec6_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Olodaterol/Tiotropium Bromide</h4><div class="NLM_p">A FDC of olodaterol/tiotropium bromide, delivered by the soft mist inhaler, is being developed in COPD.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Olodaterol/tiotropium FDC 5/2.5 μg and 5/5 μg once daily was selected for evaluation in phase III trials.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><div class="NLM_p">Two phase III randomized, double-blind, parallel group studies to assess the efficacy and safety of 52 weeks of once daily treatment with inhaled tiotropium/olodaterol FDC (2.5/5 μg; 5/5 μg) (delivered by the soft mist inhaler) compared with the individual components (2.5 μg and 5 μg tiotropium bromide, 5 μg olodaterol) (delivered by the soft mist inhaler) in patients with COPD have been completed, and results are to be published [TOnado TM 1, NCT01431274; TOnado TM 2, NCT01431287) (information available at <a href="https://clinicaltrials.gov" class="extLink">https://clinicaltrials.gov</a>). A combination of FEV<sub>1</sub> AUC<sub>0–3h</sub> response, trough FEV<sub>1</sub>, and SGRQ total score at 24 week was the primary outcome.</div><div class="NLM_p">A phase III, randomized, double-blind, placebo-controlled, 6-treatment, 4-period, incomplete crossover trial to characterize the 24 h lung function profiles (primary outcome, FEV<sub>1</sub> AUC<sub>0–24h</sub>) of tiotropium/olodaterol FDC (2.5/5 μg, 5/5 μg), tiotropium (2.5 μg, 5 μg) and olodaterol (5 μg) (delivered by the soft mist inhaler) after 6 weeks once daily treatment in patients with COPD has been completed (VIVACITOTM, NCT01559116) (information available at <a href="https://clinicaltrials.gov" class="extLink">https://clinicaltrials.gov</a>). A similar study comparing the effect of tiotropium/olodaterol FDC (2.5/5 μg, 5/5 μg) with FDC of fluticasone/salmeterol (250/50 μg and 500/50 μg b.i.d., delivered by the Accuhaler) on lung function is ongoing (NCT0196972) (information available at: <a href="https://clinicaltrials.gov" class="extLink">https://clinicaltrials.gov</a>).</div><div class="NLM_p">Two phase III randomized, double-blind, 5-treatment arms, 4-period, incomplete crossover studies to determine the effect of 6 weeks treatment of inhaled tiotropium/olodaterol FDC (2.5/5 μg and 5/5 μg) (delivered by the soft mist inhaler) compared with tiotropium (5 μg), olodaterol (5 μg), and placebo (delivered by the soft mist inhaler) on lung hyperinflation and exercise endurance time during constant work rate cycle ergometry in patients with COPD (MORACTO TM 1, NCT01533922; MORACTO TM 2, NCT01533935) (information available at <a href="https://clinicaltrials.gov" class="extLink">https://clinicaltrials.gov</a>) and one 12-week, placebo controlled, study to determine the effect of tiotropium/olodaterol FDC (2.5/5 μg and 5/5 μg) on exercise endurance time during constant work rate cycle ergometry in patients with COPD (Torracto TM, NCT01525615) (information available at: <a href="https://clinicaltrials.gov" class="extLink">https://clinicaltrials.gov</a>) have been completed and results are to be published.</div><div class="NLM_p last">Two phase III, randomized, double-blind, placebo- and active-controlled (tiotropium alone) parallel group studies to assess the efficacy of 12 weeks of once daily treatment of two doses of inhaled tiotropium/olodaterol FDC (2.5/5 μg and 5/5 μg) in patients with moderate to severe COPD are ongoing (OTEMTO 1, NCT01964352; OTEMTO 2, NCT02006732) (information available at <a href="https://clinicaltrials.gov" class="extLink">https://clinicaltrials.gov</a>). A combination of FEV<sub>1</sub> AUC<sub>0–3h</sub> response, trough FEV<sub>1</sub>, and SGRQ total score is the primary outcome (information available at <a href="https://clinicaltrials.gov" class="extLink">https://clinicaltrials.gov</a>).</div></div></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Dual Muscarinic Antagonist−β<sub>2</sub>-Agonist (MABA) Compounds</h3><div class="NLM_p">Inhaled dual-pharmacology muscarinic antagonist−β<sub>2</sub>-agonist (MABA) molecules present a novel approach to the treatment of COPD by combining mAcChR antagonism and β<sub>2</sub>-adrenoreceptor agonism in a single molecule.<a onclick="showRef(event, 'ref180 ref181'); return false;" href="javascript:void(0);" class="ref ref180 ref181">(179, 180)</a> This pharmacological strategy has the potential to demonstrate additive or synergistic bronchodilation over either inhaled mAcChR antagonists or β<sub>2</sub> agonists alone.<a onclick="showRef(event, 'ref180 ref181'); return false;" href="javascript:void(0);" class="ref ref180 ref181">(179, 180)</a> Several companies have reported MABA discovery efforts through a conjugated/linked strategy. At least one candidate, batefenterol (GSK-961081, formerly TD-5959), (<i>R</i>)-1-(3-((2-chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl[1,1′-biphenyl]-2-yl)carbamate] (Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a>),<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(179)</a> has demonstrated clinical proof of concept.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(180)</a> Information of batefenterol is also available at <a href="http://chem.sis.nlm.nih.gov/chemidplus/rn/743461-65-6" class="extLink">http://chem.sis.nlm.nih.gov/chemidplus/rn/743461-65-6</a>.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0016.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Chemical structure of batefenterol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Pharmacological properties of batefenterol, a novel first-in-class inhaled bifunctional MABA, have been recently described.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(179)</a> At human recombinant receptors, batefenterol shows high affinity for M<sub>2</sub> [inhibition constant (<i>K</i><sub>i</sub>) = 1.4 nM], M<sub>3</sub> receptors (<i>K</i><sub>i</sub> = 1.3 nM), and β<sub>2</sub>-adrenoceptors (<i>K</i><sub>i</sub> = 3.7 nM) and potent β<sub>2</sub>-adrenoceptor agonist activity [effective concentration<sub>50</sub> (EC<sub>50</sub>) of 0.29 nM assessed by stimulation of cAMP production).<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(179)</a> Batefenterol has 440- and 320-fold functional selectivity over human β<sub>1</sub>- and β<sub>3</sub>-adrenoceptors, respectively.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(179)</a> In guinea pig isolated tracheal tissues, batefenterol induces smooth muscle relaxation through muscarinic antagonist (EC<sub>50</sub> = 50.2 nM), β<sub>2</sub>-agonist (EC<sub>50</sub> = 24.6 nM), and MABA (EC<sub>50</sub> = 11 nM) mechanisms.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(179)</a> In the guinea pig bronchoprotection assay, inhaled batefenterol causes potent, dose-dependent inhibition of bronchoconstrictor responses through muscarinic antagonism [effective dose<sub>50</sub> (ED<sub>50</sub>) = 33.9 μg/mL), β<sub>2</sub>-agonism (ED<sub>50</sub> = 14.1 μg/mL), and MABA mechanism (ED<sub>50</sub> = 6.4 μg/mL).<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(179)</a> The bronchoprotective effects of batefenterol were maintained up to 7 days after dosing.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(179)</a> In guinea pigs, batefenterol has a lung selectivity index which is 55- to 110-fold greater than that of tiotropium with respect to systemic antimuscarinic inhibition of salivation and 10-fold greater than that of salmeterol with respect to systemic β<sub>2</sub>-adrenoceptor hypotensive effects.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(179)</a> These preclinical findings suggest that batefenterol might be a promising next-generation inhaled lung-selective bronchodilator for the pharmacological treatment of COPD.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(179)</a></div><div class="NLM_p last">In a randomized, double-blind, double-dummy, placebo controlled, 14-day crossover study including 50 patients with moderate COPD, subjects were treated with batefenterol 400 μg once daily (<i>n</i> = 29), batefenterol 1200 μg once daily (<i>n</i> = 32), tiotropium 18 μg once daily plus salmeterol 50 μg twice daily (<i>n</i> = 41), or placebo.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(180)</a> The primary end point was FEV<sub>1</sub> at 24 h on days 1 and 14.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(180)</a> Compared with placebo, all active treatments resulted in significant increases in FEV<sub>1</sub> over 24 h on both day 1 and day 14.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(180)</a> No clinically relevant systemic pharmacodynamic effects were observed. Adverse events were similar across groups.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(180)</a> However, tremor, (<i>n</i> = 2, batefenterol 1200 μg), dysgeusia (<i>n</i> = 2, batefenterol 1200 μg; <i>n</i> = 2, batefenterol 400 μg) and dry mouth (<i>n</i> = 1, batefenterol 1200 μg) were reported after batefenterol only.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(180)</a> These data suggest that batefenterol provides long-lasting bronchodilation similar to tiotropium plus salmeterol, but with a more rapid onset, and is well tolerated at the tested doses.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(180)</a></div></div><div id="sec6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Safety of LAMA/LABA Fixed Dose Combinations</h3><div class="NLM_p">Inhaled glycopyrronium bromide/indacaterol FDC was generally well tolerated in patients with moderate to very severe COPD.<a onclick="showRef(event, 'ref167 ref168 ref170 ref172 ref176'); return false;" href="javascript:void(0);" class="ref ref167 ref168 ref170 ref172 ref176">(166, 167, 169, 171, 175)</a> COPD worsening was the most common treatment-emergent adverse event and serious adverse event.<a onclick="showRef(event, 'ref168 ref170 ref172'); return false;" href="javascript:void(0);" class="ref ref168 ref170 ref172">(167, 169, 171)</a> Other common adverse events (incidence of ≥2%) include nasopharyngitis, cough, upper and lower respiratory tract infections, headache, and oropharyngeal pain.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(166)</a> Adverse events in patients with moderate to severe COPD who were being treated with indacaterol/glycopyrronium bromide FDC up to 52 weeks were generally similar to placebo group.<a onclick="showRef(event, 'ref168 ref170'); return false;" href="javascript:void(0);" class="ref ref168 ref170">(167, 169)</a> Likewise, indacaterol/glycopyrronium bromide FDC was well tolerated with no potential safety signals reported compared with tiotropium, glycopyrronium, and indacaterol.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(173)</a> Its overall profile of cardiovascular safety was similar to tiotropium, glycopyrronium, and indacaterol.<a onclick="showRef(event, 'ref168 ref174'); return false;" href="javascript:void(0);" class="ref ref168 ref174">(167, 173)</a></div><div class="NLM_p last">Inhaled umeclidinium/vilanterol FDC was generally well tolerated as indicated by a pooled analysis of the 24-week phase III trials including 4733 patients with COPD and a 52-week multicenter, double-blind, placebo-controlled safety trial (NCT01316887) including 562 patients.<a onclick="showRef(event, 'ref7 ref182'); return false;" href="javascript:void(0);" class="ref ref7 ref182">(7, 181)</a> At least one dose of umeclidinium/vilanterol FDC of 125/25 μg once daily was received by 1330 patients and at least one dose of the 62.5/25 μg FDC once daily was received by 1124 patients.<a onclick="showRef(event, 'ref7 ref182'); return false;" href="javascript:void(0);" class="ref ref7 ref182">(7, 181)</a> In the four pivotal trials, the most common adverse effects (≥1% and with higher incidence than in the placebo group) observed in COPD patients receiving umeclidinium/vilanterol once daily at a dose of 62.5/25 μg (<i>n</i> = 842) were pharyngitis, diarrhea, pain in extreimity, sinusitis, lower respiratory tract infection, constipation, muscle spasms, neck and chest pain.<a onclick="showRef(event, 'ref7 ref182'); return false;" href="javascript:void(0);" class="ref ref7 ref182">(7, 181)</a> In the safety trial, after 52-week once daily treatment with umeclidinium/vilanterol 125/25 μg, umeclidinium 125 μg, or placebo, the incidence of treatment emergent (52–58%) and serious (6–7%) adverse events was similar in all groups, with the most common adverse effect being headache.<a onclick="showRef(event, 'ref7 ref182'); return false;" href="javascript:void(0);" class="ref ref7 ref182">(7, 181)</a> The most common adverse effects in the combination group were headache, back pain, sinusitis, cough, urinary tract infection, arthralgia, nausea, vertigo, abdominal pain, viral respiratory tract infection, and diabetes mellitus.<a onclick="showRef(event, 'ref7 ref182'); return false;" href="javascript:void(0);" class="ref ref7 ref182">(7, 181)</a> There was no clinically significant changes in vital signs, electrocardiography, or laboratory parameters.<a onclick="showRef(event, 'ref7 ref182'); return false;" href="javascript:void(0);" class="ref ref7 ref182">(7, 181)</a></div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37327" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37327" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Inhaled mAcChR antagonists are effective bronchodilators in the management of patients with COPD. Ipratropium is generally effective in both short- and long-term studies of acute bronchodilation and enables long-term improvement in dyspnoea and quality of life. However, because of its relatively short duration of action, treatment with ipratropium is limited to a short-acting FDC with salbutamol, as this combination provides greater bronchodilation than either monocomponents. Tiotropium bromide does not induce a rapid bronchodilating effect, but has a 24 h duration of action and is a first choice treatment of patients with stable COPD with severe airflow limitation and frequent exacerbations. In patients with COPD, tiotropium bromide is more effective than ipratropium bromide in providing long-term improvements in pulmonary function, reduces the rate of COPD exacerbations and hospitalizations, and improves dyspnoea when compared with LABA. Studies comparing the efficacy of once daily LAMA, including tiotropium, and once daily LABA are required. Whether tiotropium reduces progressive decline in pulmonary function in patients with COPD is not defined. The issue of possible adverse cardiovascular effects of tiotropium soft mist inhaler in patients with COPD is still a matter of debate. A large safety trial (TIOSPIR) has shown that tiotropium soft mist inhaler was not inferior to tiotropium DPI with respect to the risk of death, although a possible association between the use of tiotropium soft mist inhaler at a dose of 5 μg once daily and fatal myocardial infarction raised further concerns about the cardiac safety of tiotropium soft mist inhaler. Generally speaking, the potential for cardiovascular risk of LAMA seems to be small and should be balanced against the known benefits of this class of bronchodilators in patients with COPD.</div><div class="NLM_p">Among new LAMA, inhaled glycocpyrronium bromide and umeclidinium bromide are suitable for once daily administration and, unlike tiotropium bromide, are fast-acting bronchodilators. These new LAMA potentially meet some of the characteristics of an ideal bronchodilator including clinically meaningful, rapid, and long-lasting bronchodilation, symptom relief, improvement in exercise tolerance and health status, prevention and treatment of COPD exacerbations, reduction of mortality risk. New LAMA and their FDC with once daily LABA seem to pave the way for a more effective pharmacological treatment of COPD.</div><div class="NLM_p">Twice-daily salmeterol and formoterol are effective in the management of patients with COPD and are generally well tolerated. These LABA improve clinical outcomes compared with placebo, although many patients remain symptomatic despite their use. New once daily LABA can improve outcomes for patients with COPD, both as monotherapy and FDC treatment. However, no pharmacological treatment to date has been shown to modify the accelerated decline in lung function which characterizes COPD. In clinical trials, most treatments result in an initial increase in FEV<sub>1</sub> that, although modest in some studies, may be sufficient to reduce lung hyperinflation which contributes to dyspnoea. However, at present, pharmacological treatment is generally unable to maintain the initial increase in FEV<sub>1</sub> observed in many studies at a constant level for longer than 12 months.</div><div class="NLM_p">When dual bronchodilation is indicated, new LAMA/LABA FDCs provide the convenience of two bronchodilators with different mechanism of action in a single inhaler and, at the same time, a simple, once-daily dosing regimen that may improve treatment compliance. LAMA/LABA FDCs, including indacaterol/glycopyrronium, umeclidinium/vilanterol, and olodaterol/tiotropium, have been approved or are under approval in various countries. As they allow maximal bronchodilatation and are more effective than individual bronchodilators, LAMA/LABA FDCs are likely to become a standard pharmacological strategy for patients with COPD in whom treatment with one bronchodilator is not sufficient.</div><div class="NLM_p">Finally, dual-pharmacology MABA compounds, which are under clinical development, combine mAcChR antagonism and β<sub>2</sub>-adrenoreceptor agonism in a single molecule. This pharmacological strategy potentially provides additive or synergistic bronchodilation over either inhaled antimuscarinic or β<sub>2</sub>-agonist monotherapy.</div><div class="NLM_p">In summary, LAMA and LABA bronchodilators are the mainstay of pharmacological treatment of COPD, although they do not modify the natural history of this disease. The identification of novel LAMA and LABA with improved pharmacological profile including 24 h duration of action allowing once daily administration, rapid onset of bronchodilation, and lack of systemic effects is a priority in this research area. Higher β<sub>1</sub>-receptor selectivity is certainly an important goal to achieve in the development of new LABA, whereas there is no general consensus on the utility of developing selective M<sub>3</sub> LAMA, although this objective is being pursued by many pharmaceutical companies. Several studies show that treatment with once daily LAMA/LABA FDC (double inhaler therapy) is effective in patients in whom COPD is not adequately controlled by a single bronchodilator. As the role of COPD phenotyping in planning a more personalized approach to COPD management is becoming central, triple inhaler therapy based on LAMA/LABA/ICS FDC might be particularly useful in moderate to severe COPD patients with ACOS and/or frequent exacerbations. Future prospective controlled clinical studies will clarify the therapeutic role of ICS in these COPD phenotypes.</div><div class="NLM_p last">MABA is a novel promising pharmacological strategy for COPD. Preclinical pharmacology of MABA is being characterized. Because of the very few clinical studies available, their role in the management of patients with stable COPD cannot be anticipated and has to be defined in future studies.</div></div><div class="NLM_back"><div class="NLM_notes" id="notes-1"><p class="first last">The authors declare no competing financial interest.</p></div><div class="NLM_notes" id="notes-2">†<span class="title" id="d69690505e4248">Dedication</span><p class="last">This article is dedicated to the loving memory of Professor Giovanni Ciabattoni, Master of Pharmacology, Science, and Life.</p></div><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm5013227" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03054" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03054" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paolo Montuschi</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmacology,
Faculty of Medicine, Catholic University
of the Sacred Heart, Largo Francesco Vito, 1, Rome, 00168, Italy</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c6b6aba9a8b2b3b5a5aeaf86b4abe8b3a8afa5a7b2b2e8afb2"><span class="__cf_email__" data-cfemail="50203d3f3e24252333383910223d7e253e39333124247e3924">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Giovanni Ciabattoni</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmacology,
Faculty of Medicine, Catholic University
of the Sacred Heart, Largo Francesco Vito, 1, Rome, 00168, Italy</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37432" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37432" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Paolo Montuschi</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=BIO-d3997e4521-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Paolo Montuschi</b> is Associate Professor of Pharmacology, Faculty of Medicine, Catholic University of the Sacred Heart, Rome, Italy, and Senior Registrar, Pharmacology Unit, University Hospital Agostino Gemelli, Rome. He got the certification for Full Professor. He received his medical degree from the Catholic University of the Sacred Heart in 1989. He was Visiting Clinical Research Fellow at Imperial College, National Heart and Lung Institute, Department of Thoracic Medicine, London, United Kingdom. His scientific activity is focused on respiratory pharmacology. Author of more than 200 publications including 88 full papers and one edited book, his H-index is 41. He is Specialty Chief Editor of <i>Frontiers in Respiratory Pharmacology</i>, and member of the Editorial Board of <i>Chest</i>, he received grants from European Union, Italian Ministry of University and Research, Italian Cystic Fibrosis Research Foundation, Cystic Fibrosis Trust.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Giovanni Ciabattoni</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=BIO-d3997e4532-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Giovanni Ciabattoni</b> was Professor of Pharmacology at the Faculty of Medicine, Catholic University of the Sacred Heart, Rome, Italy, and at University of Chieti-Pescara G. D’Annunzio, where he was Chairman of Pharmacology and Chemotherapy, Department of Drug Sciences. He received his medical degree from the Catholic University of the Sacred Heart in 1975. He pioneered research on eicosanoids and isoeicosanoids and provided important contributions to the understanding of mechanisms of action of bronchodilators. He was author of more that 350 publications including 187 full papers. His H-index is 57. He sadly passed away on July 21, 2014 at the University Hospital Agostino Gemelli, Catholic University of the Sacred Heart in Rome, which he considered his home.</p></figure></div><div class="ack" id="ACK-d3997e4537-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83816" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83816" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by Catholic University of the Sacred Heart, Fondi di Ateneo 2012–2014.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i50" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i50"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i51" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i51"> Abbreviations:</h2><tr><td class="NLM_term">AC</td><td class="NLM_def"><p class="first last">adenylyl cyclase</p></td></tr><tr><td class="NLM_term">Ach</td><td class="NLM_def"><p class="first last">acetylcholine</p></td></tr><tr><td class="NLM_term">ACOS</td><td class="NLM_def"><p class="first last">asthma–chronic obstructive pulmonary disease overlap syndrome</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">β<sub>2</sub>, β<sub>2</sub></td><td class="NLM_def"><p class="first last">adrenergic receptor</p></td></tr><tr><td class="NLM_term">Ca<sup>2+</sup></td><td class="NLM_def"><p class="first last">calcium ion</p></td></tr><tr><td class="NLM_term">cAMP</td><td class="NLM_def"><p class="first last">cyclic adenosine monophosphate</p></td></tr><tr><td class="NLM_term">COPD</td><td class="NLM_def"><p class="first last">chronic obstructive pulmonary disease</p></td></tr><tr><td class="NLM_term">DAG</td><td class="NLM_def"><p class="first last">diacylglycerol</p></td></tr><tr><td class="NLM_term">DPI</td><td class="NLM_def"><p class="first last">dry powder inhaler</p></td></tr><tr><td class="NLM_term">EC<sub>50</sub></td><td class="NLM_def"><p class="first last">effective concentration<sub>50</sub></p></td></tr><tr><td class="NLM_term">ED<sub>50</sub></td><td class="NLM_def"><p class="first last">effective dose<sub>50</sub></p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">endoplasmic reticulum</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">FDC</td><td class="NLM_def"><p class="first last">fixed dose combination</p></td></tr><tr><td class="NLM_term">FF</td><td class="NLM_def"><p class="first last">fluticasone furoate</p></td></tr><tr><td class="NLM_term">FEV<sub>1</sub></td><td class="NLM_def"><p class="first last">forced expiratory volume in 1 s</p></td></tr><tr><td class="NLM_term">FP</td><td class="NLM_def"><p class="first last">fluticasone propionate</p></td></tr><tr><td class="NLM_term">FRC</td><td class="NLM_def"><p class="first last">functional residual capacity</p></td></tr><tr><td class="NLM_term">G<sub>i</sub></td><td class="NLM_def"><p class="first last">inhibitory G protein</p></td></tr><tr><td class="NLM_term">G<sub>q</sub></td><td class="NLM_def"><p class="first last">G<sub>q</sub> protein</p></td></tr><tr><td class="NLM_term">G<sub>s</sub></td><td class="NLM_def"><p class="first last">stimulatory G protein</p></td></tr><tr><td class="NLM_term">GOLD</td><td class="NLM_def"><p class="first last">global obstructive lung disease</p></td></tr><tr><td class="NLM_term">HR</td><td class="NLM_def"><p class="first last">hazard ratio</p></td></tr><tr><td class="NLM_term">IC</td><td class="NLM_def"><p class="first last">inspiratory capacity</p></td></tr><tr><td class="NLM_term">ICS</td><td class="NLM_def"><p class="first last">inhaled corticosteroid</p></td></tr><tr><td class="NLM_term">IL</td><td class="NLM_def"><p class="first last">interleukin</p></td></tr><tr><td class="NLM_term">IP3</td><td class="NLM_def"><p class="first last">inositol 1,4,5-trisphosphate</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>D</sub></td><td class="NLM_def"><p class="first last">dissociation constant</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>i</sub></td><td class="NLM_def"><p class="first last">inhibition constant</p></td></tr><tr><td class="NLM_term">LABA</td><td class="NLM_def"><p class="first last">long-acting β<sub>2</sub>-adrenenoreceptor agonists</p></td></tr><tr><td class="NLM_term">LAMA</td><td class="NLM_def"><p class="first last">long-acting muscarinic receptor antagonists</p></td></tr><tr><td class="NLM_term">M</td><td class="NLM_def"><p class="first last">muscarinic acetylcholine receptor</p></td></tr><tr><td class="NLM_term">MABA</td><td class="NLM_def"><p class="first last">dual muscarinic antagonist-β<sub>2</sub>-agonist compound</p></td></tr><tr><td class="NLM_term">MCID</td><td class="NLM_def"><p class="first last">minimal clinically important difference</p></td></tr><tr><td class="NLM_term">mAcChR</td><td class="NLM_def"><p class="first last">muscarinic acethylcholine receptor</p></td></tr><tr><td class="NLM_term">N</td><td class="NLM_def"><p class="first last">nicotinic acetylcholine receptor</p></td></tr><tr><td class="NLM_term">OR</td><td class="NLM_def"><p class="first last">odds ratio</p></td></tr><tr><td class="NLM_term">PDE<sub>4</sub></td><td class="NLM_def"><p class="first last">phosphodiesterase 4</p></td></tr><tr><td class="NLM_term">PIP2</td><td class="NLM_def"><p class="first last">phosphatidylinositol 4,5-bisphosphate</p></td></tr><tr><td class="NLM_term">PLC</td><td class="NLM_def"><p class="first last">phospholipase C</p></td></tr><tr><td class="NLM_term">PKA</td><td class="NLM_def"><p class="first last">protein kinase A</p></td></tr><tr><td class="NLM_term">pMDI</td><td class="NLM_def"><p class="first last">pressurized metered dose inhaler</p></td></tr><tr><td class="NLM_term">RR</td><td class="NLM_def"><p class="first last">risk ratio</p></td></tr><tr><td class="NLM_term">SABA</td><td class="NLM_def"><p class="first last">short-acting β<sub>2</sub>-adrenoreceptor agonists</p></td></tr><tr><td class="NLM_term">SAMA</td><td class="NLM_def"><p class="first last">short-acting muscarinic receptor antagonists</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SDDPI</td><td class="NLM_def"><p class="first last">single-dose dry powder inhaler</p></td></tr><tr><td class="NLM_term">SGRQ</td><td class="NLM_def"><p class="first last">St. George’s Respiratory Questionnaire</p></td></tr><tr><td class="NLM_term">TDI</td><td class="NLM_def"><p class="first last">transition dyspnoea index</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i52">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83731" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83731" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 181 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span>Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD),<span class="NLM_x"> </span><span class="NLM_year">2014</span>. Available from <a href="http://www.goldcopd.org" class="extLink">www.goldcopd.org</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Global+Strategy+for+the+Diagnosis%2C+Management+and+Prevention+of+COPD%2C+Global+Initiative+for+Chronic+Obstructive+Lung+Disease+%28GOLD%29%2C+2014.+Available+from+www.goldcopd.org."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Montuschi, P.</span><span> </span><span class="NLM_article-title">Drugs for chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1461</span><span class="NLM_x">–</span> <span class="NLM_lpage">1463</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.2174%2F0929867311320120001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23016550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt1ynsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1461-1463&author=P.+Montuschi&title=Drugs+for+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Montuschi, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1461-1463</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfVjNlcyAdzLVg90H21EOLACvtfcHk0ljiUYctvLnd5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmt1ynsLs%253D&md5=7fe5d3e1fa2824e9bf64b8576b7276e9</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2174%2F0929867311320120001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320120001%26sid%3Dliteratum%253Aachs%26aulast%3DMontuschi%26aufirst%3DP.%26atitle%3DDrugs%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26spage%3D1461%26epage%3D1463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Montuschi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valente, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuso, L.</span><span> </span><span class="NLM_article-title">Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1464</span><span class="NLM_x">–</span> <span class="NLM_lpage">1476</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.2174%2F0929867311320120002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=22963553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt1ynsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1464-1476&author=P.+Montuschiauthor=F.+Macagnoauthor=S.+Valenteauthor=L.+Fuso&title=Inhaled+muscarinic+acetylcholine+receptor+antagonists+for+treatment+of+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD</span></div><div class="casAuthors">Montuschi, P.; Macagno, F.; Valente, S.; Fuso, L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1464-1476</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Bronchodilators, generally administered via metered dose or dry powder inhalers, are the mainstays of pharmacol. treatment of stable COPD.  Inhaled long-acting beta-agonists (LABA) and anticholinergics are the broncholidators primarily used in the chronic treatment of COPD.  Anticholinergics act as muscarinic acetylcholine receptor antagonists and are frequently preferred over beta-agonists for their minimal cardiac stimulatory effects and greater efficacy in most studies.  Their therapeutic efficacy is based on the fact that vagally mediated bronchoconstriction is the major reversible component of airflow obstruction in patients with COPD.  However, bronchodilators are effective only on the reversible component of airflow obstruction, which by definition is limited, as COPD is characterized by a fixed or poorly reversible airflow obstruction.  Inhaled anticholinergic antimuscarinic drugs approved for the treatment of COPD include ipratropium bromide, oxitropium bromide and tiotropium bromide.  Ipratropium bromide, the prototype of anticholinergic bronchodilators, is a short-acting agent.  Oxitropium bromide is administered twice a day.  Tiotropium bromide, the only long-acting antimuscarinic agent (LAMA) currently approved, is administered once a day.  Newer LAMAs including aclidinium bromide and glycopyrrolate bromide are currently in phase III development for treatment of COPD.  Some new LAMAs, including glycocpyrrolate, are suitable for once daily administration and, unlike tiotropium, have a rapid onset of action.  New LAMAs and their combination with ultra-LABA and, possibly, inhaled corticosteroids, seem to open new perspectives in the management of COPD.  Dual-pharmacol. muscarinic antagonist-beta2 agonist (MABA) mols. present a novel approach to the treatment of COPD by combining muscarinic antagonism and beta2 agonism in a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYOw4zXsYanrVg90H21EOLACvtfcHk0ljOGytX6nPAYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmt1ynsLg%253D&md5=3e12b45f2c1c0bc03f7d54f62096b48f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F0929867311320120002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320120002%26sid%3Dliteratum%253Aachs%26aulast%3DMontuschi%26aufirst%3DP.%26aulast%3DMacagno%26aufirst%3DF.%26aulast%3DValente%26aufirst%3DS.%26aulast%3DFuso%26aufirst%3DL.%26atitle%3DInhaled%2520muscarinic%2520acetylcholine%2520receptor%2520antagonists%2520for%2520treatment%2520of%2520COPD%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26spage%3D1464%26epage%3D1476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Fuso, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mores, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valente, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malerba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montuschi, P.</span><span> </span><span class="NLM_article-title">Long-acting beta-agonists and their association with inhaled corticosteroids in COPD</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1477</span><span class="NLM_x">–</span> <span class="NLM_lpage">1495</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.2174%2F0929867311320120003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23409722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt1ynsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1477-1495&author=L.+Fusoauthor=N.+Moresauthor=S.+Valenteauthor=M.+Malerbaauthor=P.+Montuschi&title=Long-acting+beta-agonists+and+their+association+with+inhaled+corticosteroids+in+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Long-acting beta-agonists and their association with inhaled corticosteroids in COPD</span></div><div class="casAuthors">Fuso, L.; Mores, N.; Valente, S.; Malerba, M.; Montuschi, P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1477-1495</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Inhaled bronchodilators, including beta2-agonists and antimuscaric receptor antagonists, are the mainstay of pharmacotherapy in chronic obstructive pulmonary disease (COPD).  The short-acting beta2-agonists, including salbutamol, and fenoterol, have a rapid onset of action, a bronchodilating effect for 3-6 h and are used on demand.  The long-acting beta2-agonists (LABAs), including salmeterol and formoterol, have 12-h duration of action and are used with a twice-daily dosing regimen for long-term COPD treatment.  Unlike salmeterol, formoterol has a rapid onset of action.  Pharmacol. characteristics required by novel inhaled LABAs include 24 h bronchodilator effect in vivo which would make them suitable for once daily administration (ultra-LABA), high potency and selectivity for beta2-adrenoceptors, rapid onset of action, low oral bioavailability (< 5%) after inhalation, and high systemic clearance.  Indacaterol, which has been approved for long-term treatment of COPD in Europe and in the USA, has a 24-h duration of action and a once-daily dosing regimen.  Newer ultra-LABAs, including olodaterol, vilanterol, milveterol, carmoterol, and abediterol, are in development.  Combination with ICS (fluticasone/salmeterol, budesonide/formoterol, beclomethasone/formoterol) appears to provide an addnl. benefit over the monocomponent therapy, although the extent of this benefit is variable and often not clin. significant in all the endpoints assessed.  In patients with COPD, treatment with ICS is assocd. with increased risk of pneumonia which should be carefully considered when assessing the risk/benefit ratio of ICS/LABA combinations.  Subphenotyping of patients with COPD (e.g., frequent exacerbations, sputum eosinophilia, mixed asthma/COPD phenotype) might help identify those patients who are most likely to benefit from addn. of ICS to bronchodilating treatment.  Ultra-LABA/ long-acting muscarinic receptor antagonist (LAMA) combination treatment is under development and is likely to become a std. pharmacol. strategy for COPD.  Dual-pharmacol. inhaled muscarinic antagonist-beta2 agonist (MABA) mols. provide a new approach to the treatment of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqtajjRd8d0LVg90H21EOLACvtfcHk0ljOGytX6nPAYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmt1ynsLk%253D&md5=32add113b9bc1d3a8e68df8d1acb7fe8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F0929867311320120003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320120003%26sid%3Dliteratum%253Aachs%26aulast%3DFuso%26aufirst%3DL.%26aulast%3DMores%26aufirst%3DN.%26aulast%3DValente%26aufirst%3DS.%26aulast%3DMalerba%26aufirst%3DM.%26aulast%3DMontuschi%26aufirst%3DP.%26atitle%3DLong-acting%2520beta-agonists%2520and%2520their%2520association%2520with%2520inhaled%2520corticosteroids%2520in%2520COPD%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26spage%3D1477%26epage%3D1495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Woods, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nealy, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrons, R. W.</span><span> </span><span class="NLM_article-title">Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Ann. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1017</span><span class="NLM_x">–</span> <span class="NLM_lpage">1028</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2013&pages=1017-1028&author=J.+A.+Woodsauthor=K.+L.+Nealyauthor=R.+W.+Barrons&title=Aclidinium+bromide%3A+an+alternative+long-acting+inhaled+anticholinergic+in+the+management+of+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWoods%26aufirst%3DJ.%2BA.%26aulast%3DNealy%26aufirst%3DK.%2BL.%26aulast%3DBarrons%26aufirst%3DR.%2BW.%26atitle%3DAclidinium%2520bromide%253A%2520an%2520alternative%2520long-acting%2520inhaled%2520anticholinergic%2520in%2520the%2520management%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2013%26volume%3D47%26spage%3D1017%26epage%3D1028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Carter, N. J.</span><span> </span><span class="NLM_article-title">Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">741</span><span class="NLM_x">–</span> <span class="NLM_lpage">753</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=741-753&author=N.+J.+Carter&title=Inhaled+glycopyrronium+bromide%3A+a+review+of+its+use+in+patients+with+moderate+to+severe+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DN.%2BJ.%26atitle%3DInhaled%2520glycopyrronium%2520bromide%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520patients%2520with%2520moderate%2520to%2520severe%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D741%26epage%3D753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Scott, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hair, P.</span><span> </span><span class="NLM_article-title">Umeclidinium/vilanterol: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">389</span><span class="NLM_x">–</span> <span class="NLM_lpage">395</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=389-395&author=L.+J.+Scottauthor=P.+Hair&title=Umeclidinium%2Fvilanterol%3A+first+global+approval"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26aulast%3DHair%26aufirst%3DP.%26atitle%3DUmeclidinium%252Fvilanterol%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D389%26epage%3D395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Moen, M. D.</span><span> </span><span class="NLM_article-title">Indacaterol: in chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">2269</span><span class="NLM_x">–</span> <span class="NLM_lpage">2280</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=2269-2280&author=M.+D.+Moen&title=Indacaterol%3A+in+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoen%26aufirst%3DM.%2BD.%26atitle%3DIndacaterol%253A%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DDrugs%26date%3D2010%26volume%3D70%26spage%3D2269%26epage%3D2280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Belmonte, K. E.</span><span> </span><span class="NLM_article-title">Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Proc. Am. Thorac. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="NLM_x">–</span> <span class="NLM_lpage">304</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1513%2Fpats.200504-043SR" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=16267352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlams7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=297-304&author=K.+E.+Belmonte&title=Cholinergic+pathways+in+the+lungs+and+anticholinergic+therapy+for+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Belmonte, Kristen E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the American Thoracic Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">297-304</span>CODEN:
                <span class="NLM_cas:coden">PATSBB</span>;
        ISSN:<span class="NLM_cas:issn">1546-3222</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">A review.  Abundant data from animal models and humans support the hypothesis that changes at the level of parasympathetic neuronal control of airway smooth muscle result in increased bronchoconstriction in response to vagal stimulation, leading to airway hyper-responsiveness.  Neuronal inhibitory M2 muscarinic acetylcholine receptors on parasympathetic nerves are responsible for limiting acetylcholine release from these nerves.  In humans with asthma, and after pulmonary inflammatory events in exptl. animals, these receptors are dysfunctional, which results in airway hyper-responsiveness.  Although it is unknown what mechanisms underlie airway hyperresponsiveness in chronic obstructive pulmonary disease, loss of parasympathetic control of airway smooth muscle is thought to be a contributing mechanism.  As such, anticholinergic therapy is used extensively and with a high degree of success in the treatment of this condition.  The future for inhaled anticholinergic compds. for the treatment of chronic obstructive pulmonary disease appears to rest in their combination with other agents, such as β2 agonists and phosphodiesterase-4 inhibitors.  Nonselective anticholinergic agents might be the best choice, because M2 muscarinic receptors on airway smooth muscle inhibit the generation and accumulation of cyclic adenosine monophosphate.  Adequate concurrent blockade of M3 muscarinic receptors would be expected to counteract the enhanced acetylcholine release that would result from blockade of neuronal inhibitory M2 muscarinic receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf5AsHs2UOPLVg90H21EOLACvtfcHk0ljdQ_nhrifAGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlams7vO&md5=98f86ecd7332496401526820d4efe9d7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1513%2Fpats.200504-043SR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1513%252Fpats.200504-043SR%26sid%3Dliteratum%253Aachs%26aulast%3DBelmonte%26aufirst%3DK.%2BE.%26atitle%3DCholinergic%2520pathways%2520in%2520the%2520lungs%2520and%2520anticholinergic%2520therapy%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DProc.%2520Am.%2520Thorac.%2520Soc.%26date%3D2005%26volume%3D2%26spage%3D297%26epage%3D304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Montuschi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malerba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miravitlles, M.</span><span> </span><span class="NLM_article-title">Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1928</span><span class="NLM_x">–</span> <span class="NLM_lpage">1935</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1928-1935&author=P.+Montuschiauthor=M.+Malerbaauthor=G.+Santiniauthor=M.+Miravitlles&title=Pharmacological+treatment+of+chronic+obstructive+pulmonary+disease%3A+from+evidence-based+medicine+to+phenotyping"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMontuschi%26aufirst%3DP.%26aulast%3DMalerba%26aufirst%3DM.%26aulast%3DSantini%26aufirst%3DG.%26aulast%3DMiravitlles%26aufirst%3DM.%26atitle%3DPharmacological%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520from%2520evidence-based%2520medicine%2520to%2520phenotyping%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D1928%26epage%3D1935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Roffel, A. F.; Meurs, H.; Zaagsma, J.</span><span> </span><span class="NLM_article-title">Identification, localization and function of muscarinic receptor subtypes in the airways</span>. In  <span class="citation_source-book">Muscarinic Receptors in Airways Diseases</span>; <span class="NLM_contrib-group">Zagsma, J.; Meurs, H.; Roffel, A. F.</span>, Ed.; <span class="NLM_publisher-name">Birkhauser Verlag</span>: <span class="NLM_publisher-loc">Basel, Switzerland</span>,<span class="NLM_x"> </span><span class="NLM_year">2001</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1007%2F978-3-0348-8358-0_3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&pages=63-85&author=A.+F.+Roffel&author=H.+Meurs&author=J.+Zaagsmaauthor=J.+Zagsma&author=H.+Meurs&author=A.+F.+Roffel&title=Muscarinic+Receptors+in+Airways+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2F978-3-0348-8358-0_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-0348-8358-0_3%26sid%3Dliteratum%253Aachs%26aulast%3DRoffel%26aufirst%3DA.%2BF.%26atitle%3DIdentification%252C%2520localization%2520and%2520function%2520of%2520muscarinic%2520receptor%2520subtypes%2520in%2520the%2520airways%26btitle%3DMuscarinic%2520Receptors%2520in%2520Airways%2520Diseases%26aulast%3DZagsma%26aufirst%3DJ.%26pub%3DBirkhauser%2520Verlag%26date%3D2001%26spage%3D63%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Brown, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koarai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturton, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnelly, L. E.</span><span> </span><span class="NLM_article-title">A role for M<sub>2</sub> and M<sub>3</sub> muscarinic receptors in the contraction of rat and human small airways</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">702</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">115</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.ejphar.2013.01.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23396230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktlOhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=702&publication_year=2013&pages=109-115&author=S.+M.+Brownauthor=A.+Koaraiauthor=R.+G.+Sturtonauthor=A.+G.+Nicholsonauthor=P.+J.+Barnesauthor=L.+E.+Donnelly&title=A+role+for+M2+and+M3+muscarinic+receptors+in+the+contraction+of+rat+and+human+small+airways"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A role for M2 and M3 muscarinic receptors in the contraction of rat and human small airways</span></div><div class="casAuthors">Brown, Stephanie M.; Koarai, Akira; Sturton, Richard G.; Nicholson, Andrew G.; Barnes, Peter J.; Donnelly, Louise E.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">702</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">109-115</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Large airway bronchoconstriction acts mainly through cholinergic pathways via muscarinic M3 receptors with some contribution from M2 receptors.  By contrast, the mechanisms of small airway contraction are largely unknown.  This study used precision cut lung slices to examine the role of muscarinic M2 and M3 receptors in the contractile response of rat and human small airways.  In rat small airways, the M3 preferential antagonist, 4-DAMP, inhibited carbachol-mediated contraction (1×10-6 M) more than that of the M2 selective antagonist, AF-DX 116 (pIC50 values: 8.85 and 6.31, resp.).  Tiotropium, inhibited the contractile response to carbachol with (pIC50: 9.86), but could not distinguish between M2 and M3 mediated effects.  Similar expts. using human small airways with tiotropium and AF-DX 116, gave a pIC50 of 10.35 and a pKB of 6.37, resp.  Therefore, M3 receptors play a key role in muscarinic contraction of small airways in both rats and humans but the effect of M2 receptors cannot be excluded.  To investigate the role of M2 receptors, carbachol-induced contraction of small airways was performed in the presence and absence of a β2-agonist in order to elevate intracellular cAMP levels prior to contraction.  Isoproterenol-induced relaxation was significantly increased by AF-DX 116 in rat small airways and by AF-DX 116, gallamine and pertussis toxin in human small airways.  Taken together, these data suggest that cholinergic antagonism of muscarinic receptors in human and rat small airways inhibits airway contraction via direct inhibition of contraction through M3 receptors, and by M2 receptor mediated inhibition of relaxation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqBUisXZhmerVg90H21EOLACvtfcHk0ljdQ_nhrifAGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktlOhsLs%253D&md5=9d490a7428d9948b0917f154b7c35eb1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2013.01.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2013.01.054%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DS.%2BM.%26aulast%3DKoarai%26aufirst%3DA.%26aulast%3DSturton%26aufirst%3DR.%2BG.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DDonnelly%26aufirst%3DL.%2BE.%26atitle%3DA%2520role%2520for%2520M2%2520and%2520M3%2520muscarinic%2520receptors%2520in%2520the%2520contraction%2520of%2520rat%2520and%2520human%2520small%2520airways%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D702%26spage%3D109%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Johnson, M.</span><span> </span><span class="NLM_article-title">The β-adrenoceptor</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">S146</span><span class="NLM_x">–</span> <span class="NLM_lpage">S153</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1164%2Fajrccm.158.supplement_2.13tac110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=9817738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADyaK1M%252FlsFSksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=1998&pages=S146-S153&author=M.+Johnson&title=The+%CE%B2-adrenoceptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The beta-adrenoceptor</span></div><div class="casAuthors">Johnson M</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">5 Pt 3</span>),
    <span class="NLM_cas:pages">S146-53</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">The human beta-adrenoceptor is a member of the seven-transmembrane family of receptors, encoded by a gene on chromosome 5. beta-Adrenoceptors have been classified into beta1, beta2, and beta3 subgroups, with beta2-receptors being widely distributed in the respiratory tract, particularly in airway smooth muscle.  Intracellular signaling following beta2-adrenoceptor activation is largely affected through a trimeric Gs protein coupled to adenylate cyclase.  Cyclic AMP (cAMP) induces airway relaxation through phosphorylation of muscle regulatory proteins and attenuation of cellular Ca2+ concentrations.  Alternative cAMP-independent pathways involving activation of membrane maxi-K+ channels and coupling through Gi to the MAP kinase system have also been described.  Site-directed mutagenesis has identified Asp 113 and Ser 204/207 within the third and fourth membrane domains as the active site of the beta2-receptor, critical for beta2-agonist binding and activity. beta2-Agonists have been characterized as those that directly activate the receptor (albuterol), those that are taken up into a membrane depot (formoterol), and those that interact with a receptor-specific auxiliary binding site (salmeterol).  These differences in mechanism of action are reflected in the kinetics of airway smooth muscle relaxation and bronchodilation in patients with asthma. beta-Adrenoceptor desensitization associated with beta2-agonist activation is a consequence of phosphorylation by beta-ARK and uncoupling of the receptor from Gs following beta-arrestin binding, of internalization and recycling of the receptor through processes of sequestration and resensitization and downregulation, modulated by an effect on receptor gene expression.  The degree of receptor desensitization appears to differ, depending on the cell or tissue type, and is reflected in the different profiles of clinical tolerance to chronic beta2-agonist therapy.  A number of polymorphisms of the beta2-receptor have been described that appear to alter the behavior of the receptor following agonist exposure.  These include Arg-Gly 16, Glu-Gln 27, and Thr-lle 164.  The Gly 16 receptor downregulates to a greater extent and is associated with increased airway hyperreactivity, nocturnal symptoms, and more severe asthma.  The Glu 27 form appears to protect against downregulation and is associated with less reactive airways.  An individual can be homozygous or heterozygous for given polymorphisms, and large populations will have to be studied to determine their importance to the asthma phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7eYHSZZemQ9yzdcP07UmufW6udTcc2eaAlFb_ZQ-Ls7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M%252FlsFSksg%253D%253D&md5=b35ba94acecce6e5da1f0373051d5c7f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.158.supplement_2.13tac110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.158.supplement_2.13tac110%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DM.%26atitle%3DThe%2520%25CE%25B2-adrenoceptor%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D1998%26volume%3D158%26spage%3DS146%26epage%3DS153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Cave, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurst, M. M.</span><span> </span><span class="NLM_article-title">The use of long acting β<sub>2</sub>-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">114</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.pharmthera.2010.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=21276815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFyiurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2011&pages=114-143&author=A.+C.+Caveauthor=M.+M.+Hurst&title=The+use+of+long+acting+%CE%B22-agonists%2C+alone+or+in+combination+with+inhaled+corticosteroids%2C+in+chronic+obstructive+pulmonary+disease+%28COPD%29%3A+a+risk-benefit+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The use of long acting β2-agonists, alone or in combination with inhaled corticosteroids, in Chronic Obstructive Pulmonary Disease (COPD)</span></div><div class="casAuthors">Cave, Alison C.; Hurst, Martin M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">114-143</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Chronic Obstructive Pulmonary Disease (COPD) is a slowly progressive, largely non-reversible pulmonary disease which is characterised by airflow limitation.  It is one of the few diseases with an increasing mortality rate and by 2020 it is predicted to be the third leading cause of death.  The mainstays of current treatment are long acting β2 agonists (LABAs) coupled with an increasing reliance on inhaled corticosteroids (ICS).  Two LABAs (salmeterol and formoterol) are currently licenced for COPD both as monotherapy and in combination with ICS (fluticasone propionate (FP) and budesonide resp.).  A comprehensive review of the risk-benefit of these medicines in COPD is provided here which concludes that there is limited efficacy for LABAs in COPD either alone or in combination with ICS and no overall modification of the disease process.  However, where directly compared, combination therapy usually provides an advantage over monotherapy.  Importantly the apparent effectiveness of treatment may significantly depend upon the outcome measure chosen with some measures possibly underestimating the extent of benefit.  ICS benefit may also be greater in those patients who respond to treatment.  Set against this benefit are recent concerns that a no. of issues related to the clin. trial design such as prior use of ICS and different withdrawal rates between groups may be significantly influencing results.  Furthermore there is no evidence of a dose response relationship with regard to ICS dose.  A key issue with combination therapy is the excess risk of pneumonia conferred by the use of an ICS in this patient population.  This risk does not appear to be proportional to the ICS dose but may differ between FP and budesonide.  We conclude that further studies are required to identify the optimal dose of ICS, in terms of both risk and benefit, and to confirm their benefit in steroid naive patients.  Furthermore it will be important to det. whether the risk of pneumonia is apparent with both FP and budesonide and to identify factors which may predict steroid responsiveness in COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Im_9h0AAEbVg90H21EOLACvtfcHk0lipoQIRNBASUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFyiurc%253D&md5=3c96fa3cf9801bb657731b17448f48d5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2010.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2010.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DCave%26aufirst%3DA.%2BC.%26aulast%3DHurst%26aufirst%3DM.%2BM.%26atitle%3DThe%2520use%2520of%2520long%2520acting%2520%25CE%25B22-agonists%252C%2520alone%2520or%2520in%2520combination%2520with%2520inhaled%2520corticosteroids%252C%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%2520%2528COPD%2529%253A%2520a%2520risk-benefit%2520analysis%26jtitle%3DPharmacol.%2520Ther.%26date%3D2011%26volume%3D130%26spage%3D114%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Procopiou, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bevan, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggadike, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butchers, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coe, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conroy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edney, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Field, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guntrip, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Looker, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLay, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteith, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutch, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasse, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. E.</span><span> </span><span class="NLM_article-title">Synthesis and structure–activity relationships of long-acting beta<sub>2</sub> adrenergic receptor agonists incorporating arylsulfonamide groups</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">2280</span><span class="NLM_x">–</span> <span class="NLM_lpage">2288</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801016j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2280-2288&author=P.+A.+Procopiouauthor=V.+J.+Barrettauthor=N.+J.+Bevanauthor=K.+Biggadikeauthor=P.+R.+Butchersauthor=D.+M.+Coeauthor=R.+Conroyauthor=D.+D.+Edneyauthor=R.+N.+Fieldauthor=A.+J.+Fordauthor=S.+B.+Guntripauthor=B.+E.+Lookerauthor=I.+M.+McLayauthor=M.+J.+Monteithauthor=V.+S.+Morrisonauthor=P.+J.+Mutchauthor=S.+A.+Richardsauthor=R.+Sasseauthor=C.+E.+Smith&title=Synthesis+and+structure%E2%80%93activity+relationships+of+long-acting+beta2+adrenergic+receptor+agonists+incorporating+arylsulfonamide+groups"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm801016j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801016j%26sid%3Dliteratum%253Aachs%26aulast%3DProcopiou%26aufirst%3DP.%2BA.%26aulast%3DBarrett%26aufirst%3DV.%2BJ.%26aulast%3DBevan%26aufirst%3DN.%2BJ.%26aulast%3DBiggadike%26aufirst%3DK.%26aulast%3DButchers%26aufirst%3DP.%2BR.%26aulast%3DCoe%26aufirst%3DD.%2BM.%26aulast%3DConroy%26aufirst%3DR.%26aulast%3DEdney%26aufirst%3DD.%2BD.%26aulast%3DField%26aufirst%3DR.%2BN.%26aulast%3DFord%26aufirst%3DA.%2BJ.%26aulast%3DGuntrip%26aufirst%3DS.%2BB.%26aulast%3DLooker%26aufirst%3DB.%2BE.%26aulast%3DMcLay%26aufirst%3DI.%2BM.%26aulast%3DMonteith%26aufirst%3DM.%2BJ.%26aulast%3DMorrison%26aufirst%3DV.%2BS.%26aulast%3DMutch%26aufirst%3DP.%2BJ.%26aulast%3DRichards%26aufirst%3DS.%2BA.%26aulast%3DSasse%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DC.%2BE.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520long-acting%2520beta2%2520adrenergic%2520receptor%2520agonists%2520incorporating%2520arylsulfonamide%2520groups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2280%26epage%3D2288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Baur, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beattie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruce, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuenoud, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernst, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairhurst, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faller, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fozard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fullerton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janus, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loeuillet-Ritzler, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moser, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steward, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sykes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tedaldi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trifilieff, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tweed, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissler, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyss, D.</span><span> </span><span class="NLM_article-title">The identification of indacaterol as an ultra long-acting inhaled beta<sub>2</sub>-adrenoceptor agonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3675</span><span class="NLM_x">–</span> <span class="NLM_lpage">3684</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100068m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3675-3684&author=F.+Baurauthor=D.+Beattieauthor=D.+Beerauthor=D.+Bentleyauthor=M.+Bradleyauthor=I.+Bruceauthor=S.+J.+Charltonauthor=B.+Cuenoudauthor=R.+Ernstauthor=R.+A.+Fairhurstauthor=B.+Fallerauthor=D.+Farrauthor=T.+Kellerauthor=J.+R.+Fozardauthor=J.+Fullertonauthor=S.+Garmanauthor=J.+Hattoauthor=C.+Haydenauthor=H.+Heauthor=C.+Howesauthor=D.+Janusauthor=Z.+Jiangauthor=C.+Lewisauthor=F.+Loeuillet-Ritzlerauthor=H.+Moserauthor=J.+Reillyauthor=A.+Stewardauthor=D.+Sykesauthor=L.+Tedaldiauthor=A.+Trifilieffauthor=M.+Tweedauthor=S.+Watsonauthor=E.+Wisslerauthor=D.+Wyss&title=The+identification+of+indacaterol+as+an+ultra+long-acting+inhaled+beta2-adrenoceptor+agonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm100068m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100068m%26sid%3Dliteratum%253Aachs%26aulast%3DBaur%26aufirst%3DF.%26aulast%3DBeattie%26aufirst%3DD.%26aulast%3DBeer%26aufirst%3DD.%26aulast%3DBentley%26aufirst%3DD.%26aulast%3DBradley%26aufirst%3DM.%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DCuenoud%26aufirst%3DB.%26aulast%3DErnst%26aufirst%3DR.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DFaller%26aufirst%3DB.%26aulast%3DFarr%26aufirst%3DD.%26aulast%3DKeller%26aufirst%3DT.%26aulast%3DFozard%26aufirst%3DJ.%2BR.%26aulast%3DFullerton%26aufirst%3DJ.%26aulast%3DGarman%26aufirst%3DS.%26aulast%3DHatto%26aufirst%3DJ.%26aulast%3DHayden%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DHowes%26aufirst%3DC.%26aulast%3DJanus%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DLoeuillet-Ritzler%26aufirst%3DF.%26aulast%3DMoser%26aufirst%3DH.%26aulast%3DReilly%26aufirst%3DJ.%26aulast%3DSteward%26aufirst%3DA.%26aulast%3DSykes%26aufirst%3DD.%26aulast%3DTedaldi%26aufirst%3DL.%26aulast%3DTrifilieff%26aufirst%3DA.%26aulast%3DTweed%26aufirst%3DM.%26aulast%3DWatson%26aufirst%3DS.%26aulast%3DWissler%26aufirst%3DE.%26aulast%3DWyss%26aufirst%3DD.%26atitle%3DThe%2520identification%2520of%2520indacaterol%2520as%2520an%2520ultra%2520long-acting%2520inhaled%2520beta2-adrenoceptor%2520agonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3675%26epage%3D3684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Szczuka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wennerberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Packeu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vauquelin, G.</span><span> </span><span class="NLM_article-title">Molecular mechanisms for the persistent bronchodilatory effect of the beta<sub>2</sub>-adrenoceptor agonist salmeterol</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">–</span> <span class="NLM_lpage">194</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1111%2Fj.1476-5381.2009.00296.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=19594756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKlsr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2009&pages=183-194&author=A.+Szczukaauthor=M.+Wennerbergauthor=A.+Packeuauthor=G.+Vauquelin&title=Molecular+mechanisms+for+the+persistent+bronchodilatory+effect+of+the+beta2-adrenoceptor+agonist+salmeterol"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms for the persistent bronchodilatory effect of the β2-adrenoceptor agonist salmeterol</span></div><div class="casAuthors">Szczuka, A.; Wennerberg, M.; Packeu, A.; Vauquelin, G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">183-194</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">β2-adrenoceptor agonists are effective bronchodilators.  In vitro studies demonstrated long-lasting airway smooth muscle relaxation by salmeterol after washout, the quick disappearance of this effect in presence of antagonists and its recovery after antagonist removal.  Current explanations invoke salmeterol accumulation in the membrane ('diffusion microkinetic' model) or the existence of salmeterol-binding 'exosites'.  An alternative model based on 'rebinding' of a dissocd. ligand to the receptor mols. also produces an apparent decrease in the ligand's dissocn. rate in the absence of competing ligands.  Computer-assisted simulations were performed to follow the receptor-occupation by a salmeterol-like ligand and a competing ligand as a function of time.  The aptness of the models to describe the above in vitro findings was evaluated.  The 'diffusion microkinetic' model is sufficient to explain a long-lasting β2-adrenoceptor stimulation and reassertion as long as the membrane harbors a high concn. of the agonist.  At lower concn., 'rebinding' and, in second place, 'exosite' binding are likely to become operational.  The 'rebinding' and 'exosite' binding mechanisms take place at a sub-cellular/mol. scale.  Pending their demonstration by expts. on appropriate, simple models such as intact cells or membranes thereof, these mechanisms remain hypothetical in the case of salmeterol.  Airway smooth muscle contraction could also be governed by addnl. mechanisms that are particular to this macroscopic approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEC9rfvp5YbbVg90H21EOLACvtfcHk0liVOy1mQi3hcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKlsr7M&md5=0515669d4f02ba8bd14f1bca84da4275</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00296.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00296.x%26sid%3Dliteratum%253Aachs%26aulast%3DSzczuka%26aufirst%3DA.%26aulast%3DWennerberg%26aufirst%3DM.%26aulast%3DPackeu%26aufirst%3DA.%26aulast%3DVauquelin%26aufirst%3DG.%26atitle%3DMolecular%2520mechanisms%2520for%2520the%2520persistent%2520bronchodilatory%2520effect%2520of%2520the%2520beta2-adrenoceptor%2520agonist%2520salmeterol%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D158%26spage%3D183%26epage%3D194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Rhodes, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbette, L.</span><span> </span><span class="NLM_article-title">Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">596</span><span class="NLM_x">–</span> <span class="NLM_lpage">602</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1992&pages=596-602&author=D.+G.+Rhodesauthor=R.+Newtonauthor=R.+Butlerauthor=L.+Herbette&title=Equilibrium+and+kinetic+studies+of+the+interactions+of+salmeterol+with+membrane+bilayers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRhodes%26aufirst%3DD.%2BG.%26aulast%3DNewton%26aufirst%3DR.%26aulast%3DButler%26aufirst%3DR.%26aulast%3DHerbette%26aufirst%3DL.%26atitle%3DEquilibrium%2520and%2520kinetic%2520studies%2520of%2520the%2520interactions%2520of%2520salmeterol%2520with%2520membrane%2520bilayers%26jtitle%3DMol.%2520Pharmacol.%26date%3D1992%26volume%3D42%26spage%3D596%26epage%3D602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Johnson, M.</span><span> </span><span class="NLM_article-title">Beta<sub>2</sub>-adrenoceptors: mechanisms of action of beta<sub>2</sub>-agonists</span> <span class="citation_source-journal">Paediatr. Respir. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1053%2Fprrv.2000.0102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=16263481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BD2Mros1amtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=57-62&author=M.+Johnson&title=Beta2-adrenoceptors%3A+mechanisms+of+action+of+beta2-agonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Beta2-adrenoceptors: mechanisms of action of beta2-agonists</span></div><div class="casAuthors">Johnson M</div><div class="citationInfo"><span class="NLM_cas:title">Paediatric respiratory reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-62</span>
        ISSN:<span class="NLM_cas:issn">1526-0542</span>.
    </div><div class="casAbstract">The human beta2-adrenoceptor is a member of the 7 transmembrane family of receptors.  It is encoded by a gene on chromosome 5 and is widely distributed in the respiratory tract.  Following beta2-adrenoceptor activation, intracellular signalling is mainly produced by inducing cyclic AMP.  This produces airway relaxation through phosphorylation of muscle regulatory proteins and modification of cellular Ca2+concentrations.  Beta2-agonists have been characterised into those which directly activate the receptor (salbutamol/terbutaline), those which are taken up into a membrane depot (formoterol) and those which interact with a receptor-specific, auxiliary binding site (salmeterol).  These differences in mechanism of action are reflected in the kinetics of airway smooth muscle relaxation and bronchodilation in asthmatic patients.  Beta-adrenoceptor desensitisation is associated with beta2-agonist activation and differs depending on the cell type.  It is reflected in the different profiles of clinical tolerance to chronic beta2-agonist therapy.  A number of polymorphisms of the beta2-receptor have been described which appear to alter the behaviour of the receptor, including the degree of downregulation and response to beta2-agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRUowsFMb9kLcvLc4ARHEmzfW6udTcc2eadxAJi42M7fLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mros1amtg%253D%253D&md5=18b08b6aa45ab53a8bf757299ad12dfe</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1053%2Fprrv.2000.0102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fprrv.2000.0102%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DM.%26atitle%3DBeta2-adrenoceptors%253A%2520mechanisms%2520of%2520action%2520of%2520beta2-agonists%26jtitle%3DPaediatr.%2520Respir.%2520Rev.%26date%3D2001%26volume%3D2%26spage%3D57%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Coleman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nials, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vardey, C. J.</span><span> </span><span class="NLM_article-title">Exosites: their current status, and their relevance to the duration of action of long-acting beta<sub>2</sub>-adrenoceptor agonists</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">324</span><span class="NLM_x">–</span> <span class="NLM_lpage">330</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1996&pages=324-330&author=R.+A.+Colemanauthor=M.+Johnsonauthor=A.+T.+Nialsauthor=C.+J.+Vardey&title=Exosites%3A+their+current+status%2C+and+their+relevance+to+the+duration+of+action+of+long-acting+beta2-adrenoceptor+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DR.%2BA.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DNials%26aufirst%3DA.%2BT.%26aulast%3DVardey%26aufirst%3DC.%2BJ.%26atitle%3DExosites%253A%2520their%2520current%2520status%252C%2520and%2520their%2520relevance%2520to%2520the%2520duration%2520of%2520action%2520of%2520long-acting%2520beta2-adrenoceptor%2520agonists%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1996%26volume%3D17%26spage%3D324%26epage%3D330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Austin, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barton, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnert, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cage, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheshire, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougall, I. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ince, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairaudeau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, A.</span><span> </span><span class="NLM_article-title">QSAR and the rational design of long-acting dual D<sub>2</sub>-receptor/beta<sub>2</sub>-adrenoceptor agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">3210</span><span class="NLM_x">–</span> <span class="NLM_lpage">3220</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020886c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=3210-3220&author=R.+P.+Austinauthor=P.+Bartonauthor=R.+V.+Bonnertauthor=R.+C.+Brownauthor=P.+A.+Cageauthor=D.+R.+Cheshireauthor=A.+M.+Davisauthor=I.+G.+Dougallauthor=F.+Inceauthor=G.+Pairaudeauauthor=A.+Young&title=QSAR+and+the+rational+design+of+long-acting+dual+D2-receptor%2Fbeta2-adrenoceptor+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm020886c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020886c%26sid%3Dliteratum%253Aachs%26aulast%3DAustin%26aufirst%3DR.%2BP.%26aulast%3DBarton%26aufirst%3DP.%26aulast%3DBonnert%26aufirst%3DR.%2BV.%26aulast%3DBrown%26aufirst%3DR.%2BC.%26aulast%3DCage%26aufirst%3DP.%2BA.%26aulast%3DCheshire%26aufirst%3DD.%2BR.%26aulast%3DDavis%26aufirst%3DA.%2BM.%26aulast%3DDougall%26aufirst%3DI.%2BG.%26aulast%3DInce%26aufirst%3DF.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DYoung%26aufirst%3DA.%26atitle%3DQSAR%2520and%2520the%2520rational%2520design%2520of%2520long-acting%2520dual%2520D2-receptor%252Fbeta2-adrenoceptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D3210%26epage%3D3220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Glossop, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strang, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeadon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perros-Huguet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevethick, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machin, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairman, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agoram, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeder, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Entwistle, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spence, F. J.</span><span> </span><span class="NLM_article-title">Inhalation by design: novel tertiary amine muscarinic M<sub>3</sub> receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6888</span><span class="NLM_x">–</span> <span class="NLM_lpage">6904</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200884j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1SltbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6888-6904&author=P.+A.+Glossopauthor=C.+A.+Watsonauthor=D.+A.+Priceauthor=M.+E.+Bunnageauthor=D.+S.+Middletonauthor=A.+Woodauthor=K.+Jamesauthor=D.+Robertsauthor=R.+S.+Strangauthor=M.+Yeadonauthor=C.+Perros-Huguetauthor=N.+P.+Clarkeauthor=M.+A.+Trevethickauthor=I.+Machinauthor=E.+F.+Stuartauthor=S.+M.+Evansauthor=A.+C.+Harrisonauthor=D.+A.+Fairmanauthor=B.+Agoramauthor=J.+L.+Burrowsauthor=N.+Feederauthor=C.+K.+Fultonauthor=B.+R.+Dillonauthor=D.+A.+Entwistleauthor=F.+J.+Spence&title=Inhalation+by+design%3A+novel+tertiary+amine+muscarinic+M3+receptor+antagonists+with+slow+off-rate+binding+kinetics+for+inhaled+once-daily+treatment+of+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Inhalation by Design: Novel Tertiary Amine Muscarinic M3 Receptor Antagonists with Slow Off-Rate Binding Kinetics for Inhaled Once-Daily Treatment of Chronic Obstructive Pulmonary Disease</span></div><div class="casAuthors">Glossop, Paul A.; Watson, Christine A. L.; Price, David A.; Bunnage, Mark E.; Middleton, Donald S.; Wood, Anthony; James, Kim; Roberts, Dannielle; Strang, Ross S.; Yeadon, Michael; Perros-Huguet, Christelle; Clarke, Nicholas P.; Trevethick, Michael A.; Machin, Ian; Stuart, Emilio F.; Evans, Steven M.; Harrison, Anthony C.; Fairman, David A.; Agoram, Balaji; Burrows, Jane L.; Feeder, Neil; Fulton, Craig K.; Dillon, Barry R.; Entwistle, David A.; Spence, Fiona J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6888-6904</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel tertiary amine series of potent muscarinic M3 receptor antagonists are described that exhibit potential as inhaled long-acting bronchodilators for the treatment of chronic obstructive pulmonary disease.  Geminal di-Me functionality present in this series of compds. confers very long dissociative half-life (slow off-rate) from the M3 receptor that mediates very long-lasting smooth muscle relaxation in guinea pig tracheal strips.  Optimization of pharmacokinetic properties was achieved by combining rapid oxidative clearance with targeted introduction of a phenolic moiety to secure rapid glucuronidation.  Together, these attributes minimize systemic exposure following inhalation, mitigate potential drug-drug interactions, and reduce systemically mediated adverse events.  Compd. 47 (PF-3635659) is identified as a Phase II clin. candidate from this series with in vivo duration of action studies confirming its potential for once-daily use in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs8Q4T5oR53bVg90H21EOLACvtfcHk0ljZ7ssWo-Do5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1SltbzM&md5=ca9b632b4c7982fb44c0d5dd17a056bf</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm200884j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200884j%26sid%3Dliteratum%253Aachs%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DWatson%26aufirst%3DC.%2BA.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DMiddleton%26aufirst%3DD.%2BS.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DRoberts%26aufirst%3DD.%26aulast%3DStrang%26aufirst%3DR.%2BS.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DClarke%26aufirst%3DN.%2BP.%26aulast%3DTrevethick%26aufirst%3DM.%2BA.%26aulast%3DMachin%26aufirst%3DI.%26aulast%3DStuart%26aufirst%3DE.%2BF.%26aulast%3DEvans%26aufirst%3DS.%2BM.%26aulast%3DHarrison%26aufirst%3DA.%2BC.%26aulast%3DFairman%26aufirst%3DD.%2BA.%26aulast%3DAgoram%26aufirst%3DB.%26aulast%3DBurrows%26aufirst%3DJ.%2BL.%26aulast%3DFeeder%26aufirst%3DN.%26aulast%3DFulton%26aufirst%3DC.%2BK.%26aulast%3DDillon%26aufirst%3DB.%2BR.%26aulast%3DEntwistle%26aufirst%3DD.%2BA.%26aulast%3DSpence%26aufirst%3DF.%2BJ.%26atitle%3DInhalation%2520by%2520design%253A%2520novel%2520tertiary%2520amine%2520muscarinic%2520M3%2520receptor%2520antagonists%2520with%2520slow%2520off-rate%2520binding%2520kinetics%2520for%2520inhaled%2520once-daily%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6888%26epage%3D6904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Brown, J. H.; Taylor, P.</span><span> </span><span class="NLM_article-title">Muscarinic receptor agonists and antagonists</span>. In  <span class="citation_source-book">Goodman and Gilman’s The Pharmacological Basis of Therapeutics</span>, <span class="NLM_edition">9</span>th ed.; <span class="NLM_contrib-group">Hardman, J. G.; Limbird, L. E.; Molinoff, P. B.; Ruddon, R. W.; Gilman, A. G.</span>, Eds.; <span class="NLM_publisher-name">McGraw-Hill</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">1996</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">160</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&pages=141-160&author=J.+H.+Brown&author=P.+Taylorauthor=J.+G.+Hardman&author=L.+E.+Limbird&author=P.+B.+Molinoff&author=R.+W.+Ruddon&author=A.+G.+Gilman&title=Goodman+and+Gilman%E2%80%99s+The+Pharmacological+Basis+of+Therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DJ.%2BH.%26atitle%3DMuscarinic%2520receptor%2520agonists%2520and%2520antagonists%26btitle%3DGoodman%2520and%2520Gilman%25E2%2580%2599s%2520The%2520Pharmacological%2520Basis%2520of%2520Therapeutics%26aulast%3DHardman%26aufirst%3DJ.%2BG.%26pub%3DMcGraw-Hill%26date%3D1996%26spage%3D141%26epage%3D160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Gordon, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breuer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padilla, F. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smejkal, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaing, P. K.</span><span> </span><span class="NLM_article-title">Distance geometry of α-substituted 2,2-diphenylpropionate antimuscarinics</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">766</span><span class="NLM_x">–</span> <span class="NLM_lpage">772</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1989&pages=766-772&author=R.+K.+Gordonauthor=E.+Breuerauthor=F.+N.+Padillaauthor=R.+M.+Smejkalauthor=P.+K.+Chaing&title=Distance+geometry+of+%CE%B1-substituted+2%2C2-diphenylpropionate+antimuscarinics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DR.%2BK.%26aulast%3DBreuer%26aufirst%3DE.%26aulast%3DPadilla%26aufirst%3DF.%2BN.%26aulast%3DSmejkal%26aufirst%3DR.%2BM.%26aulast%3DChaing%26aufirst%3DP.%2BK.%26atitle%3DDistance%2520geometry%2520of%2520%25CE%25B1-substituted%25202%252C2-diphenylpropionate%2520antimuscarinics%26jtitle%3DMol.%2520Pharmacol.%26date%3D1989%26volume%3D36%26spage%3D766%26epage%3D772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Tautermann, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiechle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeliger, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wex, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banholzer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gantner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieper, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casarosa, P.</span><span> </span><span class="NLM_article-title">Molecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M<sub>3</sub> receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">8746</span><span class="NLM_x">–</span> <span class="NLM_lpage">8756</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm401219y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFKksrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8746-8756&author=C.+S.+Tautermannauthor=T.+Kiechleauthor=D.+Seeligerauthor=S.+Diehlauthor=E.+Wexauthor=R.+Banholzerauthor=F.+Gantnerauthor=M.+P.+Pieperauthor=P.+Casarosa&title=Molecular+basis+for+the+long+duration+of+action+and+kinetic+selectivity+of+tiotropium+for+the+muscarinic+M3+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Basis for the Long Duration of Action and Kinetic Selectivity of Tiotropium for the Muscarinic M3 Receptor</span></div><div class="casAuthors">Tautermann, Christofer S.; Kiechle, Tobias; Seeliger, Daniel; Diehl, Sonja; Wex, Eva; Banholzer, Rolf; Gantner, Florian; Pieper, Michael P.; Casarosa, Paola</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8746-8756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antagonizing the human M3 muscarinic receptor (hM3R) over a long time is a key feature of modern bronchodilating COPD drugs aiming at symptom relief.  The long duration of action of the antimuscarinic drug tiotropium and its kinetic subtype selectivity over hM2R are investigated by kinetic mapping of the binding site and the exit channel of hM3R.  Hence, dissocn. expts. have been performed with a set of mol. matched pairs of tiotropium on a large variety of mutated variants of hM3R.  The exceedingly long half-life of tiotropium (of more than 24 h) is attributed to interactions in the binding site; particularly a highly directed interaction of the ligands' hydroxy group with an asparagine (N5086.52) prevents rapid dissocn. via a snap-lock mechanism.  The kinetic selectivity over hM2R, however, is caused by differences in the electrostatics and in the flexibility of the extracellular vestibule.  Extensive mol. dynamics simulations (several microseconds) support exptl. results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo95cclma8dobVg90H21EOLACvtfcHk0ljZ7ssWo-Do5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFKksrvF&md5=2dd0ce91408c70ba97cf99cdab16b8b2</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm401219y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401219y%26sid%3Dliteratum%253Aachs%26aulast%3DTautermann%26aufirst%3DC.%2BS.%26aulast%3DKiechle%26aufirst%3DT.%26aulast%3DSeeliger%26aufirst%3DD.%26aulast%3DDiehl%26aufirst%3DS.%26aulast%3DWex%26aufirst%3DE.%26aulast%3DBanholzer%26aufirst%3DR.%26aulast%3DGantner%26aufirst%3DF.%26aulast%3DPieper%26aufirst%3DM.%2BP.%26aulast%3DCasarosa%26aufirst%3DP.%26atitle%3DMolecular%2520basis%2520for%2520the%2520long%2520duration%2520of%2520action%2520and%2520kinetic%2520selectivity%2520of%2520tiotropium%2520for%2520the%2520muscarinic%2520M3%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8746%26epage%3D8756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Lainé, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busch-Petersen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neipp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdowson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaney, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttmann, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarau, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palovich, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmonte, K.</span><span> </span><span class="NLM_article-title">Design, synthesis, and structure–activity relationship of tropane muscarinic acetylcholine receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5241</span><span class="NLM_x">–</span> <span class="NLM_lpage">5252</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900736e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5241-5252&author=D.+I.+Lain%C3%A9author=Z.+Wanauthor=H.+Yanauthor=C.+Zhuauthor=H.+Xieauthor=W.+Fuauthor=J.+Busch-Petersenauthor=C.+Neippauthor=R.+Davisauthor=K.+L.+Widdowsonauthor=F.+E.+Blaneyauthor=J.+Foleyauthor=A.+M.+Baconauthor=E.+F.+Webbauthor=M.+A.+Luttmannauthor=M.+Burmanauthor=H.+M.+Sarauauthor=M.+Salmonauthor=M.+R.+Palovichauthor=K.+Belmonte&title=Design%2C+synthesis%2C+and+structure%E2%80%93activity+relationship+of+tropane+muscarinic+acetylcholine+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm900736e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900736e%26sid%3Dliteratum%253Aachs%26aulast%3DLain%25C3%25A9%26aufirst%3DD.%2BI.%26aulast%3DWan%26aufirst%3DZ.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DBusch-Petersen%26aufirst%3DJ.%26aulast%3DNeipp%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DWiddowson%26aufirst%3DK.%2BL.%26aulast%3DBlaney%26aufirst%3DF.%2BE.%26aulast%3DFoley%26aufirst%3DJ.%26aulast%3DBacon%26aufirst%3DA.%2BM.%26aulast%3DWebb%26aufirst%3DE.%2BF.%26aulast%3DLuttmann%26aufirst%3DM.%2BA.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DSarau%26aufirst%3DH.%2BM.%26aulast%3DSalmon%26aufirst%3DM.%26aulast%3DPalovich%26aufirst%3DM.%2BR.%26aulast%3DBelmonte%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure%25E2%2580%2593activity%2520relationship%2520of%2520tropane%2520muscarinic%2520acetylcholine%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5241%26epage%3D5252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Stocks, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alcaraz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowers, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donald, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kindon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairaudeau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theaker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, D. J.</span><span> </span><span class="NLM_article-title">The discovery of new spirocyclic muscarinic M<sub>3</sub> antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">7458</span><span class="NLM_x">–</span> <span class="NLM_lpage">7461</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7458-7461&author=M.+J.+Stocksauthor=L.+Alcarazauthor=A.+Baileyauthor=K.+Bowersauthor=D.+Donaldauthor=H.+Edwardsauthor=F.+Huntauthor=N.+Kindonauthor=G.+Pairaudeauauthor=J.+Theakerauthor=D.+J.+Warner&title=The+discovery+of+new+spirocyclic+muscarinic+M3+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26aulast%3DAlcaraz%26aufirst%3DL.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DBowers%26aufirst%3DK.%26aulast%3DDonald%26aufirst%3DD.%26aulast%3DEdwards%26aufirst%3DH.%26aulast%3DHunt%26aufirst%3DF.%26aulast%3DKindon%26aufirst%3DN.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DTheaker%26aufirst%3DJ.%26aulast%3DWarner%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520discovery%2520of%2520new%2520spirocyclic%2520muscarinic%2520M3%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D7458%26epage%3D7461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Lainé, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCleland, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neipp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underwood, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dufour, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdowson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palovich, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaney, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttmann, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmonte, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmon, M.</span><span> </span><span class="NLM_article-title">Discovery of novel 1-azoniabicyclo[2.2.2]octane muscarinic acetylcholine receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">2493</span><span class="NLM_x">–</span> <span class="NLM_lpage">2505</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801601v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2493-2505&author=D.+I.+Lain%C3%A9author=B.+McClelandauthor=S.+Thomasauthor=C.+Neippauthor=B.+Underwoodauthor=J.+Dufourauthor=K.+L.+Widdowsonauthor=M.+R.+Palovichauthor=F.+E.+Blaneyauthor=J.+J.+Foleyauthor=E.+F.+Webbauthor=M.+A.+Luttmannauthor=M.+Burmanauthor=K.+Belmonteauthor=M.+Salmon&title=Discovery+of+novel+1-azoniabicyclo%5B2.2.2%5Doctane+muscarinic+acetylcholine+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm801601v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801601v%26sid%3Dliteratum%253Aachs%26aulast%3DLain%25C3%25A9%26aufirst%3DD.%2BI.%26aulast%3DMcCleland%26aufirst%3DB.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DNeipp%26aufirst%3DC.%26aulast%3DUnderwood%26aufirst%3DB.%26aulast%3DDufour%26aufirst%3DJ.%26aulast%3DWiddowson%26aufirst%3DK.%2BL.%26aulast%3DPalovich%26aufirst%3DM.%2BR.%26aulast%3DBlaney%26aufirst%3DF.%2BE.%26aulast%3DFoley%26aufirst%3DJ.%2BJ.%26aulast%3DWebb%26aufirst%3DE.%2BF.%26aulast%3DLuttmann%26aufirst%3DM.%2BA.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DBelmonte%26aufirst%3DK.%26aulast%3DSalmon%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520novel%25201-azoniabicyclo%255B2.2.2%255Doctane%2520muscarinic%2520acetylcholine%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2493%26epage%3D2505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Kiesewetter, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverton, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckelman, W. C.</span><span> </span><span class="NLM_article-title">Syntheses and biological properties of chiral fluoroalkyl quinuclidinyl benzilates</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1711</span><span class="NLM_x">–</span> <span class="NLM_lpage">1719</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00010a016" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=1711-1719&author=D.+O.+Kiesewetterauthor=J.+V.+Silvertonauthor=W.+C.+Eckelman&title=Syntheses+and+biological+properties+of+chiral+fluoroalkyl+quinuclidinyl+benzilates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm00010a016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00010a016%26sid%3Dliteratum%253Aachs%26aulast%3DKiesewetter%26aufirst%3DD.%2BO.%26aulast%3DSilverton%26aufirst%3DJ.%2BV.%26aulast%3DEckelman%26aufirst%3DW.%2BC.%26atitle%3DSyntheses%2520and%2520biological%2520properties%2520of%2520chiral%2520fluoroalkyl%2520quinuclidinyl%2520benzilates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D1711%26epage%3D1719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Noronha-Blob, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturm, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, V.</span><span> </span><span class="NLM_article-title">Stereoselective antimuscarinic effects of 3-quinuclidinyl atrolactate and 3-quinuclidinyl xanthene-9-carboxylate</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">211</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2F0014-2999%2892%2990268-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=1618272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADyaK38XhsVCmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=211&publication_year=1992&pages=97-103&author=L.+Noronha-Blobauthor=B.+Sturmauthor=V.+Lowe&title=Stereoselective+antimuscarinic+effects+of+3-quinuclidinyl+atrolactate+and+3-quinuclidinyl+xanthene-9-carboxylate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Stereoselective antimuscarinic effects of 3-quinuclidinyl atrolactate and 3-quinuclidinyl xanthene-9-carboxylate</span></div><div class="casAuthors">Noronha-Blob, Lalita; Sturm, Bonnie; Lowe, Valerie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">211</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-103</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">The relative affinity and selectivity of the stereoisomers of 3-quinuclidinyl atrolactate (I) and the enantiomers of 3-quinuclidinyl xanthene-9-carboxylate (II) for the pharmacol. defined muscarinic receptor subtypes was detd. using functional responses of rabbit vas deferens (M1), guinea pig atria (M2) and bladder detrusor muscle (M3).  All the stereoisomers behaved as competitive antagonists yielding the same rank order of potency at each receptor subtype: (RR)-I > (RS)-I > (SR)-I > (SS)-I and (R)-II > (S)-II.  Moreover, the eudismic ratios relative to (RR)-I for (RS)-, (SR)- and (SS)-I, resp., ranged from 4 to 308 at all 3 subtypes.  Stereoselective effects were also obsd. for II; (S)-II/(R)-II ratios ranged from 76 to 248.  In contrast, there was a distinct lack of receptor selectivity among the isomers of I and II for either the M1, M2 or M3 muscarinic receptor subtypes.  Stereoselective effects were also evident in vivo in the guinea pig cystometrogram where the rank order of potency of the isomers of I and II was similar to that obsd. in vitro.  (RR)-I and (R)-II equipotently depressed intravesical bladder pressure (ID50=0.06 mg/kg i.v.).  Other parameters (bladder capacity, threshold pressure) were unaltered by the stereoisomers.  The data demonstrate that despite the high affinity of the eutomers of I and II for muscarinic receptor, they discriminate poorly among muscarinic subpopulations, thus limiting their utility to subclassify muscarinic receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-5gAtSUMrFbVg90H21EOLACvtfcHk0lglcU8Rr8u3HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhsVCmsb0%253D&md5=c1418c68c19d091fe413b7cf412b9ab8</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2892%2990268-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252892%252990268-9%26sid%3Dliteratum%253Aachs%26aulast%3DNoronha-Blob%26aufirst%3DL.%26aulast%3DSturm%26aufirst%3DB.%26aulast%3DLowe%26aufirst%3DV.%26atitle%3DStereoselective%2520antimuscarinic%2520effects%2520of%25203-quinuclidinyl%2520atrolactate%2520and%25203-quinuclidinyl%2520xanthene-9-carboxylate%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1992%26volume%3D211%26spage%3D97%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Prat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernández, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buil, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crespo, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casals, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tort, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monleón, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavaldà, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralpeix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doménech, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vilella, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antón, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huerta, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espinosa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">López, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sentellas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">González, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albertí, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segarra, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cárdenas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beleta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, H.</span><span> </span><span class="NLM_article-title">Discovery of novel quaternary ammonium derivatives of (3<i>R</i>)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3<i>R</i>)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane bromide (aclidinium bromide)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5076</span><span class="NLM_x">–</span> <span class="NLM_lpage">5092</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900132z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5076-5092&author=M.+Pratauthor=D.+Fern%C3%A1ndezauthor=M.+A.+Builauthor=M.+I.+Crespoauthor=G.+Casalsauthor=M.+Ferrerauthor=L.+Tortauthor=J.+Castroauthor=J.+M.+Monle%C3%B3nauthor=A.+Gavald%C3%A0author=M.+Miralpeixauthor=I.+Ramosauthor=T.+Dom%C3%A9nechauthor=D.+Vilellaauthor=F.+Ant%C3%B3nauthor=J.+M.+Huertaauthor=S.+Espinosaauthor=M.+L%C3%B3pezauthor=S.+Sentellasauthor=M.+Gonz%C3%A1lezauthor=J.+Albert%C3%ADauthor=V.+Segarraauthor=A.+C%C3%A1rdenasauthor=J.+Beletaauthor=H.+Ryder&title=Discovery+of+novel+quaternary+ammonium+derivatives+of+%283R%29-quinuclidinol+esters+as+potent+and+long-acting+muscarinic+antagonists+with+potential+for+minimal+systemic+exposure+after+inhaled+administration%3A+identification+of+%283R%29-3-%7B%5Bhydroxy%28di-2-thienyl%29acetyl%5Doxy%7D-1-%283-phenoxypropyl%29-1-azoniabicyclo%5B2.2.2%5D+octane+bromide+%28aclidinium+bromide%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm900132z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900132z%26sid%3Dliteratum%253Aachs%26aulast%3DPrat%26aufirst%3DM.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DD.%26aulast%3DBuil%26aufirst%3DM.%2BA.%26aulast%3DCrespo%26aufirst%3DM.%2BI.%26aulast%3DCasals%26aufirst%3DG.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DTort%26aufirst%3DL.%26aulast%3DCastro%26aufirst%3DJ.%26aulast%3DMonle%25C3%25B3n%26aufirst%3DJ.%2BM.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DRamos%26aufirst%3DI.%26aulast%3DDom%25C3%25A9nech%26aufirst%3DT.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DAnt%25C3%25B3n%26aufirst%3DF.%26aulast%3DHuerta%26aufirst%3DJ.%2BM.%26aulast%3DEspinosa%26aufirst%3DS.%26aulast%3DL%25C3%25B3pez%26aufirst%3DM.%26aulast%3DSentellas%26aufirst%3DS.%26aulast%3DGonz%25C3%25A1lez%26aufirst%3DM.%26aulast%3DAlbert%25C3%25AD%26aufirst%3DJ.%26aulast%3DSegarra%26aufirst%3DV.%26aulast%3DC%25C3%25A1rdenas%26aufirst%3DA.%26aulast%3DBeleta%26aufirst%3DJ.%26aulast%3DRyder%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520novel%2520quaternary%2520ammonium%2520derivatives%2520of%2520%25283R%2529-quinuclidinol%2520esters%2520as%2520potent%2520and%2520long-acting%2520muscarinic%2520antagonists%2520with%2520potential%2520for%2520minimal%2520systemic%2520exposure%2520after%2520inhaled%2520administration%253A%2520identification%2520of%2520%25283R%2529-3-%257B%255Bhydroxy%2528di-2-thienyl%2529acetyl%255Doxy%257D-1-%25283-phenoxypropyl%2529-1-azoniabicyclo%255B2.2.2%255D%2520octane%2520bromide%2520%2528aclidinium%2520bromide%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5076%26epage%3D5092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Martel, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabasseda, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castañer, J.</span><span> </span><span class="NLM_article-title">Revatropate. Bronchodilator muscarinic M<sub>3</sub> antagonist</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1358%2Fdof.1997.022.02.394838" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADyaK2sXivVehtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1997&pages=135-137&author=A.+M.+Martelauthor=X.+Rabassedaauthor=J.+Casta%C3%B1er&title=Revatropate.+Bronchodilator+muscarinic+M3+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Revatropate. Bronchodilator. Muscarinic M3 antagonist</span></div><div class="casAuthors">Martel, A.M.; Rabasseda, X.; Castaner, J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-137</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous</span>)
        </div><div class="casAbstract">A review, with 6 refs., describing the synthesis, pharmacol. actions, and the results of some clin. studies of revatropate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj93cfuBLRL7Vg90H21EOLACvtfcHk0lglcU8Rr8u3HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivVehtLo%253D&md5=6304071f8770d450874adccf2b2693ba</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1358%2Fdof.1997.022.02.394838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.1997.022.02.394838%26sid%3Dliteratum%253Aachs%26aulast%3DMartel%26aufirst%3DA.%2BM.%26aulast%3DRabasseda%26aufirst%3DX.%26aulast%3DCasta%25C3%25B1er%26aufirst%3DJ.%26atitle%3DRevatropate.%2520Bronchodilator%2520muscarinic%2520M3%2520antagonist%26jtitle%3DDrugs%2520Future%26date%3D1997%26volume%3D22%26spage%3D135%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Tropsha, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nizhnii, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iaguzhinskii, L. S.</span><span> </span><span class="NLM_article-title">Structure–activity relationship in the series of muscarinic acetylcholine receptor antagonists: four types of antagonist-receptor binding</span> <span class="citation_source-journal">Bioorg. Khim.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1402</span><span class="NLM_x">–</span> <span class="NLM_lpage">1416</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1985&pages=1402-1416&author=A.+E.+Tropshaauthor=S.+V.+Nizhniiauthor=L.+S.+Iaguzhinskii&title=Structure%E2%80%93activity+relationship+in+the+series+of+muscarinic+acetylcholine+receptor+antagonists%3A+four+types+of+antagonist-receptor+binding"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTropsha%26aufirst%3DA.%2BE.%26aulast%3DNizhnii%26aufirst%3DS.%2BV.%26aulast%3DIaguzhinskii%26aufirst%3DL.%2BS.%26atitle%3DStructure%25E2%2580%2593activity%2520relationship%2520in%2520the%2520series%2520of%2520muscarinic%2520acetylcholine%2520receptor%2520antagonists%253A%2520four%2520types%2520of%2520antagonist-receptor%2520binding%26jtitle%3DBioorg.%2520Khim.%26date%3D1985%26volume%3D11%26spage%3D1402%26epage%3D1416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Gavaldà, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralpeix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreño, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viñals, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doménech, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carcasona, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vilella, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gras, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortijo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morcillo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llenas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beleta, J.</span><span> </span><span class="NLM_article-title">Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">331</span><span class="NLM_x">, </span> <span class="NLM_fpage">740</span><span class="NLM_x">–</span> <span class="NLM_lpage">751</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1124%2Fjpet.109.151639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=19710368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKnu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2009&pages=740-751&author=A.+Gavald%C3%A0author=M.+Miralpeixauthor=I.+Ramosauthor=R.+Otalauthor=C.+Carre%C3%B1oauthor=M.+Vi%C3%B1alsauthor=T.+Dom%C3%A9nechauthor=C.+Carcasonaauthor=B.+Reyesauthor=D.+Vilellaauthor=J.+Grasauthor=J.+Cortijoauthor=E.+Morcilloauthor=J.+Llenasauthor=H.+Ryderauthor=J.+Beleta&title=Characterization+of+aclidinium+bromide%2C+a+novel+inhaled+muscarinic+antagonist%2C+with+long+duration+of+action+and+a+favorable+pharmacological+profile"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile</span></div><div class="casAuthors">Gavalda, Amadeu; Miralpeix, Montserrat; Ramos, Israel; Otal, Raquel; Carreno, Cristina; Vinals, Marisa; Domenech, Teresa; Carcasona, Carla; Reyes, Blanca; Vilella, Dolors; Gras, Jordi; Cortijo, Julio; Morcillo, Esteban; Llenas, Jesus; Ryder, Hamish; Beleta, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">740-751</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Aclidinium bromide is a novel potent, long-acting inhaled muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease.  Aclidinium showed subnanomolar affinity for the five human muscarinic receptors (M1-M5).  [3H]Aclidinium dissocd. slightly faster from M2 and M3 receptors than [3H]tiotropium but much more slowly than [3H]ipratropium.  Its assocn. rate for the M3 receptor was similar to [3H]ipratropium and 2.6 times faster than [3H]tiotropium.  Residence half-life of [3H]aclidinium at the M2 receptor was shorter than at the M3 receptor, demonstrating kinetic selectivity for the M3 receptor.  In isolated guinea pig trachea, aclidinium showed comparable potency to ipratropium and tiotropium, faster onset of action than tiotropium, and duration of action similar to tiotropium and significantly longer than ipratropium.  Nebulized aclidinium inhibited bronchoconstriction induced by acetylcholine in guinea pigs in a concn.-dependent manner with an onset of action faster than tiotropium.  Duration of action of aclidinium (t1/2 = 29 h) was much longer than ipratropium (8 h) but shorter than tiotropium (64 h).  In dogs, aclidinium induced a smaller and more transient increase in heart rate than tiotropium at comparable supratherapeutic doses.  Therefore, under these conditions, aclidinium showed a greater therapeutic index than tiotropium (4.2 vs. 1.6).  These results indicate that aclidinium is a potent muscarinic antagonist with a fast onset of action, a long duration of effect, and a favorable cardiovascular safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZpskcHCQILLVg90H21EOLACvtfcHk0ljLvgOf1JGq7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKnu7rF&md5=c66b0d729cd5c6dcba6e3a80e0c5f468</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.151639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.151639%26sid%3Dliteratum%253Aachs%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DRamos%26aufirst%3DI.%26aulast%3DOtal%26aufirst%3DR.%26aulast%3DCarre%25C3%25B1o%26aufirst%3DC.%26aulast%3DVi%25C3%25B1als%26aufirst%3DM.%26aulast%3DDom%25C3%25A9nech%26aufirst%3DT.%26aulast%3DCarcasona%26aufirst%3DC.%26aulast%3DReyes%26aufirst%3DB.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DGras%26aufirst%3DJ.%26aulast%3DCortijo%26aufirst%3DJ.%26aulast%3DMorcillo%26aufirst%3DE.%26aulast%3DLlenas%26aufirst%3DJ.%26aulast%3DRyder%26aufirst%3DH.%26aulast%3DBeleta%26aufirst%3DJ.%26atitle%3DCharacterization%2520of%2520aclidinium%2520bromide%252C%2520a%2520novel%2520inhaled%2520muscarinic%2520antagonist%252C%2520with%2520long%2520duration%2520of%2520action%2520and%2520a%2520favorable%2520pharmacological%2520profile%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D331%26spage%3D740%26epage%3D751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Beier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirsten, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mróz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segarra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuecos, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caracta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, E. G.</span><span> </span><span class="NLM_article-title">Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIb study</span> <span class="citation_source-journal">COPD</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">511</span><span class="NLM_x">–</span> <span class="NLM_lpage">522</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.3109%2F15412555.2013.814626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23819698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC3sjnsVekug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=511-522&author=J.+Beierauthor=A.+M.+Kirstenauthor=R.+Mr%C3%B3zauthor=R.+Segarraauthor=F.+Chuecosauthor=C.+Caractaauthor=E.+G.+Gil&title=Efficacy+and+safety+of+aclidinium+bromide+compared+with+placebo+and+tiotropium+in+patients+with+moderate-to-severe+chronic+obstructive+pulmonary+disease%3A+results+from+a+6-week%2C+randomized%2C+controlled+phase+IIIb+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study</span></div><div class="casAuthors">Beier Jutta; Kirsten Anne-Marie; Mroz Robert; Segarra Rosa; Chuecos Ferran; Caracta Cynthia; Gil Esther Garcia</div><div class="citationInfo"><span class="NLM_cas:title">COPD</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">511-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  This randomized, double-blind, Phase IIIb study evaluated the 24-hour bronchodilatory efficacy of aclidinium bromide versus placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).  METHODS:  Patients received aclidinium 400 μg twice daily (morning and evening), tiotropium 18 μg once daily (morning), or placebo for 6 weeks.  The primary endpoint was change from baseline in forced expiratory volume in 1 second area under the curve for the 24-hour period post-morning dose (FEV1 AUC0-24) at week 6.  Secondary and additional endpoints included FEV1 AUC12-24, COPD symptoms (EXAcerbations of chronic pulmonary disease Tool-Respiratory Symptoms [E-RS] total score and additional symptoms questionnaire), and safety.  RESULTS:  Overall, 414 patients were randomized and treated (FEV1 1.63 L [55.8% predicted]).  Compared with placebo, FEV1 AUC0-24 and FEV1 AUC12-24 were significantly increased from baseline with aclidinium (α = 150 mL and 160 mL, respectively; p < 0.0001) and tiotropium (α = 140 mL and 123 mL, respectively; p < 0.0001) at week 6.  Significant improvements in E-RS total scores over 6 weeks were numerically greater with aclidinium (p < 0.0001) than tiotropium (p < 0.05) versus placebo.  Only aclidinium significantly reduced the severity of early-morning cough, wheeze, shortness of breath, and phlegm, and of nighttime symptoms versus placebo (p < 0.05).  Adverse-event (AE) incidence (28%) was similar between treatments.  Few anticholinergic AEs (<1.5%) or serious AEs (<3%) occurred in any group.  CONCLUSIONS:  Aclidinium provided significant 24-hour bronchodilation versus placebo from day 1 with comparable efficacy to tiotropium after 6 weeks.  Improvements in COPD symptoms were consistently numerically greater with aclidinium versus tiotropium.  Aclidinium was generally well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRexzWJG0sJO5QHPYJuLg8TfW6udTcc2ebHLpT4uaKiDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjnsVekug%253D%253D&md5=ef3866abc3d13612c2c7dd1a8273cfe4</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.3109%2F15412555.2013.814626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F15412555.2013.814626%26sid%3Dliteratum%253Aachs%26aulast%3DBeier%26aufirst%3DJ.%26aulast%3DKirsten%26aufirst%3DA.%2BM.%26aulast%3DMr%25C3%25B3z%26aufirst%3DR.%26aulast%3DSegarra%26aufirst%3DR.%26aulast%3DChuecos%26aufirst%3DF.%26aulast%3DCaracta%26aufirst%3DC.%26aulast%3DGil%26aufirst%3DE.%2BG.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520aclidinium%2520bromide%2520compared%2520with%2520placebo%2520and%2520tiotropium%2520in%2520patients%2520with%2520moderate-to-severe%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520results%2520from%2520a%25206-week%252C%2520randomized%252C%2520controlled%2520phase%2520IIIb%2520study%26jtitle%3DCOPD%26date%3D2013%26volume%3D10%26spage%3D511%26epage%3D522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Milara, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peiró, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavaldà, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralpeix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morcillo, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortijo, J.</span><span> </span><span class="NLM_article-title">Aclidinium inhibits human lung fibroblast to myofibroblast transition</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">237</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2012&pages=229-237&author=J.+Milaraauthor=A.+Serranoauthor=T.+Peir%C3%B3author=A.+Gavald%C3%A0author=M.+Miralpeixauthor=E.+J.+Morcilloauthor=J.+Cortijo&title=Aclidinium+inhibits+human+lung+fibroblast+to+myofibroblast+transition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMilara%26aufirst%3DJ.%26aulast%3DSerrano%26aufirst%3DA.%26aulast%3DPeir%25C3%25B3%26aufirst%3DT.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DMorcillo%26aufirst%3DE.%2BJ.%26aulast%3DCortijo%26aufirst%3DJ.%26atitle%3DAclidinium%2520inhibits%2520human%2520lung%2520fibroblast%2520to%2520myofibroblast%2520transition%26jtitle%3DThorax%26date%3D2012%26volume%3D67%26spage%3D229%26epage%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Milara, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peiró, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artigues, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavaldà, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralpeix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morcillo, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortijo, J.</span><span> </span><span class="NLM_article-title">Aclidinium inhibits cigarette smoke-induced lung fibroblast-to-myofibroblast transition</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1264</span><span class="NLM_x">–</span> <span class="NLM_lpage">1274</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.00017712" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23018909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtV2mur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=1264-1274&author=J.+Milaraauthor=A.+Serranoauthor=T.+Peir%C3%B3author=E.+Artiguesauthor=A.+Gavald%C3%A0author=M.+Miralpeixauthor=E.+J.+Morcilloauthor=J.+Cortijo&title=Aclidinium+inhibits+cigarette+smoke-induced+lung+fibroblast-to-myofibroblast+transition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Aclidinium inhibits cigarette smoke-induced lung fibroblast-to-myofibroblast transition</span></div><div class="casAuthors">Milara, Javier; Serrano, Adela; Peiro, Teresa; Artigues, Enrique; Gavalda, Amadeu; Miralpeix, Montse; Morcillo, Esteban J.; Cortijo, Julio</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1264-1274</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Cigarette smoking contributes to lung remodelling in chronic obstructive pulmonary disease (COPD).  As part of this remodelling, peribronchiolar fibrosis is obsd. in the small airways of COPD patients and contributes to airway obstruction.  Fibroblast-to-myofibroblast transition is a key step in peribronchiolar fibrosis formation.  This in vitro study examd. the effect of cigarette smoke on bronchial fibroblast-to-myofibroblast transition, and whether aclidinium bromide inhibits this process.  Human bronchial fibroblasts were incubated with aclidinium bromide (10-9-10-7 M) and exposed to cigarette smoke ext.  Collagen type I and α-smooth muscle actin (α-SMA) expression were measured by real-time PCR and Western blotting, as myofibroblast markers.  Intracellular reactive oxygen species, cAMP (cAMP), extracellular signal-regulated kinase (ERK)1/2 and choline acetyltransferase were measured as intracellular signalling mediators.  Cigarette smoke-induced collagen type I and α-SMA was mediated by the prodn. of reactive oxygen species, the depletion of intracellular cAMP and the increase of ERK1/2 phosphorylation and choline acetyltransferase.  These effects could be reversed by treatment with the anticholinergic aclidinium bromide, by silencing the mRNA of muscarinic receptors M1, M2 or M3, or by the depletion of extracellular acetylcholine by treatment with acetylcholinesterase.  A non-neuronal cholinergic system is implicated in cigarette smoke-induced bronchial fibroblast-to-myofibroblast transition, which is inhibited by aclidinium bromide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDBALLuwbgHrVg90H21EOLACvtfcHk0liYs0GX0zWZYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtV2mur%252FF&md5=8374ed7c1c820cc5626ce79bcb828ab3</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1183%2F09031936.00017712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00017712%26sid%3Dliteratum%253Aachs%26aulast%3DMilara%26aufirst%3DJ.%26aulast%3DSerrano%26aufirst%3DA.%26aulast%3DPeir%25C3%25B3%26aufirst%3DT.%26aulast%3DArtigues%26aufirst%3DE.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DMorcillo%26aufirst%3DE.%2BJ.%26aulast%3DCortijo%26aufirst%3DJ.%26atitle%3DAclidinium%2520inhibits%2520cigarette%2520smoke-induced%2520lung%2520fibroblast-to-myofibroblast%2520transition%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2013%26volume%3D41%26spage%3D1264%26epage%3D1274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Domínguez-Fandos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puig-Pey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreño, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prats, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aparici, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musri, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavaldà, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peinado, V. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralpeix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barberà, J. A.</span><span> </span><span class="NLM_article-title">Effects of aclidinium bromide in a cigarette smoke-exposed guinea pig model of chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Am. J. Respir. Cell Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">337</span><span class="NLM_x">–</span> <span class="NLM_lpage">346</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=24032416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsVOlsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=337-346&author=D.+Dom%C3%ADnguez-Fandosauthor=E.+Ferrerauthor=R.+Puig-Peyauthor=C.+Carre%C3%B1oauthor=N.+Pratsauthor=M.+Apariciauthor=M.+M.+Musriauthor=A.+Gavald%C3%A0author=V.+I.+Peinadoauthor=M.+Miralpeixauthor=J.+A.+Barber%C3%A0&title=Effects+of+aclidinium+bromide+in+a+cigarette+smoke-exposed+guinea+pig+model+of+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of aclidinium bromide in a cigarette smoke-exposed guinea pig model of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Dominguez-Fandos, David; Ferrer, Elisabet; Puig-Pey, Raquel; Carreno, Cristina; Prats, Neus; Aparici, Monica; Musri, Melina Mara; Gavalda, Amadeu; Peinado, Victor I.; Miralpeix, Montserrat; Barbera, Joan A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">337-346, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Long-acting muscarinic antagonists are widely used to treat chronic obstructive pulmonary disease (COPD).  In addn. to bronchodilation, muscarinic antagonism may affect pulmonary histopathol. changes.  The effects of long-acting muscarinic antagonists have not been thoroughly evaluated in exptl. models of COPD induced by chronic exposure to cigarette smoke (CS).  We investigated the effects of aclidinium bromide on pulmonary function, airway remodeling, and lung inflammation in a CS-exposed model of COPD.  A total of 36 guinea pigs were exposed to CS and 22 were sham exposed for 24 wk.  Animals were nebulized daily with vehicle, 10 μg/mL, or 30 μg/mL aclidinium, resulting in six exptl. groups.  Pulmonary function was assessed weekly by whole-body plethysmog., detg. the enhanced pause (Penh) at baseline, after treatment, and after CS/sham exposure.  Lung changes were evaluated by morphometry and immunohistochem.  CS exposure increased Penh in all conditions.  CS-exposed animals treated with aclidinium showed lower baseline Penh than untreated animals (P = 0.02).  CS induced thickening of all bronchial wall layers, airspace enlargement, and inflammatory cell infiltrate in airways and septa.  Treatment with aclidinium abrogated the CS-induced smooth muscle enlargement in small airways (P = 0.001), and tended to reduce airspace enlargement (P = 0.054).  Aclidinium also attenuated CS-induced neutrophilia in alveolar septa (P = 0.04).  We conclude that, in guinea pigs chronically exposed to CS, aclidinium has an antiremodeling effect on small airways, which is assocd. with improved respiratory function, and attenuates neutrophilic infiltration in alveolar septa.  These results indicate that, in COPD, aclidinium may exert beneficial effects on lung structure in addn. to its bronchodilator action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGJy4MHEIkWrVg90H21EOLACvtfcHk0liYs0GX0zWZYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsVOlsbo%253D&md5=f0cdafcc73a363ff0e83c15cd1082382</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDom%25C3%25ADnguez-Fandos%26aufirst%3DD.%26aulast%3DFerrer%26aufirst%3DE.%26aulast%3DPuig-Pey%26aufirst%3DR.%26aulast%3DCarre%25C3%25B1o%26aufirst%3DC.%26aulast%3DPrats%26aufirst%3DN.%26aulast%3DAparici%26aufirst%3DM.%26aulast%3DMusri%26aufirst%3DM.%2BM.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DPeinado%26aufirst%3DV.%2BI.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DBarber%25C3%25A0%26aufirst%3DJ.%2BA.%26atitle%3DEffects%2520of%2520aclidinium%2520bromide%2520in%2520a%2520cigarette%2520smoke-exposed%2520guinea%2520pig%2520model%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2014%26volume%3D50%26spage%3D337%26epage%3D346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Lainé, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dufour, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdowson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palovich, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunsberger, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttmann, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarau, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umbrecht, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landis, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peck, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busch-Petersen, J.</span><span> </span><span class="NLM_article-title">Design, synthesis and structure-activity relationship of N-substituted tropane muscarinic acetylcholine receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3366</span><span class="NLM_x">–</span> <span class="NLM_lpage">3369</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3366-3369&author=D.+I.+Lain%C3%A9author=H.+Yanauthor=H.+Xieauthor=R.+S.+Davisauthor=J.+Dufourauthor=K.+L.+Widdowsonauthor=M.+R.+Palovichauthor=Z.+Wanauthor=J.+J.+Foleyauthor=D.+B.+Schmidtauthor=G.+E.+Hunsbergerauthor=M.+Burmanauthor=A.+M.+Baconauthor=E.+F.+Webbauthor=M.+A.+Luttmannauthor=M.+Salmonauthor=H.+M.+Sarauauthor=S.+T.+Umbrechtauthor=P.+S.+Landisauthor=B.+J.+Peckauthor=J.+Busch-Petersen&title=Design%2C+synthesis+and+structure-activity+relationship+of+N-substituted+tropane+muscarinic+acetylcholine+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLain%25C3%25A9%26aufirst%3DD.%2BI.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DDavis%26aufirst%3DR.%2BS.%26aulast%3DDufour%26aufirst%3DJ.%26aulast%3DWiddowson%26aufirst%3DK.%2BL.%26aulast%3DPalovich%26aufirst%3DM.%2BR.%26aulast%3DWan%26aufirst%3DZ.%26aulast%3DFoley%26aufirst%3DJ.%2BJ.%26aulast%3DSchmidt%26aufirst%3DD.%2BB.%26aulast%3DHunsberger%26aufirst%3DG.%2BE.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DBacon%26aufirst%3DA.%2BM.%26aulast%3DWebb%26aufirst%3DE.%2BF.%26aulast%3DLuttmann%26aufirst%3DM.%2BA.%26aulast%3DSalmon%26aufirst%3DM.%26aulast%3DSarau%26aufirst%3DH.%2BM.%26aulast%3DUmbrecht%26aufirst%3DS.%2BT.%26aulast%3DLandis%26aufirst%3DP.%2BS.%26aulast%3DPeck%26aufirst%3DB.%2BJ.%26aulast%3DBusch-Petersen%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520structure-activity%2520relationship%2520of%2520N-substituted%2520tropane%2520muscarinic%2520acetylcholine%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D3366%26epage%3D3369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Nagashima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamaguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kontani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moritomo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koshika, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, M.</span><span> </span><span class="NLM_article-title">Novel quinuclidinyl heteroarylcarbamate derivatives as muscarinic receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3478</span><span class="NLM_x">–</span> <span class="NLM_lpage">3487</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=3478-3487&author=S.+Nagashimaauthor=Y.+Matsushimaauthor=H.+Hamaguchiauthor=H.+Nagataauthor=T.+Kontaniauthor=A.+Moritomoauthor=T.+Koshikaauthor=M.+Takeuchi&title=Novel+quinuclidinyl+heteroarylcarbamate+derivatives+as+muscarinic+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagashima%26aufirst%3DS.%26aulast%3DMatsushima%26aufirst%3DY.%26aulast%3DHamaguchi%26aufirst%3DH.%26aulast%3DNagata%26aufirst%3DH.%26aulast%3DKontani%26aufirst%3DT.%26aulast%3DMoritomo%26aufirst%3DA.%26aulast%3DKoshika%26aufirst%3DT.%26aulast%3DTakeuchi%26aufirst%3DM.%26atitle%3DNovel%2520quinuclidinyl%2520heteroarylcarbamate%2520derivatives%2520as%2520muscarinic%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D3478%26epage%3D3487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Peretto, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forlani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossati, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giardina, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giardini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guala, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Porta, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrillo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radaelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radice, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raveglia, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scudellaro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarpitta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigogno, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misiano, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dondio, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villetti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patacchini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergamaschi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delcanale, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salcedo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernández, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imbimbo, B. P.</span><span> </span><span class="NLM_article-title">Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M<sub>3</sub> selective antagonists (Part 1)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1571</span><span class="NLM_x">–</span> <span class="NLM_lpage">1583</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061159a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1571-1583&author=I.+Perettoauthor=R.+Forlaniauthor=C.+Fossatiauthor=G.+A.+Giardinaauthor=A.+Giardiniauthor=M.+Gualaauthor=E.+La+Portaauthor=P.+Petrilloauthor=S.+Radaelliauthor=L.+Radiceauthor=L.+F.+Ravegliaauthor=E.+Santoroauthor=R.+Scudellaroauthor=F.+Scarpittaauthor=C.+Bigognoauthor=P.+Misianoauthor=G.+M.+Dondioauthor=A.+Rizziauthor=E.+Armaniauthor=G.+Amariauthor=M.+Civelliauthor=G.+Villettiauthor=R.+Patacchiniauthor=M.+Bergamaschiauthor=M.+Delcanaleauthor=C.+Salcedoauthor=A.+G.+Fern%C3%A1ndezauthor=B.+P.+Imbimbo&title=Discovery+of+diaryl+imidazolidin-2-one+derivatives%2C+a+novel+class+of+muscarinic+M3+selective+antagonists+%28Part+1%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm061159a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061159a%26sid%3Dliteratum%253Aachs%26aulast%3DPeretto%26aufirst%3DI.%26aulast%3DForlani%26aufirst%3DR.%26aulast%3DFossati%26aufirst%3DC.%26aulast%3DGiardina%26aufirst%3DG.%2BA.%26aulast%3DGiardini%26aufirst%3DA.%26aulast%3DGuala%26aufirst%3DM.%26aulast%3DLa%2BPorta%26aufirst%3DE.%26aulast%3DPetrillo%26aufirst%3DP.%26aulast%3DRadaelli%26aufirst%3DS.%26aulast%3DRadice%26aufirst%3DL.%26aulast%3DRaveglia%26aufirst%3DL.%2BF.%26aulast%3DSantoro%26aufirst%3DE.%26aulast%3DScudellaro%26aufirst%3DR.%26aulast%3DScarpitta%26aufirst%3DF.%26aulast%3DBigogno%26aufirst%3DC.%26aulast%3DMisiano%26aufirst%3DP.%26aulast%3DDondio%26aufirst%3DG.%2BM.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DArmani%26aufirst%3DE.%26aulast%3DAmari%26aufirst%3DG.%26aulast%3DCivelli%26aufirst%3DM.%26aulast%3DVilletti%26aufirst%3DG.%26aulast%3DPatacchini%26aufirst%3DR.%26aulast%3DBergamaschi%26aufirst%3DM.%26aulast%3DDelcanale%26aufirst%3DM.%26aulast%3DSalcedo%26aufirst%3DC.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DA.%2BG.%26aulast%3DImbimbo%26aufirst%3DB.%2BP.%26atitle%3DDiscovery%2520of%2520diaryl%2520imidazolidin-2-one%2520derivatives%252C%2520a%2520novel%2520class%2520of%2520muscarinic%2520M3%2520selective%2520antagonists%2520%2528Part%25201%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1571%26epage%3D1583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Peretto, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossati, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giardina, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giardini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guala, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Porta, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrillo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radaelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radice, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raveglia, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scudellaro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarpitta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menegon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dondio, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villetti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patacchini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergamaschi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delcanale, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imbimbo, B. P.</span><span> </span><span class="NLM_article-title">Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M<sub>3</sub> selective antagonists (part 2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1693</span><span class="NLM_x">–</span> <span class="NLM_lpage">1697</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061160%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1693-1697&author=I.+Perettoauthor=C.+Fossatiauthor=G.+A.+Giardinaauthor=A.+Giardiniauthor=M.+Gualaauthor=E.+La+Portaauthor=P.+Petrilloauthor=S.+Radaelliauthor=L.+Radiceauthor=L.+F.+Ravegliaauthor=E.+Santoroauthor=R.+Scudellaroauthor=F.+Scarpittaauthor=A.+Cerriauthor=S.+Menegonauthor=G.+M.+Dondioauthor=A.+Rizziauthor=E.+Armaniauthor=G.+Amariauthor=M.+Civelliauthor=G.+Villettiauthor=R.+Patacchiniauthor=M.+Bergamaschiauthor=F.+Bassaniauthor=M.+Delcanaleauthor=B.+P.+Imbimbo&title=Discovery+of+diaryl+imidazolidin-2-one+derivatives%2C+a+novel+class+of+muscarinic+M3+selective+antagonists+%28part+2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm061160%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061160%252B%26sid%3Dliteratum%253Aachs%26aulast%3DPeretto%26aufirst%3DI.%26aulast%3DFossati%26aufirst%3DC.%26aulast%3DGiardina%26aufirst%3DG.%2BA.%26aulast%3DGiardini%26aufirst%3DA.%26aulast%3DGuala%26aufirst%3DM.%26aulast%3DLa%2BPorta%26aufirst%3DE.%26aulast%3DPetrillo%26aufirst%3DP.%26aulast%3DRadaelli%26aufirst%3DS.%26aulast%3DRadice%26aufirst%3DL.%26aulast%3DRaveglia%26aufirst%3DL.%2BF.%26aulast%3DSantoro%26aufirst%3DE.%26aulast%3DScudellaro%26aufirst%3DR.%26aulast%3DScarpitta%26aufirst%3DF.%26aulast%3DCerri%26aufirst%3DA.%26aulast%3DMenegon%26aufirst%3DS.%26aulast%3DDondio%26aufirst%3DG.%2BM.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DArmani%26aufirst%3DE.%26aulast%3DAmari%26aufirst%3DG.%26aulast%3DCivelli%26aufirst%3DM.%26aulast%3DVilletti%26aufirst%3DG.%26aulast%3DPatacchini%26aufirst%3DR.%26aulast%3DBergamaschi%26aufirst%3DM.%26aulast%3DBassani%26aufirst%3DF.%26aulast%3DDelcanale%26aufirst%3DM.%26aulast%3DImbimbo%26aufirst%3DB.%2BP.%26atitle%3DDiscovery%2520of%2520diaryl%2520imidazolidin-2-one%2520derivatives%252C%2520a%2520novel%2520class%2520of%2520muscarinic%2520M3%2520selective%2520antagonists%2520%2528part%25202%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1693%26epage%3D1697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Villetti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastore, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergamaschi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolzoni, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battipaglia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delcanale, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cenacchi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cacciani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaniboni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrillo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scudellaro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mannini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geppetti, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Razzetti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patacchini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civelli, M.</span><span> </span><span class="NLM_article-title">Bronchodilator activity of (3<i>R</i>)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M<sub>3</sub> receptor antagonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">335</span><span class="NLM_x">, </span> <span class="NLM_fpage">622</span><span class="NLM_x">–</span> <span class="NLM_lpage">635</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1124%2Fjpet.110.170035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=20805306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2010&pages=622-635&author=G.+Villettiauthor=F.+Pastoreauthor=M.+Bergamaschiauthor=F.+Bassaniauthor=P.+T.+Bolzoniauthor=L.+Battipagliaauthor=G.+Amariauthor=A.+Rizziauthor=M.+Delcanaleauthor=R.+Voltaauthor=V.+Cenacchiauthor=F.+Caccianiauthor=M.+Zaniboniauthor=F.+Bertiauthor=G.+Rossoniauthor=S.+Harrisonauthor=P.+Petrilloauthor=E.+Santoroauthor=R.+Scudellaroauthor=F.+Manniniauthor=P.+A.+Geppettiauthor=R.+Razzettiauthor=R.+Patacchiniauthor=M.+Civelli&title=Bronchodilator+activity+of+%283R%29-3-%5B%5B%5B%283-fluorophenyl%29%5B%283%2C4%2C5-trifluorophenyl%29methyl%5Damino%5Dcarbonyl%5Doxy%5D-1-%5B2-oxo-2-%282-thienyl%29ethyl%5D-1-azoniabicyclo%5B2.2.2%5Doctane+bromide+%28CHF5407%29%2C+a+potent%2C+long-acting%2C+and+selective+muscarinic+M3+receptor+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 receptor antagonist</span></div><div class="casAuthors">Villetti, G.; Pastore, F.; Bergamaschi, M.; Bassani, F.; Bolzoni, P. T.; Battipaglia, L.; Amari, G.; Rizzi, A.; Delcanale, M.; Volta, R.; Cenacchi, V.; Cacciani, F.; Zaniboni, M.; Berti, F.; Rossoni, G.; Harrison, S.; Petrillo, P.; Santoro, E.; Scudellaro, R.; Mannini, F.; Geppetti, P. A.; Razzetti, R.; Patacchini, R.; Civelli, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">622-635</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The novel quaternary ammonium salt (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407) showed subnanomolar affinities for human muscarinic M1 (hM1), M2 (hM2), and M3 (hM3) receptors and dissocd. very slowly from hM3 receptors (t1/2 = 166 min) with a large part of the receptorial complex (54%) remaining undissociated at 32 h from radioligand washout.  In contrast, [3H]CHF5407 dissocd. quickly from hM2 receptors (t1/2 = 31 min), whereas [3H]tiotropium dissocd. slowly from both hM3 (t1/2 = 163 min) and hM2 receptor (t1/2 = 297 min).  In the guinea pig isolated trachea and human isolated bronchus, CHF5407 produced a potent (pIC50 = 9.0-9.6) and long-lasting (up to 24 h) inhibition of M3 receptor-mediated contractile responses to carbachol.  In the guinea pig elec. driven left atrium, the M2 receptor-mediated inhibitory response to carbachol was recovered more quickly in CHF5407-pretreated than in tiotropium-pretreated prepns.  CHF5407, administered intratracheally to anesthetized guinea pigs, potently inhibited acetylcholine (Ach)-induced bronchoconstriction with an ED50 value of 0.15 nmol/kg.  The effect was sustained over a period of 24 h, with a residual 57% inhibition 48 h after antagonist administration at 1 nmol/kg.  In conscious guinea pigs, inhaled CHF5407 inhibited Ach-induced bronchoconstriction for at least 24 h as did tiotropium at similar dosages.  Cardiovascular parameters in anesthetized guinea pigs were not significantly changed by CHF5407, up to 100 nmol/kg i.v. and up to 1000 nmol/kg i.t.  In conclusion, CHF5407 shows a prolonged antibronchospastic activity both in vitro and in vivo, caused by a very slow dissocn. from M3 receptors.  In contrast, CHF5407 is markedly short-acting at M2 receptors, a behavior not shared by tiotropium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnCU6YfyC1MLVg90H21EOLACvtfcHk0livJBphYjh9uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrnJ&md5=54ae71e74a98081c6c574a5f7dd0faad</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.170035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.170035%26sid%3Dliteratum%253Aachs%26aulast%3DVilletti%26aufirst%3DG.%26aulast%3DPastore%26aufirst%3DF.%26aulast%3DBergamaschi%26aufirst%3DM.%26aulast%3DBassani%26aufirst%3DF.%26aulast%3DBolzoni%26aufirst%3DP.%2BT.%26aulast%3DBattipaglia%26aufirst%3DL.%26aulast%3DAmari%26aufirst%3DG.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DDelcanale%26aufirst%3DM.%26aulast%3DVolta%26aufirst%3DR.%26aulast%3DCenacchi%26aufirst%3DV.%26aulast%3DCacciani%26aufirst%3DF.%26aulast%3DZaniboni%26aufirst%3DM.%26aulast%3DBerti%26aufirst%3DF.%26aulast%3DRossoni%26aufirst%3DG.%26aulast%3DHarrison%26aufirst%3DS.%26aulast%3DPetrillo%26aufirst%3DP.%26aulast%3DSantoro%26aufirst%3DE.%26aulast%3DScudellaro%26aufirst%3DR.%26aulast%3DMannini%26aufirst%3DF.%26aulast%3DGeppetti%26aufirst%3DP.%2BA.%26aulast%3DRazzetti%26aufirst%3DR.%26aulast%3DPatacchini%26aufirst%3DR.%26aulast%3DCivelli%26aufirst%3DM.%26atitle%3DBronchodilator%2520activity%2520of%2520%25283R%2529-3-%255B%255B%255B%25283-fluorophenyl%2529%255B%25283%252C4%252C5-trifluorophenyl%2529methyl%255Damino%255Dcarbonyl%255Doxy%255D-1-%255B2-oxo-2-%25282-thienyl%2529ethyl%255D-1-azoniabicyclo%255B2.2.2%255Doctane%2520bromide%2520%2528CHF5407%2529%252C%2520a%2520potent%252C%2520long-acting%252C%2520and%2520selective%2520muscarinic%2520M3%2520receptor%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D335%26spage%3D622%26epage%3D635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Herbette, L. G.</span><span> </span><span class="NLM_article-title">Membrane pathways for drug/ion channel interactions: molecular basis for pharmacokinetic properties</span> <span class="citation_source-journal">Drug Dev. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">214</span><span class="NLM_x">–</span> <span class="NLM_lpage">222</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1994&pages=214-222&author=L.+G.+Herbette&title=Membrane+pathways+for+drug%2Fion+channel+interactions%3A+molecular+basis+for+pharmacokinetic+properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHerbette%26aufirst%3DL.%2BG.%26atitle%3DMembrane%2520pathways%2520for%2520drug%252Fion%2520channel%2520interactions%253A%2520molecular%2520basis%2520for%2520pharmacokinetic%2520properties%26jtitle%3DDrug%2520Dev.%2520Res.%26date%3D1994%26volume%3D33%26spage%3D214%26epage%3D222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Brown, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glossop, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewthwaite, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perros-Huguet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevethick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span> </span><span class="NLM_article-title">The discovery of long acting β<sub>2</sub>-adrenoreceptor agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4012</span><span class="NLM_x">–</span> <span class="NLM_lpage">4015</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=4012-4015&author=A.+D.+Brownauthor=M.+E.+Bunnageauthor=P.+A.+Glossopauthor=K.+Jamesauthor=R.+Jonesauthor=C.+A.+Laneauthor=R.+A.+Lewthwaiteauthor=S.+Mantellauthor=C.+Perros-Huguetauthor=D.+A.+Priceauthor=M.+Trevethickauthor=R.+Webster&title=The+discovery+of+long+acting+%CE%B22-adrenoreceptor+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DA.%2BD.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DLane%26aufirst%3DC.%2BA.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DMantell%26aufirst%3DS.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DTrevethick%26aufirst%3DM.%26aulast%3DWebster%26aufirst%3DR.%26atitle%3DThe%2520discovery%2520of%2520long%2520acting%2520%25CE%25B22-adrenoreceptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D4012%26epage%3D4015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Blaney, F. E.; Tennant, M.</span><span> </span><span class="NLM_article-title">Computational tools and results in the construction of G protein-coupled receptor models</span>. In  <span class="citation_source-book">Membrane Protein Models</span>; <span class="NLM_contrib-group">Findlay, J. B. C.</span>, Ed.; <span class="NLM_publisher-name">Bios Scientific Publishers, Ltd.</span>: <span class="NLM_publisher-loc">Oxford, U.K.</span>,<span class="NLM_x"> </span><span class="NLM_year">1996</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">176</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&pages=161-176&author=F.+E.+Blaney&author=M.+Tennantauthor=J.+B.+C.+Findlay&title=Membrane+Protein+Models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBlaney%26aufirst%3DF.%2BE.%26atitle%3DComputational%2520tools%2520and%2520results%2520in%2520the%2520construction%2520of%2520G%2520protein-coupled%2520receptor%2520models%26btitle%3DMembrane%2520Protein%2520Models%26aulast%3DFindlay%26aufirst%3DJ.%2BB.%2BC.%26pub%3DBios%2520Scientific%2520Publishers%252C%2520Ltd%26date%3D1996%26spage%3D161%26epage%3D176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Isogaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamagiwa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugimoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagao, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurose, H.</span><span> </span><span class="NLM_article-title">Identification of a key amino acid of the β<sub>2</sub>-adrenergic receptor for high affinity binding of salmeterol</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">616</span><span class="NLM_x">–</span> <span class="NLM_lpage">622</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1998&pages=616-622&author=M.+Isogayaauthor=Y.+Yamagiwaauthor=S.+Fujitaauthor=Y.+Sugimotoauthor=T.+Nagaoauthor=H.+Kurose&title=Identification+of+a+key+amino+acid+of+the+%CE%B22-adrenergic+receptor+for+high+affinity+binding+of+salmeterol"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIsogaya%26aufirst%3DM.%26aulast%3DYamagiwa%26aufirst%3DY.%26aulast%3DFujita%26aufirst%3DS.%26aulast%3DSugimoto%26aufirst%3DY.%26aulast%3DNagao%26aufirst%3DT.%26aulast%3DKurose%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520a%2520key%2520amino%2520acid%2520of%2520the%2520%25CE%25B22-adrenergic%2520receptor%2520for%2520high%2520affinity%2520binding%2520of%2520salmeterol%26jtitle%3DMol.%2520Pharmacol.%26date%3D1998%26volume%3D54%26spage%3D616%26epage%3D622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Isogaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugimoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanimura, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikkawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagao, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurose, H.</span><span> </span><span class="NLM_article-title">Binding pockets of the β<sub>1</sub> and β<sub>2</sub> adrenergic receptors for subtype-selective agonists</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">875</span><span class="NLM_x">–</span> <span class="NLM_lpage">885</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1999&pages=875-885&author=M.+Isogayaauthor=Y.+Sugimotoauthor=R.+Tanimuraauthor=R.+Tanakaauthor=H.+Kikkawaauthor=T.+Nagaoauthor=H.+Kurose&title=Binding+pockets+of+the+%CE%B21+and+%CE%B22+adrenergic+receptors+for+subtype-selective+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIsogaya%26aufirst%3DM.%26aulast%3DSugimoto%26aufirst%3DY.%26aulast%3DTanimura%26aufirst%3DR.%26aulast%3DTanaka%26aufirst%3DR.%26aulast%3DKikkawa%26aufirst%3DH.%26aulast%3DNagao%26aufirst%3DT.%26aulast%3DKurose%26aufirst%3DH.%26atitle%3DBinding%2520pockets%2520of%2520the%2520%25CE%25B21%2520and%2520%25CE%25B22%2520adrenergic%2520receptors%2520for%2520subtype-selective%2520agonists%26jtitle%3DMol.%2520Pharmacol.%26date%3D1999%26volume%3D56%26spage%3D875%26epage%3D885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Green, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spasoff, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liggett, S. B.</span><span> </span><span class="NLM_article-title">Sustained activation of a G-protein-coupled receptor via “anchored” agonist binding. Molecular localization of the salmeterol exosite within the β<sub>2</sub>-adrenergic receptor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">24029</span><span class="NLM_x">–</span> <span class="NLM_lpage">24035</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=24029-24035&author=S.+A.+Greenauthor=A.+P.+Spasoffauthor=R.+R.+Colemanauthor=M.+Johnsonauthor=S.+B.+Liggett&title=Sustained+activation+of+a+G-protein-coupled+receptor+via+%E2%80%9Canchored%E2%80%9D+agonist+binding.+Molecular+localization+of+the+salmeterol+exosite+within+the+%CE%B22-adrenergic+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGreen%26aufirst%3DS.%2BA.%26aulast%3DSpasoff%26aufirst%3DA.%2BP.%26aulast%3DColeman%26aufirst%3DR.%2BR.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DLiggett%26aufirst%3DS.%2BB.%26atitle%3DSustained%2520activation%2520of%2520a%2520G-protein-coupled%2520receptor%2520via%2520%25E2%2580%259Canchored%25E2%2580%259D%2520agonist%2520binding.%2520Molecular%2520localization%2520of%2520the%2520salmeterol%2520exosite%2520within%2520the%2520%25CE%25B22-adrenergic%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D24029%26epage%3D24035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Prashad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Har, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repic, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blacklock, T. J.</span><span> </span><span class="NLM_article-title">An efficient and economical synthesis of 5,6-diethyl-2,3-dihydro-1<i>H</i>-inden-2-amine hydrochloride</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/doi/10.1021/op0502093" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2006&pages=135-141&author=M.+Prashadauthor=B.+Huauthor=D.+Harauthor=O.+Repicauthor=T.+J.+Blacklock&title=An+efficient+and+economical+synthesis+of+5%2C6-diethyl-2%2C3-dihydro-1H-inden-2-amine+hydrochloride"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fop0502093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop0502093%26sid%3Dliteratum%253Aachs%26aulast%3DPrashad%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DHar%26aufirst%3DD.%26aulast%3DRepic%26aufirst%3DO.%26aulast%3DBlacklock%26aufirst%3DT.%2BJ.%26atitle%3DAn%2520efficient%2520and%2520economical%2520synthesis%2520of%25205%252C6-diethyl-2%252C3-dihydro-1H-inden-2-amine%2520hydrochloride%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2006%26volume%3D10%26spage%3D135%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Beattie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruce, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuenoud, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairhurst, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fozard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janus, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosethorne, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandham, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sykes, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trifilieff, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissler, E.</span><span> </span><span class="NLM_article-title">An investigation into the structure–activity relationships associated with the systematic modification of the β<sub>2</sub>-adrenoceptor agonist indacaterol</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">6280</span><span class="NLM_x">–</span> <span class="NLM_lpage">6285</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6280-6285&author=D.+Beattieauthor=D.+Beerauthor=M.+E.+Bradleyauthor=I.+Bruceauthor=S.+J.+Charltonauthor=B.+M.+Cuenoudauthor=R.+A.+Fairhurstauthor=D.+Farrauthor=J.+R.+Fozardauthor=D.+Janusauthor=E.+M.+Rosethorneauthor=D.+A.+Sandhamauthor=D.+A.+Sykesauthor=A.+Trifilieffauthor=K.+L.+Turnerauthor=E.+Wissler&title=An+investigation+into+the+structure%E2%80%93activity+relationships+associated+with+the+systematic+modification+of+the+%CE%B22-adrenoceptor+agonist+indacaterol"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeattie%26aufirst%3DD.%26aulast%3DBeer%26aufirst%3DD.%26aulast%3DBradley%26aufirst%3DM.%2BE.%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DCuenoud%26aufirst%3DB.%2BM.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DFarr%26aufirst%3DD.%26aulast%3DFozard%26aufirst%3DJ.%2BR.%26aulast%3DJanus%26aufirst%3DD.%26aulast%3DRosethorne%26aufirst%3DE.%2BM.%26aulast%3DSandham%26aufirst%3DD.%2BA.%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DTrifilieff%26aufirst%3DA.%26aulast%3DTurner%26aufirst%3DK.%2BL.%26aulast%3DWissler%26aufirst%3DE.%26atitle%3DAn%2520investigation%2520into%2520the%2520structure%25E2%2580%2593activity%2520relationships%2520associated%2520with%2520the%2520systematic%2520modification%2520of%2520the%2520%25CE%25B22-adrenoceptor%2520agonist%2520indacaterol%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6280%26epage%3D6285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Rosenbaum, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, S. G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thian, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, X.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span> </span><span class="NLM_article-title">GPCR engineering yields high-resolution structural insights into β<sub>2</sub>-adrenergic receptor function</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">318</span><span class="NLM_x">, </span> <span class="NLM_fpage">1266</span><span class="NLM_x">–</span> <span class="NLM_lpage">1273</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1126%2Fscience.1150609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=17962519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGmur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2007&pages=1266-1273&author=D.+M.+Rosenbaumauthor=V.+Cherezovauthor=M.+A.+Hansonauthor=S.+G.+F.+Rasmussenauthor=F.+S.+Thianauthor=T.+S.+Kobilkaauthor=H.-J.+Choiauthor=X.-J.+Yaoauthor=W.+I.+Weisauthor=R.+C.+Stevensauthor=B.+K.+Kobilka&title=GPCR+engineering+yields+high-resolution+structural+insights+into+%CE%B22-adrenergic+receptor+function"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function</span></div><div class="casAuthors">Rosenbaum, Daniel M.; Cherezov, Vadim; Hanson, Michael A.; Rasmussen, Soren G. F.; Thian, Foon Sun; Kobilka, Tong Sun; Choi, Hee-Jung; Yao, Xiao-Jie; Weis, William I.; Stevens, Raymond C.; Kobilka, Brian K.; Pierce, K. L.; Premont, R. T.; Lefkowitz, R. J.; Kobilka, B. K.; Deupi, X.; Cherezov, V.; Rasmussen, S. G. F.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">5854</span>),
    <span class="NLM_cas:pages">1266-1273</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The β2-adrenergic receptor (β2AR) is a well-studied prototype for heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors (GPCRs) that respond to diffusible hormones and neurotransmitters.  To overcome the structural flexibility of the β2AR and to facilitate its crystn., we engineered a β2AR fusion protein in which T4 lysozyme (T4L) replaces most of the third intracellular loop of the GPCR ("β2AR-T4L") and showed that this protein retains near-native pharmacol. properties.  Anal. of adrenergic receptor ligand-binding mutants within the context of the reported high-resoln. structure of β2AR-T4L provides insights into inverse-agonist binding and the structural changes required to accommodate catecholamine agonists.  Amino acids known to regulate receptor function are linked through packing interactions and a network of hydrogen bonds, suggesting a conformational pathway from the ligand-binding pocket to regions that interact with G proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6gmrMhXnVl7Vg90H21EOLACvtfcHk0liXRY1uFc5rOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGmur7J&md5=d422ff1e7a28719848c0e16fede045db</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1126%2Fscience.1150609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1150609%26sid%3Dliteratum%253Aachs%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%2BF.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DChoi%26aufirst%3DH.-J.%26aulast%3DYao%26aufirst%3DX.-J.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DGPCR%2520engineering%2520yields%2520high-resolution%2520structural%2520insights%2520into%2520%25CE%25B22-adrenergic%2520receptor%2520function%26jtitle%3DScience%26date%3D2007%26volume%3D318%26spage%3D1266%26epage%3D1273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Rasmussen, S. G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbaum, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thian, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burghammer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratnala, V. R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanishvili, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischetti, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schertler, G. F. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span> </span><span class="NLM_article-title">Crystal structure of the human β<sub>2</sub> adrenergic G-protein-coupled receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">450</span><span class="NLM_x">, </span> <span class="NLM_fpage">383</span><span class="NLM_x">–</span> <span class="NLM_lpage">388</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1038%2Fnature06325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=17952055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlajs77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=450&publication_year=2007&pages=383-388&author=S.+G.+F.+Rasmussenauthor=H.-J.+Choiauthor=D.+M.+Rosenbaumauthor=T.+S.+Kobilkaauthor=F.+S.+Thianauthor=P.+C.+Edwardsauthor=M.+Burghammerauthor=V.+R.+P.+Ratnalaauthor=R.+Sanishviliauthor=R.+F.+Fischettiauthor=G.+F.+X.+Schertlerauthor=W.+I.+Weisauthor=B.+K.+Kobilka&title=Crystal+structure+of+the+human+%CE%B22+adrenergic+G-protein-coupled+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the human β2 adrenergic G-protein-coupled receptor</span></div><div class="casAuthors">Rasmussen, Soren G. F.; Choi, Hee-Jung; Rosenbaum, Daniel M.; Kobilka, Tong Sun; Thian, Foon Sun; Edwards, Patricia C.; Burghammer, Manfred; Ratnala, Venkata R. P.; Sanishvili, Ruslan; Fischetti, Robert F.; Schertler, Gebhard F. X.; Weis, William I.; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">450</span>
        (<span class="NLM_cas:issue">7168</span>),
    <span class="NLM_cas:pages">383-387</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Structural anal. of G-protein-coupled receptors (GPCRs) for hormones and neurotransmitters has been hindered by their low natural abundance, inherent structural flexibility, and instability in detergent solns.  Here we report a structure of the human β2 adrenoceptor (β2AR), which was crystd. in a lipid environment when bound to an inverse agonist and in complex with a Fab that binds to the third intracellular loop.  Diffraction data were obtained by high-brilliance microcrystallog. and the structure detd. at 3.4 Å/3.7 Å resoln.  The cytoplasmic ends of the β2AR transmembrane segments and the connecting loops are well resolved, whereas the extracellular regions of the β2AR are not seen.  The β2AR structure differs from rhodopsin in having weaker interactions between the cytoplasmic ends of transmembrane (TM)3 and TM6, involving the conserved E/DRY sequences.  These differences may be responsible for the relatively high basal activity and structural instability of the β2AR, and contribute to the challenges in obtaining diffraction-quality crystals of non-rhodopsin GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTx0B_3Vn2M7Vg90H21EOLACvtfcHk0liXRY1uFc5rOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlajs77N&md5=79026a0a69ddb4b0ea25063e409ad2cd</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnature06325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature06325%26sid%3Dliteratum%253Aachs%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%2BF.%26aulast%3DChoi%26aufirst%3DH.-J.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DEdwards%26aufirst%3DP.%2BC.%26aulast%3DBurghammer%26aufirst%3DM.%26aulast%3DRatnala%26aufirst%3DV.%2BR.%2BP.%26aulast%3DSanishvili%26aufirst%3DR.%26aulast%3DFischetti%26aufirst%3DR.%2BF.%26aulast%3DSchertler%26aufirst%3DG.%2BF.%2BX.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520%25CE%25B22%2520adrenergic%2520G-protein-coupled%2520receptor%26jtitle%3DNature%26date%3D2007%26volume%3D450%26spage%3D383%26epage%3D388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Procopiou, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bevan, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggadike, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butchers, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coe, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conroy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmons, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsley, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li-Kwai-Cheung, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Looker, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mann, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLay, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutch, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlin, P.</span><span> </span><span class="NLM_article-title">Synthesis and structure–activity relationships of long-acting beta<sub>2</sub> adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4522</span><span class="NLM_x">–</span> <span class="NLM_lpage">4530</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100326d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4522-4530&author=P.+A.+Procopiouauthor=V.+J.+Barrettauthor=N.+J.+Bevanauthor=K.+Biggadikeauthor=P.+C.+Boxauthor=P.+R.+Butchersauthor=D.+M.+Coeauthor=R.+Conroyauthor=A.+Emmonsauthor=A.+J.+Fordauthor=D.+S.+Holmesauthor=H.+Horsleyauthor=F.+Kerrauthor=A.+M.+Li-Kwai-Cheungauthor=B.+E.+Lookerauthor=I.+S.+Mannauthor=I.+M.+McLayauthor=V.+S.+Morrisonauthor=P.+J.+Mutchauthor=C.+E.+Smithauthor=P.+Tomlin&title=Synthesis+and+structure%E2%80%93activity+relationships+of+long-acting+beta2+adrenergic+receptor+agonists+incorporating+metabolic+inactivation%3A+an+antedrug+approach"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm100326d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100326d%26sid%3Dliteratum%253Aachs%26aulast%3DProcopiou%26aufirst%3DP.%2BA.%26aulast%3DBarrett%26aufirst%3DV.%2BJ.%26aulast%3DBevan%26aufirst%3DN.%2BJ.%26aulast%3DBiggadike%26aufirst%3DK.%26aulast%3DBox%26aufirst%3DP.%2BC.%26aulast%3DButchers%26aufirst%3DP.%2BR.%26aulast%3DCoe%26aufirst%3DD.%2BM.%26aulast%3DConroy%26aufirst%3DR.%26aulast%3DEmmons%26aufirst%3DA.%26aulast%3DFord%26aufirst%3DA.%2BJ.%26aulast%3DHolmes%26aufirst%3DD.%2BS.%26aulast%3DHorsley%26aufirst%3DH.%26aulast%3DKerr%26aufirst%3DF.%26aulast%3DLi-Kwai-Cheung%26aufirst%3DA.%2BM.%26aulast%3DLooker%26aufirst%3DB.%2BE.%26aulast%3DMann%26aufirst%3DI.%2BS.%26aulast%3DMcLay%26aufirst%3DI.%2BM.%26aulast%3DMorrison%26aufirst%3DV.%2BS.%26aulast%3DMutch%26aufirst%3DP.%2BJ.%26aulast%3DSmith%26aufirst%3DC.%2BE.%26aulast%3DTomlin%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520long-acting%2520beta2%2520adrenergic%2520receptor%2520agonists%2520incorporating%2520metabolic%2520inactivation%253A%2520an%2520antedrug%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4522%26epage%3D4530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Kempsford, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siederer, S.</span><span> </span><span class="NLM_article-title">Vilanterol trifenatate, a novel inhaled long-acting β<sub>2</sub> adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD</span> <span class="citation_source-journal">Pulm. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">256</span><span class="NLM_x">–</span> <span class="NLM_lpage">264</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.pupt.2012.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23232038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=256-264&author=R.+Kempsfordauthor=V.+Norrisauthor=S.+Siederer&title=Vilanterol+trifenatate%2C+a+novel+inhaled+long-acting+%CE%B22+adrenoceptor+agonist%2C+is+well+tolerated+in+healthy+subjects+and+demonstrates+prolonged+bronchodilation+in+subjects+with+asthma+and+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD</span></div><div class="casAuthors">Kempsford, Rodger; Norris, Virginia; Siederer, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">256-264</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Vilanterol (VI; GW642444M) is a novel inhaled long-acting β2-agonist with inherent 24 h activity in vitro in development as a combination with the inhaled corticosteroid fluticasone furoate for both COPD and asthma.  These studies were conducted to det. the safety, tolerability, pharmacodynamics and pharmacokinetics of VI in healthy subjects and subjects with mild to moderate persistent asthma and moderate to severe COPD.Single doses of VI (25-100 μg) were given once daily to subjects with asthma and COPD and repeat doses once daily for 14 days to healthy subjects.  Adverse events (AEs), vital signs, ECGs, pharmacodynamic endpoints, FEV1 and VI plasma pharmacokinetics (AUC, Cmax and Tmax) were detd. following dosing.VI (25-100 μg) was well tolerated.  The incidence and severity of AEs were comparable to placebo.  Following VI administration there were no clin. significant abnormalities in vital signs, 12-lead ECG, Holter ECG, blood glucose or potassium.  There were no statistically significant effects on QTc of single and repeat VI doses up to 50 μg; some differences were seen following the 100 μg VI dose after single and repeat dose in healthy subjects and single dose in asthmatic subjects.  All VI doses produced increases in FEV1 from as early as 5 min after dosing which were maintained up to 24 h post-dose in subjects with asthma and COPD.  In all subjects VI was rapidly absorbed (healthy subjects median Tmax at 5 min; asthma and COPD subjects median Tmax at 10 min) with systemic exposure increasing in an approx. dose proportional manner across the VI dose range.  Marginal accumulation was seen on repeat dosing.Single doses of inhaled VI in subjects with asthma and COPD and repeat doses in healthy subjects were well tolerated with no clin. significant unwanted systemic effects.  VI produced a rapid and prolonged bronchodilation over 24 h suggesting the potential for once daily administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8cX6SSS6wyrVg90H21EOLACvtfcHk0ljReRxiK5dd8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSrsQ%253D%253D&md5=5f2cf2326c8ffa20acc16256c484ddb9</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2012.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2012.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DKempsford%26aufirst%3DR.%26aulast%3DNorris%26aufirst%3DV.%26aulast%3DSiederer%26aufirst%3DS.%26atitle%3DVilanterol%2520trifenatate%252C%2520a%2520novel%2520inhaled%2520long-acting%2520%25CE%25B22%2520adrenoceptor%2520agonist%252C%2520is%2520well%2520tolerated%2520in%2520healthy%2520subjects%2520and%2520demonstrates%2520prolonged%2520bronchodilation%2520in%2520subjects%2520with%2520asthma%2520and%2520COPD%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D26%26spage%3D256%26epage%3D264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Slack, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturton, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmons, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knowles, R. G.</span><span> </span><span class="NLM_article-title">In vitro pharmacological characterization of vilanterol, a novel long-acting β<sub>2</sub>-adrenoceptor agonist with 24-hour duration of action</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">218</span><span class="NLM_x">–</span> <span class="NLM_lpage">230</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1124%2Fjpet.112.198481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23131596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Cruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2013&pages=218-230&author=R.+J.+Slackauthor=V.+J.+Barrettauthor=V.+S.+Morrisonauthor=R.+G.+Sturtonauthor=A.+J.+Emmonsauthor=A.+J.+Fordauthor=R.+G.+Knowles&title=In+vitro+pharmacological+characterization+of+vilanterol%2C+a+novel+long-acting+%CE%B22-adrenoceptor+agonist+with+24-hour+duration+of+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action</span></div><div class="casAuthors">Slack, Robert J.; Barrett, Victoria J.; Morrison, Valerie S.; Sturton, Richard G.; Emmons, Amanda J.; Ford, Alison J.; Knowles, Richard G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">218-230</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Vilanterol trifenatate (vilanterol) is a novel, long-acting β2-adrenoceptor (β2-AR) agonist with 24 h activity.  In this study, we describe the preclin. pharmacol. profile of vilanterol using radioligand binding and cAMP studies in recombinant assays as well as human and guinea pig tissue systems to characterize β2-AR binding and functional properties.  Vilanterol displayed a subnanomolar affinity for the β2-AR that was comparable with that of salmeterol but higher than olodaterol, formoterol, and indacaterol.  In cAMP functional activity studies, vilanterol demonstrated similar selectivity as salmeterol for β2- over β1-AR and β3-AR, but a significantly improved selectivity profile than formoterol and indacaterol.  Vilanterol also showed a level of intrinsic efficacy that was comparable to indacaterol but significantly greater than that of salmeterol.  In cellular cAMP prodn. and tissue-based studies measuring persistence and reassertion, vilanterol had a persistence of action comparable with indacaterol and longer than formoterol.  In addn., vilanterol demonstrated reassertion activity in both cell and tissue systems that was comparable with salmeterol and indacaterol but longer than formoterol.  In human airways, vilanterol was shown to have a faster onset and longer duration of action than salmeterol, exhibiting a significant level of bronchodilation 22 h after treatment.  From these investigations, the data for vilanterol are consistent, showing that it is a novel, potent, and selective β2-AR receptor agonist with a long duration of action.  This pharmacol. profile combined with clin. data is consistent with once a day dosing of vilanterol in the treatment of both asthma and chronic obstructive pulmonary disease (COPD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp95t1JgsCjK7Vg90H21EOLACvtfcHk0ljReRxiK5dd8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Cruw%253D%253D&md5=e2e1d7bdb72404ea5a934c79fd7f92d0</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.198481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.198481%26sid%3Dliteratum%253Aachs%26aulast%3DSlack%26aufirst%3DR.%2BJ.%26aulast%3DBarrett%26aufirst%3DV.%2BJ.%26aulast%3DMorrison%26aufirst%3DV.%2BS.%26aulast%3DSturton%26aufirst%3DR.%2BG.%26aulast%3DEmmons%26aufirst%3DA.%2BJ.%26aulast%3DFord%26aufirst%3DA.%2BJ.%26aulast%3DKnowles%26aufirst%3DR.%2BG.%26atitle%3DIn%2520vitro%2520pharmacological%2520characterization%2520of%2520vilanterol%252C%2520a%2520novel%2520long-acting%2520%25CE%25B22-adrenoceptor%2520agonist%2520with%252024-hour%2520duration%2520of%2520action%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D344%26spage%3D218%26epage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Brown, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glossop, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewthwaite, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perros-Huguet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevethick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span> </span><span class="NLM_article-title">The discovery of adamantyl-derived, inhaled, long acting beta<sub>2</sub>-adrenoreceptor agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1280</span><span class="NLM_x">–</span> <span class="NLM_lpage">1283</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1280-1283&author=A.+D.+Brownauthor=M.+E.+Bunnageauthor=P.+A.+Glossopauthor=K.+Jamesauthor=R.+Jonesauthor=C.+A.+Laneauthor=R.+A.+Lewthwaiteauthor=S.+Mantellauthor=C.+Perros-Huguetauthor=D.+A.+Priceauthor=M.+Trevethickauthor=R.+Webster&title=The+discovery+of+adamantyl-derived%2C+inhaled%2C+long+acting+beta2-adrenoreceptor+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DA.%2BD.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DLane%26aufirst%3DC.%2BA.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DMantell%26aufirst%3DS.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DTrevethick%26aufirst%3DM.%26aulast%3DWebster%26aufirst%3DR.%26atitle%3DThe%2520discovery%2520of%2520adamantyl-derived%252C%2520inhaled%252C%2520long%2520acting%2520beta2-adrenoreceptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D1280%26epage%3D1283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Brown, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glossop, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holbrook, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewthwaite, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perros-Huguet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span> </span><span class="NLM_article-title">The discovery of indole-derived long acting beta<sub>2</sub>-adrenoceptor agonists for the treatment of asthma and COPD</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">6188</span><span class="NLM_x">–</span> <span class="NLM_lpage">6191</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=6188-6191&author=A.+D.+Brownauthor=M.+E.+Bunnageauthor=P.+A.+Glossopauthor=M.+Holbrookauthor=R.+D.+Jonesauthor=C.+A.+Laneauthor=R.+A.+Lewthwaiteauthor=S.+Mantellauthor=C.+Perros-Huguetauthor=D.+A.+Priceauthor=R.+Webster&title=The+discovery+of+indole-derived+long+acting+beta2-adrenoceptor+agonists+for+the+treatment+of+asthma+and+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DA.%2BD.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DHolbrook%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DR.%2BD.%26aulast%3DLane%26aufirst%3DC.%2BA.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DMantell%26aufirst%3DS.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DWebster%26aufirst%3DR.%26atitle%3DThe%2520discovery%2520of%2520indole-derived%2520long%2520acting%2520beta2-adrenoceptor%2520agonists%2520for%2520the%2520treatment%2520of%2520asthma%2520and%2520COPD%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D6188%26epage%3D6191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Glossop, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewthwaite, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeadon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perros-Huguet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevethick, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeder, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spence, F. J.</span><span> </span><span class="NLM_article-title">Inhalation by design: novel ultra-long-acting β<sub>2</sub>-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6640</span><span class="NLM_x">–</span> <span class="NLM_lpage">6652</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1005989" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6640-6652&author=P.+A.+Glossopauthor=C.+A.+Laneauthor=D.+A.+Priceauthor=M.+E.+Bunnageauthor=R.+A.+Lewthwaiteauthor=K.+Jamesauthor=A.+D.+Brownauthor=M.+Yeadonauthor=C.+Perros-Huguetauthor=M.+A.+Trevethickauthor=N.+P.+Clarkeauthor=R.+Websterauthor=R.+M.+Jonesauthor=J.+L.+Burrowsauthor=N.+Feederauthor=S.+C.+Taylorauthor=F.+J.+Spence&title=Inhalation+by+design%3A+novel+ultra-long-acting+%CE%B22-adrenoreceptor+agonists+for+inhaled+once-daily+treatment+of+asthma+and+chronic+obstructive+pulmonary+disease+that+utilize+a+sulfonamide+agonist+headgroup"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm1005989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1005989%26sid%3Dliteratum%253Aachs%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DLane%26aufirst%3DC.%2BA.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DA.%2BD.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DTrevethick%26aufirst%3DM.%2BA.%26aulast%3DClarke%26aufirst%3DN.%2BP.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DBurrows%26aufirst%3DJ.%2BL.%26aulast%3DFeeder%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DS.%2BC.%26aulast%3DSpence%26aufirst%3DF.%2BJ.%26atitle%3DInhalation%2520by%2520design%253A%2520novel%2520ultra-long-acting%2520%25CE%25B22-adrenoreceptor%2520agonists%2520for%2520inhaled%2520once-daily%2520treatment%2520of%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%2520that%2520utilize%2520a%2520sulfonamide%2520agonist%2520headgroup%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6640%26epage%3D6652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Bouyssou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolf, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoenke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lustenberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konetzki, I.</span><span> </span><span class="NLM_article-title">Studies towards topical selective β<sub>2</sub>-adrenoceptor agonists with a long duration of action</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5237</span><span class="NLM_x">–</span> <span class="NLM_lpage">5240</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5237-5240&author=T.+Bouyssouauthor=K.+Rudolfauthor=C.+Hoenkeauthor=P.+Lustenbergerauthor=A.+Schnappauthor=I.+Konetzki&title=Studies+towards+topical+selective+%CE%B22-adrenoceptor+agonists+with+a+long+duration+of+action"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBouyssou%26aufirst%3DT.%26aulast%3DRudolf%26aufirst%3DK.%26aulast%3DHoenke%26aufirst%3DC.%26aulast%3DLustenberger%26aufirst%3DP.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DKonetzki%26aufirst%3DI.%26atitle%3DStudies%2520towards%2520topical%2520selective%2520%25CE%25B22-adrenoceptor%2520agonists%2520with%2520a%2520long%2520duration%2520of%2520action%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5237%26epage%3D5240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Hoenke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouyssou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tautermann, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolf, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konetzki, I.</span><span> </span><span class="NLM_article-title">Use of 5-hydroxy-4<i>H</i>-benzo[1,4]oxazin-3-ones as β<sub>2</sub>-adrenoceptor agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6640</span><span class="NLM_x">–</span> <span class="NLM_lpage">6644</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6640-6644&author=C.+Hoenkeauthor=T.+Bouyssouauthor=C.+S.+Tautermannauthor=K.+Rudolfauthor=A.+Schnappauthor=I.+Konetzki&title=Use+of+5-hydroxy-4H-benzo%5B1%2C4%5Doxazin-3-ones+as+%CE%B22-adrenoceptor+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoenke%26aufirst%3DC.%26aulast%3DBouyssou%26aufirst%3DT.%26aulast%3DTautermann%26aufirst%3DC.%2BS.%26aulast%3DRudolf%26aufirst%3DK.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DKonetzki%26aufirst%3DI.%26atitle%3DUse%2520of%25205-hydroxy-4H-benzo%255B1%252C4%255Doxazin-3-ones%2520as%2520%25CE%25B22-adrenoceptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6640%26epage%3D6644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Bouyssou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoenke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolf, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lustenberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pestel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sieger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heine, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buttner, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konetzki, I.</span><span> </span><span class="NLM_article-title">Discovery of olodaterol, a novel inhaled β<sub>2</sub>-adrenoceptor agonist with a 24 h bronchodilatory efficacy</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1410</span><span class="NLM_x">–</span> <span class="NLM_lpage">1414</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.bmcl.2009.12.087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=20096576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslSmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1410-1414&author=T.+Bouyssouauthor=C.+Hoenkeauthor=K.+Rudolfauthor=P.+Lustenbergerauthor=S.+Pestelauthor=P.+Siegerauthor=R.+Lotzauthor=C.+Heineauthor=F.+H.+Buttnerauthor=A.+Schnappauthor=I.+Konetzki&title=Discovery+of+olodaterol%2C+a+novel+inhaled+%CE%B22-adrenoceptor+agonist+with+a+24+h+bronchodilatory+efficacy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24h bronchodilatory efficacy</span></div><div class="casAuthors">Bouyssou, Thierry; Hoenke, Christoph; Rudolf, Klaus; Lustenberger, Philipp; Pestel, Sabine; Sieger, Peter; Lotz, Ralf; Heine, Claudia; Buettner, Frank H.; Schnapp, Andreas; Konetzki, Ingo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1410-1414</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Compd. 4p (I) was identified from a series of 6-hydroxy-4H-benzo[1,4]oxazin-3-ones as potent agonist of the human β2-adrenoceptor with a high β1/β2-selectivity.  A complete reversal of acetylcholine-induced bronchoconstriction which lasted over the whole study period of 5 h was demonstrated for 4p in a guinea pig in vivo model without any signs of cardiovascular effects up to 10-fold above the first dose reaching 100% bronchoprotection.  The enantiomerically pure (R)-form of 4p exerted a bronchodilatory efficacy over 24 h in dogs and guinea pigs in the absence of systemic pharmacodynamic effects.  Formoterol which was tested as comparator in the same in vivo models of acetylcholine-induced bronchoconstriction did not retain efficacy after 24 h.  In summary, the preclin. profile of compd. (R)-4p (olodaterol, also known as BI 1744 CL) suggests a potential for once-daily dosing in man accompanied with an improved safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq_OHb0Lpw87Vg90H21EOLACvtfcHk0ljEUwU7jBn2ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslSmt7c%253D&md5=4527e1e074c1ee33eccc2d9f3293bdef</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.12.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.12.087%26sid%3Dliteratum%253Aachs%26aulast%3DBouyssou%26aufirst%3DT.%26aulast%3DHoenke%26aufirst%3DC.%26aulast%3DRudolf%26aufirst%3DK.%26aulast%3DLustenberger%26aufirst%3DP.%26aulast%3DPestel%26aufirst%3DS.%26aulast%3DSieger%26aufirst%3DP.%26aulast%3DLotz%26aufirst%3DR.%26aulast%3DHeine%26aufirst%3DC.%26aulast%3DButtner%26aufirst%3DF.%2BH.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DKonetzki%26aufirst%3DI.%26atitle%3DDiscovery%2520of%2520olodaterol%252C%2520a%2520novel%2520inhaled%2520%25CE%25B22-adrenoceptor%2520agonist%2520with%2520a%252024%2520h%2520bronchodilatory%2520efficacy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1410%26epage%3D1414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Gibb, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L. P.</span><span> </span><span class="NLM_article-title">Olodaterol: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1841</span><span class="NLM_x">–</span> <span class="NLM_lpage">1846</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1841-1846&author=A.+Gibbauthor=L.+P.+Yang&title=Olodaterol%3A+first+global+approval"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGibb%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DL.%2BP.%26atitle%3DOlodaterol%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D1841%26epage%3D1846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Connolly, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alcaraz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cadogan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphries, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingall, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairaudeau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stocks, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, A.</span><span> </span><span class="NLM_article-title">Design-driven LO: the discovery of new ultra long acting dibasic β<sub>2</sub>-adrenoceptor agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4612</span><span class="NLM_x">–</span> <span class="NLM_lpage">4616</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4612-4616&author=S.+Connollyauthor=L.+Alcarazauthor=A.+Baileyauthor=E.+Cadoganauthor=J.+Christieauthor=A.+R.+Cookauthor=A.+J.+Fisherauthor=S.+Hillauthor=A.+Humphriesauthor=A.+H.+Ingallauthor=Z.+Kaneauthor=S.+Paineauthor=G.+Pairaudeauauthor=M.+J.+Stocksauthor=A.+Young&title=Design-driven+LO%3A+the+discovery+of+new+ultra+long+acting+dibasic+%CE%B22-adrenoceptor+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DS.%26aulast%3DAlcaraz%26aufirst%3DL.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DCadogan%26aufirst%3DE.%26aulast%3DChristie%26aufirst%3DJ.%26aulast%3DCook%26aufirst%3DA.%2BR.%26aulast%3DFisher%26aufirst%3DA.%2BJ.%26aulast%3DHill%26aufirst%3DS.%26aulast%3DHumphries%26aufirst%3DA.%26aulast%3DIngall%26aufirst%3DA.%2BH.%26aulast%3DKane%26aufirst%3DZ.%26aulast%3DPaine%26aufirst%3DS.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26aulast%3DYoung%26aufirst%3DA.%26atitle%3DDesign-driven%2520LO%253A%2520the%2520discovery%2520of%2520new%2520ultra%2520long%2520acting%2520dibasic%2520%25CE%25B22-adrenoceptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4612%26epage%3D4616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Alcaraz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cadogan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kindon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lister, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dainty, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholls, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairaudeau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stocks, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorne, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, A.</span><span> </span><span class="NLM_article-title">From libraries to candidate: the discovery of new ultra long-acting dibasic β<sub>2</sub>-adrenoceptor agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">689</span><span class="NLM_x">–</span> <span class="NLM_lpage">695</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=689-695&author=L.+Alcarazauthor=A.+Baileyauthor=E.+Cadoganauthor=S.+Connollyauthor=R.+Jewellauthor=S.+Jordanauthor=N.+Kindonauthor=A.+Listerauthor=M.+Lawsonauthor=A.+Mullenauthor=I.+Daintyauthor=D.+Nichollsauthor=S.+Paineauthor=G.+Pairaudeauauthor=M.+J.+Stocksauthor=P.+Thorneauthor=A.+Young&title=From+libraries+to+candidate%3A+the+discovery+of+new+ultra+long-acting+dibasic+%CE%B22-adrenoceptor+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlcaraz%26aufirst%3DL.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DCadogan%26aufirst%3DE.%26aulast%3DConnolly%26aufirst%3DS.%26aulast%3DJewell%26aufirst%3DR.%26aulast%3DJordan%26aufirst%3DS.%26aulast%3DKindon%26aufirst%3DN.%26aulast%3DLister%26aufirst%3DA.%26aulast%3DLawson%26aufirst%3DM.%26aulast%3DMullen%26aufirst%3DA.%26aulast%3DDainty%26aufirst%3DI.%26aulast%3DNicholls%26aufirst%3DD.%26aulast%3DPaine%26aufirst%3DS.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26aulast%3DThorne%26aufirst%3DP.%26aulast%3DYoung%26aufirst%3DA.%26atitle%3DFrom%2520libraries%2520to%2520candidate%253A%2520the%2520discovery%2520of%2520new%2520ultra%2520long-acting%2520dibasic%2520%25CE%25B22-adrenoceptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D689%26epage%3D695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Beattie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brearley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuenoud, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairhurst, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gedeck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gosling, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janus, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oakman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stringer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuffnell, A.</span><span> </span><span class="NLM_article-title">A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta<sub>2</sub>-adrenoceptor agonists as inhaled long-acting bronchodilators</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5302</span><span class="NLM_x">–</span> <span class="NLM_lpage">5307</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5302-5307&author=D.+Beattieauthor=M.+Bradleyauthor=A.+Brearleyauthor=S.+J.+Charltonauthor=B.+M.+Cuenoudauthor=R.+A.+Fairhurstauthor=P.+Gedeckauthor=M.+Goslingauthor=D.+Janusauthor=D.+Jonesauthor=C.+Lewisauthor=C.+McCarthyauthor=H.+Oakmanauthor=R.+Stringerauthor=R.+J.+Taylorauthor=A.+Tuffnell&title=A+physical+properties+based+approach+for+the+exploration+of+a+4-hydroxybenzothiazolone+series+of+beta2-adrenoceptor+agonists+as+inhaled+long-acting+bronchodilators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeattie%26aufirst%3DD.%26aulast%3DBradley%26aufirst%3DM.%26aulast%3DBrearley%26aufirst%3DA.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DCuenoud%26aufirst%3DB.%2BM.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DGedeck%26aufirst%3DP.%26aulast%3DGosling%26aufirst%3DM.%26aulast%3DJanus%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DOakman%26aufirst%3DH.%26aulast%3DStringer%26aufirst%3DR.%26aulast%3DTaylor%26aufirst%3DR.%2BJ.%26aulast%3DTuffnell%26aufirst%3DA.%26atitle%3DA%2520physical%2520properties%2520based%2520approach%2520for%2520the%2520exploration%2520of%2520a%25204-hydroxybenzothiazolone%2520series%2520of%2520beta2-adrenoceptor%2520agonists%2520as%2520inhaled%2520long-acting%2520bronchodilators%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5302%26epage%3D5307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Sin, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, J. V.</span><span> </span><span class="NLM_article-title">Lack of association between ipratropium bromide and mortality in elderly patients with chronic obstructive airway disease</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">194</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2000&pages=194-197&author=D.+D.+Sinauthor=J.+V.+Tu&title=Lack+of+association+between+ipratropium+bromide+and+mortality+in+elderly+patients+with+chronic+obstructive+airway+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSin%26aufirst%3DD.%2BD.%26aulast%3DTu%26aufirst%3DJ.%2BV.%26atitle%3DLack%2520of%2520association%2520between%2520ipratropium%2520bromide%2520and%2520mortality%2520in%2520elderly%2520patients%2520with%2520chronic%2520obstructive%2520airway%2520disease%26jtitle%3DThorax%26date%3D2000%26volume%3D55%26spage%3D194%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Anthonisen, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connett, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiley, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altose, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buist, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, W. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enright, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanner, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Hara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scanlon, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tashkin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, R. A.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV<sub>1</sub>. The Lung Health Study</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">272</span><span class="NLM_x">, </span> <span class="NLM_fpage">1497</span><span class="NLM_x">–</span> <span class="NLM_lpage">1505</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1994&pages=1497-1505&author=N.+R.+Anthonisenauthor=J.+E.+Connettauthor=J.+P.+Kileyauthor=M.+D.+Altoseauthor=W.+C.+Baileyauthor=A.+S.+Buistauthor=W.+A.+Conwayauthor=P.+L.+Enrightauthor=R.+E.+Kannerauthor=P.+O%E2%80%99Haraauthor=G.+R.+Owensauthor=P.+D.+Scanlonauthor=D.+P.+Tashkinauthor=R.+A.+Wise&title=Effects+of+smoking+intervention+and+the+use+of+an+inhaled+anticholinergic+bronchodilator+on+the+rate+of+decline+of+FEV1.+The+Lung+Health+Study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAnthonisen%26aufirst%3DN.%2BR.%26aulast%3DConnett%26aufirst%3DJ.%2BE.%26aulast%3DKiley%26aufirst%3DJ.%2BP.%26aulast%3DAltose%26aufirst%3DM.%2BD.%26aulast%3DBailey%26aufirst%3DW.%2BC.%26aulast%3DBuist%26aufirst%3DA.%2BS.%26aulast%3DConway%26aufirst%3DW.%2BA.%26aulast%3DEnright%26aufirst%3DP.%2BL.%26aulast%3DKanner%26aufirst%3DR.%2BE.%26aulast%3DO%25E2%2580%2599Hara%26aufirst%3DP.%26aulast%3DOwens%26aufirst%3DG.%2BR.%26aulast%3DScanlon%26aufirst%3DP.%2BD.%26aulast%3DTashkin%26aufirst%3DD.%2BP.%26aulast%3DWise%26aufirst%3DR.%2BA.%26atitle%3DEffects%2520of%2520smoking%2520intervention%2520and%2520the%2520use%2520of%2520an%2520inhaled%2520anticholinergic%2520bronchodilator%2520on%2520the%2520rate%2520of%2520decline%2520of%2520FEV1.%2520The%2520Lung%2520Health%2520Study%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D1994%26volume%3D272%26spage%3D1497%26epage%3D1505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Tashkin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashutosh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleecker, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britt, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cugell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummiskey, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeLorenzo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lakshminarayan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maguire, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plummer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renzetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sackner, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skorodin, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, S.</span><span> </span><span class="NLM_article-title">Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. A 90-day multi-center study</span> <span class="citation_source-journal">Am. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2F0002-9343%2886%2990468-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=2947465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADyaL2s%252FntlCqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1986&pages=81-90&author=D.+P.+Tashkinauthor=K.+Ashutoshauthor=E.+R.+Bleeckerauthor=E.+J.+Brittauthor=D.+W.+Cugellauthor=J.+M.+Cummiskeyauthor=L.+DeLorenzoauthor=M.+J.+Gilmanauthor=G.+N.+Grossauthor=N.+J.+Grossauthor=A.+Kotchauthor=S.+Lakshminarayanauthor=G.+Maguireauthor=M.+Millerauthor=A.+Plummerauthor=A.+Renzettiauthor=M.+A.+Sacknerauthor=M.+S.+Skorodinauthor=A.+Wannerauthor=S.+Watanabe&title=Comparison+of+the+anticholinergic+bronchodilator+ipratropium+bromide+with+metaproterenol+in+chronic+obstructive+pulmonary+disease.+A+90-day+multi-center+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. A 90-day multi-center study</span></div><div class="casAuthors">Tashkin D P; Ashutosh K; Bleecker E R; Britt E J; Cugell D W; Cummiskey J M; DeLorenzo L; Gilman M J; Gross G N; Gross N J</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of medicine</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">5A</span>),
    <span class="NLM_cas:pages">81-90</span>
        ISSN:<span class="NLM_cas:issn">0002-9343</span>.
    </div><div class="casAbstract">The short- and long-term efficacy and safety of an inhaled quaternary ammonium anticholinergic agent, ipratropium bromide, and a beta agonist aerosol, metaproterenol, were compared in 261 nonatopic patients with chronic obstructive pulmonary disease (COPD).  The study was a randomized, double-blind, 90-day, parallel-group trial.  On three test days-one, 45, and 90-mean peak responses for forced expiratory volume in one second and forced vital capacity and mean area under the time-response curve were higher for ipratropium than for metaproterenol.  Clinical improvement was noted in both treatment groups, especially during the first treatment month, with persistence of improvement throughout the remainder of the study.  Side effects were relatively infrequent and generally mild; tremor, a complication of beta agonists, was not reported by any subject receiving ipratropium.  These results support the effectiveness and safety of long-term treatment with inhaled ipratropium in COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSuL6fox8M3jUNHe_gFldTbfW6udTcc2ea1Kh7bc_td_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2s%252FntlCqsQ%253D%253D&md5=fce8aaed4508db3ad685070a29845bfc</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2F0002-9343%2886%2990468-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0002-9343%252886%252990468-7%26sid%3Dliteratum%253Aachs%26aulast%3DTashkin%26aufirst%3DD.%2BP.%26aulast%3DAshutosh%26aufirst%3DK.%26aulast%3DBleecker%26aufirst%3DE.%2BR.%26aulast%3DBritt%26aufirst%3DE.%2BJ.%26aulast%3DCugell%26aufirst%3DD.%2BW.%26aulast%3DCummiskey%26aufirst%3DJ.%2BM.%26aulast%3DDeLorenzo%26aufirst%3DL.%26aulast%3DGilman%26aufirst%3DM.%2BJ.%26aulast%3DGross%26aufirst%3DG.%2BN.%26aulast%3DGross%26aufirst%3DN.%2BJ.%26aulast%3DKotch%26aufirst%3DA.%26aulast%3DLakshminarayan%26aufirst%3DS.%26aulast%3DMaguire%26aufirst%3DG.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DPlummer%26aufirst%3DA.%26aulast%3DRenzetti%26aufirst%3DA.%26aulast%3DSackner%26aufirst%3DM.%2BA.%26aulast%3DSkorodin%26aufirst%3DM.%2BS.%26aulast%3DWanner%26aufirst%3DA.%26aulast%3DWatanabe%26aufirst%3DS.%26atitle%3DComparison%2520of%2520the%2520anticholinergic%2520bronchodilator%2520ipratropium%2520bromide%2520with%2520metaproterenol%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease.%2520A%252090-day%2520multi-center%2520study%26jtitle%3DAm.%2520J.%2520Med.%26date%3D1986%26volume%3D81%26spage%3D81%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Chervinsky, P.</span><span> </span><span class="NLM_article-title">Concomitant bronchodilator therapy and ipratropium bromide. A clinical review</span> <span class="citation_source-journal">Am. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2F0002-9343%2886%2990465-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=2947463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADyaL2s%252FntlCqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1986&pages=67-73&author=P.+Chervinsky&title=Concomitant+bronchodilator+therapy+and+ipratropium+bromide.+A+clinical+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Concomitant bronchodilator therapy and ipratropium bromide. A clinical review</span></div><div class="casAuthors">Chervinsky P</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of medicine</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">5A</span>),
    <span class="NLM_cas:pages">67-73</span>
        ISSN:<span class="NLM_cas:issn">0002-9343</span>.
    </div><div class="casAbstract">This article reviews the use of ipratropium bromide concomitantly with other bronchodilators, with a focus on its use in patients with asthma.  Patients with asthma generally have demonstrated a greater response to the combination of ipratropium and other anti-asthma drugs than to either drug alone.  No increase in side effects has been observed when ipratropium has been used in combination with other bronchodilating drugs.  Overall, the combination of ipratropium with other agents appears to offer promise in therapy for asthma; further investigation of combinations in larger patient populations is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSuL6fox8M3jUH3Rlp_k91zfW6udTcc2ea1Kh7bc_td_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2s%252FntlCqsg%253D%253D&md5=dcc815f157d6ebf8d9f10f2e05c53638</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2F0002-9343%2886%2990465-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0002-9343%252886%252990465-1%26sid%3Dliteratum%253Aachs%26aulast%3DChervinsky%26aufirst%3DP.%26atitle%3DConcomitant%2520bronchodilator%2520therapy%2520and%2520ipratropium%2520bromide.%2520A%2520clinical%2520review%26jtitle%3DAm.%2520J.%2520Med.%26date%3D1986%26volume%3D81%26spage%3D67%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Wadbo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lofdahl, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skoogh, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tornling, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arwestrom, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bengtsson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strom, K.</span><span> </span><span class="NLM_article-title">Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1138</span><span class="NLM_x">–</span> <span class="NLM_lpage">1146</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.02.00301702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=12449166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD38XptlCmtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=1138-1146&author=M.+Wadboauthor=C.+G.+Lofdahlauthor=K.+Larssonauthor=B.+E.+Skooghauthor=G.+Tornlingauthor=E.+Arwestromauthor=T.+Bengtssonauthor=K.+Strom&title=Effects+of+formoterol+and+ipratropium+bromide+in+COPD%3A+a+3-month+placebo-controlled+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study</span></div><div class="casAuthors">Wadbo, M.; Loefdahl, C.-G.; Larsson, K.; Skoogh, B. E.; Tornling, G.; Arwestroem, E.; Bengtsson, T.; Stroem, K.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1138-1146</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">The aim of this study was to compare the effects of formoterol, ipratropium bromide and a placebo on walking distance, lung function, symptoms and quality of life (QoL) in chronic obstructive pulmonary disease (COPD) patients.  A total of 183 patients (mean age 64 yrs, 86 female) with moderate-to-severe nonreversible COPD participated in this randomized, double-blind, parallel-group study.  After a 2-wk placebo run-in, patients were randomized to formoterol Turbuhaler 18 μg b.i.d. (delivered dose), ipratropium bromide 80 μg t.i.d. via a pressurized metered dose inhaler, or placebo for 12 wk.  Inhaled short-acting β2-agonists were allowed as relief medication and inhaled glucocorticosteroids were allowed at a const. dose.  The primary variable was walking distance in the shuttle walking test (SWT).  Baseline mean SWT distance was 325 m, mean forced expiratory vol. in one second (FEV1) was 40% predicted.  Clin. significant improvements in SWT (>30 m) were seen in 41, 38 and 30% of formoterol, ipratropium and placebo patients, resp. (not significant).  Mean increases from run-in were 19, 17 and 5 m in the formoterol, ipratropium and placebo groups, resp.  Both active treatments significantly improved FEV1, forced vital capacity, peak expiratory flow and daytime dyspnea score compared with placebo.  Formoterol reduced relief medication use compared with placebo.  Neither active treatment improved QoL.  Formoterol and ipratropium improved airway function and symptoms, without significant improvements in the shuttle walking test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohe7INffhs47Vg90H21EOLACvtfcHk0ljS_-axbkDGjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptlCmtrs%253D&md5=d5952c2092ab69bbccdb7c55d8cb4f5e</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1183%2F09031936.02.00301702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.02.00301702%26sid%3Dliteratum%253Aachs%26aulast%3DWadbo%26aufirst%3DM.%26aulast%3DLofdahl%26aufirst%3DC.%2BG.%26aulast%3DLarsson%26aufirst%3DK.%26aulast%3DSkoogh%26aufirst%3DB.%2BE.%26aulast%3DTornling%26aufirst%3DG.%26aulast%3DArwestrom%26aufirst%3DE.%26aulast%3DBengtsson%26aufirst%3DT.%26aulast%3DStrom%26aufirst%3DK.%26atitle%3DEffects%2520of%2520formoterol%2520and%2520ipratropium%2520bromide%2520in%2520COPD%253A%2520a%25203-month%2520placebo-controlled%2520study%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2002%26volume%3D20%26spage%3D1138%26epage%3D1146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Colice, G. L.</span><span> </span><span class="NLM_article-title">Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Am. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">11S</span><span class="NLM_x">–</span> <span class="NLM_lpage">18S</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=1996&pages=11S-18S&author=G.+L.+Colice&title=Nebulized+bronchodilators+for+outpatient+management+of+stable+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DColice%26aufirst%3DG.%2BL.%26atitle%3DNebulized%2520bronchodilators%2520for%2520outpatient%2520management%2520of%2520stable%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAm.%2520J.%2520Med.%26date%3D1996%26volume%3D100%26spage%3D11S%26epage%3D18S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">COMBIVENT Inhalation Aerosol Study Group</span><span> </span><span class="NLM_article-title">In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">1411</span><span class="NLM_x">–</span> <span class="NLM_lpage">1419</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=1994&pages=1411-1419&author=COMBIVENT+Inhalation+Aerosol+Study+Group&title=In+chronic+obstructive+pulmonary+disease%2C+a+combination+of+ipratropium+and+albuterol+is+more+effective+than+either+agent+alone.+An+85-day+multicenter+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DIn%2520chronic%2520obstructive%2520pulmonary%2520disease%252C%2520a%2520combination%2520of%2520ipratropium%2520and%2520albuterol%2520is%2520more%2520effective%2520than%2520either%2520agent%2520alone.%2520An%252085-day%2520multicenter%2520trial%26jtitle%3DChest%26date%3D1994%26volume%3D105%26spage%3D1411%26epage%3D1419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Gross, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tashkin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linberg, S.</span><span> </span><span class="NLM_article-title">Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group</span> <span class="citation_source-journal">Respiration</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">354</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1998&pages=354-362&author=N.+Grossauthor=D.+Tashkinauthor=R.+Millerauthor=J.+Orenauthor=W.+Colemanauthor=S.+Linberg&title=Inhalation+by+nebulization+of+albuterol-ipratropium+combination+%28Dey+combination%29+is+superior+to+either+agent+alone+in+the+treatment+of+chronic+obstructive+pulmonary+disease.+Dey+Combination+Solution+Study+Group"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGross%26aufirst%3DN.%26aulast%3DTashkin%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DOren%26aufirst%3DJ.%26aulast%3DColeman%26aufirst%3DW.%26aulast%3DLinberg%26aufirst%3DS.%26atitle%3DInhalation%2520by%2520nebulization%2520of%2520albuterol-ipratropium%2520combination%2520%2528Dey%2520combination%2529%2520is%2520superior%2520to%2520either%2520agent%2520alone%2520in%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease.%2520Dey%2520Combination%2520Solution%2520Study%2520Group%26jtitle%3DRespiration%26date%3D1998%26volume%3D65%26spage%3D354%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Friedman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serby, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menjoge, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilleman, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witek, T. J.,  Jr.</span><span> </span><span class="NLM_article-title">Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">635</span><span class="NLM_x">–</span> <span class="NLM_lpage">641</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=1999&pages=635-641&author=M.+Friedmanauthor=C.+W.+Serbyauthor=S.+S.+Menjogeauthor=J.+D.+Wilsonauthor=D.+E.+Hillemanauthor=T.+J.+Witek&title=Pharmacoeconomic+evaluation+of+a+combination+of+ipratropium+plus+albuterol+compared+with+ipratropium+alone+and+albuterol+alone+in+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFriedman%26aufirst%3DM.%26aulast%3DSerby%26aufirst%3DC.%2BW.%26aulast%3DMenjoge%26aufirst%3DS.%2BS.%26aulast%3DWilson%26aufirst%3DJ.%2BD.%26aulast%3DHilleman%26aufirst%3DD.%2BE.%26aulast%3DWitek%26aufirst%3DT.%2BJ.%26atitle%3DPharmacoeconomic%2520evaluation%2520of%2520a%2520combination%2520of%2520ipratropium%2520plus%2520albuterol%2520compared%2520with%2520ipratropium%2520alone%2520and%2520albuterol%2520alone%2520in%2520COPD%26jtitle%3DChest%26date%3D1999%26volume%3D115%26spage%3D635%26epage%3D641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Disse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speck, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rominger, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witek, T. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammer, R.</span><span> </span><span class="NLM_article-title">Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">457</span><span class="NLM_x">–</span> <span class="NLM_lpage">464</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=457-464&author=B.+Disseauthor=G.+A.+Speckauthor=K.+L.+Romingerauthor=T.+J.+Witekauthor=R.+Hammer&title=Tiotropium+%28Spiriva%29%3A+mechanistical+considerations+and+clinical+profile+in+obstructive+lung+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDisse%26aufirst%3DB.%26aulast%3DSpeck%26aufirst%3DG.%2BA.%26aulast%3DRominger%26aufirst%3DK.%2BL.%26aulast%3DWitek%26aufirst%3DT.%2BJ.%26aulast%3DHammer%26aufirst%3DR.%26atitle%3DTiotropium%2520%2528Spiriva%2529%253A%2520mechanistical%2520considerations%2520and%2520clinical%2520profile%2520in%2520obstructive%2520lung%2520disease%26jtitle%3DLife%2520Sci.%26date%3D1999%26volume%3D64%26spage%3D457%26epage%3D464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Calverley, P. M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towse, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Noord, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witek, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelsen, S.</span><span> </span><span class="NLM_article-title">Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">855</span><span class="NLM_x">–</span> <span class="NLM_lpage">860</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2003&pages=855-860&author=P.+M.+A.+Calverleyauthor=A.+Leeauthor=L.+Towseauthor=J.+van+Noordauthor=T.+J.+Witekauthor=S.+Kelsen&title=Effect+of+tiotropium+bromide+on+circadian+variation+in+airflow+limitation+in+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCalverley%26aufirst%3DP.%2BM.%2BA.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DTowse%26aufirst%3DL.%26aulast%3Dvan%2BNoord%26aufirst%3DJ.%26aulast%3DWitek%26aufirst%3DT.%2BJ.%26aulast%3DKelsen%26aufirst%3DS.%26atitle%3DEffect%2520of%2520tiotropium%2520bromide%2520on%2520circadian%2520variation%2520in%2520airflow%2520limitation%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DThorax%26date%3D2003%26volume%3D58%26spage%3D855%26epage%3D860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Barr, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourbeau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camargo, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ram, F. S.</span><span> </span><span class="NLM_article-title">Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">854</span><span class="NLM_x">–</span> <span class="NLM_lpage">862</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2006&pages=854-862&author=R.+G.+Barrauthor=J.+Bourbeauauthor=C.+A.+Camargoauthor=F.+S.+Ram&title=Tiotropium+for+stable+chronic+obstructive+pulmonary+disease%3A+a+meta-analysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBarr%26aufirst%3DR.%2BG.%26aulast%3DBourbeau%26aufirst%3DJ.%26aulast%3DCamargo%26aufirst%3DC.%2BA.%26aulast%3DRam%26aufirst%3DF.%2BS.%26atitle%3DTiotropium%2520for%2520stable%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520meta-analysis%26jtitle%3DThorax%26date%3D2006%26volume%3D61%26spage%3D854%26epage%3D862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Casaburi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briggs, D. D.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donohue, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serby, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menjoge, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witek, T. J.,  Jr.</span><span> </span><span class="NLM_article-title">The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">1294</span><span class="NLM_x">–</span> <span class="NLM_lpage">1302</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2000&pages=1294-1302&author=R.+Casaburiauthor=D.+D.+Briggsauthor=J.+F.+Donohueauthor=C.+W.+Serbyauthor=S.+S.+Menjogeauthor=T.+J.+Witek&title=The+spirometric+efficacy+of+once-daily+dosing+with+tiotropium+in+stable+COPD%3A+a+13-week+multicenter+trial.+The+US+Tiotropium+Study+Group"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCasaburi%26aufirst%3DR.%26aulast%3DBriggs%26aufirst%3DD.%2BD.%26aulast%3DDonohue%26aufirst%3DJ.%2BF.%26aulast%3DSerby%26aufirst%3DC.%2BW.%26aulast%3DMenjoge%26aufirst%3DS.%2BS.%26aulast%3DWitek%26aufirst%3DT.%2BJ.%26atitle%3DThe%2520spirometric%2520efficacy%2520of%2520once-daily%2520dosing%2520with%2520tiotropium%2520in%2520stable%2520COPD%253A%2520a%252013-week%2520multicenter%2520trial.%2520The%2520US%2520Tiotropium%2520Study%2520Group%26jtitle%3DChest%26date%3D2000%26volume%3D118%26spage%3D1294%26epage%3D1302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">van Noord, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bantje, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eland, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korducki, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelissen, P. J.</span><span> </span><span class="NLM_article-title">A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2000&pages=289-294&author=J.+A.+van+Noordauthor=T.+A.+Bantjeauthor=M.+E.+Elandauthor=L.+Korduckiauthor=P.+J.+Cornelissen&title=A+randomised+controlled+comparison+of+tiotropium+and+ipratropium+in+the+treatment+of+chronic+obstructive+pulmonary+disease.+The+Dutch+Tiotropium+Study+Group"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BNoord%26aufirst%3DJ.%2BA.%26aulast%3DBantje%26aufirst%3DT.%2BA.%26aulast%3DEland%26aufirst%3DM.%2BE.%26aulast%3DKorducki%26aufirst%3DL.%26aulast%3DCornelissen%26aufirst%3DP.%2BJ.%26atitle%3DA%2520randomised%2520controlled%2520comparison%2520of%2520tiotropium%2520and%2520ipratropium%2520in%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease.%2520The%2520Dutch%2520Tiotropium%2520Study%2520Group%26jtitle%3DThorax%26date%3D2000%26volume%3D55%26spage%3D289%26epage%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Niewoehner, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cote, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paulson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, J. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korducki, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassino, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S.</span><span> </span><span class="NLM_article-title">Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">143</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.7326%2F0003-4819-143-5-200509060-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=16144890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKgs7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2005&pages=317-326&author=D.+E.+Niewoehnerauthor=K.+Riceauthor=C.+Coteauthor=D.+Paulsonauthor=J.+A.+Cooperauthor=L.+Korduckiauthor=C.+Cassinoauthor=S.+Kesten&title=Prevention+of+exacerbations+of+chronic+obstructive+pulmonary+disease+with+tiotropium%2C+a+once-daily+inhaled+anticholinergic+bronchodilator%3A+a+randomized+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial</span></div><div class="casAuthors">Niewoehner, Dennis E.; Rice, Kathryn; Cote, Claudia; Paulson, Daniel; Cooper, Allen D., Jr.; Korducki, Larry; Cassino, Cara; Kesten, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Internal Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">317-326</span>CODEN:
                <span class="NLM_cas:coden">AIMEAS</span>;
        ISSN:<span class="NLM_cas:issn">0003-4819</span>.
    
            (<span class="NLM_cas:orgname">American College of Physicians</span>)
        </div><div class="casAbstract">Background: Patients with chronic obstructive pulmonary disease (COPD) frequently develop exacerbations, leading to major clin. and health resource use ramifications.  Objective: To prospectively evaluate the effectiveness of a long-acting inhaled anticholinergic bronchodilator, tiotropium, in reducing COPD exacerbations and exacerbation-related health care utilization.  Design: Randomized, double-blind study.  Setting: 26 Veterans Affairs medical centers.  Patients: 1829 patients with moderate to severe COPD (mean baseline FEV1, 36% predicted).  Intervention: Once-daily tiotropium (18 μg) or placebo for 6 mo.  Patients otherwise received usual care, except for other anticholinergic bronchodilators.  Measurements: The coprimary end points were the percentage of patients with a COPD exacerbation and the percentage of patients with a COPD-related hospitalization.  Results: Tiotropium significantly reduced the percentage of patients experiencing 1 or more exacerbations compared with placebo (27.9% vs. 32.3%, resp.; difference, -5.7 percentage points [95% CI, -10.4 to -1.0 percentage points]; P = 0.037).  Fewer tiotropium patients were hospitalized because of COPD exacerbation (7.0% vs. 9.5%, resp.; difference, -3.0 percentage points [CI, -5.9 to -0.1 percentage points]; P = 0.056), although this difference was of borderline statistical significance.  Anal. of secondary outcomes indicates that tiotropium may lengthen the time to first COPD exacerbation (P= 0.028) and reduce health care utilization for exacerbations, including the frequency of hospitalizations (P = 0.047), unscheduled clinic visits (P = 0.019), and days of antibiotic treatment (P = 0.015).  Tiotropium did not statistically significantly reduce all-cause hospitalization rates.  Limitations: Trial participants were enrolled from 1 health care system, and 99% were men.  The follow-up period extended for only 6 mo.  Conclusions: Tiotropium reduces COPD exacerbations and may reduce related health care utilization in patients with moderate to severe COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot1pxR3blT1rVg90H21EOLACvtfcHk0lhOAPv0tTW9GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKgs7jK&md5=3538aa381c51cee08198c104852aac23</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-143-5-200509060-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-143-5-200509060-00007%26sid%3Dliteratum%253Aachs%26aulast%3DNiewoehner%26aufirst%3DD.%2BE.%26aulast%3DRice%26aufirst%3DK.%26aulast%3DCote%26aufirst%3DC.%26aulast%3DPaulson%26aufirst%3DD.%26aulast%3DCooper%26aufirst%3DJ.%2BA.%26aulast%3DKorducki%26aufirst%3DL.%26aulast%3DCassino%26aufirst%3DC.%26aulast%3DKesten%26aufirst%3DS.%26atitle%3DPrevention%2520of%2520exacerbations%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520with%2520tiotropium%252C%2520a%2520once-daily%2520inhaled%2520anticholinergic%2520bronchodilator%253A%2520a%2520randomized%2520trial%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2005%26volume%3D143%26spage%3D317%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Casaburi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahler, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">San, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ZuWallack, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menjoge, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serby, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witek, T.,  Jr.</span><span> </span><span class="NLM_article-title">A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">224</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.02.00269802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=11866001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD38XitVKgu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2002&pages=217-224&author=R.+Casaburiauthor=D.+A.+Mahlerauthor=P.+W.+Jonesauthor=A.+Wannerauthor=P.+G.+Sanauthor=R.+L.+ZuWallackauthor=S.+S.+Menjogeauthor=C.+W.+Serbyauthor=T.+Witek&title=A+long-term+evaluation+of+once-daily+inhaled+tiotropium+in+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Casaburi, R.; Mahler, D. A.; Jones, P. W.; Wanner, A.; San Pedro, G.; ZuWallack, R. L.; Menjoge, S. S.; Serby, C. W.; Witek, T., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-224</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Currently available inhaled bronchodilators used as therapy for chronic obstructive pulmonary disease (COPD) necessitate multiple daily dosing.  The present study evaluates the long-term safety and efficacy of tiotropium, a new once-daily anticholinergic in COPD.  Patients with stable COPD (age 65.2±8.7 yrs (mean±SD), n=921) were enrolled in two identical randomized double-blind placebo-controlled 1-yr studies.  Patients inhaled tiotropium 18 μg or placebo (mean screening forced expiratory vol. in one second (FEV1) 1.01 vs. 0.99 L, 39.1 and 38.1% of the predicted value) once daily as a dry powder.  The primary spirometric outcome was trough FEV1 (i.e. FEV1 prior to dosing).  Changes in dyspnea were measured using the Transition Dyspnea Index, and health status with the disease-specific St. George's Respiratory Questionnaire and the generic Short Form 36.  Medication use and adverse events were recorded.  Tiotropium provided significantly superior bronchodilation relative to placebo for trough FEV1 response (∼12% over baseline) (p<0.01) and mean response during the 3 h following dosing (∼22% over baseline) (p<0.001) over the 12-mo period.  Tiotropium recipients showed less dyspnea (p<0.001), superior health status scores, and fewer COPD exacerbations and hospitalizations (p<0.05).  Adverse events were comparable with placebo, except for dry mouth incidence (tiotropium 16.0% vs. placebo 2.7%, p<0.05).  Tiotropium is an effective, once-daily bronchodilator that reduces dyspnea and chronic obstructive pulmonary disease exacerbation frequency and improves health status.  This suggests that tiotropium will make an important contribution to chronic obstructive pulmonary disease therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFFCXDqogoHrVg90H21EOLACvtfcHk0li4YunWYGmCcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitVKgu7g%253D&md5=47f4052c4b78f43f2fa1da71521164a9</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1183%2F09031936.02.00269802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.02.00269802%26sid%3Dliteratum%253Aachs%26aulast%3DCasaburi%26aufirst%3DR.%26aulast%3DMahler%26aufirst%3DD.%2BA.%26aulast%3DJones%26aufirst%3DP.%2BW.%26aulast%3DWanner%26aufirst%3DA.%26aulast%3DSan%26aufirst%3DP.%2BG.%26aulast%3DZuWallack%26aufirst%3DR.%2BL.%26aulast%3DMenjoge%26aufirst%3DS.%2BS.%26aulast%3DSerby%26aufirst%3DC.%2BW.%26aulast%3DWitek%26aufirst%3DT.%26atitle%3DA%2520long-term%2520evaluation%2520of%2520once-daily%2520inhaled%2520tiotropium%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2002%26volume%3D19%26spage%3D217%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">O’Donnell, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flüge, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerken, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguilaniu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Make, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnussen, H.</span><span> </span><span class="NLM_article-title">Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">832</span><span class="NLM_x">–</span> <span class="NLM_lpage">840</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.04.00116004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=15218994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsF2qt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=832-840&author=D.+E.+O%E2%80%99Donnellauthor=T.+Fl%C3%BCgeauthor=F.+Gerkenauthor=A.+Hamiltonauthor=K.+Webbauthor=B.+Aguilaniuauthor=B.+Makeauthor=H.+Magnussen&title=Effects+of+tiotropium+on+lung+hyperinflation%2C+dyspnoea+and+exercise+tolerance+in+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD</span></div><div class="casAuthors">O'Donnell, D. E.; Fluge, T.; Gerken, F.; Hamilton, A.; Webb, K.; Aguilaniu, B.; Make, B.; Magnussen, H.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">832-840</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">The aim of this study was to test the hypothesis that use of tiotropium, a new long-acting anticholinergic bronchodilator, would be assocd. with sustained redn. in lung hyperinflation and, thereby, would improve exertional dyspnoea and exercise performance in patients with chronic obstructive pulmonary disease.  A randomised, double-blind, placebo-controlled, parallel-group study was conducted in 187 patients (forced expiratory vol. in one second 44±13% pred): 96 patients received 18 μg tiotropium and 91 patients received placebo once daily for 42 days.  Spirometry, plethysmog. lung vols., cycle exercise endurance and exertional dyspnoea intensity at 75% of each patient's maximal work capacity were compared.  On day 42, the use of tiotropium was assocd. with the following effects at pre-dose and post-dose measurements as compared to placebo: vital capacity and inspiratory capacity (IC) increased, with inverse decreases in residual vol. and functional residual capacity.  Tiotropium increased post-dose exercise endurance time by 105±40 s (21%) as compared to placebo on day 42.  At a standardized time near end-exercise (isotime), IC, tidal vol. and minute ventilation all increased, while dyspnoea decreased by 0.9±0.3 Borg scale units.  In conclusion, the use of tiotropium was assocd. with sustained redns. of lung hyperinflation at rest and during exercise.  Resultant increases in inspiratory capacity permitted greater expansion of tidal vol. and contributed to improvements in both exertional dyspnoea and exercise endurance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAakdNLFWXS7Vg90H21EOLACvtfcHk0li4YunWYGmCcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsF2qt7g%253D&md5=bfdc506331ccf3657ed837908b6f0227</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1183%2F09031936.04.00116004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.04.00116004%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DD.%2BE.%26aulast%3DFl%25C3%25BCge%26aufirst%3DT.%26aulast%3DGerken%26aufirst%3DF.%26aulast%3DHamilton%26aufirst%3DA.%26aulast%3DWebb%26aufirst%3DK.%26aulast%3DAguilaniu%26aufirst%3DB.%26aulast%3DMake%26aufirst%3DB.%26aulast%3DMagnussen%26aufirst%3DH.%26atitle%3DEffects%2520of%2520tiotropium%2520on%2520lung%2520hyperinflation%252C%2520dyspnoea%2520and%2520exercise%2520tolerance%2520in%2520COPD%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2004%26volume%3D23%26spage%3D832%26epage%3D840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">McNicholas, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calverley, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiotropium Sleep Study in COPD Investigators.</span><span> </span><span class="NLM_article-title">Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">825</span><span class="NLM_x">–</span> <span class="NLM_lpage">831</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.04.00085804" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=15218993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsF2qt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=825-831&author=W.+T.+McNicholasauthor=P.+M.+Calverleyauthor=A.+Leeauthor=J.+C.+Edwardsauthor=Tiotropium+Sleep+Study+in+COPD+Investigators.&title=Long-acting+inhaled+anticholinergic+therapy+improves+sleeping+oxygen+saturation+in+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD</span></div><div class="casAuthors">McNicholas, W. T.; Calverley, P. M. A.; Lee, A.; Edwards, J. C.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">825-831</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Oxygen desatn. occurs during sleep in severe chronic obstructive pulmonary disease (COPD), esp. during rapid eye movement (REM) sleep, due to hypoventilation and ventilation-perfusion mismatching, but the possible contribution of airflow limitation is unclear.  In a randomised, placebo-controlled, double-blind study of severe, stable COPD patients, the authors compared 4 wk treatment with a long-acting inhaled anticholinergic agent (tiotropium), taken in the morning (tiotropium-AM), or in the evening (tiotropium-PM), on sleeping arterial oxygen satn. (Sa,O2) and sleep quality.  Overnight polysomnog. was performed at baseline and after 4 wk treatment.  A total of 95 patients with awake resting arterial oxygen tension ≤9.98 kPa (75 mmHg) were randomised, with a mean age of 66.4 yrs and mean forced expiratory vol. in one second (FEV1) of 32% predicted.  A total of 80 patients completed the study, of which 56 fulfilled the polysomnog. criterion of at least 2 h sleep in both sleep study nights and represent the group analyzed.  Tiotropium significantly improved spirometry compared with placebo.  Both tiotropium-AM and tiotropium-PM groups had higher Sa,O2 during REM than placebo (+2.41% and +2.42%, resp.), and both pooled and tiotropium-PM groups had higher Sa,O2 during total sleep time (+2.49% and +3.06%, resp.).  End-of-treatment FEV1 correlated with Sa,O2 during REM sleep, however, tiotropium did not change sleep quality.  Sustained anticholinergic blockade improves sleeping arterial oxygen satn. without affecting sleep quality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroDXeV5w-G1rVg90H21EOLACvtfcHk0lgZZ5vOotEm0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsF2qt7o%253D&md5=2d30f8947466b27ec175560d4179131e</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1183%2F09031936.04.00085804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.04.00085804%26sid%3Dliteratum%253Aachs%26aulast%3DMcNicholas%26aufirst%3DW.%2BT.%26aulast%3DCalverley%26aufirst%3DP.%2BM.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DEdwards%26aufirst%3DJ.%2BC.%26aulast%3D%26atitle%3DLong-acting%2520inhaled%2520anticholinergic%2520therapy%2520improves%2520sleeping%2520oxygen%2520saturation%2520in%2520COPD%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2004%26volume%3D23%26spage%3D825%26epage%3D831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Tashkin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S.</span><span> </span><span class="NLM_article-title">Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">1441</span><span class="NLM_x">–</span> <span class="NLM_lpage">1449</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2003&pages=1441-1449&author=D.+Tashkinauthor=S.+Kesten&title=Long-term+treatment+benefits+with+tiotropium+in+COPD+patients+with+and+without+short-term+bronchodilator+responses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTashkin%26aufirst%3DD.%26aulast%3DKesten%26aufirst%3DS.%26atitle%3DLong-term%2520treatment%2520benefits%2520with%2520tiotropium%2520in%2520COPD%2520patients%2520with%2520and%2520without%2520short-term%2520bronchodilator%2520responses%26jtitle%3DChest%26date%3D2003%26volume%3D123%26spage%3D1441%26epage%3D1449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Tashkin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkhart, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menjoge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decramer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">UPLIFT Study Investigators.</span><span> </span><span class="NLM_article-title">A four-year trial of tiotropium in chronic obstructive pulmonary disease</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">359</span><span class="NLM_x">, </span> <span class="NLM_fpage">1543</span><span class="NLM_x">–</span> <span class="NLM_lpage">1554</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1056%2FNEJMoa0805800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=18836213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1WgsrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2008&pages=1543-1554&author=D.+P.+Tashkinauthor=B.+Celliauthor=S.+Sennauthor=D.+Burkhartauthor=S.+Kestenauthor=S.+Menjogeauthor=M.+Decramerauthor=UPLIFT+Study+Investigators.&title=A+four-year+trial+of+tiotropium+in+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">A 4-year trial of tiotropium in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Tashkin, Donald P.; Celli, Bartolome; Senn, Stephen; Burkhart, Deborah; Kesten, Steven; Menjoge, Shailendra; Decramer, Marc</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1543-1554</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Previous studies showing that tiotropium improves multiple end points in patients with chronic obstructive pulmonary disease (COPD) led us to examine the longterm effects of tiotropium therapy.  Methods: In this randomized, double-blind trial, we compared 4 years of therapy with either tiotropium or placebo in patients with COPD who were permitted to use all respiratory medications except inhaled anticholinergic drugs.  The patients were at least 40 years of age, with a forced expiratory vol. in 1 s (FEV1) of 70% or less after bronchodilation and a ratio of FEV1 to forced vital capacity (FVC) of 70% or less.  Coprimary end points were the rate of decline in the mean FEV1 before and after bronchodilation beginning on day 30.  Secondary end points included measures of FVC, changes in response on St.  George's Respiratory Questionnaire (SGRQ), exacerbations of COPD, and mortality.  Results: Of a total of 5993 patients (mean age, 65 ± 8 years) with a mean FEV1 of 1.32 ± 0.44 L after bronchodilation (48% of predicted value), we randomly assigned 2987 to the tiotropium group and 3006 to the placebo group.  Mean abs. improvements in FEV, in the tiotropium group were maintained throughout the trial (ranging from 87 to 103 mL before bronchodilation and from 47 to 65 mL after bronchodilation), as compared with the placebo group (P < 0.001).  After day 30, the differences between the two groups in the rate of decline in the mean FEV, before and after bronchodilation were not significant.  The mean abs. total score on the SGRQ was improved (lower) in the tiotropium group, as compared with the placebo group, at each time point throughout the 4-yr period (ranging from 2.3 to 3.3 units, P < 0.001).  At 4 years and 30 days, tiotropium was assocd. with a redn. in the risks of exacerbations, related hospitalizations, and respiratory failure.  Conclusions: In patients with COPD, therapy with tiotropium was assocd. with improvements in lung function, quality of life, and exacerbations during a 4-yr period but did not significantly reduce the rate of decline in FEV1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTh6idIwH0mbVg90H21EOLACvtfcHk0lgZZ5vOotEm0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1WgsrjJ&md5=018fee7a91d4637c2379473ab7d5fb5a</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0805800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0805800%26sid%3Dliteratum%253Aachs%26aulast%3DTashkin%26aufirst%3DD.%2BP.%26aulast%3DCelli%26aufirst%3DB.%26aulast%3DSenn%26aufirst%3DS.%26aulast%3DBurkhart%26aufirst%3DD.%26aulast%3DKesten%26aufirst%3DS.%26aulast%3DMenjoge%26aufirst%3DS.%26aulast%3DDecramer%26aufirst%3DM.%26aulast%3D%26atitle%3DA%2520four-year%2520trial%2520of%2520tiotropium%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D359%26spage%3D1543%26epage%3D1554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Decramer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lystig, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tashkin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">UPLIFT Investigators.</span><span> </span><span class="NLM_article-title">Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">374</span><span class="NLM_x">, </span> <span class="NLM_fpage">1171</span><span class="NLM_x">–</span> <span class="NLM_lpage">1178</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2009&pages=1171-1178&author=M.+Decramerauthor=B.+Celliauthor=S.+Kestenauthor=T.+Lystigauthor=S.+Mehraauthor=D.+P.+Tashkinauthor=UPLIFT+Investigators.&title=Effect+of+tiotropium+on+outcomes+in+patients+with+moderate+chronic+obstructive+pulmonary+disease+%28UPLIFT%29%3A+a+prespecified+subgroup+analysis+of+a+randomised+controlled+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDecramer%26aufirst%3DM.%26aulast%3DCelli%26aufirst%3DB.%26aulast%3DKesten%26aufirst%3DS.%26aulast%3DLystig%26aufirst%3DT.%26aulast%3DMehra%26aufirst%3DS.%26aulast%3DTashkin%26aufirst%3DD.%2BP.%26aulast%3D%26atitle%3DEffect%2520of%2520tiotropium%2520on%2520outcomes%2520in%2520patients%2520with%2520moderate%2520chronic%2520obstructive%2520pulmonary%2520disease%2520%2528UPLIFT%2529%253A%2520a%2520prespecified%2520subgroup%2520analysis%2520of%2520a%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2009%26volume%3D374%26spage%3D1171%26epage%3D1178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Tashkin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lystig, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decramer, M.</span><span> </span><span class="NLM_article-title">Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.00082909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=19717481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtV2jtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=287-294&author=D.+P.+Tashkinauthor=B.+Celliauthor=S.+Kestenauthor=T.+Lystigauthor=S.+Mehraauthor=M.+Decramer&title=Long-term+efficacy+of+tiotropium+in+relation+to+smoking+status+in+the+UPLIFT+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial</span></div><div class="casAuthors">Tashkin, D. P.; Celli, B.; Kesten, S.; Lystig, T.; Mehra, S.; Decramer, M.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">287-294</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">UPLIFT (Understanding Potential Long-Term Improvements in Function with Tiotropium), a 4-yr trial of tiotropium in chronic obstructive pulmonary disease, allowed for assessment of smoking status on long-term responses to maintenance bronchodilator therapy.  5,993 Patients were randomised (tiotropium/placebo).  Lung function, St George's Respiratory Questionnaire, exacerbations and adverse events were followed.  Patients were characterised as continuing smokers (CS), continuing ex-smokers (CE), or intermittent smokers (IS) based on self-reporting smoking behavior.  60%, 14% And 26% of patients were CE, CS and IS, resp.  The rate of forced expiratory vol. in 1 s (FEV1) decline for placebo patients was most rapid in CS (-51±4, -36±2 and -23±2 mL·yr-1 in CS, IS, and CE, resp.).  Tiotropium did not alter FEV1 decline, but was assocd. with significant improvements in pre- and post-bronchodilator FEV1 over placebo that persisted throughout the 4-yr trial for each smoking status (pre-bronchodilator: 125, 55 and 97 mL at 48 mo in CS, IS and CE, resp.; p≤0.0003).  Tiotropium reduced exacerbation risk in CS (HR (95%CI) 0.81 (0.68-0.97)), in CE (0.86 (0.79-0.93)) and trended towards significance in IS (0.89 (0.80-1.01)).  At 4 yrs, St George's Respiratory Questionnaire for tiotropium patients improved the most in CS (-4.62 units, p = 0.0006) and the least in IS (-0.54 units, p = 0.55), compared with control.  Tiotropium provided long-term benefits irresp. of smoking status, although differences among categories were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriG43pvPPhVLVg90H21EOLACvtfcHk0lhV77zPTxsTlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtV2jtbo%253D&md5=824cb7fa0c4c92edf0043ff5b19c53ab</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1183%2F09031936.00082909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00082909%26sid%3Dliteratum%253Aachs%26aulast%3DTashkin%26aufirst%3DD.%2BP.%26aulast%3DCelli%26aufirst%3DB.%26aulast%3DKesten%26aufirst%3DS.%26aulast%3DLystig%26aufirst%3DT.%26aulast%3DMehra%26aufirst%3DS.%26aulast%3DDecramer%26aufirst%3DM.%26atitle%3DLong-term%2520efficacy%2520of%2520tiotropium%2520in%2520relation%2520to%2520smoking%2520status%2520in%2520the%2520UPLIFT%2520trial%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2010%26volume%3D35%26spage%3D287%26epage%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Celli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decramer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tashkin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">UPLIFT Study Investigators.</span><span> </span><span class="NLM_article-title">Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">180</span><span class="NLM_x">, </span> <span class="NLM_fpage">948</span><span class="NLM_x">–</span> <span class="NLM_lpage">955</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1164%2Frccm.200906-0876OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=19729663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFahur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2009&pages=948-955&author=B.+Celliauthor=M.+Decramerauthor=S.+Kestenauthor=D.+Liuauthor=S.+Mehraauthor=D.+P.+Tashkinauthor=UPLIFT+Study+Investigators.&title=Mortality+in+the+4-year+trial+of+tiotropium+%28UPLIFT%29+in+patients+with+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease</span></div><div class="casAuthors">Celli, Bartolome; Decramer, Marc; Kesten, Steven; Liu, Dacheng; Mehra, Sunil; Tashkin, Donald P.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">948-955</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: In the 4-yr UPLIFT trial, tiotropium improved lung function and health-related quality of life and decreased exacerbations compared with usual respiratory medications except inhaled anticholinergics in patients with chronic obstructive pulmonary disease (COPD).  Mortality and its causes was a secondary endpoint in UPLIFT.  Objectives: We describe the effect of tiotropium on survival and analyze differences between mortality during treatment and during follow-up of discontinued patients.  Methods: This study involved a randomized, double-blind trial comparing tiotropium with placebo in patients with COPD (≥40 yr of age; postbronchodilator FEV1 ≤70%; FEV1/FVC ≤70%).  Mortality was evaluated during treatment and with follow-up of discontinued patients.  Cause of death was adjudicated by an endpoint committee.  Measurements and Main Results: A total of 5,993 patients were randomized, 3,006 to placebo and 2,987 to tiotropium.  While patients were receiving treatment, there were 792 deaths, with a lower risk in the tiotropium group (hazard ratio, 0.84; 95% confidence interval [CI], 0.73-0.97).  Statistical significance was obsd. at the end of the protocol-defined treatment period (P = 0.034) but not 30 days thereafter (P = 0.086).  Adjustment by COLD stage, sex, age, baseline smoking behavior, and baseline respiratory medications subgroups did not alter the results of the anal.  The most common causes of death adjudicated by an independent end-point committee were lower respiratory, cancer, general disorders, and cardiac disorders.  The hazard ratios for lower respiratory and cardiac mortality during treatment were 0.86 (95% CI, 0.68-1.09) and 0.86 (95% CI, 0.75-0.99), resp.  Conclusions: Treatment with tiotropium over 4 years is assocd. with decreased mortality, with the effect being most prominent in the cardiac and respiratory systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVXI-MiN1KWbVg90H21EOLACvtfcHk0lhV77zPTxsTlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFahur%252FF&md5=2df4322f834620b15a9d30087f001943</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1164%2Frccm.200906-0876OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200906-0876OC%26sid%3Dliteratum%253Aachs%26aulast%3DCelli%26aufirst%3DB.%26aulast%3DDecramer%26aufirst%3DM.%26aulast%3DKesten%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DMehra%26aufirst%3DS.%26aulast%3DTashkin%26aufirst%3DD.%2BP.%26aulast%3D%26atitle%3DMortality%2520in%2520the%25204-year%2520trial%2520of%2520tiotropium%2520%2528UPLIFT%2529%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2009%26volume%3D180%26spage%3D948%26epage%3D955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Dusser, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravo, M.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacono, P.</span><span> </span><span class="NLM_article-title">The effect of tiotropium on exacerbations and airflow in patients with COPD</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">547</span><span class="NLM_x">–</span> <span class="NLM_lpage">555</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.06.00062705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=16507855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtVKqtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=547-555&author=D.+Dusserauthor=M.-L.+Bravoauthor=P.+Iacono&title=The+effect+of+tiotropium+on+exacerbations+and+airflow+in+patients+with+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of tiotropium on exacerbations and airflow in patients with COPD</span></div><div class="casAuthors">Dusser, D.; Bravo, M.-L.; Iacono, P.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">547-555</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">This randomized, double-blind, parallel-group, 1-yr study compared the effect of tiotropium 18 μg once daily (n = 500) and placebo (n = 510) on exacerbations, assocd. health resource use (HRU) and airflow limitation in chronic obstructive pulmonary disease (COPD) patients.  The mean ± SD no. of exacerbations during the past year was 2.14 ± 1.40, the mean weekly morning peak expiratory flow (PEF) was 259.6 ± 96.1 L·min-1 and the mean forced expiratory vol. in one second (FEV1) was 1.37 ± 0.45 L.  Tiotropium significantly delayed the time to first exacerbation by ∼100 days, reduced the proportion of patients experiencing more than one exacerbation by 17%, and decreased the no. of exacerbations by 35% and exacerbation days by 37% vs. placebo.  Tiotropium also decreased HRU vs. placebo, as indicated by the significant redns. in the use of concomitant respiratory medications, antibiotics and oral steroids, and the no. of unscheduled physician contacts.  Mean weekly morning PEF improved significantly with tiotropium vs. placebo from week 1 until the end of the study.  At the end of the study, tiotropium significantly improved trough (pre-dose) FEV1, forced vital capacity, slow vital capacity and inspiratory capacity vs. placebo.  In conclusion, tiotropium reduced exacerbations and assocd. health resource use, and improved airflow over 1 yr in chronic obstructive pulmonary disease patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLLj0h8L4MlLVg90H21EOLACvtfcHk0ljl7cUKpyKqCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtVKqtbc%253D&md5=c573d56fc0bc606fcafb65c6ea45adfb</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1183%2F09031936.06.00062705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.06.00062705%26sid%3Dliteratum%253Aachs%26aulast%3DDusser%26aufirst%3DD.%26aulast%3DBravo%26aufirst%3DM.-L.%26aulast%3DIacono%26aufirst%3DP.%26atitle%3DThe%2520effect%2520of%2520tiotropium%2520on%2520exacerbations%2520and%2520airflow%2520in%2520patients%2520with%2520COPD%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2006%26volume%3D27%26spage%3D547%26epage%3D555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Powrie, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, T. M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donaldson, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scrine, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedzicha, J. A.</span><span> </span><span class="NLM_article-title">Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">472</span><span class="NLM_x">–</span> <span class="NLM_lpage">478</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.00023907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=17504798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGgsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2007&pages=472-478&author=D.+J.+Powrieauthor=T.+M.+A.+Wilkinsonauthor=G.+C.+Donaldsonauthor=P.+Jonesauthor=K.+Scrineauthor=K.+Vielauthor=S.+Kestenauthor=J.+A.+Wedzicha&title=Effect+of+tiotropium+on+sputum+and+serum+inflammatory+markers+and+exacerbations+in+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD</span></div><div class="casAuthors">Powrie, D. J.; Wilkinson, T. M. A.; Donaldson, G. C.; Jones, P.; Scrine, K.; Viel, K.; Kesten, S.; Wedzicha, J. A.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">472-478</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) patients experiencing frequent exacerbations demonstrate increased stable-state airway inflammation.  Tiotropium has been shown to reduce exacerbation frequency, but its effect on airway inflammation is unknown.  The aim of the present study was to investigate the effect of tiotropium on sputum inflammatory markers and exacerbation frequency.  Patients (n = 142) were randomized to receive tiotropium or placebo in addn. to their usual medication for 1 yr.  Sputum and serum cytokines were assayed by ELISA and exacerbation frequency calcd. using a symptom-based diary.  There was no difference in the area under the curve for sputum interleukin (IL)-6 or myeloperoxidase between the groups, but sputum IL-8 level was increased in the tiotropium arm.  There was no difference between start and end of study in serum IL-6 or C-reactive protein level.  Tiotropium was assocd. with a 52% redn. in exacerbation frequency (1.17 vs. 2.46 exacerbations yr-1).  Of patients on tiotropium, 43% experienced at least one exacerbation, compared with 64% on placebo.  The total no. of exacerbation days was reduced compared with placebo (17.3 vs. 34.5 days).  Tiotropium reduces exacerbation frequency in chronic obstructive pulmonary disease, but this effect does not appear to be due to a redn. in airway or systemic inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNrrPRfCQFBrVg90H21EOLACvtfcHk0ljl7cUKpyKqCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGgsbzE&md5=b320abde10710f1ea1c9eacaf61939d4</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1183%2F09031936.00023907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00023907%26sid%3Dliteratum%253Aachs%26aulast%3DPowrie%26aufirst%3DD.%2BJ.%26aulast%3DWilkinson%26aufirst%3DT.%2BM.%2BA.%26aulast%3DDonaldson%26aufirst%3DG.%2BC.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DScrine%26aufirst%3DK.%26aulast%3DViel%26aufirst%3DK.%26aulast%3DKesten%26aufirst%3DS.%26aulast%3DWedzicha%26aufirst%3DJ.%2BA.%26atitle%3DEffect%2520of%2520tiotropium%2520on%2520sputum%2520and%2520serum%2520inflammatory%2520markers%2520and%2520exacerbations%2520in%2520COPD%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2007%26volume%3D30%26spage%3D472%26epage%3D478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Rodrigo, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nannini, L. J.</span><span> </span><span class="NLM_article-title">Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis</span> <span class="citation_source-journal">Pulm. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.pupt.2006.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=16621638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvFyksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=495-502&author=G.+J.+Rodrigoauthor=L.+J.+Nannini&title=Tiotropium+for+the+treatment+of+stable+chronic+obstructive+pulmonary+disease%3A+a+systematic+review+with+meta-analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Tiotropium for the treatment of stable chronic obstructive pulmonary disease: A systematic review with meta-analysis</span></div><div class="casAuthors">Rodrigo, Gustavo J.; Nannini, Luis J.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">495-502</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Background: Current guidelines recommend the use of inhaled tiotropium in patients with stable chronic obstructive pulmonary disease (COPD).  However, this statement is based on a relatively small no. of randomized controlled trials (RCTs) and related systematic reviews.  This review was undertaken to incorporate the more recent evidence available about the effectiveness of tiotropium bromide compared with placebo, iptratropium bromide or long-acting beta-agonists (LABAs), for the treatment of stable COPD patients.  Data source: Medline, EMBASE, CINAHL, and the Cochrane Controlled Trials Register (to Feb. 2006) were searched to identify all published RCTs.  We also searched bibliogs. of relevant articles.  Results: Data from 13 RCT (6078 subjects, 80% male) showed that tiotropium reduced COPD-related exacerbations (OR = 0.76; 95% CI: 0.68-0.87) and hospital admissions (OR=0.59; 95% CI: 0.47-0.73) compared with placebo.  Also, tiotropium showed statistically significant improvement in lung function, including trough, av., and peak FEV1 and FVC from baseline, compared with placebo and ipratropium.  The administration of inhaled tiotropium lead to 30% redn. in COPD-related admissions (OR = 0.67; 95% CI: 0.46-0.98) compared with LABAs.  Finally, increases in FEV1 and FVC from baseline were significantly larger with tiotropium than with LABAs.  Conclusions: This review clearly supports the beneficial effects of the use of tiotropium in stable moderate-to-severe COPD patients, and increases the evidence in favor of the superiority of tiotropium on LABAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU7RKrhhnsELVg90H21EOLACvtfcHk0ljZfzuKBNJ9Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvFyksro%253D&md5=44e5adada4b1be4c51b003e70b4a6944</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2006.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2006.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigo%26aufirst%3DG.%2BJ.%26aulast%3DNannini%26aufirst%3DL.%2BJ.%26atitle%3DTiotropium%2520for%2520the%2520treatment%2520of%2520stable%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520systematic%2520review%2520with%2520meta-analysis%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2007%26volume%3D20%26spage%3D495%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Vogelmeier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hederer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaab, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutten-van Mölken, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beeh, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabe, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbri, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">POET-COPD Investigators.</span><span> </span><span class="NLM_article-title">Tiotropium versus salmeterol for the prevention of exacerbations of COPD</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">1093</span><span class="NLM_x">–</span> <span class="NLM_lpage">1103</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1056%2FNEJMoa1008378" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=21428765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVyjs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=1093-1103&author=C.+Vogelmeierauthor=B.+Hedererauthor=T.+Glaabauthor=H.+Schmidtauthor=M.+P.+Rutten-van+M%C3%B6lkenauthor=K.+M.+Beehauthor=K.+F.+Rabeauthor=L.+M.+Fabbriauthor=POET-COPD+Investigators.&title=Tiotropium+versus+salmeterol+for+the+prevention+of+exacerbations+of+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Tiotropium versus salmeterol for the prevention of exacerbations of COPD</span></div><div class="casAuthors">Vogelmeier, Claus; Hederer, Bettina; Glaab, Thomas; Schmidt, Hendrik; Rutten-Van Molken, Maureen P. M. H.; Beeh, Kai M.; Rabe, Klaus F.; Fabbri, Leonardo M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1093-1103</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Treatment guidelines recommend the use of inhaled long-acting bronchodilators to alleviate symptoms and reduce the risk of exacerbations in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) but do not specify whether a long-acting anticholinergic drug or a β2-agonist is the preferred agent.  The authors investigated whether the anticholinergic drug tiotropium is superior to the β2-agonist salmeterol in preventing exacerbations of COPD.  In a 1-yr, randomized, double-blind, double-dummy, parallel-group trial, the authors compared the effect of treatment with 18 μg of tiotropium once daily with that of 50 μg of salmeterol twice daily on the incidence of moderate or severe exacerbations in patients with moderate-to-very-severe COPD and a history of exacerbations in the preceding year.  A total of 7376 patients were randomly assigned to and treated with tiotropium (3707 patients) or salmeterol (3669 patients).  Tiotropium, as compared with salmeterol, increased the time to the first exacerbation (187 days vs. 145 days), with a 17% redn. in risk (hazard ratio, 0.83; 95% confidence interval [CI], 0.77 to 0.90; P < 0.001).  Tiotropium also increased the time to the first severe exacerbation (hazard ratio, 0.72; 95% CI, 0.61 to 0.85; P < 0.001), reduced the annual no. of moderate or severe exacerbations (0.64 vs. 0.72; rate ratio, 0.89; 95% CI, 0.83 to 0.96; P = 0.002), and reduced the annual no. of severe exacerbations (0.09 vs. 0.13; rate ratio, 0.73; 95% CI, 0.66 to 0.82; P < 0.001).  Overall, the incidence of serious adverse events and of adverse events leading to the discontinuation of treatment was similar in the two study groups.  There were 64 deaths (1.7%) in the tiotropium group and 78 (2.1%) in the salmeterol group.  These results show that, in patients with moderate-to-very-severe COPD, tiotropium is more effective than salmeterol in preventing exacerbations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcGS8pytm0HLVg90H21EOLACvtfcHk0ljZfzuKBNJ9Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVyjs7Y%253D&md5=11c34e28f119601621494b4705a91fd9</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1008378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1008378%26sid%3Dliteratum%253Aachs%26aulast%3DVogelmeier%26aufirst%3DC.%26aulast%3DHederer%26aufirst%3DB.%26aulast%3DGlaab%26aufirst%3DT.%26aulast%3DSchmidt%26aufirst%3DH.%26aulast%3DRutten-van%2BM%25C3%25B6lken%26aufirst%3DM.%2BP.%26aulast%3DBeeh%26aufirst%3DK.%2BM.%26aulast%3DRabe%26aufirst%3DK.%2BF.%26aulast%3DFabbri%26aufirst%3DL.%2BM.%26aulast%3D%26atitle%3DTiotropium%2520versus%2520salmeterol%2520for%2520the%2520prevention%2520of%2520exacerbations%2520of%2520COPD%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D1093%26epage%3D1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Wedzicha, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calverley, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seemungal, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ansari, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockley, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">INSPIRE Investigators.</span><span> </span><span class="NLM_article-title">The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">177</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1164%2Frccm.200707-973OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=17916806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht12mt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2008&pages=19-26&author=J.+A.+Wedzichaauthor=P.+M.+Calverleyauthor=T.+A.+Seemungalauthor=G.+Haganauthor=Z.+Ansariauthor=R.+A.+Stockleyauthor=INSPIRE+Investigators.&title=The+prevention+of+chronic+obstructive+pulmonary+disease+exacerbations+by+salmeterol%2Ffluticasone+propionate+or+tiotropium+bromide"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide</span></div><div class="casAuthors">Wedzicha, Jadwiga A.; Calverley, Peter M. A.; Seemungal, Terence A.; Hagan, Gerry; Ansari, Zainab; Stockley, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-26</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Exacerbations are key drivers of morbidity and mortality in chronic obstructive pulmonary disease (COPD).  Objectives: We compared the relative efficacy of the long-acting inhaled bronchodilator/antiinflammatory combination (salmeterol/fluticasone propionate) 50/500 μg twice daily and the long-acting bronchodilator (tiotropium) 18 μg once daily in preventing exacerbations and related outcomes in severe and very severe COPD.  Methods: A total of 1,323 patients (mean age, 64 yr, post-bronchodilator FEV1, 39% predicted) were randomized in this 2-yr, double-blind, double-dummy parallel study.  Measurements and Main Results: Primary endpoint was health care utilization exacerbation rate.  Other endpoints included health status measured by St. George's Respiratory Questionnaire (SGRQ), mortality, adverse events, and study withdrawal.  Probability of withdrawing from the study was 29% greater with tiotropium than salmeterol/fluticasone propionate (P = 0.005).  The modeled annual exacerbation rate was 1.28 in the salmeterol/fluticasone propionate group and 1.32 in the tiotropium group (rate ratio, 0.967; 95% confidence interval [CI], 0.836-1.119]; P = 0.656).  The SGRQ total score was statistically significantly lower at 2 years on salmeterol/fluticasone propionate vs. tiotropium (difference 2.1 units; 95% CI, 0.1-4.0; P = 0.038).  Mortality was significantly lower in the salmeterol/fluticasone propionate group; 21 (3%) of patients in this group died compared with 38 (6%) in the tiotropium group (P = 0.032).  More pneumonias were reported in the salmeterol/fluticasone propionate group relative to tiotropium (P = 0.008).  Conclusions: We found no difference in exacerbation rate between salmeterol/fluticasone propionate and tiotropium.  More patients failed to complete the study while receiving tiotropium.  A small statistically significant beneficial effect was found on health status, with an unexpected finding of lower deaths in salmeterol/fluticasone propionate-treated patients.  Clin. trial registered with www.clinicaltrials.gov (NCT 00361959).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp2H4qbYw7WLVg90H21EOLACvtfcHk0ljZfzuKBNJ9Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht12mt74%253D&md5=b0df385f67351e42bb5e1a49b79e0268</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1164%2Frccm.200707-973OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200707-973OC%26sid%3Dliteratum%253Aachs%26aulast%3DWedzicha%26aufirst%3DJ.%2BA.%26aulast%3DCalverley%26aufirst%3DP.%2BM.%26aulast%3DSeemungal%26aufirst%3DT.%2BA.%26aulast%3DHagan%26aufirst%3DG.%26aulast%3DAnsari%26aufirst%3DZ.%26aulast%3DStockley%26aufirst%3DR.%2BA.%26aulast%3D%26atitle%3DThe%2520prevention%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520exacerbations%2520by%2520salmeterol%252Ffluticasone%2520propionate%2520or%2520tiotropium%2520bromide%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2008%26volume%3D177%26spage%3D19%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Chan, C. K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maltais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sigouin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haddon, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SAFE Study Group.</span><span> </span><span class="NLM_article-title">A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Can. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">465</span><span class="NLM_x">–</span> <span class="NLM_lpage">472</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1155%2F2007%2F192961" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=18060091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BD2sjisl2hug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=465-472&author=C.+K.+N.+Chanauthor=R.+Maltaisauthor=C.+Sigouinauthor=J.+M.+Haddonauthor=G.+T.+Fordauthor=SAFE+Study+Group.&title=A+randomized+controlled+trial+to+assess+the+efficacy+of+tiotropium+in+Canadian+patients+with+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease</span></div><div class="casAuthors">Chan Charles K N; Maltais Francois; Sigouin Chris; Haddon Jennifer M; Ford Gordon T</div><div class="citationInfo"><span class="NLM_cas:title">Canadian respiratory journal : journal of the Canadian Thoracic Society</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">465-72</span>
        ISSN:<span class="NLM_cas:issn">1198-2241</span>.
    </div><div class="casAbstract">BACKGROUND:  Patients with chronic obstructive pulmonary disease (COPD) who smoke have a greater annual rate of decline in forced expiratory volume in 1 s (FEV(1)) than those patients who have stopped smoking.  OBJECTIVES:  To assess the effect of tiotropium on pre-dose (trough) FEV(1) in patients with COPD followed in Canada.  METHODS:  A total of 913 patients were randomly assigned to receive either tiotropium 18 mug once daily (n=608) or placebo (usual care minus inhaled anticholinergics) (n=305) for 48 weeks in the present randomized, double-blind, parallel-group study.  The effect of tiotropium on measurements of lung function (FEV(1), FEV(6) and forced vital capacity), symptoms, health-related quality of life (St George's Respiratory Questionnaire) and exacerbations were examined.  RESULTS:  Tiotropium improved trough FEV(1) in both current and ex-smokers compared with placebo.  Baseline FEV(1) in smokers and ex-smokers was 1.03 L and 0.93 L, respectively (P<0.001).  At week 48, the mean difference between the tiotropium and placebo groups was 0.14+/-0.04 L (P<0.001) in the smoker group and 0.08+/-0.02 L (P<0.0001) in the ex-smoker group.  Tiotropium also significantly improved trough forced vital capacity and FEV(6) compared with placebo throughout the treatment period (P<0.05, for all).  Furthermore, tiotropium significantly improved the St George's Respiratory Questionnaire total score compared with placebo at week 48 (40.9 versus 43.7 units, P<0.005).  CONCLUSIONS:  Compared with the placebo group, tiotropium provides sustained improvements in lung function in patients with COPD, with improvements for smokers and ex-smokers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzIBLURIWBZkHdcurJClFcfW6udTcc2ebPZeODNd5p-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjisl2hug%253D%253D&md5=03575c89ca7bd122dc5609a4687bc729</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1155%2F2007%2F192961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2007%252F192961%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DC.%2BK.%2BN.%26aulast%3DMaltais%26aufirst%3DR.%26aulast%3DSigouin%26aufirst%3DC.%26aulast%3DHaddon%26aufirst%3DJ.%2BM.%26aulast%3DFord%26aufirst%3DG.%2BT.%26aulast%3D%26atitle%3DA%2520randomized%2520controlled%2520trial%2520to%2520assess%2520the%2520efficacy%2520of%2520tiotropium%2520in%2520Canadian%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DCan.%2520Respir.%2520J.%26date%3D2007%26volume%3D14%26spage%3D465%26epage%3D472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Tonnel, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosbois, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verkindre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravo, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">TIPHON Study Group.</span><span> </span><span class="NLM_article-title">Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD</span> <span class="citation_source-journal">Int. J. Chronic Obstruct. Pulm. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">301</span><span class="NLM_x">–</span> <span class="NLM_lpage">310</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=18686739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1Wrt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=301-310&author=A.+B.+Tonnelauthor=T.+Perezauthor=J.+M.+Grosboisauthor=C.+Verkindreauthor=M.+L.+Bravoauthor=M.+Brunauthor=TIPHON+Study+Group.&title=Effect+of+tiotropium+on+health-related+quality+of+life+as+a+primary+efficacy+endpoint+in+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD</span></div><div class="casAuthors">Tonnel, A-B.; Perez, T.; Grosbois, J-M.; Verkindre, C.; Bravo, M-L.; Brun, M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Chronic Obstructive Pulmonary Disease</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">301-310</span>CODEN:
                <span class="NLM_cas:coden">IJCOC3</span>;
        ISSN:<span class="NLM_cas:issn">1176-9106</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">Clin. manifestations of chronic obstructive pulmonary disease (COPD), including airflow limitation, dyspnea, and activity limitation, ultimately lead to impaired health-related quality of life (HRQoL).  This 9-mo, randomized, double-blind, multicenter study compared the effect of once-daily tiotropium 18 μg and placebo on HRQoL, spirometric parameters, and exacerbations in 554 patients with moderate-to-severe COPD.  HRQoL was assessed using the St. George's Respiratory Questionnaire (SGRQ) and the new 8-item Visual Simplified Respiratory Questionnaire (VSRQ), which is currently being validated.  The primary efficacy endpoint was the proportion of patients achieving a redn. of at least 4 units in the SGRQ total score at study end (Month 9).  Mean ± SD baseline SGRQ total score was 47.4 ± 18.1.  Significantly more tiotropium-treated patients achieved a redn. of at least 4 units in the SGRQ score vs placebo at study end (59.1% vs 48.2%, resp.; p = 0.029).  Tiotropium significantly improved spirometric parameters (forced expiratory vol. in 1 s [FEV1]: 0.11 ± 0.02 L vs 0.01 ± 0.02 L; between-group difference: 0.10 ± 0.03 L, p = 0.0001) and reduced exacerbations vs placebo.  Maintenance treatment with tiotropium provided significant and clin. relevant improvements in HRQoL, as measured by the SGRQ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY0ZPv1xl_TbVg90H21EOLACvtfcHk0ljoaAyAViEMDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1Wrt7w%253D&md5=645bbfd9981c920a5602b62e9159c845</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTonnel%26aufirst%3DA.%2BB.%26aulast%3DPerez%26aufirst%3DT.%26aulast%3DGrosbois%26aufirst%3DJ.%2BM.%26aulast%3DVerkindre%26aufirst%3DC.%26aulast%3DBravo%26aufirst%3DM.%2BL.%26aulast%3DBrun%26aufirst%3DM.%26aulast%3D%26atitle%3DEffect%2520of%2520tiotropium%2520on%2520health-related%2520quality%2520of%2520life%2520as%2520a%2520primary%2520efficacy%2520endpoint%2520in%2520COPD%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2008%26volume%3D3%26spage%3D301%26epage%3D310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Verkindre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bart, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguilaniu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fortin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guérin, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Merre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacono, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huchon, G.</span><span> </span><span class="NLM_article-title">The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Respiration</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">420</span><span class="NLM_x">–</span> <span class="NLM_lpage">427</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2006&pages=420-427&author=C.+Verkindreauthor=F.+Bartauthor=B.+Aguilaniuauthor=F.+Fortinauthor=J.+C.+Gu%C3%A9rinauthor=C.+Le+Merreauthor=P.+Iaconoauthor=G.+Huchon&title=The+effect+of+tiotropium+on+hyperinflation+and+exercise+capacity+in+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerkindre%26aufirst%3DC.%26aulast%3DBart%26aufirst%3DF.%26aulast%3DAguilaniu%26aufirst%3DB.%26aulast%3DFortin%26aufirst%3DF.%26aulast%3DGu%25C3%25A9rin%26aufirst%3DJ.%2BC.%26aulast%3DLe%2BMerre%26aufirst%3DC.%26aulast%3DIacono%26aufirst%3DP.%26aulast%3DHuchon%26aufirst%3DG.%26atitle%3DThe%2520effect%2520of%2520tiotropium%2520on%2520hyperinflation%2520and%2520exercise%2520capacity%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DRespiration%26date%3D2006%26volume%3D73%26spage%3D420%26epage%3D427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Brusasco, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miravitlles, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korducki, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towse, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S.</span><span> </span><span class="NLM_article-title">Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">404</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2003&pages=399-404&author=V.+Brusascoauthor=R.+Hodderauthor=M.+Miravitllesauthor=L.+Korduckiauthor=L.+Towseauthor=S.+Kesten&title=Health+outcomes+following+treatment+for+six+months+with+once+daily+tiotropium+compared+with+twice+daily+salmeterol+in+patients+with+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrusasco%26aufirst%3DV.%26aulast%3DHodder%26aufirst%3DR.%26aulast%3DMiravitlles%26aufirst%3DM.%26aulast%3DKorducki%26aufirst%3DL.%26aulast%3DTowse%26aufirst%3DL.%26aulast%3DKesten%26aufirst%3DS.%26atitle%3DHealth%2520outcomes%2520following%2520treatment%2520for%2520six%2520months%2520with%2520once%2520daily%2520tiotropium%2520compared%2520with%2520twice%2520daily%2520salmeterol%2520in%2520patients%2520with%2520COPD%26jtitle%3DThorax%26date%3D2003%26volume%3D58%26spage%3D399%26epage%3D404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Tashkin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C. B.</span><span> </span><span class="NLM_article-title">The role of long-acting bronchodilators in the management of stable COPD</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span><span class="NLM_x">–</span> <span class="NLM_lpage">259</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2004&pages=249-259&author=D.+P.+Tashkinauthor=C.+B.+Cooper&title=The+role+of+long-acting+bronchodilators+in+the+management+of+stable+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTashkin%26aufirst%3DD.%2BP.%26aulast%3DCooper%26aufirst%3DC.%2BB.%26atitle%3DThe%2520role%2520of%2520long-acting%2520bronchodilators%2520in%2520the%2520management%2520of%2520stable%2520COPD%26jtitle%3DChest%26date%3D2004%26volume%3D125%26spage%3D249%26epage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Sykes, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowling, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighton-Davies, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fawcett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renard, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trifilieff, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, S. J.</span><span> </span><span class="NLM_article-title">The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">520</span><span class="NLM_x">–</span> <span class="NLM_lpage">528</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1124%2Fjpet.112.194456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=22854200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKktb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2012&pages=520-528&author=D.+A.+Sykesauthor=M.+R.+Dowlingauthor=J.+Leighton-Daviesauthor=T.+C.+Kentauthor=L.+Fawcettauthor=E.+Renardauthor=A.+Trifilieffauthor=S.+J.+Charlton&title=The+influence+of+receptor+kinetics+on+the+onset+and+duration+of+action+and+the+therapeutic+index+of+NVA237+and+tiotropium"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium</span></div><div class="casAuthors">Sykes, David A.; Dowling, Mark R.; Leighton-Davies, Juliet; Kent, Toby C.; Fawcett, Lindsay; Renard, Emilie; Trifilieff, Alexandre; Charlton, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">520-528</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Studies under nonphysiol. conditions suggest that long receptor residency time is responsible for the 24-h duration of action of the long-acting muscarinic antagonist (LAMA) tiotropium.  Our aim was to det. how clin. relevant dissocn. rates under more physiol. conditions influence the differences in onset of action between tiotropium and 3-[(cyclopentylhydroxyphenylacetyl oxy]-1,1-dimethyl-pyrrolidinium bromide (NVA237), a once-daily dry-powder formulation of the LAMA glycopyrronium bromide in development for chronic obstructive pulmonary disease.  In addn., we have investigated kinetic selectivity at each of the muscarinic receptor subtypes to det. whether the improved cardiovascular therapeutic index obtained with NVA237 in animal models is attributable to differences in kinetic rate consts.  The binding of radioligand [3H]N-methyl-scopolamine was measured in the presence/absence of several concns. of unlabeled competitors, and data were analyzed using a competition kinetic model to provide on/off rates for the competitor.  We found shorter dissocn. half-lives for NVA237 and tiotropium under physiol. (11.4 and 46.2 min, resp.) vs. nonphysiol. conditions (173 and 462 min, resp.).  NVA237 had a more rapid onset of action (3-4.8 times) vs. tiotropium, detd. in an vitro calcium and rat tracheal strip assay.  Simulations suggested that the more rapid onset of NVA237 action could be explained by differences in kinetic parameters.  NVA237 had greater equil. binding and kinetic selectivity for muscarinic type 3 (M3) vs. muscarinic type 2 (M2) receptors, with a faster off rate from M2 vs. M3 receptors than tiotropium, potentially affording it a more favorable therapeutic index.  This study suggests that the 24-h duration of action of NVA237 and tiotropium is not solely the result of their slow dissocn. from the M3 receptor and highlights the importance of conducting in vitro expts. in conditions reflecting those in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPg9FL15nv-bVg90H21EOLACvtfcHk0lhEx2BX-2GaoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKktb3M&md5=922e31d6cafa771f3cc66aad519c07e8</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.194456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.194456%26sid%3Dliteratum%253Aachs%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DDowling%26aufirst%3DM.%2BR.%26aulast%3DLeighton-Davies%26aufirst%3DJ.%26aulast%3DKent%26aufirst%3DT.%2BC.%26aulast%3DFawcett%26aufirst%3DL.%26aulast%3DRenard%26aufirst%3DE.%26aulast%3DTrifilieff%26aufirst%3DA.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520influence%2520of%2520receptor%2520kinetics%2520on%2520the%2520onset%2520and%2520duration%2520of%2520action%2520and%2520the%2520therapeutic%2520index%2520of%2520NVA237%2520and%2520tiotropium%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D343%26spage%3D520%26epage%3D528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Verkindre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flémale, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overend, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasad, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolker, M.</span><span> </span><span class="NLM_article-title">Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">1482</span><span class="NLM_x">–</span> <span class="NLM_lpage">1489</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2010.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=20541381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC3cjpvFKltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2010&pages=1482-1489&author=C.+Verkindreauthor=Y.+Fukuchiauthor=A.+Fl%C3%A9maleauthor=A.+Takedaauthor=T.+Overendauthor=N.+Prasadauthor=M.+Dolker&title=Sustained+24-h+efficacy+of+NVA237%2C+a+once-daily+long-acting+muscarinic+antagonist%2C+in+COPD+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients</span></div><div class="casAuthors">Verkindre C; Fukuchi Y; Flemale A; Takeda A; Overend T; Prasad N; Dolker M</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1482-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">NVA237 is a once-daily inhaled long-acting muscarinic antagonist in development for the treatment of COPD.  This randomized, double-blind, placebo-controlled, four-period, incomplete block crossover study, with open-label active comparator (tiotropium), assessed the efficacy and safety of NVA237.  Patients (>or=40 years; smoking history >or=10 pack-years) with stable moderate-to-severe COPD (post-bronchodilator FEV(1) >or= 30% and <80% predicted, FEV(1)/FVC < 0.7) received NVA237 12.5, 25, 50 or 100 microg, placebo, or tiotropium 18 microg once-daily for 7 days.  The primary endpoint was mean trough (23-24 h post-dose) FEV(1) on Day 7.  Secondary endpoints included mean trough FEV(1) on Day 1, and FEV(1) and FVC at individual time points post-dose on Days 1 and 7. 83 patients (mean age 64.4 years; male 83.1%; mean COPD duration 6.7 years; mean post-bronchodilator FEV(1) 1.5 L/52.7% predicted) were randomized; 78 completed.  Mean trough FEV(1) on Day 7 and Day 1 was significantly higher with all active treatments versus placebo (p < 0.05).  NVA237 50 microg, 100 microg and tiotropium showed clinically relevant improvements versus placebo on Day 7 (differences of 131, 142 and 127 mL, respectively; p < 0.0001) and 1 (differences of 121, 135 and 112 mL, respectively; p < 0.0001).  On Day 1, but not Day 7, FEV(1) was significantly higher (p < 0.05) with NVA237 50 and 100 microg versus tiotropium from 5 min up to 2 and 4 h post-dose, respectively.  All doses of NVA237 and tiotropium were well tolerated.  NVA237 once-daily was effective and well tolerated versus placebo, and demonstrated rapid and sustained 24-h bronchodilation. (ClinicalTrials.gov Identifier: NCT00501852).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ8w_3LthW3Ka__Jf7-eMvJfW6udTcc2eZDt1u_hpWLArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjpvFKltA%253D%253D&md5=ced49657659c0c7b06ca136d5b27953e</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2010.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2010.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DVerkindre%26aufirst%3DC.%26aulast%3DFukuchi%26aufirst%3DY.%26aulast%3DFl%25C3%25A9male%26aufirst%3DA.%26aulast%3DTakeda%26aufirst%3DA.%26aulast%3DOverend%26aufirst%3DT.%26aulast%3DPrasad%26aufirst%3DN.%26aulast%3DDolker%26aufirst%3DM.%26atitle%3DSustained%252024-h%2520efficacy%2520of%2520NVA237%252C%2520a%2520once-daily%2520long-acting%2520muscarinic%2520antagonist%252C%2520in%2520COPD%2520patients%26jtitle%3DRespir.%2520Med.%26date%3D2010%26volume%3D104%26spage%3D1482%26epage%3D1489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Casarosa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouyssou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germeyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gantner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieper, M.</span><span> </span><span class="NLM_article-title">Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">330</span><span class="NLM_x">, </span> <span class="NLM_fpage">660</span><span class="NLM_x">–</span> <span class="NLM_lpage">668</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1124%2Fjpet.109.152470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=19478135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsFCltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2009&pages=660-668&author=P.+Casarosaauthor=T.+Bouyssouauthor=S.+Germeyerauthor=A.+Schnappauthor=F.+Gantnerauthor=M.+Pieper&title=Preclinical+evaluation+of+long-acting+muscarinic+antagonists%3A+comparison+of+tiotropium+and+investigational+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs</span></div><div class="casAuthors">Casarosa, Paola; Bouyssou, Thierry; Germeyer, Sabine; Schnapp, Andreas; Gantner, Florian; Pieper, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">660-668</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation caused by persistent inflammatory processes in the airways.  An increased cholinergic tone mediates different pathophysiol. features of COPD, such as bronchoconstriction and mucus hypersecretion, mostly through activation of the human muscarinic M3 receptor (hM3) subtype.  Tiotropium bromide (Spiriva) is a well established muscarinic antagonist in the pharmacol. management of COPD with a once-daily posol.  The rationale behind the sustained bronchodilation obtained with tiotropium consists in its slow dissocn. from hM3 receptors.  In this study, we performed a comprehensive preclin. comparison of tiotropium with other long-acting muscarinic antagonists (LAMAs) currently in clin. development, namely aclidinium bromide and glycopyrrolate.  The different muscarinic antagonists were characterized for their (1) affinity toward the different human muscarinic receptor subtypes expressed in Chinese hamster ovary cells and kinetics of receptor dissocn., (2) potency in inhibiting the agonist-induced activation of muscarinic receptors through measurement of second messengers, and (3) efficacy and duration of bronchoprotection, as tested in a model of acetylcholine-induced bronchoconstriction in anesthetized dogs over a period of 24 h.  All of the tested LAMAs showed high affinity and potency toward the hM3 receptor (tiotropium, pA2 = 10.4; aclidinium, pA2 = 9.6; and glycopyrrolate, pA2 = 9.7).  However, dissocn. half-lives of the LA-MAs from the hM3 receptor differed significantly (tiotropium, t1/2=27 h; aclidinium, t1/2=10.7 h; and glycopyrrolate, t1/2=6.1 h).  In line with their kinetic properties at the hM3, the tested LAMAs provided different levels of bronchoprotection in the in vivo setting 24 h after administration (tiotropium = 35%, aclidinium = 21%, and glycopyrrolate = 0% at 24 h) when applied at equieffective doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorQCmscRp-17Vg90H21EOLACvtfcHk0lhEx2BX-2GaoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsFCltrk%253D&md5=060333cce96f1491b192e4bdbe4bfec5</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.152470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.152470%26sid%3Dliteratum%253Aachs%26aulast%3DCasarosa%26aufirst%3DP.%26aulast%3DBouyssou%26aufirst%3DT.%26aulast%3DGermeyer%26aufirst%3DS.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DGantner%26aufirst%3DF.%26aulast%3DPieper%26aufirst%3DM.%26atitle%3DPreclinical%2520evaluation%2520of%2520long-acting%2520muscarinic%2520antagonists%253A%2520comparison%2520of%2520tiotropium%2520and%2520investigational%2520drugs%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D330%26spage%3D660%26epage%3D668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Villetti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergamaschi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolzoni, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gigli, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geppetti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patacchini, R.</span><span> </span><span class="NLM_article-title">Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">148</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1038%2Fsj.bjp.0706724" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=16565730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD28XltVCjtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2006&pages=291-298&author=G.+Villettiauthor=M.+Bergamaschiauthor=F.+Bassaniauthor=P.+T.+Bolzoniauthor=S.+Harrisonauthor=P.+M.+Gigliauthor=A.+Janniauthor=P.+Geppettiauthor=M.+Civelliauthor=R.+Patacchini&title=Pharmacological+assessment+of+the+duration+of+action+of+glycopyrrolate+vs+tiotropium+and+ipratropium+in+guinea-pig+and+human+airways"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways</span></div><div class="casAuthors">Villetti, Gino; Bergamaschi, Marco; Bassani, Franco; Bolzoni, Pier Tonino; Harrison, Selena; Gigli, Paolo M.; Janni, Alberto; Geppetti, Pierangelo; Civelli, Maurizio; Patacchini, Riccardo</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">291-298</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Our study was aimed at investigating the duration of the bronchodilator action of the antimuscarinic drug glycopyrrolate compared to tiotropium and ipratropium.  In the guinea-pig isolated trachea, the time (t1/2) necessary for a contractile response to carbachol (0.3 μM) to return to 50% recovery after washout of the antagonist was studied.  The offset of the antagonist effect of glycopyrrolate, tiotropium and ipratropium (10 nM each) was t1/2=4.0±0.5, >4.5 and 0.5±0.1 h, resp.  At 4.5 h from the washout of the antagonist, the recovery of the response to carbachol was 50±8, 10±4 and 70±7%, resp.  In the human isolated bronchus, the offset of the bronchodilator effects of glycopyrrolate (3 nM), tiotropium (1 nM) and ipratropium (10 nM) was t1/2=3.7±0.2; >6 and 3.0±0.2 h, resp.  At 6.0 h from the washout of the antagonist, the recovery of the response to carbachol (1 μM) was 101±10, 27±3 and 110±10%, resp.  In anesthetized guinea-pigs, acetylcholine-induced bronchoconstriction was markedly reduced by intratracheal instillation of glycopyrrolate (3 nmol kg-1; 88.1±4% inhibition), tiotropium (1.3 nmol kg-1; 86.2±5% inhibition) or ipratropium (1.45 nmol kg-1; 88.1±10% inhibition).  These inhibitory effects assessed 3 or 24 h after antagonist administration were reduced to 69.9±5 and 29.7±6%; 28.3±5 and 14.2±5% for glycopyrrolate and ipratropium, resp., whereas they remained stable (83.5±4; 70.6±6) for tiotropium.  The residual inhibitory effect of glycopyrrolate was also assessed at 16 h from administration, and proved to be as low as that found at 24 h (31.2±10 vs 29.7±6%, resp.).  In conclusion, glycopyrrolate-induced bronchodilation has a longer duration than that of ipratropium, but less than that of tiotropium.  The efficacy of a possible glycopyrrolate-based therapy for asthma or chronic obstructive pulmonary disease given once-a-day is not guaranteed by the present investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoemLMYN9VSL7Vg90H21EOLACvtfcHk0ljsINY-Jrcbrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltVCjtr8%253D&md5=c45290df0f271378d3dd045ee3e51c49</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0706724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0706724%26sid%3Dliteratum%253Aachs%26aulast%3DVilletti%26aufirst%3DG.%26aulast%3DBergamaschi%26aufirst%3DM.%26aulast%3DBassani%26aufirst%3DF.%26aulast%3DBolzoni%26aufirst%3DP.%2BT.%26aulast%3DHarrison%26aufirst%3DS.%26aulast%3DGigli%26aufirst%3DP.%2BM.%26aulast%3DJanni%26aufirst%3DA.%26aulast%3DGeppetti%26aufirst%3DP.%26aulast%3DCivelli%26aufirst%3DM.%26aulast%3DPatacchini%26aufirst%3DR.%26atitle%3DPharmacological%2520assessment%2520of%2520the%2520duration%2520of%2520action%2520of%2520glycopyrrolate%2520vs%2520tiotropium%2520and%2520ipratropium%2520in%2520guinea-pig%2520and%2520human%2520airways%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D148%26spage%3D291%26epage%3D298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Fogarty, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattersley, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Scala, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drollmann, A.</span><span> </span><span class="NLM_article-title">Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">337</span><span class="NLM_x">–</span> <span class="NLM_lpage">342</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2010.10.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=21144724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC3M7jvVKqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2011&pages=337-342&author=C.+Fogartyauthor=H.+Hattersleyauthor=L.+Di+Scalaauthor=A.+Drollmann&title=Bronchodilatory+effects+of+NVA237%2C+a+once+daily+long-acting+muscarinic+antagonist%2C+in+COPD+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients</span></div><div class="casAuthors">Fogarty Charles; Hattersley Helen; Di Scala Lilla; Drollmann Anton</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">337-42</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">NVA237 is a novel, once daily inhaled long-acting muscarinic antagonist administered via a dry powder inhaler.  This study aimed to assess the 24-h bronchodilatory effect following 14 days of treatment with inhaled NVA237 in patients with mild, moderate or severe COPD.  This was a randomized, double-blind, placebo-controlled, two-period, crossover, multicenter study.  A total of 33 patients (≥ 40 years; smoking history of ≥ 10 pack-years) were randomized to receive NVA237 50 μg once daily followed by placebo or placebo followed by NVA237 50 μg for 14 days.  Treatment periods were separated by a 7-14 day washout period.  The primary variable was the mean forced expiratory volume in 1 s (FEV(1)) derived from the area under the curve (AUC) between 0 and 24 h post-dose on Day 14.  The 24-h FEV(1) profiles showed a consistent bronchodilator effect for NVA237 versus placebo on Day 14.  Least square (LS) mean difference in FEV(1) AUC(0-24 h) values between NVA237 and placebo was 163 mL (P < 0.001).  There were significant increases in mean FEV(1) AUC(0-12 h) (LS mean difference 165 mL, P = 0.001) and FEV(1) AUC(12-24 h) (161 mL, P < 0.001) versus placebo.  NVA237 significantly improved peak FEV(1) (by 208 mL, P < 0.001) and trough FEV(1) (by 154 mL, P = 0.003) versus placebo on Day 14.  NVA237 was well tolerated; all adverse events were mild or moderate in intensity and not related to study drug.  NVA237 50 μg once daily was well tolerated and showed significant and sustained 24-h bronchodilation in patients with COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRaHsHpSC3Wd9ts4TFFB11gfW6udTcc2ebOJ4ugRJvzILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7jvVKqsg%253D%253D&md5=1613e181a48e12c17e11adfb5671893c</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2010.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2010.10.021%26sid%3Dliteratum%253Aachs%26aulast%3DFogarty%26aufirst%3DC.%26aulast%3DHattersley%26aufirst%3DH.%26aulast%3DDi%2BScala%26aufirst%3DL.%26aulast%3DDrollmann%26aufirst%3DA.%26atitle%3DBronchodilatory%2520effects%2520of%2520NVA237%252C%2520a%2520once%2520daily%2520long-acting%2520muscarinic%2520antagonist%252C%2520in%2520COPD%2520patients%26jtitle%3DRespir.%2520Med.%26date%3D2011%26volume%3D105%26spage%3D337%26epage%3D342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Vauquelin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, S. J.</span><span> </span><span class="NLM_article-title">Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">161</span><span class="NLM_x">, </span> <span class="NLM_fpage">488</span><span class="NLM_x">–</span> <span class="NLM_lpage">508</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1111%2Fj.1476-5381.2010.00936.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=20880390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Kju7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2010&pages=488-508&author=G.+Vauquelinauthor=S.+J.+Charlton&title=Long-lasting+target+binding+and+rebinding+as+mechanisms+to+prolong+in+vivo+drug+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action</span></div><div class="casAuthors">Vauquelin, Georges; Charlton, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">488-508</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  An increasing no. of examples in the literature suggest that the in vivo duration of drug action not only depends on macroscopic pharmacokinetic properties like plasma half-life and the time needed to equilibrate between the plasma and the effect compartments, but is also influenced by long-lasting target binding and rebinding.  The present review combines information from different research areas and simulations to explore the nature of these mechanisms and the conditions in which they are most prevalent.  Simulations reveal that these latter phenomena become esp. influential when there is no longer sufficient free drug around to maintain high levels of receptor occupancy.  There is not always a direct link between slow dissocn. and long-lasting in vivo target protection, as the rate of free drug elimination from the effect compartment is also a key influencing factor.  Local phenomena that hinder the diffusion of free drug mols. away from their target may allow them to consecutively bind to the same target and/or targets nearby (denoted as 'rebinding') even when their concn. in the bulk phase has already dropped to insignificant levels.  The micro-anat. properties of many effect compartments are likely to intensify this phenomenon.  By mimicking the complexity of tissues, intact cells offer the opportunity to investigate both mechanisms under the same, physiol. relevant conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzSGNmKeaTzrVg90H21EOLACvtfcHk0ljsINY-Jrcbrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Kju7zE&md5=bd91e09a0fd79a2de6bf9ef0cfd3443e</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00936.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00936.x%26sid%3Dliteratum%253Aachs%26aulast%3DVauquelin%26aufirst%3DG.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DLong-lasting%2520target%2520binding%2520and%2520rebinding%2520as%2520mechanisms%2520to%2520prolong%2520in%2520vivo%2520drug%2520action%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D161%26spage%3D488%26epage%3D508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Vogelmeier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, D.</span><span> </span><span class="NLM_article-title">NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Ther. Adv. Respir. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">–</span> <span class="NLM_lpage">173</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1177%2F1753465811406001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVKlu7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=163-173&author=C.+Vogelmeierauthor=D.+Banerji&title=NVA237%2C+a+long-acting+muscarinic+antagonist%2C+as+an+emerging+therapy+for+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Vogelmeier, Claus; Banerji, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Respiratory Disease</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">163-173</span>CODEN:
                <span class="NLM_cas:coden">TARDCZ</span>;
        ISSN:<span class="NLM_cas:issn">1753-4658</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Bronchodilation with a long-acting muscarinic antagonist (LAMA) or long-acting β2-agonist is central to the management of chronic obstructive pulmonary disease (COPD).  Tiotropium, the first LAMA available for use in COPD, has been shown to be an effective bronchodilator and is generally safe and well tolerated.  However, tiotropium has limitations that include a high incidence of dry mouth, slow onset of action and, in some studies, a part of the patient population did not achieve clin. significant bronchodilation.  It also remains unclear whether tiotropium reduces progressive deterioration of lung function in patients with COPD.  An ideal LAMA would provide clin. meaningful bronchodilation, deliver symptom relief, prevent disease progression, improve exercise tolerance and health status, prevent and treat complications and exacerbations and reduce mortality risk.  A 24-h duration of action, rapid onset of action and a good safety and tolerability profile are also desirable.  The once-daily LAMA, NVA237 (glycopyrronium bromide), may meet some of these characteristics.  NVA237 has high selectivity for the muscarinic type-3 (M3) receptor which might potentially result in a higher therapeutic index than tiotropium, which is less selective for M3.  Phase II studies showed that NVA237 once daily provides clin. significant 24-h bronchodilation with a rapid onset of action and a favorable safety and tolerability profile.  Phase III studies are ongoing that will assess the long-term safety and efficacy of NVA237.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyitI7JsybLLVg90H21EOLACvtfcHk0lhi3d6iSvTCSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVKlu7rN&md5=1e00ee6ba8f5500453dbef68261de1ce</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1177%2F1753465811406001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1753465811406001%26sid%3Dliteratum%253Aachs%26aulast%3DVogelmeier%26aufirst%3DC.%26aulast%3DBanerji%26aufirst%3DD.%26atitle%3DNVA237%252C%2520a%2520long-acting%2520muscarinic%2520antagonist%252C%2520as%2520an%2520emerging%2520therapy%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DTher.%2520Adv.%2520Respir.%2520Dis.%26date%3D2011%26volume%3D5%26spage%3D163%26epage%3D173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">D’Urzo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Noord, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overend, T.</span><span> </span><span class="NLM_article-title">Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial</span> <span class="citation_source-journal">Respir. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">156</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1186%2F1465-9921-12-156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=22151296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC38Xitleiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=156&author=A.+D%E2%80%99Urzoauthor=G.+T.+Fergusonauthor=J.+A.+van+Noordauthor=K.+Hirataauthor=C.+Martinauthor=R.+Hortonauthor=Y.+Luauthor=D.+Banerjiauthor=T.+Overend&title=Efficacy+and+safety+of+once-daily+NVA237+in+patients+with+moderate-to-severe+COPD%3A+the+GLOW1+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial</span></div><div class="casAuthors">D'Urzo, Anthony; Ferguson, Gary T.; van Noord, Jan A.; Hirata, Kazuto; Martin, Carmen; Horton, Rachael; Lu, Yimeng; Banerji, Donald; Overend, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">156</span>CODEN:
                <span class="NLM_cas:coden">RREEBZ</span>;
        ISSN:<span class="NLM_cas:issn">1465-993X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: NVA237 is a once-daily dry-powder formulation of the long-acting muscarinic antagonist glycopyrronium bromide in development for the treatment of chronic obstructive pulmonary disease (COPD).  The glycopyrronium bromide in COPD airways clin. study 1 (GLOW1) evaluated the efficacy, safety and tolerability of NVA237 in patients with moderate-to-severe COPD.  Methods: Patients with COPD with a smoking history of ≥10 pack-years, post-bronchodilator forced expiratory vol. in 1 s (FEV1) <80% and ≥30% predicted normal and FEV1/forced vital capacity < 0.70 were enrolled.  Patients were randomized to double-blind treatment with NVA237 50 μg once daily or placebo for 26 wk with inhaled/intranasal corticosteroids or H1 antagonists permitted in patients stabilized on them prior to study entry.  The primary outcome measure was trough FEV1 at Week 12.  Results: A total of 822 patients were randomized to NVA237 (n = 552) or placebo (n = 270).  Least squares mean (± std. error) trough FEV1 at Week 12 was significantly higher in patients receiving NVA237 (1.408 ± 0.0105 L), vs. placebo (1.301 ± 0.0137 L; treatment difference 108 ± 14.8 mL, p < 0.001).  Significant improvements in trough FEV1 were apparent at the end of Day 1 and sustained through Week 26.  FEV1 was significantly improved in the NVA237 group vs. placebo throughout the 24-h periods on day 1 and at weeks 12 and 26 and at all other visits and timepoints.  Transition dyspnoea index focal scores and St. George's Respiratory Questionnaire scores were significantly improved with NVA237 vs. placebo at Week 26, with treatment differences of 1.04 (p < 0.001) and -2.81 (p = 0.004), resp.  NVA237 significantly reduced the risk of first moderate/severe COPD exacerbation by 31% (p = 0.023) and use of rescue medication by 0.46 puffs per day (p = 0.005), vs. placebo.  NVA237 was well tolerated and had an acceptable safety profile, with a low frequency of cardiac and typical antimuscarinic adverse effects.  Conclusions: Once-daily NVA237 was safe and well tolerated and provided rapid, sustained improvements in lung function, improvements in dyspnoea and health-related quality of life and reduced the risk of exacerbations and the use of rescue medication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp0LAPulEqjbVg90H21EOLACvtfcHk0lhi3d6iSvTCSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xitleiur8%253D&md5=9f339a685604f95d65f62490fff9f81e</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-12-156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-12-156%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Urzo%26aufirst%3DA.%26aulast%3DFerguson%26aufirst%3DG.%2BT.%26aulast%3Dvan%2BNoord%26aufirst%3DJ.%2BA.%26aulast%3DHirata%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DC.%26aulast%3DHorton%26aufirst%3DR.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DBanerji%26aufirst%3DD.%26aulast%3DOverend%26aufirst%3DT.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520once-daily%2520NVA237%2520in%2520patients%2520with%2520moderate-to-severe%2520COPD%253A%2520the%2520GLOW1%2520trial%26jtitle%3DRespir.%2520Res.%26date%3D2011%26volume%3D12%26spage%3D156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Kerwin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hébert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overend, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alagappan, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, D.</span><span> </span><span class="NLM_article-title">Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1106</span><span class="NLM_x">–</span> <span class="NLM_lpage">1114</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.00040712" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23060624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFelt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=1106-1114&author=E.+Kerwinauthor=J.+H%C3%A9bertauthor=N.+Gallagherauthor=C.+Martinauthor=T.+Overendauthor=V.+K.+Alagappanauthor=Y.+Luauthor=D.+Banerji&title=Efficacy+and+safety+of+NVA237+versus+placebo+and+tiotropium+in+patients+with+COPD%3A+the+GLOW2+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study</span></div><div class="casAuthors">Kerwin, Edward; Hebert, Jacques; Gallagher, Nicola; Martin, Carmen; Overend, Tim; Alagappan, Vijay K. T.; Lu, Yimeng; Banerji, Donald</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1106-1114</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist (LAMA) in development for chronic obstructive pulmonary disease (COPD).  The GLycopyrronium bromide in COPD airWays clin. Study 2 (GLOW2) evaluated the efficacy and safety of NVA237 in moderate-to-severe COPD over 52 wk.  Patients were randomised 2:1:1 to NVA237 50 μg, placebo or open-label tiotropium 18 μg for 52 wk.  Primary end-point was trough forced expiratory vol. in 1 s (FEV1) at 12 wk.  1,066 Patients were randomised, 810 completed the study.  At week 12, trough FEV1 increased significantly by 97 mL with NVA237 (95% CI 64.6-130.2; p<0.001) and 83 mL with tiotropium (95% CI 45.6-121.4; p<0.001).  Compared with placebo, NVA237 produced significant improvements in dyspnoea (Transition Dyspnoea Index at week 26; p=0.002) and health status (St George's Respiratory Questionnaire at week 52; p<0.001).  NVA237 significantly reduced the risk of moderate-to-severe COPD exacerbations by 34% (p=0.001) and the use of rescue medication (p=0.039), vs. placebo.  NVA237-placebo and tiotropium-placebo differences were comparable for all outcomes.  Safety profiles were similar across groups.  NVA237 50 μg provided significant improvements in lung function, dyspnoea, health status, exacerbations and rescue medication use, vs. placebo, and was comparable to tiotropium.  NVA237 can potentially be an alternative choice of LAMA for COPD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSUlbKeoyAgbVg90H21EOLACvtfcHk0li0JxyHl4gxRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFelt7o%253D&md5=2edd1f1595e071ecc2c9063e7fef71d8</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1183%2F09031936.00040712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00040712%26sid%3Dliteratum%253Aachs%26aulast%3DKerwin%26aufirst%3DE.%26aulast%3DH%25C3%25A9bert%26aufirst%3DJ.%26aulast%3DGallagher%26aufirst%3DN.%26aulast%3DMartin%26aufirst%3DC.%26aulast%3DOverend%26aufirst%3DT.%26aulast%3DAlagappan%26aufirst%3DV.%2BK.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DBanerji%26aufirst%3DD.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520NVA237%2520versus%2520placebo%2520and%2520tiotropium%2520in%2520patients%2520with%2520COPD%253A%2520the%2520GLOW2%2520study%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2012%26volume%3D40%26spage%3D1106%26epage%3D1114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Beeh, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Scala, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drollmann, A.</span><span> </span><span class="NLM_article-title">Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial</span> <span class="citation_source-journal">Int. J. Chronic Obstruct. Pulm. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">503</span><span class="NLM_x">–</span> <span class="NLM_lpage">513</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.2147%2FCOPD.S32451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=22973092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCqsbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=503-513&author=K.+M.+Beehauthor=D.+Singhauthor=L.+Di+Scalaauthor=A.+Drollmann&title=Once-daily+NVA237+improves+exercise+tolerance+from+the+first+dose+in+patients+with+COPD%3A+the+GLOW3+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial</span></div><div class="casAuthors">Beeh, Kai M.; Singh, Dave; Di Scala, Lilla; Drollmann, Anton</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Chronic Obstructive Pulmonary Disease</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">503-513</span>CODEN:
                <span class="NLM_cas:coden">IJCOC3</span>;
        ISSN:<span class="NLM_cas:issn">1178-2005</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Introduction: Exercise limitation, dynamic hyperinflation, and exertional dyspnea are key features of symptomatic chronic obstructive pulmonary disease (COPD).  We assessed the effects of glycopyrronium bromide (NVA237), a once-daily, long-acting muscarinic antagonist, on exercise tolerance in patients with moderate to severe COPD.  Methods: Patients were randomized to a cross-over design of once-daily NVA237 50 μg or placebo for 3 wk, with a 14-day washout.  Exercise endurance, inspiratory capacity (IC) during exercise, IC and expiratory vols. from spirometry, plethysmog. lung vols., leg discomfort and dyspnea under exercise (Borg scales), and transition dyspnea index were measured on days 1 and 21 of treatment.  The primary endpoint was endurance time during a submaximal const.-load cycle ergometry test on day 21.  Results: A total of 108 patients were randomized to different treatment groups (mean age, 60.5 years; mean post-bronchodilator, forced expiratory vol. in 1 s [FEV1] 57.1% predicted).  Ninety-five patients completed the study.  On day 21, a 21% difference in endurance time was obsd. between patients treated with NVA237 and those treated with placebo (P < 0.001); the effect was also significant from day 1, with an increase of 10%.  Dynamic IC at exercise isotime and trough FEV1 showed significant and clin. relevant improvements from Day 1 of treatment that were maintained throughout the study.  This was accompanied by inverse decreases in residual vol. and functional residual capacity.  NVA237 was superior to placebo (P < 0.05) in decreasing leg discomfort (Borg CR10 scale) on Day 21 and exertional dyspnea on Days 1 and 21 (transition dyspnea index and Borg CR10 scale at isotime).  The safety profile of NVA237 was similar to that of the placebo.  Conclusion: NVA237 50 μg once daily produced immediate and significant improvement in exercise tolerance from day 1.  This was accompanied by sustained redns. in lung hyperinflation (indicated by sustained and significant improvements in IC at isotime), and meaningful improvements in trough FEV1 and dyspnea.  Improvements in exercise endurance increased over time, suggesting that mechanisms beyond improved lung function may be involved in enhanced exercise tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3HSwcLky9DbVg90H21EOLACvtfcHk0li0JxyHl4gxRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCqsbrO&md5=52b28b1bd2aff9ce1ae066c2c8146019</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S32451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S32451%26sid%3Dliteratum%253Aachs%26aulast%3DBeeh%26aufirst%3DK.%2BM.%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DDi%2BScala%26aufirst%3DL.%26aulast%3DDrollmann%26aufirst%3DA.%26atitle%3DOnce-daily%2520NVA237%2520improves%2520exercise%2520tolerance%2520from%2520the%2520first%2520dose%2520in%2520patients%2520with%2520COPD%253A%2520the%2520GLOW3%2520trial%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2012%26volume%3D7%26spage%3D503%26epage%3D513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Chapman, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beeh, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bateman, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Urzo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nutbrown, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overend, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, P.</span><span> </span><span class="NLM_article-title">A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study</span> <span class="citation_source-journal">BMC Pulm. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1186%2F1471-2466-14-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=24438744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC2czmsFKmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=4&author=K.+R.+Chapmanauthor=K.+M.+Beehauthor=J.+Beierauthor=E.+D.+Batemanauthor=A.+D%E2%80%99Urzoauthor=R.+Nutbrownauthor=M.+Henleyauthor=H.+Chenauthor=T.+Overendauthor=P.+D%E2%80%99Andrea&title=A+blinded+evaluation+of+the+efficacy+and+safety+of+glycopyrronium%2C+a+once-daily+long-acting+muscarinic+antagonist%2C+versus+tiotropium%2C+in+patients+with+COPD%3A+the+GLOW5+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study</span></div><div class="casAuthors">Chapman Kenneth R; Beeh Kai-Michael; Beier Jutta; Bateman Eric D; D'Urzo Anthony; Nutbrown Robert; Henley Michelle; Chen Hungta; Overend Tim; D'Andrea Peter</div><div class="citationInfo"><span class="NLM_cas:title">BMC pulmonary medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Two once-daily long-acting muscarinic antagonists (LAMAs) are currently available for the treatment of chronic obstructive pulmonary disease (COPD) - tiotropium and glycopyrronium.  Previous studies have compared glycopyrronium with open-label tiotropium.  In the GLOW5 study, we compare glycopyrronium with blinded tiotropium.  METHODS:  In this blinded, double-dummy, parallel group, 12-week study, patients with moderate-to-severe COPD were randomized 1:1 to glycopyrronium 50 μg once daily or tiotropium 18 μg once daily.  The primary objective was to demonstrate the non-inferiority of glycopyrronium versus blinded tiotropium with respect to trough forced expiratory volume in 1 second (FEV1) following 12 weeks of treatment (non-inferiority margin: -50 mL).  Secondary objectives were to evaluate glycopyrronium versus tiotropium for other spirometric outcomes, breathlessness (Transition Dyspnea Index; TDI), health status (St George's Respiratory Questionnaire; SGRQ), daily rescue medication use, COPD exacerbations and COPD symptoms over 12 weeks of treatment.  RESULTS:  657 patients were randomized (glycopyrronium: 327; tiotropium: 330); 96% (630 patients) completed the study.  Least squares mean trough FEV1 for both glycopyrronium and tiotropium was 1.405 L at Week 12, meeting the criterion for non-inferiority (mean treatment difference: 0 mL, 95% CI: -32, 31 mL).  Glycopyrronium demonstrated rapid bronchodilation following first dose on Day 1, with significantly higher FEV1 at all time points from 0-4 h post-dose versus tiotropium (all p < 0.001).  FEV1 area under the curve from 0-4 h (AUC0-4h) post-dose with glycopyrronium was significantly superior to tiotropium on Day 1 (p < 0.001) and was comparable to tiotropium at Week 12.  Glycopyrronium demonstrated comparable improvements to tiotropium in TDI focal score, SGRQ total score, rescue medication use and the rate of COPD exacerbations (all p = not significant).  Patients on glycopyrronium also had a significantly lower total COPD symptom score versus patients on tiotropium after 12 weeks (p = 0.035).  Adverse events were reported by a similar percentage of patients receiving glycopyrronium (40.4%) and tiotropium (40.6%).  CONCLUSION:  In patients with moderate-to-severe COPD, 12-week blinded treatment with once-daily glycopyrronium 50 μg or tiotropium 18 μg, provided similar efficacy and safety, with glycopyrronium having a faster onset of action on Day 1 versus tiotropium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWvhlVOxUiRGHOrQ6qeX-mfW6udTcc2eZx9vdUmXZ_lbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2czmsFKmsw%253D%253D&md5=59ac336a5b821763ddbcc5da646e4f32</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1186%2F1471-2466-14-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2466-14-4%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DK.%2BR.%26aulast%3DBeeh%26aufirst%3DK.%2BM.%26aulast%3DBeier%26aufirst%3DJ.%26aulast%3DBateman%26aufirst%3DE.%2BD.%26aulast%3DD%25E2%2580%2599Urzo%26aufirst%3DA.%26aulast%3DNutbrown%26aufirst%3DR.%26aulast%3DHenley%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DOverend%26aufirst%3DT.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DP.%26atitle%3DA%2520blinded%2520evaluation%2520of%2520the%2520efficacy%2520and%2520safety%2520of%2520glycopyrronium%252C%2520a%2520once-daily%2520long-acting%2520muscarinic%2520antagonist%252C%2520versus%2520tiotropium%252C%2520in%2520patients%2520with%2520COPD%253A%2520the%2520GLOW5%2520study%26jtitle%3DBMC%2520Pulm.%2520Med.%26date%3D2014%26volume%3D14%26spage%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Jansat, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia Gil, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrer, P.</span><span> </span><span class="NLM_article-title">Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects</span> <span class="citation_source-journal">Int. J. Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">460</span><span class="NLM_x">–</span> <span class="NLM_lpage">468</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.5414%2FCPP47460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=19640353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVGjsbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2009&pages=460-468&author=J.+M.+Jansatauthor=R.+Lamarcaauthor=E.+Garcia+Gilauthor=P.+Ferrer&title=Safety+and+pharmacokinetics+of+single+doses+of+aclidinium+bromide%2C+a+novel+long-acting%2C+inhaled+antimuscarinic%2C+in+healthy+subjects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects</span></div><div class="casAuthors">Jansat, J. M.; Lamarca, R.; Gil, E. Garcia; Ferrer, P.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">460-468</span>CODEN:
                <span class="NLM_cas:coden">ICTHEK</span>;
        ISSN:<span class="NLM_cas:issn">0946-1965</span>.
    
            (<span class="NLM_cas:orgname">Dustri-Verlag Dr. Karl Feistle</span>)
        </div><div class="casAbstract">Aclidinium bromide is a novel antimuscarinic being developed for the treatment of chronic obstructive pulmonary disease.  The objective of this Phase I study was to det. the max. tolerated dose (MTD) as well as the tolerability, safety and pharmacokinetics of aclidinium in healthy subjects.  16 healthy subjects were randomized to receive 5 single ascending doses of aclidinium 600-6000 μg or placebo inhaled via dry powder inhaler, with 7 day washouts.  Safety measurements included adverse events (AEs), phys. examn., vital signs, pupillometry examn., clin. lab. tests, and 12-lead ECG.  Pharmacokinetic parameters of aclidinium and its metabolites were assessed.  The incidence of AEs was comparable between aclidinium and placebo at all doses.  Most AEs were mild to moderate with no dose-related or anticholinergic/cardiac AEs.  At doses ≥2400 μg, only 13 AEs were considered treatment related.  Aclidinium (600-6000 μg) did not produce function-limiting or severe AEs in ≥50% of subjects; hence, the prospectively-defined MTD was not established.  Aclidinium was rapidly converted in plasma into alc. and carboxylic acid metabolites, and was no longer detectable after 3 h post-dose for all doses.  At lower doses, aclidinium was quantifiable only up to 1 h post-dose in the majority of subjects.  Maximum plasma concns. for aclidinium were reached within 5-7 min (all doses) and declined rapidly.  Mean elimination half-lives of aclidinium >2400 μg were approx. 1 h.  AUC and Cmax increased proportionately up to 4800 μg.  Aclidinium appears to be safe and well tolerated in single doses of 600-6000 μg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmAmPkH7WVi7Vg90H21EOLACvtfcHk0ljy-yQuAaOtbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVGjsbrM&md5=8e2dd9ac12ceeb68a0dd3bfa6a937500</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.5414%2FCPP47460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5414%252FCPP47460%26sid%3Dliteratum%253Aachs%26aulast%3DJansat%26aufirst%3DJ.%2BM.%26aulast%3DLamarca%26aufirst%3DR.%26aulast%3DGarcia%2BGil%26aufirst%3DE.%26aulast%3DFerrer%26aufirst%3DP.%26atitle%3DSafety%2520and%2520pharmacokinetics%2520of%2520single%2520doses%2520of%2520aclidinium%2520bromide%252C%2520a%2520novel%2520long-acting%252C%2520inhaled%2520antimuscarinic%252C%2520in%2520healthy%2520subjects%26jtitle%3DInt.%2520J.%2520Clin.%2520Pharmacol.%2520Ther.%26date%3D2009%26volume%3D47%26spage%3D460%26epage%3D468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Jones, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rennard, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agusti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chanez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnussen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbri, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donohue, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bateman, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caracta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Gil, E.</span><span> </span><span class="NLM_article-title">Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Respir. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1186%2F1465-9921-12-55" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=21518460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVamurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=55&author=P.+W.+Jonesauthor=S.+I.+Rennardauthor=A.+Agustiauthor=P.+Chanezauthor=H.+Magnussenauthor=L.+Fabbriauthor=J.+F.+Donohueauthor=E.+D.+Batemanauthor=N.+J.+Grossauthor=R.+Lamarcaauthor=C.+Caractaauthor=E.+Garcia-Gil&title=Efficacy+and+safety+of+once-daily+aclidinium+in+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Jones, Paul W.; Rennard, Stephen I.; Agusti, Alvar; Chanez, Pascal; Magnussen, Helgo; Fabbri, Leonardo; Donohue, James F.; Bateman, Eric D.; Gross, Nicholas J.; Lamarca, Rosa; Caracta, Cynthia; Gil, Esther Garcia</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">55</span>CODEN:
                <span class="NLM_cas:coden">RREEBZ</span>;
        ISSN:<span class="NLM_cas:issn">1465-993X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The long-term efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist, were investigated in patients with moderate to severe chronic obstructive pulmonary disease (COPD).  In two double-blind, 52-wk studies, ACCLAIM/COPD I (n = 843) and II (n = 804), patients were randomized to inhaled aclidinium 200 μg or placebo once-daily.  Patients were required to have a post-bronchodilator forced expiratory vol. in 1 s (FEV1)/forced vital capacity ratio of ≤70% and FEV1 <80% of the predicted value.  The primary endpoint was trough FEV1 at 12 and 28 wk.  Secondary endpoints were health status measured by St. George's Respiratory Questionnaire (SGRQ) and time to first moderate or severe COPD exacerbation.  At 12 and 28 wk, aclidinium improved trough FEV1 vs. placebo in ACCLAIM/COPD I (by 61 and 67 mL; both p < 0.001) and ACCLAIM/COPD II (by 63 and 59 mL; both p < 0.001).  More patients had a SGRQ improvement ≥4 units at 52 wk with aclidinium vs. placebo in ACCLAIM/COPD I (48.1% vs. 39.5%; p = 0.025) and ACCLAIM/COPD II (39.0% vs. 32.8%; p = 0.074).  The time to first exacerbation was significantly delayed by aclidinium in ACCLAIM/COPD II (hazard ratio [HR] 0.7; 95% confidence interval [CI] 0.55 to 0.92; p = 0.01), but not ACCLAIM/COPD I (HR 1.0; 95% CI 0.72 to 1.33; p = 0.9).  Adverse events were minor in both studies.  Aclidinium is effective and well tolerated in patients with moderate to severe COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5kEg2cALstLVg90H21EOLACvtfcHk0ljy-yQuAaOtbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVamurg%253D&md5=7aa275b7bde0e549fd29ef391b93b0db</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-12-55&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-12-55%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%2BW.%26aulast%3DRennard%26aufirst%3DS.%2BI.%26aulast%3DAgusti%26aufirst%3DA.%26aulast%3DChanez%26aufirst%3DP.%26aulast%3DMagnussen%26aufirst%3DH.%26aulast%3DFabbri%26aufirst%3DL.%26aulast%3DDonohue%26aufirst%3DJ.%2BF.%26aulast%3DBateman%26aufirst%3DE.%2BD.%26aulast%3DGross%26aufirst%3DN.%2BJ.%26aulast%3DLamarca%26aufirst%3DR.%26aulast%3DCaracta%26aufirst%3DC.%26aulast%3DGarcia-Gil%26aufirst%3DE.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520once-daily%2520aclidinium%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DRespir.%2520Res.%26date%3D2011%26volume%3D12%26spage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Maltais, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casaburi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porszasz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarreta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seoane, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caracta, C.</span><span> </span><span class="NLM_article-title">Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">580</span><span class="NLM_x">–</span> <span class="NLM_lpage">587</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2010.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=21183326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC3M3hvFyrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2011&pages=580-587&author=F.+Maltaisauthor=B.+Celliauthor=R.+Casaburiauthor=J.+Porszaszauthor=D.+Jarretaauthor=B.+Seoaneauthor=C.+Caracta&title=Aclidinium+bromide+improves+exercise+endurance+and+lung+hyperinflation+in+patients+with+moderate+to+severe+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD</span></div><div class="casAuthors">Maltais Francois; Celli Bartolome; Casaburi Richard; Porszasz Janos; Jarreta Diana; Seoane Beatriz; Caracta Cynthia</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">580-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Static and dynamic lung hyperinflation are associated with exercise impairment and poor outcomes in COPD patients.  Aclidinium bromide is a novel, long-acting inhaled muscarinic antagonist currently in development for COPD treatment.  METHODS:  Patients with moderate to severe COPD (N = 181) were randomized to once-daily aclidinium 200 μg or placebo for 6 weeks.  Constant work rate cycling exercises at 75% of peak work rate were performed at baseline, Day 1, Week 3, and Week 6.  The primary efficacy measure was change in exercise endurance time (ET) from baseline to Week 6.  Secondary outcomes included changes in trough forced expiratory volume in 1 s (FEV(1)), inspiratory capacity (IC), IC/total lung capacity (TLC), and functional residual capacity (FRC) from baseline to Day 1, Week 3, and Week 6.  Borg dyspnea scores during exercise, locus of symptom limitation, and safety measures were assessed.  RESULTS:  Aclidinium significantly improved ET on Day 1 (P = 0.0002), and improvements were sustained through Week 3 (P = 0.0007) and Week 6 (P = 0.0042) vs placebo.  Compared with placebo, aclidinium improved trough FEV(1), IC, and IC/TLC at Weeks 3 and 6 (P < 0.05 for all).  Exertional dyspnea scores at isotime were reduced on Day 1, Week 3, and Week 6 for aclidinium vs placebo (P < 0.05).  Furthermore, the likelihood of stopping exercise due to breathing discomfort was lower in the aclidinium group at study end (P = 0.0208) compared with placebo.  No differences in safety outcomes were reported between treatments.  CONCLUSIONS:  Aclidinium significantly increased exercise tolerance, improved airflow obstruction and lung hyperinflation, and was safe and well tolerated.  REGISTRATION OF TRIAL: This trial was registered with ClinicalTrials.gov (NCT00500318) under the name "A Study of Exercise Endurance and Lung Hyperinflation in Patients with Moderate to Severe COPD".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSEJ86GtNp_Rcr74wzj5o5fW6udTcc2eZ-zeypUA3cPLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3hvFyrsA%253D%253D&md5=fbd03314ffbf36218ddb9a19d5f076fd</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2010.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2010.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DMaltais%26aufirst%3DF.%26aulast%3DCelli%26aufirst%3DB.%26aulast%3DCasaburi%26aufirst%3DR.%26aulast%3DPorszasz%26aufirst%3DJ.%26aulast%3DJarreta%26aufirst%3DD.%26aulast%3DSeoane%26aufirst%3DB.%26aulast%3DCaracta%26aufirst%3DC.%26atitle%3DAclidinium%2520bromide%2520improves%2520exercise%2520endurance%2520and%2520lung%2520hyperinflation%2520in%2520patients%2520with%2520moderate%2520to%2520severe%2520COPD%26jtitle%3DRespir.%2520Med.%26date%3D2011%26volume%3D105%26spage%3D580%26epage%3D587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Singh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loke, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furberg, C. D.</span><span> </span><span class="NLM_article-title">Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">300</span><span class="NLM_x">, </span> <span class="NLM_fpage">1439</span><span class="NLM_x">–</span> <span class="NLM_lpage">1450</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=300&publication_year=2008&pages=1439-1450&author=S.+Singhauthor=Y.+K.+Lokeauthor=C.+D.+Furberg&title=Inhaled+anticholinergics+and+risk+of+major+adverse+cardiovascular+events+in+patients+with+chronic+obstructive+pulmonary+disease%3A+a+systematic+review+and+meta-analysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DLoke%26aufirst%3DY.%2BK.%26aulast%3DFurberg%26aufirst%3DC.%2BD.%26atitle%3DInhaled%2520anticholinergics%2520and%2520risk%2520of%2520major%2520adverse%2520cardiovascular%2520events%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2008%26volume%3D300%26spage%3D1439%26epage%3D1450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Ogale, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Au, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boudreau, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, S. D.</span><span> </span><span class="NLM_article-title">Cardiovascular events associated with ipratropium bromide in COPD</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">–</span> <span class="NLM_lpage">19</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2010&pages=13-19&author=S.+S.+Ogaleauthor=T.+A.+Leeauthor=D.+H.+Auauthor=D.+M.+Boudreauauthor=S.+D.+Sullivan&title=Cardiovascular+events+associated+with+ipratropium+bromide+in+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOgale%26aufirst%3DS.%2BS.%26aulast%3DLee%26aufirst%3DT.%2BA.%26aulast%3DAu%26aufirst%3DD.%2BH.%26aulast%3DBoudreau%26aufirst%3DD.%2BM.%26aulast%3DSullivan%26aufirst%3DS.%2BD.%26atitle%3DCardiovascular%2520events%2520associated%2520with%2520ipratropium%2520bromide%2520in%2520COPD%26jtitle%3DChest%26date%3D2010%26volume%3D137%26spage%3D13%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">Celli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decramer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leimer, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tashkin, D. P.</span><span> </span><span class="NLM_article-title">Cardiovascular safety of tiotropium in patients with COPD</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2010&pages=20-30&author=B.+Celliauthor=M.+Decramerauthor=I.+Leimerauthor=U.+Vogelauthor=S.+Kestenauthor=D.+P.+Tashkin&title=Cardiovascular+safety+of+tiotropium+in+patients+with+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCelli%26aufirst%3DB.%26aulast%3DDecramer%26aufirst%3DM.%26aulast%3DLeimer%26aufirst%3DI.%26aulast%3DVogel%26aufirst%3DU.%26aulast%3DKesten%26aufirst%3DS.%26aulast%3DTashkin%26aufirst%3DD.%2BP.%26atitle%3DCardiovascular%2520safety%2520of%2520tiotropium%2520in%2520patients%2520with%2520COPD%26jtitle%3DChest%26date%3D2010%26volume%3D137%26spage%3D20%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">McGarvey, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magder, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkhart, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manuel, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niewoehner, D. E.</span><span> </span><span class="NLM_article-title">Cause-specific mortality adjudication in the UPLIFT COPD trial: findings and recommendations</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">515</span><span class="NLM_x">–</span> <span class="NLM_lpage">521</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2011.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=22100536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC383otVSltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2012&pages=515-521&author=L.+P.+McGarveyauthor=S.+Magderauthor=D.+Burkhartauthor=S.+Kestenauthor=D.+Liuauthor=R.+C.+Manuelauthor=D.+E.+Niewoehner&title=Cause-specific+mortality+adjudication+in+the+UPLIFT+COPD+trial%3A+findings+and+recommendations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Cause-specific mortality adjudication in the UPLIFT® COPD trial: findings and recommendations</span></div><div class="casAuthors">McGarvey Lorcan P; Magder Sheldon; Burkhart Deborah; Kesten Steven; Liu Dacheng; Manuel Raymond C; Niewoehner Denis E</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">515-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Mortality is an important endpoint in chronic obstructive pulmonary disease (COPD) trials, although accurately determining cause of death is difficult.  In the Understanding the Potential Long-term Impacts on Function with Tiotropium (UPLIFT®) trial, a mortality adjudication committee (MAC) provided systematic, independent and blinded assessment of cause-specific mortality of all 981 reported deaths.  Here we describe this process of mortality adjudication and methodological revisions introduced to help standardise the adjudication of two areas recognised to pose particular difficulty; firstly, the classification of fatal COPD exacerbations that occur in the setting of pneumonia and secondly, the categorisation of sudden death.  In addition MAC determined cause of death was compared with that reported by site investigators (SIs).  MAC-assigned causes of death were: respiratory, 35%; cancer, 25%; cardiovascular, 11%; sudden cardiac death, 4.4%; sudden death, 3.4%; other, 8.8%; unknown, 12.4%.  Cancer/cardiac deaths were more common in Global Initiative for Chronic Obstructive Lung Disease stage II, respiratory deaths in stages III and IV.  Agreement between MAC and SI regarding cause of death was complete (50.2%), incomplete (18.5%) or none (31.3%).  The SI classified deaths as cardiac three-fold more frequently than MAC (incidence rate [IR]/100 patient-years 0.797 vs. 0.257), although IR ratios for cardiac deaths for tiotropium vs. control were similar between SI and MAC.  Discrepancies between MAC- and SI-adjudicated causes of death are common, especially increased reporting of cardiac deaths by the SI.  Future multicentre COPD trials should plan appropriate infrastructure before study initiation to ensure collection and interpretation of fatal events data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTr_UZgzuuEu_x2phytoz6_fW6udTcc2eYkR9TZwc38OLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383otVSltQ%253D%253D&md5=6a7321c1bf6907fe9e658b5a97207113</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2011.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2011.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DMcGarvey%26aufirst%3DL.%2BP.%26aulast%3DMagder%26aufirst%3DS.%26aulast%3DBurkhart%26aufirst%3DD.%26aulast%3DKesten%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DManuel%26aufirst%3DR.%2BC.%26aulast%3DNiewoehner%26aufirst%3DD.%2BE.%26atitle%3DCause-specific%2520mortality%2520adjudication%2520in%2520the%2520UPLIFT%2520COPD%2520trial%253A%2520findings%2520and%2520recommendations%26jtitle%3DRespir.%2520Med.%26date%3D2012%26volume%3D106%26spage%3D515%26epage%3D521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Lee, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroupe, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schumock, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickard, A. S.</span><span> </span><span class="NLM_article-title">Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Arch. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">169</span><span class="NLM_x">, </span> <span class="NLM_fpage">1403</span><span class="NLM_x">–</span> <span class="NLM_lpage">1410</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2009&pages=1403-1410&author=T.+A.+Leeauthor=C.+Wilkeauthor=M.+Jooauthor=K.+T.+Stroupeauthor=J.+A.+Krishnanauthor=G.+T.+Schumockauthor=A.+S.+Pickard&title=Outcomes+associated+with+tiotropium+use+in+patients+with+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DT.%2BA.%26aulast%3DWilke%26aufirst%3DC.%26aulast%3DJoo%26aufirst%3DM.%26aulast%3DStroupe%26aufirst%3DK.%2BT.%26aulast%3DKrishnan%26aufirst%3DJ.%2BA.%26aulast%3DSchumock%26aufirst%3DG.%2BT.%26aulast%3DPickard%26aufirst%3DA.%2BS.%26atitle%3DOutcomes%2520associated%2520with%2520tiotropium%2520use%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DArch.%2520Intern.%2520Med.%26date%3D2009%26volume%3D169%26spage%3D1403%26epage%3D1410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Dong, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shau, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, M. S.</span><span> </span><span class="NLM_article-title">Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">56</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=48-56&author=Y.+H.+Dongauthor=H.+H.+Linauthor=W.+Y.+Shauauthor=Y.+C.+Wuauthor=C.+H.+Changauthor=M.+S.+Lai&title=Comparative+safety+of+inhaled+medications+in+patients+with+chronic+obstructive+pulmonary+disease%3A+systematic+review+and+mixed+treatment+comparison+meta-analysis+of+randomised+controlled+trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DY.%2BH.%26aulast%3DLin%26aufirst%3DH.%2BH.%26aulast%3DShau%26aufirst%3DW.%2BY.%26aulast%3DWu%26aufirst%3DY.%2BC.%26aulast%3DChang%26aufirst%3DC.%2BH.%26aulast%3DLai%26aufirst%3DM.%2BS.%26atitle%3DComparative%2520safety%2520of%2520inhaled%2520medications%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520systematic%2520review%2520and%2520mixed%2520treatment%2520comparison%2520meta-analysis%2520of%2520randomised%2520controlled%2520trials%26jtitle%3DThorax%26date%3D2013%26volume%3D68%26spage%3D48%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Singh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loke, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enright, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furberg, C. D.</span><span> </span><span class="NLM_article-title">Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials</span> <span class="citation_source-journal">BMJ</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">342</span><span class="NLM_x">, </span> <span class="NLM_fpage">d3215</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2011&pages=d3215&author=S.+Singhauthor=Y.+K.+Lokeauthor=P.+L.+Enrightauthor=C.+D.+Furberg&title=Mortality+associated+with+tiotropium+mist+inhaler+in+patients+with+chronic+obstructive+pulmonary+disease%3A+systematic+review+and+meta-analysis+of+randomised+controlled+trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DLoke%26aufirst%3DY.%2BK.%26aulast%3DEnright%26aufirst%3DP.%2BL.%26aulast%3DFurberg%26aufirst%3DC.%2BD.%26atitle%3DMortality%2520associated%2520with%2520tiotropium%2520mist%2520inhaler%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520systematic%2520review%2520and%2520meta-analysis%2520of%2520randomised%2520controlled%2520trials%26jtitle%3DBMJ%26date%3D2011%26volume%3D342%26spage%3Dd3215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Wise, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anzueto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cotton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devins, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Disse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dusser, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kattenbeck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koenen-Bergmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pledger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calverley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">TIOSPIR Investigators.</span><span> </span><span class="NLM_article-title">Tiotropium Respimat inhaler and the risk of death in COPD</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">1491</span><span class="NLM_x">–</span> <span class="NLM_lpage">1501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1056%2FNEJMoa1303342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23992515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1CgsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=1491-1501&author=R.+A.+Wiseauthor=A.+Anzuetoauthor=D.+Cottonauthor=R.+Dahlauthor=T.+Devinsauthor=B.+Disseauthor=D.+Dusserauthor=E.+Josephauthor=S.+Kattenbeckauthor=M.+Koenen-Bergmannauthor=G.+Pledgerauthor=P.+Calverleyauthor=TIOSPIR+Investigators.&title=Tiotropium+Respimat+inhaler+and+the+risk+of+death+in+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Tiotropium respimat inhaler and the risk of death in COPD</span></div><div class="casAuthors">Wise, Robert A.; Anzueto, Antonio; Cotton, Daniel; Dahl, Ronald; Devins, Theresa; Disse, Bernd; Dusser, Daniel; Joseph, Elizabeth; Kattenbeck, Sabine; Koenen-Bergmann, Michael; Pledger, Gordon; Calverley, Peter</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1491-1501</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Tiotropium delivered at a dose of 5 μg with the Respimat inhaler showed efficacy similar to that of 18 μg of tiotropium delivered with the HandiHaler inhalation device in placebo-controlled trials involving patients with chronic obstructive pulmonary disease (COPD).  Although tiotropium HandiHaler was assocd. with reduced mortality, as compared with placebo, more deaths were reported with tiotropium Respimat than with placebo.  In this randomized, double-blind, parallel-group trial involving 17,135 patients with COPD, we evaluated the safety and efficacy of tiotropium Respimat at a once-daily dose of 2.5 μg or 5 μg, as compared with tiotropium HandiHaler at a once-daily dose of 18 μg.  Primary end points were the risk of death (noninferiority study, Respimat at a dose of 5 μg or 2.5 μg vs. HandiHaler) and the risk of the first COPD exacerbation (superiority study, Respimat at a dose of 5 μg vs. HandiHaler).  We also assessed cardiovascular safety, including safety in patients with stable cardiac disease.  During a mean follow-up of 2.3 years, Respimat was noninferior to HandiHaler with respect to the risk of death (Respimat at a dose of 5 μg vs. HandiHaler: hazard ratio, 0.96; 95% confidence interval [CI], 0.84 to 1.09; Respimat at a dose of 2.5 μg vs. HandiHaler: hazard ratio, 1.00; 95% CI, 0.87 to 1.14) and not superior to HandiHaler with respect to the risk of the first exacerbation (Respimat at a dose of 5 μg vs. HandiHaler: hazard ratio, 0.98; 95% CI, 0.93 to 1.03).  Causes of death and incidences of major cardiovascular adverse events were similar in the three groups.  Tiotropium Respimat at a dose of 5 μg or 2.5 μg had a safety profile and exacerbation efficacy similar to those of tiotropium HandiHaler at a dose of 18 μg in patients with COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6TmIvfcAMkbVg90H21EOLACvtfcHk0liwBDJy29WtDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1CgsbzE&md5=a1e7bc0b55c8cd7a8500335331154dfb</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1303342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1303342%26sid%3Dliteratum%253Aachs%26aulast%3DWise%26aufirst%3DR.%2BA.%26aulast%3DAnzueto%26aufirst%3DA.%26aulast%3DCotton%26aufirst%3DD.%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DDevins%26aufirst%3DT.%26aulast%3DDisse%26aufirst%3DB.%26aulast%3DDusser%26aufirst%3DD.%26aulast%3DJoseph%26aufirst%3DE.%26aulast%3DKattenbeck%26aufirst%3DS.%26aulast%3DKoenen-Bergmann%26aufirst%3DM.%26aulast%3DPledger%26aufirst%3DG.%26aulast%3DCalverley%26aufirst%3DP.%26aulast%3D%26atitle%3DTiotropium%2520Respimat%2520inhaler%2520and%2520the%2520risk%2520of%2520death%2520in%2520COPD%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D1491%26epage%3D1501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">Loke, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furberg, C. D.</span><span> </span><span class="NLM_article-title">Tiotropium and the risk of death in COPD</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">480</span><span class="NLM_x">–</span> <span class="NLM_lpage">481</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1056%2FNEJMc1314411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=24476442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFers7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=480-481&author=Y.+K.+Lokeauthor=S.+Singhauthor=C.+D.+Furberg&title=Tiotropium+and+the+risk+of+death+in+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Comment on: tiotropium and the risk of death in COPD</span></div><div class="casAuthors">Loke, Yoon K.; Singh, Sonal; Furberg, Curt D.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">480-482</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUM5bFFhtB37Vg90H21EOLACvtfcHk0li8efZZv8mGVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFers7o%253D&md5=9e69576afa0a8e2b4214436046107347</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1056%2FNEJMc1314411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMc1314411%26sid%3Dliteratum%253Aachs%26aulast%3DLoke%26aufirst%3DY.%2BK.%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DFurberg%26aufirst%3DC.%2BD.%26atitle%3DTiotropium%2520and%2520the%2520risk%2520of%2520death%2520in%2520COPD%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D480%26epage%3D481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group">Kesten, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wentworth, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanes, S.</span><span> </span><span class="NLM_article-title">Pooled clinical trial analysis of tiotropium safety</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">1695</span><span class="NLM_x">–</span> <span class="NLM_lpage">1703</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2006&pages=1695-1703&author=S.+Kestenauthor=M.+Jaraauthor=C.+Wentworthauthor=S.+Lanes&title=Pooled+clinical+trial+analysis+of+tiotropium+safety"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKesten%26aufirst%3DS.%26aulast%3DJara%26aufirst%3DM.%26aulast%3DWentworth%26aufirst%3DC.%26aulast%3DLanes%26aufirst%3DS.%26atitle%3DPooled%2520clinical%2520trial%2520analysis%2520of%2520tiotropium%2520safety%26jtitle%3DChest%26date%3D2006%26volume%3D130%26spage%3D1695%26epage%3D1703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group">Rennard, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ZuWallack, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broughton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisniewski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickard, K.</span><span> </span><span class="NLM_article-title">Use of a long-acting inhaled beta<sub>2</sub>-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">1087</span><span class="NLM_x">–</span> <span class="NLM_lpage">1092</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1164%2Fajrccm.163.5.9903053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=11316640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BD3M3lsFWhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2001&pages=1087-1092&author=S.+I.+Rennardauthor=W.+Andersonauthor=R.+ZuWallackauthor=J.+Broughtonauthor=W.+Baileyauthor=M.+Friedmanauthor=M.+Wisniewskiauthor=K.+Rickard&title=Use+of+a+long-acting+inhaled+beta2-adrenergic+agonist%2C+salmeterol+xinafoate%2C+in+patients+with+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease</span></div><div class="casAuthors">Rennard S I; Anderson W; ZuWallack R; Broughton J; Bailey W; Friedman M; Wisniewski M; Rickard K</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1087-92</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is a condition in which continuous bronchodilation may have clinical advantages.  This study evaluated salmeterol, a beta-agonist bronchodilator with a duration of action substantially longer than that of short-acting beta-agonists, compared with ipratropium, an anticholinergic bronchodilator, and placebo in patients with COPD.  Four hundred and five patients with COPD received either salmeterol 42 microg twice daily, ipratropium bromide 36 microg four times daily, or placebo for 12 wk in this randomized, double-blind, parallel-group study.  Patients were stratified on the basis of bronchodilator response to albuterol (> 12% and > 200-ml improvement) and were randomized within each stratum.  Bronchodilator response was measured over 12 h four times during the treatment period.  Salmeterol provided similar maximal bronchodilatation to ipratropium but had a longer duration of action and a more constant bronchodilatory effect with no evidence of bronchodilator tolerance.  Both active treatments were well tolerated.  Salmeterol was an effective bronchodilator with a consistent effect over this 12-wk study in patients with COPD, including those "unresponsive" to albuterol.  The long duration of action of salmeterol offers the advantage of twice daily dosing compared with the required four times a day dosing with ipratropium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRqa0hIsf6uC86Js-BCLiifW6udTcc2eaG4ihqvvxbO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3lsFWhsg%253D%253D&md5=809a65d0fe109a6999306940abdbe454</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.163.5.9903053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.163.5.9903053%26sid%3Dliteratum%253Aachs%26aulast%3DRennard%26aufirst%3DS.%2BI.%26aulast%3DAnderson%26aufirst%3DW.%26aulast%3DZuWallack%26aufirst%3DR.%26aulast%3DBroughton%26aufirst%3DJ.%26aulast%3DBailey%26aufirst%3DW.%26aulast%3DFriedman%26aufirst%3DM.%26aulast%3DWisniewski%26aufirst%3DM.%26aulast%3DRickard%26aufirst%3DK.%26atitle%3DUse%2520of%2520a%2520long-acting%2520inhaled%2520beta2-adrenergic%2520agonist%252C%2520salmeterol%2520xinafoate%252C%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2001%26volume%3D163%26spage%3D1087%26epage%3D1092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group">Dahl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnussen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonikov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jack, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleasdale, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators</span><span> </span><span class="NLM_article-title">Efficacy of a new once-daily long-acting inhaled β<sub>2</sub>-agonist indacaterol versus twice-daily formoterol in COPD</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">473</span><span class="NLM_x">–</span> <span class="NLM_lpage">479</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2010&pages=473-479&author=R.+Dahlauthor=K.+F.+Chungauthor=R.+Buhlauthor=H.+Magnussenauthor=V.+Nonikovauthor=D.+Jackauthor=P.+Bleasdaleauthor=R.+Owenauthor=M.+Higginsauthor=B.+Kramerauthor=INVOLVE+%28INdacaterol%3A+Value+in+COPD%3A+Longer+Term+Validation+of+Efficacy+and+Safety%29+Study+Investigators&title=Efficacy+of+a+new+once-daily+long-acting+inhaled+%CE%B22-agonist+indacaterol+versus+twice-daily+formoterol+in+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DChung%26aufirst%3DK.%2BF.%26aulast%3DBuhl%26aufirst%3DR.%26aulast%3DMagnussen%26aufirst%3DH.%26aulast%3DNonikov%26aufirst%3DV.%26aulast%3DJack%26aufirst%3DD.%26aulast%3DBleasdale%26aufirst%3DP.%26aulast%3DOwen%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DM.%26aulast%3DKramer%26aufirst%3DB.%26aulast%3D%26atitle%3DEfficacy%2520of%2520a%2520new%2520once-daily%2520long-acting%2520inhaled%2520%25CE%25B22-agonist%2520indacaterol%2520versus%2520twice-daily%2520formoterol%2520in%2520COPD%26jtitle%3DThorax%26date%3D2010%26volume%3D65%26spage%3D473%26epage%3D479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">Feldman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasad, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jack, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piggott, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">INLIGHT 1 Study Group.</span><span> </span><span class="NLM_article-title">Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study</span> <span class="citation_source-journal">BMC Pulm. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1186%2F1471-2466-10-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=20211002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC3c3is1GhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=11&author=G.+Feldmanauthor=T.+Silerauthor=N.+Prasadauthor=D.+Jackauthor=S.+Piggottauthor=R.+Owenauthor=M.+Higginsauthor=B.+Kramerauthor=INLIGHT+1+Study+Group.&title=Efficacy+and+safety+of+indacaterol+150+%CE%BCg+once-daily+in+COPD%3A+a+double-blind%2C+randomised%2C+12-week+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study</span></div><div class="casAuthors">Feldman Gregory; Siler Thomas; Prasad Niyati; Jack Damon; Piggott Simon; Owen Roger; Higgins Mark; Kramer Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">BMC pulmonary medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Indacaterol is a novel, once-daily (o.d.) inhaled, long-acting beta2-agonist in development for chronic obstructive pulmonary disease (COPD).  This 12-week, double-blind study compared the efficacy, safety, and tolerability of indacaterol to that of placebo in patients with moderate-to-severe COPD.  METHODS:  Efficacy variables included 24-h trough FEV1 (mean of 23 h 10 min and 23 h 45 min post-dose) at Week 12 (primary endpoint) and after Day 1, and the percentage of COPD days with poor control (i.e., worsening symptoms).  Safety was assessed by adverse events (AEs), mean serum potassium and blood glucose, QTc (Fridericia), and vital signs.  RESULTS:  Patients were randomised (n = 416, mean age 63 years) to receive either indacaterol 150 microg o.d. (n = 211) or placebo (n = 205) via a single-dose dry-powder inhaler; 87.5% completed the study.  Trough FEV1 (LSM +/- SEM) at Week 12 was 1.48 +/- 0.018 L for indacaterol and 1.35 +/- 0.019 L for placebo, a clinically relevant difference of 130 +/- 24 mL (p < 0.001).  Trough FEV1 after one dose was significantly higher with indacaterol than placebo (p < 0.001).  Indacaterol demonstrated significantly higher peak FEV1 than placebo, both on Day 1 and at Week 12, with indacaterol-placebo differences (LSM +/- SEM) of 190 +/- 28 (p < 0.001) and 160 +/- 28 mL (p < 0.001), respectively.  Standardised AUC measurements for FEV1 (between 5 min and 4 h, 5 min and 1 h, and 1 and 4 h post-dose) at Week 12 were all significantly greater with indacaterol than placebo (p < 0.001), with LSM (+/- SEM) differences of 170 +/- 24, 180 +/- 24, and 170 +/- 24 mL, respectively.  Indacaterol significantly reduced the percentage of days of poor control versus placebo by 22.5% (p < 0.001) and was also associated with significantly reduced use of rescue medication (p < 0.001).  The overall rates of AEs were comparable between the groups (indacaterol 49.3%, placebo 46.8%), with the most common AEs being COPD worsening (indacaterol 8.5%, placebo 12.2%) and cough (indacaterol 6.2%, placebo 7.3%).  One patient died in the placebo group.  Serum potassium and blood glucose levels did not differ significantly between the two groups, and no patient had QTc >500 ms.  CONCLUSIONS:  Indacaterol 150 microg o.d. provided clinically significant and sustained bronchodilation, reduced rescue medication use, and had a safety and tolerability profile similar to placebo.  TRIAL REGISTRATION:  NCT00624286.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR7D6F7dJyM5kkUaC_kzhvyfW6udTcc2ebjA8K_lruHlrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3is1GhtA%253D%253D&md5=0b213dd728e720176f77f4f8c63c8b57</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1186%2F1471-2466-10-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2466-10-11%26sid%3Dliteratum%253Aachs%26aulast%3DFeldman%26aufirst%3DG.%26aulast%3DSiler%26aufirst%3DT.%26aulast%3DPrasad%26aufirst%3DN.%26aulast%3DJack%26aufirst%3DD.%26aulast%3DPiggott%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DM.%26aulast%3DKramer%26aufirst%3DB.%26aulast%3D%26atitle%3DEfficacy%2520and%2520safety%2520of%2520indacaterol%2520150%2520%25CE%25BCg%2520once-daily%2520in%2520COPD%253A%2520a%2520double-blind%252C%2520randomised%252C%252012-week%2520study%26jtitle%3DBMC%2520Pulm.%2520Med.%26date%3D2010%26volume%3D10%26spage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group">Donohue, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogarty, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotval, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahler, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worth, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yorgancioglu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iqbal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swales, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">INHANCE Study Investigators</span><span> </span><span class="NLM_article-title">Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">182</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">162</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1164%2Frccm.200910-1500OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=20463178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyhs7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2010&pages=155-162&author=J.+F.+Donohueauthor=C.+Fogartyauthor=J.+Lotvalauthor=D.+A.+Mahlerauthor=H.+Worthauthor=A.+Yorganciogluauthor=A.+Iqbalauthor=J.+Swalesauthor=R.+Owenauthor=M.+Higginsauthor=B.+Kramerauthor=INHANCE+Study+Investigators&title=Once-daily+bronchodilators+for+chronic+obstructive+pulmonary+disease%3A+indacaterol+versus+tiotropium"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Once-daily bronchodilators for chronic obstructive pulmonary disease indacaterol versus tiotropium</span></div><div class="casAuthors">Donohue, James F.; Fogarty, Charles; Lotvall, Jan; Mahler, Donald A.; Worth, Heinrich; Yorgancioglu, Arzu; Iqbal, Amir; Swales, James; Owen, Roger; Higgins, Mark; Kramer, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">155-162</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Indacaterol is the first once-daily, long-acting inhaled β2-agonist bronchodilator studied in patients with chronic obstructive pulmonary disease (COPD).  Objectives: To demonstrate greater efficacy of indacaterol vs. placebo on FEV1 at 24 h post dose (trough) after 12 wk, to compare efficacy with placebo and tiotropium, and to evaluate safety and tolerability over 26 wk.  Measurements: Patients with moderate-to-severe COPD were randomized to double-blind indacaterol 150 or 300 μg or placebo, or open-label tiotropium 18 μg, all once daily, for 26 wk.  The primary efficacy outcome was trough FEV1 at 12 wk.  Addnl. analyses (not adjusted for multiplicity) included transition dyspnea index (TDI), health status (St George's Respiratory Questionnaire [SGRQ]), and exacerbations.  Serum potassium, blood glucose, and QTc interval were measured.  Results: A total of 1,683 patients (age, 63.3 yr; post-bronchodilator FEV1, 56% predicted; FEV1/FVC, 0.53) were randomized to the four treatment arms.  Trough FEV1 at Week 12 increased vs. placebo by 180 mL with both indacaterol doses and by 140 mL with tiotropium (all P < 0.001 vs. placebo).  At Week 26, for indacaterol 150/300 μg, resp., vs. placebo, TDI increased (1.00/1.18, P < 0.001) and SGRQ total score decreased (-3.3/-2.4, P < 0.01); corresponding results with tiotropium were 0.87 (P < 0.001) for TDI and (-1.0, P = not significant) for SGRQ total score.  The incidence of adverse events, low serum potassium, high blood glucose, and prolonged QTc interval was similar across treatments.  Conclusions: Indacaterol was an effective once-daily bronchodilator and was at least as effective as tiotropium in improving clin. outcomes for patients with COPD.  Clin. trial registered with clinicaltrials.gov (NCT 00463567).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1kzzp0j-0A7Vg90H21EOLACvtfcHk0lgyG8KpCqLooA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyhs7vM&md5=f4d5bae010d002072704b9ab22e08bc0</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1164%2Frccm.200910-1500OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200910-1500OC%26sid%3Dliteratum%253Aachs%26aulast%3DDonohue%26aufirst%3DJ.%2BF.%26aulast%3DFogarty%26aufirst%3DC.%26aulast%3DLotval%26aufirst%3DJ.%26aulast%3DMahler%26aufirst%3DD.%2BA.%26aulast%3DWorth%26aufirst%3DH.%26aulast%3DYorgancioglu%26aufirst%3DA.%26aulast%3DIqbal%26aufirst%3DA.%26aulast%3DSwales%26aufirst%3DJ.%26aulast%3DOwen%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DM.%26aulast%3DKramer%26aufirst%3DB.%26aulast%3D%26atitle%3DOnce-daily%2520bronchodilators%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520indacaterol%2520versus%2520tiotropium%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2010%26volume%3D182%26spage%3D155%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Kornmann, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Centanni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dogra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-μg Doses with COPD Patients) Study Investigators</span><span> </span><span class="NLM_article-title">Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">279</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.00045810" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=20693243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvVeit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2011&pages=273-279&author=O.+Kornmannauthor=R.+Dahlauthor=S.+Centanniauthor=A.+Dograauthor=R.+Owenauthor=C.+Lassenauthor=B.+Kramerauthor=INLIGHT-2+%28Indacaterol+Efficacy+Evaluation+Using+150-%CE%BCg+Doses+with+COPD+Patients%29+Study+Investigators&title=Once-daily+indacaterol+versus+twice-daily+salmeterol+for+COPD%3A+a+placebo-controlled+comparison"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison</span></div><div class="casAuthors">Kornmann, O.; Dahl, R.; Centanni, S.; Dogra, A.; Owen, R.; Lassen, C.; Kramer, B.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">273-279</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β2-agonist bronchodilator recently approved in Europe for the treatment of chronic obstructive pulmonary disease (COPD).  The aim of the present study was to investigate the efficacy and safety of indacaterol compared with placebo and the twice-daily β2-agonist, salmeterol, as an active control.  Patients with moderate-to-severe COPD were randomized to 6 mo double-blind treatment with indacaterol (150 μg once daily), salmeterol (50 μg twice daily) or placebo.  The primary efficacy end-point was trough (24 h post-dose) forced expiratory vol. in 1 s (FEV1) after 12 wk.  1,002 Patients were randomized and 838 (84%) completed the study.  Indacaterol increased trough FEV1 at week 12 by 170 mL over placebo (p<0.001) and by 60 mL over salmeterol (p<0.001).  Both active treatments improved health status (St George's Respiratory Questionnaire) and dyspnea (transition dyspnea index) compared with placebo, with differences between them favoring indacaterol.  Safety profiles were similar across the treatment groups, and both indacaterol and salmeterol were well tolerated.  Once-daily treatment with 150 μg indacaterol had a significant and clin. relevant bronchodilator effect over 24 h post-dose and improved health status and dyspnea to a greater extent than twice-daily 50 μg salmeterol.  Indacaterol should prove a useful addnl. treatment for patients with COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYqMAhhUrstbVg90H21EOLACvtfcHk0lgyG8KpCqLooA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvVeit70%253D&md5=607595eabbabeb233282795b07d0a034</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1183%2F09031936.00045810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00045810%26sid%3Dliteratum%253Aachs%26aulast%3DKornmann%26aufirst%3DO.%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DCentanni%26aufirst%3DS.%26aulast%3DDogra%26aufirst%3DA.%26aulast%3DOwen%26aufirst%3DR.%26aulast%3DLassen%26aufirst%3DC.%26aulast%3DKramer%26aufirst%3DB.%26aulast%3D%26atitle%3DOnce-daily%2520indacaterol%2520versus%2520twice-daily%2520salmeterol%2520for%2520COPD%253A%2520a%2520placebo-controlled%2520comparison%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2011%26volume%3D37%26spage%3D273%26epage%3D279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group">Calverley, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boonsawat, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cseke, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsson, H.</span><span> </span><span class="NLM_article-title">Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">912</span><span class="NLM_x">–</span> <span class="NLM_lpage">919</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.03.00027003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=14680078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVOkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=912-919&author=P.+M.+Calverleyauthor=W.+Boonsawatauthor=Z.+Csekeauthor=N.+Zhongauthor=S.+Petersonauthor=H.+Olsson&title=Maintenance+therapy+with+budesonide+and+formoterol+in+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Calverley, P. M.; Boonsawat, W.; Cseke, Z.; Zhong, N.; Peterson, S.; Olsson, H.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">912-919</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Lung function in chronic obstructive pulmonary disease (COPD) can be improved acutely by oral corticosteroids and bronchodilators.  Whether clin. improvement can be maintained by subsequent inhaled therapy is unknown.  COPD patients (n=1022, mean prebronchodilator forced expiratory vol. in one second (FEV1) 36% predicted) initially received formoterol (9 μg b.i.d.) and oral prednisolone (30 mg o.d.) for 2 wk.  After this time, patients were randomised to b.i.d. inhaled budesonide/formoterol 320/9 μg, budesonide 400 μg, formoterol 9 μg or placebo for 12 mo.  Postmedication FEV1 improved by 0.21 L and health-related quality of life using the St George's Respiratory Questionnaire (SGRQ) by 4.5 units after run-in.  Fewer patients receiving budesonide/formoterol withdrew from the study than those receiving budesonide, formoterol or placebo.  Budesonide/formoterol patients had a prolonged time to first exacerbation (254 vs. 96 days) and maintained higher FEV1 (99% vs. 87% of baseline), both primary variables vs. placebo.  They had fewer exacerbations (1.38 vs. 1.80 exacerbations per patient per yr), had higher prebronchodilator peak expiratory flow, and showed clin. relevant improvements in SGRQ vs. placebo (-7.5 units).  Budesonide/formoterol was more effective than either monocomponent in both primary variables.  Budesonide/formoterol in a single inhaler Symbicort maintains the benefit of treatment optimization, stabilizing lung function and delaying exacerbations more effectively than either component drug alone or placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTZnDora5DRrVg90H21EOLACvtfcHk0liCLryXHX4Szg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVOkuw%253D%253D&md5=7aefd2fe0a63057a29cfa3f5f9932897</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1183%2F09031936.03.00027003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.03.00027003%26sid%3Dliteratum%253Aachs%26aulast%3DCalverley%26aufirst%3DP.%2BM.%26aulast%3DBoonsawat%26aufirst%3DW.%26aulast%3DCseke%26aufirst%3DZ.%26aulast%3DZhong%26aufirst%3DN.%26aulast%3DPeterson%26aufirst%3DS.%26aulast%3DOlsson%26aufirst%3DH.%26atitle%3DMaintenance%2520therapy%2520with%2520budesonide%2520and%2520formoterol%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2003%26volume%3D22%26spage%3D912%26epage%3D919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">Calverley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauwels, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vestbo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pride, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulsvik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">TRial of Inhaled STeroids ANd long-acting β<sub>2</sub> agonists study group</span><span> </span><span class="NLM_article-title">Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">449</span><span class="NLM_x">–</span> <span class="NLM_lpage">456</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2003&pages=449-456&author=P.+Calverleyauthor=R.+Pauwelsauthor=J.+Vestboauthor=P.+Jonesauthor=N.+Prideauthor=A.+Gulsvikauthor=J.+Andersonauthor=C.+Madenauthor=TRial+of+Inhaled+STeroids+ANd+long-acting+%CE%B22+agonists+study+group&title=Combined+salmeterol+and+fluticasone+in+the+treatment+of+chronic+obstructive+pulmonary+disease%3A+a+randomised+controlled+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCalverley%26aufirst%3DP.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DVestbo%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DPride%26aufirst%3DN.%26aulast%3DGulsvik%26aufirst%3DA.%26aulast%3DAnderson%26aufirst%3DJ.%26aulast%3DMaden%26aufirst%3DC.%26aulast%3D%26atitle%3DCombined%2520salmeterol%2520and%2520fluticasone%2520in%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2003%26volume%3D361%26spage%3D449%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Gross, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapidus, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rinehart, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denis-Mize, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Formoterol Study Group.</span><span> </span><span class="NLM_article-title">Efficacy and safety of formoterol fumarate delivered by nebulisation to COPD patients</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">189</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2007.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=18363201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BD1c3gsVGnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2008&pages=189-197&author=N.+J.+Grossauthor=H.+S.+Nelsonauthor=R.+J.+Lapidusauthor=L.+Dunnauthor=L.+Lynnauthor=M.+Rinehartauthor=K.+Denis-Mizeauthor=Formoterol+Study+Group.&title=Efficacy+and+safety+of+formoterol+fumarate+delivered+by+nebulisation+to+COPD+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients</span></div><div class="casAuthors">Gross Nicholas J; Nelson Harold S; Lapidus Robert J; Dunn Leonard; Lynn Lon; Rinehart Mike; Denis-Mize Kimberly</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">189-97</span>
        ISSN:<span class="NLM_cas:issn">0954-6111</span>.
    </div><div class="casAbstract">Nebulized solutions of long-acting bronchodilators provide an alternative to DPI and MDI delivery, particularly for COPD patients unable to use hand-held devices easily or correctly.  The long-acting beta2-agonist, formoterol fumarate, is differentiated by its onset of significant bronchodilation within 5 min of administration.  In a randomized, double-blind, double-dummy trial, COPD subjects (n=351, mean forced expiratory volume FEV1=1.3 L, 44% predicted) received nebulized formoterol fumarate (Perforomist inhalation solution; FFIS 20 microg) or DPI (Foradil Aerolizer; FA 12 microg), or placebo twice daily for 12 weeks.  Efficacy was assessed with 12-h pulmonary function tests, and quality of life was assessed before and after treatment with the St.  George's Respiratory Questionnaire (SGRQ).  At the 12-week endpoint, FFIS significantly increased FEV1 AUC0-12h relative to placebo (p<0.0001).  No evidence of tachyphylaxis was observed as indicated by maintained FEV1 AUC and reduced rescue albuterol use throughout treatment.  FFIS also significantly increased peak FEV1, trough FEV1, and standardized FVC AUC0-12h compared with placebo.  SGRQ assessment at Week 12 demonstrated significant and clinically meaningful improvements in total score (FFIS vs placebo, -4.9, p=0.0067), symptom, and impact scores.  No significant differences in efficacy were observed between the two active treatments.  Drug related AEs in the FFIS arm with a frequency > or = 1% and exceeding placebo were dry mouth, nausea, and insomnia.  Nebulized FFIS provided significant improvement in respiratory status and quality of life in subjects with COPD relative to placebo and was well tolerated.  The efficacy and safety profile of FFIS was comparable to FA DPI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0GddEhWAH9P_I8Jvzw4xCfW6udTcc2eZlavbZNFT7kbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3gsVGnsA%253D%253D&md5=65786022d39bf93d2520508e1298511e</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2007.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2007.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DGross%26aufirst%3DN.%2BJ.%26aulast%3DNelson%26aufirst%3DH.%2BS.%26aulast%3DLapidus%26aufirst%3DR.%2BJ.%26aulast%3DDunn%26aufirst%3DL.%26aulast%3DLynn%26aufirst%3DL.%26aulast%3DRinehart%26aufirst%3DM.%26aulast%3DDenis-Mize%26aufirst%3DK.%26aulast%3D%26atitle%3DEfficacy%2520and%2520safety%2520of%2520formoterol%2520fumarate%2520delivered%2520by%2520nebulisation%2520to%2520COPD%2520patients%26jtitle%3DRespir.%2520Med.%26date%3D2008%26volume%3D102%26spage%3D189%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">Neder, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuld, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overend, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thirlwell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. A.</span><span> </span><span class="NLM_article-title">Effects of formoterol on exercise tolerance in severely disabled patients with COPD</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">2056</span><span class="NLM_x">–</span> <span class="NLM_lpage">2064</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2007.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=17658249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BD2srisVWisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2007&pages=2056-2064&author=J.+A.+Nederauthor=J.+P.+Fuldauthor=T.+Overendauthor=J.+Thirlwellauthor=R.+Carterauthor=R.+Stevensonauthor=S.+A.+Ward&title=Effects+of+formoterol+on+exercise+tolerance+in+severely+disabled+patients+with+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of formoterol on exercise tolerance in severely disabled patients with COPD</span></div><div class="casAuthors">Neder J Alberto; Fuld Jonathan P; Overend Tim; Thirlwell Jackie; Carter Roger; Stevenson Robin; Ward Susan A</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2056-64</span>
        ISSN:<span class="NLM_cas:issn">0954-6111</span>.
    </div><div class="casAbstract">OBJECTIVE:  We wished to evaluate the effects of inhaled formoterol, a long-acting beta(2)-adrenergic agonist, on exercise tolerance and dynamic hyperinflation (DH) in severely disabled chronic obstructive pulmonary disease (COPD) patients.  DESIGN:  In a two-period, crossover study, 21 patients with advanced COPD (FEV(1)=38.8+/-11.7% predicted, 16 patients GOLD stages III-IV) were randomly allocated to receive inhaled formoterol fumarate 12 microg twice daily for 14 days followed by placebo for 14 days, or vice versa.  Patients performed constant work-rate cardiopulmonary exercise tests to the limit of tolerance (Tlim) on a cycle ergometer: inspiratory capacity (IC) was obtained at rest and each minute during exercise.  Baseline and transitional dyspnoea indices (BDI and TDI) were also recorded.  RESULTS:  Eighteen patients completed both treatment periods.  Formoterol treatment was associated with an estimated increase of 130 s in Tlim compared with placebo (P=0.052): this corresponded to a 37.8% improvement over placebo (P=0.012).  Enhanced exercise tolerance after bronchodilator was associated with diminished DH marked by higher inspiratory reserve and tidal volumes at isotime and exercise cessation (P<0.05).  There was no significant difference between formoterol and placebo on exercise dyspnoea ratings; however, all domains of the TDI improved (P<or=0.02) following formoterol, compared with placebo.  CONCLUSION:  Inhaled formoterol 12 microg twice daily is effective in ameliorating DH, daily dyspnoea and exercise intolerance even in patients with advanced COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQsSN0eieM27rjnyZkbE8yXfW6udTcc2eaFkJDSuLyNVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srisVWisg%253D%253D&md5=8c56f131560774fbcdf2a8896773b06e</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2007.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2007.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DNeder%26aufirst%3DJ.%2BA.%26aulast%3DFuld%26aufirst%3DJ.%2BP.%26aulast%3DOverend%26aufirst%3DT.%26aulast%3DThirlwell%26aufirst%3DJ.%26aulast%3DCarter%26aufirst%3DR.%26aulast%3DStevenson%26aufirst%3DR.%26aulast%3DWard%26aufirst%3DS.%2BA.%26atitle%3DEffects%2520of%2520formoterol%2520on%2520exercise%2520tolerance%2520in%2520severely%2520disabled%2520patients%2520with%2520COPD%26jtitle%3DRespir.%2520Med.%26date%3D2007%26volume%3D101%26spage%3D2056%26epage%3D2064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">O’Donnell, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voduc, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzpatrick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, K. A.</span><span> </span><span class="NLM_article-title">Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">86</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.04.00072703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=15293609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmsVanu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=86-94&author=D.+E.+O%E2%80%99Donnellauthor=N.+Voducauthor=M.+Fitzpatrickauthor=K.+A.+Webb&title=Effect+of+salmeterol+on+the+ventilatory+response+to+exercise+in+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease</span></div><div class="casAuthors">O'Donnell, D. E.; Voduc, N.; Fitzpatrick, M.; Webb, K. A.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-94</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">This study examd. the effects of bronchodilator-induced redns. in lung hyperinflation on breathing pattern, ventilation and dyspnoea during exercise in chronic obstructive pulmonary disease (COPD).  Quant. tidal flow/vol. loop anal. was used to evaluate abnormalities in dynamic ventilatory mechanics and their manipulation by a bronchodilator.  In a randomized double-blind crossover study, 23 patients with COPD (mean±SEM forced expiratory vol. in one second 42±3% of the predicted value) inhaled salmeterol 50 μg or placebo twice daily for 2 wk each.  After each treatment period, 2 h after dose, patients performed pulmonary function tests and symptom-limited cycle exercise at 75% of their maximal work-rate.  After salmeterol vs. placebo at rest, vol.-cor. maximal expiratory flow rates increased by 175±52%, inspiratory capacity (IC) increased by 11±2% pred and functional residual capacity decreased by 11±3% pred.  At a standardized time during exercise, salmeterol increased IC, tidal vol. (VT), mean inspiratory and expiratory flows, ventilation, oxygen uptake (V'O2) and carbon dioxide output.  Salmeterol increased peak exercise endurance, V'O2 and ventilation by 58±19, 8±3 and 12±3%, resp.  Improvements in peak V'O2 correlated best with increases in peak VT; increases in peak VT and resting IC were interrelated.  The redn. in dyspnoea ratings at a standardized time correlated with the increased VT.  Mech. factors play an important role in shaping the ventilatory response to exercise in chronic obstructive pulmonary disease.  Bronchodilator-induced lung deflation reduced mech. restriction, increased ventilatory capacity and decreased respiratory discomfort, thereby increasing exercise endurance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_Pf8mlxOpprVg90H21EOLACvtfcHk0lg45SROc5_ixw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmsVanu74%253D&md5=fdc24d4f348a1662910926817e151492</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1183%2F09031936.04.00072703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.04.00072703%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DD.%2BE.%26aulast%3DVoduc%26aufirst%3DN.%26aulast%3DFitzpatrick%26aufirst%3DM.%26aulast%3DWebb%26aufirst%3DK.%2BA.%26atitle%3DEffect%2520of%2520salmeterol%2520on%2520the%2520ventilatory%2520response%2520to%2520exercise%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2004%26volume%3D24%26spage%3D86%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group">Cooper, C. B.</span><span> </span><span class="NLM_article-title">The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function</span> <span class="citation_source-journal">Am. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">S21</span><span class="NLM_x">–</span> <span class="NLM_lpage">S31</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2006&pages=S21-S31&author=C.+B.+Cooper&title=The+connection+between+chronic+obstructive+pulmonary+disease+symptoms+and+hyperinflation+and+its+impact+on+exercise+and+function"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DC.%2BB.%26atitle%3DThe%2520connection%2520between%2520chronic%2520obstructive%2520pulmonary%2520disease%2520symptoms%2520and%2520hyperinflation%2520and%2520its%2520impact%2520on%2520exercise%2520and%2520function%26jtitle%3DAm.%2520J.%2520Med.%26date%3D2006%26volume%3D119%26spage%3DS21%26epage%3DS31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group">Donohue, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Noord, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bateman, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witek, T. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towse, L.</span><span> </span><span class="NLM_article-title">A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2002&pages=47-55&author=J.+F.+Donohueauthor=J.+A.+van+Noordauthor=E.+D.+Batemanauthor=S.+J.+Langleyauthor=A.+Leeauthor=T.+J.+Witekauthor=S.+Kestenauthor=L.+Towse&title=A+6-month%2C+placebo-controlled+study+comparing+lung+function+and+health+status+changes+in+COPD+patients+treated+with+tiotropium+or+salmeterol"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDonohue%26aufirst%3DJ.%2BF.%26aulast%3Dvan%2BNoord%26aufirst%3DJ.%2BA.%26aulast%3DBateman%26aufirst%3DE.%2BD.%26aulast%3DLangley%26aufirst%3DS.%2BJ.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DWitek%26aufirst%3DT.%2BJ.%26aulast%3DKesten%26aufirst%3DS.%26aulast%3DTowse%26aufirst%3DL.%26atitle%3DA%25206-month%252C%2520placebo-controlled%2520study%2520comparing%2520lung%2520function%2520and%2520health%2520status%2520changes%2520in%2520COPD%2520patients%2520treated%2520with%2520tiotropium%2520or%2520salmeterol%26jtitle%3DChest%26date%3D2002%26volume%3D122%26spage%3D47%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">Rodrigo, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nannini, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodríguez-Roisin, R.</span><span> </span><span class="NLM_article-title">Safety of long-acting β-agonists in stable COPD. A systematic review</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">1079</span><span class="NLM_x">–</span> <span class="NLM_lpage">1087</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2008&pages=1079-1087&author=G.+J.+Rodrigoauthor=L.+J.+Nanniniauthor=R.+Rodr%C3%ADguez-Roisin&title=Safety+of+long-acting+%CE%B2-agonists+in+stable+COPD.+A+systematic+review"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigo%26aufirst%3DG.%2BJ.%26aulast%3DNannini%26aufirst%3DL.%2BJ.%26aulast%3DRodr%25C3%25ADguez-Roisin%26aufirst%3DR.%26atitle%3DSafety%2520of%2520long-acting%2520%25CE%25B2-agonists%2520in%2520stable%2520COPD.%2520A%2520systematic%2520review%26jtitle%3DChest%26date%3D2008%26volume%3D133%26spage%3D1079%26epage%3D1087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group">Baker, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, C. I.</span><span> </span><span class="NLM_article-title">Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed treatment comparison meta-analysis</span> <span class="citation_source-journal">Pharmacotherapy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">891</span><span class="NLM_x">–</span> <span class="NLM_lpage">905</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2009&pages=891-905&author=W.+L.+Bakerauthor=E.+L.+Bakerauthor=C.+I.+Coleman&title=Pharmacologic+treatments+for+chronic+obstructive+pulmonary+disease%3A+a+mixed+treatment+comparison+meta-analysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DW.%2BL.%26aulast%3DBaker%26aufirst%3DE.%2BL.%26aulast%3DColeman%26aufirst%3DC.%2BI.%26atitle%3DPharmacologic%2520treatments%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520mixed%2520treatment%2520comparison%2520meta-analysis%26jtitle%3DPharmacotherapy%26date%3D2009%26volume%3D29%26spage%3D891%26epage%3D905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Kliber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynd, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, D. D.</span><span> </span><span class="NLM_article-title">The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Respir. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1186%2F1465-9921-11-56" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=20459831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC3czmt1SitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=56&author=A.+Kliberauthor=L.+D.+Lyndauthor=D.+D.+Sin&title=The+effects+of+long-acting+bronchodilators+on+total+mortality+in+patients+with+stable+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease</span></div><div class="casAuthors">Kliber Agnes; Lynd Larry D; Sin Don D</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">56</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Chronic obstructive pulmonary disease (COPD) is the 4th leading cause of mortality worldwide.  Long-acting bronchodilators are considered first line therapies for patients with COPD but their effects on mortality are not well known.  We performed a comprehensive systematic review and meta-analysis to evaluate the effects of long-acting bronchodilators on total mortality in stable COPD.  METHODS:  Using MEDLINE, EMBASE and Cochrane Systematic Review databases, we identified high quality randomized controlled trials of tiotropium, formoterol, salmeterol, formoterol/budesonide or salmeterol/fluticasone in COPD that had a follow-up of 6 months or longer and reported on total mortality.  Two reviewers independently abstracted data from the original trials and disagreements were resolved by iteration and consensus.  RESULTS:  Twenty-seven trials that included 30,495 patients were included in the review.  Relative risk (RR) for total mortality was calculated for each of the study and pooled together using a random-effects model.  The combination of inhaled corticosteroid (ICS) and long-acting beta-2 agonist (LABA) therapy was associated with reduced total mortality compared with placebo (RR, 0.80; p = 0.005).  Neither tiotropium (RR, 1.08; p = 0.61) nor LABA by itself (RR, 0.90; p = 0.21) was associated with mortality.  CONCLUSIONS:  A combination of ICS and LABA reduced mortality by approximately 20%.  Neither tiotropium nor LABA by itself modifies all-cause mortality in COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQftyzQKYKgJYNpW7w2tapOfW6udTcc2eYBCuJxgL04Dbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czmt1SitA%253D%253D&md5=4a9a87b48816102a21d9e3ef0148cc5c</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-11-56&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-11-56%26sid%3Dliteratum%253Aachs%26aulast%3DKliber%26aufirst%3DA.%26aulast%3DLynd%26aufirst%3DL.%2BD.%26aulast%3DSin%26aufirst%3DD.%2BD.%26atitle%3DThe%2520effects%2520of%2520long-acting%2520bronchodilators%2520on%2520total%2520mortality%2520in%2520patients%2520with%2520stable%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DRespir.%2520Res.%26date%3D2010%26volume%3D11%26spage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Nannini, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasserson, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poole, P.</span><span> </span><span class="NLM_article-title">Combined corticosteroid and long-acting beta<sub>2</sub>-agonist in one inhaler versus long-acting beta<sub>2</sub>-agonists for chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Cochrane Database Syst. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">CD006829</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=CD006829&author=L.+J.+Nanniniauthor=T.+J.+Lassersonauthor=P.+Poole&title=Combined+corticosteroid+and+long-acting+beta2-agonist+in+one+inhaler+versus+long-acting+beta2-agonists+for+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNannini%26aufirst%3DL.%2BJ.%26aulast%3DLasserson%26aufirst%3DT.%2BJ.%26aulast%3DPoole%26aufirst%3DP.%26atitle%3DCombined%2520corticosteroid%2520and%2520long-acting%2520beta2-agonist%2520in%2520one%2520inhaler%2520versus%2520long-acting%2520beta2-agonists%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2012%26volume%3D9%26spage%3DCD006829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group">Appleton, S.; Poole, P.; Smith, B. J.; Veale, A.; Lasserson, T. J.; Chan, M. M.; Cates, C. J.</span><span> </span><span class="NLM_article-title">Long-acting beta<sub>2</sub>-agonists or poorly reversible chronic obstructive pulmonary disease</span>.  <span class="citation_source-journal">Cochrane Libr.</span> Published Online: 19 July 2006. DOI:<span class="refDoi"> DOI: 10.1002/14651858.CD001104.pub2</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1002%2F14651858.CD001104.pub2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Appleton%2C+S.%3B+Poole%2C+P.%3B+Smith%2C+B.+J.%3B+Veale%2C+A.%3B+Lasserson%2C+T.+J.%3B+Chan%2C+M.+M.%3B+Cates%2C+C.+J.+Long-acting+beta2-agonists+or+poorly+reversible+chronic+obstructive+pulmonary+disease.+Cochrane+Libr.+Published+Online%3A+19+July+2006.+DOI%3A+10.1002%2F14651858.CD001104.pub2."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD001104.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD001104.pub2%26sid%3Dliteratum%253Aachs%26aulast%3DAppleton%26aufirst%3DS.%26atitle%3DLong-acting%2520beta2-agonists%2520or%2520poorly%2520reversible%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DCochrane%2520Libr.%26doi%3D10.1002%2F14651858.CD001104.pub2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Calverley, P. M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yates, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vestbo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">TORCH Investigators.</span><span> </span><span class="NLM_article-title">Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease</span> <span class="citation_source-journal">N. Eng. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">775</span><span class="NLM_x">–</span> <span class="NLM_lpage">789</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1056%2FNEJMoa063070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=17314337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvFKltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=775-789&author=P.+M.+A.+Calverleyauthor=J.+A.+Andersonauthor=B.+Celliauthor=G.+T.+Fergusonauthor=C.+Jenkinsauthor=P.+W.+Jonesauthor=J.+C.+Yatesauthor=J.+Vestboauthor=TORCH+Investigators.&title=Salmeterol+and+fluticasone+propionate+and+survival+in+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Calverley, Peter M. A.; Anderson, Julie A.; Celli, Bartolome; Ferguson, Gary T.; Jenkins, Christine; Jones, Paul W.; Yates, Julie C.; Vestbo, Jorgen</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">775-789</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Long-acting β-agonists and inhaled corticosteroids are used to treat chronic obstructive pulmonary disease (COPD), but their effect on survival is unknown.  We conducted a randomized, double-blind trial comparing salmeterol at a dose of 50 μg plus fluticasone propionate at a dose of 500 μg twice daily (combination regimen), administered with a single inhaler, with placebo, salmeterol alone, or fluticasone propionate alone for a period of 3 years.  The primary outcome was death from any cause for the comparison between the combination regimen and placebo; the frequency of exacerbations, health status, and spirometric values were also assessed.  Of 6112 patients in the efficacy population, 875 died within 3 years after the start of the study treatment.  All-cause mortality rates were 12.6% in the combination-therapy group, 15.2% in the placebo group, 13.5% in the salmeterol group, and 16.0% in the fluticasone group.  The hazard ratio for death in the combination-therapy group, as compared with the placebo group, was 0.825 (95% confidence interval [CI], 0.681 to 1.002; P = 0.052, adjusted for the interim analyses), corresponding to a difference of 2.6 percentage points or a redn. in the risk of death of 17.5%.  The mortality rate for salmeterol alone or fluticasone propionate alone did not differ significantly from that for placebo.  As compared with placebo, the combination regimen reduced the annual rate of exacerbations from 1.13 to 0.85 and improved health status and spirometric values.  There was no difference in the incidence of ocular or bone side effects.  The probability of having pneumonia reported as an adverse event was higher among patients receiving medications contg. fluticasone propionate (19.6% in the combination-therapy group and 18.3% in the fluticasone group) than in the placebo group (12.3%).  The redn. in death from all causes among patients with COPD in the combination-therapy group did not reach the predetd. level of statistical significance.  There were significant benefits in all other outcomes among these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCgp-k1GZ8D7Vg90H21EOLACvtfcHk0limSPaXczcUTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvFKltL0%253D&md5=4ad1e46b0908dbc6318ad9a3c82353ef</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa063070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa063070%26sid%3Dliteratum%253Aachs%26aulast%3DCalverley%26aufirst%3DP.%2BM.%2BA.%26aulast%3DAnderson%26aufirst%3DJ.%2BA.%26aulast%3DCelli%26aufirst%3DB.%26aulast%3DFerguson%26aufirst%3DG.%2BT.%26aulast%3DJenkins%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DP.%2BW.%26aulast%3DYates%26aufirst%3DJ.%2BC.%26aulast%3DVestbo%26aufirst%3DJ.%26aulast%3D%26atitle%3DSalmeterol%2520and%2520fluticasone%2520propionate%2520and%2520survival%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DN.%2520Eng.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D775%26epage%3D789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">Celli, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vestbo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knobil, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yates, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calverley, P. M.</span><span> </span><span class="NLM_article-title">Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">178</span><span class="NLM_x">, </span> <span class="NLM_fpage">332</span><span class="NLM_x">–</span> <span class="NLM_lpage">338</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1164%2Frccm.200712-1869OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=18511702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BD1cvpt1Sksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2008&pages=332-338&author=B.+R.+Celliauthor=N.+E.+Thomasauthor=J.+A.+Andersonauthor=G.+T.+Fergusonauthor=C.+R.+Jenkinsauthor=P.+W.+Jonesauthor=J.+Vestboauthor=K.+Knobilauthor=J.+C.+Yatesauthor=P.+M.+Calverley&title=Effect+of+pharmacotherapy+on+rate+of+decline+of+lung+function+in+chronic+obstructive+pulmonary+disease%3A+results+from+the+TORCH+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study</span></div><div class="casAuthors">Celli Bartolome R; Thomas Nicola E; Anderson Julie A; Ferguson Gary T; Jenkins Christine R; Jones Paul W; Vestbo Jorgen; Knobil Katharine; Yates Julie C; Calverley Peter M A</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">332-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RATIONALE:  Chronic obstructive pulmonary disease (COPD) is characterized by an accelerated decline in lung function.  No drug has been shown conclusively to reduce this decline.  OBJECTIVES:  In a post hoc analysis of the Toward a Revolution in COPD Health (TORCH) study, we investigated the effects of combined salmeterol 50 microg plus fluticasone propionate 500 microg, either component alone or placebo, on the rate of post-bronchodilator FEV(1) decline in patients with moderate or severe COPD.  METHODS:  A randomized, double-blind, placebo-controlled study was conducted from September 2000 to November 2005 in 42 countries.  Of 6,112 patients from the efficacy population, 5,343 were included in this analysis.  MEASUREMENTS AND MAIN RESULTS:  Spirometry was measured every 24 weeks for 3 years.  There were 26,539 on-treatment observations.  The adjusted rate of decline in FEV(1) was 55 ml/year for placebo, 42 ml/year for salmeterol, 42 ml/year for fluticasone propionate, and 39 ml/year for salmeterol plus fluticasone propionate.  Salmeterol plus fluticasone propionate reduced the rate of FEV(1) decline by 16 ml/year compared with placebo (95% confidence interval [CI], 7-25; P < 0.001).  The difference was smaller for fluticasone propionate and salmeterol compared with placebo (13 ml/year; 95% CI, 5-22; P = 0.003).  Rates of decline were similar among the active treatment arms.  FEV(1) declined faster in current smokers and patients with a lower body mass index, and varied between world regions.  Patients who exacerbated more frequently had a faster FEV(1) decline.  CONCLUSIONS:  Pharmacotherapy with salmeterol plus fluticasone propionate, or the components, reduces the rate of decline of FEV(1) in patients with moderate-to-severe COPD, thus slowing disease progression.  Clinical trial (GSK Study Code SCO30003) registered with www.clinicaltrials.gov (NCT00268216).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRFg-vMUBak3EwlCcfExbvbfW6udTcc2eZ380oBeRrHUbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvpt1Sksg%253D%253D&md5=e52d6a4d1be9ab8c751e2e20b253e76b</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1164%2Frccm.200712-1869OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200712-1869OC%26sid%3Dliteratum%253Aachs%26aulast%3DCelli%26aufirst%3DB.%2BR.%26aulast%3DThomas%26aufirst%3DN.%2BE.%26aulast%3DAnderson%26aufirst%3DJ.%2BA.%26aulast%3DFerguson%26aufirst%3DG.%2BT.%26aulast%3DJenkins%26aufirst%3DC.%2BR.%26aulast%3DJones%26aufirst%3DP.%2BW.%26aulast%3DVestbo%26aufirst%3DJ.%26aulast%3DKnobil%26aufirst%3DK.%26aulast%3DYates%26aufirst%3DJ.%2BC.%26aulast%3DCalverley%26aufirst%3DP.%2BM.%26atitle%3DEffect%2520of%2520pharmacotherapy%2520on%2520rate%2520of%2520decline%2520of%2520lung%2520function%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520results%2520from%2520the%2520TORCH%2520study%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2008%26volume%3D178%26spage%3D332%26epage%3D338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group">Nannini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cates, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasserson, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poole, P.</span><span> </span><span class="NLM_article-title">Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Cochrane Database Syst. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">CD003794</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=CD003794&author=L.+Nanniniauthor=C.+J.+Catesauthor=T.+J.+Lassersonauthor=P.+Poole&title=Combined+corticosteroid+and+long-acting+beta-agonist+in+one+inhaler+versus+placebo+for+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNannini%26aufirst%3DL.%26aulast%3DCates%26aufirst%3DC.%2BJ.%26aulast%3DLasserson%26aufirst%3DT.%2BJ.%26aulast%3DPoole%26aufirst%3DP.%26atitle%3DCombined%2520corticosteroid%2520and%2520long-acting%2520beta-agonist%2520in%2520one%2520inhaler%2520versus%2520placebo%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2007%26volume%3D4%26spage%3DCD003794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Campbell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eliraz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tornling, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nihlén, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bengtsson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabe, K. F.</span><span> </span><span class="NLM_article-title">Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">1511</span><span class="NLM_x">–</span> <span class="NLM_lpage">1520</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2005.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=16199148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BD2MnhsVWhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2005&pages=1511-1520&author=M.+Campbellauthor=A.+Elirazauthor=G.+Johanssonauthor=G.+Tornlingauthor=U.+Nihl%C3%A9nauthor=T.+Bengtssonauthor=K.+F.+Rabe&title=Formoterol+for+maintenance+and+as-needed+treatment+of+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Campbell Malcolm; Eliraz Abraham; Johansson Gunnar; Tornling Goran; Nihlen Ulf; Bengtsson Thomas; Rabe Klaus F</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1511-20</span>
        ISSN:<span class="NLM_cas:issn">0954-6111</span>.
    </div><div class="casAbstract">Formoterol is a long-acting beta2-agonist with a rapid onset of effect in patients with chronic obstructive pulmonary disease (COPD), making it potentially suitable for both maintenance and as-needed bronchodilator treatment.  To evaluate the efficacy and tolerability of maintenance formoterol in patients with COPD and to compare the effects of additional formoterol as needed with terbutaline.  In this 6-month, double-blind study, 657 patients with COPD (40 years, forced expiratory volume in 1s [FEV1] 40-70% predicted normal) were randomized to formoterol 9 microg twice daily (bid) plus terbutaline 0.5 mg as needed (FORM bid), formoterol 9 microg bid plus formoterol 4.5 microg as needed (FORM bid+prn), or placebo bid plus terbutaline 0.5 mg as needed (placebo), all administered via Turbuhaler.  Primary efficacy variables were FEV1 and the sum of breathlessness and chest tightness scores combined symptom score.  Formoterol significantly (P<0.01) increased FEV(1) compared with placebo: FORM bid 6.5% (95% CI: 2.5, 10.7%); FORM bid+prn 11.8% (95% CI: 7.7, 16.2%).  Combined symptom score decreased significantly in both formoterol groups compared with placebo: FORM bid -0.27 (95% CI: -0.49, -0.06; P=0.012); FORM bid+prn -0.32 (95% CI: -0.53, -0.11; P=0.0026).  Similar significant (P<0.05) improvements were seen in both formoterol groups for morning peak expiratory flow, cough and sleep scores, and reliever use.  In this study, formoterol 9 microg bid via Turbuhaler as maintenance therapy, with either formoterol or terbutaline as rescue medication, provided sustained improvements in lung function and COPD symptoms.  Both formoterol regimens were well tolerated with no differences in adverse events or electrocardiogram profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRA_zOkMScMATdblLE_E9PWfW6udTcc2eZ380oBeRrHUbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnhsVWhsw%253D%253D&md5=8bb1da86e7d852d1266b98859069d0bb</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2005.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2005.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DEliraz%26aufirst%3DA.%26aulast%3DJohansson%26aufirst%3DG.%26aulast%3DTornling%26aufirst%3DG.%26aulast%3DNihl%25C3%25A9n%26aufirst%3DU.%26aulast%3DBengtsson%26aufirst%3DT.%26aulast%3DRabe%26aufirst%3DK.%2BF.%26atitle%3DFormoterol%2520for%2520maintenance%2520and%2520as-needed%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DRespir.%2520Med.%26date%3D2005%26volume%3D99%26spage%3D1511%26epage%3D1520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group">Szafranski, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cukier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramirez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menga, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sansores, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nahabedian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsson, H.</span><span> </span><span class="NLM_article-title">Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">74</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.03.00031402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=12570112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsFahu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=74-81&author=W.+Szafranskiauthor=A.+Cukierauthor=A.+Ramirezauthor=G.+Mengaauthor=R.+Sansoresauthor=S.+Nahabedianauthor=S.+Petersonauthor=H.+Olsson&title=Efficacy+and+safety+of+budesonide%2Fformoterol+in+the+management+of+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Szafranski, W.; Cukier, A.; Ramirez, A.; Menga, G.; Sansores, R.; Nahabedian, S.; Peterson, S.; Olsson, H.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-81</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">The efficacy and safety of budesonide/formoterol in a single inhaler compared with placebo, budesonide and formoterol were evaluated in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).  In a 12-mo, randomized, double-blind, placebo-controlled, parallel-group study in 812 adults (mean age 64 yrs, mean forced expiratory vol. in one second (FEV1) 36% predicted normal), patients received two inhalations twice daily of either budesonide/formoterol (Symbicort) 160/4.5 μg (delivered dose), budesonide 200 μg (metered dose), formoterol 4.5 μg or placebo.  Severe exacerbations and FEV1 (primary variables), peak expiratory flow (PEF), COPD symptoms, health-related quality of life (HRQL), mild exacerbations, use of reliever β2-agonist and safety variables were recorded.  Budesonide/formoterol reduced the mean no. of severe exacerbations per patient per yr by 24% vs. placebo and 23% vs. formoterol.  FEV1 increased by 15% vs. placebo and 9% vs. budesonide.  Morning PEF improved significantly on day 1 vs. placebo and budesonide; after 1 wk, morning PEF was improved vs. placebo, budesonide and formoterol.  Improvements in morning and evening PEF vs. comparators were maintained over 12 mo.  Budesonide/formoterol decreased all symptom scores and use of reliever β2-agonists significantly vs. placebo and budesonide, and improved HRQL vs. placebo.  All treatments were well tolerated.  These results suggest a role for budesonide/formoterol in the long-term management of moderate-to-severe chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlUXMXT1zCKbVg90H21EOLACvtfcHk0lhe5B6YpnAKjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsFahu7c%253D&md5=dbadf6f2baec75e9323cd622798a4611</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1183%2F09031936.03.00031402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.03.00031402%26sid%3Dliteratum%253Aachs%26aulast%3DSzafranski%26aufirst%3DW.%26aulast%3DCukier%26aufirst%3DA.%26aulast%3DRamirez%26aufirst%3DA.%26aulast%3DMenga%26aufirst%3DG.%26aulast%3DSansores%26aufirst%3DR.%26aulast%3DNahabedian%26aufirst%3DS.%26aulast%3DPeterson%26aufirst%3DS.%26aulast%3DOlsson%26aufirst%3DH.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520budesonide%252Fformoterol%2520in%2520the%2520management%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2003%26volume%3D21%26spage%3D74%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group">Battram, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuenoud, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowling, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairhurst, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fozard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighton-Davies, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEvoy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trifilieff, A.</span><span> </span><span class="NLM_article-title">In vitro and in vivo pharmacological characterization of 5-[(<i>R</i>)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1<i>H</i>-quinolin-2-one (indacaterol), a novel inhaled beta<sub>2</sub> adrenoceptor agonist with a 24-h duration of action</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">317</span><span class="NLM_x">, </span> <span class="NLM_fpage">762</span><span class="NLM_x">–</span> <span class="NLM_lpage">770</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1124%2Fjpet.105.098251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=16434564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD28XktFamu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2006&pages=762-770&author=C.+Battramauthor=S.+J.+Charltonauthor=B.+Cuenoudauthor=M.+R.+Dowlingauthor=R.+A.+Fairhurstauthor=D.+Farrauthor=J.+R.+Fozardauthor=J.+R.+Leighton-Daviesauthor=C.+A.+Lewisauthor=L.+McEvoyauthor=R.+J.+Turnerauthor=A.+Trifilieff&title=In+vitro+and+in+vivo+pharmacological+characterization+of+5-%5B%28R%29-2-%285%2C6-diethyl-indan-2-ylamino%29-1-hydroxy-ethyl%5D-8-hydroxy-1H-quinolin-2-one+%28indacaterol%29%2C+a+novel+inhaled+beta2+adrenoceptor+agonist+with+a+24-h+duration+of+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled β2 adrenoceptor agonist with a 24-h duration of action</span></div><div class="casAuthors">Battram, Cliff; Charlton, Steven J.; Cuenoud, Bernard; Dowling, Mark R.; Fairhurst, Robin A.; Farr, David; Fozard, John R.; Leighton-Davies, Juliet R.; Lewis, Christine A.; McEvoy, Lorraine; Turner, Robert J.; Trifilieff, Alexandre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">762-770</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Here, we describe the preclin. pharmacol. profile of indacaterol, a novel, chirally pure inhaled β2 adrenoceptor agonist, in comparison with marketed drugs.  Indacaterol is close to a full agonist at the human β2 adrenoceptor (Emax = 73±1% of the maximal effect of isoprenaline; pEC50 = 8.06±0.02), whereas salmeterol displays only partial efficacy (38±1%).  The functional selectivity profile of indacaterol over β1 human adrenoceptors is similar to that of formoterol, whereas its β3 adrenoceptor selectivity profile is similar to that of formoterol and salbutamol.  In isolated superfused guinea pig trachea, indacaterol has a fast onset of action (30±4 min) similar to formoterol and salbutamol, and a long duration of action (529±99 min) comparable with salmeterol.  In the conscious guinea pig, when given intratracheally as a dry powder, indacaterol inhibits 5-hydroxytryptamine-induced bronchoconstriction for at least 24 h, whereas salmeterol, formoterol, and salbutamol have durations of action of 12, 4, and 2 h, resp.  When given via nebulization to anesthetized rhesus monkeys, all of the compds. dose-dependently inhibit methacholine-induced bronchoconstriction, although indacaterol produces the most prolonged bronchoprotective effect and induces the lowest increase in heart rate for a similar degree of antibronchoconstrictor activity.  In conclusion, the preclin. profile of indacaterol suggests that this compd. has a superior duration of action compatible with once-daily dosing in human, together with a fast onset of action and an improved cardiovascular safety profile over marketed inhaled β2 adrenoceptor agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNpFkEE8xZvbVg90H21EOLACvtfcHk0lhe5B6YpnAKjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktFamu70%253D&md5=0ea4e459100f0d3971d8a7f89c5de059</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.098251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.098251%26sid%3Dliteratum%253Aachs%26aulast%3DBattram%26aufirst%3DC.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DCuenoud%26aufirst%3DB.%26aulast%3DDowling%26aufirst%3DM.%2BR.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DFarr%26aufirst%3DD.%26aulast%3DFozard%26aufirst%3DJ.%2BR.%26aulast%3DLeighton-Davies%26aufirst%3DJ.%2BR.%26aulast%3DLewis%26aufirst%3DC.%2BA.%26aulast%3DMcEvoy%26aufirst%3DL.%26aulast%3DTurner%26aufirst%3DR.%2BJ.%26aulast%3DTrifilieff%26aufirst%3DA.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520pharmacological%2520characterization%2520of%25205-%255B%2528R%2529-2-%25285%252C6-diethyl-indan-2-ylamino%2529-1-hydroxy-ethyl%255D-8-hydroxy-1H-quinolin-2-one%2520%2528indacaterol%2529%252C%2520a%2520novel%2520inhaled%2520beta2%2520adrenoceptor%2520agonist%2520with%2520a%252024-h%2520duration%2520of%2520action%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D317%26spage%3D762%26epage%3D770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group">Hawkins, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfeffer, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swedberg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granger, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yusuf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostergren, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michelson, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pocock, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maggioni, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMurray, J. J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">CHARM Investigators and Committees.</span><span> </span><span class="NLM_article-title">Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme</span> <span class="citation_source-journal">Eur. J. Heart Failure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">557</span><span class="NLM_x">–</span> <span class="NLM_lpage">565</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1093%2Feurjhf%2Fhfq040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=20356870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC3czmsFKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=557-565&author=N.+M.+Hawkinsauthor=D.+Wangauthor=M.+Petrieauthor=M.+A.+Pfefferauthor=K.+Swedbergauthor=C.+B.+Grangerauthor=S.+Yusufauthor=S.+D.+Solomonauthor=J.+O.+Ostergrenauthor=E.+L.+Michelsonauthor=S.+J.+Pocockauthor=A.+P.+Maggioniauthor=J.+J.+V.+McMurrayauthor=CHARM+Investigators+and+Committees.&title=Baseline+characteristics+and+outcomes+of+patients+with+heart+failure+receiving+bronchodilators+in+the+CHARM+programme"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme</span></div><div class="casAuthors">Hawkins Nathaniel M; Wang Duolao; Petrie Mark C; Pfeffer Marc A; Swedberg Karl; Granger Christopher B; Yusuf Salim; Solomon Scott D; Ostergren Jan; Michelson Eric L; Pocock Stuart J; Maggioni Aldo P; McMurray John J V</div><div class="citationInfo"><span class="NLM_cas:title">European journal of heart failure</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">557-65</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIMS:  Heart failure (HF) and chronic obstructive pulmonary disease are common partners.  Bronchodilators are associated with adverse cardiovascular outcomes in patients with pulmonary disease.  The outcome of patients with HF prescribed bronchodilators is poorly defined.  METHODS AND RESULTS:  The Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme randomized 7599 patients with symptomatic HF to receive candesartan or placebo.  The relative risk conveyed by bronchodilator therapy was examined using a multivariable Cox proportional hazards model.  The prevalence of bronchodilator therapy was similar in patients with reduced and preserved systolic function (respectively, 8.7 vs. 9.2%, P = 0.46).  Beta-blocker utilization was markedly lower in patients receiving bronchodilators compared with those without (overall 31.9 vs. 57.6%, P < 0.0001).  Bronchodilator use was associated with increased all-cause mortality [HR 1.26 (1.09-1.45), P = 0.0015], cardiovascular death [HR 1.21 (1.03-1.42), P = 0.0216], HF hospitalization [HR 1.49 (1.29-1.72), P < 0.0001], and major adverse cardiovascular events [HR 1.32 (1.17-1.76), P < 0.0001].  The adverse outcomes were consistent in patients with reduced and preserved systolic function.  No significant interaction was observed between bronchodilators and beta-blockade with respect to outcomes.  CONCLUSION:  Bronchodilator use is a powerful independent predictor of worsening HF and increased mortality in a broad spectrum of patients with HF.  Whether this relates to a toxic effect of bronchodilators, underlying pulmonary disease, or both is unclear and warrants further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSojbo8wkBw3XthwrmtH4OBfW6udTcc2eZYr4r4B-bxeLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czmsFKlsQ%253D%253D&md5=fe5e87a1ca9d26a6efbca356bcf9ee20</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1093%2Feurjhf%2Fhfq040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurjhf%252Fhfq040%26sid%3Dliteratum%253Aachs%26aulast%3DHawkins%26aufirst%3DN.%2BM.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DPetrie%26aufirst%3DM.%26aulast%3DPfeffer%26aufirst%3DM.%2BA.%26aulast%3DSwedberg%26aufirst%3DK.%26aulast%3DGranger%26aufirst%3DC.%2BB.%26aulast%3DYusuf%26aufirst%3DS.%26aulast%3DSolomon%26aufirst%3DS.%2BD.%26aulast%3DOstergren%26aufirst%3DJ.%2BO.%26aulast%3DMichelson%26aufirst%3DE.%2BL.%26aulast%3DPocock%26aufirst%3DS.%2BJ.%26aulast%3DMaggioni%26aufirst%3DA.%2BP.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%2BV.%26aulast%3D%26atitle%3DBaseline%2520characteristics%2520and%2520outcomes%2520of%2520patients%2520with%2520heart%2520failure%2520receiving%2520bronchodilators%2520in%2520the%2520CHARM%2520programme%26jtitle%3DEur.%2520J.%2520Heart%2520Failure%26date%3D2010%26volume%3D12%26spage%3D557%26epage%3D565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group">Hanrahan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grogan, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgartner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimetbaum, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morganroth, J.</span><span> </span><span class="NLM_article-title">Arrhythmias in patients with chronic obstructive pulmonary disease (COPD) occurrence frequency and the effect of treatment with the inhaled long-acting beta<sub>2</sub>-agonists arformoterol and salmeterol</span> <span class="citation_source-journal">Medicine (Baltimore)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1097%2FMD.0b013e31818fcc02" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=19011503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BD1cjltFGitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2008&pages=319-328&author=J.+P.+Hanrahanauthor=D.+R.+Groganauthor=R.+A.+Baumgartnerauthor=A.+Wilsonauthor=H.+Chengauthor=P.+J.+Zimetbaumauthor=J.+Morganroth&title=Arrhythmias+in+patients+with+chronic+obstructive+pulmonary+disease+%28COPD%29+occurrence+frequency+and+the+effect+of+treatment+with+the+inhaled+long-acting+beta2-agonists+arformoterol+and+salmeterol"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol</span></div><div class="casAuthors">Hanrahan John P; Grogan Donna R; Baumgartner Rudolf A; Wilson Amy; Cheng Hailong; Zimetbaum Peter J; Morganroth Joel</div><div class="citationInfo"><span class="NLM_cas:title">Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">319-28</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Beta-adrenergic stimulation may increase heart rate and the potential for cardiac arrhythmias.  The effect of inhaled long-acting beta2-agonists (LABAs) on these outcomes was evaluated in patients with chronic obstructive pulmonary disease (COPD) in 2 double-blind randomized clinical trials.  The pretreatment arrhythmia occurrence frequency in these patients was also described.  In this analysis, 24-hour Holter monitoring data were pooled from 2 identically designed Phase III trials.  Patients were randomized to LABA treatment or placebo for 12 weeks: a) nebulized arformoterol 15 microg BID, b) 25 microg BID, or c) 50 microg QD; d) salmeterol metered dose inhaler 42 microg BID; or e) placebo.  The 24-hour Holter monitoring was performed pretreatment and at Weeks 0 (first day of dosing), 6, and 12.  We assessed the proportion of patients with each of 4 arrhythmias: atrial tachycardia, atrial fibrillation/flutter, and "nonsustained"; (4-10 beats) and "sustained"; (>10 beats) ventricular tachycardia.  There were 5226 Holter recordings in 1429 treated patients.  At baseline, there was a low frequency of occurrence of atrial fibrillation/flutter (0.1%), nonsustained ventricular tachycardia (3.1%), and >10 beat ventricular tachycardia (0.3%).  Atrial tachycardia occurred frequently (41.8%).  The proportion of patients with treatment-emergent atrial tachycardia ranged from 27% to 32% and was non-significantly higher, by approximately 2%-5% (p = 0.70), in the LABA groups compared with the placebo group.  The rates of the other more serious arrhythmias did not increase with LABA treatment and were similar to placebo.  All treatment groups (LABA and placebo) had consistent small decreases from baseline in mean 24-hour and maximum hourly heart rate.  In conclusion, in this large cohort of COPD patients with no or stable cardiac comorbidities, a high proportion ( approximately 40%) of patients were observed to have atrial tachycardia before treatment, which increased by 2%-5% with LABA treatment.  More serious arrhythmias were infrequent and did not increase with inhaled LABA therapy.  LABA administration did not increase mean heart rate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQw-TVpH1jTQ825P7XSLhESfW6udTcc2eZYr4r4B-bxeLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjltFGitQ%253D%253D&md5=f243b081a2f6a306e6a8aa8e1149b22d</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1097%2FMD.0b013e31818fcc02&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMD.0b013e31818fcc02%26sid%3Dliteratum%253Aachs%26aulast%3DHanrahan%26aufirst%3DJ.%2BP.%26aulast%3DGrogan%26aufirst%3DD.%2BR.%26aulast%3DBaumgartner%26aufirst%3DR.%2BA.%26aulast%3DWilson%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DZimetbaum%26aufirst%3DP.%2BJ.%26aulast%3DMorganroth%26aufirst%3DJ.%26atitle%3DArrhythmias%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%2520%2528COPD%2529%2520occurrence%2520frequency%2520and%2520the%2520effect%2520of%2520treatment%2520with%2520the%2520inhaled%2520long-acting%2520beta2-agonists%2520arformoterol%2520and%2520salmeterol%26jtitle%3DMedicine%2520%2528Baltimore%2529%26date%3D2008%26volume%3D87%26spage%3D319%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group">Nelson, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleecker, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yancey, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorinsky, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SMART Study Group.</span><span> </span><span class="NLM_article-title">The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2006&pages=15-26&author=H.+S.+Nelsonauthor=S.+T.+Weissauthor=E.+R.+Bleeckerauthor=S.+W.+Yanceyauthor=P.+M.+Dorinskyauthor=SMART+Study+Group.&title=The+Salmeterol+Multicenter+Asthma+Research+Trial%3A+a+comparison+of+usual+pharmacotherapy+for+asthma+or+usual+pharmacotherapy+plus+salmeterol"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DH.%2BS.%26aulast%3DWeiss%26aufirst%3DS.%2BT.%26aulast%3DBleecker%26aufirst%3DE.%2BR.%26aulast%3DYancey%26aufirst%3DS.%2BW.%26aulast%3DDorinsky%26aufirst%3DP.%2BM.%26aulast%3D%26atitle%3DThe%2520Salmeterol%2520Multicenter%2520Asthma%2520Research%2520Trial%253A%2520a%2520comparison%2520of%2520usual%2520pharmacotherapy%2520for%2520asthma%2520or%2520usual%2520pharmacotherapy%2520plus%2520salmeterol%26jtitle%3DChest%26date%3D2006%26volume%3D129%26spage%3D15%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group">Vogelmeier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kardos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gans, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stenglein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thirlwell, J.</span><span> </span><span class="NLM_article-title">Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">1511</span><span class="NLM_x">–</span> <span class="NLM_lpage">1520</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2008.07.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=18804362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BD1cjktFOisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2008&pages=1511-1520&author=C.+Vogelmeierauthor=P.+Kardosauthor=S.+Harariauthor=S.+J.+Gansauthor=S.+Stengleinauthor=J.+Thirlwell&title=Formoterol+mono-+and+combination+therapy+with+tiotropium+in+patients+with+COPD%3A+a+6-month+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study</span></div><div class="casAuthors">Vogelmeier Claus; Kardos Peter; Harari Sergio; Gans Steven J M; Stenglein Stephan; Thirlwell Jackie</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1511-20</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although guidelines recommend combining long-acting bronchodilators in COPD, data are limited.  We examined the clinical efficacy and safety of formoterol, tiotropium and the combination in patients with COPD.  Eight hundred and forty-seven patients with COPD (mean FEV(1) 52% predicted; FEV(1)/FVC 53%) were randomized to receive one of the following four treatments for 24 weeks: formoterol 10 microg b.i.d. plus tiotropium 18 microg o.d.; formoterol 10 microg b.i.d.; tiotropium 18 microg o.d., or placebo.  The study was partially blinded (formoterol and placebo).  For the primary endpoint, FEV(1) 2h post-dose after 24 weeks, there were small differences in favour of the combination therapy versus formoterol (0.07 L, p=0.044) or tiotropium (0.06 L, p=0.066).  All three treatments were superior to placebo (p<0.001).  The combination was statistically superior to monotherapy for: the primary endpoint (p=0.044 vs. formoterol); FEV(1) 5 min after the first dose (p<0.001) and at 12 weeks (p<0.05 vs. tiotropium); and peak expiratory flow averaged over the first 6 weeks (p<0.001 vs. both).  The three active treatments were significantly more effective than placebo for secondary endpoints: COPD-related 'bad days', symptoms, use of rescue medication and peak expiratory flow, and aspects of health-related quality of life.  The overall incidence of adverse events was similar with all active treatments, although COPD-related adverse events were more common with tiotropium.  Combined bronchodilator therapy may be a valuable treatment option for patients with COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQI4mu9SYWimevW160gIxP_fW6udTcc2ea0gf89u46SwLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjktFOisQ%253D%253D&md5=9ad0975b9efb39e3043ddbb90302b5c8</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2008.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2008.07.020%26sid%3Dliteratum%253Aachs%26aulast%3DVogelmeier%26aufirst%3DC.%26aulast%3DKardos%26aufirst%3DP.%26aulast%3DHarari%26aufirst%3DS.%26aulast%3DGans%26aufirst%3DS.%2BJ.%26aulast%3DStenglein%26aufirst%3DS.%26aulast%3DThirlwell%26aufirst%3DJ.%26atitle%3DFormoterol%2520mono-%2520and%2520combination%2520therapy%2520with%2520tiotropium%2520in%2520patients%2520with%2520COPD%253A%2520a%25206-month%2520study%26jtitle%3DRespir.%2520Med.%26date%3D2008%26volume%3D102%26spage%3D1511%26epage%3D1520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group">Tashkin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donohue, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahler, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodwin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanrahan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, W. T.</span><span> </span><span class="NLM_article-title">Effects of arformoterol twice daily, tiotropium once daily and their combination in patients with COPD</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">516</span><span class="NLM_x">–</span> <span class="NLM_lpage">524</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2008.12.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=19208459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BD1M7nsVChtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2009&pages=516-524&author=D.+P.+Tashkinauthor=J.+F.+Donohueauthor=D.+A.+Mahlerauthor=H.+Huangauthor=E.+Goodwinauthor=K.+Schaeferauthor=J.+P.+Hanrahanauthor=W.+T.+Andrews&title=Effects+of+arformoterol+twice+daily%2C+tiotropium+once+daily+and+their+combination+in+patients+with+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD</span></div><div class="casAuthors">Tashkin D P; Donohue J F; Mahler D A; Huang H; Goodwin E; Schaefer K; Hanrahan J P; Andrews W T</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">516-24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Current guidelines support using in combination more than one class of long-acting bronchodilator for COPD patients whose symptoms are not controlled by mono-therapy.  This 2-week, multi-center (34 sites), randomized, modified-blind, parallel group study evaluated the efficacy and safety of concomitant treatment with nebulized arformoterol (the formoterol(R,R)-isomer) BID and tiotropium DPI QD.  METHODS:  COPD patients (mean FEV(1) 1.37L, 45.4% predicted) were randomized to receive mono-therapy (either arformoterol 15microg BID [n=76] or tiotropium 18microg QD [n=80]), or combined therapy (sequential dosing of arformoterol 15microg BID and tiotropium 18microg QD [n=78]).  Changes in pulmonary function, dyspnea, and rescue levalbuterol use were evaluated, as were safety outcomes.  RESULTS:  Mean FEV(1)AUC(0-24) (the primary endpoint) improved similarly from baseline for arformoterol (0.10L) and tiotropium (0.08L) treatment groups and greater for the combined therapy group (0.22L; all p-values <0.005).  Peak FEV(1), peak FVC, 24-h trough FEV(1), and inspiratory capacity also improved similarly for the mono-therapies and greatest for the combined therapy.  Dyspnea (mean transition dyspnea index) improved similarly for arformoterol (+2.3) and tiotropium (+1.8) and greatest with combined therapy (+3.1; p-values <0.05).  Levalbuterol use decreased for all treatment groups (range -1.8 to -2.5 actuations/day).  All treatments had similar frequency of adverse events.  CONCLUSION:  In this study, the combination of nebulized arformoterol 15microg BID plus tiotropium 18microg DPI QD was the most effective in improving pulmonary function and disease symptoms.  Mono-therapy improvement with arformoterol or tiotropium was similar.  All three treatments were well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlIXjjeizOy1VwdslNBF-tfW6udTcc2ea0gf89u46SwLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M7nsVChtA%253D%253D&md5=9ab9999aaefab79fb7d7cc3bebce1f41</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2008.12.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2008.12.014%26sid%3Dliteratum%253Aachs%26aulast%3DTashkin%26aufirst%3DD.%2BP.%26aulast%3DDonohue%26aufirst%3DJ.%2BF.%26aulast%3DMahler%26aufirst%3DD.%2BA.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DGoodwin%26aufirst%3DE.%26aulast%3DSchaefer%26aufirst%3DK.%26aulast%3DHanrahan%26aufirst%3DJ.%2BP.%26aulast%3DAndrews%26aufirst%3DW.%2BT.%26atitle%3DEffects%2520of%2520arformoterol%2520twice%2520daily%252C%2520tiotropium%2520once%2520daily%2520and%2520their%2520combination%2520in%2520patients%2520with%2520COPD%26jtitle%3DRespir.%2520Med.%26date%3D2009%26volume%3D103%26spage%3D516%26epage%3D524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group">Rabe, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timmer, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sagkriotis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viel, K.</span><span> </span><span class="NLM_article-title">Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2008&pages=255-262&author=K.+F.+Rabeauthor=W.+Timmerauthor=A.+Sagkriotisauthor=K.+Viel&title=Comparison+of+a+combination+of+tiotropium+plus+formoterol+to+salmeterol+plus+fluticasone+in+moderate+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRabe%26aufirst%3DK.%2BF.%26aulast%3DTimmer%26aufirst%3DW.%26aulast%3DSagkriotis%26aufirst%3DA.%26aulast%3DViel%26aufirst%3DK.%26atitle%3DComparison%2520of%2520a%2520combination%2520of%2520tiotropium%2520plus%2520formoterol%2520to%2520salmeterol%2520plus%2520fluticasone%2520in%2520moderate%2520COPD%26jtitle%3DChest%26date%3D2008%26volume%3D134%26spage%3D255%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group">Aaron, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandemheen, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fergusson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maltais, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourbeau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIvor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anthony, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowie, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Field, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivington, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Road, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffstein, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marciniuk, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormack, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prins, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleskie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doucette, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayers, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">FitzGerald, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium.</span><span> </span><span class="NLM_article-title">Tiotropium in combination with placebo, salmeterol or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">545</span><span class="NLM_x">–</span> <span class="NLM_lpage">555</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.7326%2F0003-4819-146-8-200704170-00152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=17310045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BD2s3islartQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2007&pages=545-555&author=S.+D.+Aaronauthor=K.+L.+Vandemheenauthor=D.+Fergussonauthor=F.+Maltaisauthor=J.+Bourbeauauthor=R.+Goldsteinauthor=M.+Balterauthor=D.+O%E2%80%99Donnellauthor=A.+McIvorauthor=S.+Sharmaauthor=G.+Bishopauthor=J.+Anthonyauthor=R.+Cowieauthor=S.+Fieldauthor=A.+Hirschauthor=P.+Hernandezauthor=R.+Rivingtonauthor=J.+Roadauthor=V.+Hoffsteinauthor=R.+Hodderauthor=D.+Marciniukauthor=D.+McCormackauthor=G.+Foxauthor=G.+Coxauthor=H.+B.+Prinsauthor=G.+Fordauthor=D.+Bleskieauthor=S.+Doucetteauthor=I.+Mayersauthor=K.+Chapmanauthor=N.+Zamelauthor=M.+FitzGeraldauthor=Canadian+Thoracic+Society%2FCanadian+Respiratory+Clinical+Research+Consortium.&title=Tiotropium+in+combination+with+placebo%2C+salmeterol+or+fluticasone-salmeterol+for+treatment+of+chronic+obstructive+pulmonary+disease%3A+a+randomized+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial</span></div><div class="casAuthors">Aaron Shawn D; Vandemheen Katherine L; Fergusson Dean; Maltais Francois; Bourbeau Jean; Goldstein Roger; Balter Meyer; O'Donnell Denis; McIvor Andrew; Sharma Sat; Bishop Graham; Anthony John; Cowie Robert; Field Stephen; Hirsch Andrew; Hernandez Paul; Rivington Robert; Road Jeremy; Hoffstein Victor; Hodder Richard; Marciniuk Darcy; McCormack David; Fox George; Cox Gerard; Prins Henry B; Ford Gordon; Bleskie Dominique; Doucette Steve; Mayers Irvin; Chapman Kenneth; Zamel Noe; FitzGerald Mark</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">545-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Treatment of moderate or severe chronic obstructive pulmonary disease (COPD) with combinations of inhaled corticosteroids, long-acting beta-agonists, and long-acting anticholinergic bronchodilators is common but unstudied.  OBJECTIVE:  To determine whether combining tiotropium with salmeterol or fluticasone-salmeterol improves clinical outcomes in adults with moderate to severe COPD compared with tiotropium alone.  DESIGN:  Randomized, double-blind, placebo-controlled trial conducted from October 2003 to January 2006.  SETTING:  27 academic and community medical centers in Canada.  PATIENTS:  449 patients with moderate or severe COPD.  INTERVENTION:  1 year of treatment with tiotropium plus placebo, tiotropium plus salmeterol, or tiotropium plus fluticasone-salmeterol.  MEASUREMENTS:  The primary end point was the proportion of patients who experienced an exacerbation of COPD that required treatment with systemic steroids or antibiotics.  RESULTS:  The proportion of patients in the tiotropium plus placebo group who experienced an exacerbation (62.8%) did not differ from that in the tiotropium plus salmeterol group (64.8%; difference, -2.0 percentage points [95% CI, -12.8 to 8.8 percentage points]) or in the tiotropium plus fluticasone-salmeterol group (60.0%; difference, 2.8 percentage points [CI, -8.2 to 13.8 percentage points]).  In sensitivity analyses, the point estimates and 95% confidence bounds shifted in the direction favoring tiotropium plus salmeterol and tiotropium plus fluticasone-salmeterol.  Tiotropium plus fluticasone-salmeterol improved lung function (P = 0.049) and disease-specific quality of life (P = 0.01) and reduced the number of hospitalizations for COPD exacerbation (incidence rate ratio, 0.53 [CI, 0.33 to 0.86]) and all-cause hospitalizations (incidence rate ratio, 0.67 [CI, 0.45 to 0.99]) compared with tiotropium plus placebo.  In contrast, tiotropium plus salmeterol did not statistically improve lung function or hospitalization rates compared with tiotropium plus placebo.  LIMITATIONS:  More than 40% of patients who received tiotropium plus placebo and tiotropium plus salmeterol discontinued therapy prematurely, and many crossed over to treatment with open-label inhaled steroids or long-acting beta-agonists.  CONCLUSIONS:  Addition of fluticasone-salmeterol to tiotropium therapy did not statistically influence rates of COPD exacerbation but did improve lung function, quality of life, and hospitalization rates in patients with moderate to severe COPD.  International Standard Randomised Controlled Trial registration number: ISRCTN29870041.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSN_40o1KWtZ9NTrvPZP1IpfW6udTcc2eZJmqlIF2osR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s3islartQ%253D%253D&md5=b189f13e74ad9db756e1299c21913a40</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-146-8-200704170-00152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-146-8-200704170-00152%26sid%3Dliteratum%253Aachs%26aulast%3DAaron%26aufirst%3DS.%2BD.%26aulast%3DVandemheen%26aufirst%3DK.%2BL.%26aulast%3DFergusson%26aufirst%3DD.%26aulast%3DMaltais%26aufirst%3DF.%26aulast%3DBourbeau%26aufirst%3DJ.%26aulast%3DGoldstein%26aufirst%3DR.%26aulast%3DBalter%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DD.%26aulast%3DMcIvor%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DBishop%26aufirst%3DG.%26aulast%3DAnthony%26aufirst%3DJ.%26aulast%3DCowie%26aufirst%3DR.%26aulast%3DField%26aufirst%3DS.%26aulast%3DHirsch%26aufirst%3DA.%26aulast%3DHernandez%26aufirst%3DP.%26aulast%3DRivington%26aufirst%3DR.%26aulast%3DRoad%26aufirst%3DJ.%26aulast%3DHoffstein%26aufirst%3DV.%26aulast%3DHodder%26aufirst%3DR.%26aulast%3DMarciniuk%26aufirst%3DD.%26aulast%3DMcCormack%26aufirst%3DD.%26aulast%3DFox%26aufirst%3DG.%26aulast%3DCox%26aufirst%3DG.%26aulast%3DPrins%26aufirst%3DH.%2BB.%26aulast%3DFord%26aufirst%3DG.%26aulast%3DBleskie%26aufirst%3DD.%26aulast%3DDoucette%26aufirst%3DS.%26aulast%3DMayers%26aufirst%3DI.%26aulast%3DChapman%26aufirst%3DK.%26aulast%3DZamel%26aufirst%3DN.%26aulast%3DFitzGerald%26aufirst%3DM.%26aulast%3D%26atitle%3DTiotropium%2520in%2520combination%2520with%2520placebo%252C%2520salmeterol%2520or%2520fluticasone-salmeterol%2520for%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520randomized%2520trial%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2007%26volume%3D146%26spage%3D545%26epage%3D555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group">Singh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cahn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, B. J.</span><span> </span><span class="NLM_article-title">Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">592</span><span class="NLM_x">–</span> <span class="NLM_lpage">598</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2008&pages=592-598&author=D.+Singhauthor=J.+Brooksauthor=G.+Haganauthor=A.+Cahnauthor=B.+J.+O%E2%80%99Connor&title=Superiority+of+%E2%80%9Ctriple%E2%80%9D+therapy+with+salmeterol%2Ffluticasone+propionate+and+tiotropium+bromide+versus+individual+components+in+moderate+to+severe+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DBrooks%26aufirst%3DJ.%26aulast%3DHagan%26aufirst%3DG.%26aulast%3DCahn%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DB.%2BJ.%26atitle%3DSuperiority%2520of%2520%25E2%2580%259Ctriple%25E2%2580%259D%2520therapy%2520with%2520salmeterol%252Ffluticasone%2520propionate%2520and%2520tiotropium%2520bromide%2520versus%2520individual%2520components%2520in%2520moderate%2520to%2520severe%2520COPD%26jtitle%3DThorax%26date%3D2008%26volume%3D63%26spage%3D592%26epage%3D598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group">Welte, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miravitlles, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eriksson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polanowski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, R.</span><span> </span><span class="NLM_article-title">Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">180</span><span class="NLM_x">, </span> <span class="NLM_fpage">741</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1164%2Frccm.200904-0492OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=19644045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlGgtbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2009&pages=741-750&author=T.+Welteauthor=M.+Miravitllesauthor=P.+Hernandezauthor=G.+Erikssonauthor=S.+Petersonauthor=T.+Polanowskiauthor=R.+Kessler&title=Efficacy+and+tolerability+of+budesonide%2Fformoterol+added+to+tiotropium+in+patients+with+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease</span></div><div class="casAuthors">Welte, Tobias; Miravitlles, Marc; Hernandez, Paul; Eriksson, Goeran; Peterson, Stefan; Polanowski, Tomasz; Kessler, Romain</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">741-750</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Budesonide/formoterol and tiotropium are commonly used maintenance treatments for patients with chronic obstructive pulmonary disease.  Combining these medications may provide addnl. benefits.  Objectives: To assess the efficacy and tolerability of budesonide/formoterol added to tiotropium in patients eligible for inhaled corticosteroid/long-acting β2-agonist combination therapy.  Methods: In this 12-wk, randomized, double-blind, parallel-group, multicenter study, after a 2-wk run-in, 660 subjects (75% male; mean age, 62 yr; FEV1, 1.1 L; 38% predicted normal), 40 years of age or older, received tiotropium (18 μg once daily) plus either budesonide/formoterol (320/9 μg) (n = 329) or placebo (n = 331) twice daily.  Measurements and Main Results: Clinic predose (primary outcome) and postdose FEV1, predose and postdose forced vital capacity and inspiratory capacity, and health status were measured.  Other outcomes included daily measurements taken at home (pre- and postdose morning FEV1 and peak expiratory flow, morning symptoms and activities, and morning reliever use), severe exacerbations, and tolerability.  Over the treatment period, budesonide/formoterol plus tiotropium significantly increased predose FEV1 by 6% (65 mL) and postdose by 11% (123 and 131 mL at 5 and 60 min postdose, resp.) vs. tiotropium alone (both P < 0.001).  Other outcomes all significantly improved with budesonide/formoterol plus tiotropium vs. tiotropium alone.  The no. of severe exacerbations decreased by 62% (rate ratio, 0.38; 95% confidence interval, 0.25-0.57; P < 0.001).  Both treatments were well tolerated.  Conclusions: In patients with chronic obstructive pulmonary disease, budesonide/formoterol added to tiotropium vs. tiotropium alone provides rapid and sustained improvements in lung function, health status, morning symptoms and activities, and reduces severe exacerbations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIInFGAKucAbVg90H21EOLACvtfcHk0lgNmTLCe-mwTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlGgtbnM&md5=fd32e7085535ca751df8544d1055a07b</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1164%2Frccm.200904-0492OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200904-0492OC%26sid%3Dliteratum%253Aachs%26aulast%3DWelte%26aufirst%3DT.%26aulast%3DMiravitlles%26aufirst%3DM.%26aulast%3DHernandez%26aufirst%3DP.%26aulast%3DEriksson%26aufirst%3DG.%26aulast%3DPeterson%26aufirst%3DS.%26aulast%3DPolanowski%26aufirst%3DT.%26aulast%3DKessler%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520tolerability%2520of%2520budesonide%252Fformoterol%2520added%2520to%2520tiotropium%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2009%26volume%3D180%26spage%3D741%26epage%3D750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group">Salmon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttmann, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeHaas, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotzer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slack, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarau, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palovich, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lainé, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rumsey, W. L.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">345</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1124%2Fjpet.112.202051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23435542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVCgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=2013&pages=260-270&author=M.+Salmonauthor=M.+A.+Luttmannauthor=J.+J.+Foleyauthor=P.+T.+Buckleyauthor=D.+B.+Schmidtauthor=M.+Burmanauthor=E.+F.+Webbauthor=C.+J.+DeHaasauthor=C.+J.+Kotzerauthor=V.+J.+Barrettauthor=R.+J.+Slackauthor=H.+M.+Sarauauthor=M.+R.+Palovichauthor=D.+I.+Lain%C3%A9author=D.+W.+Hayauthor=W.+L.+Rumsey&title=Pharmacological+characterization+of+GSK573719+%28umeclidinium%29%3A+a+novel%2C+long-acting%2C+inhaled+antagonist+of+the+muscarinic+cholinergic+receptors+for+treatment+of+pulmonary+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases</span></div><div class="casAuthors">Salmon, Michael; Luttmann, Mark A.; Foley, James J.; Buckley, Peter T.; Schmidt, Dulcie B.; Burman, Miriam; Webb, Edward F.; DeHaas, Christopher J.; Kotzer, Charles J.; Barrett, Victoria J.; Slack, Robert J.; Sarau, Henry M.; Palovich, Michael R.; Laine, Dramane I.; Hay, Douglas W. P.; Rumsey, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">260-270</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Activation of muscarinic subtype 3 (M3) muscarinic cholinergic receptors (mAChRs) increases airway tone, whereas its blockade improves lung function and quality of life in patients with pulmonary diseases.  The present study evaluated the pharmacol. properties of a novel mAChR antagonist, GSK573719 (4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane; umeclidinium).  The affinity (Ki) of GSK573719 for the cloned human M1-M5 mAChRs ranged from 0.05 to 0.16 nM.  Dissocn. of [3H]GSK573719 from the M3 mAChR was slower than that for the M2 mAChR [half-life (t1/2) values: 82 and 9 min, resp.].  In Chinese hamster ovary cells transfected with recombinant human M3 mAChRs, GSK573719 demonstrated picomolar potency (-log pA2 = 23.9 pM) in an acetylcholine (Ach)-mediated Ca2+ mobilization assay.  Concn.-response curves indicate competitive antagonism with partial reversibility after drug washout.  Using isolated human bronchial strips, GSK573719 was also potent and showed competitive antagonism (-log pA2 = 316 pM) vs. carbachol, and was slowly reversible in a concn.-dependent manner (1-100 nM).  The time to 50% restoration of contraction at 10 nM was about 381 min (vs. 413 min for tiotropium bromide).  In mice, the ED50 value was 0.02 μg/mouse intranasally.  In conscious guinea pigs, intratracheal administration of GSK573719 dose dependently blocked Ach-induced bronchoconstriction with long duration of action, and was comparable to tiotropium; 2.5 μg elicited 50% bronchoprotection for >24 h.  Thus, GSK573719 is a potent anticholinergic agent that demonstrates slow functional reversibility at the human M3 mAChR and long duration of action in animal models.  This pharmacol. profile translated into a 24-h duration of bronchodilation in vivo, which suggested umeclidinium will be a once-daily inhaled treatment of pulmonary diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrepD_oaItRirVg90H21EOLACvtfcHk0li1dqJHjYzbOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVCgsb0%253D&md5=eceacf0294d1b749e0463c85c8bb8724</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.202051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.202051%26sid%3Dliteratum%253Aachs%26aulast%3DSalmon%26aufirst%3DM.%26aulast%3DLuttmann%26aufirst%3DM.%2BA.%26aulast%3DFoley%26aufirst%3DJ.%2BJ.%26aulast%3DBuckley%26aufirst%3DP.%2BT.%26aulast%3DSchmidt%26aufirst%3DD.%2BB.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DWebb%26aufirst%3DE.%2BF.%26aulast%3DDeHaas%26aufirst%3DC.%2BJ.%26aulast%3DKotzer%26aufirst%3DC.%2BJ.%26aulast%3DBarrett%26aufirst%3DV.%2BJ.%26aulast%3DSlack%26aufirst%3DR.%2BJ.%26aulast%3DSarau%26aufirst%3DH.%2BM.%26aulast%3DPalovich%26aufirst%3DM.%2BR.%26aulast%3DLain%25C3%25A9%26aufirst%3DD.%2BI.%26aulast%3DHay%26aufirst%3DD.%2BW.%26aulast%3DRumsey%26aufirst%3DW.%2BL.%26atitle%3DPharmacological%2520characterization%2520of%2520GSK573719%2520%2528umeclidinium%2529%253A%2520a%2520novel%252C%2520long-acting%252C%2520inhaled%2520antagonist%2520of%2520the%2520muscarinic%2520cholinergic%2520receptors%2520for%2520treatment%2520of%2520pulmonary%2520diseases%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D345%26spage%3D260%26epage%3D270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group">Donohue, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anzueto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crater, G.</span><span> </span><span class="NLM_article-title">A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">970</span><span class="NLM_x">–</span> <span class="NLM_lpage">979</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2012.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=22498110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC38rksFClsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2012&pages=970-979&author=J.+F.+Donohueauthor=A.+Anzuetoauthor=J.+Brooksauthor=R.+Mehtaauthor=C.+Kalbergauthor=G.+Crater&title=A+randomized%2C+double-blind+dose-ranging+study+of+the+novel+LAMA+GSK573719+in+patients+with+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD</span></div><div class="casAuthors">Donohue James F; Anzueto Antonio; Brooks Jean; Mehta Rashmi; Kalberg Christopher; Crater Glenn</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">970-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  This study evaluated the dose-response and dosing interval of the novel long-acting muscarinic receptor antagonist (LAMA) GSK573719 in patients with COPD.  METHODS:  This randomized, double-blind, placebo-controlled, 3-way cross-over, incomplete block study evaluated 5 once-daily doses of GSK573719 (62.5-1000 μg), 3 twice-daily doses (62.5-250 μg), and open-label tiotropium for 14 days in patients (N = 176) with COPD (FEV(1) of 35-70% predicted).  The primary endpoint was morning trough FEV(1) at Day 15.  Secondary endpoints included 0-24 h weighted mean FEV(1) and serial FEV(1) values over 28 h.  Safety measures and pharmacokinetics were assessed.  RESULTS:  All once-daily doses of GSK573719 significantly increased trough FEV(1) at Day 15 with improvements ranging from 95 to 186 mL over placebo (p ≤ 0.006), from 79 to 172 mL with twice-daily dosing (p ≤ 0.03), and 105 mL with tiotropium (p = 0.003).  No clear dose ordering was observed.  Once-daily doses significantly (p < 0.001) increased 0-24 h weighted mean FEV(1) at Day 14 by 131-143 mL over placebo, comparable to increases with the twice-daily doses (120-142 mL) and tiotropium (127 mL).  Significant reductions in rescue albuterol use and improvements in FVC were also observed with once-daily dosing.  Plasma C(max) occurred within 5-15 min of dosing after which the drug was rapidly cleared and eliminated.  GSK573719 was well tolerated, with no apparent treatment-related changes in vital signs, ECG and Holter assessments, or clinical laboratory parameters.  CONCLUSION:  Once-daily dosing with GSK573719 in COPD provides clinically significant and sustained improvement in lung function over 24 h with similar efficacy to twice-daily dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJ3p0V_2egAMKL0FlyGHDofW6udTcc2eYbCWOPXJamxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rksFClsw%253D%253D&md5=ac974735ef628d984ff2185ec5a4c55f</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2012.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2012.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DDonohue%26aufirst%3DJ.%2BF.%26aulast%3DAnzueto%26aufirst%3DA.%26aulast%3DBrooks%26aufirst%3DJ.%26aulast%3DMehta%26aufirst%3DR.%26aulast%3DKalberg%26aufirst%3DC.%26aulast%3DCrater%26aufirst%3DG.%26atitle%3DA%2520randomized%252C%2520double-blind%2520dose-ranging%2520study%2520of%2520the%2520novel%2520LAMA%2520GSK573719%2520in%2520patients%2520with%2520COPD%26jtitle%3DRespir.%2520Med.%26date%3D2012%26volume%3D106%26spage%3D970%26epage%3D979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group">Decramer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maltais, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crater, G.</span><span> </span><span class="NLM_article-title">Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients</span> <span class="citation_source-journal">Respir. Physiol. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">185</span><span class="NLM_x">, </span> <span class="NLM_fpage">393</span><span class="NLM_x">–</span> <span class="NLM_lpage">409</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.resp.2012.08.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23026438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2htrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=2013&pages=393-409&author=M.+Decramerauthor=F.+Maltaisauthor=G.+Feldmanauthor=J.+Brooksauthor=S.+Harrisauthor=R.+Mehtaauthor=G.+Crater&title=Bronchodilation+of+umeclidinium%2C+a+new+long-acting+muscarinic+antagonist%2C+in+COPD+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients</span></div><div class="casAuthors">Decramer, Marc; Maltais, Francois; Feldman, Gregory; Brooks, Jean; Harris, Stephanie; Mehta, Rashmi; Crater, Glenn</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory Physiology & Neurobiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">393-399</span>CODEN:
                <span class="NLM_cas:coden">RPNEAV</span>;
        ISSN:<span class="NLM_cas:issn">1569-9048</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This study evaluated the dose-response of the new long-acting muscarinic antagonist umeclidinium (GSK573719) in patients with COPD.This randomized, double-blind, placebo-controlled, parallel-group study evaluated three once-daily doses of umeclidinium (125, 250 and 500 μg) for 28 days in 285 patients with COPD having FEV1 of 35-70% predicted (mean (SD) age = 61.4 (8.41); mean (SD) post-bronchodilator FEV1 = 1.577 (0.450)).  The primary endpoint was morning trough FEV1 at Day 29.  Secondary endpoints included 0-6 h weighted mean FEV1 and serial FEV1 measured over 6 h post-dose and at trough.  Safety and pharmacokinetics were also assessed.All doses of umeclidinium significantly increased trough FEV1 over placebo from 150 to 168 mL (p < 0.001), 0-6 h weighted mean FEV1 from 113 to 211 mL (p < 0.001), and serial FEV1 at each point in time over 24 h.  Redns. in salbutamol use and improvements in FVC were noted for all doses.  Umeclidinium was well tolerated with no apparent treatment-related changes in vital signs.Once-daily umeclidinium provides clin. significant, sustained improvement in lung function and is well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0A6mpnWPriLVg90H21EOLACvtfcHk0lguoYWFF-kbHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2htrfJ&md5=d537a3e997eefbdec4080410f6b944a2</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.resp.2012.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.resp.2012.08.022%26sid%3Dliteratum%253Aachs%26aulast%3DDecramer%26aufirst%3DM.%26aulast%3DMaltais%26aufirst%3DF.%26aulast%3DFeldman%26aufirst%3DG.%26aulast%3DBrooks%26aufirst%3DJ.%26aulast%3DHarris%26aufirst%3DS.%26aulast%3DMehta%26aufirst%3DR.%26aulast%3DCrater%26aufirst%3DG.%26atitle%3DBronchodilation%2520of%2520umeclidinium%252C%2520a%2520new%2520long-acting%2520muscarinic%2520antagonist%252C%2520in%2520COPD%2520patients%26jtitle%3DRespir.%2520Physiol.%2520Neurobiol.%26date%3D2013%26volume%3D185%26spage%3D393%26epage%3D409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group">Tal-Singer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cahn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preece, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crater, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelleher, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pouliquen, I. J.</span><span> </span><span class="NLM_article-title">Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studies</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">701</span><span class="NLM_x">, </span> <span class="NLM_fpage">40</span><span class="NLM_x">–</span> <span class="NLM_lpage">48</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.ejphar.2012.12.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23276660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFCmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=701&publication_year=2013&pages=40-48&author=R.+Tal-Singerauthor=A.+Cahnauthor=R.+Mehtaauthor=A.+Preeceauthor=G.+Craterauthor=D.+Kelleherauthor=I.+J.+Pouliquen&title=Initial+assessment+of+single+and+repeat+doses+of+inhaled+umeclidinium+in+patients+with+chronic+obstructive+pulmonary+disease%3A+two+randomised+studies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: Two randomised studies</span></div><div class="casAuthors">Tal-Singer, Ruth; Cahn, Anthony; Mehta, Rashmi; Preece, Andrew; Crater, Glenn; Kelleher, Dennis; Pouliquen, Isabelle J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">701</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">40-48</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To characterize the safety, tolerability, pharmacodynamics (bronchodilatory effect) and pharmacokinetics of inhaled umeclidinium in patients with chronic obstructive pulmonary disease (COPD).  The first investigation was a single dose, randomized, double-blind, placebo-controlled study (clinicaltrials.gov: NCT00515502) in which ipratropium bromide-sensitive patients received umeclidinium (250 μg, 500 μg, and 1000 μg), tiotropium bromide 18 μg or placebo.  Patients were randomized to receive four out of five possible treatments as an incomplete block four-way cross-over.  A subsequent study (clinicaltrials.gov: NCT700732472) was focused on assessment of safety, tolerability and pharmacokinetics of umeclidinium (250 μg and 1000 μg) administered once-daily for 7 days in a randomized, double-blind, placebo-controlled, parallel-group design.  Of the 24 patients randomized for the single dose study, 20 completed; 31 out of 38 patients completed the repeat dose study.  Most adverse events were mild-to-moderate and transient.  Examn. of heart rate, QTc interval, blood pressure and clin. lab. assessments raised no concern over the safety of umeclidinium.  Evidence of pharmacol. was demonstrated in first study by statistically significant increases in specific airway conductance (sGaw) for up to 24 h for all active treatments compared with placebo.  Increases in forced expiratory vol. in 1 s were also obsd.  Pharmacokinetic anal. demonstrated that max. obsd. plasma umeclidinium concn. (Cmax) was reached rapidly (time to Cmax: ∼5-15 min) after single and repeat doses; 1.5-1.9-fold accumulation was obsd. after repeat-dosing.  Single and repeat doses of umeclidinium were well tolerated and produced clin. relevant lung function improvements over 24 h in patients with COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr77JXR0LYSTLVg90H21EOLACvtfcHk0lguoYWFF-kbHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFCmu7w%253D&md5=916349ac3d5b966d7be88a8e900ddb18</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2012.12.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2012.12.019%26sid%3Dliteratum%253Aachs%26aulast%3DTal-Singer%26aufirst%3DR.%26aulast%3DCahn%26aufirst%3DA.%26aulast%3DMehta%26aufirst%3DR.%26aulast%3DPreece%26aufirst%3DA.%26aulast%3DCrater%26aufirst%3DG.%26aulast%3DKelleher%26aufirst%3DD.%26aulast%3DPouliquen%26aufirst%3DI.%2BJ.%26atitle%3DInitial%2520assessment%2520of%2520single%2520and%2520repeat%2520doses%2520of%2520inhaled%2520umeclidinium%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520two%2520randomised%2520studies%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D701%26spage%3D40%26epage%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group">Bouyssou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casarosa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naline, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pestel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konetzki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devillier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of olodaterol, a novel inhaled beta<sub>2</sub>-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">334</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1124%2Fjpet.110.167007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=20371707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Klt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2010&pages=53-62&author=T.+Bouyssouauthor=P.+Casarosaauthor=E.+Nalineauthor=S.+Pestelauthor=I.+Konetzkiauthor=P.+Devillierauthor=A.+Schnapp&title=Pharmacological+characterization+of+olodaterol%2C+a+novel+inhaled+beta2-adrenoceptor+agonist+exerting+a+24-hour-long+duration+of+action+in+preclinical+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models</span></div><div class="casAuthors">Bouyssou, T.; Casarosa, P.; Naline, E.; Pestel, S.; Konetzki, I.; Devillier, P.; Schnapp, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-62</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The preclin. pharmacol. profile of 6-hydroxy-8-[(1R)-1-hydroxy-2-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]ethyl]-2H-1,4-benzoxazin-3(4H)-one monohydrochloride (olodaterol, previously known as BI 1744 CL), a novel, enantiomeric pure, inhaled human β2-adrenoceptor (hβ2-AR) agonist, was compared with marked drugs, such as salmeterol and formoterol.  In vitro, olodaterol showed a potent, nearly full agonistic response at the hβ2-AR (EC50 = 0.1 nM; intrinsic activity = 88% compared with isoprenaline) and a significant selectivity profile (241- and 2299-fold against the hβ1- and hβ3-ARs, resp.).  Likewise, olodaterol was able to potently reverse contraction induced by different stimuli in isolated human bronchi.  In vivo, antagonistic effects of single doses of olodaterol and formoterol were measured against acetylcholine challenges in anesthetized guinea pigs and dogs for up to 24 h by using the Respimat Soft Mist inhaler.  Heart rate and metabolic parameters (serum potassium, lactate, and glucose) were monitored to evaluate systemic pharmacodynamic effects in the dog model.  In both models, olodaterol provided bronchoprotection over 24 h.  Formoterol applied at an equally ED did not retain efficacy over 24 h.  In both models olodaterol showed a rapid onset of action comparable with formoterol.  Taken together, the preclin. behavior of olodaterol suggests that this novel β2-AR agonist has the profile for once-daily dosing in humans concomitant with a fast onset of action and a favorable systemic pharmacodynamic profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDfOG9fwv5TbVg90H21EOLACvtfcHk0lguoYWFF-kbHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Klt78%253D&md5=8e88a0ceea3ede36e4ef29188224a8ab</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.167007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.167007%26sid%3Dliteratum%253Aachs%26aulast%3DBouyssou%26aufirst%3DT.%26aulast%3DCasarosa%26aufirst%3DP.%26aulast%3DNaline%26aufirst%3DE.%26aulast%3DPestel%26aufirst%3DS.%26aulast%3DKonetzki%26aufirst%3DI.%26aulast%3DDevillier%26aufirst%3DP.%26aulast%3DSchnapp%26aufirst%3DA.%26atitle%3DPharmacological%2520characterization%2520of%2520olodaterol%252C%2520a%2520novel%2520inhaled%2520beta2-adrenoceptor%2520agonist%2520exerting%2520a%252024-hour-long%2520duration%2520of%2520action%2520in%2520preclinical%2520models%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D334%26spage%3D53%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group">Lamyel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warnken-Uhlich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seemann, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostenis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmedat, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gosens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meurs, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller-Larsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Racké, K.</span><span> </span><span class="NLM_article-title">The beta<sub>2</sub>-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts</span> <span class="citation_source-journal">Naunyn-Schmiedeberg’s Arch. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">384</span><span class="NLM_x">, </span> <span class="NLM_fpage">133</span><span class="NLM_x">–</span> <span class="NLM_lpage">145</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1007%2Fs00210-011-0655-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=21603974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFOksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=384&publication_year=2011&pages=133-145&author=F.+Lamyelauthor=M.+Warnken-Uhlichauthor=W.+K.+Seemannauthor=K.+Mohrauthor=E.+Kostenisauthor=A.+S.+Ahmedatauthor=M.+Smitauthor=R.+Gosensauthor=H.+Meursauthor=A.+Miller-Larssonauthor=K.+Rack%C3%A9&title=The+beta2-subtype+of+adrenoceptors+mediates+inhibition+of+pro-fibrotic+events+in+human+lung+fibroblasts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">The β2-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts</span></div><div class="casAuthors">Lamyel, F.; Warnken-Uhlich, M.; Seemann, W. K.; Mohr, K.; Kostenis, E.; Ahmedat, A. S.; Smit, M.; Gosens, R.; Meurs, H.; Miller-Larsson, A.; Racke, Kurt</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">384</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-145</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Fibrosis is part of airway remodelling obsd. in bronchial asthma and COPD.  Pro-fibrotic activity of lung fibroblasts may be suppressed by β-adrenoceptor activation.  We aimed, first, to characterize the expression pattern of β-adrenoceptor subtypes in human lung fibroblasts and, second, to probe β-adrenoceptor signaling with an emphasis on anti-fibrotic actions.  Using reverse transcription PCR, mRNA encoding β2-adrenoceptors was detected in MRC-5, HEL-299 and primary human lung fibroblasts, whereas transcripts for β1- and β3-adrenoceptors were not found.  Real-time measurement of dynamic mass redistribution in MRC-5 cells revealed β-agonist-induced Gs-signaling.  Proliferation of MRC-5 cells (detd. by [3H]-thymidine incorporation) was significantly inhibited by β-agonists including the β2-selective agonist formoterol (-logIC50, 10.2) and olodaterol (-logIC50, 10.6).  Formoterol's effect was insensitive to β1-antagonism (GCP 20712, 3 μM), but sensitive to β2-antagonism (ICI 118,551; apparent, pA 2, 9.6).  Collagen synthesis in MRC-5 cells (detd. by [3H]-proline incorporation) was inhibited by β-agonists including formoterol (-logIC50, 10.0) and olodaterol (-logIC50, 10.3) in a β2-blocker-sensitive manner. α-Smooth muscle actin, a marker of myo-fibroblast differentiation, was down-regulated at the mRNA and the protein level by about 50% following 24 and 48 h exposure to 1 nM formoterol, a maximally active concn.  In conclusion, human lung fibroblasts exclusively express β2-adrenoceptors and these mediate inhibition of various markers of pro-fibrotic cellular activity.  Under clin. conditions, anti-fibrotic actions may accompany the therapeutic effect of long-term β2-agonist treatment of bronchial asthma and COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcrrxy9mSlR7Vg90H21EOLACvtfcHk0lhpt7irZwtfoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFOksbc%253D&md5=f72d9809b80589d1a5dc921d1dc09971</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1007%2Fs00210-011-0655-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-011-0655-5%26sid%3Dliteratum%253Aachs%26aulast%3DLamyel%26aufirst%3DF.%26aulast%3DWarnken-Uhlich%26aufirst%3DM.%26aulast%3DSeemann%26aufirst%3DW.%2BK.%26aulast%3DMohr%26aufirst%3DK.%26aulast%3DKostenis%26aufirst%3DE.%26aulast%3DAhmedat%26aufirst%3DA.%2BS.%26aulast%3DSmit%26aufirst%3DM.%26aulast%3DGosens%26aufirst%3DR.%26aulast%3DMeurs%26aufirst%3DH.%26aulast%3DMiller-Larsson%26aufirst%3DA.%26aulast%3DRack%25C3%25A9%26aufirst%3DK.%26atitle%3DThe%2520beta2-subtype%2520of%2520adrenoceptors%2520mediates%2520inhibition%2520of%2520pro-fibrotic%2520events%2520in%2520human%2520lung%2520fibroblasts%26jtitle%3DNaunyn-Schmiedeberg%25E2%2580%2599s%2520Arch.%2520Pharmacol.%26date%3D2011%26volume%3D384%26spage%3D133%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group">Casarosa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kollak, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiechle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostermann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiesling, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieper, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sieger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gantner, F.</span><span> </span><span class="NLM_article-title">Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">337</span><span class="NLM_x">, </span> <span class="NLM_fpage">600</span><span class="NLM_x">–</span> <span class="NLM_lpage">609</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1124%2Fjpet.111.179259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=21357659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFeitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2011&pages=600-609&author=P.+Casarosaauthor=I.+Kollakauthor=T.+Kiechleauthor=A.+Ostermannauthor=A.+Schnappauthor=R.+Kieslingauthor=M.+Pieperauthor=P.+Siegerauthor=F.+Gantner&title=Functional+and+biochemical+rationales+for+the+24-hour-long+duration+of+action+of+olodaterol"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol</span></div><div class="casAuthors">Casarosa, Paola; Kollak, Ines; Kiechle, Tobias; Ostermann, Angela; Schnapp, Andreas; Kiesling, Ralf; Pieper, Michael; Sieger, Peter; Gantner, Florian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">600-609</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">β2-Adrenoceptor (β2-AR) agonists are powerful bronchodilators and play a pivotal role in the management of pulmonary obstructive diseases, such as asthma and chronic obstructive pulmonary disease.  Although these agents 1st were used many years ago, progress in drug development has resulted in better tolerated, long-acting β2-AR agonists (LABAs), such as formoterol and salmeterol.  Although LABAs were on the market for several years, relatively little is known on the rationale(s) behind their long duration of action.  In this study, we focused on olodaterol (previously known as BI1744CL), a novel inhaled LABA, which provides a bronchodilating effect lasting 24 h and is currently in Phase III clin. trials.  To understand the rationale behind its long duration of action, different aspects of olodaterol were analyzed (i.e., its lipophilicity and propensity to accumulate in the lipid bilayer as well as its tight binding to the β2-AR).  In line with its physicochem. properties, olodaterol assocd. moderately with lipid bilayers.  Instead, kinetic as well as equil. binding studies indicated the presence of a stable [3H]olodaterol/β2-AR complex with a dissocn. half-life of 17.8 h due to ternary complex formation.  The tight binding of olodaterol to the human β2-AR and stabilization of the ternary complex were confirmed in functional expts. monitoring adenylyl cyclase activity after extensive washout.  Taken together, binding, kinetic, and functional data support the existence of a stable complex with the β2-AR that, with a dissocn. half-life >17 h, might indeed be a rationale for the 24-h duration of action of olodaterol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlUqEwPj-SPrVg90H21EOLACvtfcHk0lhpt7irZwtfoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFeitb0%253D&md5=a36582775c7a2e91388e33be2c175e59</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.179259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.179259%26sid%3Dliteratum%253Aachs%26aulast%3DCasarosa%26aufirst%3DP.%26aulast%3DKollak%26aufirst%3DI.%26aulast%3DKiechle%26aufirst%3DT.%26aulast%3DOstermann%26aufirst%3DA.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DKiesling%26aufirst%3DR.%26aulast%3DPieper%26aufirst%3DM.%26aulast%3DSieger%26aufirst%3DP.%26aulast%3DGantner%26aufirst%3DF.%26atitle%3DFunctional%2520and%2520biochemical%2520rationales%2520for%2520the%252024-hour-long%2520duration%2520of%2520action%2520of%2520olodaterol%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D337%26spage%3D600%26epage%3D609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group">Aparici, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gómez-Angelats, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vilella, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carcasona, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viñals, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavaldà, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Alba, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gras, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortijo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morcillo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puig, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beleta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralpeix, M.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of abediterol, a novel inhaled β<sub>2</sub>-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">342</span><span class="NLM_x">, </span> <span class="NLM_fpage">497</span><span class="NLM_x">–</span> <span class="NLM_lpage">509</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1124%2Fjpet.112.193284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=22588259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOru7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2012&pages=497-509&author=M.+Apariciauthor=M.+G%C3%B3mez-Angelatsauthor=D.+Vilellaauthor=R.+Otalauthor=C.+Carcasonaauthor=M.+Vi%C3%B1alsauthor=I.+Ramosauthor=A.+Gavald%C3%A0author=J.+De+Albaauthor=J.+Grasauthor=J.+Cortijoauthor=E.+Morcilloauthor=C.+Puigauthor=H.+Ryderauthor=J.+Beletaauthor=M.+Miralpeix&title=Pharmacological+characterization+of+abediterol%2C+a+novel+inhaled+%CE%B22-adrenoceptor+agonist+with+long+duration+of+action+and+a+favorable+safety+profile+in+preclinical+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of abediterol, a novel inhaled β2-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models</span></div><div class="casAuthors">Aparici, Monica; Gomez-Angelats, Mireia; Vilella, Dolors; Otal, Raquel; Carcasona, Carla; Vinals, Marisa; Ramos, Israel; Gavalda, Amadeu; De Alba, Jorge; Gras, Jordi; Cortijo, Julio; Morcillo, Esteban; Puig, Carlos; Ryder, Hamish; Beleta, Jorge; Miralpeix, Montserrat</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">497-509</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Abediterol is a novel potent, long-acting inhaled β2-adrenoceptor agonist in development for the treatment of asthma and chronic obstructive pulmonary disease.  Abediterol shows subnanomolar affinity for the human β2-adrenoceptor and a functional selectivity over β1-adrenoceptors higher than that of formoterol and indacaterol in both a cellular model with overexpressed human receptors and isolated guinea pig tissue.  Abediterol is a full agonist at the human β2-adrenoceptor (Emax = 91 ± 5% of the maximal effect of isoprenaline).  The potency and onset of action that abediterol shows in isolated human bronchi (EC50 = 1.9 ± 0.4 nM; t1/2 onset = 7-10 min) is not significantly different from that of formoterol, but its duration of action (t1/2 ∼ 690 min) is similar to that of indacaterol.  Nebulized abediterol inhibits acetylcholine-induced bronchoconstriction in guinea pigs in a concn.-dependent manner, with higher potency and longer duration of action (t1/2 = 36 h) than salmeterol (t1/2 = 6 h) and formoterol (t1/2 = 4 h) and similar duration of action to indacaterol up to 48 h.  In dogs, the bronchoprotective effect of abediterol is more sustained than that of salmeterol and indacaterol at doses without effects on heart rate, thus showing a greater safety margin (defined as the ratio of dose increasing heart rate by 5% and dose inhibiting bronchospasm by 50%) than salmeterol, formoterol, and indacaterol (5.6 vs. 3.3, 2.2, and 0.3, resp.).  In conclusion, our results suggest that abediterol has a preclin. profile for once-daily dosing in humans together with a fast onset of action and a favorable cardiovascular safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfsT0Jt09WvbVg90H21EOLACvtfcHk0lgruwX6MncTiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOru7vK&md5=a102a6455f01c296d2beda412fa527c0</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.193284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.193284%26sid%3Dliteratum%253Aachs%26aulast%3DAparici%26aufirst%3DM.%26aulast%3DG%25C3%25B3mez-Angelats%26aufirst%3DM.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DOtal%26aufirst%3DR.%26aulast%3DCarcasona%26aufirst%3DC.%26aulast%3DVi%25C3%25B1als%26aufirst%3DM.%26aulast%3DRamos%26aufirst%3DI.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DDe%2BAlba%26aufirst%3DJ.%26aulast%3DGras%26aufirst%3DJ.%26aulast%3DCortijo%26aufirst%3DJ.%26aulast%3DMorcillo%26aufirst%3DE.%26aulast%3DPuig%26aufirst%3DC.%26aulast%3DRyder%26aufirst%3DH.%26aulast%3DBeleta%26aufirst%3DJ.%26aulast%3DMiralpeix%26aufirst%3DM.%26atitle%3DPharmacological%2520characterization%2520of%2520abediterol%252C%2520a%2520novel%2520inhaled%2520%25CE%25B22-adrenoceptor%2520agonist%2520with%2520long%2520duration%2520of%2520action%2520and%2520a%2520favorable%2520safety%2520profile%2520in%2520preclinical%2520models%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D342%26spage%3D497%26epage%3D509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group">Timmer, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massana, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimenez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seoane, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Miquel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz, S.</span><span> </span><span class="NLM_article-title">First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long-acting β<sub>2</sub>-agonist</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1347</span><span class="NLM_x">–</span> <span class="NLM_lpage">1353</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1002%2Fjcph.355" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=24989946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFagt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=1347-1353&author=W.+Timmerauthor=E.+Massanaauthor=E.+Jimenezauthor=B.+Seoaneauthor=G.+de+Miquelauthor=S.+Ruiz&title=First-in-human+study+of+the+safety%2C+tolerability%2C+pharmacokinetics+and+pharmacodynamics+of+abediterol+%28LAS100977%29%2C+a+novel+long-acting+%CE%B22-agonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long-acting Β2-agonist</span></div><div class="casAuthors">Timmer, Wolfgang; Massana, Eric; Jimenez, Eulalia; Seoane, Beatriz; de Miquel, Gonzalo; Ruiz, Sandrine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1347-1353</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Here we report the results of a first-in-human study to evaluate the safety, tolerability pharmacokinetics, and pharmacodynamics of abediterol, a new β2-adrenergic agonist.  Forty-eight healthy males aged 18-45 years received abediterol doses of 5, 10, 25, or 50 μg, or placebo.  Safety and tolerability assessments included adverse event reporting, pulse and blood pressure monitoring, 12-lead electrocardiograms, lab. tests, and phys. examn.  Pharmacodynamic assessments included whole body plethysmog. to det. the bronchodilatory effect by means of airway conductance and resistance.  Blood and urine samples were obtained for pharmacokinetic analyses.  Abediterol showed an overall good safety and tolerability profile in the dose range tested, consistent with the expected characteristics of a β2-adrenergic agonist.  A dose-dependent increase of systemic treatment-emergent adverse events was obsd., the most frequent being palpitations, tremor, nausea, and asthenia; most were mild in intensity and resolved without the need for intervention.  Improvements in airway conductance (increase) and resistance (decrease) were greater for all doses of abediterol tested compared with placebo at all time-points up to 36 h.  This first-in-human study suggests a potent, rapid, and sustained bronchodilatory effect of abediterol in healthy male subjects.  Lower doses are currently under investigation in patients with asthma and in patients with COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE8xpmQp8DfLVg90H21EOLACvtfcHk0lgruwX6MncTiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFagt7%252FM&md5=1299c729b8dd92206e63c6fe326db666</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1002%2Fjcph.355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.355%26sid%3Dliteratum%253Aachs%26aulast%3DTimmer%26aufirst%3DW.%26aulast%3DMassana%26aufirst%3DE.%26aulast%3DJimenez%26aufirst%3DE.%26aulast%3DSeoane%26aufirst%3DB.%26aulast%3Dde%2BMiquel%26aufirst%3DG.%26aulast%3DRuiz%26aufirst%3DS.%26atitle%3DFirst-in-human%2520study%2520of%2520the%2520safety%252C%2520tolerability%252C%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520abediterol%2520%2528LAS100977%2529%252C%2520a%2520novel%2520long-acting%2520%25CE%25B22-agonist%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2014%26volume%3D54%26spage%3D1347%26epage%3D1353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group">Capacchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipreri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caló, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peveri, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catinella, S.</span><span> </span><span class="NLM_article-title"><sup>1</sup>H NMR discrimination of CHF4226.01 diastereoisomers in DMSO-d6</span> <span class="citation_source-journal">Magn. Reson. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">551</span><span class="NLM_x">–</span> <span class="NLM_lpage">561</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1002%2Fmrc.2427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=19373771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVGltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2009&pages=551-561&author=S.+Capacchiauthor=M.+Lipreriauthor=A.+Rizziauthor=C.+Cal%C3%B3author=T.+Peveriauthor=S.+Catinella&title=1H+NMR+discrimination+of+CHF4226.01+diastereoisomers+in+DMSO-d6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">1H NMR discrimination of CHF4226.01 diastereoisomers in DMSO-d6</span></div><div class="casAuthors">Capacchi, Silvia; Lipreri, Milco; Rizzi, Andrea; Calo, Claudia; Peveri, Tiziana; Catinella, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Magnetic Resonance in Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">551-561</span>CODEN:
                <span class="NLM_cas:coden">MRCHEG</span>;
        ISSN:<span class="NLM_cas:issn">0749-1581</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Two diastereoisomers CHF4226.01 (R, R) and CHF4232.01 (S, R), differing for a chiral center, have been studied to investigate their possible discrimination using NMR. 1D NMR and 2D NMR expts., such as COSY, NOESY and ROESY, were performed on pure isomers and on the assocn. complexes formed in the presence of the chiral reagent (S)-(-)-1-(2-naphthyl)ethylamine (S-NEA).  Moreover, computational studies, concerning conformational anal. and mol. dynamics, were started and supported the NMR results.  Copyright © 2009 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIGr8OLz1Pm7Vg90H21EOLACvtfcHk0lgruwX6MncTiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVGltbg%253D&md5=a998695778865672c2b2d15c2b163dad</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1002%2Fmrc.2427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmrc.2427%26sid%3Dliteratum%253Aachs%26aulast%3DCapacchi%26aufirst%3DS.%26aulast%3DLipreri%26aufirst%3DM.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DCal%25C3%25B3%26aufirst%3DC.%26aulast%3DPeveri%26aufirst%3DT.%26aulast%3DCatinella%26aufirst%3DS.%26atitle%3D1H%2520NMR%2520discrimination%2520of%2520CHF4226.01%2520diastereoisomers%2520in%2520DMSO-d6%26jtitle%3DMagn.%2520Reson.%2520Chem.%26date%3D2009%26volume%3D47%26spage%3D551%26epage%3D561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group">Frampton, J. E.</span><span> </span><span class="NLM_article-title">QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">465</span><span class="NLM_x">–</span> <span class="NLM_lpage">488</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=465-488&author=J.+E.+Frampton&title=QVA149+%28indacaterol%2Fglycopyrronium+fixed-dose+combination%29%3A+a+review+of+its+use+in+patients+with+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFrampton%26aufirst%3DJ.%2BE.%26atitle%3DQVA149%2520%2528indacaterol%252Fglycopyrronium%2520fixed-dose%2520combination%2529%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D465%26epage%3D488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group">Bateman, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, D.</span><span> </span><span class="NLM_article-title">Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1484</span><span class="NLM_x">–</span> <span class="NLM_lpage">1494</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.00200212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23722616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktlahsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2013&pages=1484-1494&author=E.+D.+Batemanauthor=G.+T.+Fergusonauthor=N.+Barnesauthor=N.+Gallagherauthor=Y.+Greenauthor=M.+Henleyauthor=D.+Banerji&title=Dual+bronchodilation+with+QVA149+versus+single+bronchodilator+therapy%3A+the+SHINE+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study</span></div><div class="casAuthors">Bateman, Eric D.; Ferguson, Gary T.; Barnes, Neil; Gallagher, Nicola; Green, Yulia; Henley, Michelle; Banerji, Donald</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1484-1494</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">We investigated the efficacy and safety of dual bronchodilation with QVA149 vs. its monocomponents indacaterol and glycopyrronium, tiotropium and placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).  This was a multicentre, randomized, double-blind, placebo- and active-controlled, 26-wk trial.  Patients (n = 2144) were randomized (2:2:2:2:1) to receive once-daily QVA149 (indacaterol 110 uμg/glycopyrronium 50 μg), indacaterol 150 μg, glycopyrronium 50 μg, open-label tiotropium 18 μg or placebo.  The primary end-point was trough forced expiratory vol. in 1 s (FEV1) at week 26 for QVA149 vs. its monocomponents.  Secondary end-points included dyspnoea, health status, rescue medication use and safety.  Trough FEV1 at week 26 was significantly improved (p<0.001) with QVA149 compared with indacaterol and glycopyrronium (least squares mean (LSM) differences 0.07 L and 0.09 L, resp.), tiotropium and placebo (LSM differences 0.08 L and 0.20 L, resp.); these beneficial effects were sustained throughout the 26-wk study.  QVA149 significantly improved dyspnoea and health status vs. placebo (p<0.001 and p = 0.002, resp.) and tiotropium (p = 0.007 and p = 0.009, resp.) at week 26.  All treatments were well tolerated.  Dual bronchodilation with once-daily QVA149 demonstrated superior and clin. meaningful outcomes vs. placebo and superiority vs. treatment with a single bronchodilator, with a safety and tolerability profile similar to placebo, supporting the concept of fixed-dose long-acting muscarinic antagonist/long-acting β2-agonist combinations for the treatment of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI38gfbCMI37Vg90H21EOLACvtfcHk0lhp0Bvw7eJpXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktlahsg%253D%253D&md5=fa55317191017e1736281011d793ea83</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1183%2F09031936.00200212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00200212%26sid%3Dliteratum%253Aachs%26aulast%3DBateman%26aufirst%3DE.%2BD.%26aulast%3DFerguson%26aufirst%3DG.%2BT.%26aulast%3DBarnes%26aufirst%3DN.%26aulast%3DGallagher%26aufirst%3DN.%26aulast%3DGreen%26aufirst%3DY.%26aulast%3DHenley%26aufirst%3DM.%26aulast%3DBanerji%26aufirst%3DD.%26atitle%3DDual%2520bronchodilation%2520with%2520QVA149%2520versus%2520single%2520bronchodilator%2520therapy%253A%2520the%2520SHINE%2520study%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2013%26volume%3D42%26spage%3D1484%26epage%3D1494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group">Mahler, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decramer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Urzo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worth, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alagappan, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulich, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, D.</span><span> </span><span class="NLM_article-title">Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE study</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1599</span><span class="NLM_x">–</span> <span class="NLM_lpage">1609</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.00124013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=24176997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC2c7hsFShsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=1599-1609&author=D.+A.+Mahlerauthor=M.+Decramerauthor=A.+D%E2%80%99Urzoauthor=H.+Worthauthor=T.+Whiteauthor=V.+K.+Alagappanauthor=H.+Chenauthor=N.+Gallagherauthor=K.+Kulichauthor=D.+Banerji&title=Dual+bronchodilation+with+QVA149+reduces+patient-reported+dyspnoea+in+COPD%3A+BLAZE+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study</span></div><div class="casAuthors">Mahler Donald A; Decramer Marc; D'Urzo Anthony; Worth Heinrich; White Tracy; Alagappan Vijay K T; Chen Hungta; Banerji Donald; Gallagher Nicola; Kulich Karoly</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1599-609</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We evaluated the effect of QVA149, a dual bronchodilator combining indacaterol and glycopyrronium, on direct patient-reported dyspnoea in patients with moderate-to-severe chronic obstructive pulmonary disease.  In this multicentre, blinded, double-dummy, three-period crossover study, 247 patients were randomised to once-daily QVA149 110/50 μg, placebo or tiotropium 18 μg.  Superiority of QVA149 versus placebo (primary objective) and tiotropium (secondary objective) was assessed for improvement in dyspnoea via the self-administered computerised (SAC) version of the Baseline and Transition Dyspnoea Index after 6 weeks.  Secondary end-points included lung function, rescue medication use and safety.  After 6 weeks, the SAC Transition Dyspnoea Index total score was significantly higher with QVA149 versus placebo (least squares mean (LSM) treatment difference 1.37, p<0.001) and tiotropium (LSM treatment difference 0.49, p=0.021).  QVA149 provided significant improvements in lung function, with higher forced expiratory volume in 1 s area under the curve from 0-4 h post-dose versus placebo and tiotropium at day 1 and week 6 (all p<0.001).  Rescue medication use was significantly lower with QVA149 versus placebo (p<0.001) and tiotropium (p=0.002).  All treatments were well tolerated.  Once-daily QVA149 provided superior improvements in patient-reported dyspnoea and lung function versus placebo and tiotropium.  These benefits were associated with improvements in other symptoms and reduced use of rescue medication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-C19TuUAlt8jl5L8hwNX0fW6udTcc2eac-vuRnuOzT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7hsFShsg%253D%253D&md5=541bf4a7479374424d7c291dd66476ac</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1183%2F09031936.00124013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00124013%26sid%3Dliteratum%253Aachs%26aulast%3DMahler%26aufirst%3DD.%2BA.%26aulast%3DDecramer%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Urzo%26aufirst%3DA.%26aulast%3DWorth%26aufirst%3DH.%26aulast%3DWhite%26aufirst%3DT.%26aulast%3DAlagappan%26aufirst%3DV.%2BK.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DGallagher%26aufirst%3DN.%26aulast%3DKulich%26aufirst%3DK.%26aulast%3DBanerji%26aufirst%3DD.%26atitle%3DDual%2520bronchodilation%2520with%2520QVA149%2520reduces%2520patient-reported%2520dyspnoea%2520in%2520COPD%253A%2520BLAZE%2520study%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2014%26volume%3D43%26spage%3D1599%26epage%3D1609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group">Dahl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kho, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alagappan, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, D.</span><span> </span><span class="NLM_article-title">Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">1558</span><span class="NLM_x">–</span> <span class="NLM_lpage">1567</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2013.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23867808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC3sfitVGqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2013&pages=1558-1567&author=R.+Dahlauthor=K.+R.+Chapmanauthor=M.+Rudolfauthor=R.+Mehtaauthor=P.+Khoauthor=V.+K.+Alagappanauthor=H.+Chenauthor=D.+Banerji&title=Safety+and+efficacy+of+dual+bronchodilation+with+QVA149+in+COPD+patients%3A+the+ENLIGHTEN+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study</span></div><div class="casAuthors">Dahl Ronald; Chapman Kenneth R; Rudolf Michael; Mehta Rajendra; Kho Pearl; Alagappan Vijay K T; Chen Hungta; Banerji Donald</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1558-67</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  QVA149 is an inhaled, once-daily fixed-dose dual bronchodilator combination of the long-acting β2-agonist indacaterol and long-acting muscarinic antagonist glycopyrronium (NVA237) for the treatment of chronic obstructive pulmonary disease (COPD).  We investigated the safety and efficacy of QVA149 over 52 weeks.  METHODS:  This 52-week, multicenter, double-blind, parallel-group, placebo-controlled study randomized (2:1) patients with moderate-to-severe COPD to once-daily QVA149 (110 μg indacaterol/50 μg glycopyrronium) or placebo delivered via the Breezhaler device.  Primary endpoint was safety and tolerability for treatment-emergent adverse events (AEs).  Secondary endpoints included safety based on vital signs, electrocardiograms (ECGs), laboratory evaluations, and pre-dose forced expiratory volume in 1 s (FEV1).  RESULTS:  Of 339 patients randomized, QVA149 [n = 226], placebo [n = 113]; 76.9% male, mean age: 62.6 years, post-bronchodilator FEV1: 57.4% predicted, 83.5% completed study.  A smaller percentage of patients discontinued in the QVA149 group (14.2%) compared with placebo (21.2%).  Overall incidence of AEs was similar in the QVA149 (57.8%) and placebo (56.6%) groups, with most AEs being mild to moderate in severity.  The numerical differences in some AEs observed could be at least in part explained by differences in baseline patient characteristics.  No clinically relevant differences were observed between treatment groups for vital signs or ECG parameters.  The five deaths reported were unrelated to study medication (QVA149, n = 4 [1.8%]; placebo, n = 1 [0.9%]).  QVA149 demonstrated rapid and clinically meaningful bronchodilation sustained over 52 weeks versus placebo.  CONCLUSION:  QVA149 demonstrated a good safety and tolerability profile, providing rapid and sustained bronchodilation over 52 weeks in patients with moderate-to-severe COPD.  ClinicalTrials.gov identifier: NCT01120717.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQwufKv2haYhsKL0FlyGHDofW6udTcc2eYLLh6y-W1jAbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfitVGqtQ%253D%253D&md5=0daaecfa3575b5f3e1e7dc18b517e778</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2013.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2013.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DChapman%26aufirst%3DK.%2BR.%26aulast%3DRudolf%26aufirst%3DM.%26aulast%3DMehta%26aufirst%3DR.%26aulast%3DKho%26aufirst%3DP.%26aulast%3DAlagappan%26aufirst%3DV.%2BK.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DBanerji%26aufirst%3DD.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520dual%2520bronchodilation%2520with%2520QVA149%2520in%2520COPD%2520patients%253A%2520the%2520ENLIGHTEN%2520study%26jtitle%3DRespir.%2520Med.%26date%3D2013%26volume%3D107%26spage%3D1558%26epage%3D1567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group">Beeh, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jadayel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, D.</span><span> </span><span class="NLM_article-title">Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">584</span><span class="NLM_x">–</span> <span class="NLM_lpage">592</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2014.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=24534204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC2cvlslSmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2014&pages=584-592&author=K.+M.+Beehauthor=S.+Kornauthor=J.+Beierauthor=D.+Jadayelauthor=M.+Henleyauthor=P.+D%E2%80%99Andreaauthor=D.+Banerji&title=Effect+of+QVA149+on+lung+volumes+and+exercise+tolerance+in+COPD+patients%3A+the+BRIGHT+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study</span></div><div class="casAuthors">Beeh Kai-Michael; Korn Stephanie; Beier Jutta; Jadayel Dalal; Henley Michelle; D'Andrea Peter; Banerji Donald</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">584-92</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  QVA149 is a novel, inhaled, once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium (NVA237), for the treatment of chronic obstructive pulmonary disease (COPD).  This study evaluated the effects of QVA149 on exercise tolerance, hyperinflation, lung function and lung volumes versus placebo and tiotropium.  METHODS:  Patients with moderate-to-severe COPD were randomized to QVA149 110/50 μg, placebo or tiotropium 18 μg once daily in a blinded, 3-period crossover study for 3 weeks.  The primary endpoint was exercise endurance time at Day 21 for QVA149 versus placebo.  RESULTS:  Eighty-five patients were randomized; 86% completed the study.  QVA149 significantly improved exercise endurance time at Day 21 compared with placebo (least squares mean treatment difference 60 s [p = 0.006]).  No significant improvements in exercise endurance time at Day 21 between QVA149 and tiotropium were found.  Dynamic inspiratory capacity (IC) at exercise isotime, trough forced expiratory volume in 1 s, residual volume and functional residual capacity showed significant improvements with QVA149 from Day 1 of treatment that were maintained throughout the study.  The safety profiles were similar across groups.  CONCLUSIONS:  In patients with moderate-to-severe COPD, once-daily QVA149 significantly improved exercise endurance time compared with placebo which was associated with sustained reductions of lung hyperinflation as indicated by significant improvement in IC at rest and during exercise.  TRIAL REGISTRATION:  ClinicalTrials.gov NCT01294787.  TAKE HOME MESSAGE:  Dual bronchodilation with QVA149 decreases lung hyperinflation and improves exercise tolerance and lung function in patients with moderate-to-severe COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJNLFWqA5MzinGiHuhFGv8fW6udTcc2eYI8kGk4MIcZrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvlslSmug%253D%253D&md5=9bc7739335095e26fb429057361eb65a</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2014.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2014.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DBeeh%26aufirst%3DK.%2BM.%26aulast%3DKorn%26aufirst%3DS.%26aulast%3DBeier%26aufirst%3DJ.%26aulast%3DJadayel%26aufirst%3DD.%26aulast%3DHenley%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DP.%26aulast%3DBanerji%26aufirst%3DD.%26atitle%3DEffect%2520of%2520QVA149%2520on%2520lung%2520volumes%2520and%2520exercise%2520tolerance%2520in%2520COPD%2520patients%253A%2520the%2520BRIGHT%2520study%26jtitle%3DRespir.%2520Med.%26date%3D2014%26volume%3D108%26spage%3D584%26epage%3D592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group">Wedzicha, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decramer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficker, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niewoehner, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandström, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrasate, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, D.</span><span> </span><span class="NLM_article-title">Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study</span> <span class="citation_source-journal">Lancet Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">–</span> <span class="NLM_lpage">209</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2FS2213-2600%2813%2970052-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFCltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=199-209&author=J.+A.+Wedzichaauthor=M.+Decramerauthor=J.+H.+Fickerauthor=D.+E.+Niewoehnerauthor=T.+Sandstr%C3%B6mauthor=A.+F.+Taylorauthor=P.+D%E2%80%99Andreaauthor=C.+Arrasateauthor=H.+Chenauthor=D.+Banerji&title=Analysis+of+chronic+obstructive+pulmonary+disease+exacerbations+with+the+dual+bronchodilator+QVA149+compared+with+glycopyrronium+and+tiotropium+%28SPARK%29%3A+a+randomised%2C+double-blind%2C+parallel-group+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study</span></div><div class="casAuthors">Wedzicha, Jadwiga A.; Decramer, Marc; Ficker, Joachim H.; Niewoehner, Dennis E.; Sandstrom, Thomas; Taylor, Angel Fowler; D'Andrea, Peter; Arrasate, Christie; Chen, Hungta; Banerji, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">199-209</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We evaluated the effect of dual, longacting inhaled bronchodilator treatment on exacerbations in patients with severe and very severe chronic obstructive pulmonary disease (COPD).  In this parallel-group study, 2224 patients (aged ≥40 years, Global Initiative for Chronic Obstructive Lung Disease stages III-IV, and one or more moderate COPD exacerbation in the past year) were randomly assigned (1:1:1; via interactive voice response or web system; stratified for smoking status) to once-daily QVA149 (fixed-dose combination of indacaterol 110 μg and glycopyrronium 50 μg), glycopyrronium 50 μg, or tiotropium 18 μg for 64 wk.  Assignment to QVA149 and glycopyrronium was double-blind; tiotropium was open-label.  Efficacy was assessed in all patients randomly assigned to treatment groups who received at least one dose of study drug; safety was assessed in all patients who received at least one dose whether or not they were assigned to a group.  The primary objective was to show superiority of QVA149 vs. glycopyrronium for rate of moderate to severe COPD exacerbations (defined by worsening symptoms and categorized by treatment requirements) during treatment.  This completed trial is registered at ClinicalTrials.gov, NCT01120691.  Between Apr. 27, 2010, and July 11, 2012, 741 patients were randomly assigned to receive QVA149, 741 to receive glycopyrronium, and 742 to receive tiotropium (729, 739, and 737 patients, resp., analyzed for efficacy).  QVA149 significantly reduced the rate of moderate to severe exacerbations vs. glycopyrronium by 12% (annualized rate of exacerbations 0·84 [95% CI 0·75-0·94] vs 0·95 [0·85-1·06]; rate ratio 0·88, 95% CI 0·77-0·99, p=0·038).  Adverse events (including exacerbations) were reported for 678 (93%) of 729 patients on QVA149, 694 (94%) of 740 on glycopyrronium, and 686 (93%) of 737 on tiotropium.  Incidence of serious adverse events was similar between groups (167 [23%] patients on QVA149, 179 [24%] on glycopyrronium, and 165 [22%] on tiotropium); COPD worsening was the most frequent serious adverse event (107 [15%] patients on QVA149, 116 [16%] on glycopyrronium, 87 [12%] on tiotropium).  The dual bronchodilator QVA149 was superior in preventing moderate to severe COPD exacerbations compared with the single longacting antimuscarinic bronchodilator glycopyrronium, with concomitant improvements in lung function and health status.  These results indicate the potential of dual bronchodilation as a treatment option for patients with severe and very severe COPD.Novartis Pharma AG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh5It-DxP4I7Vg90H21EOLACvtfcHk0lhd9kr-HzyzRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFCltL8%253D&md5=5395598ea51ec5290a241a947aef44b9</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2813%2970052-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252813%252970052-3%26sid%3Dliteratum%253Aachs%26aulast%3DWedzicha%26aufirst%3DJ.%2BA.%26aulast%3DDecramer%26aufirst%3DM.%26aulast%3DFicker%26aufirst%3DJ.%2BH.%26aulast%3DNiewoehner%26aufirst%3DD.%2BE.%26aulast%3DSandstr%25C3%25B6m%26aufirst%3DT.%26aulast%3DTaylor%26aufirst%3DA.%2BF.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DP.%26aulast%3DArrasate%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DBanerji%26aufirst%3DD.%26atitle%3DAnalysis%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520exacerbations%2520with%2520the%2520dual%2520bronchodilator%2520QVA149%2520compared%2520with%2520glycopyrronium%2520and%2520tiotropium%2520%2528SPARK%2529%253A%2520a%2520randomised%252C%2520double-blind%252C%2520parallel-group%2520study%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2013%26volume%3D1%26spage%3D199%26epage%3D209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group">Dahl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jadayel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alagappan, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, D.</span><span> </span><span class="NLM_article-title">Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study</span> <span class="citation_source-journal">Int. J. Chronic Obstruct. Pulm. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">501</span><span class="NLM_x">–</span> <span class="NLM_lpage">508</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.2147%2FCOPD.S49615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=24159259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVejt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=501-508&author=R.+Dahlauthor=D.+Jadayelauthor=V.+K.+Alagappanauthor=H.+Chenauthor=D.+Banerji&title=Efficacy+and+safety+of+QVA149+compared+to+the+concurrent+administration+of+its+monocomponents+indacaterol+and+glycopyrronium%3A+the+BEACON+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study</span></div><div class="casAuthors">Dahl, Ronald; Jadayel, Dalal; Alagappan, Vijay K. T.; Chen, Hungta; Banerji, Donald</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Chronic Obstructive Pulmonary Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">501-508, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">IJCOC3</span>;
        ISSN:<span class="NLM_cas:issn">1178-2005</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Introduction: The BEACON study evaluated the efficacy and safety of QVA149, a once-daily dual bronchodilator contg. a fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol and long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237), in development for the treatment of patients with chronic obstructive pulmonary disease (COPD), compared with the free-dose concurrent administration of indacaterol plus glycopyrronium (IND+GLY).  Methods: In this multicenter, double-blind, parallel group study, patients with stage II or stage III COPD (Global initiative for chronic Obstructive Lung Disease [GOLD] 2010) were randomized (1:1) to once-daily QVA149 (110 μg indacaterol/50 μg glycopyrronium) or concurrent administration of indacaterol (150 μg) and glycopyrronium (50 μg) via the Breezhaler device for 4 wk.  The primary endpoint was to evaluate the noninferiority of QVA149 as compared with concurrent administration of IND+GLY, for trough forced expiratory vol. in 1 s (FEV1) after 4 wk of treatment.  The other assessments included FEV1 area under the curve from 0 to 4 h (AUC0-4 h) at day 1 and week 4, symptom scores, rescue medication use, safety and tolerability over the 4 wk study period.  Results: Of 193 patients randomized, 187 (96.9%) completed the study.  Trough FEV1 at week 4 for QVA149 and IND+GLY was 1.46 L ± 0.02 and 1.46 L ± 0.18, resp.  The FEV1 AUC0-4 h at day 1 and week 4 were similar between the two treatment groups.  Both treatment groups had a similar redn. in symptom scores and rescue medication use for the 4 wk treatment period.  Overall, 25.6% of patients in QVA149 group and 25.2% in the IND+GLY group experienced an adverse event, with the majority being mild-to-moderate in severity.  No deaths were reported during the study or during the 30 days follow-up period.  Conclusion: The BEACON study demonstrated that once-daily QVA149 provides an efficacy and safety profile similar to the concurrent administration of its monocomponents indacaterol and glycopyrronium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpRDctxMO58rVg90H21EOLACvtfcHk0lhyypSN_EIJ9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVejt7s%253D&md5=65d22196e8b19472e30307a520319e88</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S49615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S49615%26sid%3Dliteratum%253Aachs%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DJadayel%26aufirst%3DD.%26aulast%3DAlagappan%26aufirst%3DV.%2BK.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DBanerji%26aufirst%3DD.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520QVA149%2520compared%2520to%2520the%2520concurrent%2520administration%2520of%2520its%2520monocomponents%2520indacaterol%2520and%2520glycopyrronium%253A%2520the%2520BEACON%2520study%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2013%26volume%3D8%26spage%3D501%26epage%3D508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group">Rodrigo, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plaza, V.</span><span> </span><span class="NLM_article-title">Efficacy and safey of fixed-dose combination of indacaterol and glycopyrronium for the treatment of COPD: a systematic review</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2014&pages=309-317&author=G.+J.+Rodrigoauthor=V.+Plaza&title=Efficacy+and+safey+of+fixed-dose+combination+of+indacaterol+and+glycopyrronium+for+the+treatment+of+COPD%3A+a+systematic+review"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigo%26aufirst%3DG.%2BJ.%26aulast%3DPlaza%26aufirst%3DV.%26atitle%3DEfficacy%2520and%2520safey%2520of%2520fixed-dose%2520combination%2520of%2520indacaterol%2520and%2520glycopyrronium%2520for%2520the%2520treatment%2520of%2520COPD%253A%2520a%2520systematic%2520review%26jtitle%3DChest%26date%3D2014%26volume%3D146%26spage%3D309%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group">Rodrigo, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plaza, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro-Rodríguez, J. A.</span><span> </span><span class="NLM_article-title">Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review</span> <span class="citation_source-journal">Pulm. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">40</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.pupt.2011.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=22085775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFOktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=40-47&author=G.+J.+Rodrigoauthor=V.+Plazaauthor=J.+A.+Castro-Rodr%C3%ADguez&title=Comparison+of+three+combined+pharmacological+approaches+with+tiotropium+monotherapy+in+stable+moderate+to+severe+COPD%3A+a+systematic+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: A systematic review</span></div><div class="casAuthors">Rodrigo, Gustavo J.; Plaza, Vicente; Castro-Rodriguez, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-47</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Background: Guidelines recommend the use of inhaled long-acting bronchodilators, inhaled corticosteroids (ICS) and their combinations for maintenance treatment of moderate to severe COPD.  However, there are limited data supporting combination therapy.  Methods: This systematic review assessed the efficacy of three therapeutic approaches: tiotropium plus long-acting beta2-agonist (LABA) ("dual" therapy), LABA/ICS ("combined" therapy), and tiotropium plus LABA/ICS ("triple" therapy), all compared with tiotropium monotherapy.  Randomized controlled trials were identified after a search of different databases of published and unpublished trials.  Results: Twenty trials (6803 participants) were included.  "Dual" therapy showed significant improvements in forced vol. in the first second (FEV1), health-related quality of life (HRQoL), and dyspnea.  However, it failed to reduce the risk of COPD exacerbations.  Compared with tiotropium, "combined" therapy presented modest but significant effects on FEV1, HRQoL, and dyspnea.  Again, there was no significant difference in exacerbations, but it was assocd. with a significant increase of serious adverse effects (SAE) (no. need to treat for harm [NNTH] = 20; 95% CI: 11-119).  Finally, "triple therapy" increased FEV1, improved HRQoL (both benefits exceeded minimal important differences) and decrease COPD exacerbations in anon-significant way. (Odds ratio [OR] = 0.57; 95% CI: 0.24 to 1.37, p = 0.21).  Conclusions: "Dual" and "triple" therapy seem like the most promising for patients with moderate to very severe COPD.  However, data are still scarce and studies too short to generate a strong recommendation.  Future studies should examine long-term efficacy and safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWgACcO1gWMLVg90H21EOLACvtfcHk0lhyypSN_EIJ9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFOktLY%253D&md5=3e2dfda05e640402d31f6c47be86ec19</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2011.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2011.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigo%26aufirst%3DG.%2BJ.%26aulast%3DPlaza%26aufirst%3DV.%26aulast%3DCastro-Rodr%25C3%25ADguez%26aufirst%3DJ.%2BA.%26atitle%3DComparison%2520of%2520three%2520combined%2520pharmacological%2520approaches%2520with%2520tiotropium%2520monotherapy%2520in%2520stable%2520moderate%2520to%2520severe%2520COPD%253A%2520a%2520systematic%2520review%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D25%26spage%3D40%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group">Vogelmeier, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bateman, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallante, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alagappan, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, D.</span><span> </span><span class="NLM_article-title">Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study</span> <span class="citation_source-journal">Lancet Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">51</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2FS2213-2600%2812%2970052-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFCmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=51-60&author=C.+F.+Vogelmeierauthor=E.+D.+Batemanauthor=J.+Pallanteauthor=V.+K.+Alagappanauthor=P.+D%E2%80%99Andreaauthor=H.+Chenauthor=D.+Banerji&title=Efficacy+and+safety+of+once-daily+QVA149+compared+with+twice-daily+salmeterol-fluticasone+in+patients+with+chronic+obstructive+pulmonary+disease+%28ILLUMINATE%29%3A+a+randomised%2C+double-blind%2C+parallel+group+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study</span></div><div class="casAuthors">Vogelmeier, Claus F.; Bateman, Eric D.; Pallante, John; Alagappan, Vijay K. T.; D'Andrea, Peter; Chen, Hungta; Banerji, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-60</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">QVA149 is an inhaled fixed-dose combination therapy under development for the treatment of chronic obstructive pulmonary disease (COPD).  It combines indacaterol (a longacting β2-agonist) with glycopyrronium (a longacting muscarinic antagonist) as a dual bronchodilator.  We aimed to compare the efficacy, safety, and tolerability of QVA149 vs. salmeterol-fluticasone (SFC) over 26 wk in patients with moderate-to-severe COPD.  In this multicentre double-blind, double-dummy, parallel-group study, 523 patients (age 40 years or older, Global Initiative for Chronic Obstructive Lung Disease [GOLD] stages II-III, without exacerbations in the previous year) were randomly assigned (1:1; via automated, interactive response technol. and stratified for smoking status) to once-daily QVA149 110/50 μg or twice-daily SFC 50/500 μg for 26 wk.  Efficacy was assessed in the full anal. set (randomised patients who received at least one dose of study drug); safety was assessed in all patients who received at least one dose of study drug.  The primary endpoint was to demonstrate the superiority of QVA149 compared with SFC for the standardized area under the curve from 0 to 12 h post dose for forced expiratory vol. in 1 s (FEV1 AUC0-12h) after 26 wk of treatment.  This trial was registered at ClinicalTrial.gov, NCT01315249.  Between March 25, 2011, and March 12, 2012, 259 patients were randomly assigned to receive QVA149 and 264 to receive SFC.  At week 26, FEV1 AUC0-12h was significantly higher with QVA149 than with SFC (treatment difference 0·138 L; 95% CI 0·100-0·176; p<0·0001).  Overall incidence of adverse events (including COPD exacerbations) was 55·4% (143 of 258) for the QVA149 group and 60·2% (159 of 264) for the SFC group.  Incidence of serious adverse events was similar between treatment groups (QVA149, 13 of 258 [5·0%]; SFC 14 of 264 [5·3%]); COPD worsening was the most frequent serious adverse event (one of 13 [0·4%] and three of 14 [1·1%], resp.).  Once-daily QVA149 provides significant, sustained, and clin. meaningful improvements in lung function vs. twice-daily SFC, with significant symptomatic benefit.  These results indicate the potential of dual bronchodilation as a treatment option for non-exacerbating symptomatic COPD patients.Novartis Pharma AG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOxmQ6p9ONmbVg90H21EOLACvtfcHk0lgAgGnTyZCDJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFCmtr4%253D&md5=c39b6cf8dd09f1165ee0373328493090</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2812%2970052-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252812%252970052-8%26sid%3Dliteratum%253Aachs%26aulast%3DVogelmeier%26aufirst%3DC.%2BF.%26aulast%3DBateman%26aufirst%3DE.%2BD.%26aulast%3DPallante%26aufirst%3DJ.%26aulast%3DAlagappan%26aufirst%3DV.%2BK.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DBanerji%26aufirst%3DD.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520once-daily%2520QVA149%2520compared%2520with%2520twice-daily%2520salmeterol-fluticasone%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%2520%2528ILLUMINATE%2529%253A%2520a%2520randomised%252C%2520double-blind%252C%2520parallel%2520group%2520study%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2013%26volume%3D1%26spage%3D51%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group">Donohue, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maleki-Yazdi, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilbride, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Church, A.</span><span> </span><span class="NLM_article-title">Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">1538</span><span class="NLM_x">–</span> <span class="NLM_lpage">1546</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2013.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23830094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC3sjosVCqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2013&pages=1538-1546&author=J.+F.+Donohueauthor=M.+R.+Maleki-Yazdiauthor=S.+Kilbrideauthor=R.+Mehtaauthor=C.+Kalbergauthor=A.+Church&title=Efficacy+and+safety+of+once-daily+umeclidinium%2Fvilanterol+62.5%2F25+mcg+in+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD</span></div><div class="casAuthors">Donohue J F; Maleki-Yazdi M R; Kilbride S; Mehta R; Kalberg C; Church A</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1538-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">STUDY OBJECTIVE:  To examine the efficacy and safety of the once-daily, inhaled, long-acting muscarinic antagonist/β2-agonist combination umeclidinium/vilanterol (UMEC/VI) compared with UMEC and VI monotherapies in patients with chronic obstructive pulmonary disease (COPD).  METHODS:  In this 24-week, double-blind, placebo-controlled, parallel-group study (ClinicalTrials.gov: NCT01313650) eligible patients were randomised 3:3:3:2 to treatment with UMEC/VI 62.5/25 mcg, UMEC 62.5 mcg, VI 25 mcg or placebo administered once daily via dry powder inhaler (N = 1532; intent-to-treat population).  Primary endpoint was trough forced expiratory volume in one second (FEV1) on Day 169 (23-24 h post-dose).  Additional lung-function, symptomatic, and health-related quality-of-life endpoints were assessed, including 0-6 h weighted-mean FEV1, rescue salbutamol use, Transition Dyspnoea Index (TDI), Shortness Of Breath With Daily Activity (SOBDA) and St.  George's Respiratory Questionnaire (SGRQ) scores.  Safety evaluations included adverse events (AEs), vital signs, 12-lead/24-h Holter electrocardiography parameters and clinical laboratory/haematology measurements.  RESULTS:  All active treatments produced statistically significant improvements in trough FEV1 compared with placebo on Day 169 (0.072-0.167 L, all p < 0.001); increases with UMEC/VI 62.5/25 mcg were significantly greater than monotherapies (0.052-0.095 L, p ≤ 0.004).  Improvements were observed for UMEC/VI 62.5/25 mcg vs placebo for weighted-mean FEV1 on Day 168 (0.242 L, p < 0.001), rescue salbutamol use during Weeks 1-24 (-0.8 puffs/day, p = 0.001), TDI (1.2 units, p < 0.001), SOBDA (-0.17 units, p < 0.001) and SGRQ (-5.51 units, p < 0.001) scores.  No clinically-significant changes in vital signs, electrocardiography, or laboratory parameters were observed.  CONCLUSION:  Once-daily UMEC/VI 62.5/25 mcg was well tolerated and provided clinically-significant improvements in lung function and symptoms in patients with COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQF77nXMFz80xcr74wzj5o5fW6udTcc2eb2nBlIfzQVxrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjosVCqsg%253D%253D&md5=0e36e3b81b44d3617bdc318adddf2b20</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2013.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2013.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DDonohue%26aufirst%3DJ.%2BF.%26aulast%3DMaleki-Yazdi%26aufirst%3DM.%2BR.%26aulast%3DKilbride%26aufirst%3DS.%26aulast%3DMehta%26aufirst%3DR.%26aulast%3DKalberg%26aufirst%3DC.%26aulast%3DChurch%26aufirst%3DA.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520once-daily%2520umeclidinium%252Fvilanterol%252062.5%252F25%2520mcg%2520in%2520COPD%26jtitle%3DRespir.%2520Med.%26date%3D2013%26volume%3D107%26spage%3D1538%26epage%3D1546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group">Celli, B.; Crater, G.; Kilbride, S.; Mehta, R.; Tabberer, M.; Kalberg, C. J.; Church, A.</span><span> </span><span class="NLM_article-title">Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study</span>.  <span class="citation_source-journal">Chest</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1378/chest.13-1579</span> . Published Online: Jan 2,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1378%2Fchest.13-1579" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=B.+Celli&author=G.+Crater&author=S.+Kilbride&author=R.+Mehta&author=M.+Tabberer&author=C.+J.+Kalberg&author=A.+Church&title=Once-daily+umeclidinium%2Fvilanterol+125%2F25+mcg+in+COPD%3A+a+randomized%2C+controlled+study&doi=10.1378%2Fchest.13-1579"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1378%2Fchest.13-1579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.13-1579%26sid%3Dliteratum%253Aachs%26aulast%3DCelli%26aufirst%3DB.%26atitle%3DOnce-daily%2520umeclidinium%252Fvilanterol%2520125%252F25%2520mcg%2520in%2520COPD%253A%2520a%2520randomized%252C%2520controlled%2520study%26jtitle%3DChest%26doi%3D10.1378%2Fchest.13-1579%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group">Decramer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anzueto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerwin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaelin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crater, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabberer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Church, A.</span><span> </span><span class="NLM_article-title">Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials</span> <span class="citation_source-journal">Lancet Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">472</span><span class="NLM_x">–</span> <span class="NLM_lpage">486</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2FS2213-2600%2814%2970065-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVajtrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=472-486&author=M.+Decramerauthor=A.+Anzuetoauthor=E.+Kerwinauthor=T.+Kaelinauthor=N.+Richardauthor=G.+Craterauthor=M.+Tabbererauthor=S.+Harrisauthor=A.+Church&title=Efficacy+and+safety+of+umeclidinium+plus+vilanterol+versus+tiotropium%2C+vilanterol%2C+or+umeclidinium+monotherapies+over+24+weeks+in+patients+with+chronic+obstructive+pulmonary+disease%3A+results+from+two+multicentre%2C+blinded%2C+randomised+controlled+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials</span></div><div class="casAuthors">Decramer, Marc; Anzueto, Antonio; Kerwin, Edward; Kaelin, Thomas; Richard, Nathalie; Crater, Glenn; Tabberer, Maggie; Harris, Stephanie; Church, Alison</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">472-486</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Combination long-acting bronchodilator treatment might be more effective than long-acting bronchodilator monotherapy for the treatment of chronic obstructive pulmonary disease (COPD).  We aimed to compare the efficacy and safety of umeclidinium (UMEC) plus vilanterol (VI) with tiotropium (TIO) monotherapy, UMEC monotherapy, or VI monotherapy in patients with moderate to very severe COPD.  In two multicentre, randomised, blinded, double-dummy, parallel-group, active-controlled trials, eligible patients (current or former smokers aged 40 years or older with an established clin. history of COPD) were randomly assigned in 1:1:1:1 ratio to UMEC 125 μg plus VI 25 μg, UMEC 62·5 μg plus VI 25 μg, TIO 18 μg, and either VI 25 μg (study 1) or UMEC 125 μg (study 2).  All study drugs were used once daily for 24 wk.  TIO was delivered via the HandiHaler inhaler and all other active treatments were delivered via the ELLIPTA dry powder inhaler.  Random assignment (by a validated computer-based system) was done by center and was not stratified.  All patients and physicians were masked to assigned treatment during the studies.  The primary efficacy endpoint of both studies was trough forced expiratory vol. in 1 s (FEV1) on day 169, which was analyzed in the intention-to-treat population.  Both studies are registered with ClinicalTrials.gov, nos. NCT01316900 (study 1) and NCT01316913 (study 2).1141 participants were recruited in study 1, and 1191 in study 2.  For study 1, after exclusions, 208, 209, 214, and 212 patients were included in the intention-to-treat analyses for TIO monotherapy, VI monotherapy, UMEC 125 μg plus VI 25 μg, and UMEC 62·5 μg plus VI 25 μg, resp.  For study 2, 215, 222, 215, and 217 patients were included in the intention-to-treat analyses for TIO monotherapy, UMEC monotherapy, UMEC 125 μg plus VI 25 μg, and UMEC 62·5 μg plus VI 25 μg, resp.  In both studies, we noted improvements in trough FEV1 on day 169 for both doses of UMEC plus VI compared with TIO monotherapy (study 1, UMEC 125 μg plus VI 25 μg: 0·088 L [95% CI 0·036 to 0·140; p=0·0010]; study 1, UMEC 62·5 μg plus VI 25 μg: 0·090 L [0·039 to 0·141; p=0·0006]; study 2, UMEC 125 μg plus VI 25 μg: 0·074 L [0·025 to 0·123; p=0·0031]; study 2, UMEC 62·5 μg plus VI 25 μg: 0·060 L [0·010 to 0·109; nominal p=0·0182]).  Both doses of UMEC plus VI also improved trough FEV1 compared with VI monotherapy (UMEC 125 μg plus VI 25 μg: 0·088 L [0·036 to 0·140; p=0·0010]; UMEC 62·5 μg plus VI 25 μg: 0·090 L [0·039 to 0·142; p=0·0006], but not compared with UMEC 125 μg monotherapy (UMEC 125 μg plus VI 25 μg: 0·037 L [-0·012 to 0·087; p=0·14]; UMEC 62·5 μg plus VI 25 μg: 0·022 L [-0·027 to 0·072; p=0·38]).  All treatments produced improvements in dyspnoea and health-related quality of life; we noted no significant differences in symptoms, health status, or risk of exacerbation between UMEC plus VI and TIO.  The most common on-treatment, severe-intensity adverse event in both studies was acute exacerbation of COPD (1-4 [<1-2%] patients across treatment groups in study 1 and 1-6 [<1-3%] patients in study 2).  We recorded five to 15 (2-7%) on-treatment serious adverse events across treatment groups in study 1, and nine to 22 (4-10%) in study 2.  We noted no substantial changes from baseline in vital signs, clin. lab. findings, or electrocardiog. findings in any of the treatment groups.  Combination treatment with once-daily UMEC plus VI improved lung function compared with VI monotherapy and TIO monotherapy in patients with COPD.  Overall our results suggest that the combination of UMEC plus VI could be beneficial for the treatment of moderate to very severe COPD.GlaxoSmithKline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSMEBX1IMgJrVg90H21EOLACvtfcHk0lhj1DjkS_Xx_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVajtrnN&md5=abc15201bb79e9bc20187efd25d83b44</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2814%2970065-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252814%252970065-7%26sid%3Dliteratum%253Aachs%26aulast%3DDecramer%26aufirst%3DM.%26aulast%3DAnzueto%26aufirst%3DA.%26aulast%3DKerwin%26aufirst%3DE.%26aulast%3DKaelin%26aufirst%3DT.%26aulast%3DRichard%26aufirst%3DN.%26aulast%3DCrater%26aufirst%3DG.%26aulast%3DTabberer%26aufirst%3DM.%26aulast%3DHarris%26aufirst%3DS.%26aulast%3DChurch%26aufirst%3DA.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520umeclidinium%2520plus%2520vilanterol%2520versus%2520tiotropium%252C%2520vilanterol%252C%2520or%2520umeclidinium%2520monotherapies%2520over%252024%2520weeks%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520results%2520from%2520two%2520multicentre%252C%2520blinded%252C%2520randomised%2520controlled%2520trials%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2014%26volume%3D2%26spage%3D472%26epage%3D486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group">Hegde, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinfeld, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jasper, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulido-Rios, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mammen, M.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β<sub>2</sub> adrenoceptor agonist properties</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">351</span><span class="NLM_x">, </span> <span class="NLM_fpage">190</span><span class="NLM_x">–</span> <span class="NLM_lpage">199</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1124%2Fjpet.114.216861" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=25100753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yksbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2014&pages=190-199&author=S.+S.+Hegdeauthor=A.+D.+Hughesauthor=Y.+Chenauthor=T.+Steinfeldauthor=J.+R.+Jasperauthor=T.+W.+Leeauthor=A.+McNamaraauthor=W.+J.+Martinauthor=M.+T.+Pulido-Riosauthor=M.+Mammen&title=Pharmacological+characterization+of+GSK-961081+%28TD-5959%29%2C+a+first-in-class+inhaled+bifunctional+bronchodilator+possessing+muscarinic+receptor+antagonist+and+%CE%B22+adrenoceptor+agonist+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2-adrenoceptor agonist properties</span></div><div class="casAuthors">Hegde, Sharath S.; Hughes, Adam D.; Chen, Yan; Steinfeld, Tod; Jasper, Jeffrey R.; Lee, Tae-Weon; McNamara, Alexander; Martin, William J.; Pulido-Rios, M. Teresa; Mammen, Mathai</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">190-199, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The objective of the present studies was to characterize the pharmacol. properties of GSK-961081 [TD-5959; (R)-1-(3-((2-chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl) piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate], a novel first-in-class inhaled bifunctional compd. possessing both muscarinic antagonist (MA) and β2-adrenoceptor agonist (BA) properties (MABA).  In competition radioligand binding studies at human recombinant receptors, GSK-961081 displayed high affinity for hM2 (Ki = 1.4 nM), hM3 muscarinic receptors (Ki = 1.3 nM) and hβ2-adrenoceptors (Ki = 3.7 nM).  GSK-961081 behaved as a potent hβ2-adrenoceptor agonist (EC50 = 0.29 nM for stimulation of cAMP levels) with 440- and 320-fold functional selectivity over hβ1- and hβ3-adrenoceptors, resp.  In guinea pig isolated tracheal tissues, GSK-961081 produced smooth muscle relaxation through MA (EC50 = 50.2 nM), BA (EC50 = 24.6 nM), and MABA (EC50 = 11 nM) mechanisms.  In the guinea pig bronchoprotection assay, inhaled GSK-961081 produced potent, dose-dependent inhibition of bronchoconstrictor responses via MA (ED50 = 33.9 μg/mL), BA (ED50 = 14.1 μg/mL), and MABA (ED50 = 6.4 μg/mL) mechanisms.  Significant bronchoprotective effects of GSK-961081 were evident in guinea pigs via MA, BA, and MABA mechanisms for up to 7 days after dosing.  The lung selectivity index of GSK-961081 in guinea pigs was 55- to 110-fold greater than that of tiotropium with respect to systemic antimuscarinic antisialagogue effects and was 10-fold greater than that of salmeterol with respect to systemic β2-adrenoceptor hypotensive effects.  These preclin. findings studies suggest that GSK-961081 has the potential to be a promising next-generation inhaled lung-selective bronchodilator for the treatment of airway diseases, including chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7s7-fKs3E47Vg90H21EOLACvtfcHk0lhj1DjkS_Xx_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yksbfJ&md5=f2b92f897950afedc02c62c056824c17</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.216861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.216861%26sid%3Dliteratum%253Aachs%26aulast%3DHegde%26aufirst%3DS.%2BS.%26aulast%3DHughes%26aufirst%3DA.%2BD.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSteinfeld%26aufirst%3DT.%26aulast%3DJasper%26aufirst%3DJ.%2BR.%26aulast%3DLee%26aufirst%3DT.%2BW.%26aulast%3DMcNamara%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DW.%2BJ.%26aulast%3DPulido-Rios%26aufirst%3DM.%2BT.%26aulast%3DMammen%26aufirst%3DM.%26atitle%3DPharmacological%2520characterization%2520of%2520GSK-961081%2520%2528TD-5959%2529%252C%2520a%2520first-in-class%2520inhaled%2520bifunctional%2520bronchodilator%2520possessing%2520muscarinic%2520receptor%2520antagonist%2520and%2520%25CE%25B22%2520adrenoceptor%2520agonist%2520properties%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D351%26spage%3D190%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group">Bateman, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornmann, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambery, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, V.</span><span> </span><span class="NLM_article-title">Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD</span> <span class="citation_source-journal">Pulm. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">581</span><span class="NLM_x">–</span> <span class="NLM_lpage">587</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.pupt.2013.03.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23538170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtValtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=581-587&author=E.+D.+Batemanauthor=O.+Kornmannauthor=C.+Amberyauthor=V.+Norris&title=Pharmacodynamics+of+GSK961081%2C+a+bi-functional+molecule%2C+in+patients+with+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD</span></div><div class="casAuthors">Bateman, Eric D.; Kornmann, Oliver; Ambery, Claire; Norris, Virginia</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">581-587</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">GSK961081 is an inhaled bi-functional mol. with both muscarinic antagonism and β2-agonism (MABA) properties.This randomised, double-blind, double-dummy, crossover study evaluated 14 days treatment with the MABA GSK961081 400 μg and 1200 μg once daily and tiotropium 18 μg once daily plus salmeterol 50 μg twice daily (TIO + SAL), vs. placebo in 50 patients with moderate COPD.  The primary endpoint was forced expiratory vol. in 1 s (FEV1) at 24 h on Days 1 and 14.MABA 400 (n = 29), MABA 1200 (n = 32) and TIO + SAL (n = 41) resulted in significant increases in FEV1 over 24 h.  Mean (95% CI) 24 h trough FEV1 (L) values relative to placebo (n = 43) were, for Day 1, MABA 400: 0.141 (0.060, 0.222); MABA 1200: 0.184 (0.105, 0.263); TIO + SAL: 0.162 (0.092, 0.231); for Day 14, MABA 400: 0.115 (0.024, 0.205); MABA 1200: 0.168 (0.080, 0.255); TIO + SAL: 0.103 (0.026, 0.180).  Onset of bronchodilation was faster for both MABA doses vs. TIO + SAL.  No clin. relevant systemic pharmacodynamic effects were obsd.  Adverse events were similar across groups; however tremor (n = 2, MABA 1200), dysgeusia (n = 2, MABA 1200; n = 2, MABA 400) and dry mouth (n = 1, MABA 1200) were reported after GSK961081 only.GSK961081 demonstrated sustained bronchodilation similar to TIO + SAL, but with a more rapid onset, and was well tolerated at the tested doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU5q2GJiknn7Vg90H21EOLACvtfcHk0lhj1DjkS_Xx_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtValtbo%253D&md5=b23901522cf7dbb18e6bfb07e553f538</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2013.03.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2013.03.015%26sid%3Dliteratum%253Aachs%26aulast%3DBateman%26aufirst%3DE.%2BD.%26aulast%3DKornmann%26aufirst%3DO.%26aulast%3DAmbery%26aufirst%3DC.%26aulast%3DNorris%26aufirst%3DV.%26atitle%3DPharmacodynamics%2520of%2520GSK961081%252C%2520a%2520bi-functional%2520molecule%252C%2520in%2520patients%2520with%2520COPD%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D26%26spage%3D581%26epage%3D587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit182"><span>Anoro Ellipta FDA prescribing information,<span class="NLM_x"> </span><span class="NLM_year">2014</span>. <a href="http://www.rxlist.com/anoro-ellipta-drug.htm" class="extLink">http://www.rxlist.com/anoro-ellipta-drug.htm</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Anoro+Ellipta+FDA+prescribing+information%2C+2014.+http%3A%2F%2Fwww.rxlist.com%2Fanoro-ellipta-drug.htm."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 48 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Zhonghua Luo, Zhongqing Wang, Guodong Sun, Weilin Jian, Fengkai Jiang, Baolei Luan, Ridong Li, <span class="NLM_string-name hlFld-ContribAuthor">Lei Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Ruthenium-Catalyzed Highly Enantioselective Synthesis of cis-3-Quinuclidinols via DKR Asymmetric Transfer Hydrogenation. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (11)
                                     , 4322-4326. <a href="https://doi.org/10.1021/acs.orglett.0c01361" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c01361</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c01361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c01361%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DRuthenium-Catalyzed%252BHighly%252BEnantioselective%252BSynthesis%252Bof%252Bcis-3-Quinuclidinols%252Bvia%252BDKR%252BAsymmetric%252BTransfer%252BHydrogenation%26aulast%3DLuo%26aufirst%3DZhonghua%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D20042020%26date%3D14052020%26volume%3D22%26issue%3D11%26spage%3D4322%26epage%3D4326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Qian Chen, Baogang Xie, Liping Zhou, Lili Sun, Shanshan Li, Yuhan Chen, Shan Shi, Yang Li, Mingan Yu, <span class="NLM_string-name hlFld-ContribAuthor">Wei Li</span>. </span><span class="cited-content_cbyCitation_article-title">A Tailor-Made Self-Sufficient Whole-Cell Biocatalyst Enables Scalable Enantioselective Synthesis of (R)-3-Quinuclidinol in a High Space-Time Yield. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (9)
                                     , 1813-1821. <a href="https://doi.org/10.1021/acs.oprd.9b00004" title="DOI URL">https://doi.org/10.1021/acs.oprd.9b00004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.9b00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.9b00004%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DA%252BTailor-Made%252BSelf-Sufficient%252BWhole-Cell%252BBiocatalyst%252BEnables%252BScalable%252BEnantioselective%252BSynthesis%252Bof%252B%252528R%252529-3-Quinuclidinol%252Bin%252Ba%252BHigh%252BSpace-Time%252BYield%26aulast%3DChen%26aufirst%3DQian%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D03012019%26date%3D12072019%26volume%3D23%26issue%3D9%26spage%3D1813%26epage%3D1821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Huihui Ti, Yang Zhou, Xue Liang, Runfeng Li, Ke Ding, <span class="NLM_string-name hlFld-ContribAuthor">Xin Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (13)
                                     , 5944-5978. <a href="https://doi.org/10.1021/acs.jmedchem.8b01520" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01520</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01520%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeted%252BTreatments%252Bfor%252BChronic%252BObstructive%252BPulmonary%252BDisease%252B%252528COPD%252529%252BUsing%252BLow-Molecular-Weight%252BDrugs%252B%252528LMWDs%252529%26aulast%3DTi%26aufirst%3DHuihui%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D30092018%26date%3D12022019%26date%3D25012019%26volume%3D62%26issue%3D13%26spage%3D5944%26epage%3D5978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Long-Yong  Xie</span>, <span class="hlFld-ContribAuthor ">Yue  Duan</span>, <span class="hlFld-ContribAuthor ">Ling-Hui  Lu</span>, <span class="hlFld-ContribAuthor ">Yong-Jian  Li</span>, <span class="hlFld-ContribAuthor ">Sha  Peng</span>, <span class="hlFld-ContribAuthor ">Chao  Wu</span>, <span class="hlFld-ContribAuthor ">Kai-Jian  Liu</span>, <span class="hlFld-ContribAuthor ">Zheng  Wang</span>, and <span class="hlFld-ContribAuthor ">Wei-Min  He</span>  . </span><span class="cited-content_cbyCitation_article-title">Fast, Base-Free and Aqueous Synthesis of Quinolin-2(1H)-ones under Ambient Conditions. </span><span class="cited-content_cbyCitation_journal-name">ACS Sustainable Chemistry & Engineering</span><span> <strong>2017,</strong> <em>5 </em>
                                    (11)
                                     , 10407-10412. <a href="https://doi.org/10.1021/acssuschemeng.7b02442" title="DOI URL">https://doi.org/10.1021/acssuschemeng.7b02442</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acssuschemeng.7b02442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facssuschemeng.7b02442%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Sustainable%2520Chemistry%2520%2526%2520Engineering%26atitle%3DFast%25252C%252BBase-Free%252Band%252BAqueous%252BSynthesis%252Bof%252BQuinolin-2%2525281H%252529-ones%252Bunder%252BAmbient%252BConditions%26aulast%3DXie%26aufirst%3DLong-Yong%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D20072017%26date%3D21082017%26date%3D27092017%26date%3D06112017%26volume%3D5%26issue%3D11%26spage%3D10407%26epage%3D10412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aateka  Patel</span>, <span class="hlFld-ContribAuthor ">Sandra D.  Keir</span>, <span class="hlFld-ContribAuthor ">Marc B.  Brown</span>, <span class="hlFld-ContribAuthor ">Robert  Hider</span>, <span class="hlFld-ContribAuthor ">Stuart A.  Jones</span>, and <span class="hlFld-ContribAuthor ">Clive P.  Page</span>  . </span><span class="cited-content_cbyCitation_article-title">Using Salt Counterions to Modify β2-Agonist Behavior in Vivo. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2016,</strong> <em>13 </em>
                                    (10)
                                     , 3439-3448. <a href="https://doi.org/10.1021/acs.molpharmaceut.6b00448" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.6b00448</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.6b00448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.6b00448%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DUsing%252BSalt%252BCounterions%252Bto%252BModify%252B%2525CE%2525B22-Agonist%252BBehavior%252Bin%252BVivo%26aulast%3DPatel%26aufirst%3DAateka%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D20052016%26date%3D11082016%26date%3D04082016%26date%3D29082016%26date%3D03102016%26volume%3D13%26issue%3D10%26spage%3D3439%26epage%3D3448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stuart T.  Onions</span>, <span class="hlFld-ContribAuthor ">Kazuhiro  Ito</span>, <span class="hlFld-ContribAuthor ">Catherine E.  Charron</span>, <span class="hlFld-ContribAuthor ">Richard J.  Brown</span>, <span class="hlFld-ContribAuthor ">Marie  Colucci</span>, <span class="hlFld-ContribAuthor ">Fritz  Frickel</span>, <span class="hlFld-ContribAuthor ">George  Hardy</span>, <span class="hlFld-ContribAuthor ">Kevin  Joly</span>, <span class="hlFld-ContribAuthor ">John  King-Underwood</span>, <span class="hlFld-ContribAuthor ">Yasuo  Kizawa</span>, <span class="hlFld-ContribAuthor ">Ian  Knowles</span>, <span class="hlFld-ContribAuthor ">P. John  Murray</span>, <span class="hlFld-ContribAuthor ">Andrew  Novak</span>, <span class="hlFld-ContribAuthor ">Anjna  Rani</span>, <span class="hlFld-ContribAuthor ">Garth  Rapeport</span>, <span class="hlFld-ContribAuthor ">Alun  Smith</span>, <span class="hlFld-ContribAuthor ">Peter  Strong</span>, <span class="hlFld-ContribAuthor ">David M.  Taddei</span>, and <span class="hlFld-ContribAuthor ">Jonathan G.  Williams</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Narrow Spectrum Kinase Inhibitors: New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (5)
                                     , 1727-1746. <a href="https://doi.org/10.1021/acs.jmedchem.5b01029" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01029%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNarrow%252BSpectrum%252BKinase%252BInhibitors%25253A%252BNew%252BTherapeutic%252BAgents%252Bfor%252Bthe%252BTreatment%252Bof%252BCOPD%252Band%252BSteroid-Resistant%252BAsthma%26aulast%3DOnions%26aufirst%3DStuart%2BT.%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D01072015%26date%3D04022016%26date%3D10032016%26date%3D22012016%26volume%3D59%26issue%3D5%26spage%3D1727%26epage%3D1746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jun  Jiang</span>, <span class="hlFld-ContribAuthor ">Fang  Xiao</span>, <span class="hlFld-ContribAuthor ">Wei-Min  He</span>, <span class="hlFld-ContribAuthor ">Leyong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">The application of clean production in organic synthesis. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2021,</strong> <em>32 </em>
                                    (5)
                                     , 1637-1644. <a href="https://doi.org/10.1016/j.cclet.2021.02.057" title="DOI URL">https://doi.org/10.1016/j.cclet.2021.02.057</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2021.02.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2021.02.057%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DThe%252Bapplication%252Bof%252Bclean%252Bproduction%252Bin%252Borganic%252Bsynthesis%26aulast%3DJiang%26aufirst%3DJun%26date%3D2021%26volume%3D32%26issue%3D5%26spage%3D1637%26epage%3D1644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kunjukrishnan Kamalakshi  Sivakala</span>, <span class="hlFld-ContribAuthor ">Karina  Gutiérrez-García</span>, <span class="hlFld-ContribAuthor ">Polpass Arul  Jose</span>, <span class="hlFld-ContribAuthor ">Thangadurai  Thinesh</span>, <span class="hlFld-ContribAuthor ">Rangasamy  Anandham</span>, <span class="hlFld-ContribAuthor ">Francisco  Barona-Gómez</span>, <span class="hlFld-ContribAuthor ">Natesan  Sivakumar</span>. </span><span class="cited-content_cbyCitation_article-title">Desert Environments Facilitate Unique Evolution of Biosynthetic Potential in Streptomyces. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (3)
                                     , 588. <a href="https://doi.org/10.3390/molecules26030588" title="DOI URL">https://doi.org/10.3390/molecules26030588</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26030588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26030588%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDesert%252BEnvironments%252BFacilitate%252BUnique%252BEvolution%252Bof%252BBiosynthetic%252BPotential%252Bin%252BStreptomyces%26aulast%3DSivakala%26aufirst%3DKunjukrishnan%2BKamalakshi%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D3%26spage%3D588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wupeng  Liao</span>, <span class="hlFld-ContribAuthor ">Albert Y. H.  Lim</span>, <span class="hlFld-ContribAuthor ">W. S. Daniel  Tan</span>, <span class="hlFld-ContribAuthor ">John  Abisheganaden</span>, <span class="hlFld-ContribAuthor ">W. S. Fred  Wong</span>. </span><span class="cited-content_cbyCitation_article-title">Restoration of HDAC2 and Nrf2 by andrographolide overcomes corticosteroid resistance in chronic obstructive pulmonary disease. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2020,</strong> <em>177 </em>
                                    (16)
                                     , 3662-3673. <a href="https://doi.org/10.1111/bph.15080" title="DOI URL">https://doi.org/10.1111/bph.15080</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.15080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.15080%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DRestoration%252Bof%252BHDAC2%252Band%252BNrf2%252Bby%252Bandrographolide%252Bovercomes%252Bcorticosteroid%252Bresistance%252Bin%252Bchronic%252Bobstructive%252Bpulmonary%252Bdisease%26aulast%3DLiao%26aufirst%3DWupeng%26date%3D2020%26date%3D2020%26volume%3D177%26issue%3D16%26spage%3D3662%26epage%3D3673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Collin M  Clark</span>, <span class="hlFld-ContribAuthor ">David M  Jacobs</span>, <span class="hlFld-ContribAuthor ">Sanjay  Sethi</span>. </span><span class="cited-content_cbyCitation_article-title">Revefenacin for the treatment of chronic obstructive pulmonary disease. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Respiratory Medicine</span><span> <strong>2020,</strong> <em>14 </em>
                                    (3)
                                     , 239-247. <a href="https://doi.org/10.1080/17476348.2020.1703676" title="DOI URL">https://doi.org/10.1080/17476348.2020.1703676</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17476348.2020.1703676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17476348.2020.1703676%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Respiratory%2520Medicine%26atitle%3DRevefenacin%252Bfor%252Bthe%252Btreatment%252Bof%252Bchronic%252Bobstructive%252Bpulmonary%252Bdisease%26aulast%3DClark%26aufirst%3DCollin%2BM%26date%3D2020%26date%3D2019%26volume%3D14%26issue%3D3%26spage%3D239%26epage%3D247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao  Hu</span>, <span class="hlFld-ContribAuthor ">Jia  Miao</span>, <span class="hlFld-ContribAuthor ">Shiqing  Shu</span>, <span class="hlFld-ContribAuthor ">Ying  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhu  Luo</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacokinetics, pharmacodynamics and safety of a novel extrafine BDP/FF/GB combination delivered via metered-dose inhaler in healthy Chinese subjects. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmaceutical Sciences</span><span> <strong>2020,</strong> <em>144 </em>, 105198. <a href="https://doi.org/10.1016/j.ejps.2019.105198" title="DOI URL">https://doi.org/10.1016/j.ejps.2019.105198</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejps.2019.105198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejps.2019.105198%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DPharmacokinetics%25252C%252Bpharmacodynamics%252Band%252Bsafety%252Bof%252Ba%252Bnovel%252Bextrafine%252BBDP%25252FFF%25252FGB%252Bcombination%252Bdelivered%252Bvia%252Bmetered-dose%252Binhaler%252Bin%252Bhealthy%252BChinese%252Bsubjects%26aulast%3DHu%26aufirst%3DChao%26date%3D2020%26volume%3D144%26spage%3D105198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stacy Gelhaus  Wendell</span>, <span class="hlFld-ContribAuthor ">Hao  Fan</span>, <span class="hlFld-ContribAuthor ">Cheng  Zhang</span>, . </span><span class="cited-content_cbyCitation_article-title">G Protein–Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Reviews</span><span> <strong>2020,</strong> <em>72 </em>
                                    (1)
                                     , 1-49. <a href="https://doi.org/10.1124/pr.118.016899" title="DOI URL">https://doi.org/10.1124/pr.118.016899</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/pr.118.016899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fpr.118.016899%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Reviews%26atitle%3DG%252BProtein%2525E2%252580%252593Coupled%252BReceptors%252Bin%252BAsthma%252BTherapy%25253A%252BPharmacology%252Band%252BDrug%252BAction%26aulast%3DWendell%26aufirst%3DStacy%2BGelhaus%26date%3D2020%26date%3D2019%26volume%3D72%26issue%3D1%26spage%3D1%26epage%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aernout  Haarst</span>, <span class="hlFld-ContribAuthor ">Lorcan  McGarvey</span>, <span class="hlFld-ContribAuthor ">Sabina  Paglialunga</span>. </span><span class="cited-content_cbyCitation_article-title">Review of Drug Development Guidance to Treat Chronic Obstructive Pulmonary Disease:
              US
              and
              EU
              Perspectives. </span><span class="cited-content_cbyCitation_journal-name">Clinical Pharmacology & Therapeutics</span><span> <strong>2019,</strong> <em>106 </em>
                                    (6)
                                     , 1222-1235. <a href="https://doi.org/10.1002/cpt.1540" title="DOI URL">https://doi.org/10.1002/cpt.1540</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cpt.1540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcpt.1540%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Pharmacology%2520%2526%2520Therapeutics%26atitle%3DReview%252Bof%252BDrug%252BDevelopment%252BGuidance%252Bto%252BTreat%252BChronic%252BObstructive%252BPulmonary%252BDisease%25253A%252BUS%252Band%252BEU%252BPerspectives%26aulast%3DHaarst%26aufirst%3DAernout%26date%3D2019%26date%3D2019%26volume%3D106%26issue%3D6%26spage%3D1222%26epage%3D1235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wijdan H.  Ramadan</span>, <span class="hlFld-ContribAuthor ">Sarah  Al Masri</span>, <span class="hlFld-ContribAuthor ">John  Rizk</span>. </span><span class="cited-content_cbyCitation_article-title">Fixed‐dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review. </span><span class="cited-content_cbyCitation_journal-name">The Clinical Respiratory Journal</span><span> <strong>2019,</strong> <em>13 </em>
                                    (11)
                                     , 663-673. <a href="https://doi.org/10.1111/crj.13073" title="DOI URL">https://doi.org/10.1111/crj.13073</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/crj.13073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcrj.13073%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Clinical%2520Respiratory%2520Journal%26atitle%3DFixed%2525E2%252580%252590dose%252Bcombination%252Bof%252Bumeclidinium%252Band%252Bvilanterol%252Bfor%252Bpatients%252Bwith%252Bchronic%252Bobstructive%252Bpulmonary%252Bdisease%25253A%252BA%252Bsystematic%252Breview%26aulast%3DRamadan%26aufirst%3DWijdan%2BH.%26date%3D2019%26date%3D2019%26volume%3D13%26issue%3D11%26spage%3D663%26epage%3D673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gang  Xing</span>, <span class="hlFld-ContribAuthor ">Li  Pan</span>, <span class="hlFld-ContribAuthor ">Ce  Yi</span>, <span class="hlFld-ContribAuthor ">Xiaoran  Li</span>, <span class="hlFld-ContribAuthor ">Xinyue  Ge</span>, <span class="hlFld-ContribAuthor ">Ying  Zhao</span>, <span class="hlFld-ContribAuthor ">Yichuang  Liu</span>, <span class="hlFld-ContribAuthor ">Jinyan  Li</span>, <span class="hlFld-ContribAuthor ">Anthony  Woo</span>, <span class="hlFld-ContribAuthor ">Bin  Lin</span>, <span class="hlFld-ContribAuthor ">Yuyang  Zhang</span>, <span class="hlFld-ContribAuthor ">Maosheng  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 5-(2-amino-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one derivatives as potent β2-adrenoceptor agonists. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (12)
                                     , 2306-2314. <a href="https://doi.org/10.1016/j.bmc.2018.10.043" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.10.043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.10.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.10.043%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B5-%2525282-amino-1-hydroxyethyl%252529-8-hydroxyquinolin-2%2525281H%252529-one%252Bderivatives%252Bas%252Bpotent%252B%2525CE%2525B22-adrenoceptor%252Bagonists%26aulast%3DXing%26aufirst%3DGang%26date%3D2019%26volume%3D27%26issue%3D12%26spage%3D2306%26epage%3D2314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Diana  Rogacz</span>, <span class="hlFld-ContribAuthor ">Jarosław  Lewkowski</span>, <span class="hlFld-ContribAuthor ">Marta  Siedlarek</span>, <span class="hlFld-ContribAuthor ">Rafał  Karpowicz</span>, <span class="hlFld-ContribAuthor ">Anna  Kowalczyk</span>, <span class="hlFld-ContribAuthor ">Piotr  Rychter</span>. </span><span class="cited-content_cbyCitation_article-title">The Effect of New Thiophene-Derived Diphenyl Aminophosphonates on Growth of Terrestrial Plants. </span><span class="cited-content_cbyCitation_journal-name">Materials</span><span> <strong>2019,</strong> <em>12 </em>
                                    (12)
                                     , 2018. <a href="https://doi.org/10.3390/ma12122018" title="DOI URL">https://doi.org/10.3390/ma12122018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ma12122018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fma12122018%26sid%3Dliteratum%253Aachs%26jtitle%3DMaterials%26atitle%3DThe%252BEffect%252Bof%252BNew%252BThiophene-Derived%252BDiphenyl%252BAminophosphonates%252Bon%252BGrowth%252Bof%252BTerrestrial%252BPlants%26aulast%3DRogacz%26aufirst%3DDiana%26date%3D2019%26date%3D2019%26volume%3D12%26issue%3D12%26spage%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mario  Malerba</span>, <span class="hlFld-ContribAuthor ">Valentina  Foci</span>, <span class="hlFld-ContribAuthor ">Filippo  Patrucco</span>, <span class="hlFld-ContribAuthor ">Patrizia  Pochetti</span>, <span class="hlFld-ContribAuthor ">Matteo  Nardin</span>, <span class="hlFld-ContribAuthor ">Corrado  Pelaia</span>, <span class="hlFld-ContribAuthor ">Alessandro  Radaeli</span>. </span><span class="cited-content_cbyCitation_article-title">Single Inhaler LABA/LAMA for COPD. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2019,</strong> <em>10 </em><a href="https://doi.org/10.3389/fphar.2019.00390" title="DOI URL">https://doi.org/10.3389/fphar.2019.00390</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2019.00390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2019.00390%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DSingle%252BInhaler%252BLABA%25252FLAMA%252Bfor%252BCOPD%26aulast%3DMalerba%26aufirst%3DMario%26date%3D2019%26date%3D2019%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luiz Henrique César  Vasconcelos</span>, <span class="hlFld-ContribAuthor ">Maria da Conceição Correia  Silva</span>, <span class="hlFld-ContribAuthor ">Alana Cristina  Costa</span>, <span class="hlFld-ContribAuthor ">Giuliana Amanda de  Oliveira</span>, <span class="hlFld-ContribAuthor ">Iara Leão Luna de  Souza</span>, <span class="hlFld-ContribAuthor ">Fernando Ramos  Queiroga</span>, <span class="hlFld-ContribAuthor ">Layanne Cabral da Cunha  Araujo</span>, <span class="hlFld-ContribAuthor ">Glêbia Alexa  Cardoso</span>, <span class="hlFld-ContribAuthor ">Renato Fraga  Righetti</span>, <span class="hlFld-ContribAuthor ">Alexandre Sérgio  Silva</span>, <span class="hlFld-ContribAuthor ">Patrícia Mirella  da Silva</span>, <span class="hlFld-ContribAuthor ">Carla Roberta de Oliveira  Carvalho</span>, <span class="hlFld-ContribAuthor ">Giciane Carvalho  Vieira</span>, <span class="hlFld-ContribAuthor ">Iolanda de Fátima Lopes Calvo  Tibério</span>, <span class="hlFld-ContribAuthor ">Fabiana de Andrade  Cavalcante</span>, <span class="hlFld-ContribAuthor ">Bagnólia Araújo da  Silva</span>. </span><span class="cited-content_cbyCitation_article-title">A Guinea Pig Model of Airway Smooth Muscle Hyperreactivity Induced by Chronic Allergic Lung Inflammation: Contribution of Epithelium and Oxidative Stress. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2019,</strong> <em>9 </em><a href="https://doi.org/10.3389/fphar.2018.01547" title="DOI URL">https://doi.org/10.3389/fphar.2018.01547</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2018.01547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2018.01547%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DA%252BGuinea%252BPig%252BModel%252Bof%252BAirway%252BSmooth%252BMuscle%252BHyperreactivity%252BInduced%252Bby%252BChronic%252BAllergic%252BLung%252BInflammation%25253A%252BContribution%252Bof%252BEpithelium%252Band%252BOxidative%252BStress%26aulast%3DVasconcelos%26aufirst%3DLuiz%2BHenrique%2BC%25C3%25A9sar%26date%3D2019%26date%3D2019%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anthony D.  D’Urzo</span>, <span class="hlFld-ContribAuthor ">Dave  Singh</span>, <span class="hlFld-ContribAuthor ">James F.  Donohue</span>, <span class="hlFld-ContribAuthor ">Kenneth R.  Chapman</span>. </span><span class="cited-content_cbyCitation_article-title">Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base. </span><span class="cited-content_cbyCitation_journal-name">Therapeutic Advances in Respiratory Disease</span><span> <strong>2019,</strong> <em>13 </em>, 175346661985072. <a href="https://doi.org/10.1177/1753466619850725" title="DOI URL">https://doi.org/10.1177/1753466619850725</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1753466619850725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1753466619850725%26sid%3Dliteratum%253Aachs%26jtitle%3DTherapeutic%2520Advances%2520in%2520Respiratory%2520Disease%26atitle%3DAclidinium%252Bbromide%252Bin%252Bfixed-dose%252Bcombination%252Bwith%252Bformoterol%252Bfumarate%252Bin%252Bthe%252Bmanagement%252Bof%252BCOPD%25253A%252Ban%252Bupdate%252Bon%252Bthe%252Bevidence%252Bbase%26aulast%3DD%25E2%2580%2599Urzo%26aufirst%3DAnthony%2BD.%26date%3D2019%26date%3D2019%26volume%3D13%26spage%3D175346661985072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neil C  Thomson</span>. </span><span class="cited-content_cbyCitation_article-title">Challenges in the management of asthma associated with smoking-induced airway diseases. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2018,</strong> <em>19 </em>
                                    (14)
                                     , 1565-1579. <a href="https://doi.org/10.1080/14656566.2018.1515912" title="DOI URL">https://doi.org/10.1080/14656566.2018.1515912</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2018.1515912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2018.1515912%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DChallenges%252Bin%252Bthe%252Bmanagement%252Bof%252Basthma%252Bassociated%252Bwith%252Bsmoking-induced%252Bairway%252Bdiseases%26aulast%3DThomson%26aufirst%3DNeil%2BC%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D14%26spage%3D1565%26epage%3D1579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mario  Malerba</span>, <span class="hlFld-ContribAuthor ">Alessandro  Radaeli</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Santini</span>, <span class="hlFld-ContribAuthor ">Jaymin  Morjaria</span>, <span class="hlFld-ContribAuthor ">Nadia  Mores</span>, <span class="hlFld-ContribAuthor ">Chiara  Mondino</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Macis</span>, <span class="hlFld-ContribAuthor ">Paolo  Montuschi</span>. </span><span class="cited-content_cbyCitation_article-title">The discovery and development of aclidinium bromide for the treatment of chronic obstructive pulmonary disease. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2018,</strong> <em>13 </em>
                                    (6)
                                     , 563-577. <a href="https://doi.org/10.1080/17460441.2018.1455661" title="DOI URL">https://doi.org/10.1080/17460441.2018.1455661</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2018.1455661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2018.1455661%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DThe%252Bdiscovery%252Band%252Bdevelopment%252Bof%252Baclidinium%252Bbromide%252Bfor%252Bthe%252Btreatment%252Bof%252Bchronic%252Bobstructive%252Bpulmonary%252Bdisease%26aulast%3DMalerba%26aufirst%3DMario%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D6%26spage%3D563%26epage%3D577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianhui  Gu</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Xuan  Wang</span>, <span class="hlFld-ContribAuthor ">Guoping  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Convenient new synthesis of umeclidinium bromide. </span><span class="cited-content_cbyCitation_journal-name">Synthetic Communications</span><span> <strong>2018,</strong> <em>48 </em>
                                    (9)
                                     , 995-1000. <a href="https://doi.org/10.1080/00397911.2017.1348525" title="DOI URL">https://doi.org/10.1080/00397911.2017.1348525</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00397911.2017.1348525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00397911.2017.1348525%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthetic%2520Communications%26atitle%3DConvenient%252Bnew%252Bsynthesis%252Bof%252Bumeclidinium%252Bbromide%26aulast%3DGu%26aufirst%3DJianhui%26date%3D2018%26date%3D2018%26volume%3D48%26issue%3D9%26spage%3D995%26epage%3D1000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chor-Shen  Lim</span>, <span class="hlFld-ContribAuthor ">Fauzi Abdul  Rani</span>, <span class="hlFld-ContribAuthor ">Lan-Eng  Tan</span>. </span><span class="cited-content_cbyCitation_article-title">Response of exhaled nitric oxide to inhaled corticosteroids in patients with stable COPD: A systematic review and meta-analysis. </span><span class="cited-content_cbyCitation_journal-name">The Clinical Respiratory Journal</span><span> <strong>2018,</strong> <em>12 </em>
                                    (1)
                                     , 218-226. <a href="https://doi.org/10.1111/crj.12518" title="DOI URL">https://doi.org/10.1111/crj.12518</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/crj.12518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcrj.12518%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Clinical%2520Respiratory%2520Journal%26atitle%3DResponse%252Bof%252Bexhaled%252Bnitric%252Boxide%252Bto%252Binhaled%252Bcorticosteroids%252Bin%252Bpatients%252Bwith%252Bstable%252BCOPD%25253A%252BA%252Bsystematic%252Breview%252Band%252Bmeta-analysis%26aulast%3DLim%26aufirst%3DChor-Shen%26date%3D2018%26date%3D2016%26volume%3D12%26issue%3D1%26spage%3D218%26epage%3D226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mario  Malerba</span>, <span class="hlFld-ContribAuthor ">Matteo  Nardin</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Santini</span>, <span class="hlFld-ContribAuthor ">Nadia  Mores</span>, <span class="hlFld-ContribAuthor ">Alessandro  Radaeli</span>, <span class="hlFld-ContribAuthor ">Paolo  Montuschi</span>. </span><span class="cited-content_cbyCitation_article-title">Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects. </span><span class="cited-content_cbyCitation_journal-name">Therapeutic Advances in Respiratory Disease</span><span> <strong>2018,</strong> <em>12 </em>, 175346661876077. <a href="https://doi.org/10.1177/1753466618760779" title="DOI URL">https://doi.org/10.1177/1753466618760779</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1753466618760779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1753466618760779%26sid%3Dliteratum%253Aachs%26jtitle%3DTherapeutic%2520Advances%2520in%2520Respiratory%2520Disease%26atitle%3DSingle-inhaler%252Btriple%252Btherapy%252Butilizing%252Bthe%252Bonce-daily%252Bcombination%252Bof%252Bfluticasone%252Bfuroate%25252C%252Bumeclidinium%252Band%252Bvilanterol%252Bin%252Bthe%252Bmanagement%252Bof%252BCOPD%25253A%252Bthe%252Bcurrent%252Bevidence%252Bbase%252Band%252Bfuture%252Bprospects%26aulast%3DMalerba%26aufirst%3DMario%26date%3D2018%26date%3D2018%26volume%3D12%26spage%3D175346661876077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fabiano  Di Marco</span>, <span class="hlFld-ContribAuthor ">Pierachille  Santus</span>, <span class="hlFld-ContribAuthor ">Silvia  Terraneo</span>, <span class="hlFld-ContribAuthor ">Elena  Peruzzi</span>, <span class="hlFld-ContribAuthor ">Elisa  Muscianisi</span>, <span class="hlFld-ContribAuthor ">Claudio  Ripellino</span>, <span class="hlFld-ContribAuthor ">Valeria  Pegoraro</span>. </span><span class="cited-content_cbyCitation_article-title">Characteristics of newly diagnosed COPD patients treated with triple inhaled therapy by general practitioners: a real world Italian study. </span><span class="cited-content_cbyCitation_journal-name">npj Primary Care Respiratory Medicine</span><span> <strong>2017,</strong> <em>27 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41533-017-0051-9" title="DOI URL">https://doi.org/10.1038/s41533-017-0051-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41533-017-0051-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41533-017-0051-9%26sid%3Dliteratum%253Aachs%26jtitle%3Dnpj%2520Primary%2520Care%2520Respiratory%2520Medicine%26atitle%3DCharacteristics%252Bof%252Bnewly%252Bdiagnosed%252BCOPD%252Bpatients%252Btreated%252Bwith%252Btriple%252Binhaled%252Btherapy%252Bby%252Bgeneral%252Bpractitioners%25253A%252Ba%252Breal%252Bworld%252BItalian%252Bstudy%26aulast%3DDi%2BMarco%26aufirst%3DFabiano%26date%3D2017%26date%3D2017%26volume%3D27%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pritam  Sukul</span>, <span class="hlFld-ContribAuthor ">Jochen K  Schubert</span>, <span class="hlFld-ContribAuthor ">Svend  Kamysek</span>, <span class="hlFld-ContribAuthor ">Phillip  Trefz</span>, <span class="hlFld-ContribAuthor ">Wolfram  Miekisch</span>. </span><span class="cited-content_cbyCitation_article-title">Applied upper-airway resistance instantly affects breath components: a unique insight into pulmonary medicine. </span><span class="cited-content_cbyCitation_journal-name">Journal of Breath Research</span><span> <strong>2017,</strong> <em>11 </em>
                                    (4)
                                     , 047108. <a href="https://doi.org/10.1088/1752-7163/aa8d86" title="DOI URL">https://doi.org/10.1088/1752-7163/aa8d86</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1088/1752-7163/aa8d86&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1088%2F1752-7163%2Faa8d86%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Breath%2520Research%26atitle%3DApplied%252Bupper-airway%252Bresistance%252Binstantly%252Baffects%252Bbreath%252Bcomponents%25253A%252Ba%252Bunique%252Binsight%252Binto%252Bpulmonary%252Bmedicine%26aulast%3DSukul%26aufirst%3DPritam%26date%3D2017%26date%3D2017%26volume%3D11%26issue%3D4%26spage%3D047108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Krishna K.  Pudi</span>, <span class="hlFld-ContribAuthor ">Chris N.  Barnes</span>, <span class="hlFld-ContribAuthor ">Edmund J.  Moran</span>, <span class="hlFld-ContribAuthor ">Brett  Haumann</span>, <span class="hlFld-ContribAuthor ">Edward  Kerwin</span>. </span><span class="cited-content_cbyCitation_article-title">A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. </span><span class="cited-content_cbyCitation_journal-name">Respiratory Research</span><span> <strong>2017,</strong> <em>18 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12931-017-0647-1" title="DOI URL">https://doi.org/10.1186/s12931-017-0647-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12931-017-0647-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12931-017-0647-1%26sid%3Dliteratum%253Aachs%26jtitle%3DRespiratory%2520Research%26atitle%3DA%252B28-day%25252C%252Brandomized%25252C%252Bdouble-blind%25252C%252Bplacebo-controlled%25252C%252Bparallel%252Bgroup%252Bstudy%252Bof%252Bnebulized%252Brevefenacin%252Bin%252Bpatients%252Bwith%252Bchronic%252Bobstructive%252Bpulmonary%252Bdisease%26aulast%3DPudi%26aufirst%3DKrishna%2BK.%26date%3D2017%26date%3D2017%26volume%3D18%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chitra  Lal</span>, <span class="hlFld-ContribAuthor ">Charlie  Strange</span>. </span><span class="cited-content_cbyCitation_article-title">A review of current and developing fixed-dose LABA/LAMA combinations for treating COPD. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2017,</strong> <em>18 </em>
                                    (17)
                                     , 1833-1843. <a href="https://doi.org/10.1080/14656566.2017.1403583" title="DOI URL">https://doi.org/10.1080/14656566.2017.1403583</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2017.1403583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2017.1403583%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DA%252Breview%252Bof%252Bcurrent%252Band%252Bdeveloping%252Bfixed-dose%252BLABA%25252FLAMA%252Bcombinations%252Bfor%252Btreating%252BCOPD%26aulast%3DLal%26aufirst%3DChitra%26date%3D2017%26date%3D2017%26volume%3D18%26issue%3D17%26spage%3D1833%26epage%3D1843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingan  Yu</span>, <span class="hlFld-ContribAuthor ">Duqiang  Liu</span>, <span class="hlFld-ContribAuthor ">Lili  Sun</span>, <span class="hlFld-ContribAuthor ">Jing  Li</span>, <span class="hlFld-ContribAuthor ">Qian  Chen</span>, <span class="hlFld-ContribAuthor ">Lijun  Pan</span>, <span class="hlFld-ContribAuthor ">Jingchuan  Shang</span>, <span class="hlFld-ContribAuthor ">Shurong  Zhang</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Facile fabrication of 3D porous hybrid sphere by co-immobilization of multi-enzyme directly from cell lysates as an efficient and recyclable biocatalyst for asymmetric reduction with coenzyme regeneration in situ. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Biological Macromolecules</span><span> <strong>2017,</strong> <em>103 </em>, 424-434. <a href="https://doi.org/10.1016/j.ijbiomac.2017.05.080" title="DOI URL">https://doi.org/10.1016/j.ijbiomac.2017.05.080</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijbiomac.2017.05.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijbiomac.2017.05.080%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Biological%2520Macromolecules%26atitle%3DFacile%252Bfabrication%252Bof%252B3D%252Bporous%252Bhybrid%252Bsphere%252Bby%252Bco-immobilization%252Bof%252Bmulti-enzyme%252Bdirectly%252Bfrom%252Bcell%252Blysates%252Bas%252Ban%252Befficient%252Band%252Brecyclable%252Bbiocatalyst%252Bfor%252Basymmetric%252Breduction%252Bwith%252Bcoenzyme%252Bregeneration%252Bin%252Bsitu%26aulast%3DYu%26aufirst%3DMingan%26date%3D2017%26volume%3D103%26spage%3D424%26epage%3D434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicola A  Hanania</span>, <span class="hlFld-ContribAuthor ">Suzanne C.  Lareau</span>, <span class="hlFld-ContribAuthor ">Barbara P.  Yawn</span>. </span><span class="cited-content_cbyCitation_article-title">Safety of inhaled long-acting anti-muscarinic agents in COPD. </span><span class="cited-content_cbyCitation_journal-name">Postgraduate Medicine</span><span> <strong>2017,</strong> <em>129 </em>
                                    (5)
                                     , 500-512. <a href="https://doi.org/10.1080/00325481.2017.1317575" title="DOI URL">https://doi.org/10.1080/00325481.2017.1317575</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00325481.2017.1317575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00325481.2017.1317575%26sid%3Dliteratum%253Aachs%26jtitle%3DPostgraduate%2520Medicine%26atitle%3DSafety%252Bof%252Binhaled%252Blong-acting%252Banti-muscarinic%252Bagents%252Bin%252BCOPD%26aulast%3DHanania%26aufirst%3DNicola%2BA%26date%3D2017%26date%3D2017%26volume%3D129%26issue%3D5%26spage%3D500%26epage%3D512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuan  Li</span>, <span class="hlFld-ContribAuthor ">Ma'en  Obeidat</span>, <span class="hlFld-ContribAuthor ">Guohai  Zhou</span>, <span class="hlFld-ContribAuthor ">Janice M.  Leung</span>, <span class="hlFld-ContribAuthor ">Donald  Tashkin</span>, <span class="hlFld-ContribAuthor ">Robert  Wise</span>, <span class="hlFld-ContribAuthor ">John  Connett</span>, <span class="hlFld-ContribAuthor ">Philippe  Joubert</span>, <span class="hlFld-ContribAuthor ">Yohan  Bossé</span>, <span class="hlFld-ContribAuthor ">Maarten  van den Berge</span>, <span class="hlFld-ContribAuthor ">Corry-Anke  Brandsma</span>, <span class="hlFld-ContribAuthor ">David C.  Nickle</span>, <span class="hlFld-ContribAuthor ">Ke  Hao</span>, <span class="hlFld-ContribAuthor ">Peter D.  Paré</span>, <span class="hlFld-ContribAuthor ">Don D.  Sin</span>. </span><span class="cited-content_cbyCitation_article-title">Responsiveness to Ipratropium Bromide in Male and Female Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease. </span><span class="cited-content_cbyCitation_journal-name">EBioMedicine</span><span> <strong>2017,</strong> <em>19 </em>, 139-145. <a href="https://doi.org/10.1016/j.ebiom.2017.04.020" title="DOI URL">https://doi.org/10.1016/j.ebiom.2017.04.020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ebiom.2017.04.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ebiom.2017.04.020%26sid%3Dliteratum%253Aachs%26jtitle%3DEBioMedicine%26atitle%3DResponsiveness%252Bto%252BIpratropium%252BBromide%252Bin%252BMale%252Band%252BFemale%252BPatients%252Bwith%252BMild%252Bto%252BModerate%252BChronic%252BObstructive%252BPulmonary%252BDisease%26aulast%3DLi%26aufirst%3DXuan%26date%3D2017%26volume%3D19%26spage%3D139%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neil C  Thomson</span>. </span><span class="cited-content_cbyCitation_article-title">New and developing non-adrenoreceptor small molecule drugs for the treatment of asthma. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2017,</strong> <em>18 </em>
                                    (3)
                                     , 283-293. <a href="https://doi.org/10.1080/14656566.2017.1284794" title="DOI URL">https://doi.org/10.1080/14656566.2017.1284794</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2017.1284794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2017.1284794%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DNew%252Band%252Bdeveloping%252Bnon-adrenoreceptor%252Bsmall%252Bmolecule%252Bdrugs%252Bfor%252Bthe%252Btreatment%252Bof%252Basthma%26aulast%3DThomson%26aufirst%3DNeil%2BC%26date%3D2017%26date%3D2017%26volume%3D18%26issue%3D3%26spage%3D283%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark A.  Mastrodicasa</span>, <span class="hlFld-ContribAuthor ">Christopher A.  Droege</span>, <span class="hlFld-ContribAuthor ">Aaron M.  Mulhall</span>, <span class="hlFld-ContribAuthor ">Neil E.  Ernst</span>, <span class="hlFld-ContribAuthor ">Ralph J.  Panos</span>, <span class="hlFld-ContribAuthor ">Muhammad A.  Zafar</span>. </span><span class="cited-content_cbyCitation_article-title">Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2017,</strong> <em>26 </em>
                                    (2)
                                     , 161-174. <a href="https://doi.org/10.1080/13543784.2017.1276167" title="DOI URL">https://doi.org/10.1080/13543784.2017.1276167</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2017.1276167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2017.1276167%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DLong%252Bacting%252Bmuscarinic%252Bantagonists%252Bfor%252Bthe%252Btreatment%252Bof%252Bchronic%252Bobstructive%252Bpulmonary%252Bdisease%25253A%252Ba%252Breview%252Bof%252Bcurrent%252Band%252Bdeveloping%252Bdrugs%26aulast%3DMastrodicasa%26aufirst%3DMark%2BA.%26date%3D2017%26date%3D2017%26volume%3D26%26issue%3D2%26spage%3D161%26epage%3D174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Taruna  Joshi</span>, <span class="hlFld-ContribAuthor ">Dong  Yan</span>, <span class="hlFld-ContribAuthor ">Omar  Hamed</span>, <span class="hlFld-ContribAuthor ">Stacey L.  Tannheimer</span>, <span class="hlFld-ContribAuthor ">Gary B.  Phillips</span>, <span class="hlFld-ContribAuthor ">Clifford D.  Wright</span>, <span class="hlFld-ContribAuthor ">Musong  Kim</span>, <span class="hlFld-ContribAuthor ">Michael  Salmon</span>, <span class="hlFld-ContribAuthor ">Robert  Newton</span>, <span class="hlFld-ContribAuthor ">Mark A.  Giembycz</span>. </span><span class="cited-content_cbyCitation_article-title">GS-5759, a Bifunctional
              β
              2
              -Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2017,</strong> <em>360 </em>
                                    (2)
                                     , 324-340. <a href="https://doi.org/10.1124/jpet.116.237743" title="DOI URL">https://doi.org/10.1124/jpet.116.237743</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.116.237743&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.116.237743%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DGS-5759%25252C%252Ba%252BBifunctional%252B%2525CE%2525B2%252B2%252B-Adrenoceptor%252BAgonist%252Band%252BPhosphodiesterase%252B4%252BInhibitor%252Bfor%252BChronic%252BObstructive%252BPulmonary%252BDisease%252Bwith%252Ba%252BUnique%252BMode%252Bof%252BAction%25253A%252BEffects%252Bon%252BGene%252BExpression%252Bin%252BHuman%252BAirway%252BEpithelial%252BCells%26aulast%3DJoshi%26aufirst%3DTaruna%26date%3D2017%26date%3D2016%26volume%3D360%26issue%3D2%26spage%3D324%26epage%3D340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy E  Albertson</span>, <span class="hlFld-ContribAuthor ">James A  Chenoweth</span>, <span class="hlFld-ContribAuthor ">Jason Y  Adams</span>, <span class="hlFld-ContribAuthor ">Mark E  Sutter</span>. </span><span class="cited-content_cbyCitation_article-title">Muscarinic antagonists in early stage clinical development for the treatment of asthma. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2017,</strong> <em>26 </em>
                                    (1)
                                     , 35-49. <a href="https://doi.org/10.1080/13543784.2017.1264388" title="DOI URL">https://doi.org/10.1080/13543784.2017.1264388</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2017.1264388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2017.1264388%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DMuscarinic%252Bantagonists%252Bin%252Bearly%252Bstage%252Bclinical%252Bdevelopment%252Bfor%252Bthe%252Btreatment%252Bof%252Basthma%26aulast%3DAlbertson%26aufirst%3DTimothy%2BE%26date%3D2017%26date%3D2016%26volume%3D26%26issue%3D1%26spage%3D35%26epage%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sarah H.  Landis</span>, <span class="hlFld-ContribAuthor ">Keele  Wurst</span>, <span class="hlFld-ContribAuthor ">Hoa Van  Le</span>, <span class="hlFld-ContribAuthor ">Kerina  Bonar</span>, <span class="hlFld-ContribAuthor ">Yogesh S.  Punekar</span>. </span><span class="cited-content_cbyCitation_article-title">Can Assessment of Disease Burden Prior to Changes in Initial COPD Maintenance Treatment Provide Insight into Remaining Unmet Needs? A Retrospective Database Study in UK Primary Care. </span><span class="cited-content_cbyCitation_journal-name">COPD: Journal of Chronic Obstructive Pulmonary Disease</span><span> <strong>2017,</strong> <em>14 </em>
                                    (1)
                                     , 80-85. <a href="https://doi.org/10.1080/15412555.2016.1240159" title="DOI URL">https://doi.org/10.1080/15412555.2016.1240159</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/15412555.2016.1240159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F15412555.2016.1240159%26sid%3Dliteratum%253Aachs%26jtitle%3DCOPD%253A%2520Journal%2520of%2520Chronic%2520Obstructive%2520Pulmonary%2520Disease%26atitle%3DCan%252BAssessment%252Bof%252BDisease%252BBurden%252BPrior%252Bto%252BChanges%252Bin%252BInitial%252BCOPD%252BMaintenance%252BTreatment%252BProvide%252BInsight%252Binto%252BRemaining%252BUnmet%252BNeeds%25253F%252BA%252BRetrospective%252BDatabase%252BStudy%252Bin%252BUK%252BPrimary%252BCare%26aulast%3DLandis%26aufirst%3DSarah%2BH.%26date%3D2017%26date%3D2016%26volume%3D14%26issue%3D1%26spage%3D80%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paolo  Montuschi</span>, <span class="hlFld-ContribAuthor ">Mario  Malerba</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Macis</span>, <span class="hlFld-ContribAuthor ">Nadia  Mores</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Santini</span>. </span><span class="cited-content_cbyCitation_article-title">Triple inhaled therapy for chronic obstructive pulmonary disease. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2016,</strong> <em>21 </em>
                                    (11)
                                     , 1820-1827. <a href="https://doi.org/10.1016/j.drudis.2016.07.009" title="DOI URL">https://doi.org/10.1016/j.drudis.2016.07.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2016.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2016.07.009%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DTriple%252Binhaled%252Btherapy%252Bfor%252Bchronic%252Bobstructive%252Bpulmonary%252Bdisease%26aulast%3DMontuschi%26aufirst%3DPaolo%26date%3D2016%26volume%3D21%26issue%3D11%26spage%3D1820%26epage%3D1827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vicky  Chang</span>, <span class="hlFld-ContribAuthor ">Emma L.  Gray</span>, <span class="hlFld-ContribAuthor ">Paul S.  Thomas</span>. </span><span class="cited-content_cbyCitation_article-title">Phamacology of fluticasone furoate and vilanterol trifenatate combination therapy for asthma. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Respiratory Medicine</span><span> <strong>2016,</strong> <em>10 </em>
                                    (10)
                                     , 1069-1078. <a href="https://doi.org/10.1080/17476348.2016.1227245" title="DOI URL">https://doi.org/10.1080/17476348.2016.1227245</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17476348.2016.1227245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17476348.2016.1227245%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Respiratory%2520Medicine%26atitle%3DPhamacology%252Bof%252Bfluticasone%252Bfuroate%252Band%252Bvilanterol%252Btrifenatate%252Bcombination%252Btherapy%252Bfor%252Basthma%26aulast%3DChang%26aufirst%3DVicky%26date%3D2016%26date%3D2016%26volume%3D10%26issue%3D10%26spage%3D1069%26epage%3D1078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pavlina A.  Andreeva-Gateva</span>, <span class="hlFld-ContribAuthor ">Eleonora  Stamenova</span>, <span class="hlFld-ContribAuthor ">Tzvetelin  Gatev</span>. </span><span class="cited-content_cbyCitation_article-title">The place of inhaled corticosteroids in the treatment of chronic obstructive pulmonary disease: a narrative review. </span><span class="cited-content_cbyCitation_journal-name">Postgraduate Medicine</span><span> <strong>2016,</strong> <em>128 </em>
                                    (5)
                                     , 474-484. <a href="https://doi.org/10.1080/00325481.2016.1186487" title="DOI URL">https://doi.org/10.1080/00325481.2016.1186487</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00325481.2016.1186487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00325481.2016.1186487%26sid%3Dliteratum%253Aachs%26jtitle%3DPostgraduate%2520Medicine%26atitle%3DThe%252Bplace%252Bof%252Binhaled%252Bcorticosteroids%252Bin%252Bthe%252Btreatment%252Bof%252Bchronic%252Bobstructive%252Bpulmonary%252Bdisease%25253A%252Ba%252Bnarrative%252Breview%26aulast%3DAndreeva-Gateva%26aufirst%3DPavlina%2BA.%26date%3D2016%26date%3D2016%26volume%3D128%26issue%3D5%26spage%3D474%26epage%3D484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adel S.  Girgis</span>, <span class="hlFld-ContribAuthor ">Marian N.  Aziz</span>, <span class="hlFld-ContribAuthor ">ElSayed M.  Shalaby</span>, <span class="hlFld-ContribAuthor ">Dalia O.  Saleh</span>, <span class="hlFld-ContribAuthor ">Fahmy M.  Asaad</span>, <span class="hlFld-ContribAuthor ">Wafaa I.  El-Eraky</span>, <span class="hlFld-ContribAuthor ">I. S.  Ahmed Farag</span>. </span><span class="cited-content_cbyCitation_article-title">Crystal Structure Studies and Bronchodilation Properties of Novel Benzocycloheptapyridines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Crystallography</span><span> <strong>2016,</strong> <em>46 </em>
                                    (6-7)
                                     , 280-289. <a href="https://doi.org/10.1007/s10870-016-0657-8" title="DOI URL">https://doi.org/10.1007/s10870-016-0657-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10870-016-0657-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10870-016-0657-8%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Crystallography%26atitle%3DCrystal%252BStructure%252BStudies%252Band%252BBronchodilation%252BProperties%252Bof%252BNovel%252BBenzocycloheptapyridines%26aulast%3DGirgis%26aufirst%3DAdel%2BS.%26date%3D2016%26date%3D2016%26volume%3D46%26issue%3D6-7%26spage%3D280%26epage%3D289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dietmar  Weichert</span>, <span class="hlFld-ContribAuthor ">Markus  Stanek</span>, <span class="hlFld-ContribAuthor ">Harald  Hübner</span>, <span class="hlFld-ContribAuthor ">Peter  Gmeiner</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (12)
                                     , 2641-2653. <a href="https://doi.org/10.1016/j.bmc.2016.04.028" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.04.028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.04.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.04.028%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DStructure-guided%252Bdevelopment%252Bof%252Bdual%252B%2525CE%2525B22%252Badrenergic%25252Fdopamine%252BD2%252Breceptor%252Bagonists%26aulast%3DWeichert%26aufirst%3DDietmar%26date%3D2016%26volume%3D24%26issue%3D12%26spage%3D2641%26epage%3D2653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hiroshi  Chantaphakul</span>, <span class="hlFld-ContribAuthor ">Kiat  Ruxrungtham</span>. </span><span class="cited-content_cbyCitation_article-title">Fixed-Dose combination of the inhaled corticosteroid and long-acting beta
              2
              -agonist therapy in adults with persistent asthma. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2016,</strong> <em>17 </em>
                                    (5)
                                     , 631-642. <a href="https://doi.org/10.1517/14656566.2016.1145659" title="DOI URL">https://doi.org/10.1517/14656566.2016.1145659</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/14656566.2016.1145659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F14656566.2016.1145659%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DFixed-Dose%252Bcombination%252Bof%252Bthe%252Binhaled%252Bcorticosteroid%252Band%252Blong-acting%252Bbeta%252B2%252B-agonist%252Btherapy%252Bin%252Badults%252Bwith%252Bpersistent%252Basthma%26aulast%3DChantaphakul%26aufirst%3DHiroshi%26date%3D2016%26date%3D2016%26volume%3D17%26issue%3D5%26spage%3D631%26epage%3D642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruben  Vardanyan</span>, <span class="hlFld-ContribAuthor ">Victor  Hruby</span>. </span><span class="cited-content_cbyCitation_article-title">Drugs for Treating Respiratory System Diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 357-381. <a href="https://doi.org/10.1016/B978-0-12-411492-0.00023-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-411492-0.00023-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-411492-0.00023-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-411492-0.00023-7%26sid%3Dliteratum%253Aachs%26atitle%3DDrugs%252Bfor%252BTreating%252BRespiratory%252BSystem%252BDiseases%26aulast%3DVardanyan%26aufirst%3DRuben%26date%3D2016%26spage%3D357%26epage%3D381%26pub%3DElsevier%26atitle%3DSynthesis%252Bof%252BBest-Seller%252BDrugs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Donald P  Tashkin</span>, <span class="hlFld-ContribAuthor ">Inge  Leimer</span>, <span class="hlFld-ContribAuthor ">Norbert  Metzdorf</span>, <span class="hlFld-ContribAuthor ">Marc  Decramer</span>. </span><span class="cited-content_cbyCitation_article-title">Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial. </span><span class="cited-content_cbyCitation_journal-name">Respiratory Research</span><span> <strong>2015,</strong> <em>16 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12931-015-0216-4" title="DOI URL">https://doi.org/10.1186/s12931-015-0216-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12931-015-0216-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12931-015-0216-4%26sid%3Dliteratum%253Aachs%26jtitle%3DRespiratory%2520Research%26atitle%3DCardiac%252Bsafety%252Bof%252Btiotropium%252Bin%252Bpatients%252Bwith%252Bcardiac%252Bevents%25253A%252Ba%252Bretrospective%252Banalysis%252Bof%252Bthe%252BUPLIFT%2525C2%2525AE%252Btrial%26aulast%3DTashkin%26aufirst%3DDonald%2BP%26date%3D2015%26date%3D2015%26volume%3D16%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul M.  O’Byrne</span>, <span class="hlFld-ContribAuthor ">Tony  D’Urzo</span>, <span class="hlFld-ContribAuthor ">Ekkehard  Beck</span>, <span class="hlFld-ContribAuthor ">Matjaž  Fležar</span>, <span class="hlFld-ContribAuthor ">Martina  Gahlemann</span>, <span class="hlFld-ContribAuthor ">Lorna  Hart</span>, <span class="hlFld-ContribAuthor ">Zuzana  Blahova</span>, <span class="hlFld-ContribAuthor ">Robert  Toorawa</span>, <span class="hlFld-ContribAuthor ">Kai-Michael  Beeh</span>. </span><span class="cited-content_cbyCitation_article-title">Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study. </span><span class="cited-content_cbyCitation_journal-name">Respiratory Research</span><span> <strong>2015,</strong> <em>16 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12931-015-0249-8" title="DOI URL">https://doi.org/10.1186/s12931-015-0249-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12931-015-0249-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12931-015-0249-8%26sid%3Dliteratum%253Aachs%26jtitle%3DRespiratory%2520Research%26atitle%3DDose-finding%252Bevaluation%252Bof%252Bonce-daily%252Btreatment%252Bwith%252Bolodaterol%25252C%252Ba%252Bnovel%252Blong-acting%252B%2525CE%2525B22-agonist%25252C%252Bin%252Bpatients%252Bwith%252Basthma%25253A%252Bresults%252Bof%252Ba%252Bparallel-group%252Bstudy%252Band%252Ba%252Bcrossover%252Bstudy%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DPaul%2BM.%26date%3D2015%26date%3D2015%26volume%3D16%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Reynold A  Panettieri Jr</span>. </span><span class="cited-content_cbyCitation_article-title">Bronchodilators, receptors and cross-talk: Together is better?. </span><span class="cited-content_cbyCitation_journal-name">Postgraduate Medicine</span><span> <strong>2015,</strong> <em>127 </em>
                                    (7)
                                     , 771-780. <a href="https://doi.org/10.1080/00325481.2015.1080589" title="DOI URL">https://doi.org/10.1080/00325481.2015.1080589</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00325481.2015.1080589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00325481.2015.1080589%26sid%3Dliteratum%253Aachs%26jtitle%3DPostgraduate%2520Medicine%26atitle%3DBronchodilators%25252C%252Breceptors%252Band%252Bcross-talk%25253A%252BTogether%252Bis%252Bbetter%25253F%26aulast%3DPanettieri%2BJr%26aufirst%3DReynold%2BA%26date%3D2015%26date%3D2015%26volume%3D127%26issue%3D7%26spage%3D771%26epage%3D780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lyn H.  Jones</span>, <span class="hlFld-ContribAuthor ">Jane  Burrows</span>, <span class="hlFld-ContribAuthor ">Neil  Feeder</span>, <span class="hlFld-ContribAuthor ">Paul  Glossop</span>, <span class="hlFld-ContribAuthor ">Kim  James</span>, <span class="hlFld-ContribAuthor ">Rhys M.  Jones</span>, <span class="hlFld-ContribAuthor ">Amy S.  Kenyon</span>, <span class="hlFld-ContribAuthor ">Sheena  Patel</span>, <span class="hlFld-ContribAuthor ">Dannielle F.  Roberts</span>, <span class="hlFld-ContribAuthor ">Matthew D.  Selby</span>, <span class="hlFld-ContribAuthor ">Ross S.  Strang</span>, <span class="hlFld-ContribAuthor ">Emilio F.  Stuart</span>, <span class="hlFld-ContribAuthor ">Michael A.  Trevethick</span>, <span class="hlFld-ContribAuthor ">Jessica  Watson</span>, <span class="hlFld-ContribAuthor ">Karen N.  Wright</span>, <span class="hlFld-ContribAuthor ">Nick  Clarke</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular hybridization yields triazole bronchodilators for the treatment of COPD. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (22)
                                     , 5121-5126. <a href="https://doi.org/10.1016/j.bmcl.2015.10.008" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.10.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.10.008%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DMolecular%252Bhybridization%252Byields%252Btriazole%252Bbronchodilators%252Bfor%252Bthe%252Btreatment%252Bof%252BCOPD%26aulast%3DJones%26aufirst%3DLyn%2BH.%26date%3D2015%26volume%3D25%26issue%3D22%26spage%3D5121%26epage%3D5126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saadoun  Bin-Hasan</span>, <span class="hlFld-ContribAuthor ">Felix  Ratjen</span>. </span><span class="cited-content_cbyCitation_article-title">Tiotropium bromide for cystic fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Orphan Drugs</span><span> <strong>2015,</strong> <em>3 </em>
                                    (8)
                                     , 957-966. <a href="https://doi.org/10.1517/21678707.2015.1065728" title="DOI URL">https://doi.org/10.1517/21678707.2015.1065728</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/21678707.2015.1065728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F21678707.2015.1065728%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Orphan%2520Drugs%26atitle%3DTiotropium%252Bbromide%252Bfor%252Bcystic%252Bfibrosis%26aulast%3DBin-Hasan%26aufirst%3DSaadoun%26date%3D2015%26date%3D2015%26volume%3D3%26issue%3D8%26spage%3D957%26epage%3D966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0017.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0019.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Drugs for pharmacological maintenance treatment of stable chronic obstructive pulmonary disease (COPD). Drugs currently approved for COPD are signed with an asterisk. Abbreviations: FDC, fixed dose combination; FF, fluticasone furoate; FP, fluticasone propionate; ICS, inhaled corticosteroids; LABA, long-acting β<sub>2</sub>-adrenoreceptor agonists; LAMA, long-acting muscarinic receptor antagonists; MABA, dual muscarinic antagonist-β<sub>2</sub>-agonist compounds; PDE<sub>4</sub>, phosphodiesterase 4; SABA, short-acting β<sub>2</sub>-adrenoreceptor agonists; SAMA, short-acting muscarinic receptor antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of ipratropium bromide (A), oxitropium bromide (B), and tiotropium bromide (C).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of aclidinium bromide (A), glycopyrronium bromide (B), and umeclidinium bromide (C).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of the short-acting β<sub>2</sub>-adrenoreceptor agonists (SABA) salbutamol (A), terbutaline (B), and fenoterol (C).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structures of the long-acting β<sub>2</sub>-adrenoreceptor agonists (LABA) salmeterol (A), formoterol (B), arformoterol (C), and indacaterol (D).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical structures of new once-daily long-acting β<sub>2</sub>-adrenoreceptor agonists (LABA) vilanterol (A), olodaterol (B), abediterol (C), milveterol (D), and carmoterol (E).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Pharmacological modulation of airway smooth muscle cell and mechanism of action of bronchodilators. Abbreviations: AC, adenylyl cyclase; Ach, acetylcholine; ATP, adenosine triphosphate; β<sub>2</sub>, β<sub>2</sub>-adrenergic receptor; Ca<sup>2+</sup>, calcium ion; cAMP, cyclic adenosine monophosphate; DAG, diacylglycerol; ER, endoplasmic reticulum; G<sub>i</sub>, inhibitory G protein; G<sub>q</sub>, G<sub>q</sub> protein, G<sub>s</sub>, stimulatory G protein; IP3, inositol 1,4,5-trisphosphate; LABA, long-acting β<sub>2</sub>-adrenenoreceptor agonists; LAMA, long-acting muscarinic receptor antagonists; M, muscarinic acetylcholine receptor; N, nicotinic acetylcholine receptor; PIP2, phosphatidylinositol 4,5-bisphosphate; PLC, phospholipase C; PKA, protein kinase A; SABA, short-acting β<sub>2</sub>-adrenoreceptor agonists; SAMA, short-acting muscarinic receptor antagonists; +, receptor activation; −, receptor antagonism.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Chemical structures of compound <b>1a</b> (A), compound <b>1h</b> (B), compound <b>34</b> (C), and revatropate (D).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Chemical structures of compound <b>47</b> (A), darotropium (B), compound <b>24</b> (C), compound <b>43a</b> (D), and compound <b>50</b> (E).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0009.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structure of salmeterol. The saligenin head, the hydrophobic phenylalkoxyalkyl chain, and the oxygen “hinge” are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0010.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Chemical structure of compound <b>29b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0011.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Postulated interactions of the <i>m</i>-sulfonamide <b>29b</b> with the β<sub>2</sub> receptor. Portions of TM6 are omitted (from <contrib-group>Procopiou, P. A.</contrib-group>;  <cite>J. Med. Chem.</cite> <span class="NLM_year">2009</span>, <em>52</em>, 2280–2288).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0012.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Chemical structures of compound <b>5</b> (A), compound <b>11</b> (B), compound <b>7</b> (C), and compound <b>38</b> (D).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0013.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structural overlays of compound <b>38</b> (orange) with salmeterol (purple) (from <contrib-group>Glossop, P. A.</contrib-group>;  <cite>J. Med. Chem.</cite> <span class="NLM_year">2010</span>, <em>53</em>, 6640–6652).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0014.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Chemical structures of compound <b>1</b> (A) and compound <b>6m</b> (B). Chemical structure of 6-hydroxy-4<i>H</i>-benzo[1,4]oxazin-3-ones from which olodaterol is derived (C).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0015.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Chemical structures of sibenadet (A), compound <b>16</b> (B), and compound <b>31</b> (C).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/medium/jm-2014-013227_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0016.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Chemical structure of batefenterol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jm5013227/20150521/images/large/jm-2014-013227_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm5013227&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i52">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84422" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84422" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 181 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span>Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD),<span class="NLM_x"> </span><span class="NLM_year">2014</span>. Available from <a href="http://www.goldcopd.org" class="extLink">www.goldcopd.org</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Global+Strategy+for+the+Diagnosis%2C+Management+and+Prevention+of+COPD%2C+Global+Initiative+for+Chronic+Obstructive+Lung+Disease+%28GOLD%29%2C+2014.+Available+from+www.goldcopd.org."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Montuschi, P.</span><span> </span><span class="NLM_article-title">Drugs for chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1461</span><span class="NLM_x">–</span> <span class="NLM_lpage">1463</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.2174%2F0929867311320120001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23016550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt1ynsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1461-1463&author=P.+Montuschi&title=Drugs+for+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Montuschi, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1461-1463</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfVjNlcyAdzLVg90H21EOLACvtfcHk0lhhRRgq6fKLkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmt1ynsLs%253D&md5=7fe5d3e1fa2824e9bf64b8576b7276e9</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2174%2F0929867311320120001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320120001%26sid%3Dliteratum%253Aachs%26aulast%3DMontuschi%26aufirst%3DP.%26atitle%3DDrugs%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26spage%3D1461%26epage%3D1463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Montuschi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valente, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuso, L.</span><span> </span><span class="NLM_article-title">Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1464</span><span class="NLM_x">–</span> <span class="NLM_lpage">1476</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.2174%2F0929867311320120002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=22963553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt1ynsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1464-1476&author=P.+Montuschiauthor=F.+Macagnoauthor=S.+Valenteauthor=L.+Fuso&title=Inhaled+muscarinic+acetylcholine+receptor+antagonists+for+treatment+of+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD</span></div><div class="casAuthors">Montuschi, P.; Macagno, F.; Valente, S.; Fuso, L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1464-1476</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Bronchodilators, generally administered via metered dose or dry powder inhalers, are the mainstays of pharmacol. treatment of stable COPD.  Inhaled long-acting beta-agonists (LABA) and anticholinergics are the broncholidators primarily used in the chronic treatment of COPD.  Anticholinergics act as muscarinic acetylcholine receptor antagonists and are frequently preferred over beta-agonists for their minimal cardiac stimulatory effects and greater efficacy in most studies.  Their therapeutic efficacy is based on the fact that vagally mediated bronchoconstriction is the major reversible component of airflow obstruction in patients with COPD.  However, bronchodilators are effective only on the reversible component of airflow obstruction, which by definition is limited, as COPD is characterized by a fixed or poorly reversible airflow obstruction.  Inhaled anticholinergic antimuscarinic drugs approved for the treatment of COPD include ipratropium bromide, oxitropium bromide and tiotropium bromide.  Ipratropium bromide, the prototype of anticholinergic bronchodilators, is a short-acting agent.  Oxitropium bromide is administered twice a day.  Tiotropium bromide, the only long-acting antimuscarinic agent (LAMA) currently approved, is administered once a day.  Newer LAMAs including aclidinium bromide and glycopyrrolate bromide are currently in phase III development for treatment of COPD.  Some new LAMAs, including glycocpyrrolate, are suitable for once daily administration and, unlike tiotropium, have a rapid onset of action.  New LAMAs and their combination with ultra-LABA and, possibly, inhaled corticosteroids, seem to open new perspectives in the management of COPD.  Dual-pharmacol. muscarinic antagonist-beta2 agonist (MABA) mols. present a novel approach to the treatment of COPD by combining muscarinic antagonism and beta2 agonism in a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYOw4zXsYanrVg90H21EOLACvtfcHk0lhhRRgq6fKLkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmt1ynsLg%253D&md5=3e12b45f2c1c0bc03f7d54f62096b48f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F0929867311320120002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320120002%26sid%3Dliteratum%253Aachs%26aulast%3DMontuschi%26aufirst%3DP.%26aulast%3DMacagno%26aufirst%3DF.%26aulast%3DValente%26aufirst%3DS.%26aulast%3DFuso%26aufirst%3DL.%26atitle%3DInhaled%2520muscarinic%2520acetylcholine%2520receptor%2520antagonists%2520for%2520treatment%2520of%2520COPD%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26spage%3D1464%26epage%3D1476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Fuso, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mores, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valente, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malerba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montuschi, P.</span><span> </span><span class="NLM_article-title">Long-acting beta-agonists and their association with inhaled corticosteroids in COPD</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1477</span><span class="NLM_x">–</span> <span class="NLM_lpage">1495</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.2174%2F0929867311320120003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23409722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt1ynsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1477-1495&author=L.+Fusoauthor=N.+Moresauthor=S.+Valenteauthor=M.+Malerbaauthor=P.+Montuschi&title=Long-acting+beta-agonists+and+their+association+with+inhaled+corticosteroids+in+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Long-acting beta-agonists and their association with inhaled corticosteroids in COPD</span></div><div class="casAuthors">Fuso, L.; Mores, N.; Valente, S.; Malerba, M.; Montuschi, P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1477-1495</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Inhaled bronchodilators, including beta2-agonists and antimuscaric receptor antagonists, are the mainstay of pharmacotherapy in chronic obstructive pulmonary disease (COPD).  The short-acting beta2-agonists, including salbutamol, and fenoterol, have a rapid onset of action, a bronchodilating effect for 3-6 h and are used on demand.  The long-acting beta2-agonists (LABAs), including salmeterol and formoterol, have 12-h duration of action and are used with a twice-daily dosing regimen for long-term COPD treatment.  Unlike salmeterol, formoterol has a rapid onset of action.  Pharmacol. characteristics required by novel inhaled LABAs include 24 h bronchodilator effect in vivo which would make them suitable for once daily administration (ultra-LABA), high potency and selectivity for beta2-adrenoceptors, rapid onset of action, low oral bioavailability (< 5%) after inhalation, and high systemic clearance.  Indacaterol, which has been approved for long-term treatment of COPD in Europe and in the USA, has a 24-h duration of action and a once-daily dosing regimen.  Newer ultra-LABAs, including olodaterol, vilanterol, milveterol, carmoterol, and abediterol, are in development.  Combination with ICS (fluticasone/salmeterol, budesonide/formoterol, beclomethasone/formoterol) appears to provide an addnl. benefit over the monocomponent therapy, although the extent of this benefit is variable and often not clin. significant in all the endpoints assessed.  In patients with COPD, treatment with ICS is assocd. with increased risk of pneumonia which should be carefully considered when assessing the risk/benefit ratio of ICS/LABA combinations.  Subphenotyping of patients with COPD (e.g., frequent exacerbations, sputum eosinophilia, mixed asthma/COPD phenotype) might help identify those patients who are most likely to benefit from addn. of ICS to bronchodilating treatment.  Ultra-LABA/ long-acting muscarinic receptor antagonist (LAMA) combination treatment is under development and is likely to become a std. pharmacol. strategy for COPD.  Dual-pharmacol. inhaled muscarinic antagonist-beta2 agonist (MABA) mols. provide a new approach to the treatment of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqtajjRd8d0LVg90H21EOLACvtfcHk0lge3jtsKF_CXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmt1ynsLk%253D&md5=32add113b9bc1d3a8e68df8d1acb7fe8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F0929867311320120003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320120003%26sid%3Dliteratum%253Aachs%26aulast%3DFuso%26aufirst%3DL.%26aulast%3DMores%26aufirst%3DN.%26aulast%3DValente%26aufirst%3DS.%26aulast%3DMalerba%26aufirst%3DM.%26aulast%3DMontuschi%26aufirst%3DP.%26atitle%3DLong-acting%2520beta-agonists%2520and%2520their%2520association%2520with%2520inhaled%2520corticosteroids%2520in%2520COPD%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26spage%3D1477%26epage%3D1495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Woods, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nealy, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrons, R. W.</span><span> </span><span class="NLM_article-title">Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Ann. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1017</span><span class="NLM_x">–</span> <span class="NLM_lpage">1028</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2013&pages=1017-1028&author=J.+A.+Woodsauthor=K.+L.+Nealyauthor=R.+W.+Barrons&title=Aclidinium+bromide%3A+an+alternative+long-acting+inhaled+anticholinergic+in+the+management+of+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWoods%26aufirst%3DJ.%2BA.%26aulast%3DNealy%26aufirst%3DK.%2BL.%26aulast%3DBarrons%26aufirst%3DR.%2BW.%26atitle%3DAclidinium%2520bromide%253A%2520an%2520alternative%2520long-acting%2520inhaled%2520anticholinergic%2520in%2520the%2520management%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2013%26volume%3D47%26spage%3D1017%26epage%3D1028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Carter, N. J.</span><span> </span><span class="NLM_article-title">Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">741</span><span class="NLM_x">–</span> <span class="NLM_lpage">753</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=741-753&author=N.+J.+Carter&title=Inhaled+glycopyrronium+bromide%3A+a+review+of+its+use+in+patients+with+moderate+to+severe+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DN.%2BJ.%26atitle%3DInhaled%2520glycopyrronium%2520bromide%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520patients%2520with%2520moderate%2520to%2520severe%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D741%26epage%3D753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Scott, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hair, P.</span><span> </span><span class="NLM_article-title">Umeclidinium/vilanterol: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">389</span><span class="NLM_x">–</span> <span class="NLM_lpage">395</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=389-395&author=L.+J.+Scottauthor=P.+Hair&title=Umeclidinium%2Fvilanterol%3A+first+global+approval"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26aulast%3DHair%26aufirst%3DP.%26atitle%3DUmeclidinium%252Fvilanterol%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D389%26epage%3D395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Moen, M. D.</span><span> </span><span class="NLM_article-title">Indacaterol: in chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">2269</span><span class="NLM_x">–</span> <span class="NLM_lpage">2280</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=2269-2280&author=M.+D.+Moen&title=Indacaterol%3A+in+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoen%26aufirst%3DM.%2BD.%26atitle%3DIndacaterol%253A%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DDrugs%26date%3D2010%26volume%3D70%26spage%3D2269%26epage%3D2280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Belmonte, K. E.</span><span> </span><span class="NLM_article-title">Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Proc. Am. Thorac. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="NLM_x">–</span> <span class="NLM_lpage">304</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1513%2Fpats.200504-043SR" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=16267352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlams7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=297-304&author=K.+E.+Belmonte&title=Cholinergic+pathways+in+the+lungs+and+anticholinergic+therapy+for+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Belmonte, Kristen E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the American Thoracic Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">297-304</span>CODEN:
                <span class="NLM_cas:coden">PATSBB</span>;
        ISSN:<span class="NLM_cas:issn">1546-3222</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">A review.  Abundant data from animal models and humans support the hypothesis that changes at the level of parasympathetic neuronal control of airway smooth muscle result in increased bronchoconstriction in response to vagal stimulation, leading to airway hyper-responsiveness.  Neuronal inhibitory M2 muscarinic acetylcholine receptors on parasympathetic nerves are responsible for limiting acetylcholine release from these nerves.  In humans with asthma, and after pulmonary inflammatory events in exptl. animals, these receptors are dysfunctional, which results in airway hyper-responsiveness.  Although it is unknown what mechanisms underlie airway hyperresponsiveness in chronic obstructive pulmonary disease, loss of parasympathetic control of airway smooth muscle is thought to be a contributing mechanism.  As such, anticholinergic therapy is used extensively and with a high degree of success in the treatment of this condition.  The future for inhaled anticholinergic compds. for the treatment of chronic obstructive pulmonary disease appears to rest in their combination with other agents, such as β2 agonists and phosphodiesterase-4 inhibitors.  Nonselective anticholinergic agents might be the best choice, because M2 muscarinic receptors on airway smooth muscle inhibit the generation and accumulation of cyclic adenosine monophosphate.  Adequate concurrent blockade of M3 muscarinic receptors would be expected to counteract the enhanced acetylcholine release that would result from blockade of neuronal inhibitory M2 muscarinic receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf5AsHs2UOPLVg90H21EOLACvtfcHk0li32HOL6BRjDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlams7vO&md5=98f86ecd7332496401526820d4efe9d7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1513%2Fpats.200504-043SR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1513%252Fpats.200504-043SR%26sid%3Dliteratum%253Aachs%26aulast%3DBelmonte%26aufirst%3DK.%2BE.%26atitle%3DCholinergic%2520pathways%2520in%2520the%2520lungs%2520and%2520anticholinergic%2520therapy%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DProc.%2520Am.%2520Thorac.%2520Soc.%26date%3D2005%26volume%3D2%26spage%3D297%26epage%3D304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Montuschi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malerba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miravitlles, M.</span><span> </span><span class="NLM_article-title">Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1928</span><span class="NLM_x">–</span> <span class="NLM_lpage">1935</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1928-1935&author=P.+Montuschiauthor=M.+Malerbaauthor=G.+Santiniauthor=M.+Miravitlles&title=Pharmacological+treatment+of+chronic+obstructive+pulmonary+disease%3A+from+evidence-based+medicine+to+phenotyping"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMontuschi%26aufirst%3DP.%26aulast%3DMalerba%26aufirst%3DM.%26aulast%3DSantini%26aufirst%3DG.%26aulast%3DMiravitlles%26aufirst%3DM.%26atitle%3DPharmacological%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520from%2520evidence-based%2520medicine%2520to%2520phenotyping%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D1928%26epage%3D1935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Roffel, A. F.; Meurs, H.; Zaagsma, J.</span><span> </span><span class="NLM_article-title">Identification, localization and function of muscarinic receptor subtypes in the airways</span>. In  <span class="citation_source-book">Muscarinic Receptors in Airways Diseases</span>; <span class="NLM_contrib-group">Zagsma, J.; Meurs, H.; Roffel, A. F.</span>, Ed.; <span class="NLM_publisher-name">Birkhauser Verlag</span>: <span class="NLM_publisher-loc">Basel, Switzerland</span>,<span class="NLM_x"> </span><span class="NLM_year">2001</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1007%2F978-3-0348-8358-0_3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&pages=63-85&author=A.+F.+Roffel&author=H.+Meurs&author=J.+Zaagsmaauthor=J.+Zagsma&author=H.+Meurs&author=A.+F.+Roffel&title=Muscarinic+Receptors+in+Airways+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2F978-3-0348-8358-0_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-0348-8358-0_3%26sid%3Dliteratum%253Aachs%26aulast%3DRoffel%26aufirst%3DA.%2BF.%26atitle%3DIdentification%252C%2520localization%2520and%2520function%2520of%2520muscarinic%2520receptor%2520subtypes%2520in%2520the%2520airways%26btitle%3DMuscarinic%2520Receptors%2520in%2520Airways%2520Diseases%26aulast%3DZagsma%26aufirst%3DJ.%26pub%3DBirkhauser%2520Verlag%26date%3D2001%26spage%3D63%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Brown, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koarai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturton, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnelly, L. E.</span><span> </span><span class="NLM_article-title">A role for M<sub>2</sub> and M<sub>3</sub> muscarinic receptors in the contraction of rat and human small airways</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">702</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">115</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.ejphar.2013.01.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23396230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktlOhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=702&publication_year=2013&pages=109-115&author=S.+M.+Brownauthor=A.+Koaraiauthor=R.+G.+Sturtonauthor=A.+G.+Nicholsonauthor=P.+J.+Barnesauthor=L.+E.+Donnelly&title=A+role+for+M2+and+M3+muscarinic+receptors+in+the+contraction+of+rat+and+human+small+airways"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A role for M2 and M3 muscarinic receptors in the contraction of rat and human small airways</span></div><div class="casAuthors">Brown, Stephanie M.; Koarai, Akira; Sturton, Richard G.; Nicholson, Andrew G.; Barnes, Peter J.; Donnelly, Louise E.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">702</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">109-115</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Large airway bronchoconstriction acts mainly through cholinergic pathways via muscarinic M3 receptors with some contribution from M2 receptors.  By contrast, the mechanisms of small airway contraction are largely unknown.  This study used precision cut lung slices to examine the role of muscarinic M2 and M3 receptors in the contractile response of rat and human small airways.  In rat small airways, the M3 preferential antagonist, 4-DAMP, inhibited carbachol-mediated contraction (1×10-6 M) more than that of the M2 selective antagonist, AF-DX 116 (pIC50 values: 8.85 and 6.31, resp.).  Tiotropium, inhibited the contractile response to carbachol with (pIC50: 9.86), but could not distinguish between M2 and M3 mediated effects.  Similar expts. using human small airways with tiotropium and AF-DX 116, gave a pIC50 of 10.35 and a pKB of 6.37, resp.  Therefore, M3 receptors play a key role in muscarinic contraction of small airways in both rats and humans but the effect of M2 receptors cannot be excluded.  To investigate the role of M2 receptors, carbachol-induced contraction of small airways was performed in the presence and absence of a β2-agonist in order to elevate intracellular cAMP levels prior to contraction.  Isoproterenol-induced relaxation was significantly increased by AF-DX 116 in rat small airways and by AF-DX 116, gallamine and pertussis toxin in human small airways.  Taken together, these data suggest that cholinergic antagonism of muscarinic receptors in human and rat small airways inhibits airway contraction via direct inhibition of contraction through M3 receptors, and by M2 receptor mediated inhibition of relaxation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqBUisXZhmerVg90H21EOLACvtfcHk0ljC8rmGz8ZwjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktlOhsLs%253D&md5=9d490a7428d9948b0917f154b7c35eb1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2013.01.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2013.01.054%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DS.%2BM.%26aulast%3DKoarai%26aufirst%3DA.%26aulast%3DSturton%26aufirst%3DR.%2BG.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DDonnelly%26aufirst%3DL.%2BE.%26atitle%3DA%2520role%2520for%2520M2%2520and%2520M3%2520muscarinic%2520receptors%2520in%2520the%2520contraction%2520of%2520rat%2520and%2520human%2520small%2520airways%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D702%26spage%3D109%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Johnson, M.</span><span> </span><span class="NLM_article-title">The β-adrenoceptor</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">S146</span><span class="NLM_x">–</span> <span class="NLM_lpage">S153</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1164%2Fajrccm.158.supplement_2.13tac110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=9817738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADyaK1M%252FlsFSksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=1998&pages=S146-S153&author=M.+Johnson&title=The+%CE%B2-adrenoceptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The beta-adrenoceptor</span></div><div class="casAuthors">Johnson M</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">5 Pt 3</span>),
    <span class="NLM_cas:pages">S146-53</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">The human beta-adrenoceptor is a member of the seven-transmembrane family of receptors, encoded by a gene on chromosome 5. beta-Adrenoceptors have been classified into beta1, beta2, and beta3 subgroups, with beta2-receptors being widely distributed in the respiratory tract, particularly in airway smooth muscle.  Intracellular signaling following beta2-adrenoceptor activation is largely affected through a trimeric Gs protein coupled to adenylate cyclase.  Cyclic AMP (cAMP) induces airway relaxation through phosphorylation of muscle regulatory proteins and attenuation of cellular Ca2+ concentrations.  Alternative cAMP-independent pathways involving activation of membrane maxi-K+ channels and coupling through Gi to the MAP kinase system have also been described.  Site-directed mutagenesis has identified Asp 113 and Ser 204/207 within the third and fourth membrane domains as the active site of the beta2-receptor, critical for beta2-agonist binding and activity. beta2-Agonists have been characterized as those that directly activate the receptor (albuterol), those that are taken up into a membrane depot (formoterol), and those that interact with a receptor-specific auxiliary binding site (salmeterol).  These differences in mechanism of action are reflected in the kinetics of airway smooth muscle relaxation and bronchodilation in patients with asthma. beta-Adrenoceptor desensitization associated with beta2-agonist activation is a consequence of phosphorylation by beta-ARK and uncoupling of the receptor from Gs following beta-arrestin binding, of internalization and recycling of the receptor through processes of sequestration and resensitization and downregulation, modulated by an effect on receptor gene expression.  The degree of receptor desensitization appears to differ, depending on the cell or tissue type, and is reflected in the different profiles of clinical tolerance to chronic beta2-agonist therapy.  A number of polymorphisms of the beta2-receptor have been described that appear to alter the behavior of the receptor following agonist exposure.  These include Arg-Gly 16, Glu-Gln 27, and Thr-lle 164.  The Gly 16 receptor downregulates to a greater extent and is associated with increased airway hyperreactivity, nocturnal symptoms, and more severe asthma.  The Glu 27 form appears to protect against downregulation and is associated with less reactive airways.  An individual can be homozygous or heterozygous for given polymorphisms, and large populations will have to be studied to determine their importance to the asthma phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7eYHSZZemQ9yzdcP07UmufW6udTcc2ebkzUTkcPX7kbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M%252FlsFSksg%253D%253D&md5=b35ba94acecce6e5da1f0373051d5c7f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.158.supplement_2.13tac110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.158.supplement_2.13tac110%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DM.%26atitle%3DThe%2520%25CE%25B2-adrenoceptor%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D1998%26volume%3D158%26spage%3DS146%26epage%3DS153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Cave, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurst, M. M.</span><span> </span><span class="NLM_article-title">The use of long acting β<sub>2</sub>-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">114</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.pharmthera.2010.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=21276815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFyiurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2011&pages=114-143&author=A.+C.+Caveauthor=M.+M.+Hurst&title=The+use+of+long+acting+%CE%B22-agonists%2C+alone+or+in+combination+with+inhaled+corticosteroids%2C+in+chronic+obstructive+pulmonary+disease+%28COPD%29%3A+a+risk-benefit+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The use of long acting β2-agonists, alone or in combination with inhaled corticosteroids, in Chronic Obstructive Pulmonary Disease (COPD)</span></div><div class="casAuthors">Cave, Alison C.; Hurst, Martin M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">114-143</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Chronic Obstructive Pulmonary Disease (COPD) is a slowly progressive, largely non-reversible pulmonary disease which is characterised by airflow limitation.  It is one of the few diseases with an increasing mortality rate and by 2020 it is predicted to be the third leading cause of death.  The mainstays of current treatment are long acting β2 agonists (LABAs) coupled with an increasing reliance on inhaled corticosteroids (ICS).  Two LABAs (salmeterol and formoterol) are currently licenced for COPD both as monotherapy and in combination with ICS (fluticasone propionate (FP) and budesonide resp.).  A comprehensive review of the risk-benefit of these medicines in COPD is provided here which concludes that there is limited efficacy for LABAs in COPD either alone or in combination with ICS and no overall modification of the disease process.  However, where directly compared, combination therapy usually provides an advantage over monotherapy.  Importantly the apparent effectiveness of treatment may significantly depend upon the outcome measure chosen with some measures possibly underestimating the extent of benefit.  ICS benefit may also be greater in those patients who respond to treatment.  Set against this benefit are recent concerns that a no. of issues related to the clin. trial design such as prior use of ICS and different withdrawal rates between groups may be significantly influencing results.  Furthermore there is no evidence of a dose response relationship with regard to ICS dose.  A key issue with combination therapy is the excess risk of pneumonia conferred by the use of an ICS in this patient population.  This risk does not appear to be proportional to the ICS dose but may differ between FP and budesonide.  We conclude that further studies are required to identify the optimal dose of ICS, in terms of both risk and benefit, and to confirm their benefit in steroid naive patients.  Furthermore it will be important to det. whether the risk of pneumonia is apparent with both FP and budesonide and to identify factors which may predict steroid responsiveness in COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Im_9h0AAEbVg90H21EOLACvtfcHk0lhCByttx7S-WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFyiurc%253D&md5=3c96fa3cf9801bb657731b17448f48d5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2010.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2010.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DCave%26aufirst%3DA.%2BC.%26aulast%3DHurst%26aufirst%3DM.%2BM.%26atitle%3DThe%2520use%2520of%2520long%2520acting%2520%25CE%25B22-agonists%252C%2520alone%2520or%2520in%2520combination%2520with%2520inhaled%2520corticosteroids%252C%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%2520%2528COPD%2529%253A%2520a%2520risk-benefit%2520analysis%26jtitle%3DPharmacol.%2520Ther.%26date%3D2011%26volume%3D130%26spage%3D114%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Procopiou, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bevan, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggadike, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butchers, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coe, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conroy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edney, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Field, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guntrip, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Looker, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLay, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteith, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutch, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasse, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. E.</span><span> </span><span class="NLM_article-title">Synthesis and structure–activity relationships of long-acting beta<sub>2</sub> adrenergic receptor agonists incorporating arylsulfonamide groups</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">2280</span><span class="NLM_x">–</span> <span class="NLM_lpage">2288</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801016j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2280-2288&author=P.+A.+Procopiouauthor=V.+J.+Barrettauthor=N.+J.+Bevanauthor=K.+Biggadikeauthor=P.+R.+Butchersauthor=D.+M.+Coeauthor=R.+Conroyauthor=D.+D.+Edneyauthor=R.+N.+Fieldauthor=A.+J.+Fordauthor=S.+B.+Guntripauthor=B.+E.+Lookerauthor=I.+M.+McLayauthor=M.+J.+Monteithauthor=V.+S.+Morrisonauthor=P.+J.+Mutchauthor=S.+A.+Richardsauthor=R.+Sasseauthor=C.+E.+Smith&title=Synthesis+and+structure%E2%80%93activity+relationships+of+long-acting+beta2+adrenergic+receptor+agonists+incorporating+arylsulfonamide+groups"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm801016j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801016j%26sid%3Dliteratum%253Aachs%26aulast%3DProcopiou%26aufirst%3DP.%2BA.%26aulast%3DBarrett%26aufirst%3DV.%2BJ.%26aulast%3DBevan%26aufirst%3DN.%2BJ.%26aulast%3DBiggadike%26aufirst%3DK.%26aulast%3DButchers%26aufirst%3DP.%2BR.%26aulast%3DCoe%26aufirst%3DD.%2BM.%26aulast%3DConroy%26aufirst%3DR.%26aulast%3DEdney%26aufirst%3DD.%2BD.%26aulast%3DField%26aufirst%3DR.%2BN.%26aulast%3DFord%26aufirst%3DA.%2BJ.%26aulast%3DGuntrip%26aufirst%3DS.%2BB.%26aulast%3DLooker%26aufirst%3DB.%2BE.%26aulast%3DMcLay%26aufirst%3DI.%2BM.%26aulast%3DMonteith%26aufirst%3DM.%2BJ.%26aulast%3DMorrison%26aufirst%3DV.%2BS.%26aulast%3DMutch%26aufirst%3DP.%2BJ.%26aulast%3DRichards%26aufirst%3DS.%2BA.%26aulast%3DSasse%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DC.%2BE.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520long-acting%2520beta2%2520adrenergic%2520receptor%2520agonists%2520incorporating%2520arylsulfonamide%2520groups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2280%26epage%3D2288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Baur, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beattie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruce, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuenoud, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernst, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairhurst, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faller, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fozard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fullerton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janus, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loeuillet-Ritzler, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moser, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steward, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sykes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tedaldi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trifilieff, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tweed, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissler, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyss, D.</span><span> </span><span class="NLM_article-title">The identification of indacaterol as an ultra long-acting inhaled beta<sub>2</sub>-adrenoceptor agonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3675</span><span class="NLM_x">–</span> <span class="NLM_lpage">3684</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100068m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3675-3684&author=F.+Baurauthor=D.+Beattieauthor=D.+Beerauthor=D.+Bentleyauthor=M.+Bradleyauthor=I.+Bruceauthor=S.+J.+Charltonauthor=B.+Cuenoudauthor=R.+Ernstauthor=R.+A.+Fairhurstauthor=B.+Fallerauthor=D.+Farrauthor=T.+Kellerauthor=J.+R.+Fozardauthor=J.+Fullertonauthor=S.+Garmanauthor=J.+Hattoauthor=C.+Haydenauthor=H.+Heauthor=C.+Howesauthor=D.+Janusauthor=Z.+Jiangauthor=C.+Lewisauthor=F.+Loeuillet-Ritzlerauthor=H.+Moserauthor=J.+Reillyauthor=A.+Stewardauthor=D.+Sykesauthor=L.+Tedaldiauthor=A.+Trifilieffauthor=M.+Tweedauthor=S.+Watsonauthor=E.+Wisslerauthor=D.+Wyss&title=The+identification+of+indacaterol+as+an+ultra+long-acting+inhaled+beta2-adrenoceptor+agonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm100068m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100068m%26sid%3Dliteratum%253Aachs%26aulast%3DBaur%26aufirst%3DF.%26aulast%3DBeattie%26aufirst%3DD.%26aulast%3DBeer%26aufirst%3DD.%26aulast%3DBentley%26aufirst%3DD.%26aulast%3DBradley%26aufirst%3DM.%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DCuenoud%26aufirst%3DB.%26aulast%3DErnst%26aufirst%3DR.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DFaller%26aufirst%3DB.%26aulast%3DFarr%26aufirst%3DD.%26aulast%3DKeller%26aufirst%3DT.%26aulast%3DFozard%26aufirst%3DJ.%2BR.%26aulast%3DFullerton%26aufirst%3DJ.%26aulast%3DGarman%26aufirst%3DS.%26aulast%3DHatto%26aufirst%3DJ.%26aulast%3DHayden%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DHowes%26aufirst%3DC.%26aulast%3DJanus%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DLoeuillet-Ritzler%26aufirst%3DF.%26aulast%3DMoser%26aufirst%3DH.%26aulast%3DReilly%26aufirst%3DJ.%26aulast%3DSteward%26aufirst%3DA.%26aulast%3DSykes%26aufirst%3DD.%26aulast%3DTedaldi%26aufirst%3DL.%26aulast%3DTrifilieff%26aufirst%3DA.%26aulast%3DTweed%26aufirst%3DM.%26aulast%3DWatson%26aufirst%3DS.%26aulast%3DWissler%26aufirst%3DE.%26aulast%3DWyss%26aufirst%3DD.%26atitle%3DThe%2520identification%2520of%2520indacaterol%2520as%2520an%2520ultra%2520long-acting%2520inhaled%2520beta2-adrenoceptor%2520agonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3675%26epage%3D3684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Szczuka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wennerberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Packeu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vauquelin, G.</span><span> </span><span class="NLM_article-title">Molecular mechanisms for the persistent bronchodilatory effect of the beta<sub>2</sub>-adrenoceptor agonist salmeterol</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">–</span> <span class="NLM_lpage">194</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1111%2Fj.1476-5381.2009.00296.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=19594756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKlsr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2009&pages=183-194&author=A.+Szczukaauthor=M.+Wennerbergauthor=A.+Packeuauthor=G.+Vauquelin&title=Molecular+mechanisms+for+the+persistent+bronchodilatory+effect+of+the+beta2-adrenoceptor+agonist+salmeterol"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms for the persistent bronchodilatory effect of the β2-adrenoceptor agonist salmeterol</span></div><div class="casAuthors">Szczuka, A.; Wennerberg, M.; Packeu, A.; Vauquelin, G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">183-194</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">β2-adrenoceptor agonists are effective bronchodilators.  In vitro studies demonstrated long-lasting airway smooth muscle relaxation by salmeterol after washout, the quick disappearance of this effect in presence of antagonists and its recovery after antagonist removal.  Current explanations invoke salmeterol accumulation in the membrane ('diffusion microkinetic' model) or the existence of salmeterol-binding 'exosites'.  An alternative model based on 'rebinding' of a dissocd. ligand to the receptor mols. also produces an apparent decrease in the ligand's dissocn. rate in the absence of competing ligands.  Computer-assisted simulations were performed to follow the receptor-occupation by a salmeterol-like ligand and a competing ligand as a function of time.  The aptness of the models to describe the above in vitro findings was evaluated.  The 'diffusion microkinetic' model is sufficient to explain a long-lasting β2-adrenoceptor stimulation and reassertion as long as the membrane harbors a high concn. of the agonist.  At lower concn., 'rebinding' and, in second place, 'exosite' binding are likely to become operational.  The 'rebinding' and 'exosite' binding mechanisms take place at a sub-cellular/mol. scale.  Pending their demonstration by expts. on appropriate, simple models such as intact cells or membranes thereof, these mechanisms remain hypothetical in the case of salmeterol.  Airway smooth muscle contraction could also be governed by addnl. mechanisms that are particular to this macroscopic approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEC9rfvp5YbbVg90H21EOLACvtfcHk0ljf3dCmQGgJJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKlsr7M&md5=0515669d4f02ba8bd14f1bca84da4275</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00296.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00296.x%26sid%3Dliteratum%253Aachs%26aulast%3DSzczuka%26aufirst%3DA.%26aulast%3DWennerberg%26aufirst%3DM.%26aulast%3DPackeu%26aufirst%3DA.%26aulast%3DVauquelin%26aufirst%3DG.%26atitle%3DMolecular%2520mechanisms%2520for%2520the%2520persistent%2520bronchodilatory%2520effect%2520of%2520the%2520beta2-adrenoceptor%2520agonist%2520salmeterol%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D158%26spage%3D183%26epage%3D194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Rhodes, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbette, L.</span><span> </span><span class="NLM_article-title">Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">596</span><span class="NLM_x">–</span> <span class="NLM_lpage">602</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1992&pages=596-602&author=D.+G.+Rhodesauthor=R.+Newtonauthor=R.+Butlerauthor=L.+Herbette&title=Equilibrium+and+kinetic+studies+of+the+interactions+of+salmeterol+with+membrane+bilayers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRhodes%26aufirst%3DD.%2BG.%26aulast%3DNewton%26aufirst%3DR.%26aulast%3DButler%26aufirst%3DR.%26aulast%3DHerbette%26aufirst%3DL.%26atitle%3DEquilibrium%2520and%2520kinetic%2520studies%2520of%2520the%2520interactions%2520of%2520salmeterol%2520with%2520membrane%2520bilayers%26jtitle%3DMol.%2520Pharmacol.%26date%3D1992%26volume%3D42%26spage%3D596%26epage%3D602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Johnson, M.</span><span> </span><span class="NLM_article-title">Beta<sub>2</sub>-adrenoceptors: mechanisms of action of beta<sub>2</sub>-agonists</span> <span class="citation_source-journal">Paediatr. Respir. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1053%2Fprrv.2000.0102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=16263481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BD2Mros1amtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=57-62&author=M.+Johnson&title=Beta2-adrenoceptors%3A+mechanisms+of+action+of+beta2-agonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Beta2-adrenoceptors: mechanisms of action of beta2-agonists</span></div><div class="casAuthors">Johnson M</div><div class="citationInfo"><span class="NLM_cas:title">Paediatric respiratory reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-62</span>
        ISSN:<span class="NLM_cas:issn">1526-0542</span>.
    </div><div class="casAbstract">The human beta2-adrenoceptor is a member of the 7 transmembrane family of receptors.  It is encoded by a gene on chromosome 5 and is widely distributed in the respiratory tract.  Following beta2-adrenoceptor activation, intracellular signalling is mainly produced by inducing cyclic AMP.  This produces airway relaxation through phosphorylation of muscle regulatory proteins and modification of cellular Ca2+concentrations.  Beta2-agonists have been characterised into those which directly activate the receptor (salbutamol/terbutaline), those which are taken up into a membrane depot (formoterol) and those which interact with a receptor-specific, auxiliary binding site (salmeterol).  These differences in mechanism of action are reflected in the kinetics of airway smooth muscle relaxation and bronchodilation in asthmatic patients.  Beta-adrenoceptor desensitisation is associated with beta2-agonist activation and differs depending on the cell type.  It is reflected in the different profiles of clinical tolerance to chronic beta2-agonist therapy.  A number of polymorphisms of the beta2-receptor have been described which appear to alter the behaviour of the receptor, including the degree of downregulation and response to beta2-agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRUowsFMb9kLcvLc4ARHEmzfW6udTcc2eYlr0Cb1wyrG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mros1amtg%253D%253D&md5=18b08b6aa45ab53a8bf757299ad12dfe</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1053%2Fprrv.2000.0102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fprrv.2000.0102%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DM.%26atitle%3DBeta2-adrenoceptors%253A%2520mechanisms%2520of%2520action%2520of%2520beta2-agonists%26jtitle%3DPaediatr.%2520Respir.%2520Rev.%26date%3D2001%26volume%3D2%26spage%3D57%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Coleman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nials, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vardey, C. J.</span><span> </span><span class="NLM_article-title">Exosites: their current status, and their relevance to the duration of action of long-acting beta<sub>2</sub>-adrenoceptor agonists</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">324</span><span class="NLM_x">–</span> <span class="NLM_lpage">330</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1996&pages=324-330&author=R.+A.+Colemanauthor=M.+Johnsonauthor=A.+T.+Nialsauthor=C.+J.+Vardey&title=Exosites%3A+their+current+status%2C+and+their+relevance+to+the+duration+of+action+of+long-acting+beta2-adrenoceptor+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DR.%2BA.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DNials%26aufirst%3DA.%2BT.%26aulast%3DVardey%26aufirst%3DC.%2BJ.%26atitle%3DExosites%253A%2520their%2520current%2520status%252C%2520and%2520their%2520relevance%2520to%2520the%2520duration%2520of%2520action%2520of%2520long-acting%2520beta2-adrenoceptor%2520agonists%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1996%26volume%3D17%26spage%3D324%26epage%3D330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Austin, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barton, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnert, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cage, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheshire, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougall, I. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ince, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairaudeau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, A.</span><span> </span><span class="NLM_article-title">QSAR and the rational design of long-acting dual D<sub>2</sub>-receptor/beta<sub>2</sub>-adrenoceptor agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">3210</span><span class="NLM_x">–</span> <span class="NLM_lpage">3220</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020886c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=3210-3220&author=R.+P.+Austinauthor=P.+Bartonauthor=R.+V.+Bonnertauthor=R.+C.+Brownauthor=P.+A.+Cageauthor=D.+R.+Cheshireauthor=A.+M.+Davisauthor=I.+G.+Dougallauthor=F.+Inceauthor=G.+Pairaudeauauthor=A.+Young&title=QSAR+and+the+rational+design+of+long-acting+dual+D2-receptor%2Fbeta2-adrenoceptor+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm020886c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020886c%26sid%3Dliteratum%253Aachs%26aulast%3DAustin%26aufirst%3DR.%2BP.%26aulast%3DBarton%26aufirst%3DP.%26aulast%3DBonnert%26aufirst%3DR.%2BV.%26aulast%3DBrown%26aufirst%3DR.%2BC.%26aulast%3DCage%26aufirst%3DP.%2BA.%26aulast%3DCheshire%26aufirst%3DD.%2BR.%26aulast%3DDavis%26aufirst%3DA.%2BM.%26aulast%3DDougall%26aufirst%3DI.%2BG.%26aulast%3DInce%26aufirst%3DF.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DYoung%26aufirst%3DA.%26atitle%3DQSAR%2520and%2520the%2520rational%2520design%2520of%2520long-acting%2520dual%2520D2-receptor%252Fbeta2-adrenoceptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D3210%26epage%3D3220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Glossop, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strang, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeadon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perros-Huguet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevethick, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machin, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairman, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agoram, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeder, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Entwistle, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spence, F. J.</span><span> </span><span class="NLM_article-title">Inhalation by design: novel tertiary amine muscarinic M<sub>3</sub> receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6888</span><span class="NLM_x">–</span> <span class="NLM_lpage">6904</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200884j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1SltbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6888-6904&author=P.+A.+Glossopauthor=C.+A.+Watsonauthor=D.+A.+Priceauthor=M.+E.+Bunnageauthor=D.+S.+Middletonauthor=A.+Woodauthor=K.+Jamesauthor=D.+Robertsauthor=R.+S.+Strangauthor=M.+Yeadonauthor=C.+Perros-Huguetauthor=N.+P.+Clarkeauthor=M.+A.+Trevethickauthor=I.+Machinauthor=E.+F.+Stuartauthor=S.+M.+Evansauthor=A.+C.+Harrisonauthor=D.+A.+Fairmanauthor=B.+Agoramauthor=J.+L.+Burrowsauthor=N.+Feederauthor=C.+K.+Fultonauthor=B.+R.+Dillonauthor=D.+A.+Entwistleauthor=F.+J.+Spence&title=Inhalation+by+design%3A+novel+tertiary+amine+muscarinic+M3+receptor+antagonists+with+slow+off-rate+binding+kinetics+for+inhaled+once-daily+treatment+of+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Inhalation by Design: Novel Tertiary Amine Muscarinic M3 Receptor Antagonists with Slow Off-Rate Binding Kinetics for Inhaled Once-Daily Treatment of Chronic Obstructive Pulmonary Disease</span></div><div class="casAuthors">Glossop, Paul A.; Watson, Christine A. L.; Price, David A.; Bunnage, Mark E.; Middleton, Donald S.; Wood, Anthony; James, Kim; Roberts, Dannielle; Strang, Ross S.; Yeadon, Michael; Perros-Huguet, Christelle; Clarke, Nicholas P.; Trevethick, Michael A.; Machin, Ian; Stuart, Emilio F.; Evans, Steven M.; Harrison, Anthony C.; Fairman, David A.; Agoram, Balaji; Burrows, Jane L.; Feeder, Neil; Fulton, Craig K.; Dillon, Barry R.; Entwistle, David A.; Spence, Fiona J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6888-6904</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel tertiary amine series of potent muscarinic M3 receptor antagonists are described that exhibit potential as inhaled long-acting bronchodilators for the treatment of chronic obstructive pulmonary disease.  Geminal di-Me functionality present in this series of compds. confers very long dissociative half-life (slow off-rate) from the M3 receptor that mediates very long-lasting smooth muscle relaxation in guinea pig tracheal strips.  Optimization of pharmacokinetic properties was achieved by combining rapid oxidative clearance with targeted introduction of a phenolic moiety to secure rapid glucuronidation.  Together, these attributes minimize systemic exposure following inhalation, mitigate potential drug-drug interactions, and reduce systemically mediated adverse events.  Compd. 47 (PF-3635659) is identified as a Phase II clin. candidate from this series with in vivo duration of action studies confirming its potential for once-daily use in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs8Q4T5oR53bVg90H21EOLACvtfcHk0lh-qNyPwVxTzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1SltbzM&md5=ca9b632b4c7982fb44c0d5dd17a056bf</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm200884j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200884j%26sid%3Dliteratum%253Aachs%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DWatson%26aufirst%3DC.%2BA.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DMiddleton%26aufirst%3DD.%2BS.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DRoberts%26aufirst%3DD.%26aulast%3DStrang%26aufirst%3DR.%2BS.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DClarke%26aufirst%3DN.%2BP.%26aulast%3DTrevethick%26aufirst%3DM.%2BA.%26aulast%3DMachin%26aufirst%3DI.%26aulast%3DStuart%26aufirst%3DE.%2BF.%26aulast%3DEvans%26aufirst%3DS.%2BM.%26aulast%3DHarrison%26aufirst%3DA.%2BC.%26aulast%3DFairman%26aufirst%3DD.%2BA.%26aulast%3DAgoram%26aufirst%3DB.%26aulast%3DBurrows%26aufirst%3DJ.%2BL.%26aulast%3DFeeder%26aufirst%3DN.%26aulast%3DFulton%26aufirst%3DC.%2BK.%26aulast%3DDillon%26aufirst%3DB.%2BR.%26aulast%3DEntwistle%26aufirst%3DD.%2BA.%26aulast%3DSpence%26aufirst%3DF.%2BJ.%26atitle%3DInhalation%2520by%2520design%253A%2520novel%2520tertiary%2520amine%2520muscarinic%2520M3%2520receptor%2520antagonists%2520with%2520slow%2520off-rate%2520binding%2520kinetics%2520for%2520inhaled%2520once-daily%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6888%26epage%3D6904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Brown, J. H.; Taylor, P.</span><span> </span><span class="NLM_article-title">Muscarinic receptor agonists and antagonists</span>. In  <span class="citation_source-book">Goodman and Gilman’s The Pharmacological Basis of Therapeutics</span>, <span class="NLM_edition">9</span>th ed.; <span class="NLM_contrib-group">Hardman, J. G.; Limbird, L. E.; Molinoff, P. B.; Ruddon, R. W.; Gilman, A. G.</span>, Eds.; <span class="NLM_publisher-name">McGraw-Hill</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">1996</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">160</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&pages=141-160&author=J.+H.+Brown&author=P.+Taylorauthor=J.+G.+Hardman&author=L.+E.+Limbird&author=P.+B.+Molinoff&author=R.+W.+Ruddon&author=A.+G.+Gilman&title=Goodman+and+Gilman%E2%80%99s+The+Pharmacological+Basis+of+Therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DJ.%2BH.%26atitle%3DMuscarinic%2520receptor%2520agonists%2520and%2520antagonists%26btitle%3DGoodman%2520and%2520Gilman%25E2%2580%2599s%2520The%2520Pharmacological%2520Basis%2520of%2520Therapeutics%26aulast%3DHardman%26aufirst%3DJ.%2BG.%26pub%3DMcGraw-Hill%26date%3D1996%26spage%3D141%26epage%3D160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Gordon, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breuer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padilla, F. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smejkal, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaing, P. K.</span><span> </span><span class="NLM_article-title">Distance geometry of α-substituted 2,2-diphenylpropionate antimuscarinics</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">766</span><span class="NLM_x">–</span> <span class="NLM_lpage">772</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1989&pages=766-772&author=R.+K.+Gordonauthor=E.+Breuerauthor=F.+N.+Padillaauthor=R.+M.+Smejkalauthor=P.+K.+Chaing&title=Distance+geometry+of+%CE%B1-substituted+2%2C2-diphenylpropionate+antimuscarinics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DR.%2BK.%26aulast%3DBreuer%26aufirst%3DE.%26aulast%3DPadilla%26aufirst%3DF.%2BN.%26aulast%3DSmejkal%26aufirst%3DR.%2BM.%26aulast%3DChaing%26aufirst%3DP.%2BK.%26atitle%3DDistance%2520geometry%2520of%2520%25CE%25B1-substituted%25202%252C2-diphenylpropionate%2520antimuscarinics%26jtitle%3DMol.%2520Pharmacol.%26date%3D1989%26volume%3D36%26spage%3D766%26epage%3D772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Tautermann, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiechle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeliger, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wex, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banholzer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gantner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieper, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casarosa, P.</span><span> </span><span class="NLM_article-title">Molecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M<sub>3</sub> receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">8746</span><span class="NLM_x">–</span> <span class="NLM_lpage">8756</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm401219y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFKksrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8746-8756&author=C.+S.+Tautermannauthor=T.+Kiechleauthor=D.+Seeligerauthor=S.+Diehlauthor=E.+Wexauthor=R.+Banholzerauthor=F.+Gantnerauthor=M.+P.+Pieperauthor=P.+Casarosa&title=Molecular+basis+for+the+long+duration+of+action+and+kinetic+selectivity+of+tiotropium+for+the+muscarinic+M3+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Basis for the Long Duration of Action and Kinetic Selectivity of Tiotropium for the Muscarinic M3 Receptor</span></div><div class="casAuthors">Tautermann, Christofer S.; Kiechle, Tobias; Seeliger, Daniel; Diehl, Sonja; Wex, Eva; Banholzer, Rolf; Gantner, Florian; Pieper, Michael P.; Casarosa, Paola</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8746-8756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antagonizing the human M3 muscarinic receptor (hM3R) over a long time is a key feature of modern bronchodilating COPD drugs aiming at symptom relief.  The long duration of action of the antimuscarinic drug tiotropium and its kinetic subtype selectivity over hM2R are investigated by kinetic mapping of the binding site and the exit channel of hM3R.  Hence, dissocn. expts. have been performed with a set of mol. matched pairs of tiotropium on a large variety of mutated variants of hM3R.  The exceedingly long half-life of tiotropium (of more than 24 h) is attributed to interactions in the binding site; particularly a highly directed interaction of the ligands' hydroxy group with an asparagine (N5086.52) prevents rapid dissocn. via a snap-lock mechanism.  The kinetic selectivity over hM2R, however, is caused by differences in the electrostatics and in the flexibility of the extracellular vestibule.  Extensive mol. dynamics simulations (several microseconds) support exptl. results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo95cclma8dobVg90H21EOLACvtfcHk0lh-qNyPwVxTzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFKksrvF&md5=2dd0ce91408c70ba97cf99cdab16b8b2</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm401219y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401219y%26sid%3Dliteratum%253Aachs%26aulast%3DTautermann%26aufirst%3DC.%2BS.%26aulast%3DKiechle%26aufirst%3DT.%26aulast%3DSeeliger%26aufirst%3DD.%26aulast%3DDiehl%26aufirst%3DS.%26aulast%3DWex%26aufirst%3DE.%26aulast%3DBanholzer%26aufirst%3DR.%26aulast%3DGantner%26aufirst%3DF.%26aulast%3DPieper%26aufirst%3DM.%2BP.%26aulast%3DCasarosa%26aufirst%3DP.%26atitle%3DMolecular%2520basis%2520for%2520the%2520long%2520duration%2520of%2520action%2520and%2520kinetic%2520selectivity%2520of%2520tiotropium%2520for%2520the%2520muscarinic%2520M3%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8746%26epage%3D8756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Lainé, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busch-Petersen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neipp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdowson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaney, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttmann, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarau, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palovich, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmonte, K.</span><span> </span><span class="NLM_article-title">Design, synthesis, and structure–activity relationship of tropane muscarinic acetylcholine receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5241</span><span class="NLM_x">–</span> <span class="NLM_lpage">5252</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900736e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5241-5252&author=D.+I.+Lain%C3%A9author=Z.+Wanauthor=H.+Yanauthor=C.+Zhuauthor=H.+Xieauthor=W.+Fuauthor=J.+Busch-Petersenauthor=C.+Neippauthor=R.+Davisauthor=K.+L.+Widdowsonauthor=F.+E.+Blaneyauthor=J.+Foleyauthor=A.+M.+Baconauthor=E.+F.+Webbauthor=M.+A.+Luttmannauthor=M.+Burmanauthor=H.+M.+Sarauauthor=M.+Salmonauthor=M.+R.+Palovichauthor=K.+Belmonte&title=Design%2C+synthesis%2C+and+structure%E2%80%93activity+relationship+of+tropane+muscarinic+acetylcholine+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm900736e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900736e%26sid%3Dliteratum%253Aachs%26aulast%3DLain%25C3%25A9%26aufirst%3DD.%2BI.%26aulast%3DWan%26aufirst%3DZ.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DBusch-Petersen%26aufirst%3DJ.%26aulast%3DNeipp%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DWiddowson%26aufirst%3DK.%2BL.%26aulast%3DBlaney%26aufirst%3DF.%2BE.%26aulast%3DFoley%26aufirst%3DJ.%26aulast%3DBacon%26aufirst%3DA.%2BM.%26aulast%3DWebb%26aufirst%3DE.%2BF.%26aulast%3DLuttmann%26aufirst%3DM.%2BA.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DSarau%26aufirst%3DH.%2BM.%26aulast%3DSalmon%26aufirst%3DM.%26aulast%3DPalovich%26aufirst%3DM.%2BR.%26aulast%3DBelmonte%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure%25E2%2580%2593activity%2520relationship%2520of%2520tropane%2520muscarinic%2520acetylcholine%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5241%26epage%3D5252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Stocks, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alcaraz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowers, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donald, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kindon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairaudeau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theaker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, D. J.</span><span> </span><span class="NLM_article-title">The discovery of new spirocyclic muscarinic M<sub>3</sub> antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">7458</span><span class="NLM_x">–</span> <span class="NLM_lpage">7461</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7458-7461&author=M.+J.+Stocksauthor=L.+Alcarazauthor=A.+Baileyauthor=K.+Bowersauthor=D.+Donaldauthor=H.+Edwardsauthor=F.+Huntauthor=N.+Kindonauthor=G.+Pairaudeauauthor=J.+Theakerauthor=D.+J.+Warner&title=The+discovery+of+new+spirocyclic+muscarinic+M3+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26aulast%3DAlcaraz%26aufirst%3DL.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DBowers%26aufirst%3DK.%26aulast%3DDonald%26aufirst%3DD.%26aulast%3DEdwards%26aufirst%3DH.%26aulast%3DHunt%26aufirst%3DF.%26aulast%3DKindon%26aufirst%3DN.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DTheaker%26aufirst%3DJ.%26aulast%3DWarner%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520discovery%2520of%2520new%2520spirocyclic%2520muscarinic%2520M3%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D7458%26epage%3D7461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Lainé, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCleland, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neipp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underwood, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dufour, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdowson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palovich, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaney, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttmann, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmonte, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmon, M.</span><span> </span><span class="NLM_article-title">Discovery of novel 1-azoniabicyclo[2.2.2]octane muscarinic acetylcholine receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">2493</span><span class="NLM_x">–</span> <span class="NLM_lpage">2505</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801601v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2493-2505&author=D.+I.+Lain%C3%A9author=B.+McClelandauthor=S.+Thomasauthor=C.+Neippauthor=B.+Underwoodauthor=J.+Dufourauthor=K.+L.+Widdowsonauthor=M.+R.+Palovichauthor=F.+E.+Blaneyauthor=J.+J.+Foleyauthor=E.+F.+Webbauthor=M.+A.+Luttmannauthor=M.+Burmanauthor=K.+Belmonteauthor=M.+Salmon&title=Discovery+of+novel+1-azoniabicyclo%5B2.2.2%5Doctane+muscarinic+acetylcholine+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm801601v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801601v%26sid%3Dliteratum%253Aachs%26aulast%3DLain%25C3%25A9%26aufirst%3DD.%2BI.%26aulast%3DMcCleland%26aufirst%3DB.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DNeipp%26aufirst%3DC.%26aulast%3DUnderwood%26aufirst%3DB.%26aulast%3DDufour%26aufirst%3DJ.%26aulast%3DWiddowson%26aufirst%3DK.%2BL.%26aulast%3DPalovich%26aufirst%3DM.%2BR.%26aulast%3DBlaney%26aufirst%3DF.%2BE.%26aulast%3DFoley%26aufirst%3DJ.%2BJ.%26aulast%3DWebb%26aufirst%3DE.%2BF.%26aulast%3DLuttmann%26aufirst%3DM.%2BA.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DBelmonte%26aufirst%3DK.%26aulast%3DSalmon%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520novel%25201-azoniabicyclo%255B2.2.2%255Doctane%2520muscarinic%2520acetylcholine%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2493%26epage%3D2505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Kiesewetter, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverton, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckelman, W. C.</span><span> </span><span class="NLM_article-title">Syntheses and biological properties of chiral fluoroalkyl quinuclidinyl benzilates</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1711</span><span class="NLM_x">–</span> <span class="NLM_lpage">1719</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00010a016" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=1711-1719&author=D.+O.+Kiesewetterauthor=J.+V.+Silvertonauthor=W.+C.+Eckelman&title=Syntheses+and+biological+properties+of+chiral+fluoroalkyl+quinuclidinyl+benzilates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm00010a016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00010a016%26sid%3Dliteratum%253Aachs%26aulast%3DKiesewetter%26aufirst%3DD.%2BO.%26aulast%3DSilverton%26aufirst%3DJ.%2BV.%26aulast%3DEckelman%26aufirst%3DW.%2BC.%26atitle%3DSyntheses%2520and%2520biological%2520properties%2520of%2520chiral%2520fluoroalkyl%2520quinuclidinyl%2520benzilates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D1711%26epage%3D1719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Noronha-Blob, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturm, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, V.</span><span> </span><span class="NLM_article-title">Stereoselective antimuscarinic effects of 3-quinuclidinyl atrolactate and 3-quinuclidinyl xanthene-9-carboxylate</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">211</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2F0014-2999%2892%2990268-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=1618272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADyaK38XhsVCmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=211&publication_year=1992&pages=97-103&author=L.+Noronha-Blobauthor=B.+Sturmauthor=V.+Lowe&title=Stereoselective+antimuscarinic+effects+of+3-quinuclidinyl+atrolactate+and+3-quinuclidinyl+xanthene-9-carboxylate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Stereoselective antimuscarinic effects of 3-quinuclidinyl atrolactate and 3-quinuclidinyl xanthene-9-carboxylate</span></div><div class="casAuthors">Noronha-Blob, Lalita; Sturm, Bonnie; Lowe, Valerie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">211</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-103</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">The relative affinity and selectivity of the stereoisomers of 3-quinuclidinyl atrolactate (I) and the enantiomers of 3-quinuclidinyl xanthene-9-carboxylate (II) for the pharmacol. defined muscarinic receptor subtypes was detd. using functional responses of rabbit vas deferens (M1), guinea pig atria (M2) and bladder detrusor muscle (M3).  All the stereoisomers behaved as competitive antagonists yielding the same rank order of potency at each receptor subtype: (RR)-I > (RS)-I > (SR)-I > (SS)-I and (R)-II > (S)-II.  Moreover, the eudismic ratios relative to (RR)-I for (RS)-, (SR)- and (SS)-I, resp., ranged from 4 to 308 at all 3 subtypes.  Stereoselective effects were also obsd. for II; (S)-II/(R)-II ratios ranged from 76 to 248.  In contrast, there was a distinct lack of receptor selectivity among the isomers of I and II for either the M1, M2 or M3 muscarinic receptor subtypes.  Stereoselective effects were also evident in vivo in the guinea pig cystometrogram where the rank order of potency of the isomers of I and II was similar to that obsd. in vitro.  (RR)-I and (R)-II equipotently depressed intravesical bladder pressure (ID50=0.06 mg/kg i.v.).  Other parameters (bladder capacity, threshold pressure) were unaltered by the stereoisomers.  The data demonstrate that despite the high affinity of the eutomers of I and II for muscarinic receptor, they discriminate poorly among muscarinic subpopulations, thus limiting their utility to subclassify muscarinic receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-5gAtSUMrFbVg90H21EOLACvtfcHk0li6qm6NKQINRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhsVCmsb0%253D&md5=c1418c68c19d091fe413b7cf412b9ab8</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2892%2990268-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252892%252990268-9%26sid%3Dliteratum%253Aachs%26aulast%3DNoronha-Blob%26aufirst%3DL.%26aulast%3DSturm%26aufirst%3DB.%26aulast%3DLowe%26aufirst%3DV.%26atitle%3DStereoselective%2520antimuscarinic%2520effects%2520of%25203-quinuclidinyl%2520atrolactate%2520and%25203-quinuclidinyl%2520xanthene-9-carboxylate%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1992%26volume%3D211%26spage%3D97%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Prat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernández, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buil, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crespo, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casals, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tort, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monleón, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavaldà, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralpeix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doménech, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vilella, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antón, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huerta, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espinosa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">López, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sentellas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">González, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albertí, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segarra, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cárdenas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beleta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, H.</span><span> </span><span class="NLM_article-title">Discovery of novel quaternary ammonium derivatives of (3<i>R</i>)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3<i>R</i>)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane bromide (aclidinium bromide)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5076</span><span class="NLM_x">–</span> <span class="NLM_lpage">5092</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900132z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5076-5092&author=M.+Pratauthor=D.+Fern%C3%A1ndezauthor=M.+A.+Builauthor=M.+I.+Crespoauthor=G.+Casalsauthor=M.+Ferrerauthor=L.+Tortauthor=J.+Castroauthor=J.+M.+Monle%C3%B3nauthor=A.+Gavald%C3%A0author=M.+Miralpeixauthor=I.+Ramosauthor=T.+Dom%C3%A9nechauthor=D.+Vilellaauthor=F.+Ant%C3%B3nauthor=J.+M.+Huertaauthor=S.+Espinosaauthor=M.+L%C3%B3pezauthor=S.+Sentellasauthor=M.+Gonz%C3%A1lezauthor=J.+Albert%C3%ADauthor=V.+Segarraauthor=A.+C%C3%A1rdenasauthor=J.+Beletaauthor=H.+Ryder&title=Discovery+of+novel+quaternary+ammonium+derivatives+of+%283R%29-quinuclidinol+esters+as+potent+and+long-acting+muscarinic+antagonists+with+potential+for+minimal+systemic+exposure+after+inhaled+administration%3A+identification+of+%283R%29-3-%7B%5Bhydroxy%28di-2-thienyl%29acetyl%5Doxy%7D-1-%283-phenoxypropyl%29-1-azoniabicyclo%5B2.2.2%5D+octane+bromide+%28aclidinium+bromide%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm900132z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900132z%26sid%3Dliteratum%253Aachs%26aulast%3DPrat%26aufirst%3DM.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DD.%26aulast%3DBuil%26aufirst%3DM.%2BA.%26aulast%3DCrespo%26aufirst%3DM.%2BI.%26aulast%3DCasals%26aufirst%3DG.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DTort%26aufirst%3DL.%26aulast%3DCastro%26aufirst%3DJ.%26aulast%3DMonle%25C3%25B3n%26aufirst%3DJ.%2BM.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DRamos%26aufirst%3DI.%26aulast%3DDom%25C3%25A9nech%26aufirst%3DT.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DAnt%25C3%25B3n%26aufirst%3DF.%26aulast%3DHuerta%26aufirst%3DJ.%2BM.%26aulast%3DEspinosa%26aufirst%3DS.%26aulast%3DL%25C3%25B3pez%26aufirst%3DM.%26aulast%3DSentellas%26aufirst%3DS.%26aulast%3DGonz%25C3%25A1lez%26aufirst%3DM.%26aulast%3DAlbert%25C3%25AD%26aufirst%3DJ.%26aulast%3DSegarra%26aufirst%3DV.%26aulast%3DC%25C3%25A1rdenas%26aufirst%3DA.%26aulast%3DBeleta%26aufirst%3DJ.%26aulast%3DRyder%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520novel%2520quaternary%2520ammonium%2520derivatives%2520of%2520%25283R%2529-quinuclidinol%2520esters%2520as%2520potent%2520and%2520long-acting%2520muscarinic%2520antagonists%2520with%2520potential%2520for%2520minimal%2520systemic%2520exposure%2520after%2520inhaled%2520administration%253A%2520identification%2520of%2520%25283R%2529-3-%257B%255Bhydroxy%2528di-2-thienyl%2529acetyl%255Doxy%257D-1-%25283-phenoxypropyl%2529-1-azoniabicyclo%255B2.2.2%255D%2520octane%2520bromide%2520%2528aclidinium%2520bromide%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5076%26epage%3D5092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Martel, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabasseda, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castañer, J.</span><span> </span><span class="NLM_article-title">Revatropate. Bronchodilator muscarinic M<sub>3</sub> antagonist</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1358%2Fdof.1997.022.02.394838" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADyaK2sXivVehtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1997&pages=135-137&author=A.+M.+Martelauthor=X.+Rabassedaauthor=J.+Casta%C3%B1er&title=Revatropate.+Bronchodilator+muscarinic+M3+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Revatropate. Bronchodilator. Muscarinic M3 antagonist</span></div><div class="casAuthors">Martel, A.M.; Rabasseda, X.; Castaner, J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-137</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous</span>)
        </div><div class="casAbstract">A review, with 6 refs., describing the synthesis, pharmacol. actions, and the results of some clin. studies of revatropate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj93cfuBLRL7Vg90H21EOLACvtfcHk0li6qm6NKQINRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivVehtLo%253D&md5=6304071f8770d450874adccf2b2693ba</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1358%2Fdof.1997.022.02.394838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.1997.022.02.394838%26sid%3Dliteratum%253Aachs%26aulast%3DMartel%26aufirst%3DA.%2BM.%26aulast%3DRabasseda%26aufirst%3DX.%26aulast%3DCasta%25C3%25B1er%26aufirst%3DJ.%26atitle%3DRevatropate.%2520Bronchodilator%2520muscarinic%2520M3%2520antagonist%26jtitle%3DDrugs%2520Future%26date%3D1997%26volume%3D22%26spage%3D135%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Tropsha, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nizhnii, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iaguzhinskii, L. S.</span><span> </span><span class="NLM_article-title">Structure–activity relationship in the series of muscarinic acetylcholine receptor antagonists: four types of antagonist-receptor binding</span> <span class="citation_source-journal">Bioorg. Khim.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1402</span><span class="NLM_x">–</span> <span class="NLM_lpage">1416</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1985&pages=1402-1416&author=A.+E.+Tropshaauthor=S.+V.+Nizhniiauthor=L.+S.+Iaguzhinskii&title=Structure%E2%80%93activity+relationship+in+the+series+of+muscarinic+acetylcholine+receptor+antagonists%3A+four+types+of+antagonist-receptor+binding"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTropsha%26aufirst%3DA.%2BE.%26aulast%3DNizhnii%26aufirst%3DS.%2BV.%26aulast%3DIaguzhinskii%26aufirst%3DL.%2BS.%26atitle%3DStructure%25E2%2580%2593activity%2520relationship%2520in%2520the%2520series%2520of%2520muscarinic%2520acetylcholine%2520receptor%2520antagonists%253A%2520four%2520types%2520of%2520antagonist-receptor%2520binding%26jtitle%3DBioorg.%2520Khim.%26date%3D1985%26volume%3D11%26spage%3D1402%26epage%3D1416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Gavaldà, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralpeix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreño, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viñals, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doménech, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carcasona, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vilella, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gras, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortijo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morcillo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llenas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beleta, J.</span><span> </span><span class="NLM_article-title">Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">331</span><span class="NLM_x">, </span> <span class="NLM_fpage">740</span><span class="NLM_x">–</span> <span class="NLM_lpage">751</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1124%2Fjpet.109.151639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=19710368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKnu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2009&pages=740-751&author=A.+Gavald%C3%A0author=M.+Miralpeixauthor=I.+Ramosauthor=R.+Otalauthor=C.+Carre%C3%B1oauthor=M.+Vi%C3%B1alsauthor=T.+Dom%C3%A9nechauthor=C.+Carcasonaauthor=B.+Reyesauthor=D.+Vilellaauthor=J.+Grasauthor=J.+Cortijoauthor=E.+Morcilloauthor=J.+Llenasauthor=H.+Ryderauthor=J.+Beleta&title=Characterization+of+aclidinium+bromide%2C+a+novel+inhaled+muscarinic+antagonist%2C+with+long+duration+of+action+and+a+favorable+pharmacological+profile"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile</span></div><div class="casAuthors">Gavalda, Amadeu; Miralpeix, Montserrat; Ramos, Israel; Otal, Raquel; Carreno, Cristina; Vinals, Marisa; Domenech, Teresa; Carcasona, Carla; Reyes, Blanca; Vilella, Dolors; Gras, Jordi; Cortijo, Julio; Morcillo, Esteban; Llenas, Jesus; Ryder, Hamish; Beleta, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">740-751</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Aclidinium bromide is a novel potent, long-acting inhaled muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease.  Aclidinium showed subnanomolar affinity for the five human muscarinic receptors (M1-M5).  [3H]Aclidinium dissocd. slightly faster from M2 and M3 receptors than [3H]tiotropium but much more slowly than [3H]ipratropium.  Its assocn. rate for the M3 receptor was similar to [3H]ipratropium and 2.6 times faster than [3H]tiotropium.  Residence half-life of [3H]aclidinium at the M2 receptor was shorter than at the M3 receptor, demonstrating kinetic selectivity for the M3 receptor.  In isolated guinea pig trachea, aclidinium showed comparable potency to ipratropium and tiotropium, faster onset of action than tiotropium, and duration of action similar to tiotropium and significantly longer than ipratropium.  Nebulized aclidinium inhibited bronchoconstriction induced by acetylcholine in guinea pigs in a concn.-dependent manner with an onset of action faster than tiotropium.  Duration of action of aclidinium (t1/2 = 29 h) was much longer than ipratropium (8 h) but shorter than tiotropium (64 h).  In dogs, aclidinium induced a smaller and more transient increase in heart rate than tiotropium at comparable supratherapeutic doses.  Therefore, under these conditions, aclidinium showed a greater therapeutic index than tiotropium (4.2 vs. 1.6).  These results indicate that aclidinium is a potent muscarinic antagonist with a fast onset of action, a long duration of effect, and a favorable cardiovascular safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZpskcHCQILLVg90H21EOLACvtfcHk0lgkg__r9rx1qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKnu7rF&md5=c66b0d729cd5c6dcba6e3a80e0c5f468</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.151639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.151639%26sid%3Dliteratum%253Aachs%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DRamos%26aufirst%3DI.%26aulast%3DOtal%26aufirst%3DR.%26aulast%3DCarre%25C3%25B1o%26aufirst%3DC.%26aulast%3DVi%25C3%25B1als%26aufirst%3DM.%26aulast%3DDom%25C3%25A9nech%26aufirst%3DT.%26aulast%3DCarcasona%26aufirst%3DC.%26aulast%3DReyes%26aufirst%3DB.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DGras%26aufirst%3DJ.%26aulast%3DCortijo%26aufirst%3DJ.%26aulast%3DMorcillo%26aufirst%3DE.%26aulast%3DLlenas%26aufirst%3DJ.%26aulast%3DRyder%26aufirst%3DH.%26aulast%3DBeleta%26aufirst%3DJ.%26atitle%3DCharacterization%2520of%2520aclidinium%2520bromide%252C%2520a%2520novel%2520inhaled%2520muscarinic%2520antagonist%252C%2520with%2520long%2520duration%2520of%2520action%2520and%2520a%2520favorable%2520pharmacological%2520profile%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D331%26spage%3D740%26epage%3D751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Beier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirsten, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mróz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segarra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuecos, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caracta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, E. G.</span><span> </span><span class="NLM_article-title">Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIb study</span> <span class="citation_source-journal">COPD</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">511</span><span class="NLM_x">–</span> <span class="NLM_lpage">522</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.3109%2F15412555.2013.814626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23819698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC3sjnsVekug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=511-522&author=J.+Beierauthor=A.+M.+Kirstenauthor=R.+Mr%C3%B3zauthor=R.+Segarraauthor=F.+Chuecosauthor=C.+Caractaauthor=E.+G.+Gil&title=Efficacy+and+safety+of+aclidinium+bromide+compared+with+placebo+and+tiotropium+in+patients+with+moderate-to-severe+chronic+obstructive+pulmonary+disease%3A+results+from+a+6-week%2C+randomized%2C+controlled+phase+IIIb+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study</span></div><div class="casAuthors">Beier Jutta; Kirsten Anne-Marie; Mroz Robert; Segarra Rosa; Chuecos Ferran; Caracta Cynthia; Gil Esther Garcia</div><div class="citationInfo"><span class="NLM_cas:title">COPD</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">511-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  This randomized, double-blind, Phase IIIb study evaluated the 24-hour bronchodilatory efficacy of aclidinium bromide versus placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).  METHODS:  Patients received aclidinium 400 μg twice daily (morning and evening), tiotropium 18 μg once daily (morning), or placebo for 6 weeks.  The primary endpoint was change from baseline in forced expiratory volume in 1 second area under the curve for the 24-hour period post-morning dose (FEV1 AUC0-24) at week 6.  Secondary and additional endpoints included FEV1 AUC12-24, COPD symptoms (EXAcerbations of chronic pulmonary disease Tool-Respiratory Symptoms [E-RS] total score and additional symptoms questionnaire), and safety.  RESULTS:  Overall, 414 patients were randomized and treated (FEV1 1.63 L [55.8% predicted]).  Compared with placebo, FEV1 AUC0-24 and FEV1 AUC12-24 were significantly increased from baseline with aclidinium (α = 150 mL and 160 mL, respectively; p < 0.0001) and tiotropium (α = 140 mL and 123 mL, respectively; p < 0.0001) at week 6.  Significant improvements in E-RS total scores over 6 weeks were numerically greater with aclidinium (p < 0.0001) than tiotropium (p < 0.05) versus placebo.  Only aclidinium significantly reduced the severity of early-morning cough, wheeze, shortness of breath, and phlegm, and of nighttime symptoms versus placebo (p < 0.05).  Adverse-event (AE) incidence (28%) was similar between treatments.  Few anticholinergic AEs (<1.5%) or serious AEs (<3%) occurred in any group.  CONCLUSIONS:  Aclidinium provided significant 24-hour bronchodilation versus placebo from day 1 with comparable efficacy to tiotropium after 6 weeks.  Improvements in COPD symptoms were consistently numerically greater with aclidinium versus tiotropium.  Aclidinium was generally well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRexzWJG0sJO5QHPYJuLg8TfW6udTcc2eYVRyF9JPIsobntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjnsVekug%253D%253D&md5=ef3866abc3d13612c2c7dd1a8273cfe4</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.3109%2F15412555.2013.814626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F15412555.2013.814626%26sid%3Dliteratum%253Aachs%26aulast%3DBeier%26aufirst%3DJ.%26aulast%3DKirsten%26aufirst%3DA.%2BM.%26aulast%3DMr%25C3%25B3z%26aufirst%3DR.%26aulast%3DSegarra%26aufirst%3DR.%26aulast%3DChuecos%26aufirst%3DF.%26aulast%3DCaracta%26aufirst%3DC.%26aulast%3DGil%26aufirst%3DE.%2BG.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520aclidinium%2520bromide%2520compared%2520with%2520placebo%2520and%2520tiotropium%2520in%2520patients%2520with%2520moderate-to-severe%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520results%2520from%2520a%25206-week%252C%2520randomized%252C%2520controlled%2520phase%2520IIIb%2520study%26jtitle%3DCOPD%26date%3D2013%26volume%3D10%26spage%3D511%26epage%3D522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Milara, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peiró, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavaldà, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralpeix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morcillo, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortijo, J.</span><span> </span><span class="NLM_article-title">Aclidinium inhibits human lung fibroblast to myofibroblast transition</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">237</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2012&pages=229-237&author=J.+Milaraauthor=A.+Serranoauthor=T.+Peir%C3%B3author=A.+Gavald%C3%A0author=M.+Miralpeixauthor=E.+J.+Morcilloauthor=J.+Cortijo&title=Aclidinium+inhibits+human+lung+fibroblast+to+myofibroblast+transition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMilara%26aufirst%3DJ.%26aulast%3DSerrano%26aufirst%3DA.%26aulast%3DPeir%25C3%25B3%26aufirst%3DT.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DMorcillo%26aufirst%3DE.%2BJ.%26aulast%3DCortijo%26aufirst%3DJ.%26atitle%3DAclidinium%2520inhibits%2520human%2520lung%2520fibroblast%2520to%2520myofibroblast%2520transition%26jtitle%3DThorax%26date%3D2012%26volume%3D67%26spage%3D229%26epage%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Milara, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peiró, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artigues, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavaldà, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralpeix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morcillo, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortijo, J.</span><span> </span><span class="NLM_article-title">Aclidinium inhibits cigarette smoke-induced lung fibroblast-to-myofibroblast transition</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1264</span><span class="NLM_x">–</span> <span class="NLM_lpage">1274</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.00017712" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23018909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtV2mur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=1264-1274&author=J.+Milaraauthor=A.+Serranoauthor=T.+Peir%C3%B3author=E.+Artiguesauthor=A.+Gavald%C3%A0author=M.+Miralpeixauthor=E.+J.+Morcilloauthor=J.+Cortijo&title=Aclidinium+inhibits+cigarette+smoke-induced+lung+fibroblast-to-myofibroblast+transition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Aclidinium inhibits cigarette smoke-induced lung fibroblast-to-myofibroblast transition</span></div><div class="casAuthors">Milara, Javier; Serrano, Adela; Peiro, Teresa; Artigues, Enrique; Gavalda, Amadeu; Miralpeix, Montse; Morcillo, Esteban J.; Cortijo, Julio</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1264-1274</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Cigarette smoking contributes to lung remodelling in chronic obstructive pulmonary disease (COPD).  As part of this remodelling, peribronchiolar fibrosis is obsd. in the small airways of COPD patients and contributes to airway obstruction.  Fibroblast-to-myofibroblast transition is a key step in peribronchiolar fibrosis formation.  This in vitro study examd. the effect of cigarette smoke on bronchial fibroblast-to-myofibroblast transition, and whether aclidinium bromide inhibits this process.  Human bronchial fibroblasts were incubated with aclidinium bromide (10-9-10-7 M) and exposed to cigarette smoke ext.  Collagen type I and α-smooth muscle actin (α-SMA) expression were measured by real-time PCR and Western blotting, as myofibroblast markers.  Intracellular reactive oxygen species, cAMP (cAMP), extracellular signal-regulated kinase (ERK)1/2 and choline acetyltransferase were measured as intracellular signalling mediators.  Cigarette smoke-induced collagen type I and α-SMA was mediated by the prodn. of reactive oxygen species, the depletion of intracellular cAMP and the increase of ERK1/2 phosphorylation and choline acetyltransferase.  These effects could be reversed by treatment with the anticholinergic aclidinium bromide, by silencing the mRNA of muscarinic receptors M1, M2 or M3, or by the depletion of extracellular acetylcholine by treatment with acetylcholinesterase.  A non-neuronal cholinergic system is implicated in cigarette smoke-induced bronchial fibroblast-to-myofibroblast transition, which is inhibited by aclidinium bromide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDBALLuwbgHrVg90H21EOLACvtfcHk0lgtvKAK6dvsWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtV2mur%252FF&md5=8374ed7c1c820cc5626ce79bcb828ab3</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1183%2F09031936.00017712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00017712%26sid%3Dliteratum%253Aachs%26aulast%3DMilara%26aufirst%3DJ.%26aulast%3DSerrano%26aufirst%3DA.%26aulast%3DPeir%25C3%25B3%26aufirst%3DT.%26aulast%3DArtigues%26aufirst%3DE.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DMorcillo%26aufirst%3DE.%2BJ.%26aulast%3DCortijo%26aufirst%3DJ.%26atitle%3DAclidinium%2520inhibits%2520cigarette%2520smoke-induced%2520lung%2520fibroblast-to-myofibroblast%2520transition%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2013%26volume%3D41%26spage%3D1264%26epage%3D1274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Domínguez-Fandos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puig-Pey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreño, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prats, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aparici, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musri, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavaldà, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peinado, V. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralpeix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barberà, J. A.</span><span> </span><span class="NLM_article-title">Effects of aclidinium bromide in a cigarette smoke-exposed guinea pig model of chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Am. J. Respir. Cell Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">337</span><span class="NLM_x">–</span> <span class="NLM_lpage">346</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=24032416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsVOlsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=337-346&author=D.+Dom%C3%ADnguez-Fandosauthor=E.+Ferrerauthor=R.+Puig-Peyauthor=C.+Carre%C3%B1oauthor=N.+Pratsauthor=M.+Apariciauthor=M.+M.+Musriauthor=A.+Gavald%C3%A0author=V.+I.+Peinadoauthor=M.+Miralpeixauthor=J.+A.+Barber%C3%A0&title=Effects+of+aclidinium+bromide+in+a+cigarette+smoke-exposed+guinea+pig+model+of+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of aclidinium bromide in a cigarette smoke-exposed guinea pig model of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Dominguez-Fandos, David; Ferrer, Elisabet; Puig-Pey, Raquel; Carreno, Cristina; Prats, Neus; Aparici, Monica; Musri, Melina Mara; Gavalda, Amadeu; Peinado, Victor I.; Miralpeix, Montserrat; Barbera, Joan A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">337-346, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Long-acting muscarinic antagonists are widely used to treat chronic obstructive pulmonary disease (COPD).  In addn. to bronchodilation, muscarinic antagonism may affect pulmonary histopathol. changes.  The effects of long-acting muscarinic antagonists have not been thoroughly evaluated in exptl. models of COPD induced by chronic exposure to cigarette smoke (CS).  We investigated the effects of aclidinium bromide on pulmonary function, airway remodeling, and lung inflammation in a CS-exposed model of COPD.  A total of 36 guinea pigs were exposed to CS and 22 were sham exposed for 24 wk.  Animals were nebulized daily with vehicle, 10 μg/mL, or 30 μg/mL aclidinium, resulting in six exptl. groups.  Pulmonary function was assessed weekly by whole-body plethysmog., detg. the enhanced pause (Penh) at baseline, after treatment, and after CS/sham exposure.  Lung changes were evaluated by morphometry and immunohistochem.  CS exposure increased Penh in all conditions.  CS-exposed animals treated with aclidinium showed lower baseline Penh than untreated animals (P = 0.02).  CS induced thickening of all bronchial wall layers, airspace enlargement, and inflammatory cell infiltrate in airways and septa.  Treatment with aclidinium abrogated the CS-induced smooth muscle enlargement in small airways (P = 0.001), and tended to reduce airspace enlargement (P = 0.054).  Aclidinium also attenuated CS-induced neutrophilia in alveolar septa (P = 0.04).  We conclude that, in guinea pigs chronically exposed to CS, aclidinium has an antiremodeling effect on small airways, which is assocd. with improved respiratory function, and attenuates neutrophilic infiltration in alveolar septa.  These results indicate that, in COPD, aclidinium may exert beneficial effects on lung structure in addn. to its bronchodilator action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGJy4MHEIkWrVg90H21EOLACvtfcHk0lgtvKAK6dvsWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsVOlsbo%253D&md5=f0cdafcc73a363ff0e83c15cd1082382</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDom%25C3%25ADnguez-Fandos%26aufirst%3DD.%26aulast%3DFerrer%26aufirst%3DE.%26aulast%3DPuig-Pey%26aufirst%3DR.%26aulast%3DCarre%25C3%25B1o%26aufirst%3DC.%26aulast%3DPrats%26aufirst%3DN.%26aulast%3DAparici%26aufirst%3DM.%26aulast%3DMusri%26aufirst%3DM.%2BM.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DPeinado%26aufirst%3DV.%2BI.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DBarber%25C3%25A0%26aufirst%3DJ.%2BA.%26atitle%3DEffects%2520of%2520aclidinium%2520bromide%2520in%2520a%2520cigarette%2520smoke-exposed%2520guinea%2520pig%2520model%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2014%26volume%3D50%26spage%3D337%26epage%3D346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Lainé, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dufour, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widdowson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palovich, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunsberger, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacon, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttmann, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarau, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umbrecht, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landis, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peck, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busch-Petersen, J.</span><span> </span><span class="NLM_article-title">Design, synthesis and structure-activity relationship of N-substituted tropane muscarinic acetylcholine receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3366</span><span class="NLM_x">–</span> <span class="NLM_lpage">3369</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3366-3369&author=D.+I.+Lain%C3%A9author=H.+Yanauthor=H.+Xieauthor=R.+S.+Davisauthor=J.+Dufourauthor=K.+L.+Widdowsonauthor=M.+R.+Palovichauthor=Z.+Wanauthor=J.+J.+Foleyauthor=D.+B.+Schmidtauthor=G.+E.+Hunsbergerauthor=M.+Burmanauthor=A.+M.+Baconauthor=E.+F.+Webbauthor=M.+A.+Luttmannauthor=M.+Salmonauthor=H.+M.+Sarauauthor=S.+T.+Umbrechtauthor=P.+S.+Landisauthor=B.+J.+Peckauthor=J.+Busch-Petersen&title=Design%2C+synthesis+and+structure-activity+relationship+of+N-substituted+tropane+muscarinic+acetylcholine+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLain%25C3%25A9%26aufirst%3DD.%2BI.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DDavis%26aufirst%3DR.%2BS.%26aulast%3DDufour%26aufirst%3DJ.%26aulast%3DWiddowson%26aufirst%3DK.%2BL.%26aulast%3DPalovich%26aufirst%3DM.%2BR.%26aulast%3DWan%26aufirst%3DZ.%26aulast%3DFoley%26aufirst%3DJ.%2BJ.%26aulast%3DSchmidt%26aufirst%3DD.%2BB.%26aulast%3DHunsberger%26aufirst%3DG.%2BE.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DBacon%26aufirst%3DA.%2BM.%26aulast%3DWebb%26aufirst%3DE.%2BF.%26aulast%3DLuttmann%26aufirst%3DM.%2BA.%26aulast%3DSalmon%26aufirst%3DM.%26aulast%3DSarau%26aufirst%3DH.%2BM.%26aulast%3DUmbrecht%26aufirst%3DS.%2BT.%26aulast%3DLandis%26aufirst%3DP.%2BS.%26aulast%3DPeck%26aufirst%3DB.%2BJ.%26aulast%3DBusch-Petersen%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520structure-activity%2520relationship%2520of%2520N-substituted%2520tropane%2520muscarinic%2520acetylcholine%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D3366%26epage%3D3369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Nagashima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamaguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kontani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moritomo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koshika, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, M.</span><span> </span><span class="NLM_article-title">Novel quinuclidinyl heteroarylcarbamate derivatives as muscarinic receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3478</span><span class="NLM_x">–</span> <span class="NLM_lpage">3487</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=3478-3487&author=S.+Nagashimaauthor=Y.+Matsushimaauthor=H.+Hamaguchiauthor=H.+Nagataauthor=T.+Kontaniauthor=A.+Moritomoauthor=T.+Koshikaauthor=M.+Takeuchi&title=Novel+quinuclidinyl+heteroarylcarbamate+derivatives+as+muscarinic+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagashima%26aufirst%3DS.%26aulast%3DMatsushima%26aufirst%3DY.%26aulast%3DHamaguchi%26aufirst%3DH.%26aulast%3DNagata%26aufirst%3DH.%26aulast%3DKontani%26aufirst%3DT.%26aulast%3DMoritomo%26aufirst%3DA.%26aulast%3DKoshika%26aufirst%3DT.%26aulast%3DTakeuchi%26aufirst%3DM.%26atitle%3DNovel%2520quinuclidinyl%2520heteroarylcarbamate%2520derivatives%2520as%2520muscarinic%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D3478%26epage%3D3487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Peretto, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forlani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossati, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giardina, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giardini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guala, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Porta, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrillo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radaelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radice, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raveglia, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scudellaro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarpitta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigogno, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misiano, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dondio, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villetti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patacchini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergamaschi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delcanale, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salcedo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernández, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imbimbo, B. P.</span><span> </span><span class="NLM_article-title">Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M<sub>3</sub> selective antagonists (Part 1)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1571</span><span class="NLM_x">–</span> <span class="NLM_lpage">1583</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061159a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1571-1583&author=I.+Perettoauthor=R.+Forlaniauthor=C.+Fossatiauthor=G.+A.+Giardinaauthor=A.+Giardiniauthor=M.+Gualaauthor=E.+La+Portaauthor=P.+Petrilloauthor=S.+Radaelliauthor=L.+Radiceauthor=L.+F.+Ravegliaauthor=E.+Santoroauthor=R.+Scudellaroauthor=F.+Scarpittaauthor=C.+Bigognoauthor=P.+Misianoauthor=G.+M.+Dondioauthor=A.+Rizziauthor=E.+Armaniauthor=G.+Amariauthor=M.+Civelliauthor=G.+Villettiauthor=R.+Patacchiniauthor=M.+Bergamaschiauthor=M.+Delcanaleauthor=C.+Salcedoauthor=A.+G.+Fern%C3%A1ndezauthor=B.+P.+Imbimbo&title=Discovery+of+diaryl+imidazolidin-2-one+derivatives%2C+a+novel+class+of+muscarinic+M3+selective+antagonists+%28Part+1%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm061159a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061159a%26sid%3Dliteratum%253Aachs%26aulast%3DPeretto%26aufirst%3DI.%26aulast%3DForlani%26aufirst%3DR.%26aulast%3DFossati%26aufirst%3DC.%26aulast%3DGiardina%26aufirst%3DG.%2BA.%26aulast%3DGiardini%26aufirst%3DA.%26aulast%3DGuala%26aufirst%3DM.%26aulast%3DLa%2BPorta%26aufirst%3DE.%26aulast%3DPetrillo%26aufirst%3DP.%26aulast%3DRadaelli%26aufirst%3DS.%26aulast%3DRadice%26aufirst%3DL.%26aulast%3DRaveglia%26aufirst%3DL.%2BF.%26aulast%3DSantoro%26aufirst%3DE.%26aulast%3DScudellaro%26aufirst%3DR.%26aulast%3DScarpitta%26aufirst%3DF.%26aulast%3DBigogno%26aufirst%3DC.%26aulast%3DMisiano%26aufirst%3DP.%26aulast%3DDondio%26aufirst%3DG.%2BM.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DArmani%26aufirst%3DE.%26aulast%3DAmari%26aufirst%3DG.%26aulast%3DCivelli%26aufirst%3DM.%26aulast%3DVilletti%26aufirst%3DG.%26aulast%3DPatacchini%26aufirst%3DR.%26aulast%3DBergamaschi%26aufirst%3DM.%26aulast%3DDelcanale%26aufirst%3DM.%26aulast%3DSalcedo%26aufirst%3DC.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DA.%2BG.%26aulast%3DImbimbo%26aufirst%3DB.%2BP.%26atitle%3DDiscovery%2520of%2520diaryl%2520imidazolidin-2-one%2520derivatives%252C%2520a%2520novel%2520class%2520of%2520muscarinic%2520M3%2520selective%2520antagonists%2520%2528Part%25201%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1571%26epage%3D1583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Peretto, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossati, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giardina, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giardini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guala, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Porta, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrillo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radaelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radice, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raveglia, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scudellaro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarpitta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menegon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dondio, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villetti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patacchini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergamaschi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delcanale, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imbimbo, B. P.</span><span> </span><span class="NLM_article-title">Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M<sub>3</sub> selective antagonists (part 2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1693</span><span class="NLM_x">–</span> <span class="NLM_lpage">1697</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061160%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1693-1697&author=I.+Perettoauthor=C.+Fossatiauthor=G.+A.+Giardinaauthor=A.+Giardiniauthor=M.+Gualaauthor=E.+La+Portaauthor=P.+Petrilloauthor=S.+Radaelliauthor=L.+Radiceauthor=L.+F.+Ravegliaauthor=E.+Santoroauthor=R.+Scudellaroauthor=F.+Scarpittaauthor=A.+Cerriauthor=S.+Menegonauthor=G.+M.+Dondioauthor=A.+Rizziauthor=E.+Armaniauthor=G.+Amariauthor=M.+Civelliauthor=G.+Villettiauthor=R.+Patacchiniauthor=M.+Bergamaschiauthor=F.+Bassaniauthor=M.+Delcanaleauthor=B.+P.+Imbimbo&title=Discovery+of+diaryl+imidazolidin-2-one+derivatives%2C+a+novel+class+of+muscarinic+M3+selective+antagonists+%28part+2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm061160%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061160%252B%26sid%3Dliteratum%253Aachs%26aulast%3DPeretto%26aufirst%3DI.%26aulast%3DFossati%26aufirst%3DC.%26aulast%3DGiardina%26aufirst%3DG.%2BA.%26aulast%3DGiardini%26aufirst%3DA.%26aulast%3DGuala%26aufirst%3DM.%26aulast%3DLa%2BPorta%26aufirst%3DE.%26aulast%3DPetrillo%26aufirst%3DP.%26aulast%3DRadaelli%26aufirst%3DS.%26aulast%3DRadice%26aufirst%3DL.%26aulast%3DRaveglia%26aufirst%3DL.%2BF.%26aulast%3DSantoro%26aufirst%3DE.%26aulast%3DScudellaro%26aufirst%3DR.%26aulast%3DScarpitta%26aufirst%3DF.%26aulast%3DCerri%26aufirst%3DA.%26aulast%3DMenegon%26aufirst%3DS.%26aulast%3DDondio%26aufirst%3DG.%2BM.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DArmani%26aufirst%3DE.%26aulast%3DAmari%26aufirst%3DG.%26aulast%3DCivelli%26aufirst%3DM.%26aulast%3DVilletti%26aufirst%3DG.%26aulast%3DPatacchini%26aufirst%3DR.%26aulast%3DBergamaschi%26aufirst%3DM.%26aulast%3DBassani%26aufirst%3DF.%26aulast%3DDelcanale%26aufirst%3DM.%26aulast%3DImbimbo%26aufirst%3DB.%2BP.%26atitle%3DDiscovery%2520of%2520diaryl%2520imidazolidin-2-one%2520derivatives%252C%2520a%2520novel%2520class%2520of%2520muscarinic%2520M3%2520selective%2520antagonists%2520%2528part%25202%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1693%26epage%3D1697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Villetti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastore, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergamaschi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolzoni, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battipaglia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delcanale, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cenacchi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cacciani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaniboni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrillo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scudellaro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mannini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geppetti, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Razzetti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patacchini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civelli, M.</span><span> </span><span class="NLM_article-title">Bronchodilator activity of (3<i>R</i>)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M<sub>3</sub> receptor antagonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">335</span><span class="NLM_x">, </span> <span class="NLM_fpage">622</span><span class="NLM_x">–</span> <span class="NLM_lpage">635</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1124%2Fjpet.110.170035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=20805306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2010&pages=622-635&author=G.+Villettiauthor=F.+Pastoreauthor=M.+Bergamaschiauthor=F.+Bassaniauthor=P.+T.+Bolzoniauthor=L.+Battipagliaauthor=G.+Amariauthor=A.+Rizziauthor=M.+Delcanaleauthor=R.+Voltaauthor=V.+Cenacchiauthor=F.+Caccianiauthor=M.+Zaniboniauthor=F.+Bertiauthor=G.+Rossoniauthor=S.+Harrisonauthor=P.+Petrilloauthor=E.+Santoroauthor=R.+Scudellaroauthor=F.+Manniniauthor=P.+A.+Geppettiauthor=R.+Razzettiauthor=R.+Patacchiniauthor=M.+Civelli&title=Bronchodilator+activity+of+%283R%29-3-%5B%5B%5B%283-fluorophenyl%29%5B%283%2C4%2C5-trifluorophenyl%29methyl%5Damino%5Dcarbonyl%5Doxy%5D-1-%5B2-oxo-2-%282-thienyl%29ethyl%5D-1-azoniabicyclo%5B2.2.2%5Doctane+bromide+%28CHF5407%29%2C+a+potent%2C+long-acting%2C+and+selective+muscarinic+M3+receptor+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 receptor antagonist</span></div><div class="casAuthors">Villetti, G.; Pastore, F.; Bergamaschi, M.; Bassani, F.; Bolzoni, P. T.; Battipaglia, L.; Amari, G.; Rizzi, A.; Delcanale, M.; Volta, R.; Cenacchi, V.; Cacciani, F.; Zaniboni, M.; Berti, F.; Rossoni, G.; Harrison, S.; Petrillo, P.; Santoro, E.; Scudellaro, R.; Mannini, F.; Geppetti, P. A.; Razzetti, R.; Patacchini, R.; Civelli, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">622-635</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The novel quaternary ammonium salt (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407) showed subnanomolar affinities for human muscarinic M1 (hM1), M2 (hM2), and M3 (hM3) receptors and dissocd. very slowly from hM3 receptors (t1/2 = 166 min) with a large part of the receptorial complex (54%) remaining undissociated at 32 h from radioligand washout.  In contrast, [3H]CHF5407 dissocd. quickly from hM2 receptors (t1/2 = 31 min), whereas [3H]tiotropium dissocd. slowly from both hM3 (t1/2 = 163 min) and hM2 receptor (t1/2 = 297 min).  In the guinea pig isolated trachea and human isolated bronchus, CHF5407 produced a potent (pIC50 = 9.0-9.6) and long-lasting (up to 24 h) inhibition of M3 receptor-mediated contractile responses to carbachol.  In the guinea pig elec. driven left atrium, the M2 receptor-mediated inhibitory response to carbachol was recovered more quickly in CHF5407-pretreated than in tiotropium-pretreated prepns.  CHF5407, administered intratracheally to anesthetized guinea pigs, potently inhibited acetylcholine (Ach)-induced bronchoconstriction with an ED50 value of 0.15 nmol/kg.  The effect was sustained over a period of 24 h, with a residual 57% inhibition 48 h after antagonist administration at 1 nmol/kg.  In conscious guinea pigs, inhaled CHF5407 inhibited Ach-induced bronchoconstriction for at least 24 h as did tiotropium at similar dosages.  Cardiovascular parameters in anesthetized guinea pigs were not significantly changed by CHF5407, up to 100 nmol/kg i.v. and up to 1000 nmol/kg i.t.  In conclusion, CHF5407 shows a prolonged antibronchospastic activity both in vitro and in vivo, caused by a very slow dissocn. from M3 receptors.  In contrast, CHF5407 is markedly short-acting at M2 receptors, a behavior not shared by tiotropium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnCU6YfyC1MLVg90H21EOLACvtfcHk0lgt3UyGOhIMXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrnJ&md5=54ae71e74a98081c6c574a5f7dd0faad</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.170035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.170035%26sid%3Dliteratum%253Aachs%26aulast%3DVilletti%26aufirst%3DG.%26aulast%3DPastore%26aufirst%3DF.%26aulast%3DBergamaschi%26aufirst%3DM.%26aulast%3DBassani%26aufirst%3DF.%26aulast%3DBolzoni%26aufirst%3DP.%2BT.%26aulast%3DBattipaglia%26aufirst%3DL.%26aulast%3DAmari%26aufirst%3DG.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DDelcanale%26aufirst%3DM.%26aulast%3DVolta%26aufirst%3DR.%26aulast%3DCenacchi%26aufirst%3DV.%26aulast%3DCacciani%26aufirst%3DF.%26aulast%3DZaniboni%26aufirst%3DM.%26aulast%3DBerti%26aufirst%3DF.%26aulast%3DRossoni%26aufirst%3DG.%26aulast%3DHarrison%26aufirst%3DS.%26aulast%3DPetrillo%26aufirst%3DP.%26aulast%3DSantoro%26aufirst%3DE.%26aulast%3DScudellaro%26aufirst%3DR.%26aulast%3DMannini%26aufirst%3DF.%26aulast%3DGeppetti%26aufirst%3DP.%2BA.%26aulast%3DRazzetti%26aufirst%3DR.%26aulast%3DPatacchini%26aufirst%3DR.%26aulast%3DCivelli%26aufirst%3DM.%26atitle%3DBronchodilator%2520activity%2520of%2520%25283R%2529-3-%255B%255B%255B%25283-fluorophenyl%2529%255B%25283%252C4%252C5-trifluorophenyl%2529methyl%255Damino%255Dcarbonyl%255Doxy%255D-1-%255B2-oxo-2-%25282-thienyl%2529ethyl%255D-1-azoniabicyclo%255B2.2.2%255Doctane%2520bromide%2520%2528CHF5407%2529%252C%2520a%2520potent%252C%2520long-acting%252C%2520and%2520selective%2520muscarinic%2520M3%2520receptor%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D335%26spage%3D622%26epage%3D635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Herbette, L. G.</span><span> </span><span class="NLM_article-title">Membrane pathways for drug/ion channel interactions: molecular basis for pharmacokinetic properties</span> <span class="citation_source-journal">Drug Dev. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">214</span><span class="NLM_x">–</span> <span class="NLM_lpage">222</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1994&pages=214-222&author=L.+G.+Herbette&title=Membrane+pathways+for+drug%2Fion+channel+interactions%3A+molecular+basis+for+pharmacokinetic+properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHerbette%26aufirst%3DL.%2BG.%26atitle%3DMembrane%2520pathways%2520for%2520drug%252Fion%2520channel%2520interactions%253A%2520molecular%2520basis%2520for%2520pharmacokinetic%2520properties%26jtitle%3DDrug%2520Dev.%2520Res.%26date%3D1994%26volume%3D33%26spage%3D214%26epage%3D222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Brown, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glossop, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewthwaite, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perros-Huguet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevethick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span> </span><span class="NLM_article-title">The discovery of long acting β<sub>2</sub>-adrenoreceptor agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4012</span><span class="NLM_x">–</span> <span class="NLM_lpage">4015</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=4012-4015&author=A.+D.+Brownauthor=M.+E.+Bunnageauthor=P.+A.+Glossopauthor=K.+Jamesauthor=R.+Jonesauthor=C.+A.+Laneauthor=R.+A.+Lewthwaiteauthor=S.+Mantellauthor=C.+Perros-Huguetauthor=D.+A.+Priceauthor=M.+Trevethickauthor=R.+Webster&title=The+discovery+of+long+acting+%CE%B22-adrenoreceptor+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DA.%2BD.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DLane%26aufirst%3DC.%2BA.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DMantell%26aufirst%3DS.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DTrevethick%26aufirst%3DM.%26aulast%3DWebster%26aufirst%3DR.%26atitle%3DThe%2520discovery%2520of%2520long%2520acting%2520%25CE%25B22-adrenoreceptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D4012%26epage%3D4015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Blaney, F. E.; Tennant, M.</span><span> </span><span class="NLM_article-title">Computational tools and results in the construction of G protein-coupled receptor models</span>. In  <span class="citation_source-book">Membrane Protein Models</span>; <span class="NLM_contrib-group">Findlay, J. B. C.</span>, Ed.; <span class="NLM_publisher-name">Bios Scientific Publishers, Ltd.</span>: <span class="NLM_publisher-loc">Oxford, U.K.</span>,<span class="NLM_x"> </span><span class="NLM_year">1996</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">176</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&pages=161-176&author=F.+E.+Blaney&author=M.+Tennantauthor=J.+B.+C.+Findlay&title=Membrane+Protein+Models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBlaney%26aufirst%3DF.%2BE.%26atitle%3DComputational%2520tools%2520and%2520results%2520in%2520the%2520construction%2520of%2520G%2520protein-coupled%2520receptor%2520models%26btitle%3DMembrane%2520Protein%2520Models%26aulast%3DFindlay%26aufirst%3DJ.%2BB.%2BC.%26pub%3DBios%2520Scientific%2520Publishers%252C%2520Ltd%26date%3D1996%26spage%3D161%26epage%3D176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Isogaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamagiwa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugimoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagao, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurose, H.</span><span> </span><span class="NLM_article-title">Identification of a key amino acid of the β<sub>2</sub>-adrenergic receptor for high affinity binding of salmeterol</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">616</span><span class="NLM_x">–</span> <span class="NLM_lpage">622</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1998&pages=616-622&author=M.+Isogayaauthor=Y.+Yamagiwaauthor=S.+Fujitaauthor=Y.+Sugimotoauthor=T.+Nagaoauthor=H.+Kurose&title=Identification+of+a+key+amino+acid+of+the+%CE%B22-adrenergic+receptor+for+high+affinity+binding+of+salmeterol"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIsogaya%26aufirst%3DM.%26aulast%3DYamagiwa%26aufirst%3DY.%26aulast%3DFujita%26aufirst%3DS.%26aulast%3DSugimoto%26aufirst%3DY.%26aulast%3DNagao%26aufirst%3DT.%26aulast%3DKurose%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520a%2520key%2520amino%2520acid%2520of%2520the%2520%25CE%25B22-adrenergic%2520receptor%2520for%2520high%2520affinity%2520binding%2520of%2520salmeterol%26jtitle%3DMol.%2520Pharmacol.%26date%3D1998%26volume%3D54%26spage%3D616%26epage%3D622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Isogaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugimoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanimura, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikkawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagao, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurose, H.</span><span> </span><span class="NLM_article-title">Binding pockets of the β<sub>1</sub> and β<sub>2</sub> adrenergic receptors for subtype-selective agonists</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">875</span><span class="NLM_x">–</span> <span class="NLM_lpage">885</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1999&pages=875-885&author=M.+Isogayaauthor=Y.+Sugimotoauthor=R.+Tanimuraauthor=R.+Tanakaauthor=H.+Kikkawaauthor=T.+Nagaoauthor=H.+Kurose&title=Binding+pockets+of+the+%CE%B21+and+%CE%B22+adrenergic+receptors+for+subtype-selective+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIsogaya%26aufirst%3DM.%26aulast%3DSugimoto%26aufirst%3DY.%26aulast%3DTanimura%26aufirst%3DR.%26aulast%3DTanaka%26aufirst%3DR.%26aulast%3DKikkawa%26aufirst%3DH.%26aulast%3DNagao%26aufirst%3DT.%26aulast%3DKurose%26aufirst%3DH.%26atitle%3DBinding%2520pockets%2520of%2520the%2520%25CE%25B21%2520and%2520%25CE%25B22%2520adrenergic%2520receptors%2520for%2520subtype-selective%2520agonists%26jtitle%3DMol.%2520Pharmacol.%26date%3D1999%26volume%3D56%26spage%3D875%26epage%3D885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Green, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spasoff, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liggett, S. B.</span><span> </span><span class="NLM_article-title">Sustained activation of a G-protein-coupled receptor via “anchored” agonist binding. Molecular localization of the salmeterol exosite within the β<sub>2</sub>-adrenergic receptor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">24029</span><span class="NLM_x">–</span> <span class="NLM_lpage">24035</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=24029-24035&author=S.+A.+Greenauthor=A.+P.+Spasoffauthor=R.+R.+Colemanauthor=M.+Johnsonauthor=S.+B.+Liggett&title=Sustained+activation+of+a+G-protein-coupled+receptor+via+%E2%80%9Canchored%E2%80%9D+agonist+binding.+Molecular+localization+of+the+salmeterol+exosite+within+the+%CE%B22-adrenergic+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGreen%26aufirst%3DS.%2BA.%26aulast%3DSpasoff%26aufirst%3DA.%2BP.%26aulast%3DColeman%26aufirst%3DR.%2BR.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DLiggett%26aufirst%3DS.%2BB.%26atitle%3DSustained%2520activation%2520of%2520a%2520G-protein-coupled%2520receptor%2520via%2520%25E2%2580%259Canchored%25E2%2580%259D%2520agonist%2520binding.%2520Molecular%2520localization%2520of%2520the%2520salmeterol%2520exosite%2520within%2520the%2520%25CE%25B22-adrenergic%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D24029%26epage%3D24035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Prashad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Har, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repic, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blacklock, T. J.</span><span> </span><span class="NLM_article-title">An efficient and economical synthesis of 5,6-diethyl-2,3-dihydro-1<i>H</i>-inden-2-amine hydrochloride</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/doi/10.1021/op0502093" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2006&pages=135-141&author=M.+Prashadauthor=B.+Huauthor=D.+Harauthor=O.+Repicauthor=T.+J.+Blacklock&title=An+efficient+and+economical+synthesis+of+5%2C6-diethyl-2%2C3-dihydro-1H-inden-2-amine+hydrochloride"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fop0502093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop0502093%26sid%3Dliteratum%253Aachs%26aulast%3DPrashad%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DHar%26aufirst%3DD.%26aulast%3DRepic%26aufirst%3DO.%26aulast%3DBlacklock%26aufirst%3DT.%2BJ.%26atitle%3DAn%2520efficient%2520and%2520economical%2520synthesis%2520of%25205%252C6-diethyl-2%252C3-dihydro-1H-inden-2-amine%2520hydrochloride%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2006%26volume%3D10%26spage%3D135%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Beattie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruce, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuenoud, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairhurst, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fozard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janus, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosethorne, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandham, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sykes, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trifilieff, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissler, E.</span><span> </span><span class="NLM_article-title">An investigation into the structure–activity relationships associated with the systematic modification of the β<sub>2</sub>-adrenoceptor agonist indacaterol</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">6280</span><span class="NLM_x">–</span> <span class="NLM_lpage">6285</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6280-6285&author=D.+Beattieauthor=D.+Beerauthor=M.+E.+Bradleyauthor=I.+Bruceauthor=S.+J.+Charltonauthor=B.+M.+Cuenoudauthor=R.+A.+Fairhurstauthor=D.+Farrauthor=J.+R.+Fozardauthor=D.+Janusauthor=E.+M.+Rosethorneauthor=D.+A.+Sandhamauthor=D.+A.+Sykesauthor=A.+Trifilieffauthor=K.+L.+Turnerauthor=E.+Wissler&title=An+investigation+into+the+structure%E2%80%93activity+relationships+associated+with+the+systematic+modification+of+the+%CE%B22-adrenoceptor+agonist+indacaterol"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeattie%26aufirst%3DD.%26aulast%3DBeer%26aufirst%3DD.%26aulast%3DBradley%26aufirst%3DM.%2BE.%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DCuenoud%26aufirst%3DB.%2BM.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DFarr%26aufirst%3DD.%26aulast%3DFozard%26aufirst%3DJ.%2BR.%26aulast%3DJanus%26aufirst%3DD.%26aulast%3DRosethorne%26aufirst%3DE.%2BM.%26aulast%3DSandham%26aufirst%3DD.%2BA.%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DTrifilieff%26aufirst%3DA.%26aulast%3DTurner%26aufirst%3DK.%2BL.%26aulast%3DWissler%26aufirst%3DE.%26atitle%3DAn%2520investigation%2520into%2520the%2520structure%25E2%2580%2593activity%2520relationships%2520associated%2520with%2520the%2520systematic%2520modification%2520of%2520the%2520%25CE%25B22-adrenoceptor%2520agonist%2520indacaterol%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6280%26epage%3D6285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Rosenbaum, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, S. G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thian, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, X.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span> </span><span class="NLM_article-title">GPCR engineering yields high-resolution structural insights into β<sub>2</sub>-adrenergic receptor function</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">318</span><span class="NLM_x">, </span> <span class="NLM_fpage">1266</span><span class="NLM_x">–</span> <span class="NLM_lpage">1273</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1126%2Fscience.1150609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=17962519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGmur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2007&pages=1266-1273&author=D.+M.+Rosenbaumauthor=V.+Cherezovauthor=M.+A.+Hansonauthor=S.+G.+F.+Rasmussenauthor=F.+S.+Thianauthor=T.+S.+Kobilkaauthor=H.-J.+Choiauthor=X.-J.+Yaoauthor=W.+I.+Weisauthor=R.+C.+Stevensauthor=B.+K.+Kobilka&title=GPCR+engineering+yields+high-resolution+structural+insights+into+%CE%B22-adrenergic+receptor+function"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function</span></div><div class="casAuthors">Rosenbaum, Daniel M.; Cherezov, Vadim; Hanson, Michael A.; Rasmussen, Soren G. F.; Thian, Foon Sun; Kobilka, Tong Sun; Choi, Hee-Jung; Yao, Xiao-Jie; Weis, William I.; Stevens, Raymond C.; Kobilka, Brian K.; Pierce, K. L.; Premont, R. T.; Lefkowitz, R. J.; Kobilka, B. K.; Deupi, X.; Cherezov, V.; Rasmussen, S. G. F.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">5854</span>),
    <span class="NLM_cas:pages">1266-1273</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The β2-adrenergic receptor (β2AR) is a well-studied prototype for heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors (GPCRs) that respond to diffusible hormones and neurotransmitters.  To overcome the structural flexibility of the β2AR and to facilitate its crystn., we engineered a β2AR fusion protein in which T4 lysozyme (T4L) replaces most of the third intracellular loop of the GPCR ("β2AR-T4L") and showed that this protein retains near-native pharmacol. properties.  Anal. of adrenergic receptor ligand-binding mutants within the context of the reported high-resoln. structure of β2AR-T4L provides insights into inverse-agonist binding and the structural changes required to accommodate catecholamine agonists.  Amino acids known to regulate receptor function are linked through packing interactions and a network of hydrogen bonds, suggesting a conformational pathway from the ligand-binding pocket to regions that interact with G proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6gmrMhXnVl7Vg90H21EOLACvtfcHk0liy8Gllir2wEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGmur7J&md5=d422ff1e7a28719848c0e16fede045db</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1126%2Fscience.1150609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1150609%26sid%3Dliteratum%253Aachs%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%2BF.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DChoi%26aufirst%3DH.-J.%26aulast%3DYao%26aufirst%3DX.-J.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DGPCR%2520engineering%2520yields%2520high-resolution%2520structural%2520insights%2520into%2520%25CE%25B22-adrenergic%2520receptor%2520function%26jtitle%3DScience%26date%3D2007%26volume%3D318%26spage%3D1266%26epage%3D1273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Rasmussen, S. G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbaum, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thian, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burghammer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratnala, V. R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanishvili, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischetti, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schertler, G. F. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span> </span><span class="NLM_article-title">Crystal structure of the human β<sub>2</sub> adrenergic G-protein-coupled receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">450</span><span class="NLM_x">, </span> <span class="NLM_fpage">383</span><span class="NLM_x">–</span> <span class="NLM_lpage">388</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1038%2Fnature06325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=17952055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlajs77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=450&publication_year=2007&pages=383-388&author=S.+G.+F.+Rasmussenauthor=H.-J.+Choiauthor=D.+M.+Rosenbaumauthor=T.+S.+Kobilkaauthor=F.+S.+Thianauthor=P.+C.+Edwardsauthor=M.+Burghammerauthor=V.+R.+P.+Ratnalaauthor=R.+Sanishviliauthor=R.+F.+Fischettiauthor=G.+F.+X.+Schertlerauthor=W.+I.+Weisauthor=B.+K.+Kobilka&title=Crystal+structure+of+the+human+%CE%B22+adrenergic+G-protein-coupled+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the human β2 adrenergic G-protein-coupled receptor</span></div><div class="casAuthors">Rasmussen, Soren G. F.; Choi, Hee-Jung; Rosenbaum, Daniel M.; Kobilka, Tong Sun; Thian, Foon Sun; Edwards, Patricia C.; Burghammer, Manfred; Ratnala, Venkata R. P.; Sanishvili, Ruslan; Fischetti, Robert F.; Schertler, Gebhard F. X.; Weis, William I.; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">450</span>
        (<span class="NLM_cas:issue">7168</span>),
    <span class="NLM_cas:pages">383-387</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Structural anal. of G-protein-coupled receptors (GPCRs) for hormones and neurotransmitters has been hindered by their low natural abundance, inherent structural flexibility, and instability in detergent solns.  Here we report a structure of the human β2 adrenoceptor (β2AR), which was crystd. in a lipid environment when bound to an inverse agonist and in complex with a Fab that binds to the third intracellular loop.  Diffraction data were obtained by high-brilliance microcrystallog. and the structure detd. at 3.4 Å/3.7 Å resoln.  The cytoplasmic ends of the β2AR transmembrane segments and the connecting loops are well resolved, whereas the extracellular regions of the β2AR are not seen.  The β2AR structure differs from rhodopsin in having weaker interactions between the cytoplasmic ends of transmembrane (TM)3 and TM6, involving the conserved E/DRY sequences.  These differences may be responsible for the relatively high basal activity and structural instability of the β2AR, and contribute to the challenges in obtaining diffraction-quality crystals of non-rhodopsin GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTx0B_3Vn2M7Vg90H21EOLACvtfcHk0liy8Gllir2wEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlajs77N&md5=79026a0a69ddb4b0ea25063e409ad2cd</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnature06325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature06325%26sid%3Dliteratum%253Aachs%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%2BF.%26aulast%3DChoi%26aufirst%3DH.-J.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DEdwards%26aufirst%3DP.%2BC.%26aulast%3DBurghammer%26aufirst%3DM.%26aulast%3DRatnala%26aufirst%3DV.%2BR.%2BP.%26aulast%3DSanishvili%26aufirst%3DR.%26aulast%3DFischetti%26aufirst%3DR.%2BF.%26aulast%3DSchertler%26aufirst%3DG.%2BF.%2BX.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520%25CE%25B22%2520adrenergic%2520G-protein-coupled%2520receptor%26jtitle%3DNature%26date%3D2007%26volume%3D450%26spage%3D383%26epage%3D388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Procopiou, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bevan, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggadike, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butchers, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coe, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conroy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmons, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsley, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li-Kwai-Cheung, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Looker, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mann, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLay, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutch, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlin, P.</span><span> </span><span class="NLM_article-title">Synthesis and structure–activity relationships of long-acting beta<sub>2</sub> adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4522</span><span class="NLM_x">–</span> <span class="NLM_lpage">4530</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100326d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4522-4530&author=P.+A.+Procopiouauthor=V.+J.+Barrettauthor=N.+J.+Bevanauthor=K.+Biggadikeauthor=P.+C.+Boxauthor=P.+R.+Butchersauthor=D.+M.+Coeauthor=R.+Conroyauthor=A.+Emmonsauthor=A.+J.+Fordauthor=D.+S.+Holmesauthor=H.+Horsleyauthor=F.+Kerrauthor=A.+M.+Li-Kwai-Cheungauthor=B.+E.+Lookerauthor=I.+S.+Mannauthor=I.+M.+McLayauthor=V.+S.+Morrisonauthor=P.+J.+Mutchauthor=C.+E.+Smithauthor=P.+Tomlin&title=Synthesis+and+structure%E2%80%93activity+relationships+of+long-acting+beta2+adrenergic+receptor+agonists+incorporating+metabolic+inactivation%3A+an+antedrug+approach"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm100326d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100326d%26sid%3Dliteratum%253Aachs%26aulast%3DProcopiou%26aufirst%3DP.%2BA.%26aulast%3DBarrett%26aufirst%3DV.%2BJ.%26aulast%3DBevan%26aufirst%3DN.%2BJ.%26aulast%3DBiggadike%26aufirst%3DK.%26aulast%3DBox%26aufirst%3DP.%2BC.%26aulast%3DButchers%26aufirst%3DP.%2BR.%26aulast%3DCoe%26aufirst%3DD.%2BM.%26aulast%3DConroy%26aufirst%3DR.%26aulast%3DEmmons%26aufirst%3DA.%26aulast%3DFord%26aufirst%3DA.%2BJ.%26aulast%3DHolmes%26aufirst%3DD.%2BS.%26aulast%3DHorsley%26aufirst%3DH.%26aulast%3DKerr%26aufirst%3DF.%26aulast%3DLi-Kwai-Cheung%26aufirst%3DA.%2BM.%26aulast%3DLooker%26aufirst%3DB.%2BE.%26aulast%3DMann%26aufirst%3DI.%2BS.%26aulast%3DMcLay%26aufirst%3DI.%2BM.%26aulast%3DMorrison%26aufirst%3DV.%2BS.%26aulast%3DMutch%26aufirst%3DP.%2BJ.%26aulast%3DSmith%26aufirst%3DC.%2BE.%26aulast%3DTomlin%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520long-acting%2520beta2%2520adrenergic%2520receptor%2520agonists%2520incorporating%2520metabolic%2520inactivation%253A%2520an%2520antedrug%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4522%26epage%3D4530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Kempsford, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siederer, S.</span><span> </span><span class="NLM_article-title">Vilanterol trifenatate, a novel inhaled long-acting β<sub>2</sub> adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD</span> <span class="citation_source-journal">Pulm. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">256</span><span class="NLM_x">–</span> <span class="NLM_lpage">264</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.pupt.2012.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23232038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=256-264&author=R.+Kempsfordauthor=V.+Norrisauthor=S.+Siederer&title=Vilanterol+trifenatate%2C+a+novel+inhaled+long-acting+%CE%B22+adrenoceptor+agonist%2C+is+well+tolerated+in+healthy+subjects+and+demonstrates+prolonged+bronchodilation+in+subjects+with+asthma+and+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD</span></div><div class="casAuthors">Kempsford, Rodger; Norris, Virginia; Siederer, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">256-264</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Vilanterol (VI; GW642444M) is a novel inhaled long-acting β2-agonist with inherent 24 h activity in vitro in development as a combination with the inhaled corticosteroid fluticasone furoate for both COPD and asthma.  These studies were conducted to det. the safety, tolerability, pharmacodynamics and pharmacokinetics of VI in healthy subjects and subjects with mild to moderate persistent asthma and moderate to severe COPD.Single doses of VI (25-100 μg) were given once daily to subjects with asthma and COPD and repeat doses once daily for 14 days to healthy subjects.  Adverse events (AEs), vital signs, ECGs, pharmacodynamic endpoints, FEV1 and VI plasma pharmacokinetics (AUC, Cmax and Tmax) were detd. following dosing.VI (25-100 μg) was well tolerated.  The incidence and severity of AEs were comparable to placebo.  Following VI administration there were no clin. significant abnormalities in vital signs, 12-lead ECG, Holter ECG, blood glucose or potassium.  There were no statistically significant effects on QTc of single and repeat VI doses up to 50 μg; some differences were seen following the 100 μg VI dose after single and repeat dose in healthy subjects and single dose in asthmatic subjects.  All VI doses produced increases in FEV1 from as early as 5 min after dosing which were maintained up to 24 h post-dose in subjects with asthma and COPD.  In all subjects VI was rapidly absorbed (healthy subjects median Tmax at 5 min; asthma and COPD subjects median Tmax at 10 min) with systemic exposure increasing in an approx. dose proportional manner across the VI dose range.  Marginal accumulation was seen on repeat dosing.Single doses of inhaled VI in subjects with asthma and COPD and repeat doses in healthy subjects were well tolerated with no clin. significant unwanted systemic effects.  VI produced a rapid and prolonged bronchodilation over 24 h suggesting the potential for once daily administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8cX6SSS6wyrVg90H21EOLACvtfcHk0ljbrB0tehfgCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSrsQ%253D%253D&md5=5f2cf2326c8ffa20acc16256c484ddb9</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2012.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2012.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DKempsford%26aufirst%3DR.%26aulast%3DNorris%26aufirst%3DV.%26aulast%3DSiederer%26aufirst%3DS.%26atitle%3DVilanterol%2520trifenatate%252C%2520a%2520novel%2520inhaled%2520long-acting%2520%25CE%25B22%2520adrenoceptor%2520agonist%252C%2520is%2520well%2520tolerated%2520in%2520healthy%2520subjects%2520and%2520demonstrates%2520prolonged%2520bronchodilation%2520in%2520subjects%2520with%2520asthma%2520and%2520COPD%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D26%26spage%3D256%26epage%3D264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Slack, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturton, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmons, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knowles, R. G.</span><span> </span><span class="NLM_article-title">In vitro pharmacological characterization of vilanterol, a novel long-acting β<sub>2</sub>-adrenoceptor agonist with 24-hour duration of action</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">218</span><span class="NLM_x">–</span> <span class="NLM_lpage">230</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1124%2Fjpet.112.198481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23131596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Cruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2013&pages=218-230&author=R.+J.+Slackauthor=V.+J.+Barrettauthor=V.+S.+Morrisonauthor=R.+G.+Sturtonauthor=A.+J.+Emmonsauthor=A.+J.+Fordauthor=R.+G.+Knowles&title=In+vitro+pharmacological+characterization+of+vilanterol%2C+a+novel+long-acting+%CE%B22-adrenoceptor+agonist+with+24-hour+duration+of+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action</span></div><div class="casAuthors">Slack, Robert J.; Barrett, Victoria J.; Morrison, Valerie S.; Sturton, Richard G.; Emmons, Amanda J.; Ford, Alison J.; Knowles, Richard G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">218-230</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Vilanterol trifenatate (vilanterol) is a novel, long-acting β2-adrenoceptor (β2-AR) agonist with 24 h activity.  In this study, we describe the preclin. pharmacol. profile of vilanterol using radioligand binding and cAMP studies in recombinant assays as well as human and guinea pig tissue systems to characterize β2-AR binding and functional properties.  Vilanterol displayed a subnanomolar affinity for the β2-AR that was comparable with that of salmeterol but higher than olodaterol, formoterol, and indacaterol.  In cAMP functional activity studies, vilanterol demonstrated similar selectivity as salmeterol for β2- over β1-AR and β3-AR, but a significantly improved selectivity profile than formoterol and indacaterol.  Vilanterol also showed a level of intrinsic efficacy that was comparable to indacaterol but significantly greater than that of salmeterol.  In cellular cAMP prodn. and tissue-based studies measuring persistence and reassertion, vilanterol had a persistence of action comparable with indacaterol and longer than formoterol.  In addn., vilanterol demonstrated reassertion activity in both cell and tissue systems that was comparable with salmeterol and indacaterol but longer than formoterol.  In human airways, vilanterol was shown to have a faster onset and longer duration of action than salmeterol, exhibiting a significant level of bronchodilation 22 h after treatment.  From these investigations, the data for vilanterol are consistent, showing that it is a novel, potent, and selective β2-AR receptor agonist with a long duration of action.  This pharmacol. profile combined with clin. data is consistent with once a day dosing of vilanterol in the treatment of both asthma and chronic obstructive pulmonary disease (COPD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp95t1JgsCjK7Vg90H21EOLACvtfcHk0ljbrB0tehfgCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Cruw%253D%253D&md5=e2e1d7bdb72404ea5a934c79fd7f92d0</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.198481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.198481%26sid%3Dliteratum%253Aachs%26aulast%3DSlack%26aufirst%3DR.%2BJ.%26aulast%3DBarrett%26aufirst%3DV.%2BJ.%26aulast%3DMorrison%26aufirst%3DV.%2BS.%26aulast%3DSturton%26aufirst%3DR.%2BG.%26aulast%3DEmmons%26aufirst%3DA.%2BJ.%26aulast%3DFord%26aufirst%3DA.%2BJ.%26aulast%3DKnowles%26aufirst%3DR.%2BG.%26atitle%3DIn%2520vitro%2520pharmacological%2520characterization%2520of%2520vilanterol%252C%2520a%2520novel%2520long-acting%2520%25CE%25B22-adrenoceptor%2520agonist%2520with%252024-hour%2520duration%2520of%2520action%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D344%26spage%3D218%26epage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Brown, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glossop, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewthwaite, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perros-Huguet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevethick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span> </span><span class="NLM_article-title">The discovery of adamantyl-derived, inhaled, long acting beta<sub>2</sub>-adrenoreceptor agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1280</span><span class="NLM_x">–</span> <span class="NLM_lpage">1283</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1280-1283&author=A.+D.+Brownauthor=M.+E.+Bunnageauthor=P.+A.+Glossopauthor=K.+Jamesauthor=R.+Jonesauthor=C.+A.+Laneauthor=R.+A.+Lewthwaiteauthor=S.+Mantellauthor=C.+Perros-Huguetauthor=D.+A.+Priceauthor=M.+Trevethickauthor=R.+Webster&title=The+discovery+of+adamantyl-derived%2C+inhaled%2C+long+acting+beta2-adrenoreceptor+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DA.%2BD.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DLane%26aufirst%3DC.%2BA.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DMantell%26aufirst%3DS.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DTrevethick%26aufirst%3DM.%26aulast%3DWebster%26aufirst%3DR.%26atitle%3DThe%2520discovery%2520of%2520adamantyl-derived%252C%2520inhaled%252C%2520long%2520acting%2520beta2-adrenoreceptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D1280%26epage%3D1283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Brown, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glossop, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holbrook, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewthwaite, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perros-Huguet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span> </span><span class="NLM_article-title">The discovery of indole-derived long acting beta<sub>2</sub>-adrenoceptor agonists for the treatment of asthma and COPD</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">6188</span><span class="NLM_x">–</span> <span class="NLM_lpage">6191</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=6188-6191&author=A.+D.+Brownauthor=M.+E.+Bunnageauthor=P.+A.+Glossopauthor=M.+Holbrookauthor=R.+D.+Jonesauthor=C.+A.+Laneauthor=R.+A.+Lewthwaiteauthor=S.+Mantellauthor=C.+Perros-Huguetauthor=D.+A.+Priceauthor=R.+Webster&title=The+discovery+of+indole-derived+long+acting+beta2-adrenoceptor+agonists+for+the+treatment+of+asthma+and+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DA.%2BD.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DHolbrook%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DR.%2BD.%26aulast%3DLane%26aufirst%3DC.%2BA.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DMantell%26aufirst%3DS.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DWebster%26aufirst%3DR.%26atitle%3DThe%2520discovery%2520of%2520indole-derived%2520long%2520acting%2520beta2-adrenoceptor%2520agonists%2520for%2520the%2520treatment%2520of%2520asthma%2520and%2520COPD%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D6188%26epage%3D6191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Glossop, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnage, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewthwaite, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeadon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perros-Huguet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevethick, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrows, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeder, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spence, F. J.</span><span> </span><span class="NLM_article-title">Inhalation by design: novel ultra-long-acting β<sub>2</sub>-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6640</span><span class="NLM_x">–</span> <span class="NLM_lpage">6652</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1005989" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6640-6652&author=P.+A.+Glossopauthor=C.+A.+Laneauthor=D.+A.+Priceauthor=M.+E.+Bunnageauthor=R.+A.+Lewthwaiteauthor=K.+Jamesauthor=A.+D.+Brownauthor=M.+Yeadonauthor=C.+Perros-Huguetauthor=M.+A.+Trevethickauthor=N.+P.+Clarkeauthor=R.+Websterauthor=R.+M.+Jonesauthor=J.+L.+Burrowsauthor=N.+Feederauthor=S.+C.+Taylorauthor=F.+J.+Spence&title=Inhalation+by+design%3A+novel+ultra-long-acting+%CE%B22-adrenoreceptor+agonists+for+inhaled+once-daily+treatment+of+asthma+and+chronic+obstructive+pulmonary+disease+that+utilize+a+sulfonamide+agonist+headgroup"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm1005989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1005989%26sid%3Dliteratum%253Aachs%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DLane%26aufirst%3DC.%2BA.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DA.%2BD.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DTrevethick%26aufirst%3DM.%2BA.%26aulast%3DClarke%26aufirst%3DN.%2BP.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DBurrows%26aufirst%3DJ.%2BL.%26aulast%3DFeeder%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DS.%2BC.%26aulast%3DSpence%26aufirst%3DF.%2BJ.%26atitle%3DInhalation%2520by%2520design%253A%2520novel%2520ultra-long-acting%2520%25CE%25B22-adrenoreceptor%2520agonists%2520for%2520inhaled%2520once-daily%2520treatment%2520of%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%2520that%2520utilize%2520a%2520sulfonamide%2520agonist%2520headgroup%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6640%26epage%3D6652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Bouyssou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolf, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoenke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lustenberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konetzki, I.</span><span> </span><span class="NLM_article-title">Studies towards topical selective β<sub>2</sub>-adrenoceptor agonists with a long duration of action</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5237</span><span class="NLM_x">–</span> <span class="NLM_lpage">5240</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5237-5240&author=T.+Bouyssouauthor=K.+Rudolfauthor=C.+Hoenkeauthor=P.+Lustenbergerauthor=A.+Schnappauthor=I.+Konetzki&title=Studies+towards+topical+selective+%CE%B22-adrenoceptor+agonists+with+a+long+duration+of+action"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBouyssou%26aufirst%3DT.%26aulast%3DRudolf%26aufirst%3DK.%26aulast%3DHoenke%26aufirst%3DC.%26aulast%3DLustenberger%26aufirst%3DP.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DKonetzki%26aufirst%3DI.%26atitle%3DStudies%2520towards%2520topical%2520selective%2520%25CE%25B22-adrenoceptor%2520agonists%2520with%2520a%2520long%2520duration%2520of%2520action%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5237%26epage%3D5240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Hoenke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouyssou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tautermann, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolf, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konetzki, I.</span><span> </span><span class="NLM_article-title">Use of 5-hydroxy-4<i>H</i>-benzo[1,4]oxazin-3-ones as β<sub>2</sub>-adrenoceptor agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6640</span><span class="NLM_x">–</span> <span class="NLM_lpage">6644</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6640-6644&author=C.+Hoenkeauthor=T.+Bouyssouauthor=C.+S.+Tautermannauthor=K.+Rudolfauthor=A.+Schnappauthor=I.+Konetzki&title=Use+of+5-hydroxy-4H-benzo%5B1%2C4%5Doxazin-3-ones+as+%CE%B22-adrenoceptor+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHoenke%26aufirst%3DC.%26aulast%3DBouyssou%26aufirst%3DT.%26aulast%3DTautermann%26aufirst%3DC.%2BS.%26aulast%3DRudolf%26aufirst%3DK.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DKonetzki%26aufirst%3DI.%26atitle%3DUse%2520of%25205-hydroxy-4H-benzo%255B1%252C4%255Doxazin-3-ones%2520as%2520%25CE%25B22-adrenoceptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6640%26epage%3D6644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Bouyssou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoenke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolf, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lustenberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pestel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sieger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heine, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buttner, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konetzki, I.</span><span> </span><span class="NLM_article-title">Discovery of olodaterol, a novel inhaled β<sub>2</sub>-adrenoceptor agonist with a 24 h bronchodilatory efficacy</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1410</span><span class="NLM_x">–</span> <span class="NLM_lpage">1414</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.bmcl.2009.12.087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=20096576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslSmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1410-1414&author=T.+Bouyssouauthor=C.+Hoenkeauthor=K.+Rudolfauthor=P.+Lustenbergerauthor=S.+Pestelauthor=P.+Siegerauthor=R.+Lotzauthor=C.+Heineauthor=F.+H.+Buttnerauthor=A.+Schnappauthor=I.+Konetzki&title=Discovery+of+olodaterol%2C+a+novel+inhaled+%CE%B22-adrenoceptor+agonist+with+a+24+h+bronchodilatory+efficacy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24h bronchodilatory efficacy</span></div><div class="casAuthors">Bouyssou, Thierry; Hoenke, Christoph; Rudolf, Klaus; Lustenberger, Philipp; Pestel, Sabine; Sieger, Peter; Lotz, Ralf; Heine, Claudia; Buettner, Frank H.; Schnapp, Andreas; Konetzki, Ingo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1410-1414</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Compd. 4p (I) was identified from a series of 6-hydroxy-4H-benzo[1,4]oxazin-3-ones as potent agonist of the human β2-adrenoceptor with a high β1/β2-selectivity.  A complete reversal of acetylcholine-induced bronchoconstriction which lasted over the whole study period of 5 h was demonstrated for 4p in a guinea pig in vivo model without any signs of cardiovascular effects up to 10-fold above the first dose reaching 100% bronchoprotection.  The enantiomerically pure (R)-form of 4p exerted a bronchodilatory efficacy over 24 h in dogs and guinea pigs in the absence of systemic pharmacodynamic effects.  Formoterol which was tested as comparator in the same in vivo models of acetylcholine-induced bronchoconstriction did not retain efficacy after 24 h.  In summary, the preclin. profile of compd. (R)-4p (olodaterol, also known as BI 1744 CL) suggests a potential for once-daily dosing in man accompanied with an improved safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq_OHb0Lpw87Vg90H21EOLACvtfcHk0ljaAkwlgnoQrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslSmt7c%253D&md5=4527e1e074c1ee33eccc2d9f3293bdef</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.12.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.12.087%26sid%3Dliteratum%253Aachs%26aulast%3DBouyssou%26aufirst%3DT.%26aulast%3DHoenke%26aufirst%3DC.%26aulast%3DRudolf%26aufirst%3DK.%26aulast%3DLustenberger%26aufirst%3DP.%26aulast%3DPestel%26aufirst%3DS.%26aulast%3DSieger%26aufirst%3DP.%26aulast%3DLotz%26aufirst%3DR.%26aulast%3DHeine%26aufirst%3DC.%26aulast%3DButtner%26aufirst%3DF.%2BH.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DKonetzki%26aufirst%3DI.%26atitle%3DDiscovery%2520of%2520olodaterol%252C%2520a%2520novel%2520inhaled%2520%25CE%25B22-adrenoceptor%2520agonist%2520with%2520a%252024%2520h%2520bronchodilatory%2520efficacy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1410%26epage%3D1414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Gibb, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L. P.</span><span> </span><span class="NLM_article-title">Olodaterol: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1841</span><span class="NLM_x">–</span> <span class="NLM_lpage">1846</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1841-1846&author=A.+Gibbauthor=L.+P.+Yang&title=Olodaterol%3A+first+global+approval"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGibb%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DL.%2BP.%26atitle%3DOlodaterol%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D1841%26epage%3D1846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Connolly, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alcaraz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cadogan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphries, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingall, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairaudeau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stocks, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, A.</span><span> </span><span class="NLM_article-title">Design-driven LO: the discovery of new ultra long acting dibasic β<sub>2</sub>-adrenoceptor agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4612</span><span class="NLM_x">–</span> <span class="NLM_lpage">4616</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4612-4616&author=S.+Connollyauthor=L.+Alcarazauthor=A.+Baileyauthor=E.+Cadoganauthor=J.+Christieauthor=A.+R.+Cookauthor=A.+J.+Fisherauthor=S.+Hillauthor=A.+Humphriesauthor=A.+H.+Ingallauthor=Z.+Kaneauthor=S.+Paineauthor=G.+Pairaudeauauthor=M.+J.+Stocksauthor=A.+Young&title=Design-driven+LO%3A+the+discovery+of+new+ultra+long+acting+dibasic+%CE%B22-adrenoceptor+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DS.%26aulast%3DAlcaraz%26aufirst%3DL.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DCadogan%26aufirst%3DE.%26aulast%3DChristie%26aufirst%3DJ.%26aulast%3DCook%26aufirst%3DA.%2BR.%26aulast%3DFisher%26aufirst%3DA.%2BJ.%26aulast%3DHill%26aufirst%3DS.%26aulast%3DHumphries%26aufirst%3DA.%26aulast%3DIngall%26aufirst%3DA.%2BH.%26aulast%3DKane%26aufirst%3DZ.%26aulast%3DPaine%26aufirst%3DS.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26aulast%3DYoung%26aufirst%3DA.%26atitle%3DDesign-driven%2520LO%253A%2520the%2520discovery%2520of%2520new%2520ultra%2520long%2520acting%2520dibasic%2520%25CE%25B22-adrenoceptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4612%26epage%3D4616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Alcaraz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cadogan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kindon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lister, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dainty, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholls, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairaudeau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stocks, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorne, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, A.</span><span> </span><span class="NLM_article-title">From libraries to candidate: the discovery of new ultra long-acting dibasic β<sub>2</sub>-adrenoceptor agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">689</span><span class="NLM_x">–</span> <span class="NLM_lpage">695</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=689-695&author=L.+Alcarazauthor=A.+Baileyauthor=E.+Cadoganauthor=S.+Connollyauthor=R.+Jewellauthor=S.+Jordanauthor=N.+Kindonauthor=A.+Listerauthor=M.+Lawsonauthor=A.+Mullenauthor=I.+Daintyauthor=D.+Nichollsauthor=S.+Paineauthor=G.+Pairaudeauauthor=M.+J.+Stocksauthor=P.+Thorneauthor=A.+Young&title=From+libraries+to+candidate%3A+the+discovery+of+new+ultra+long-acting+dibasic+%CE%B22-adrenoceptor+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlcaraz%26aufirst%3DL.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DCadogan%26aufirst%3DE.%26aulast%3DConnolly%26aufirst%3DS.%26aulast%3DJewell%26aufirst%3DR.%26aulast%3DJordan%26aufirst%3DS.%26aulast%3DKindon%26aufirst%3DN.%26aulast%3DLister%26aufirst%3DA.%26aulast%3DLawson%26aufirst%3DM.%26aulast%3DMullen%26aufirst%3DA.%26aulast%3DDainty%26aufirst%3DI.%26aulast%3DNicholls%26aufirst%3DD.%26aulast%3DPaine%26aufirst%3DS.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26aulast%3DThorne%26aufirst%3DP.%26aulast%3DYoung%26aufirst%3DA.%26atitle%3DFrom%2520libraries%2520to%2520candidate%253A%2520the%2520discovery%2520of%2520new%2520ultra%2520long-acting%2520dibasic%2520%25CE%25B22-adrenoceptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D689%26epage%3D695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Beattie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brearley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuenoud, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairhurst, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gedeck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gosling, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janus, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oakman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stringer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuffnell, A.</span><span> </span><span class="NLM_article-title">A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta<sub>2</sub>-adrenoceptor agonists as inhaled long-acting bronchodilators</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5302</span><span class="NLM_x">–</span> <span class="NLM_lpage">5307</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5302-5307&author=D.+Beattieauthor=M.+Bradleyauthor=A.+Brearleyauthor=S.+J.+Charltonauthor=B.+M.+Cuenoudauthor=R.+A.+Fairhurstauthor=P.+Gedeckauthor=M.+Goslingauthor=D.+Janusauthor=D.+Jonesauthor=C.+Lewisauthor=C.+McCarthyauthor=H.+Oakmanauthor=R.+Stringerauthor=R.+J.+Taylorauthor=A.+Tuffnell&title=A+physical+properties+based+approach+for+the+exploration+of+a+4-hydroxybenzothiazolone+series+of+beta2-adrenoceptor+agonists+as+inhaled+long-acting+bronchodilators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeattie%26aufirst%3DD.%26aulast%3DBradley%26aufirst%3DM.%26aulast%3DBrearley%26aufirst%3DA.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DCuenoud%26aufirst%3DB.%2BM.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DGedeck%26aufirst%3DP.%26aulast%3DGosling%26aufirst%3DM.%26aulast%3DJanus%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMcCarthy%26aufirst%3DC.%26aulast%3DOakman%26aufirst%3DH.%26aulast%3DStringer%26aufirst%3DR.%26aulast%3DTaylor%26aufirst%3DR.%2BJ.%26aulast%3DTuffnell%26aufirst%3DA.%26atitle%3DA%2520physical%2520properties%2520based%2520approach%2520for%2520the%2520exploration%2520of%2520a%25204-hydroxybenzothiazolone%2520series%2520of%2520beta2-adrenoceptor%2520agonists%2520as%2520inhaled%2520long-acting%2520bronchodilators%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5302%26epage%3D5307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Sin, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, J. V.</span><span> </span><span class="NLM_article-title">Lack of association between ipratropium bromide and mortality in elderly patients with chronic obstructive airway disease</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">194</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2000&pages=194-197&author=D.+D.+Sinauthor=J.+V.+Tu&title=Lack+of+association+between+ipratropium+bromide+and+mortality+in+elderly+patients+with+chronic+obstructive+airway+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSin%26aufirst%3DD.%2BD.%26aulast%3DTu%26aufirst%3DJ.%2BV.%26atitle%3DLack%2520of%2520association%2520between%2520ipratropium%2520bromide%2520and%2520mortality%2520in%2520elderly%2520patients%2520with%2520chronic%2520obstructive%2520airway%2520disease%26jtitle%3DThorax%26date%3D2000%26volume%3D55%26spage%3D194%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Anthonisen, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connett, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiley, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altose, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buist, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, W. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enright, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanner, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Hara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scanlon, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tashkin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, R. A.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV<sub>1</sub>. The Lung Health Study</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">272</span><span class="NLM_x">, </span> <span class="NLM_fpage">1497</span><span class="NLM_x">–</span> <span class="NLM_lpage">1505</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1994&pages=1497-1505&author=N.+R.+Anthonisenauthor=J.+E.+Connettauthor=J.+P.+Kileyauthor=M.+D.+Altoseauthor=W.+C.+Baileyauthor=A.+S.+Buistauthor=W.+A.+Conwayauthor=P.+L.+Enrightauthor=R.+E.+Kannerauthor=P.+O%E2%80%99Haraauthor=G.+R.+Owensauthor=P.+D.+Scanlonauthor=D.+P.+Tashkinauthor=R.+A.+Wise&title=Effects+of+smoking+intervention+and+the+use+of+an+inhaled+anticholinergic+bronchodilator+on+the+rate+of+decline+of+FEV1.+The+Lung+Health+Study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAnthonisen%26aufirst%3DN.%2BR.%26aulast%3DConnett%26aufirst%3DJ.%2BE.%26aulast%3DKiley%26aufirst%3DJ.%2BP.%26aulast%3DAltose%26aufirst%3DM.%2BD.%26aulast%3DBailey%26aufirst%3DW.%2BC.%26aulast%3DBuist%26aufirst%3DA.%2BS.%26aulast%3DConway%26aufirst%3DW.%2BA.%26aulast%3DEnright%26aufirst%3DP.%2BL.%26aulast%3DKanner%26aufirst%3DR.%2BE.%26aulast%3DO%25E2%2580%2599Hara%26aufirst%3DP.%26aulast%3DOwens%26aufirst%3DG.%2BR.%26aulast%3DScanlon%26aufirst%3DP.%2BD.%26aulast%3DTashkin%26aufirst%3DD.%2BP.%26aulast%3DWise%26aufirst%3DR.%2BA.%26atitle%3DEffects%2520of%2520smoking%2520intervention%2520and%2520the%2520use%2520of%2520an%2520inhaled%2520anticholinergic%2520bronchodilator%2520on%2520the%2520rate%2520of%2520decline%2520of%2520FEV1.%2520The%2520Lung%2520Health%2520Study%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D1994%26volume%3D272%26spage%3D1497%26epage%3D1505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Tashkin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashutosh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleecker, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britt, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cugell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummiskey, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeLorenzo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lakshminarayan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maguire, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plummer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renzetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sackner, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skorodin, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, S.</span><span> </span><span class="NLM_article-title">Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. A 90-day multi-center study</span> <span class="citation_source-journal">Am. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2F0002-9343%2886%2990468-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=2947465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADyaL2s%252FntlCqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1986&pages=81-90&author=D.+P.+Tashkinauthor=K.+Ashutoshauthor=E.+R.+Bleeckerauthor=E.+J.+Brittauthor=D.+W.+Cugellauthor=J.+M.+Cummiskeyauthor=L.+DeLorenzoauthor=M.+J.+Gilmanauthor=G.+N.+Grossauthor=N.+J.+Grossauthor=A.+Kotchauthor=S.+Lakshminarayanauthor=G.+Maguireauthor=M.+Millerauthor=A.+Plummerauthor=A.+Renzettiauthor=M.+A.+Sacknerauthor=M.+S.+Skorodinauthor=A.+Wannerauthor=S.+Watanabe&title=Comparison+of+the+anticholinergic+bronchodilator+ipratropium+bromide+with+metaproterenol+in+chronic+obstructive+pulmonary+disease.+A+90-day+multi-center+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. A 90-day multi-center study</span></div><div class="casAuthors">Tashkin D P; Ashutosh K; Bleecker E R; Britt E J; Cugell D W; Cummiskey J M; DeLorenzo L; Gilman M J; Gross G N; Gross N J</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of medicine</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">5A</span>),
    <span class="NLM_cas:pages">81-90</span>
        ISSN:<span class="NLM_cas:issn">0002-9343</span>.
    </div><div class="casAbstract">The short- and long-term efficacy and safety of an inhaled quaternary ammonium anticholinergic agent, ipratropium bromide, and a beta agonist aerosol, metaproterenol, were compared in 261 nonatopic patients with chronic obstructive pulmonary disease (COPD).  The study was a randomized, double-blind, 90-day, parallel-group trial.  On three test days-one, 45, and 90-mean peak responses for forced expiratory volume in one second and forced vital capacity and mean area under the time-response curve were higher for ipratropium than for metaproterenol.  Clinical improvement was noted in both treatment groups, especially during the first treatment month, with persistence of improvement throughout the remainder of the study.  Side effects were relatively infrequent and generally mild; tremor, a complication of beta agonists, was not reported by any subject receiving ipratropium.  These results support the effectiveness and safety of long-term treatment with inhaled ipratropium in COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSuL6fox8M3jUNHe_gFldTbfW6udTcc2ebFeS_eo-DKfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2s%252FntlCqsQ%253D%253D&md5=fce8aaed4508db3ad685070a29845bfc</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2F0002-9343%2886%2990468-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0002-9343%252886%252990468-7%26sid%3Dliteratum%253Aachs%26aulast%3DTashkin%26aufirst%3DD.%2BP.%26aulast%3DAshutosh%26aufirst%3DK.%26aulast%3DBleecker%26aufirst%3DE.%2BR.%26aulast%3DBritt%26aufirst%3DE.%2BJ.%26aulast%3DCugell%26aufirst%3DD.%2BW.%26aulast%3DCummiskey%26aufirst%3DJ.%2BM.%26aulast%3DDeLorenzo%26aufirst%3DL.%26aulast%3DGilman%26aufirst%3DM.%2BJ.%26aulast%3DGross%26aufirst%3DG.%2BN.%26aulast%3DGross%26aufirst%3DN.%2BJ.%26aulast%3DKotch%26aufirst%3DA.%26aulast%3DLakshminarayan%26aufirst%3DS.%26aulast%3DMaguire%26aufirst%3DG.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DPlummer%26aufirst%3DA.%26aulast%3DRenzetti%26aufirst%3DA.%26aulast%3DSackner%26aufirst%3DM.%2BA.%26aulast%3DSkorodin%26aufirst%3DM.%2BS.%26aulast%3DWanner%26aufirst%3DA.%26aulast%3DWatanabe%26aufirst%3DS.%26atitle%3DComparison%2520of%2520the%2520anticholinergic%2520bronchodilator%2520ipratropium%2520bromide%2520with%2520metaproterenol%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease.%2520A%252090-day%2520multi-center%2520study%26jtitle%3DAm.%2520J.%2520Med.%26date%3D1986%26volume%3D81%26spage%3D81%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Chervinsky, P.</span><span> </span><span class="NLM_article-title">Concomitant bronchodilator therapy and ipratropium bromide. A clinical review</span> <span class="citation_source-journal">Am. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2F0002-9343%2886%2990465-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=2947463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADyaL2s%252FntlCqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1986&pages=67-73&author=P.+Chervinsky&title=Concomitant+bronchodilator+therapy+and+ipratropium+bromide.+A+clinical+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Concomitant bronchodilator therapy and ipratropium bromide. A clinical review</span></div><div class="casAuthors">Chervinsky P</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of medicine</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">5A</span>),
    <span class="NLM_cas:pages">67-73</span>
        ISSN:<span class="NLM_cas:issn">0002-9343</span>.
    </div><div class="casAbstract">This article reviews the use of ipratropium bromide concomitantly with other bronchodilators, with a focus on its use in patients with asthma.  Patients with asthma generally have demonstrated a greater response to the combination of ipratropium and other anti-asthma drugs than to either drug alone.  No increase in side effects has been observed when ipratropium has been used in combination with other bronchodilating drugs.  Overall, the combination of ipratropium with other agents appears to offer promise in therapy for asthma; further investigation of combinations in larger patient populations is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSuL6fox8M3jUH3Rlp_k91zfW6udTcc2ebFeS_eo-DKfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2s%252FntlCqsg%253D%253D&md5=dcc815f157d6ebf8d9f10f2e05c53638</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2F0002-9343%2886%2990465-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0002-9343%252886%252990465-1%26sid%3Dliteratum%253Aachs%26aulast%3DChervinsky%26aufirst%3DP.%26atitle%3DConcomitant%2520bronchodilator%2520therapy%2520and%2520ipratropium%2520bromide.%2520A%2520clinical%2520review%26jtitle%3DAm.%2520J.%2520Med.%26date%3D1986%26volume%3D81%26spage%3D67%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Wadbo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lofdahl, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skoogh, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tornling, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arwestrom, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bengtsson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strom, K.</span><span> </span><span class="NLM_article-title">Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1138</span><span class="NLM_x">–</span> <span class="NLM_lpage">1146</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.02.00301702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=12449166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD38XptlCmtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=1138-1146&author=M.+Wadboauthor=C.+G.+Lofdahlauthor=K.+Larssonauthor=B.+E.+Skooghauthor=G.+Tornlingauthor=E.+Arwestromauthor=T.+Bengtssonauthor=K.+Strom&title=Effects+of+formoterol+and+ipratropium+bromide+in+COPD%3A+a+3-month+placebo-controlled+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study</span></div><div class="casAuthors">Wadbo, M.; Loefdahl, C.-G.; Larsson, K.; Skoogh, B. E.; Tornling, G.; Arwestroem, E.; Bengtsson, T.; Stroem, K.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1138-1146</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">The aim of this study was to compare the effects of formoterol, ipratropium bromide and a placebo on walking distance, lung function, symptoms and quality of life (QoL) in chronic obstructive pulmonary disease (COPD) patients.  A total of 183 patients (mean age 64 yrs, 86 female) with moderate-to-severe nonreversible COPD participated in this randomized, double-blind, parallel-group study.  After a 2-wk placebo run-in, patients were randomized to formoterol Turbuhaler 18 μg b.i.d. (delivered dose), ipratropium bromide 80 μg t.i.d. via a pressurized metered dose inhaler, or placebo for 12 wk.  Inhaled short-acting β2-agonists were allowed as relief medication and inhaled glucocorticosteroids were allowed at a const. dose.  The primary variable was walking distance in the shuttle walking test (SWT).  Baseline mean SWT distance was 325 m, mean forced expiratory vol. in one second (FEV1) was 40% predicted.  Clin. significant improvements in SWT (>30 m) were seen in 41, 38 and 30% of formoterol, ipratropium and placebo patients, resp. (not significant).  Mean increases from run-in were 19, 17 and 5 m in the formoterol, ipratropium and placebo groups, resp.  Both active treatments significantly improved FEV1, forced vital capacity, peak expiratory flow and daytime dyspnea score compared with placebo.  Formoterol reduced relief medication use compared with placebo.  Neither active treatment improved QoL.  Formoterol and ipratropium improved airway function and symptoms, without significant improvements in the shuttle walking test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohe7INffhs47Vg90H21EOLACvtfcHk0liopOmGJOaVXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptlCmtrs%253D&md5=d5952c2092ab69bbccdb7c55d8cb4f5e</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1183%2F09031936.02.00301702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.02.00301702%26sid%3Dliteratum%253Aachs%26aulast%3DWadbo%26aufirst%3DM.%26aulast%3DLofdahl%26aufirst%3DC.%2BG.%26aulast%3DLarsson%26aufirst%3DK.%26aulast%3DSkoogh%26aufirst%3DB.%2BE.%26aulast%3DTornling%26aufirst%3DG.%26aulast%3DArwestrom%26aufirst%3DE.%26aulast%3DBengtsson%26aufirst%3DT.%26aulast%3DStrom%26aufirst%3DK.%26atitle%3DEffects%2520of%2520formoterol%2520and%2520ipratropium%2520bromide%2520in%2520COPD%253A%2520a%25203-month%2520placebo-controlled%2520study%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2002%26volume%3D20%26spage%3D1138%26epage%3D1146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Colice, G. L.</span><span> </span><span class="NLM_article-title">Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Am. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">11S</span><span class="NLM_x">–</span> <span class="NLM_lpage">18S</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=1996&pages=11S-18S&author=G.+L.+Colice&title=Nebulized+bronchodilators+for+outpatient+management+of+stable+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DColice%26aufirst%3DG.%2BL.%26atitle%3DNebulized%2520bronchodilators%2520for%2520outpatient%2520management%2520of%2520stable%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAm.%2520J.%2520Med.%26date%3D1996%26volume%3D100%26spage%3D11S%26epage%3D18S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">COMBIVENT Inhalation Aerosol Study Group</span><span> </span><span class="NLM_article-title">In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">1411</span><span class="NLM_x">–</span> <span class="NLM_lpage">1419</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=1994&pages=1411-1419&author=COMBIVENT+Inhalation+Aerosol+Study+Group&title=In+chronic+obstructive+pulmonary+disease%2C+a+combination+of+ipratropium+and+albuterol+is+more+effective+than+either+agent+alone.+An+85-day+multicenter+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DIn%2520chronic%2520obstructive%2520pulmonary%2520disease%252C%2520a%2520combination%2520of%2520ipratropium%2520and%2520albuterol%2520is%2520more%2520effective%2520than%2520either%2520agent%2520alone.%2520An%252085-day%2520multicenter%2520trial%26jtitle%3DChest%26date%3D1994%26volume%3D105%26spage%3D1411%26epage%3D1419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Gross, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tashkin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linberg, S.</span><span> </span><span class="NLM_article-title">Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group</span> <span class="citation_source-journal">Respiration</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">354</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1998&pages=354-362&author=N.+Grossauthor=D.+Tashkinauthor=R.+Millerauthor=J.+Orenauthor=W.+Colemanauthor=S.+Linberg&title=Inhalation+by+nebulization+of+albuterol-ipratropium+combination+%28Dey+combination%29+is+superior+to+either+agent+alone+in+the+treatment+of+chronic+obstructive+pulmonary+disease.+Dey+Combination+Solution+Study+Group"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGross%26aufirst%3DN.%26aulast%3DTashkin%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DOren%26aufirst%3DJ.%26aulast%3DColeman%26aufirst%3DW.%26aulast%3DLinberg%26aufirst%3DS.%26atitle%3DInhalation%2520by%2520nebulization%2520of%2520albuterol-ipratropium%2520combination%2520%2528Dey%2520combination%2529%2520is%2520superior%2520to%2520either%2520agent%2520alone%2520in%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease.%2520Dey%2520Combination%2520Solution%2520Study%2520Group%26jtitle%3DRespiration%26date%3D1998%26volume%3D65%26spage%3D354%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Friedman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serby, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menjoge, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilleman, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witek, T. J.,  Jr.</span><span> </span><span class="NLM_article-title">Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">635</span><span class="NLM_x">–</span> <span class="NLM_lpage">641</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=1999&pages=635-641&author=M.+Friedmanauthor=C.+W.+Serbyauthor=S.+S.+Menjogeauthor=J.+D.+Wilsonauthor=D.+E.+Hillemanauthor=T.+J.+Witek&title=Pharmacoeconomic+evaluation+of+a+combination+of+ipratropium+plus+albuterol+compared+with+ipratropium+alone+and+albuterol+alone+in+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFriedman%26aufirst%3DM.%26aulast%3DSerby%26aufirst%3DC.%2BW.%26aulast%3DMenjoge%26aufirst%3DS.%2BS.%26aulast%3DWilson%26aufirst%3DJ.%2BD.%26aulast%3DHilleman%26aufirst%3DD.%2BE.%26aulast%3DWitek%26aufirst%3DT.%2BJ.%26atitle%3DPharmacoeconomic%2520evaluation%2520of%2520a%2520combination%2520of%2520ipratropium%2520plus%2520albuterol%2520compared%2520with%2520ipratropium%2520alone%2520and%2520albuterol%2520alone%2520in%2520COPD%26jtitle%3DChest%26date%3D1999%26volume%3D115%26spage%3D635%26epage%3D641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Disse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speck, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rominger, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witek, T. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammer, R.</span><span> </span><span class="NLM_article-title">Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">457</span><span class="NLM_x">–</span> <span class="NLM_lpage">464</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=457-464&author=B.+Disseauthor=G.+A.+Speckauthor=K.+L.+Romingerauthor=T.+J.+Witekauthor=R.+Hammer&title=Tiotropium+%28Spiriva%29%3A+mechanistical+considerations+and+clinical+profile+in+obstructive+lung+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDisse%26aufirst%3DB.%26aulast%3DSpeck%26aufirst%3DG.%2BA.%26aulast%3DRominger%26aufirst%3DK.%2BL.%26aulast%3DWitek%26aufirst%3DT.%2BJ.%26aulast%3DHammer%26aufirst%3DR.%26atitle%3DTiotropium%2520%2528Spiriva%2529%253A%2520mechanistical%2520considerations%2520and%2520clinical%2520profile%2520in%2520obstructive%2520lung%2520disease%26jtitle%3DLife%2520Sci.%26date%3D1999%26volume%3D64%26spage%3D457%26epage%3D464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Calverley, P. M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towse, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Noord, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witek, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelsen, S.</span><span> </span><span class="NLM_article-title">Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">855</span><span class="NLM_x">–</span> <span class="NLM_lpage">860</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2003&pages=855-860&author=P.+M.+A.+Calverleyauthor=A.+Leeauthor=L.+Towseauthor=J.+van+Noordauthor=T.+J.+Witekauthor=S.+Kelsen&title=Effect+of+tiotropium+bromide+on+circadian+variation+in+airflow+limitation+in+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCalverley%26aufirst%3DP.%2BM.%2BA.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DTowse%26aufirst%3DL.%26aulast%3Dvan%2BNoord%26aufirst%3DJ.%26aulast%3DWitek%26aufirst%3DT.%2BJ.%26aulast%3DKelsen%26aufirst%3DS.%26atitle%3DEffect%2520of%2520tiotropium%2520bromide%2520on%2520circadian%2520variation%2520in%2520airflow%2520limitation%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DThorax%26date%3D2003%26volume%3D58%26spage%3D855%26epage%3D860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Barr, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourbeau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camargo, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ram, F. S.</span><span> </span><span class="NLM_article-title">Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">854</span><span class="NLM_x">–</span> <span class="NLM_lpage">862</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2006&pages=854-862&author=R.+G.+Barrauthor=J.+Bourbeauauthor=C.+A.+Camargoauthor=F.+S.+Ram&title=Tiotropium+for+stable+chronic+obstructive+pulmonary+disease%3A+a+meta-analysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBarr%26aufirst%3DR.%2BG.%26aulast%3DBourbeau%26aufirst%3DJ.%26aulast%3DCamargo%26aufirst%3DC.%2BA.%26aulast%3DRam%26aufirst%3DF.%2BS.%26atitle%3DTiotropium%2520for%2520stable%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520meta-analysis%26jtitle%3DThorax%26date%3D2006%26volume%3D61%26spage%3D854%26epage%3D862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Casaburi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briggs, D. D.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donohue, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serby, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menjoge, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witek, T. J.,  Jr.</span><span> </span><span class="NLM_article-title">The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">1294</span><span class="NLM_x">–</span> <span class="NLM_lpage">1302</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2000&pages=1294-1302&author=R.+Casaburiauthor=D.+D.+Briggsauthor=J.+F.+Donohueauthor=C.+W.+Serbyauthor=S.+S.+Menjogeauthor=T.+J.+Witek&title=The+spirometric+efficacy+of+once-daily+dosing+with+tiotropium+in+stable+COPD%3A+a+13-week+multicenter+trial.+The+US+Tiotropium+Study+Group"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCasaburi%26aufirst%3DR.%26aulast%3DBriggs%26aufirst%3DD.%2BD.%26aulast%3DDonohue%26aufirst%3DJ.%2BF.%26aulast%3DSerby%26aufirst%3DC.%2BW.%26aulast%3DMenjoge%26aufirst%3DS.%2BS.%26aulast%3DWitek%26aufirst%3DT.%2BJ.%26atitle%3DThe%2520spirometric%2520efficacy%2520of%2520once-daily%2520dosing%2520with%2520tiotropium%2520in%2520stable%2520COPD%253A%2520a%252013-week%2520multicenter%2520trial.%2520The%2520US%2520Tiotropium%2520Study%2520Group%26jtitle%3DChest%26date%3D2000%26volume%3D118%26spage%3D1294%26epage%3D1302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">van Noord, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bantje, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eland, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korducki, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelissen, P. J.</span><span> </span><span class="NLM_article-title">A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2000&pages=289-294&author=J.+A.+van+Noordauthor=T.+A.+Bantjeauthor=M.+E.+Elandauthor=L.+Korduckiauthor=P.+J.+Cornelissen&title=A+randomised+controlled+comparison+of+tiotropium+and+ipratropium+in+the+treatment+of+chronic+obstructive+pulmonary+disease.+The+Dutch+Tiotropium+Study+Group"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BNoord%26aufirst%3DJ.%2BA.%26aulast%3DBantje%26aufirst%3DT.%2BA.%26aulast%3DEland%26aufirst%3DM.%2BE.%26aulast%3DKorducki%26aufirst%3DL.%26aulast%3DCornelissen%26aufirst%3DP.%2BJ.%26atitle%3DA%2520randomised%2520controlled%2520comparison%2520of%2520tiotropium%2520and%2520ipratropium%2520in%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease.%2520The%2520Dutch%2520Tiotropium%2520Study%2520Group%26jtitle%3DThorax%26date%3D2000%26volume%3D55%26spage%3D289%26epage%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Niewoehner, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cote, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paulson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, J. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korducki, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassino, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S.</span><span> </span><span class="NLM_article-title">Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">143</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.7326%2F0003-4819-143-5-200509060-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=16144890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKgs7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2005&pages=317-326&author=D.+E.+Niewoehnerauthor=K.+Riceauthor=C.+Coteauthor=D.+Paulsonauthor=J.+A.+Cooperauthor=L.+Korduckiauthor=C.+Cassinoauthor=S.+Kesten&title=Prevention+of+exacerbations+of+chronic+obstructive+pulmonary+disease+with+tiotropium%2C+a+once-daily+inhaled+anticholinergic+bronchodilator%3A+a+randomized+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial</span></div><div class="casAuthors">Niewoehner, Dennis E.; Rice, Kathryn; Cote, Claudia; Paulson, Daniel; Cooper, Allen D., Jr.; Korducki, Larry; Cassino, Cara; Kesten, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Internal Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">317-326</span>CODEN:
                <span class="NLM_cas:coden">AIMEAS</span>;
        ISSN:<span class="NLM_cas:issn">0003-4819</span>.
    
            (<span class="NLM_cas:orgname">American College of Physicians</span>)
        </div><div class="casAbstract">Background: Patients with chronic obstructive pulmonary disease (COPD) frequently develop exacerbations, leading to major clin. and health resource use ramifications.  Objective: To prospectively evaluate the effectiveness of a long-acting inhaled anticholinergic bronchodilator, tiotropium, in reducing COPD exacerbations and exacerbation-related health care utilization.  Design: Randomized, double-blind study.  Setting: 26 Veterans Affairs medical centers.  Patients: 1829 patients with moderate to severe COPD (mean baseline FEV1, 36% predicted).  Intervention: Once-daily tiotropium (18 μg) or placebo for 6 mo.  Patients otherwise received usual care, except for other anticholinergic bronchodilators.  Measurements: The coprimary end points were the percentage of patients with a COPD exacerbation and the percentage of patients with a COPD-related hospitalization.  Results: Tiotropium significantly reduced the percentage of patients experiencing 1 or more exacerbations compared with placebo (27.9% vs. 32.3%, resp.; difference, -5.7 percentage points [95% CI, -10.4 to -1.0 percentage points]; P = 0.037).  Fewer tiotropium patients were hospitalized because of COPD exacerbation (7.0% vs. 9.5%, resp.; difference, -3.0 percentage points [CI, -5.9 to -0.1 percentage points]; P = 0.056), although this difference was of borderline statistical significance.  Anal. of secondary outcomes indicates that tiotropium may lengthen the time to first COPD exacerbation (P= 0.028) and reduce health care utilization for exacerbations, including the frequency of hospitalizations (P = 0.047), unscheduled clinic visits (P = 0.019), and days of antibiotic treatment (P = 0.015).  Tiotropium did not statistically significantly reduce all-cause hospitalization rates.  Limitations: Trial participants were enrolled from 1 health care system, and 99% were men.  The follow-up period extended for only 6 mo.  Conclusions: Tiotropium reduces COPD exacerbations and may reduce related health care utilization in patients with moderate to severe COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot1pxR3blT1rVg90H21EOLACvtfcHk0liA3kAUIxhUfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKgs7jK&md5=3538aa381c51cee08198c104852aac23</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-143-5-200509060-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-143-5-200509060-00007%26sid%3Dliteratum%253Aachs%26aulast%3DNiewoehner%26aufirst%3DD.%2BE.%26aulast%3DRice%26aufirst%3DK.%26aulast%3DCote%26aufirst%3DC.%26aulast%3DPaulson%26aufirst%3DD.%26aulast%3DCooper%26aufirst%3DJ.%2BA.%26aulast%3DKorducki%26aufirst%3DL.%26aulast%3DCassino%26aufirst%3DC.%26aulast%3DKesten%26aufirst%3DS.%26atitle%3DPrevention%2520of%2520exacerbations%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520with%2520tiotropium%252C%2520a%2520once-daily%2520inhaled%2520anticholinergic%2520bronchodilator%253A%2520a%2520randomized%2520trial%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2005%26volume%3D143%26spage%3D317%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Casaburi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahler, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">San, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ZuWallack, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menjoge, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serby, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witek, T.,  Jr.</span><span> </span><span class="NLM_article-title">A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">224</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.02.00269802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=11866001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD38XitVKgu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2002&pages=217-224&author=R.+Casaburiauthor=D.+A.+Mahlerauthor=P.+W.+Jonesauthor=A.+Wannerauthor=P.+G.+Sanauthor=R.+L.+ZuWallackauthor=S.+S.+Menjogeauthor=C.+W.+Serbyauthor=T.+Witek&title=A+long-term+evaluation+of+once-daily+inhaled+tiotropium+in+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Casaburi, R.; Mahler, D. A.; Jones, P. W.; Wanner, A.; San Pedro, G.; ZuWallack, R. L.; Menjoge, S. S.; Serby, C. W.; Witek, T., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-224</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Currently available inhaled bronchodilators used as therapy for chronic obstructive pulmonary disease (COPD) necessitate multiple daily dosing.  The present study evaluates the long-term safety and efficacy of tiotropium, a new once-daily anticholinergic in COPD.  Patients with stable COPD (age 65.2±8.7 yrs (mean±SD), n=921) were enrolled in two identical randomized double-blind placebo-controlled 1-yr studies.  Patients inhaled tiotropium 18 μg or placebo (mean screening forced expiratory vol. in one second (FEV1) 1.01 vs. 0.99 L, 39.1 and 38.1% of the predicted value) once daily as a dry powder.  The primary spirometric outcome was trough FEV1 (i.e. FEV1 prior to dosing).  Changes in dyspnea were measured using the Transition Dyspnea Index, and health status with the disease-specific St. George's Respiratory Questionnaire and the generic Short Form 36.  Medication use and adverse events were recorded.  Tiotropium provided significantly superior bronchodilation relative to placebo for trough FEV1 response (∼12% over baseline) (p<0.01) and mean response during the 3 h following dosing (∼22% over baseline) (p<0.001) over the 12-mo period.  Tiotropium recipients showed less dyspnea (p<0.001), superior health status scores, and fewer COPD exacerbations and hospitalizations (p<0.05).  Adverse events were comparable with placebo, except for dry mouth incidence (tiotropium 16.0% vs. placebo 2.7%, p<0.05).  Tiotropium is an effective, once-daily bronchodilator that reduces dyspnea and chronic obstructive pulmonary disease exacerbation frequency and improves health status.  This suggests that tiotropium will make an important contribution to chronic obstructive pulmonary disease therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFFCXDqogoHrVg90H21EOLACvtfcHk0ljP8JTHo5CZgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitVKgu7g%253D&md5=47f4052c4b78f43f2fa1da71521164a9</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1183%2F09031936.02.00269802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.02.00269802%26sid%3Dliteratum%253Aachs%26aulast%3DCasaburi%26aufirst%3DR.%26aulast%3DMahler%26aufirst%3DD.%2BA.%26aulast%3DJones%26aufirst%3DP.%2BW.%26aulast%3DWanner%26aufirst%3DA.%26aulast%3DSan%26aufirst%3DP.%2BG.%26aulast%3DZuWallack%26aufirst%3DR.%2BL.%26aulast%3DMenjoge%26aufirst%3DS.%2BS.%26aulast%3DSerby%26aufirst%3DC.%2BW.%26aulast%3DWitek%26aufirst%3DT.%26atitle%3DA%2520long-term%2520evaluation%2520of%2520once-daily%2520inhaled%2520tiotropium%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2002%26volume%3D19%26spage%3D217%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">O’Donnell, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flüge, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerken, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguilaniu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Make, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnussen, H.</span><span> </span><span class="NLM_article-title">Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">832</span><span class="NLM_x">–</span> <span class="NLM_lpage">840</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.04.00116004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=15218994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsF2qt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=832-840&author=D.+E.+O%E2%80%99Donnellauthor=T.+Fl%C3%BCgeauthor=F.+Gerkenauthor=A.+Hamiltonauthor=K.+Webbauthor=B.+Aguilaniuauthor=B.+Makeauthor=H.+Magnussen&title=Effects+of+tiotropium+on+lung+hyperinflation%2C+dyspnoea+and+exercise+tolerance+in+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD</span></div><div class="casAuthors">O'Donnell, D. E.; Fluge, T.; Gerken, F.; Hamilton, A.; Webb, K.; Aguilaniu, B.; Make, B.; Magnussen, H.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">832-840</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">The aim of this study was to test the hypothesis that use of tiotropium, a new long-acting anticholinergic bronchodilator, would be assocd. with sustained redn. in lung hyperinflation and, thereby, would improve exertional dyspnoea and exercise performance in patients with chronic obstructive pulmonary disease.  A randomised, double-blind, placebo-controlled, parallel-group study was conducted in 187 patients (forced expiratory vol. in one second 44±13% pred): 96 patients received 18 μg tiotropium and 91 patients received placebo once daily for 42 days.  Spirometry, plethysmog. lung vols., cycle exercise endurance and exertional dyspnoea intensity at 75% of each patient's maximal work capacity were compared.  On day 42, the use of tiotropium was assocd. with the following effects at pre-dose and post-dose measurements as compared to placebo: vital capacity and inspiratory capacity (IC) increased, with inverse decreases in residual vol. and functional residual capacity.  Tiotropium increased post-dose exercise endurance time by 105±40 s (21%) as compared to placebo on day 42.  At a standardized time near end-exercise (isotime), IC, tidal vol. and minute ventilation all increased, while dyspnoea decreased by 0.9±0.3 Borg scale units.  In conclusion, the use of tiotropium was assocd. with sustained redns. of lung hyperinflation at rest and during exercise.  Resultant increases in inspiratory capacity permitted greater expansion of tidal vol. and contributed to improvements in both exertional dyspnoea and exercise endurance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAakdNLFWXS7Vg90H21EOLACvtfcHk0ljP8JTHo5CZgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsF2qt7g%253D&md5=bfdc506331ccf3657ed837908b6f0227</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1183%2F09031936.04.00116004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.04.00116004%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DD.%2BE.%26aulast%3DFl%25C3%25BCge%26aufirst%3DT.%26aulast%3DGerken%26aufirst%3DF.%26aulast%3DHamilton%26aufirst%3DA.%26aulast%3DWebb%26aufirst%3DK.%26aulast%3DAguilaniu%26aufirst%3DB.%26aulast%3DMake%26aufirst%3DB.%26aulast%3DMagnussen%26aufirst%3DH.%26atitle%3DEffects%2520of%2520tiotropium%2520on%2520lung%2520hyperinflation%252C%2520dyspnoea%2520and%2520exercise%2520tolerance%2520in%2520COPD%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2004%26volume%3D23%26spage%3D832%26epage%3D840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">McNicholas, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calverley, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiotropium Sleep Study in COPD Investigators.</span><span> </span><span class="NLM_article-title">Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">825</span><span class="NLM_x">–</span> <span class="NLM_lpage">831</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.04.00085804" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=15218993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsF2qt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=825-831&author=W.+T.+McNicholasauthor=P.+M.+Calverleyauthor=A.+Leeauthor=J.+C.+Edwardsauthor=Tiotropium+Sleep+Study+in+COPD+Investigators.&title=Long-acting+inhaled+anticholinergic+therapy+improves+sleeping+oxygen+saturation+in+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD</span></div><div class="casAuthors">McNicholas, W. T.; Calverley, P. M. A.; Lee, A.; Edwards, J. C.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">825-831</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Oxygen desatn. occurs during sleep in severe chronic obstructive pulmonary disease (COPD), esp. during rapid eye movement (REM) sleep, due to hypoventilation and ventilation-perfusion mismatching, but the possible contribution of airflow limitation is unclear.  In a randomised, placebo-controlled, double-blind study of severe, stable COPD patients, the authors compared 4 wk treatment with a long-acting inhaled anticholinergic agent (tiotropium), taken in the morning (tiotropium-AM), or in the evening (tiotropium-PM), on sleeping arterial oxygen satn. (Sa,O2) and sleep quality.  Overnight polysomnog. was performed at baseline and after 4 wk treatment.  A total of 95 patients with awake resting arterial oxygen tension ≤9.98 kPa (75 mmHg) were randomised, with a mean age of 66.4 yrs and mean forced expiratory vol. in one second (FEV1) of 32% predicted.  A total of 80 patients completed the study, of which 56 fulfilled the polysomnog. criterion of at least 2 h sleep in both sleep study nights and represent the group analyzed.  Tiotropium significantly improved spirometry compared with placebo.  Both tiotropium-AM and tiotropium-PM groups had higher Sa,O2 during REM than placebo (+2.41% and +2.42%, resp.), and both pooled and tiotropium-PM groups had higher Sa,O2 during total sleep time (+2.49% and +3.06%, resp.).  End-of-treatment FEV1 correlated with Sa,O2 during REM sleep, however, tiotropium did not change sleep quality.  Sustained anticholinergic blockade improves sleeping arterial oxygen satn. without affecting sleep quality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroDXeV5w-G1rVg90H21EOLACvtfcHk0liasOrglT0nHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsF2qt7o%253D&md5=2d30f8947466b27ec175560d4179131e</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1183%2F09031936.04.00085804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.04.00085804%26sid%3Dliteratum%253Aachs%26aulast%3DMcNicholas%26aufirst%3DW.%2BT.%26aulast%3DCalverley%26aufirst%3DP.%2BM.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DEdwards%26aufirst%3DJ.%2BC.%26aulast%3D%26atitle%3DLong-acting%2520inhaled%2520anticholinergic%2520therapy%2520improves%2520sleeping%2520oxygen%2520saturation%2520in%2520COPD%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2004%26volume%3D23%26spage%3D825%26epage%3D831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Tashkin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S.</span><span> </span><span class="NLM_article-title">Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">1441</span><span class="NLM_x">–</span> <span class="NLM_lpage">1449</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2003&pages=1441-1449&author=D.+Tashkinauthor=S.+Kesten&title=Long-term+treatment+benefits+with+tiotropium+in+COPD+patients+with+and+without+short-term+bronchodilator+responses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTashkin%26aufirst%3DD.%26aulast%3DKesten%26aufirst%3DS.%26atitle%3DLong-term%2520treatment%2520benefits%2520with%2520tiotropium%2520in%2520COPD%2520patients%2520with%2520and%2520without%2520short-term%2520bronchodilator%2520responses%26jtitle%3DChest%26date%3D2003%26volume%3D123%26spage%3D1441%26epage%3D1449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Tashkin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkhart, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menjoge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decramer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">UPLIFT Study Investigators.</span><span> </span><span class="NLM_article-title">A four-year trial of tiotropium in chronic obstructive pulmonary disease</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">359</span><span class="NLM_x">, </span> <span class="NLM_fpage">1543</span><span class="NLM_x">–</span> <span class="NLM_lpage">1554</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1056%2FNEJMoa0805800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=18836213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1WgsrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2008&pages=1543-1554&author=D.+P.+Tashkinauthor=B.+Celliauthor=S.+Sennauthor=D.+Burkhartauthor=S.+Kestenauthor=S.+Menjogeauthor=M.+Decramerauthor=UPLIFT+Study+Investigators.&title=A+four-year+trial+of+tiotropium+in+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">A 4-year trial of tiotropium in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Tashkin, Donald P.; Celli, Bartolome; Senn, Stephen; Burkhart, Deborah; Kesten, Steven; Menjoge, Shailendra; Decramer, Marc</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1543-1554</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Previous studies showing that tiotropium improves multiple end points in patients with chronic obstructive pulmonary disease (COPD) led us to examine the longterm effects of tiotropium therapy.  Methods: In this randomized, double-blind trial, we compared 4 years of therapy with either tiotropium or placebo in patients with COPD who were permitted to use all respiratory medications except inhaled anticholinergic drugs.  The patients were at least 40 years of age, with a forced expiratory vol. in 1 s (FEV1) of 70% or less after bronchodilation and a ratio of FEV1 to forced vital capacity (FVC) of 70% or less.  Coprimary end points were the rate of decline in the mean FEV1 before and after bronchodilation beginning on day 30.  Secondary end points included measures of FVC, changes in response on St.  George's Respiratory Questionnaire (SGRQ), exacerbations of COPD, and mortality.  Results: Of a total of 5993 patients (mean age, 65 ± 8 years) with a mean FEV1 of 1.32 ± 0.44 L after bronchodilation (48% of predicted value), we randomly assigned 2987 to the tiotropium group and 3006 to the placebo group.  Mean abs. improvements in FEV, in the tiotropium group were maintained throughout the trial (ranging from 87 to 103 mL before bronchodilation and from 47 to 65 mL after bronchodilation), as compared with the placebo group (P < 0.001).  After day 30, the differences between the two groups in the rate of decline in the mean FEV, before and after bronchodilation were not significant.  The mean abs. total score on the SGRQ was improved (lower) in the tiotropium group, as compared with the placebo group, at each time point throughout the 4-yr period (ranging from 2.3 to 3.3 units, P < 0.001).  At 4 years and 30 days, tiotropium was assocd. with a redn. in the risks of exacerbations, related hospitalizations, and respiratory failure.  Conclusions: In patients with COPD, therapy with tiotropium was assocd. with improvements in lung function, quality of life, and exacerbations during a 4-yr period but did not significantly reduce the rate of decline in FEV1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTh6idIwH0mbVg90H21EOLACvtfcHk0liasOrglT0nHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1WgsrjJ&md5=018fee7a91d4637c2379473ab7d5fb5a</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0805800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0805800%26sid%3Dliteratum%253Aachs%26aulast%3DTashkin%26aufirst%3DD.%2BP.%26aulast%3DCelli%26aufirst%3DB.%26aulast%3DSenn%26aufirst%3DS.%26aulast%3DBurkhart%26aufirst%3DD.%26aulast%3DKesten%26aufirst%3DS.%26aulast%3DMenjoge%26aufirst%3DS.%26aulast%3DDecramer%26aufirst%3DM.%26aulast%3D%26atitle%3DA%2520four-year%2520trial%2520of%2520tiotropium%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D359%26spage%3D1543%26epage%3D1554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Decramer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lystig, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tashkin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">UPLIFT Investigators.</span><span> </span><span class="NLM_article-title">Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">374</span><span class="NLM_x">, </span> <span class="NLM_fpage">1171</span><span class="NLM_x">–</span> <span class="NLM_lpage">1178</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2009&pages=1171-1178&author=M.+Decramerauthor=B.+Celliauthor=S.+Kestenauthor=T.+Lystigauthor=S.+Mehraauthor=D.+P.+Tashkinauthor=UPLIFT+Investigators.&title=Effect+of+tiotropium+on+outcomes+in+patients+with+moderate+chronic+obstructive+pulmonary+disease+%28UPLIFT%29%3A+a+prespecified+subgroup+analysis+of+a+randomised+controlled+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDecramer%26aufirst%3DM.%26aulast%3DCelli%26aufirst%3DB.%26aulast%3DKesten%26aufirst%3DS.%26aulast%3DLystig%26aufirst%3DT.%26aulast%3DMehra%26aufirst%3DS.%26aulast%3DTashkin%26aufirst%3DD.%2BP.%26aulast%3D%26atitle%3DEffect%2520of%2520tiotropium%2520on%2520outcomes%2520in%2520patients%2520with%2520moderate%2520chronic%2520obstructive%2520pulmonary%2520disease%2520%2528UPLIFT%2529%253A%2520a%2520prespecified%2520subgroup%2520analysis%2520of%2520a%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2009%26volume%3D374%26spage%3D1171%26epage%3D1178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Tashkin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lystig, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decramer, M.</span><span> </span><span class="NLM_article-title">Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.00082909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=19717481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtV2jtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=287-294&author=D.+P.+Tashkinauthor=B.+Celliauthor=S.+Kestenauthor=T.+Lystigauthor=S.+Mehraauthor=M.+Decramer&title=Long-term+efficacy+of+tiotropium+in+relation+to+smoking+status+in+the+UPLIFT+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial</span></div><div class="casAuthors">Tashkin, D. P.; Celli, B.; Kesten, S.; Lystig, T.; Mehra, S.; Decramer, M.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">287-294</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">UPLIFT (Understanding Potential Long-Term Improvements in Function with Tiotropium), a 4-yr trial of tiotropium in chronic obstructive pulmonary disease, allowed for assessment of smoking status on long-term responses to maintenance bronchodilator therapy.  5,993 Patients were randomised (tiotropium/placebo).  Lung function, St George's Respiratory Questionnaire, exacerbations and adverse events were followed.  Patients were characterised as continuing smokers (CS), continuing ex-smokers (CE), or intermittent smokers (IS) based on self-reporting smoking behavior.  60%, 14% And 26% of patients were CE, CS and IS, resp.  The rate of forced expiratory vol. in 1 s (FEV1) decline for placebo patients was most rapid in CS (-51±4, -36±2 and -23±2 mL·yr-1 in CS, IS, and CE, resp.).  Tiotropium did not alter FEV1 decline, but was assocd. with significant improvements in pre- and post-bronchodilator FEV1 over placebo that persisted throughout the 4-yr trial for each smoking status (pre-bronchodilator: 125, 55 and 97 mL at 48 mo in CS, IS and CE, resp.; p≤0.0003).  Tiotropium reduced exacerbation risk in CS (HR (95%CI) 0.81 (0.68-0.97)), in CE (0.86 (0.79-0.93)) and trended towards significance in IS (0.89 (0.80-1.01)).  At 4 yrs, St George's Respiratory Questionnaire for tiotropium patients improved the most in CS (-4.62 units, p = 0.0006) and the least in IS (-0.54 units, p = 0.55), compared with control.  Tiotropium provided long-term benefits irresp. of smoking status, although differences among categories were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriG43pvPPhVLVg90H21EOLACvtfcHk0li9kB6o7KM-1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtV2jtbo%253D&md5=824cb7fa0c4c92edf0043ff5b19c53ab</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1183%2F09031936.00082909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00082909%26sid%3Dliteratum%253Aachs%26aulast%3DTashkin%26aufirst%3DD.%2BP.%26aulast%3DCelli%26aufirst%3DB.%26aulast%3DKesten%26aufirst%3DS.%26aulast%3DLystig%26aufirst%3DT.%26aulast%3DMehra%26aufirst%3DS.%26aulast%3DDecramer%26aufirst%3DM.%26atitle%3DLong-term%2520efficacy%2520of%2520tiotropium%2520in%2520relation%2520to%2520smoking%2520status%2520in%2520the%2520UPLIFT%2520trial%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2010%26volume%3D35%26spage%3D287%26epage%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Celli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decramer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tashkin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">UPLIFT Study Investigators.</span><span> </span><span class="NLM_article-title">Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">180</span><span class="NLM_x">, </span> <span class="NLM_fpage">948</span><span class="NLM_x">–</span> <span class="NLM_lpage">955</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1164%2Frccm.200906-0876OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=19729663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFahur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2009&pages=948-955&author=B.+Celliauthor=M.+Decramerauthor=S.+Kestenauthor=D.+Liuauthor=S.+Mehraauthor=D.+P.+Tashkinauthor=UPLIFT+Study+Investigators.&title=Mortality+in+the+4-year+trial+of+tiotropium+%28UPLIFT%29+in+patients+with+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease</span></div><div class="casAuthors">Celli, Bartolome; Decramer, Marc; Kesten, Steven; Liu, Dacheng; Mehra, Sunil; Tashkin, Donald P.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">948-955</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: In the 4-yr UPLIFT trial, tiotropium improved lung function and health-related quality of life and decreased exacerbations compared with usual respiratory medications except inhaled anticholinergics in patients with chronic obstructive pulmonary disease (COPD).  Mortality and its causes was a secondary endpoint in UPLIFT.  Objectives: We describe the effect of tiotropium on survival and analyze differences between mortality during treatment and during follow-up of discontinued patients.  Methods: This study involved a randomized, double-blind trial comparing tiotropium with placebo in patients with COPD (≥40 yr of age; postbronchodilator FEV1 ≤70%; FEV1/FVC ≤70%).  Mortality was evaluated during treatment and with follow-up of discontinued patients.  Cause of death was adjudicated by an endpoint committee.  Measurements and Main Results: A total of 5,993 patients were randomized, 3,006 to placebo and 2,987 to tiotropium.  While patients were receiving treatment, there were 792 deaths, with a lower risk in the tiotropium group (hazard ratio, 0.84; 95% confidence interval [CI], 0.73-0.97).  Statistical significance was obsd. at the end of the protocol-defined treatment period (P = 0.034) but not 30 days thereafter (P = 0.086).  Adjustment by COLD stage, sex, age, baseline smoking behavior, and baseline respiratory medications subgroups did not alter the results of the anal.  The most common causes of death adjudicated by an independent end-point committee were lower respiratory, cancer, general disorders, and cardiac disorders.  The hazard ratios for lower respiratory and cardiac mortality during treatment were 0.86 (95% CI, 0.68-1.09) and 0.86 (95% CI, 0.75-0.99), resp.  Conclusions: Treatment with tiotropium over 4 years is assocd. with decreased mortality, with the effect being most prominent in the cardiac and respiratory systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVXI-MiN1KWbVg90H21EOLACvtfcHk0li9kB6o7KM-1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFahur%252FF&md5=2df4322f834620b15a9d30087f001943</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1164%2Frccm.200906-0876OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200906-0876OC%26sid%3Dliteratum%253Aachs%26aulast%3DCelli%26aufirst%3DB.%26aulast%3DDecramer%26aufirst%3DM.%26aulast%3DKesten%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DMehra%26aufirst%3DS.%26aulast%3DTashkin%26aufirst%3DD.%2BP.%26aulast%3D%26atitle%3DMortality%2520in%2520the%25204-year%2520trial%2520of%2520tiotropium%2520%2528UPLIFT%2529%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2009%26volume%3D180%26spage%3D948%26epage%3D955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Dusser, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravo, M.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacono, P.</span><span> </span><span class="NLM_article-title">The effect of tiotropium on exacerbations and airflow in patients with COPD</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">547</span><span class="NLM_x">–</span> <span class="NLM_lpage">555</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.06.00062705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=16507855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtVKqtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=547-555&author=D.+Dusserauthor=M.-L.+Bravoauthor=P.+Iacono&title=The+effect+of+tiotropium+on+exacerbations+and+airflow+in+patients+with+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of tiotropium on exacerbations and airflow in patients with COPD</span></div><div class="casAuthors">Dusser, D.; Bravo, M.-L.; Iacono, P.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">547-555</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">This randomized, double-blind, parallel-group, 1-yr study compared the effect of tiotropium 18 μg once daily (n = 500) and placebo (n = 510) on exacerbations, assocd. health resource use (HRU) and airflow limitation in chronic obstructive pulmonary disease (COPD) patients.  The mean ± SD no. of exacerbations during the past year was 2.14 ± 1.40, the mean weekly morning peak expiratory flow (PEF) was 259.6 ± 96.1 L·min-1 and the mean forced expiratory vol. in one second (FEV1) was 1.37 ± 0.45 L.  Tiotropium significantly delayed the time to first exacerbation by ∼100 days, reduced the proportion of patients experiencing more than one exacerbation by 17%, and decreased the no. of exacerbations by 35% and exacerbation days by 37% vs. placebo.  Tiotropium also decreased HRU vs. placebo, as indicated by the significant redns. in the use of concomitant respiratory medications, antibiotics and oral steroids, and the no. of unscheduled physician contacts.  Mean weekly morning PEF improved significantly with tiotropium vs. placebo from week 1 until the end of the study.  At the end of the study, tiotropium significantly improved trough (pre-dose) FEV1, forced vital capacity, slow vital capacity and inspiratory capacity vs. placebo.  In conclusion, tiotropium reduced exacerbations and assocd. health resource use, and improved airflow over 1 yr in chronic obstructive pulmonary disease patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLLj0h8L4MlLVg90H21EOLACvtfcHk0li9kB6o7KM-1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtVKqtbc%253D&md5=c573d56fc0bc606fcafb65c6ea45adfb</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1183%2F09031936.06.00062705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.06.00062705%26sid%3Dliteratum%253Aachs%26aulast%3DDusser%26aufirst%3DD.%26aulast%3DBravo%26aufirst%3DM.-L.%26aulast%3DIacono%26aufirst%3DP.%26atitle%3DThe%2520effect%2520of%2520tiotropium%2520on%2520exacerbations%2520and%2520airflow%2520in%2520patients%2520with%2520COPD%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2006%26volume%3D27%26spage%3D547%26epage%3D555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Powrie, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, T. M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donaldson, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scrine, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedzicha, J. A.</span><span> </span><span class="NLM_article-title">Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">472</span><span class="NLM_x">–</span> <span class="NLM_lpage">478</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.00023907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=17504798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGgsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2007&pages=472-478&author=D.+J.+Powrieauthor=T.+M.+A.+Wilkinsonauthor=G.+C.+Donaldsonauthor=P.+Jonesauthor=K.+Scrineauthor=K.+Vielauthor=S.+Kestenauthor=J.+A.+Wedzicha&title=Effect+of+tiotropium+on+sputum+and+serum+inflammatory+markers+and+exacerbations+in+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD</span></div><div class="casAuthors">Powrie, D. J.; Wilkinson, T. M. A.; Donaldson, G. C.; Jones, P.; Scrine, K.; Viel, K.; Kesten, S.; Wedzicha, J. A.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">472-478</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) patients experiencing frequent exacerbations demonstrate increased stable-state airway inflammation.  Tiotropium has been shown to reduce exacerbation frequency, but its effect on airway inflammation is unknown.  The aim of the present study was to investigate the effect of tiotropium on sputum inflammatory markers and exacerbation frequency.  Patients (n = 142) were randomized to receive tiotropium or placebo in addn. to their usual medication for 1 yr.  Sputum and serum cytokines were assayed by ELISA and exacerbation frequency calcd. using a symptom-based diary.  There was no difference in the area under the curve for sputum interleukin (IL)-6 or myeloperoxidase between the groups, but sputum IL-8 level was increased in the tiotropium arm.  There was no difference between start and end of study in serum IL-6 or C-reactive protein level.  Tiotropium was assocd. with a 52% redn. in exacerbation frequency (1.17 vs. 2.46 exacerbations yr-1).  Of patients on tiotropium, 43% experienced at least one exacerbation, compared with 64% on placebo.  The total no. of exacerbation days was reduced compared with placebo (17.3 vs. 34.5 days).  Tiotropium reduces exacerbation frequency in chronic obstructive pulmonary disease, but this effect does not appear to be due to a redn. in airway or systemic inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNrrPRfCQFBrVg90H21EOLACvtfcHk0lg-nGVHw6b2Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGgsbzE&md5=b320abde10710f1ea1c9eacaf61939d4</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1183%2F09031936.00023907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00023907%26sid%3Dliteratum%253Aachs%26aulast%3DPowrie%26aufirst%3DD.%2BJ.%26aulast%3DWilkinson%26aufirst%3DT.%2BM.%2BA.%26aulast%3DDonaldson%26aufirst%3DG.%2BC.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DScrine%26aufirst%3DK.%26aulast%3DViel%26aufirst%3DK.%26aulast%3DKesten%26aufirst%3DS.%26aulast%3DWedzicha%26aufirst%3DJ.%2BA.%26atitle%3DEffect%2520of%2520tiotropium%2520on%2520sputum%2520and%2520serum%2520inflammatory%2520markers%2520and%2520exacerbations%2520in%2520COPD%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2007%26volume%3D30%26spage%3D472%26epage%3D478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Rodrigo, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nannini, L. J.</span><span> </span><span class="NLM_article-title">Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis</span> <span class="citation_source-journal">Pulm. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.pupt.2006.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=16621638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvFyksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=495-502&author=G.+J.+Rodrigoauthor=L.+J.+Nannini&title=Tiotropium+for+the+treatment+of+stable+chronic+obstructive+pulmonary+disease%3A+a+systematic+review+with+meta-analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Tiotropium for the treatment of stable chronic obstructive pulmonary disease: A systematic review with meta-analysis</span></div><div class="casAuthors">Rodrigo, Gustavo J.; Nannini, Luis J.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">495-502</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Background: Current guidelines recommend the use of inhaled tiotropium in patients with stable chronic obstructive pulmonary disease (COPD).  However, this statement is based on a relatively small no. of randomized controlled trials (RCTs) and related systematic reviews.  This review was undertaken to incorporate the more recent evidence available about the effectiveness of tiotropium bromide compared with placebo, iptratropium bromide or long-acting beta-agonists (LABAs), for the treatment of stable COPD patients.  Data source: Medline, EMBASE, CINAHL, and the Cochrane Controlled Trials Register (to Feb. 2006) were searched to identify all published RCTs.  We also searched bibliogs. of relevant articles.  Results: Data from 13 RCT (6078 subjects, 80% male) showed that tiotropium reduced COPD-related exacerbations (OR = 0.76; 95% CI: 0.68-0.87) and hospital admissions (OR=0.59; 95% CI: 0.47-0.73) compared with placebo.  Also, tiotropium showed statistically significant improvement in lung function, including trough, av., and peak FEV1 and FVC from baseline, compared with placebo and ipratropium.  The administration of inhaled tiotropium lead to 30% redn. in COPD-related admissions (OR = 0.67; 95% CI: 0.46-0.98) compared with LABAs.  Finally, increases in FEV1 and FVC from baseline were significantly larger with tiotropium than with LABAs.  Conclusions: This review clearly supports the beneficial effects of the use of tiotropium in stable moderate-to-severe COPD patients, and increases the evidence in favor of the superiority of tiotropium on LABAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU7RKrhhnsELVg90H21EOLACvtfcHk0lg-nGVHw6b2Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvFyksro%253D&md5=44e5adada4b1be4c51b003e70b4a6944</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2006.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2006.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigo%26aufirst%3DG.%2BJ.%26aulast%3DNannini%26aufirst%3DL.%2BJ.%26atitle%3DTiotropium%2520for%2520the%2520treatment%2520of%2520stable%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520systematic%2520review%2520with%2520meta-analysis%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2007%26volume%3D20%26spage%3D495%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Vogelmeier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hederer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaab, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutten-van Mölken, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beeh, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabe, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbri, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">POET-COPD Investigators.</span><span> </span><span class="NLM_article-title">Tiotropium versus salmeterol for the prevention of exacerbations of COPD</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">1093</span><span class="NLM_x">–</span> <span class="NLM_lpage">1103</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1056%2FNEJMoa1008378" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=21428765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVyjs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=1093-1103&author=C.+Vogelmeierauthor=B.+Hedererauthor=T.+Glaabauthor=H.+Schmidtauthor=M.+P.+Rutten-van+M%C3%B6lkenauthor=K.+M.+Beehauthor=K.+F.+Rabeauthor=L.+M.+Fabbriauthor=POET-COPD+Investigators.&title=Tiotropium+versus+salmeterol+for+the+prevention+of+exacerbations+of+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Tiotropium versus salmeterol for the prevention of exacerbations of COPD</span></div><div class="casAuthors">Vogelmeier, Claus; Hederer, Bettina; Glaab, Thomas; Schmidt, Hendrik; Rutten-Van Molken, Maureen P. M. H.; Beeh, Kai M.; Rabe, Klaus F.; Fabbri, Leonardo M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1093-1103</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Treatment guidelines recommend the use of inhaled long-acting bronchodilators to alleviate symptoms and reduce the risk of exacerbations in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) but do not specify whether a long-acting anticholinergic drug or a β2-agonist is the preferred agent.  The authors investigated whether the anticholinergic drug tiotropium is superior to the β2-agonist salmeterol in preventing exacerbations of COPD.  In a 1-yr, randomized, double-blind, double-dummy, parallel-group trial, the authors compared the effect of treatment with 18 μg of tiotropium once daily with that of 50 μg of salmeterol twice daily on the incidence of moderate or severe exacerbations in patients with moderate-to-very-severe COPD and a history of exacerbations in the preceding year.  A total of 7376 patients were randomly assigned to and treated with tiotropium (3707 patients) or salmeterol (3669 patients).  Tiotropium, as compared with salmeterol, increased the time to the first exacerbation (187 days vs. 145 days), with a 17% redn. in risk (hazard ratio, 0.83; 95% confidence interval [CI], 0.77 to 0.90; P < 0.001).  Tiotropium also increased the time to the first severe exacerbation (hazard ratio, 0.72; 95% CI, 0.61 to 0.85; P < 0.001), reduced the annual no. of moderate or severe exacerbations (0.64 vs. 0.72; rate ratio, 0.89; 95% CI, 0.83 to 0.96; P = 0.002), and reduced the annual no. of severe exacerbations (0.09 vs. 0.13; rate ratio, 0.73; 95% CI, 0.66 to 0.82; P < 0.001).  Overall, the incidence of serious adverse events and of adverse events leading to the discontinuation of treatment was similar in the two study groups.  There were 64 deaths (1.7%) in the tiotropium group and 78 (2.1%) in the salmeterol group.  These results show that, in patients with moderate-to-very-severe COPD, tiotropium is more effective than salmeterol in preventing exacerbations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcGS8pytm0HLVg90H21EOLACvtfcHk0lg-nGVHw6b2Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVyjs7Y%253D&md5=11c34e28f119601621494b4705a91fd9</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1008378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1008378%26sid%3Dliteratum%253Aachs%26aulast%3DVogelmeier%26aufirst%3DC.%26aulast%3DHederer%26aufirst%3DB.%26aulast%3DGlaab%26aufirst%3DT.%26aulast%3DSchmidt%26aufirst%3DH.%26aulast%3DRutten-van%2BM%25C3%25B6lken%26aufirst%3DM.%2BP.%26aulast%3DBeeh%26aufirst%3DK.%2BM.%26aulast%3DRabe%26aufirst%3DK.%2BF.%26aulast%3DFabbri%26aufirst%3DL.%2BM.%26aulast%3D%26atitle%3DTiotropium%2520versus%2520salmeterol%2520for%2520the%2520prevention%2520of%2520exacerbations%2520of%2520COPD%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D1093%26epage%3D1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Wedzicha, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calverley, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seemungal, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ansari, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockley, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">INSPIRE Investigators.</span><span> </span><span class="NLM_article-title">The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">177</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1164%2Frccm.200707-973OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=17916806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht12mt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2008&pages=19-26&author=J.+A.+Wedzichaauthor=P.+M.+Calverleyauthor=T.+A.+Seemungalauthor=G.+Haganauthor=Z.+Ansariauthor=R.+A.+Stockleyauthor=INSPIRE+Investigators.&title=The+prevention+of+chronic+obstructive+pulmonary+disease+exacerbations+by+salmeterol%2Ffluticasone+propionate+or+tiotropium+bromide"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide</span></div><div class="casAuthors">Wedzicha, Jadwiga A.; Calverley, Peter M. A.; Seemungal, Terence A.; Hagan, Gerry; Ansari, Zainab; Stockley, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-26</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Exacerbations are key drivers of morbidity and mortality in chronic obstructive pulmonary disease (COPD).  Objectives: We compared the relative efficacy of the long-acting inhaled bronchodilator/antiinflammatory combination (salmeterol/fluticasone propionate) 50/500 μg twice daily and the long-acting bronchodilator (tiotropium) 18 μg once daily in preventing exacerbations and related outcomes in severe and very severe COPD.  Methods: A total of 1,323 patients (mean age, 64 yr, post-bronchodilator FEV1, 39% predicted) were randomized in this 2-yr, double-blind, double-dummy parallel study.  Measurements and Main Results: Primary endpoint was health care utilization exacerbation rate.  Other endpoints included health status measured by St. George's Respiratory Questionnaire (SGRQ), mortality, adverse events, and study withdrawal.  Probability of withdrawing from the study was 29% greater with tiotropium than salmeterol/fluticasone propionate (P = 0.005).  The modeled annual exacerbation rate was 1.28 in the salmeterol/fluticasone propionate group and 1.32 in the tiotropium group (rate ratio, 0.967; 95% confidence interval [CI], 0.836-1.119]; P = 0.656).  The SGRQ total score was statistically significantly lower at 2 years on salmeterol/fluticasone propionate vs. tiotropium (difference 2.1 units; 95% CI, 0.1-4.0; P = 0.038).  Mortality was significantly lower in the salmeterol/fluticasone propionate group; 21 (3%) of patients in this group died compared with 38 (6%) in the tiotropium group (P = 0.032).  More pneumonias were reported in the salmeterol/fluticasone propionate group relative to tiotropium (P = 0.008).  Conclusions: We found no difference in exacerbation rate between salmeterol/fluticasone propionate and tiotropium.  More patients failed to complete the study while receiving tiotropium.  A small statistically significant beneficial effect was found on health status, with an unexpected finding of lower deaths in salmeterol/fluticasone propionate-treated patients.  Clin. trial registered with www.clinicaltrials.gov (NCT 00361959).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp2H4qbYw7WLVg90H21EOLACvtfcHk0lh-IUNW4Xg2iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht12mt74%253D&md5=b0df385f67351e42bb5e1a49b79e0268</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1164%2Frccm.200707-973OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200707-973OC%26sid%3Dliteratum%253Aachs%26aulast%3DWedzicha%26aufirst%3DJ.%2BA.%26aulast%3DCalverley%26aufirst%3DP.%2BM.%26aulast%3DSeemungal%26aufirst%3DT.%2BA.%26aulast%3DHagan%26aufirst%3DG.%26aulast%3DAnsari%26aufirst%3DZ.%26aulast%3DStockley%26aufirst%3DR.%2BA.%26aulast%3D%26atitle%3DThe%2520prevention%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520exacerbations%2520by%2520salmeterol%252Ffluticasone%2520propionate%2520or%2520tiotropium%2520bromide%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2008%26volume%3D177%26spage%3D19%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Chan, C. K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maltais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sigouin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haddon, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SAFE Study Group.</span><span> </span><span class="NLM_article-title">A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Can. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">465</span><span class="NLM_x">–</span> <span class="NLM_lpage">472</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1155%2F2007%2F192961" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=18060091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BD2sjisl2hug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=465-472&author=C.+K.+N.+Chanauthor=R.+Maltaisauthor=C.+Sigouinauthor=J.+M.+Haddonauthor=G.+T.+Fordauthor=SAFE+Study+Group.&title=A+randomized+controlled+trial+to+assess+the+efficacy+of+tiotropium+in+Canadian+patients+with+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease</span></div><div class="casAuthors">Chan Charles K N; Maltais Francois; Sigouin Chris; Haddon Jennifer M; Ford Gordon T</div><div class="citationInfo"><span class="NLM_cas:title">Canadian respiratory journal : journal of the Canadian Thoracic Society</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">465-72</span>
        ISSN:<span class="NLM_cas:issn">1198-2241</span>.
    </div><div class="casAbstract">BACKGROUND:  Patients with chronic obstructive pulmonary disease (COPD) who smoke have a greater annual rate of decline in forced expiratory volume in 1 s (FEV(1)) than those patients who have stopped smoking.  OBJECTIVES:  To assess the effect of tiotropium on pre-dose (trough) FEV(1) in patients with COPD followed in Canada.  METHODS:  A total of 913 patients were randomly assigned to receive either tiotropium 18 mug once daily (n=608) or placebo (usual care minus inhaled anticholinergics) (n=305) for 48 weeks in the present randomized, double-blind, parallel-group study.  The effect of tiotropium on measurements of lung function (FEV(1), FEV(6) and forced vital capacity), symptoms, health-related quality of life (St George's Respiratory Questionnaire) and exacerbations were examined.  RESULTS:  Tiotropium improved trough FEV(1) in both current and ex-smokers compared with placebo.  Baseline FEV(1) in smokers and ex-smokers was 1.03 L and 0.93 L, respectively (P<0.001).  At week 48, the mean difference between the tiotropium and placebo groups was 0.14+/-0.04 L (P<0.001) in the smoker group and 0.08+/-0.02 L (P<0.0001) in the ex-smoker group.  Tiotropium also significantly improved trough forced vital capacity and FEV(6) compared with placebo throughout the treatment period (P<0.05, for all).  Furthermore, tiotropium significantly improved the St George's Respiratory Questionnaire total score compared with placebo at week 48 (40.9 versus 43.7 units, P<0.005).  CONCLUSIONS:  Compared with the placebo group, tiotropium provides sustained improvements in lung function in patients with COPD, with improvements for smokers and ex-smokers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzIBLURIWBZkHdcurJClFcfW6udTcc2eaKvNCM4AM8Vrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjisl2hug%253D%253D&md5=03575c89ca7bd122dc5609a4687bc729</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1155%2F2007%2F192961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2007%252F192961%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DC.%2BK.%2BN.%26aulast%3DMaltais%26aufirst%3DR.%26aulast%3DSigouin%26aufirst%3DC.%26aulast%3DHaddon%26aufirst%3DJ.%2BM.%26aulast%3DFord%26aufirst%3DG.%2BT.%26aulast%3D%26atitle%3DA%2520randomized%2520controlled%2520trial%2520to%2520assess%2520the%2520efficacy%2520of%2520tiotropium%2520in%2520Canadian%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DCan.%2520Respir.%2520J.%26date%3D2007%26volume%3D14%26spage%3D465%26epage%3D472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Tonnel, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosbois, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verkindre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravo, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">TIPHON Study Group.</span><span> </span><span class="NLM_article-title">Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD</span> <span class="citation_source-journal">Int. J. Chronic Obstruct. Pulm. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">301</span><span class="NLM_x">–</span> <span class="NLM_lpage">310</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=18686739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1Wrt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=301-310&author=A.+B.+Tonnelauthor=T.+Perezauthor=J.+M.+Grosboisauthor=C.+Verkindreauthor=M.+L.+Bravoauthor=M.+Brunauthor=TIPHON+Study+Group.&title=Effect+of+tiotropium+on+health-related+quality+of+life+as+a+primary+efficacy+endpoint+in+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD</span></div><div class="casAuthors">Tonnel, A-B.; Perez, T.; Grosbois, J-M.; Verkindre, C.; Bravo, M-L.; Brun, M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Chronic Obstructive Pulmonary Disease</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">301-310</span>CODEN:
                <span class="NLM_cas:coden">IJCOC3</span>;
        ISSN:<span class="NLM_cas:issn">1176-9106</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">Clin. manifestations of chronic obstructive pulmonary disease (COPD), including airflow limitation, dyspnea, and activity limitation, ultimately lead to impaired health-related quality of life (HRQoL).  This 9-mo, randomized, double-blind, multicenter study compared the effect of once-daily tiotropium 18 μg and placebo on HRQoL, spirometric parameters, and exacerbations in 554 patients with moderate-to-severe COPD.  HRQoL was assessed using the St. George's Respiratory Questionnaire (SGRQ) and the new 8-item Visual Simplified Respiratory Questionnaire (VSRQ), which is currently being validated.  The primary efficacy endpoint was the proportion of patients achieving a redn. of at least 4 units in the SGRQ total score at study end (Month 9).  Mean ± SD baseline SGRQ total score was 47.4 ± 18.1.  Significantly more tiotropium-treated patients achieved a redn. of at least 4 units in the SGRQ score vs placebo at study end (59.1% vs 48.2%, resp.; p = 0.029).  Tiotropium significantly improved spirometric parameters (forced expiratory vol. in 1 s [FEV1]: 0.11 ± 0.02 L vs 0.01 ± 0.02 L; between-group difference: 0.10 ± 0.03 L, p = 0.0001) and reduced exacerbations vs placebo.  Maintenance treatment with tiotropium provided significant and clin. relevant improvements in HRQoL, as measured by the SGRQ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY0ZPv1xl_TbVg90H21EOLACvtfcHk0lh-IUNW4Xg2iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1Wrt7w%253D&md5=645bbfd9981c920a5602b62e9159c845</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTonnel%26aufirst%3DA.%2BB.%26aulast%3DPerez%26aufirst%3DT.%26aulast%3DGrosbois%26aufirst%3DJ.%2BM.%26aulast%3DVerkindre%26aufirst%3DC.%26aulast%3DBravo%26aufirst%3DM.%2BL.%26aulast%3DBrun%26aufirst%3DM.%26aulast%3D%26atitle%3DEffect%2520of%2520tiotropium%2520on%2520health-related%2520quality%2520of%2520life%2520as%2520a%2520primary%2520efficacy%2520endpoint%2520in%2520COPD%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2008%26volume%3D3%26spage%3D301%26epage%3D310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Verkindre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bart, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguilaniu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fortin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guérin, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Merre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacono, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huchon, G.</span><span> </span><span class="NLM_article-title">The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Respiration</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">420</span><span class="NLM_x">–</span> <span class="NLM_lpage">427</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2006&pages=420-427&author=C.+Verkindreauthor=F.+Bartauthor=B.+Aguilaniuauthor=F.+Fortinauthor=J.+C.+Gu%C3%A9rinauthor=C.+Le+Merreauthor=P.+Iaconoauthor=G.+Huchon&title=The+effect+of+tiotropium+on+hyperinflation+and+exercise+capacity+in+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerkindre%26aufirst%3DC.%26aulast%3DBart%26aufirst%3DF.%26aulast%3DAguilaniu%26aufirst%3DB.%26aulast%3DFortin%26aufirst%3DF.%26aulast%3DGu%25C3%25A9rin%26aufirst%3DJ.%2BC.%26aulast%3DLe%2BMerre%26aufirst%3DC.%26aulast%3DIacono%26aufirst%3DP.%26aulast%3DHuchon%26aufirst%3DG.%26atitle%3DThe%2520effect%2520of%2520tiotropium%2520on%2520hyperinflation%2520and%2520exercise%2520capacity%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DRespiration%26date%3D2006%26volume%3D73%26spage%3D420%26epage%3D427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Brusasco, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miravitlles, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korducki, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towse, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S.</span><span> </span><span class="NLM_article-title">Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">404</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2003&pages=399-404&author=V.+Brusascoauthor=R.+Hodderauthor=M.+Miravitllesauthor=L.+Korduckiauthor=L.+Towseauthor=S.+Kesten&title=Health+outcomes+following+treatment+for+six+months+with+once+daily+tiotropium+compared+with+twice+daily+salmeterol+in+patients+with+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrusasco%26aufirst%3DV.%26aulast%3DHodder%26aufirst%3DR.%26aulast%3DMiravitlles%26aufirst%3DM.%26aulast%3DKorducki%26aufirst%3DL.%26aulast%3DTowse%26aufirst%3DL.%26aulast%3DKesten%26aufirst%3DS.%26atitle%3DHealth%2520outcomes%2520following%2520treatment%2520for%2520six%2520months%2520with%2520once%2520daily%2520tiotropium%2520compared%2520with%2520twice%2520daily%2520salmeterol%2520in%2520patients%2520with%2520COPD%26jtitle%3DThorax%26date%3D2003%26volume%3D58%26spage%3D399%26epage%3D404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Tashkin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C. B.</span><span> </span><span class="NLM_article-title">The role of long-acting bronchodilators in the management of stable COPD</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span><span class="NLM_x">–</span> <span class="NLM_lpage">259</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2004&pages=249-259&author=D.+P.+Tashkinauthor=C.+B.+Cooper&title=The+role+of+long-acting+bronchodilators+in+the+management+of+stable+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTashkin%26aufirst%3DD.%2BP.%26aulast%3DCooper%26aufirst%3DC.%2BB.%26atitle%3DThe%2520role%2520of%2520long-acting%2520bronchodilators%2520in%2520the%2520management%2520of%2520stable%2520COPD%26jtitle%3DChest%26date%3D2004%26volume%3D125%26spage%3D249%26epage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Sykes, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowling, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighton-Davies, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fawcett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renard, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trifilieff, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, S. J.</span><span> </span><span class="NLM_article-title">The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">520</span><span class="NLM_x">–</span> <span class="NLM_lpage">528</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1124%2Fjpet.112.194456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=22854200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKktb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2012&pages=520-528&author=D.+A.+Sykesauthor=M.+R.+Dowlingauthor=J.+Leighton-Daviesauthor=T.+C.+Kentauthor=L.+Fawcettauthor=E.+Renardauthor=A.+Trifilieffauthor=S.+J.+Charlton&title=The+influence+of+receptor+kinetics+on+the+onset+and+duration+of+action+and+the+therapeutic+index+of+NVA237+and+tiotropium"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium</span></div><div class="casAuthors">Sykes, David A.; Dowling, Mark R.; Leighton-Davies, Juliet; Kent, Toby C.; Fawcett, Lindsay; Renard, Emilie; Trifilieff, Alexandre; Charlton, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">520-528</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Studies under nonphysiol. conditions suggest that long receptor residency time is responsible for the 24-h duration of action of the long-acting muscarinic antagonist (LAMA) tiotropium.  Our aim was to det. how clin. relevant dissocn. rates under more physiol. conditions influence the differences in onset of action between tiotropium and 3-[(cyclopentylhydroxyphenylacetyl oxy]-1,1-dimethyl-pyrrolidinium bromide (NVA237), a once-daily dry-powder formulation of the LAMA glycopyrronium bromide in development for chronic obstructive pulmonary disease.  In addn., we have investigated kinetic selectivity at each of the muscarinic receptor subtypes to det. whether the improved cardiovascular therapeutic index obtained with NVA237 in animal models is attributable to differences in kinetic rate consts.  The binding of radioligand [3H]N-methyl-scopolamine was measured in the presence/absence of several concns. of unlabeled competitors, and data were analyzed using a competition kinetic model to provide on/off rates for the competitor.  We found shorter dissocn. half-lives for NVA237 and tiotropium under physiol. (11.4 and 46.2 min, resp.) vs. nonphysiol. conditions (173 and 462 min, resp.).  NVA237 had a more rapid onset of action (3-4.8 times) vs. tiotropium, detd. in an vitro calcium and rat tracheal strip assay.  Simulations suggested that the more rapid onset of NVA237 action could be explained by differences in kinetic parameters.  NVA237 had greater equil. binding and kinetic selectivity for muscarinic type 3 (M3) vs. muscarinic type 2 (M2) receptors, with a faster off rate from M2 vs. M3 receptors than tiotropium, potentially affording it a more favorable therapeutic index.  This study suggests that the 24-h duration of action of NVA237 and tiotropium is not solely the result of their slow dissocn. from the M3 receptor and highlights the importance of conducting in vitro expts. in conditions reflecting those in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPg9FL15nv-bVg90H21EOLACvtfcHk0lgw4tDBXKtt2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKktb3M&md5=922e31d6cafa771f3cc66aad519c07e8</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.194456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.194456%26sid%3Dliteratum%253Aachs%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DDowling%26aufirst%3DM.%2BR.%26aulast%3DLeighton-Davies%26aufirst%3DJ.%26aulast%3DKent%26aufirst%3DT.%2BC.%26aulast%3DFawcett%26aufirst%3DL.%26aulast%3DRenard%26aufirst%3DE.%26aulast%3DTrifilieff%26aufirst%3DA.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520influence%2520of%2520receptor%2520kinetics%2520on%2520the%2520onset%2520and%2520duration%2520of%2520action%2520and%2520the%2520therapeutic%2520index%2520of%2520NVA237%2520and%2520tiotropium%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D343%26spage%3D520%26epage%3D528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Verkindre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flémale, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overend, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasad, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolker, M.</span><span> </span><span class="NLM_article-title">Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">1482</span><span class="NLM_x">–</span> <span class="NLM_lpage">1489</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2010.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=20541381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC3cjpvFKltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2010&pages=1482-1489&author=C.+Verkindreauthor=Y.+Fukuchiauthor=A.+Fl%C3%A9maleauthor=A.+Takedaauthor=T.+Overendauthor=N.+Prasadauthor=M.+Dolker&title=Sustained+24-h+efficacy+of+NVA237%2C+a+once-daily+long-acting+muscarinic+antagonist%2C+in+COPD+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients</span></div><div class="casAuthors">Verkindre C; Fukuchi Y; Flemale A; Takeda A; Overend T; Prasad N; Dolker M</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1482-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">NVA237 is a once-daily inhaled long-acting muscarinic antagonist in development for the treatment of COPD.  This randomized, double-blind, placebo-controlled, four-period, incomplete block crossover study, with open-label active comparator (tiotropium), assessed the efficacy and safety of NVA237.  Patients (>or=40 years; smoking history >or=10 pack-years) with stable moderate-to-severe COPD (post-bronchodilator FEV(1) >or= 30% and <80% predicted, FEV(1)/FVC < 0.7) received NVA237 12.5, 25, 50 or 100 microg, placebo, or tiotropium 18 microg once-daily for 7 days.  The primary endpoint was mean trough (23-24 h post-dose) FEV(1) on Day 7.  Secondary endpoints included mean trough FEV(1) on Day 1, and FEV(1) and FVC at individual time points post-dose on Days 1 and 7. 83 patients (mean age 64.4 years; male 83.1%; mean COPD duration 6.7 years; mean post-bronchodilator FEV(1) 1.5 L/52.7% predicted) were randomized; 78 completed.  Mean trough FEV(1) on Day 7 and Day 1 was significantly higher with all active treatments versus placebo (p < 0.05).  NVA237 50 microg, 100 microg and tiotropium showed clinically relevant improvements versus placebo on Day 7 (differences of 131, 142 and 127 mL, respectively; p < 0.0001) and 1 (differences of 121, 135 and 112 mL, respectively; p < 0.0001).  On Day 1, but not Day 7, FEV(1) was significantly higher (p < 0.05) with NVA237 50 and 100 microg versus tiotropium from 5 min up to 2 and 4 h post-dose, respectively.  All doses of NVA237 and tiotropium were well tolerated.  NVA237 once-daily was effective and well tolerated versus placebo, and demonstrated rapid and sustained 24-h bronchodilation. (ClinicalTrials.gov Identifier: NCT00501852).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ8w_3LthW3Ka__Jf7-eMvJfW6udTcc2eZltga-2WLdTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjpvFKltA%253D%253D&md5=ced49657659c0c7b06ca136d5b27953e</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2010.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2010.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DVerkindre%26aufirst%3DC.%26aulast%3DFukuchi%26aufirst%3DY.%26aulast%3DFl%25C3%25A9male%26aufirst%3DA.%26aulast%3DTakeda%26aufirst%3DA.%26aulast%3DOverend%26aufirst%3DT.%26aulast%3DPrasad%26aufirst%3DN.%26aulast%3DDolker%26aufirst%3DM.%26atitle%3DSustained%252024-h%2520efficacy%2520of%2520NVA237%252C%2520a%2520once-daily%2520long-acting%2520muscarinic%2520antagonist%252C%2520in%2520COPD%2520patients%26jtitle%3DRespir.%2520Med.%26date%3D2010%26volume%3D104%26spage%3D1482%26epage%3D1489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Casarosa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouyssou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germeyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gantner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieper, M.</span><span> </span><span class="NLM_article-title">Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">330</span><span class="NLM_x">, </span> <span class="NLM_fpage">660</span><span class="NLM_x">–</span> <span class="NLM_lpage">668</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1124%2Fjpet.109.152470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=19478135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsFCltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2009&pages=660-668&author=P.+Casarosaauthor=T.+Bouyssouauthor=S.+Germeyerauthor=A.+Schnappauthor=F.+Gantnerauthor=M.+Pieper&title=Preclinical+evaluation+of+long-acting+muscarinic+antagonists%3A+comparison+of+tiotropium+and+investigational+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs</span></div><div class="casAuthors">Casarosa, Paola; Bouyssou, Thierry; Germeyer, Sabine; Schnapp, Andreas; Gantner, Florian; Pieper, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">660-668</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation caused by persistent inflammatory processes in the airways.  An increased cholinergic tone mediates different pathophysiol. features of COPD, such as bronchoconstriction and mucus hypersecretion, mostly through activation of the human muscarinic M3 receptor (hM3) subtype.  Tiotropium bromide (Spiriva) is a well established muscarinic antagonist in the pharmacol. management of COPD with a once-daily posol.  The rationale behind the sustained bronchodilation obtained with tiotropium consists in its slow dissocn. from hM3 receptors.  In this study, we performed a comprehensive preclin. comparison of tiotropium with other long-acting muscarinic antagonists (LAMAs) currently in clin. development, namely aclidinium bromide and glycopyrrolate.  The different muscarinic antagonists were characterized for their (1) affinity toward the different human muscarinic receptor subtypes expressed in Chinese hamster ovary cells and kinetics of receptor dissocn., (2) potency in inhibiting the agonist-induced activation of muscarinic receptors through measurement of second messengers, and (3) efficacy and duration of bronchoprotection, as tested in a model of acetylcholine-induced bronchoconstriction in anesthetized dogs over a period of 24 h.  All of the tested LAMAs showed high affinity and potency toward the hM3 receptor (tiotropium, pA2 = 10.4; aclidinium, pA2 = 9.6; and glycopyrrolate, pA2 = 9.7).  However, dissocn. half-lives of the LA-MAs from the hM3 receptor differed significantly (tiotropium, t1/2=27 h; aclidinium, t1/2=10.7 h; and glycopyrrolate, t1/2=6.1 h).  In line with their kinetic properties at the hM3, the tested LAMAs provided different levels of bronchoprotection in the in vivo setting 24 h after administration (tiotropium = 35%, aclidinium = 21%, and glycopyrrolate = 0% at 24 h) when applied at equieffective doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorQCmscRp-17Vg90H21EOLACvtfcHk0lj0RaYIRnLz-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsFCltrk%253D&md5=060333cce96f1491b192e4bdbe4bfec5</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.152470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.152470%26sid%3Dliteratum%253Aachs%26aulast%3DCasarosa%26aufirst%3DP.%26aulast%3DBouyssou%26aufirst%3DT.%26aulast%3DGermeyer%26aufirst%3DS.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DGantner%26aufirst%3DF.%26aulast%3DPieper%26aufirst%3DM.%26atitle%3DPreclinical%2520evaluation%2520of%2520long-acting%2520muscarinic%2520antagonists%253A%2520comparison%2520of%2520tiotropium%2520and%2520investigational%2520drugs%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D330%26spage%3D660%26epage%3D668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Villetti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergamaschi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolzoni, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gigli, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geppetti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patacchini, R.</span><span> </span><span class="NLM_article-title">Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">148</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1038%2Fsj.bjp.0706724" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=16565730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD28XltVCjtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2006&pages=291-298&author=G.+Villettiauthor=M.+Bergamaschiauthor=F.+Bassaniauthor=P.+T.+Bolzoniauthor=S.+Harrisonauthor=P.+M.+Gigliauthor=A.+Janniauthor=P.+Geppettiauthor=M.+Civelliauthor=R.+Patacchini&title=Pharmacological+assessment+of+the+duration+of+action+of+glycopyrrolate+vs+tiotropium+and+ipratropium+in+guinea-pig+and+human+airways"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways</span></div><div class="casAuthors">Villetti, Gino; Bergamaschi, Marco; Bassani, Franco; Bolzoni, Pier Tonino; Harrison, Selena; Gigli, Paolo M.; Janni, Alberto; Geppetti, Pierangelo; Civelli, Maurizio; Patacchini, Riccardo</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">291-298</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Our study was aimed at investigating the duration of the bronchodilator action of the antimuscarinic drug glycopyrrolate compared to tiotropium and ipratropium.  In the guinea-pig isolated trachea, the time (t1/2) necessary for a contractile response to carbachol (0.3 μM) to return to 50% recovery after washout of the antagonist was studied.  The offset of the antagonist effect of glycopyrrolate, tiotropium and ipratropium (10 nM each) was t1/2=4.0±0.5, >4.5 and 0.5±0.1 h, resp.  At 4.5 h from the washout of the antagonist, the recovery of the response to carbachol was 50±8, 10±4 and 70±7%, resp.  In the human isolated bronchus, the offset of the bronchodilator effects of glycopyrrolate (3 nM), tiotropium (1 nM) and ipratropium (10 nM) was t1/2=3.7±0.2; >6 and 3.0±0.2 h, resp.  At 6.0 h from the washout of the antagonist, the recovery of the response to carbachol (1 μM) was 101±10, 27±3 and 110±10%, resp.  In anesthetized guinea-pigs, acetylcholine-induced bronchoconstriction was markedly reduced by intratracheal instillation of glycopyrrolate (3 nmol kg-1; 88.1±4% inhibition), tiotropium (1.3 nmol kg-1; 86.2±5% inhibition) or ipratropium (1.45 nmol kg-1; 88.1±10% inhibition).  These inhibitory effects assessed 3 or 24 h after antagonist administration were reduced to 69.9±5 and 29.7±6%; 28.3±5 and 14.2±5% for glycopyrrolate and ipratropium, resp., whereas they remained stable (83.5±4; 70.6±6) for tiotropium.  The residual inhibitory effect of glycopyrrolate was also assessed at 16 h from administration, and proved to be as low as that found at 24 h (31.2±10 vs 29.7±6%, resp.).  In conclusion, glycopyrrolate-induced bronchodilation has a longer duration than that of ipratropium, but less than that of tiotropium.  The efficacy of a possible glycopyrrolate-based therapy for asthma or chronic obstructive pulmonary disease given once-a-day is not guaranteed by the present investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoemLMYN9VSL7Vg90H21EOLACvtfcHk0lj0RaYIRnLz-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltVCjtr8%253D&md5=c45290df0f271378d3dd045ee3e51c49</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0706724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0706724%26sid%3Dliteratum%253Aachs%26aulast%3DVilletti%26aufirst%3DG.%26aulast%3DBergamaschi%26aufirst%3DM.%26aulast%3DBassani%26aufirst%3DF.%26aulast%3DBolzoni%26aufirst%3DP.%2BT.%26aulast%3DHarrison%26aufirst%3DS.%26aulast%3DGigli%26aufirst%3DP.%2BM.%26aulast%3DJanni%26aufirst%3DA.%26aulast%3DGeppetti%26aufirst%3DP.%26aulast%3DCivelli%26aufirst%3DM.%26aulast%3DPatacchini%26aufirst%3DR.%26atitle%3DPharmacological%2520assessment%2520of%2520the%2520duration%2520of%2520action%2520of%2520glycopyrrolate%2520vs%2520tiotropium%2520and%2520ipratropium%2520in%2520guinea-pig%2520and%2520human%2520airways%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D148%26spage%3D291%26epage%3D298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Fogarty, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattersley, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Scala, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drollmann, A.</span><span> </span><span class="NLM_article-title">Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">337</span><span class="NLM_x">–</span> <span class="NLM_lpage">342</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2010.10.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=21144724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC3M7jvVKqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2011&pages=337-342&author=C.+Fogartyauthor=H.+Hattersleyauthor=L.+Di+Scalaauthor=A.+Drollmann&title=Bronchodilatory+effects+of+NVA237%2C+a+once+daily+long-acting+muscarinic+antagonist%2C+in+COPD+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients</span></div><div class="casAuthors">Fogarty Charles; Hattersley Helen; Di Scala Lilla; Drollmann Anton</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">337-42</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">NVA237 is a novel, once daily inhaled long-acting muscarinic antagonist administered via a dry powder inhaler.  This study aimed to assess the 24-h bronchodilatory effect following 14 days of treatment with inhaled NVA237 in patients with mild, moderate or severe COPD.  This was a randomized, double-blind, placebo-controlled, two-period, crossover, multicenter study.  A total of 33 patients (≥ 40 years; smoking history of ≥ 10 pack-years) were randomized to receive NVA237 50 μg once daily followed by placebo or placebo followed by NVA237 50 μg for 14 days.  Treatment periods were separated by a 7-14 day washout period.  The primary variable was the mean forced expiratory volume in 1 s (FEV(1)) derived from the area under the curve (AUC) between 0 and 24 h post-dose on Day 14.  The 24-h FEV(1) profiles showed a consistent bronchodilator effect for NVA237 versus placebo on Day 14.  Least square (LS) mean difference in FEV(1) AUC(0-24 h) values between NVA237 and placebo was 163 mL (P < 0.001).  There were significant increases in mean FEV(1) AUC(0-12 h) (LS mean difference 165 mL, P = 0.001) and FEV(1) AUC(12-24 h) (161 mL, P < 0.001) versus placebo.  NVA237 significantly improved peak FEV(1) (by 208 mL, P < 0.001) and trough FEV(1) (by 154 mL, P = 0.003) versus placebo on Day 14.  NVA237 was well tolerated; all adverse events were mild or moderate in intensity and not related to study drug.  NVA237 50 μg once daily was well tolerated and showed significant and sustained 24-h bronchodilation in patients with COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRaHsHpSC3Wd9ts4TFFB11gfW6udTcc2eZasV1SDKo_obntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7jvVKqsg%253D%253D&md5=1613e181a48e12c17e11adfb5671893c</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2010.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2010.10.021%26sid%3Dliteratum%253Aachs%26aulast%3DFogarty%26aufirst%3DC.%26aulast%3DHattersley%26aufirst%3DH.%26aulast%3DDi%2BScala%26aufirst%3DL.%26aulast%3DDrollmann%26aufirst%3DA.%26atitle%3DBronchodilatory%2520effects%2520of%2520NVA237%252C%2520a%2520once%2520daily%2520long-acting%2520muscarinic%2520antagonist%252C%2520in%2520COPD%2520patients%26jtitle%3DRespir.%2520Med.%26date%3D2011%26volume%3D105%26spage%3D337%26epage%3D342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Vauquelin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, S. J.</span><span> </span><span class="NLM_article-title">Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">161</span><span class="NLM_x">, </span> <span class="NLM_fpage">488</span><span class="NLM_x">–</span> <span class="NLM_lpage">508</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1111%2Fj.1476-5381.2010.00936.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=20880390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Kju7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2010&pages=488-508&author=G.+Vauquelinauthor=S.+J.+Charlton&title=Long-lasting+target+binding+and+rebinding+as+mechanisms+to+prolong+in+vivo+drug+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action</span></div><div class="casAuthors">Vauquelin, Georges; Charlton, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">488-508</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  An increasing no. of examples in the literature suggest that the in vivo duration of drug action not only depends on macroscopic pharmacokinetic properties like plasma half-life and the time needed to equilibrate between the plasma and the effect compartments, but is also influenced by long-lasting target binding and rebinding.  The present review combines information from different research areas and simulations to explore the nature of these mechanisms and the conditions in which they are most prevalent.  Simulations reveal that these latter phenomena become esp. influential when there is no longer sufficient free drug around to maintain high levels of receptor occupancy.  There is not always a direct link between slow dissocn. and long-lasting in vivo target protection, as the rate of free drug elimination from the effect compartment is also a key influencing factor.  Local phenomena that hinder the diffusion of free drug mols. away from their target may allow them to consecutively bind to the same target and/or targets nearby (denoted as 'rebinding') even when their concn. in the bulk phase has already dropped to insignificant levels.  The micro-anat. properties of many effect compartments are likely to intensify this phenomenon.  By mimicking the complexity of tissues, intact cells offer the opportunity to investigate both mechanisms under the same, physiol. relevant conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzSGNmKeaTzrVg90H21EOLACvtfcHk0lh30SzxE5rxeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Kju7zE&md5=bd91e09a0fd79a2de6bf9ef0cfd3443e</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00936.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00936.x%26sid%3Dliteratum%253Aachs%26aulast%3DVauquelin%26aufirst%3DG.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DLong-lasting%2520target%2520binding%2520and%2520rebinding%2520as%2520mechanisms%2520to%2520prolong%2520in%2520vivo%2520drug%2520action%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D161%26spage%3D488%26epage%3D508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Vogelmeier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, D.</span><span> </span><span class="NLM_article-title">NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Ther. Adv. Respir. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">–</span> <span class="NLM_lpage">173</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1177%2F1753465811406001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVKlu7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=163-173&author=C.+Vogelmeierauthor=D.+Banerji&title=NVA237%2C+a+long-acting+muscarinic+antagonist%2C+as+an+emerging+therapy+for+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Vogelmeier, Claus; Banerji, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Respiratory Disease</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">163-173</span>CODEN:
                <span class="NLM_cas:coden">TARDCZ</span>;
        ISSN:<span class="NLM_cas:issn">1753-4658</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Bronchodilation with a long-acting muscarinic antagonist (LAMA) or long-acting β2-agonist is central to the management of chronic obstructive pulmonary disease (COPD).  Tiotropium, the first LAMA available for use in COPD, has been shown to be an effective bronchodilator and is generally safe and well tolerated.  However, tiotropium has limitations that include a high incidence of dry mouth, slow onset of action and, in some studies, a part of the patient population did not achieve clin. significant bronchodilation.  It also remains unclear whether tiotropium reduces progressive deterioration of lung function in patients with COPD.  An ideal LAMA would provide clin. meaningful bronchodilation, deliver symptom relief, prevent disease progression, improve exercise tolerance and health status, prevent and treat complications and exacerbations and reduce mortality risk.  A 24-h duration of action, rapid onset of action and a good safety and tolerability profile are also desirable.  The once-daily LAMA, NVA237 (glycopyrronium bromide), may meet some of these characteristics.  NVA237 has high selectivity for the muscarinic type-3 (M3) receptor which might potentially result in a higher therapeutic index than tiotropium, which is less selective for M3.  Phase II studies showed that NVA237 once daily provides clin. significant 24-h bronchodilation with a rapid onset of action and a favorable safety and tolerability profile.  Phase III studies are ongoing that will assess the long-term safety and efficacy of NVA237.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyitI7JsybLLVg90H21EOLACvtfcHk0lh30SzxE5rxeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVKlu7rN&md5=1e00ee6ba8f5500453dbef68261de1ce</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1177%2F1753465811406001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1753465811406001%26sid%3Dliteratum%253Aachs%26aulast%3DVogelmeier%26aufirst%3DC.%26aulast%3DBanerji%26aufirst%3DD.%26atitle%3DNVA237%252C%2520a%2520long-acting%2520muscarinic%2520antagonist%252C%2520as%2520an%2520emerging%2520therapy%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DTher.%2520Adv.%2520Respir.%2520Dis.%26date%3D2011%26volume%3D5%26spage%3D163%26epage%3D173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">D’Urzo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Noord, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overend, T.</span><span> </span><span class="NLM_article-title">Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial</span> <span class="citation_source-journal">Respir. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">156</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1186%2F1465-9921-12-156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=22151296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC38Xitleiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=156&author=A.+D%E2%80%99Urzoauthor=G.+T.+Fergusonauthor=J.+A.+van+Noordauthor=K.+Hirataauthor=C.+Martinauthor=R.+Hortonauthor=Y.+Luauthor=D.+Banerjiauthor=T.+Overend&title=Efficacy+and+safety+of+once-daily+NVA237+in+patients+with+moderate-to-severe+COPD%3A+the+GLOW1+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial</span></div><div class="casAuthors">D'Urzo, Anthony; Ferguson, Gary T.; van Noord, Jan A.; Hirata, Kazuto; Martin, Carmen; Horton, Rachael; Lu, Yimeng; Banerji, Donald; Overend, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">156</span>CODEN:
                <span class="NLM_cas:coden">RREEBZ</span>;
        ISSN:<span class="NLM_cas:issn">1465-993X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: NVA237 is a once-daily dry-powder formulation of the long-acting muscarinic antagonist glycopyrronium bromide in development for the treatment of chronic obstructive pulmonary disease (COPD).  The glycopyrronium bromide in COPD airways clin. study 1 (GLOW1) evaluated the efficacy, safety and tolerability of NVA237 in patients with moderate-to-severe COPD.  Methods: Patients with COPD with a smoking history of ≥10 pack-years, post-bronchodilator forced expiratory vol. in 1 s (FEV1) <80% and ≥30% predicted normal and FEV1/forced vital capacity < 0.70 were enrolled.  Patients were randomized to double-blind treatment with NVA237 50 μg once daily or placebo for 26 wk with inhaled/intranasal corticosteroids or H1 antagonists permitted in patients stabilized on them prior to study entry.  The primary outcome measure was trough FEV1 at Week 12.  Results: A total of 822 patients were randomized to NVA237 (n = 552) or placebo (n = 270).  Least squares mean (± std. error) trough FEV1 at Week 12 was significantly higher in patients receiving NVA237 (1.408 ± 0.0105 L), vs. placebo (1.301 ± 0.0137 L; treatment difference 108 ± 14.8 mL, p < 0.001).  Significant improvements in trough FEV1 were apparent at the end of Day 1 and sustained through Week 26.  FEV1 was significantly improved in the NVA237 group vs. placebo throughout the 24-h periods on day 1 and at weeks 12 and 26 and at all other visits and timepoints.  Transition dyspnoea index focal scores and St. George's Respiratory Questionnaire scores were significantly improved with NVA237 vs. placebo at Week 26, with treatment differences of 1.04 (p < 0.001) and -2.81 (p = 0.004), resp.  NVA237 significantly reduced the risk of first moderate/severe COPD exacerbation by 31% (p = 0.023) and use of rescue medication by 0.46 puffs per day (p = 0.005), vs. placebo.  NVA237 was well tolerated and had an acceptable safety profile, with a low frequency of cardiac and typical antimuscarinic adverse effects.  Conclusions: Once-daily NVA237 was safe and well tolerated and provided rapid, sustained improvements in lung function, improvements in dyspnoea and health-related quality of life and reduced the risk of exacerbations and the use of rescue medication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp0LAPulEqjbVg90H21EOLACvtfcHk0li_fddkgeD8-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xitleiur8%253D&md5=9f339a685604f95d65f62490fff9f81e</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-12-156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-12-156%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Urzo%26aufirst%3DA.%26aulast%3DFerguson%26aufirst%3DG.%2BT.%26aulast%3Dvan%2BNoord%26aufirst%3DJ.%2BA.%26aulast%3DHirata%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DC.%26aulast%3DHorton%26aufirst%3DR.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DBanerji%26aufirst%3DD.%26aulast%3DOverend%26aufirst%3DT.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520once-daily%2520NVA237%2520in%2520patients%2520with%2520moderate-to-severe%2520COPD%253A%2520the%2520GLOW1%2520trial%26jtitle%3DRespir.%2520Res.%26date%3D2011%26volume%3D12%26spage%3D156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Kerwin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hébert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overend, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alagappan, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, D.</span><span> </span><span class="NLM_article-title">Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1106</span><span class="NLM_x">–</span> <span class="NLM_lpage">1114</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.00040712" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23060624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFelt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=1106-1114&author=E.+Kerwinauthor=J.+H%C3%A9bertauthor=N.+Gallagherauthor=C.+Martinauthor=T.+Overendauthor=V.+K.+Alagappanauthor=Y.+Luauthor=D.+Banerji&title=Efficacy+and+safety+of+NVA237+versus+placebo+and+tiotropium+in+patients+with+COPD%3A+the+GLOW2+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study</span></div><div class="casAuthors">Kerwin, Edward; Hebert, Jacques; Gallagher, Nicola; Martin, Carmen; Overend, Tim; Alagappan, Vijay K. T.; Lu, Yimeng; Banerji, Donald</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1106-1114</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist (LAMA) in development for chronic obstructive pulmonary disease (COPD).  The GLycopyrronium bromide in COPD airWays clin. Study 2 (GLOW2) evaluated the efficacy and safety of NVA237 in moderate-to-severe COPD over 52 wk.  Patients were randomised 2:1:1 to NVA237 50 μg, placebo or open-label tiotropium 18 μg for 52 wk.  Primary end-point was trough forced expiratory vol. in 1 s (FEV1) at 12 wk.  1,066 Patients were randomised, 810 completed the study.  At week 12, trough FEV1 increased significantly by 97 mL with NVA237 (95% CI 64.6-130.2; p<0.001) and 83 mL with tiotropium (95% CI 45.6-121.4; p<0.001).  Compared with placebo, NVA237 produced significant improvements in dyspnoea (Transition Dyspnoea Index at week 26; p=0.002) and health status (St George's Respiratory Questionnaire at week 52; p<0.001).  NVA237 significantly reduced the risk of moderate-to-severe COPD exacerbations by 34% (p=0.001) and the use of rescue medication (p=0.039), vs. placebo.  NVA237-placebo and tiotropium-placebo differences were comparable for all outcomes.  Safety profiles were similar across groups.  NVA237 50 μg provided significant improvements in lung function, dyspnoea, health status, exacerbations and rescue medication use, vs. placebo, and was comparable to tiotropium.  NVA237 can potentially be an alternative choice of LAMA for COPD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSUlbKeoyAgbVg90H21EOLACvtfcHk0li_fddkgeD8-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFelt7o%253D&md5=2edd1f1595e071ecc2c9063e7fef71d8</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1183%2F09031936.00040712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00040712%26sid%3Dliteratum%253Aachs%26aulast%3DKerwin%26aufirst%3DE.%26aulast%3DH%25C3%25A9bert%26aufirst%3DJ.%26aulast%3DGallagher%26aufirst%3DN.%26aulast%3DMartin%26aufirst%3DC.%26aulast%3DOverend%26aufirst%3DT.%26aulast%3DAlagappan%26aufirst%3DV.%2BK.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DBanerji%26aufirst%3DD.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520NVA237%2520versus%2520placebo%2520and%2520tiotropium%2520in%2520patients%2520with%2520COPD%253A%2520the%2520GLOW2%2520study%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2012%26volume%3D40%26spage%3D1106%26epage%3D1114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Beeh, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Scala, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drollmann, A.</span><span> </span><span class="NLM_article-title">Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial</span> <span class="citation_source-journal">Int. J. Chronic Obstruct. Pulm. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">503</span><span class="NLM_x">–</span> <span class="NLM_lpage">513</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.2147%2FCOPD.S32451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=22973092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCqsbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=503-513&author=K.+M.+Beehauthor=D.+Singhauthor=L.+Di+Scalaauthor=A.+Drollmann&title=Once-daily+NVA237+improves+exercise+tolerance+from+the+first+dose+in+patients+with+COPD%3A+the+GLOW3+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial</span></div><div class="casAuthors">Beeh, Kai M.; Singh, Dave; Di Scala, Lilla; Drollmann, Anton</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Chronic Obstructive Pulmonary Disease</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">503-513</span>CODEN:
                <span class="NLM_cas:coden">IJCOC3</span>;
        ISSN:<span class="NLM_cas:issn">1178-2005</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Introduction: Exercise limitation, dynamic hyperinflation, and exertional dyspnea are key features of symptomatic chronic obstructive pulmonary disease (COPD).  We assessed the effects of glycopyrronium bromide (NVA237), a once-daily, long-acting muscarinic antagonist, on exercise tolerance in patients with moderate to severe COPD.  Methods: Patients were randomized to a cross-over design of once-daily NVA237 50 μg or placebo for 3 wk, with a 14-day washout.  Exercise endurance, inspiratory capacity (IC) during exercise, IC and expiratory vols. from spirometry, plethysmog. lung vols., leg discomfort and dyspnea under exercise (Borg scales), and transition dyspnea index were measured on days 1 and 21 of treatment.  The primary endpoint was endurance time during a submaximal const.-load cycle ergometry test on day 21.  Results: A total of 108 patients were randomized to different treatment groups (mean age, 60.5 years; mean post-bronchodilator, forced expiratory vol. in 1 s [FEV1] 57.1% predicted).  Ninety-five patients completed the study.  On day 21, a 21% difference in endurance time was obsd. between patients treated with NVA237 and those treated with placebo (P < 0.001); the effect was also significant from day 1, with an increase of 10%.  Dynamic IC at exercise isotime and trough FEV1 showed significant and clin. relevant improvements from Day 1 of treatment that were maintained throughout the study.  This was accompanied by inverse decreases in residual vol. and functional residual capacity.  NVA237 was superior to placebo (P < 0.05) in decreasing leg discomfort (Borg CR10 scale) on Day 21 and exertional dyspnea on Days 1 and 21 (transition dyspnea index and Borg CR10 scale at isotime).  The safety profile of NVA237 was similar to that of the placebo.  Conclusion: NVA237 50 μg once daily produced immediate and significant improvement in exercise tolerance from day 1.  This was accompanied by sustained redns. in lung hyperinflation (indicated by sustained and significant improvements in IC at isotime), and meaningful improvements in trough FEV1 and dyspnea.  Improvements in exercise endurance increased over time, suggesting that mechanisms beyond improved lung function may be involved in enhanced exercise tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3HSwcLky9DbVg90H21EOLACvtfcHk0li_fddkgeD8-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCqsbrO&md5=52b28b1bd2aff9ce1ae066c2c8146019</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S32451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S32451%26sid%3Dliteratum%253Aachs%26aulast%3DBeeh%26aufirst%3DK.%2BM.%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DDi%2BScala%26aufirst%3DL.%26aulast%3DDrollmann%26aufirst%3DA.%26atitle%3DOnce-daily%2520NVA237%2520improves%2520exercise%2520tolerance%2520from%2520the%2520first%2520dose%2520in%2520patients%2520with%2520COPD%253A%2520the%2520GLOW3%2520trial%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2012%26volume%3D7%26spage%3D503%26epage%3D513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Chapman, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beeh, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bateman, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Urzo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nutbrown, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overend, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, P.</span><span> </span><span class="NLM_article-title">A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study</span> <span class="citation_source-journal">BMC Pulm. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1186%2F1471-2466-14-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=24438744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC2czmsFKmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=4&author=K.+R.+Chapmanauthor=K.+M.+Beehauthor=J.+Beierauthor=E.+D.+Batemanauthor=A.+D%E2%80%99Urzoauthor=R.+Nutbrownauthor=M.+Henleyauthor=H.+Chenauthor=T.+Overendauthor=P.+D%E2%80%99Andrea&title=A+blinded+evaluation+of+the+efficacy+and+safety+of+glycopyrronium%2C+a+once-daily+long-acting+muscarinic+antagonist%2C+versus+tiotropium%2C+in+patients+with+COPD%3A+the+GLOW5+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study</span></div><div class="casAuthors">Chapman Kenneth R; Beeh Kai-Michael; Beier Jutta; Bateman Eric D; D'Urzo Anthony; Nutbrown Robert; Henley Michelle; Chen Hungta; Overend Tim; D'Andrea Peter</div><div class="citationInfo"><span class="NLM_cas:title">BMC pulmonary medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Two once-daily long-acting muscarinic antagonists (LAMAs) are currently available for the treatment of chronic obstructive pulmonary disease (COPD) - tiotropium and glycopyrronium.  Previous studies have compared glycopyrronium with open-label tiotropium.  In the GLOW5 study, we compare glycopyrronium with blinded tiotropium.  METHODS:  In this blinded, double-dummy, parallel group, 12-week study, patients with moderate-to-severe COPD were randomized 1:1 to glycopyrronium 50 μg once daily or tiotropium 18 μg once daily.  The primary objective was to demonstrate the non-inferiority of glycopyrronium versus blinded tiotropium with respect to trough forced expiratory volume in 1 second (FEV1) following 12 weeks of treatment (non-inferiority margin: -50 mL).  Secondary objectives were to evaluate glycopyrronium versus tiotropium for other spirometric outcomes, breathlessness (Transition Dyspnea Index; TDI), health status (St George's Respiratory Questionnaire; SGRQ), daily rescue medication use, COPD exacerbations and COPD symptoms over 12 weeks of treatment.  RESULTS:  657 patients were randomized (glycopyrronium: 327; tiotropium: 330); 96% (630 patients) completed the study.  Least squares mean trough FEV1 for both glycopyrronium and tiotropium was 1.405 L at Week 12, meeting the criterion for non-inferiority (mean treatment difference: 0 mL, 95% CI: -32, 31 mL).  Glycopyrronium demonstrated rapid bronchodilation following first dose on Day 1, with significantly higher FEV1 at all time points from 0-4 h post-dose versus tiotropium (all p < 0.001).  FEV1 area under the curve from 0-4 h (AUC0-4h) post-dose with glycopyrronium was significantly superior to tiotropium on Day 1 (p < 0.001) and was comparable to tiotropium at Week 12.  Glycopyrronium demonstrated comparable improvements to tiotropium in TDI focal score, SGRQ total score, rescue medication use and the rate of COPD exacerbations (all p = not significant).  Patients on glycopyrronium also had a significantly lower total COPD symptom score versus patients on tiotropium after 12 weeks (p = 0.035).  Adverse events were reported by a similar percentage of patients receiving glycopyrronium (40.4%) and tiotropium (40.6%).  CONCLUSION:  In patients with moderate-to-severe COPD, 12-week blinded treatment with once-daily glycopyrronium 50 μg or tiotropium 18 μg, provided similar efficacy and safety, with glycopyrronium having a faster onset of action on Day 1 versus tiotropium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWvhlVOxUiRGHOrQ6qeX-mfW6udTcc2eZC1DRIMczeybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2czmsFKmsw%253D%253D&md5=59ac336a5b821763ddbcc5da646e4f32</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1186%2F1471-2466-14-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2466-14-4%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DK.%2BR.%26aulast%3DBeeh%26aufirst%3DK.%2BM.%26aulast%3DBeier%26aufirst%3DJ.%26aulast%3DBateman%26aufirst%3DE.%2BD.%26aulast%3DD%25E2%2580%2599Urzo%26aufirst%3DA.%26aulast%3DNutbrown%26aufirst%3DR.%26aulast%3DHenley%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DOverend%26aufirst%3DT.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DP.%26atitle%3DA%2520blinded%2520evaluation%2520of%2520the%2520efficacy%2520and%2520safety%2520of%2520glycopyrronium%252C%2520a%2520once-daily%2520long-acting%2520muscarinic%2520antagonist%252C%2520versus%2520tiotropium%252C%2520in%2520patients%2520with%2520COPD%253A%2520the%2520GLOW5%2520study%26jtitle%3DBMC%2520Pulm.%2520Med.%26date%3D2014%26volume%3D14%26spage%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Jansat, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia Gil, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrer, P.</span><span> </span><span class="NLM_article-title">Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects</span> <span class="citation_source-journal">Int. J. Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">460</span><span class="NLM_x">–</span> <span class="NLM_lpage">468</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.5414%2FCPP47460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=19640353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVGjsbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2009&pages=460-468&author=J.+M.+Jansatauthor=R.+Lamarcaauthor=E.+Garcia+Gilauthor=P.+Ferrer&title=Safety+and+pharmacokinetics+of+single+doses+of+aclidinium+bromide%2C+a+novel+long-acting%2C+inhaled+antimuscarinic%2C+in+healthy+subjects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects</span></div><div class="casAuthors">Jansat, J. M.; Lamarca, R.; Gil, E. Garcia; Ferrer, P.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">460-468</span>CODEN:
                <span class="NLM_cas:coden">ICTHEK</span>;
        ISSN:<span class="NLM_cas:issn">0946-1965</span>.
    
            (<span class="NLM_cas:orgname">Dustri-Verlag Dr. Karl Feistle</span>)
        </div><div class="casAbstract">Aclidinium bromide is a novel antimuscarinic being developed for the treatment of chronic obstructive pulmonary disease.  The objective of this Phase I study was to det. the max. tolerated dose (MTD) as well as the tolerability, safety and pharmacokinetics of aclidinium in healthy subjects.  16 healthy subjects were randomized to receive 5 single ascending doses of aclidinium 600-6000 μg or placebo inhaled via dry powder inhaler, with 7 day washouts.  Safety measurements included adverse events (AEs), phys. examn., vital signs, pupillometry examn., clin. lab. tests, and 12-lead ECG.  Pharmacokinetic parameters of aclidinium and its metabolites were assessed.  The incidence of AEs was comparable between aclidinium and placebo at all doses.  Most AEs were mild to moderate with no dose-related or anticholinergic/cardiac AEs.  At doses ≥2400 μg, only 13 AEs were considered treatment related.  Aclidinium (600-6000 μg) did not produce function-limiting or severe AEs in ≥50% of subjects; hence, the prospectively-defined MTD was not established.  Aclidinium was rapidly converted in plasma into alc. and carboxylic acid metabolites, and was no longer detectable after 3 h post-dose for all doses.  At lower doses, aclidinium was quantifiable only up to 1 h post-dose in the majority of subjects.  Maximum plasma concns. for aclidinium were reached within 5-7 min (all doses) and declined rapidly.  Mean elimination half-lives of aclidinium >2400 μg were approx. 1 h.  AUC and Cmax increased proportionately up to 4800 μg.  Aclidinium appears to be safe and well tolerated in single doses of 600-6000 μg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmAmPkH7WVi7Vg90H21EOLACvtfcHk0lhRfkcikVZOrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVGjsbrM&md5=8e2dd9ac12ceeb68a0dd3bfa6a937500</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.5414%2FCPP47460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5414%252FCPP47460%26sid%3Dliteratum%253Aachs%26aulast%3DJansat%26aufirst%3DJ.%2BM.%26aulast%3DLamarca%26aufirst%3DR.%26aulast%3DGarcia%2BGil%26aufirst%3DE.%26aulast%3DFerrer%26aufirst%3DP.%26atitle%3DSafety%2520and%2520pharmacokinetics%2520of%2520single%2520doses%2520of%2520aclidinium%2520bromide%252C%2520a%2520novel%2520long-acting%252C%2520inhaled%2520antimuscarinic%252C%2520in%2520healthy%2520subjects%26jtitle%3DInt.%2520J.%2520Clin.%2520Pharmacol.%2520Ther.%26date%3D2009%26volume%3D47%26spage%3D460%26epage%3D468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Jones, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rennard, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agusti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chanez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnussen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbri, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donohue, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bateman, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caracta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Gil, E.</span><span> </span><span class="NLM_article-title">Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Respir. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1186%2F1465-9921-12-55" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=21518460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVamurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=55&author=P.+W.+Jonesauthor=S.+I.+Rennardauthor=A.+Agustiauthor=P.+Chanezauthor=H.+Magnussenauthor=L.+Fabbriauthor=J.+F.+Donohueauthor=E.+D.+Batemanauthor=N.+J.+Grossauthor=R.+Lamarcaauthor=C.+Caractaauthor=E.+Garcia-Gil&title=Efficacy+and+safety+of+once-daily+aclidinium+in+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Jones, Paul W.; Rennard, Stephen I.; Agusti, Alvar; Chanez, Pascal; Magnussen, Helgo; Fabbri, Leonardo; Donohue, James F.; Bateman, Eric D.; Gross, Nicholas J.; Lamarca, Rosa; Caracta, Cynthia; Gil, Esther Garcia</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">55</span>CODEN:
                <span class="NLM_cas:coden">RREEBZ</span>;
        ISSN:<span class="NLM_cas:issn">1465-993X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The long-term efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist, were investigated in patients with moderate to severe chronic obstructive pulmonary disease (COPD).  In two double-blind, 52-wk studies, ACCLAIM/COPD I (n = 843) and II (n = 804), patients were randomized to inhaled aclidinium 200 μg or placebo once-daily.  Patients were required to have a post-bronchodilator forced expiratory vol. in 1 s (FEV1)/forced vital capacity ratio of ≤70% and FEV1 <80% of the predicted value.  The primary endpoint was trough FEV1 at 12 and 28 wk.  Secondary endpoints were health status measured by St. George's Respiratory Questionnaire (SGRQ) and time to first moderate or severe COPD exacerbation.  At 12 and 28 wk, aclidinium improved trough FEV1 vs. placebo in ACCLAIM/COPD I (by 61 and 67 mL; both p < 0.001) and ACCLAIM/COPD II (by 63 and 59 mL; both p < 0.001).  More patients had a SGRQ improvement ≥4 units at 52 wk with aclidinium vs. placebo in ACCLAIM/COPD I (48.1% vs. 39.5%; p = 0.025) and ACCLAIM/COPD II (39.0% vs. 32.8%; p = 0.074).  The time to first exacerbation was significantly delayed by aclidinium in ACCLAIM/COPD II (hazard ratio [HR] 0.7; 95% confidence interval [CI] 0.55 to 0.92; p = 0.01), but not ACCLAIM/COPD I (HR 1.0; 95% CI 0.72 to 1.33; p = 0.9).  Adverse events were minor in both studies.  Aclidinium is effective and well tolerated in patients with moderate to severe COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5kEg2cALstLVg90H21EOLACvtfcHk0lgMVIXixXPn5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVamurg%253D&md5=7aa275b7bde0e549fd29ef391b93b0db</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-12-55&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-12-55%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%2BW.%26aulast%3DRennard%26aufirst%3DS.%2BI.%26aulast%3DAgusti%26aufirst%3DA.%26aulast%3DChanez%26aufirst%3DP.%26aulast%3DMagnussen%26aufirst%3DH.%26aulast%3DFabbri%26aufirst%3DL.%26aulast%3DDonohue%26aufirst%3DJ.%2BF.%26aulast%3DBateman%26aufirst%3DE.%2BD.%26aulast%3DGross%26aufirst%3DN.%2BJ.%26aulast%3DLamarca%26aufirst%3DR.%26aulast%3DCaracta%26aufirst%3DC.%26aulast%3DGarcia-Gil%26aufirst%3DE.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520once-daily%2520aclidinium%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DRespir.%2520Res.%26date%3D2011%26volume%3D12%26spage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Maltais, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casaburi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porszasz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarreta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seoane, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caracta, C.</span><span> </span><span class="NLM_article-title">Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">580</span><span class="NLM_x">–</span> <span class="NLM_lpage">587</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2010.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=21183326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC3M3hvFyrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2011&pages=580-587&author=F.+Maltaisauthor=B.+Celliauthor=R.+Casaburiauthor=J.+Porszaszauthor=D.+Jarretaauthor=B.+Seoaneauthor=C.+Caracta&title=Aclidinium+bromide+improves+exercise+endurance+and+lung+hyperinflation+in+patients+with+moderate+to+severe+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD</span></div><div class="casAuthors">Maltais Francois; Celli Bartolome; Casaburi Richard; Porszasz Janos; Jarreta Diana; Seoane Beatriz; Caracta Cynthia</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">580-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Static and dynamic lung hyperinflation are associated with exercise impairment and poor outcomes in COPD patients.  Aclidinium bromide is a novel, long-acting inhaled muscarinic antagonist currently in development for COPD treatment.  METHODS:  Patients with moderate to severe COPD (N = 181) were randomized to once-daily aclidinium 200 μg or placebo for 6 weeks.  Constant work rate cycling exercises at 75% of peak work rate were performed at baseline, Day 1, Week 3, and Week 6.  The primary efficacy measure was change in exercise endurance time (ET) from baseline to Week 6.  Secondary outcomes included changes in trough forced expiratory volume in 1 s (FEV(1)), inspiratory capacity (IC), IC/total lung capacity (TLC), and functional residual capacity (FRC) from baseline to Day 1, Week 3, and Week 6.  Borg dyspnea scores during exercise, locus of symptom limitation, and safety measures were assessed.  RESULTS:  Aclidinium significantly improved ET on Day 1 (P = 0.0002), and improvements were sustained through Week 3 (P = 0.0007) and Week 6 (P = 0.0042) vs placebo.  Compared with placebo, aclidinium improved trough FEV(1), IC, and IC/TLC at Weeks 3 and 6 (P < 0.05 for all).  Exertional dyspnea scores at isotime were reduced on Day 1, Week 3, and Week 6 for aclidinium vs placebo (P < 0.05).  Furthermore, the likelihood of stopping exercise due to breathing discomfort was lower in the aclidinium group at study end (P = 0.0208) compared with placebo.  No differences in safety outcomes were reported between treatments.  CONCLUSIONS:  Aclidinium significantly increased exercise tolerance, improved airflow obstruction and lung hyperinflation, and was safe and well tolerated.  REGISTRATION OF TRIAL: This trial was registered with ClinicalTrials.gov (NCT00500318) under the name "A Study of Exercise Endurance and Lung Hyperinflation in Patients with Moderate to Severe COPD".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSEJ86GtNp_Rcr74wzj5o5fW6udTcc2eaNxvlG-Kpkvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3hvFyrsA%253D%253D&md5=fbd03314ffbf36218ddb9a19d5f076fd</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2010.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2010.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DMaltais%26aufirst%3DF.%26aulast%3DCelli%26aufirst%3DB.%26aulast%3DCasaburi%26aufirst%3DR.%26aulast%3DPorszasz%26aufirst%3DJ.%26aulast%3DJarreta%26aufirst%3DD.%26aulast%3DSeoane%26aufirst%3DB.%26aulast%3DCaracta%26aufirst%3DC.%26atitle%3DAclidinium%2520bromide%2520improves%2520exercise%2520endurance%2520and%2520lung%2520hyperinflation%2520in%2520patients%2520with%2520moderate%2520to%2520severe%2520COPD%26jtitle%3DRespir.%2520Med.%26date%3D2011%26volume%3D105%26spage%3D580%26epage%3D587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Singh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loke, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furberg, C. D.</span><span> </span><span class="NLM_article-title">Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">300</span><span class="NLM_x">, </span> <span class="NLM_fpage">1439</span><span class="NLM_x">–</span> <span class="NLM_lpage">1450</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=300&publication_year=2008&pages=1439-1450&author=S.+Singhauthor=Y.+K.+Lokeauthor=C.+D.+Furberg&title=Inhaled+anticholinergics+and+risk+of+major+adverse+cardiovascular+events+in+patients+with+chronic+obstructive+pulmonary+disease%3A+a+systematic+review+and+meta-analysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DLoke%26aufirst%3DY.%2BK.%26aulast%3DFurberg%26aufirst%3DC.%2BD.%26atitle%3DInhaled%2520anticholinergics%2520and%2520risk%2520of%2520major%2520adverse%2520cardiovascular%2520events%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2008%26volume%3D300%26spage%3D1439%26epage%3D1450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Ogale, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Au, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boudreau, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, S. D.</span><span> </span><span class="NLM_article-title">Cardiovascular events associated with ipratropium bromide in COPD</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">13</span><span class="NLM_x">–</span> <span class="NLM_lpage">19</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2010&pages=13-19&author=S.+S.+Ogaleauthor=T.+A.+Leeauthor=D.+H.+Auauthor=D.+M.+Boudreauauthor=S.+D.+Sullivan&title=Cardiovascular+events+associated+with+ipratropium+bromide+in+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOgale%26aufirst%3DS.%2BS.%26aulast%3DLee%26aufirst%3DT.%2BA.%26aulast%3DAu%26aufirst%3DD.%2BH.%26aulast%3DBoudreau%26aufirst%3DD.%2BM.%26aulast%3DSullivan%26aufirst%3DS.%2BD.%26atitle%3DCardiovascular%2520events%2520associated%2520with%2520ipratropium%2520bromide%2520in%2520COPD%26jtitle%3DChest%26date%3D2010%26volume%3D137%26spage%3D13%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">Celli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decramer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leimer, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tashkin, D. P.</span><span> </span><span class="NLM_article-title">Cardiovascular safety of tiotropium in patients with COPD</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2010&pages=20-30&author=B.+Celliauthor=M.+Decramerauthor=I.+Leimerauthor=U.+Vogelauthor=S.+Kestenauthor=D.+P.+Tashkin&title=Cardiovascular+safety+of+tiotropium+in+patients+with+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCelli%26aufirst%3DB.%26aulast%3DDecramer%26aufirst%3DM.%26aulast%3DLeimer%26aufirst%3DI.%26aulast%3DVogel%26aufirst%3DU.%26aulast%3DKesten%26aufirst%3DS.%26aulast%3DTashkin%26aufirst%3DD.%2BP.%26atitle%3DCardiovascular%2520safety%2520of%2520tiotropium%2520in%2520patients%2520with%2520COPD%26jtitle%3DChest%26date%3D2010%26volume%3D137%26spage%3D20%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">McGarvey, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magder, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkhart, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manuel, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niewoehner, D. E.</span><span> </span><span class="NLM_article-title">Cause-specific mortality adjudication in the UPLIFT COPD trial: findings and recommendations</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">515</span><span class="NLM_x">–</span> <span class="NLM_lpage">521</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2011.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=22100536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC383otVSltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2012&pages=515-521&author=L.+P.+McGarveyauthor=S.+Magderauthor=D.+Burkhartauthor=S.+Kestenauthor=D.+Liuauthor=R.+C.+Manuelauthor=D.+E.+Niewoehner&title=Cause-specific+mortality+adjudication+in+the+UPLIFT+COPD+trial%3A+findings+and+recommendations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Cause-specific mortality adjudication in the UPLIFT® COPD trial: findings and recommendations</span></div><div class="casAuthors">McGarvey Lorcan P; Magder Sheldon; Burkhart Deborah; Kesten Steven; Liu Dacheng; Manuel Raymond C; Niewoehner Denis E</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">515-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Mortality is an important endpoint in chronic obstructive pulmonary disease (COPD) trials, although accurately determining cause of death is difficult.  In the Understanding the Potential Long-term Impacts on Function with Tiotropium (UPLIFT®) trial, a mortality adjudication committee (MAC) provided systematic, independent and blinded assessment of cause-specific mortality of all 981 reported deaths.  Here we describe this process of mortality adjudication and methodological revisions introduced to help standardise the adjudication of two areas recognised to pose particular difficulty; firstly, the classification of fatal COPD exacerbations that occur in the setting of pneumonia and secondly, the categorisation of sudden death.  In addition MAC determined cause of death was compared with that reported by site investigators (SIs).  MAC-assigned causes of death were: respiratory, 35%; cancer, 25%; cardiovascular, 11%; sudden cardiac death, 4.4%; sudden death, 3.4%; other, 8.8%; unknown, 12.4%.  Cancer/cardiac deaths were more common in Global Initiative for Chronic Obstructive Lung Disease stage II, respiratory deaths in stages III and IV.  Agreement between MAC and SI regarding cause of death was complete (50.2%), incomplete (18.5%) or none (31.3%).  The SI classified deaths as cardiac three-fold more frequently than MAC (incidence rate [IR]/100 patient-years 0.797 vs. 0.257), although IR ratios for cardiac deaths for tiotropium vs. control were similar between SI and MAC.  Discrepancies between MAC- and SI-adjudicated causes of death are common, especially increased reporting of cardiac deaths by the SI.  Future multicentre COPD trials should plan appropriate infrastructure before study initiation to ensure collection and interpretation of fatal events data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTr_UZgzuuEu_x2phytoz6_fW6udTcc2eYzMVGvvDmyeLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383otVSltQ%253D%253D&md5=6a7321c1bf6907fe9e658b5a97207113</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2011.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2011.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DMcGarvey%26aufirst%3DL.%2BP.%26aulast%3DMagder%26aufirst%3DS.%26aulast%3DBurkhart%26aufirst%3DD.%26aulast%3DKesten%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DManuel%26aufirst%3DR.%2BC.%26aulast%3DNiewoehner%26aufirst%3DD.%2BE.%26atitle%3DCause-specific%2520mortality%2520adjudication%2520in%2520the%2520UPLIFT%2520COPD%2520trial%253A%2520findings%2520and%2520recommendations%26jtitle%3DRespir.%2520Med.%26date%3D2012%26volume%3D106%26spage%3D515%26epage%3D521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Lee, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroupe, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schumock, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickard, A. S.</span><span> </span><span class="NLM_article-title">Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Arch. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">169</span><span class="NLM_x">, </span> <span class="NLM_fpage">1403</span><span class="NLM_x">–</span> <span class="NLM_lpage">1410</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2009&pages=1403-1410&author=T.+A.+Leeauthor=C.+Wilkeauthor=M.+Jooauthor=K.+T.+Stroupeauthor=J.+A.+Krishnanauthor=G.+T.+Schumockauthor=A.+S.+Pickard&title=Outcomes+associated+with+tiotropium+use+in+patients+with+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DT.%2BA.%26aulast%3DWilke%26aufirst%3DC.%26aulast%3DJoo%26aufirst%3DM.%26aulast%3DStroupe%26aufirst%3DK.%2BT.%26aulast%3DKrishnan%26aufirst%3DJ.%2BA.%26aulast%3DSchumock%26aufirst%3DG.%2BT.%26aulast%3DPickard%26aufirst%3DA.%2BS.%26atitle%3DOutcomes%2520associated%2520with%2520tiotropium%2520use%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DArch.%2520Intern.%2520Med.%26date%3D2009%26volume%3D169%26spage%3D1403%26epage%3D1410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Dong, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shau, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, M. S.</span><span> </span><span class="NLM_article-title">Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">56</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=48-56&author=Y.+H.+Dongauthor=H.+H.+Linauthor=W.+Y.+Shauauthor=Y.+C.+Wuauthor=C.+H.+Changauthor=M.+S.+Lai&title=Comparative+safety+of+inhaled+medications+in+patients+with+chronic+obstructive+pulmonary+disease%3A+systematic+review+and+mixed+treatment+comparison+meta-analysis+of+randomised+controlled+trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DY.%2BH.%26aulast%3DLin%26aufirst%3DH.%2BH.%26aulast%3DShau%26aufirst%3DW.%2BY.%26aulast%3DWu%26aufirst%3DY.%2BC.%26aulast%3DChang%26aufirst%3DC.%2BH.%26aulast%3DLai%26aufirst%3DM.%2BS.%26atitle%3DComparative%2520safety%2520of%2520inhaled%2520medications%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520systematic%2520review%2520and%2520mixed%2520treatment%2520comparison%2520meta-analysis%2520of%2520randomised%2520controlled%2520trials%26jtitle%3DThorax%26date%3D2013%26volume%3D68%26spage%3D48%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Singh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loke, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enright, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furberg, C. D.</span><span> </span><span class="NLM_article-title">Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials</span> <span class="citation_source-journal">BMJ</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">342</span><span class="NLM_x">, </span> <span class="NLM_fpage">d3215</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2011&pages=d3215&author=S.+Singhauthor=Y.+K.+Lokeauthor=P.+L.+Enrightauthor=C.+D.+Furberg&title=Mortality+associated+with+tiotropium+mist+inhaler+in+patients+with+chronic+obstructive+pulmonary+disease%3A+systematic+review+and+meta-analysis+of+randomised+controlled+trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DLoke%26aufirst%3DY.%2BK.%26aulast%3DEnright%26aufirst%3DP.%2BL.%26aulast%3DFurberg%26aufirst%3DC.%2BD.%26atitle%3DMortality%2520associated%2520with%2520tiotropium%2520mist%2520inhaler%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520systematic%2520review%2520and%2520meta-analysis%2520of%2520randomised%2520controlled%2520trials%26jtitle%3DBMJ%26date%3D2011%26volume%3D342%26spage%3Dd3215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Wise, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anzueto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cotton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devins, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Disse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dusser, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kattenbeck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koenen-Bergmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pledger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calverley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">TIOSPIR Investigators.</span><span> </span><span class="NLM_article-title">Tiotropium Respimat inhaler and the risk of death in COPD</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">1491</span><span class="NLM_x">–</span> <span class="NLM_lpage">1501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1056%2FNEJMoa1303342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23992515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1CgsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=1491-1501&author=R.+A.+Wiseauthor=A.+Anzuetoauthor=D.+Cottonauthor=R.+Dahlauthor=T.+Devinsauthor=B.+Disseauthor=D.+Dusserauthor=E.+Josephauthor=S.+Kattenbeckauthor=M.+Koenen-Bergmannauthor=G.+Pledgerauthor=P.+Calverleyauthor=TIOSPIR+Investigators.&title=Tiotropium+Respimat+inhaler+and+the+risk+of+death+in+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Tiotropium respimat inhaler and the risk of death in COPD</span></div><div class="casAuthors">Wise, Robert A.; Anzueto, Antonio; Cotton, Daniel; Dahl, Ronald; Devins, Theresa; Disse, Bernd; Dusser, Daniel; Joseph, Elizabeth; Kattenbeck, Sabine; Koenen-Bergmann, Michael; Pledger, Gordon; Calverley, Peter</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1491-1501</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Tiotropium delivered at a dose of 5 μg with the Respimat inhaler showed efficacy similar to that of 18 μg of tiotropium delivered with the HandiHaler inhalation device in placebo-controlled trials involving patients with chronic obstructive pulmonary disease (COPD).  Although tiotropium HandiHaler was assocd. with reduced mortality, as compared with placebo, more deaths were reported with tiotropium Respimat than with placebo.  In this randomized, double-blind, parallel-group trial involving 17,135 patients with COPD, we evaluated the safety and efficacy of tiotropium Respimat at a once-daily dose of 2.5 μg or 5 μg, as compared with tiotropium HandiHaler at a once-daily dose of 18 μg.  Primary end points were the risk of death (noninferiority study, Respimat at a dose of 5 μg or 2.5 μg vs. HandiHaler) and the risk of the first COPD exacerbation (superiority study, Respimat at a dose of 5 μg vs. HandiHaler).  We also assessed cardiovascular safety, including safety in patients with stable cardiac disease.  During a mean follow-up of 2.3 years, Respimat was noninferior to HandiHaler with respect to the risk of death (Respimat at a dose of 5 μg vs. HandiHaler: hazard ratio, 0.96; 95% confidence interval [CI], 0.84 to 1.09; Respimat at a dose of 2.5 μg vs. HandiHaler: hazard ratio, 1.00; 95% CI, 0.87 to 1.14) and not superior to HandiHaler with respect to the risk of the first exacerbation (Respimat at a dose of 5 μg vs. HandiHaler: hazard ratio, 0.98; 95% CI, 0.93 to 1.03).  Causes of death and incidences of major cardiovascular adverse events were similar in the three groups.  Tiotropium Respimat at a dose of 5 μg or 2.5 μg had a safety profile and exacerbation efficacy similar to those of tiotropium HandiHaler at a dose of 18 μg in patients with COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6TmIvfcAMkbVg90H21EOLACvtfcHk0lgsgzv-xHTXLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1CgsbzE&md5=a1e7bc0b55c8cd7a8500335331154dfb</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1303342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1303342%26sid%3Dliteratum%253Aachs%26aulast%3DWise%26aufirst%3DR.%2BA.%26aulast%3DAnzueto%26aufirst%3DA.%26aulast%3DCotton%26aufirst%3DD.%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DDevins%26aufirst%3DT.%26aulast%3DDisse%26aufirst%3DB.%26aulast%3DDusser%26aufirst%3DD.%26aulast%3DJoseph%26aufirst%3DE.%26aulast%3DKattenbeck%26aufirst%3DS.%26aulast%3DKoenen-Bergmann%26aufirst%3DM.%26aulast%3DPledger%26aufirst%3DG.%26aulast%3DCalverley%26aufirst%3DP.%26aulast%3D%26atitle%3DTiotropium%2520Respimat%2520inhaler%2520and%2520the%2520risk%2520of%2520death%2520in%2520COPD%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D1491%26epage%3D1501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">Loke, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furberg, C. D.</span><span> </span><span class="NLM_article-title">Tiotropium and the risk of death in COPD</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">480</span><span class="NLM_x">–</span> <span class="NLM_lpage">481</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1056%2FNEJMc1314411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=24476442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFers7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=480-481&author=Y.+K.+Lokeauthor=S.+Singhauthor=C.+D.+Furberg&title=Tiotropium+and+the+risk+of+death+in+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Comment on: tiotropium and the risk of death in COPD</span></div><div class="casAuthors">Loke, Yoon K.; Singh, Sonal; Furberg, Curt D.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">480-482</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUM5bFFhtB37Vg90H21EOLACvtfcHk0lhWhieriowxsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFers7o%253D&md5=9e69576afa0a8e2b4214436046107347</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1056%2FNEJMc1314411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMc1314411%26sid%3Dliteratum%253Aachs%26aulast%3DLoke%26aufirst%3DY.%2BK.%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DFurberg%26aufirst%3DC.%2BD.%26atitle%3DTiotropium%2520and%2520the%2520risk%2520of%2520death%2520in%2520COPD%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D480%26epage%3D481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group">Kesten, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wentworth, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanes, S.</span><span> </span><span class="NLM_article-title">Pooled clinical trial analysis of tiotropium safety</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">1695</span><span class="NLM_x">–</span> <span class="NLM_lpage">1703</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2006&pages=1695-1703&author=S.+Kestenauthor=M.+Jaraauthor=C.+Wentworthauthor=S.+Lanes&title=Pooled+clinical+trial+analysis+of+tiotropium+safety"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKesten%26aufirst%3DS.%26aulast%3DJara%26aufirst%3DM.%26aulast%3DWentworth%26aufirst%3DC.%26aulast%3DLanes%26aufirst%3DS.%26atitle%3DPooled%2520clinical%2520trial%2520analysis%2520of%2520tiotropium%2520safety%26jtitle%3DChest%26date%3D2006%26volume%3D130%26spage%3D1695%26epage%3D1703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group">Rennard, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ZuWallack, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broughton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisniewski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickard, K.</span><span> </span><span class="NLM_article-title">Use of a long-acting inhaled beta<sub>2</sub>-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">1087</span><span class="NLM_x">–</span> <span class="NLM_lpage">1092</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1164%2Fajrccm.163.5.9903053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=11316640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BD3M3lsFWhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2001&pages=1087-1092&author=S.+I.+Rennardauthor=W.+Andersonauthor=R.+ZuWallackauthor=J.+Broughtonauthor=W.+Baileyauthor=M.+Friedmanauthor=M.+Wisniewskiauthor=K.+Rickard&title=Use+of+a+long-acting+inhaled+beta2-adrenergic+agonist%2C+salmeterol+xinafoate%2C+in+patients+with+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease</span></div><div class="casAuthors">Rennard S I; Anderson W; ZuWallack R; Broughton J; Bailey W; Friedman M; Wisniewski M; Rickard K</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1087-92</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is a condition in which continuous bronchodilation may have clinical advantages.  This study evaluated salmeterol, a beta-agonist bronchodilator with a duration of action substantially longer than that of short-acting beta-agonists, compared with ipratropium, an anticholinergic bronchodilator, and placebo in patients with COPD.  Four hundred and five patients with COPD received either salmeterol 42 microg twice daily, ipratropium bromide 36 microg four times daily, or placebo for 12 wk in this randomized, double-blind, parallel-group study.  Patients were stratified on the basis of bronchodilator response to albuterol (> 12% and > 200-ml improvement) and were randomized within each stratum.  Bronchodilator response was measured over 12 h four times during the treatment period.  Salmeterol provided similar maximal bronchodilatation to ipratropium but had a longer duration of action and a more constant bronchodilatory effect with no evidence of bronchodilator tolerance.  Both active treatments were well tolerated.  Salmeterol was an effective bronchodilator with a consistent effect over this 12-wk study in patients with COPD, including those "unresponsive" to albuterol.  The long duration of action of salmeterol offers the advantage of twice daily dosing compared with the required four times a day dosing with ipratropium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRqa0hIsf6uC86Js-BCLiifW6udTcc2eZwN9l-bXKsy7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3lsFWhsg%253D%253D&md5=809a65d0fe109a6999306940abdbe454</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.163.5.9903053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.163.5.9903053%26sid%3Dliteratum%253Aachs%26aulast%3DRennard%26aufirst%3DS.%2BI.%26aulast%3DAnderson%26aufirst%3DW.%26aulast%3DZuWallack%26aufirst%3DR.%26aulast%3DBroughton%26aufirst%3DJ.%26aulast%3DBailey%26aufirst%3DW.%26aulast%3DFriedman%26aufirst%3DM.%26aulast%3DWisniewski%26aufirst%3DM.%26aulast%3DRickard%26aufirst%3DK.%26atitle%3DUse%2520of%2520a%2520long-acting%2520inhaled%2520beta2-adrenergic%2520agonist%252C%2520salmeterol%2520xinafoate%252C%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2001%26volume%3D163%26spage%3D1087%26epage%3D1092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group">Dahl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnussen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonikov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jack, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleasdale, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators</span><span> </span><span class="NLM_article-title">Efficacy of a new once-daily long-acting inhaled β<sub>2</sub>-agonist indacaterol versus twice-daily formoterol in COPD</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">473</span><span class="NLM_x">–</span> <span class="NLM_lpage">479</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2010&pages=473-479&author=R.+Dahlauthor=K.+F.+Chungauthor=R.+Buhlauthor=H.+Magnussenauthor=V.+Nonikovauthor=D.+Jackauthor=P.+Bleasdaleauthor=R.+Owenauthor=M.+Higginsauthor=B.+Kramerauthor=INVOLVE+%28INdacaterol%3A+Value+in+COPD%3A+Longer+Term+Validation+of+Efficacy+and+Safety%29+Study+Investigators&title=Efficacy+of+a+new+once-daily+long-acting+inhaled+%CE%B22-agonist+indacaterol+versus+twice-daily+formoterol+in+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DChung%26aufirst%3DK.%2BF.%26aulast%3DBuhl%26aufirst%3DR.%26aulast%3DMagnussen%26aufirst%3DH.%26aulast%3DNonikov%26aufirst%3DV.%26aulast%3DJack%26aufirst%3DD.%26aulast%3DBleasdale%26aufirst%3DP.%26aulast%3DOwen%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DM.%26aulast%3DKramer%26aufirst%3DB.%26aulast%3D%26atitle%3DEfficacy%2520of%2520a%2520new%2520once-daily%2520long-acting%2520inhaled%2520%25CE%25B22-agonist%2520indacaterol%2520versus%2520twice-daily%2520formoterol%2520in%2520COPD%26jtitle%3DThorax%26date%3D2010%26volume%3D65%26spage%3D473%26epage%3D479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">Feldman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasad, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jack, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piggott, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">INLIGHT 1 Study Group.</span><span> </span><span class="NLM_article-title">Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study</span> <span class="citation_source-journal">BMC Pulm. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1186%2F1471-2466-10-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=20211002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC3c3is1GhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=11&author=G.+Feldmanauthor=T.+Silerauthor=N.+Prasadauthor=D.+Jackauthor=S.+Piggottauthor=R.+Owenauthor=M.+Higginsauthor=B.+Kramerauthor=INLIGHT+1+Study+Group.&title=Efficacy+and+safety+of+indacaterol+150+%CE%BCg+once-daily+in+COPD%3A+a+double-blind%2C+randomised%2C+12-week+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study</span></div><div class="casAuthors">Feldman Gregory; Siler Thomas; Prasad Niyati; Jack Damon; Piggott Simon; Owen Roger; Higgins Mark; Kramer Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">BMC pulmonary medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Indacaterol is a novel, once-daily (o.d.) inhaled, long-acting beta2-agonist in development for chronic obstructive pulmonary disease (COPD).  This 12-week, double-blind study compared the efficacy, safety, and tolerability of indacaterol to that of placebo in patients with moderate-to-severe COPD.  METHODS:  Efficacy variables included 24-h trough FEV1 (mean of 23 h 10 min and 23 h 45 min post-dose) at Week 12 (primary endpoint) and after Day 1, and the percentage of COPD days with poor control (i.e., worsening symptoms).  Safety was assessed by adverse events (AEs), mean serum potassium and blood glucose, QTc (Fridericia), and vital signs.  RESULTS:  Patients were randomised (n = 416, mean age 63 years) to receive either indacaterol 150 microg o.d. (n = 211) or placebo (n = 205) via a single-dose dry-powder inhaler; 87.5% completed the study.  Trough FEV1 (LSM +/- SEM) at Week 12 was 1.48 +/- 0.018 L for indacaterol and 1.35 +/- 0.019 L for placebo, a clinically relevant difference of 130 +/- 24 mL (p < 0.001).  Trough FEV1 after one dose was significantly higher with indacaterol than placebo (p < 0.001).  Indacaterol demonstrated significantly higher peak FEV1 than placebo, both on Day 1 and at Week 12, with indacaterol-placebo differences (LSM +/- SEM) of 190 +/- 28 (p < 0.001) and 160 +/- 28 mL (p < 0.001), respectively.  Standardised AUC measurements for FEV1 (between 5 min and 4 h, 5 min and 1 h, and 1 and 4 h post-dose) at Week 12 were all significantly greater with indacaterol than placebo (p < 0.001), with LSM (+/- SEM) differences of 170 +/- 24, 180 +/- 24, and 170 +/- 24 mL, respectively.  Indacaterol significantly reduced the percentage of days of poor control versus placebo by 22.5% (p < 0.001) and was also associated with significantly reduced use of rescue medication (p < 0.001).  The overall rates of AEs were comparable between the groups (indacaterol 49.3%, placebo 46.8%), with the most common AEs being COPD worsening (indacaterol 8.5%, placebo 12.2%) and cough (indacaterol 6.2%, placebo 7.3%).  One patient died in the placebo group.  Serum potassium and blood glucose levels did not differ significantly between the two groups, and no patient had QTc >500 ms.  CONCLUSIONS:  Indacaterol 150 microg o.d. provided clinically significant and sustained bronchodilation, reduced rescue medication use, and had a safety and tolerability profile similar to placebo.  TRIAL REGISTRATION:  NCT00624286.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR7D6F7dJyM5kkUaC_kzhvyfW6udTcc2ebvmGp-wSGu_bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3is1GhtA%253D%253D&md5=0b213dd728e720176f77f4f8c63c8b57</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1186%2F1471-2466-10-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2466-10-11%26sid%3Dliteratum%253Aachs%26aulast%3DFeldman%26aufirst%3DG.%26aulast%3DSiler%26aufirst%3DT.%26aulast%3DPrasad%26aufirst%3DN.%26aulast%3DJack%26aufirst%3DD.%26aulast%3DPiggott%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DM.%26aulast%3DKramer%26aufirst%3DB.%26aulast%3D%26atitle%3DEfficacy%2520and%2520safety%2520of%2520indacaterol%2520150%2520%25CE%25BCg%2520once-daily%2520in%2520COPD%253A%2520a%2520double-blind%252C%2520randomised%252C%252012-week%2520study%26jtitle%3DBMC%2520Pulm.%2520Med.%26date%3D2010%26volume%3D10%26spage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group">Donohue, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogarty, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotval, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahler, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worth, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yorgancioglu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iqbal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swales, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">INHANCE Study Investigators</span><span> </span><span class="NLM_article-title">Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">182</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">162</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1164%2Frccm.200910-1500OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=20463178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyhs7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2010&pages=155-162&author=J.+F.+Donohueauthor=C.+Fogartyauthor=J.+Lotvalauthor=D.+A.+Mahlerauthor=H.+Worthauthor=A.+Yorganciogluauthor=A.+Iqbalauthor=J.+Swalesauthor=R.+Owenauthor=M.+Higginsauthor=B.+Kramerauthor=INHANCE+Study+Investigators&title=Once-daily+bronchodilators+for+chronic+obstructive+pulmonary+disease%3A+indacaterol+versus+tiotropium"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Once-daily bronchodilators for chronic obstructive pulmonary disease indacaterol versus tiotropium</span></div><div class="casAuthors">Donohue, James F.; Fogarty, Charles; Lotvall, Jan; Mahler, Donald A.; Worth, Heinrich; Yorgancioglu, Arzu; Iqbal, Amir; Swales, James; Owen, Roger; Higgins, Mark; Kramer, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">155-162</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Indacaterol is the first once-daily, long-acting inhaled β2-agonist bronchodilator studied in patients with chronic obstructive pulmonary disease (COPD).  Objectives: To demonstrate greater efficacy of indacaterol vs. placebo on FEV1 at 24 h post dose (trough) after 12 wk, to compare efficacy with placebo and tiotropium, and to evaluate safety and tolerability over 26 wk.  Measurements: Patients with moderate-to-severe COPD were randomized to double-blind indacaterol 150 or 300 μg or placebo, or open-label tiotropium 18 μg, all once daily, for 26 wk.  The primary efficacy outcome was trough FEV1 at 12 wk.  Addnl. analyses (not adjusted for multiplicity) included transition dyspnea index (TDI), health status (St George's Respiratory Questionnaire [SGRQ]), and exacerbations.  Serum potassium, blood glucose, and QTc interval were measured.  Results: A total of 1,683 patients (age, 63.3 yr; post-bronchodilator FEV1, 56% predicted; FEV1/FVC, 0.53) were randomized to the four treatment arms.  Trough FEV1 at Week 12 increased vs. placebo by 180 mL with both indacaterol doses and by 140 mL with tiotropium (all P < 0.001 vs. placebo).  At Week 26, for indacaterol 150/300 μg, resp., vs. placebo, TDI increased (1.00/1.18, P < 0.001) and SGRQ total score decreased (-3.3/-2.4, P < 0.01); corresponding results with tiotropium were 0.87 (P < 0.001) for TDI and (-1.0, P = not significant) for SGRQ total score.  The incidence of adverse events, low serum potassium, high blood glucose, and prolonged QTc interval was similar across treatments.  Conclusions: Indacaterol was an effective once-daily bronchodilator and was at least as effective as tiotropium in improving clin. outcomes for patients with COPD.  Clin. trial registered with clinicaltrials.gov (NCT 00463567).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1kzzp0j-0A7Vg90H21EOLACvtfcHk0lh4q-Wh4_AiLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyhs7vM&md5=f4d5bae010d002072704b9ab22e08bc0</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1164%2Frccm.200910-1500OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200910-1500OC%26sid%3Dliteratum%253Aachs%26aulast%3DDonohue%26aufirst%3DJ.%2BF.%26aulast%3DFogarty%26aufirst%3DC.%26aulast%3DLotval%26aufirst%3DJ.%26aulast%3DMahler%26aufirst%3DD.%2BA.%26aulast%3DWorth%26aufirst%3DH.%26aulast%3DYorgancioglu%26aufirst%3DA.%26aulast%3DIqbal%26aufirst%3DA.%26aulast%3DSwales%26aufirst%3DJ.%26aulast%3DOwen%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DM.%26aulast%3DKramer%26aufirst%3DB.%26aulast%3D%26atitle%3DOnce-daily%2520bronchodilators%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520indacaterol%2520versus%2520tiotropium%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2010%26volume%3D182%26spage%3D155%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Kornmann, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Centanni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dogra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-μg Doses with COPD Patients) Study Investigators</span><span> </span><span class="NLM_article-title">Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">279</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.00045810" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=20693243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvVeit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2011&pages=273-279&author=O.+Kornmannauthor=R.+Dahlauthor=S.+Centanniauthor=A.+Dograauthor=R.+Owenauthor=C.+Lassenauthor=B.+Kramerauthor=INLIGHT-2+%28Indacaterol+Efficacy+Evaluation+Using+150-%CE%BCg+Doses+with+COPD+Patients%29+Study+Investigators&title=Once-daily+indacaterol+versus+twice-daily+salmeterol+for+COPD%3A+a+placebo-controlled+comparison"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison</span></div><div class="casAuthors">Kornmann, O.; Dahl, R.; Centanni, S.; Dogra, A.; Owen, R.; Lassen, C.; Kramer, B.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">273-279</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β2-agonist bronchodilator recently approved in Europe for the treatment of chronic obstructive pulmonary disease (COPD).  The aim of the present study was to investigate the efficacy and safety of indacaterol compared with placebo and the twice-daily β2-agonist, salmeterol, as an active control.  Patients with moderate-to-severe COPD were randomized to 6 mo double-blind treatment with indacaterol (150 μg once daily), salmeterol (50 μg twice daily) or placebo.  The primary efficacy end-point was trough (24 h post-dose) forced expiratory vol. in 1 s (FEV1) after 12 wk.  1,002 Patients were randomized and 838 (84%) completed the study.  Indacaterol increased trough FEV1 at week 12 by 170 mL over placebo (p<0.001) and by 60 mL over salmeterol (p<0.001).  Both active treatments improved health status (St George's Respiratory Questionnaire) and dyspnea (transition dyspnea index) compared with placebo, with differences between them favoring indacaterol.  Safety profiles were similar across the treatment groups, and both indacaterol and salmeterol were well tolerated.  Once-daily treatment with 150 μg indacaterol had a significant and clin. relevant bronchodilator effect over 24 h post-dose and improved health status and dyspnea to a greater extent than twice-daily 50 μg salmeterol.  Indacaterol should prove a useful addnl. treatment for patients with COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYqMAhhUrstbVg90H21EOLACvtfcHk0lh4q-Wh4_AiLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvVeit70%253D&md5=607595eabbabeb233282795b07d0a034</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1183%2F09031936.00045810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00045810%26sid%3Dliteratum%253Aachs%26aulast%3DKornmann%26aufirst%3DO.%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DCentanni%26aufirst%3DS.%26aulast%3DDogra%26aufirst%3DA.%26aulast%3DOwen%26aufirst%3DR.%26aulast%3DLassen%26aufirst%3DC.%26aulast%3DKramer%26aufirst%3DB.%26aulast%3D%26atitle%3DOnce-daily%2520indacaterol%2520versus%2520twice-daily%2520salmeterol%2520for%2520COPD%253A%2520a%2520placebo-controlled%2520comparison%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2011%26volume%3D37%26spage%3D273%26epage%3D279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group">Calverley, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boonsawat, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cseke, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsson, H.</span><span> </span><span class="NLM_article-title">Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">912</span><span class="NLM_x">–</span> <span class="NLM_lpage">919</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.03.00027003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=14680078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVOkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=912-919&author=P.+M.+Calverleyauthor=W.+Boonsawatauthor=Z.+Csekeauthor=N.+Zhongauthor=S.+Petersonauthor=H.+Olsson&title=Maintenance+therapy+with+budesonide+and+formoterol+in+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Calverley, P. M.; Boonsawat, W.; Cseke, Z.; Zhong, N.; Peterson, S.; Olsson, H.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">912-919</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Lung function in chronic obstructive pulmonary disease (COPD) can be improved acutely by oral corticosteroids and bronchodilators.  Whether clin. improvement can be maintained by subsequent inhaled therapy is unknown.  COPD patients (n=1022, mean prebronchodilator forced expiratory vol. in one second (FEV1) 36% predicted) initially received formoterol (9 μg b.i.d.) and oral prednisolone (30 mg o.d.) for 2 wk.  After this time, patients were randomised to b.i.d. inhaled budesonide/formoterol 320/9 μg, budesonide 400 μg, formoterol 9 μg or placebo for 12 mo.  Postmedication FEV1 improved by 0.21 L and health-related quality of life using the St George's Respiratory Questionnaire (SGRQ) by 4.5 units after run-in.  Fewer patients receiving budesonide/formoterol withdrew from the study than those receiving budesonide, formoterol or placebo.  Budesonide/formoterol patients had a prolonged time to first exacerbation (254 vs. 96 days) and maintained higher FEV1 (99% vs. 87% of baseline), both primary variables vs. placebo.  They had fewer exacerbations (1.38 vs. 1.80 exacerbations per patient per yr), had higher prebronchodilator peak expiratory flow, and showed clin. relevant improvements in SGRQ vs. placebo (-7.5 units).  Budesonide/formoterol was more effective than either monocomponent in both primary variables.  Budesonide/formoterol in a single inhaler Symbicort maintains the benefit of treatment optimization, stabilizing lung function and delaying exacerbations more effectively than either component drug alone or placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTZnDora5DRrVg90H21EOLACvtfcHk0lgPXKc66SeZEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVOkuw%253D%253D&md5=7aefd2fe0a63057a29cfa3f5f9932897</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1183%2F09031936.03.00027003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.03.00027003%26sid%3Dliteratum%253Aachs%26aulast%3DCalverley%26aufirst%3DP.%2BM.%26aulast%3DBoonsawat%26aufirst%3DW.%26aulast%3DCseke%26aufirst%3DZ.%26aulast%3DZhong%26aufirst%3DN.%26aulast%3DPeterson%26aufirst%3DS.%26aulast%3DOlsson%26aufirst%3DH.%26atitle%3DMaintenance%2520therapy%2520with%2520budesonide%2520and%2520formoterol%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2003%26volume%3D22%26spage%3D912%26epage%3D919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">Calverley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauwels, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vestbo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pride, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulsvik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">TRial of Inhaled STeroids ANd long-acting β<sub>2</sub> agonists study group</span><span> </span><span class="NLM_article-title">Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">449</span><span class="NLM_x">–</span> <span class="NLM_lpage">456</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2003&pages=449-456&author=P.+Calverleyauthor=R.+Pauwelsauthor=J.+Vestboauthor=P.+Jonesauthor=N.+Prideauthor=A.+Gulsvikauthor=J.+Andersonauthor=C.+Madenauthor=TRial+of+Inhaled+STeroids+ANd+long-acting+%CE%B22+agonists+study+group&title=Combined+salmeterol+and+fluticasone+in+the+treatment+of+chronic+obstructive+pulmonary+disease%3A+a+randomised+controlled+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCalverley%26aufirst%3DP.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DVestbo%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DPride%26aufirst%3DN.%26aulast%3DGulsvik%26aufirst%3DA.%26aulast%3DAnderson%26aufirst%3DJ.%26aulast%3DMaden%26aufirst%3DC.%26aulast%3D%26atitle%3DCombined%2520salmeterol%2520and%2520fluticasone%2520in%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2003%26volume%3D361%26spage%3D449%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Gross, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapidus, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rinehart, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denis-Mize, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Formoterol Study Group.</span><span> </span><span class="NLM_article-title">Efficacy and safety of formoterol fumarate delivered by nebulisation to COPD patients</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">189</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2007.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=18363201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BD1c3gsVGnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2008&pages=189-197&author=N.+J.+Grossauthor=H.+S.+Nelsonauthor=R.+J.+Lapidusauthor=L.+Dunnauthor=L.+Lynnauthor=M.+Rinehartauthor=K.+Denis-Mizeauthor=Formoterol+Study+Group.&title=Efficacy+and+safety+of+formoterol+fumarate+delivered+by+nebulisation+to+COPD+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients</span></div><div class="casAuthors">Gross Nicholas J; Nelson Harold S; Lapidus Robert J; Dunn Leonard; Lynn Lon; Rinehart Mike; Denis-Mize Kimberly</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">189-97</span>
        ISSN:<span class="NLM_cas:issn">0954-6111</span>.
    </div><div class="casAbstract">Nebulized solutions of long-acting bronchodilators provide an alternative to DPI and MDI delivery, particularly for COPD patients unable to use hand-held devices easily or correctly.  The long-acting beta2-agonist, formoterol fumarate, is differentiated by its onset of significant bronchodilation within 5 min of administration.  In a randomized, double-blind, double-dummy trial, COPD subjects (n=351, mean forced expiratory volume FEV1=1.3 L, 44% predicted) received nebulized formoterol fumarate (Perforomist inhalation solution; FFIS 20 microg) or DPI (Foradil Aerolizer; FA 12 microg), or placebo twice daily for 12 weeks.  Efficacy was assessed with 12-h pulmonary function tests, and quality of life was assessed before and after treatment with the St.  George's Respiratory Questionnaire (SGRQ).  At the 12-week endpoint, FFIS significantly increased FEV1 AUC0-12h relative to placebo (p<0.0001).  No evidence of tachyphylaxis was observed as indicated by maintained FEV1 AUC and reduced rescue albuterol use throughout treatment.  FFIS also significantly increased peak FEV1, trough FEV1, and standardized FVC AUC0-12h compared with placebo.  SGRQ assessment at Week 12 demonstrated significant and clinically meaningful improvements in total score (FFIS vs placebo, -4.9, p=0.0067), symptom, and impact scores.  No significant differences in efficacy were observed between the two active treatments.  Drug related AEs in the FFIS arm with a frequency > or = 1% and exceeding placebo were dry mouth, nausea, and insomnia.  Nebulized FFIS provided significant improvement in respiratory status and quality of life in subjects with COPD relative to placebo and was well tolerated.  The efficacy and safety profile of FFIS was comparable to FA DPI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0GddEhWAH9P_I8Jvzw4xCfW6udTcc2eaah9qqClc2Z7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3gsVGnsA%253D%253D&md5=65786022d39bf93d2520508e1298511e</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2007.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2007.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DGross%26aufirst%3DN.%2BJ.%26aulast%3DNelson%26aufirst%3DH.%2BS.%26aulast%3DLapidus%26aufirst%3DR.%2BJ.%26aulast%3DDunn%26aufirst%3DL.%26aulast%3DLynn%26aufirst%3DL.%26aulast%3DRinehart%26aufirst%3DM.%26aulast%3DDenis-Mize%26aufirst%3DK.%26aulast%3D%26atitle%3DEfficacy%2520and%2520safety%2520of%2520formoterol%2520fumarate%2520delivered%2520by%2520nebulisation%2520to%2520COPD%2520patients%26jtitle%3DRespir.%2520Med.%26date%3D2008%26volume%3D102%26spage%3D189%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">Neder, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuld, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overend, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thirlwell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. A.</span><span> </span><span class="NLM_article-title">Effects of formoterol on exercise tolerance in severely disabled patients with COPD</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">2056</span><span class="NLM_x">–</span> <span class="NLM_lpage">2064</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2007.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=17658249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BD2srisVWisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2007&pages=2056-2064&author=J.+A.+Nederauthor=J.+P.+Fuldauthor=T.+Overendauthor=J.+Thirlwellauthor=R.+Carterauthor=R.+Stevensonauthor=S.+A.+Ward&title=Effects+of+formoterol+on+exercise+tolerance+in+severely+disabled+patients+with+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of formoterol on exercise tolerance in severely disabled patients with COPD</span></div><div class="casAuthors">Neder J Alberto; Fuld Jonathan P; Overend Tim; Thirlwell Jackie; Carter Roger; Stevenson Robin; Ward Susan A</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2056-64</span>
        ISSN:<span class="NLM_cas:issn">0954-6111</span>.
    </div><div class="casAbstract">OBJECTIVE:  We wished to evaluate the effects of inhaled formoterol, a long-acting beta(2)-adrenergic agonist, on exercise tolerance and dynamic hyperinflation (DH) in severely disabled chronic obstructive pulmonary disease (COPD) patients.  DESIGN:  In a two-period, crossover study, 21 patients with advanced COPD (FEV(1)=38.8+/-11.7% predicted, 16 patients GOLD stages III-IV) were randomly allocated to receive inhaled formoterol fumarate 12 microg twice daily for 14 days followed by placebo for 14 days, or vice versa.  Patients performed constant work-rate cardiopulmonary exercise tests to the limit of tolerance (Tlim) on a cycle ergometer: inspiratory capacity (IC) was obtained at rest and each minute during exercise.  Baseline and transitional dyspnoea indices (BDI and TDI) were also recorded.  RESULTS:  Eighteen patients completed both treatment periods.  Formoterol treatment was associated with an estimated increase of 130 s in Tlim compared with placebo (P=0.052): this corresponded to a 37.8% improvement over placebo (P=0.012).  Enhanced exercise tolerance after bronchodilator was associated with diminished DH marked by higher inspiratory reserve and tidal volumes at isotime and exercise cessation (P<0.05).  There was no significant difference between formoterol and placebo on exercise dyspnoea ratings; however, all domains of the TDI improved (P<or=0.02) following formoterol, compared with placebo.  CONCLUSION:  Inhaled formoterol 12 microg twice daily is effective in ameliorating DH, daily dyspnoea and exercise intolerance even in patients with advanced COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQsSN0eieM27rjnyZkbE8yXfW6udTcc2eaah9qqClc2Z7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srisVWisg%253D%253D&md5=8c56f131560774fbcdf2a8896773b06e</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2007.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2007.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DNeder%26aufirst%3DJ.%2BA.%26aulast%3DFuld%26aufirst%3DJ.%2BP.%26aulast%3DOverend%26aufirst%3DT.%26aulast%3DThirlwell%26aufirst%3DJ.%26aulast%3DCarter%26aufirst%3DR.%26aulast%3DStevenson%26aufirst%3DR.%26aulast%3DWard%26aufirst%3DS.%2BA.%26atitle%3DEffects%2520of%2520formoterol%2520on%2520exercise%2520tolerance%2520in%2520severely%2520disabled%2520patients%2520with%2520COPD%26jtitle%3DRespir.%2520Med.%26date%3D2007%26volume%3D101%26spage%3D2056%26epage%3D2064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">O’Donnell, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voduc, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzpatrick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, K. A.</span><span> </span><span class="NLM_article-title">Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">86</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.04.00072703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=15293609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmsVanu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=86-94&author=D.+E.+O%E2%80%99Donnellauthor=N.+Voducauthor=M.+Fitzpatrickauthor=K.+A.+Webb&title=Effect+of+salmeterol+on+the+ventilatory+response+to+exercise+in+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease</span></div><div class="casAuthors">O'Donnell, D. E.; Voduc, N.; Fitzpatrick, M.; Webb, K. A.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-94</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">This study examd. the effects of bronchodilator-induced redns. in lung hyperinflation on breathing pattern, ventilation and dyspnoea during exercise in chronic obstructive pulmonary disease (COPD).  Quant. tidal flow/vol. loop anal. was used to evaluate abnormalities in dynamic ventilatory mechanics and their manipulation by a bronchodilator.  In a randomized double-blind crossover study, 23 patients with COPD (mean±SEM forced expiratory vol. in one second 42±3% of the predicted value) inhaled salmeterol 50 μg or placebo twice daily for 2 wk each.  After each treatment period, 2 h after dose, patients performed pulmonary function tests and symptom-limited cycle exercise at 75% of their maximal work-rate.  After salmeterol vs. placebo at rest, vol.-cor. maximal expiratory flow rates increased by 175±52%, inspiratory capacity (IC) increased by 11±2% pred and functional residual capacity decreased by 11±3% pred.  At a standardized time during exercise, salmeterol increased IC, tidal vol. (VT), mean inspiratory and expiratory flows, ventilation, oxygen uptake (V'O2) and carbon dioxide output.  Salmeterol increased peak exercise endurance, V'O2 and ventilation by 58±19, 8±3 and 12±3%, resp.  Improvements in peak V'O2 correlated best with increases in peak VT; increases in peak VT and resting IC were interrelated.  The redn. in dyspnoea ratings at a standardized time correlated with the increased VT.  Mech. factors play an important role in shaping the ventilatory response to exercise in chronic obstructive pulmonary disease.  Bronchodilator-induced lung deflation reduced mech. restriction, increased ventilatory capacity and decreased respiratory discomfort, thereby increasing exercise endurance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_Pf8mlxOpprVg90H21EOLACvtfcHk0ljeofg4PZImHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmsVanu74%253D&md5=fdc24d4f348a1662910926817e151492</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1183%2F09031936.04.00072703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.04.00072703%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DD.%2BE.%26aulast%3DVoduc%26aufirst%3DN.%26aulast%3DFitzpatrick%26aufirst%3DM.%26aulast%3DWebb%26aufirst%3DK.%2BA.%26atitle%3DEffect%2520of%2520salmeterol%2520on%2520the%2520ventilatory%2520response%2520to%2520exercise%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2004%26volume%3D24%26spage%3D86%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group">Cooper, C. B.</span><span> </span><span class="NLM_article-title">The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function</span> <span class="citation_source-journal">Am. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">S21</span><span class="NLM_x">–</span> <span class="NLM_lpage">S31</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2006&pages=S21-S31&author=C.+B.+Cooper&title=The+connection+between+chronic+obstructive+pulmonary+disease+symptoms+and+hyperinflation+and+its+impact+on+exercise+and+function"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DC.%2BB.%26atitle%3DThe%2520connection%2520between%2520chronic%2520obstructive%2520pulmonary%2520disease%2520symptoms%2520and%2520hyperinflation%2520and%2520its%2520impact%2520on%2520exercise%2520and%2520function%26jtitle%3DAm.%2520J.%2520Med.%26date%3D2006%26volume%3D119%26spage%3DS21%26epage%3DS31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group">Donohue, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Noord, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bateman, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witek, T. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towse, L.</span><span> </span><span class="NLM_article-title">A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2002&pages=47-55&author=J.+F.+Donohueauthor=J.+A.+van+Noordauthor=E.+D.+Batemanauthor=S.+J.+Langleyauthor=A.+Leeauthor=T.+J.+Witekauthor=S.+Kestenauthor=L.+Towse&title=A+6-month%2C+placebo-controlled+study+comparing+lung+function+and+health+status+changes+in+COPD+patients+treated+with+tiotropium+or+salmeterol"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDonohue%26aufirst%3DJ.%2BF.%26aulast%3Dvan%2BNoord%26aufirst%3DJ.%2BA.%26aulast%3DBateman%26aufirst%3DE.%2BD.%26aulast%3DLangley%26aufirst%3DS.%2BJ.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DWitek%26aufirst%3DT.%2BJ.%26aulast%3DKesten%26aufirst%3DS.%26aulast%3DTowse%26aufirst%3DL.%26atitle%3DA%25206-month%252C%2520placebo-controlled%2520study%2520comparing%2520lung%2520function%2520and%2520health%2520status%2520changes%2520in%2520COPD%2520patients%2520treated%2520with%2520tiotropium%2520or%2520salmeterol%26jtitle%3DChest%26date%3D2002%26volume%3D122%26spage%3D47%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">Rodrigo, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nannini, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodríguez-Roisin, R.</span><span> </span><span class="NLM_article-title">Safety of long-acting β-agonists in stable COPD. A systematic review</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">1079</span><span class="NLM_x">–</span> <span class="NLM_lpage">1087</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2008&pages=1079-1087&author=G.+J.+Rodrigoauthor=L.+J.+Nanniniauthor=R.+Rodr%C3%ADguez-Roisin&title=Safety+of+long-acting+%CE%B2-agonists+in+stable+COPD.+A+systematic+review"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigo%26aufirst%3DG.%2BJ.%26aulast%3DNannini%26aufirst%3DL.%2BJ.%26aulast%3DRodr%25C3%25ADguez-Roisin%26aufirst%3DR.%26atitle%3DSafety%2520of%2520long-acting%2520%25CE%25B2-agonists%2520in%2520stable%2520COPD.%2520A%2520systematic%2520review%26jtitle%3DChest%26date%3D2008%26volume%3D133%26spage%3D1079%26epage%3D1087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group">Baker, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, C. I.</span><span> </span><span class="NLM_article-title">Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed treatment comparison meta-analysis</span> <span class="citation_source-journal">Pharmacotherapy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">891</span><span class="NLM_x">–</span> <span class="NLM_lpage">905</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2009&pages=891-905&author=W.+L.+Bakerauthor=E.+L.+Bakerauthor=C.+I.+Coleman&title=Pharmacologic+treatments+for+chronic+obstructive+pulmonary+disease%3A+a+mixed+treatment+comparison+meta-analysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DW.%2BL.%26aulast%3DBaker%26aufirst%3DE.%2BL.%26aulast%3DColeman%26aufirst%3DC.%2BI.%26atitle%3DPharmacologic%2520treatments%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520mixed%2520treatment%2520comparison%2520meta-analysis%26jtitle%3DPharmacotherapy%26date%3D2009%26volume%3D29%26spage%3D891%26epage%3D905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Kliber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynd, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, D. D.</span><span> </span><span class="NLM_article-title">The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Respir. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1186%2F1465-9921-11-56" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=20459831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC3czmt1SitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=56&author=A.+Kliberauthor=L.+D.+Lyndauthor=D.+D.+Sin&title=The+effects+of+long-acting+bronchodilators+on+total+mortality+in+patients+with+stable+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease</span></div><div class="casAuthors">Kliber Agnes; Lynd Larry D; Sin Don D</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">56</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Chronic obstructive pulmonary disease (COPD) is the 4th leading cause of mortality worldwide.  Long-acting bronchodilators are considered first line therapies for patients with COPD but their effects on mortality are not well known.  We performed a comprehensive systematic review and meta-analysis to evaluate the effects of long-acting bronchodilators on total mortality in stable COPD.  METHODS:  Using MEDLINE, EMBASE and Cochrane Systematic Review databases, we identified high quality randomized controlled trials of tiotropium, formoterol, salmeterol, formoterol/budesonide or salmeterol/fluticasone in COPD that had a follow-up of 6 months or longer and reported on total mortality.  Two reviewers independently abstracted data from the original trials and disagreements were resolved by iteration and consensus.  RESULTS:  Twenty-seven trials that included 30,495 patients were included in the review.  Relative risk (RR) for total mortality was calculated for each of the study and pooled together using a random-effects model.  The combination of inhaled corticosteroid (ICS) and long-acting beta-2 agonist (LABA) therapy was associated with reduced total mortality compared with placebo (RR, 0.80; p = 0.005).  Neither tiotropium (RR, 1.08; p = 0.61) nor LABA by itself (RR, 0.90; p = 0.21) was associated with mortality.  CONCLUSIONS:  A combination of ICS and LABA reduced mortality by approximately 20%.  Neither tiotropium nor LABA by itself modifies all-cause mortality in COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQftyzQKYKgJYNpW7w2tapOfW6udTcc2ebOaeTKyOY6XLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czmt1SitA%253D%253D&md5=4a9a87b48816102a21d9e3ef0148cc5c</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-11-56&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-11-56%26sid%3Dliteratum%253Aachs%26aulast%3DKliber%26aufirst%3DA.%26aulast%3DLynd%26aufirst%3DL.%2BD.%26aulast%3DSin%26aufirst%3DD.%2BD.%26atitle%3DThe%2520effects%2520of%2520long-acting%2520bronchodilators%2520on%2520total%2520mortality%2520in%2520patients%2520with%2520stable%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DRespir.%2520Res.%26date%3D2010%26volume%3D11%26spage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Nannini, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasserson, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poole, P.</span><span> </span><span class="NLM_article-title">Combined corticosteroid and long-acting beta<sub>2</sub>-agonist in one inhaler versus long-acting beta<sub>2</sub>-agonists for chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Cochrane Database Syst. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">CD006829</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=CD006829&author=L.+J.+Nanniniauthor=T.+J.+Lassersonauthor=P.+Poole&title=Combined+corticosteroid+and+long-acting+beta2-agonist+in+one+inhaler+versus+long-acting+beta2-agonists+for+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNannini%26aufirst%3DL.%2BJ.%26aulast%3DLasserson%26aufirst%3DT.%2BJ.%26aulast%3DPoole%26aufirst%3DP.%26atitle%3DCombined%2520corticosteroid%2520and%2520long-acting%2520beta2-agonist%2520in%2520one%2520inhaler%2520versus%2520long-acting%2520beta2-agonists%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2012%26volume%3D9%26spage%3DCD006829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group">Appleton, S.; Poole, P.; Smith, B. J.; Veale, A.; Lasserson, T. J.; Chan, M. M.; Cates, C. J.</span><span> </span><span class="NLM_article-title">Long-acting beta<sub>2</sub>-agonists or poorly reversible chronic obstructive pulmonary disease</span>.  <span class="citation_source-journal">Cochrane Libr.</span> Published Online: 19 July 2006. DOI:<span class="refDoi"> DOI: 10.1002/14651858.CD001104.pub2</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1002%2F14651858.CD001104.pub2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Appleton%2C+S.%3B+Poole%2C+P.%3B+Smith%2C+B.+J.%3B+Veale%2C+A.%3B+Lasserson%2C+T.+J.%3B+Chan%2C+M.+M.%3B+Cates%2C+C.+J.+Long-acting+beta2-agonists+or+poorly+reversible+chronic+obstructive+pulmonary+disease.+Cochrane+Libr.+Published+Online%3A+19+July+2006.+DOI%3A+10.1002%2F14651858.CD001104.pub2."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD001104.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD001104.pub2%26sid%3Dliteratum%253Aachs%26aulast%3DAppleton%26aufirst%3DS.%26atitle%3DLong-acting%2520beta2-agonists%2520or%2520poorly%2520reversible%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DCochrane%2520Libr.%26doi%3D10.1002%2F14651858.CD001104.pub2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Calverley, P. M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yates, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vestbo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">TORCH Investigators.</span><span> </span><span class="NLM_article-title">Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease</span> <span class="citation_source-journal">N. Eng. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">775</span><span class="NLM_x">–</span> <span class="NLM_lpage">789</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1056%2FNEJMoa063070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=17314337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvFKltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=775-789&author=P.+M.+A.+Calverleyauthor=J.+A.+Andersonauthor=B.+Celliauthor=G.+T.+Fergusonauthor=C.+Jenkinsauthor=P.+W.+Jonesauthor=J.+C.+Yatesauthor=J.+Vestboauthor=TORCH+Investigators.&title=Salmeterol+and+fluticasone+propionate+and+survival+in+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Calverley, Peter M. A.; Anderson, Julie A.; Celli, Bartolome; Ferguson, Gary T.; Jenkins, Christine; Jones, Paul W.; Yates, Julie C.; Vestbo, Jorgen</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">775-789</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Long-acting β-agonists and inhaled corticosteroids are used to treat chronic obstructive pulmonary disease (COPD), but their effect on survival is unknown.  We conducted a randomized, double-blind trial comparing salmeterol at a dose of 50 μg plus fluticasone propionate at a dose of 500 μg twice daily (combination regimen), administered with a single inhaler, with placebo, salmeterol alone, or fluticasone propionate alone for a period of 3 years.  The primary outcome was death from any cause for the comparison between the combination regimen and placebo; the frequency of exacerbations, health status, and spirometric values were also assessed.  Of 6112 patients in the efficacy population, 875 died within 3 years after the start of the study treatment.  All-cause mortality rates were 12.6% in the combination-therapy group, 15.2% in the placebo group, 13.5% in the salmeterol group, and 16.0% in the fluticasone group.  The hazard ratio for death in the combination-therapy group, as compared with the placebo group, was 0.825 (95% confidence interval [CI], 0.681 to 1.002; P = 0.052, adjusted for the interim analyses), corresponding to a difference of 2.6 percentage points or a redn. in the risk of death of 17.5%.  The mortality rate for salmeterol alone or fluticasone propionate alone did not differ significantly from that for placebo.  As compared with placebo, the combination regimen reduced the annual rate of exacerbations from 1.13 to 0.85 and improved health status and spirometric values.  There was no difference in the incidence of ocular or bone side effects.  The probability of having pneumonia reported as an adverse event was higher among patients receiving medications contg. fluticasone propionate (19.6% in the combination-therapy group and 18.3% in the fluticasone group) than in the placebo group (12.3%).  The redn. in death from all causes among patients with COPD in the combination-therapy group did not reach the predetd. level of statistical significance.  There were significant benefits in all other outcomes among these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCgp-k1GZ8D7Vg90H21EOLACvtfcHk0li_vakzVFDOjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvFKltL0%253D&md5=4ad1e46b0908dbc6318ad9a3c82353ef</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa063070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa063070%26sid%3Dliteratum%253Aachs%26aulast%3DCalverley%26aufirst%3DP.%2BM.%2BA.%26aulast%3DAnderson%26aufirst%3DJ.%2BA.%26aulast%3DCelli%26aufirst%3DB.%26aulast%3DFerguson%26aufirst%3DG.%2BT.%26aulast%3DJenkins%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DP.%2BW.%26aulast%3DYates%26aufirst%3DJ.%2BC.%26aulast%3DVestbo%26aufirst%3DJ.%26aulast%3D%26atitle%3DSalmeterol%2520and%2520fluticasone%2520propionate%2520and%2520survival%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DN.%2520Eng.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D775%26epage%3D789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">Celli, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vestbo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knobil, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yates, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calverley, P. M.</span><span> </span><span class="NLM_article-title">Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">178</span><span class="NLM_x">, </span> <span class="NLM_fpage">332</span><span class="NLM_x">–</span> <span class="NLM_lpage">338</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1164%2Frccm.200712-1869OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=18511702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BD1cvpt1Sksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2008&pages=332-338&author=B.+R.+Celliauthor=N.+E.+Thomasauthor=J.+A.+Andersonauthor=G.+T.+Fergusonauthor=C.+R.+Jenkinsauthor=P.+W.+Jonesauthor=J.+Vestboauthor=K.+Knobilauthor=J.+C.+Yatesauthor=P.+M.+Calverley&title=Effect+of+pharmacotherapy+on+rate+of+decline+of+lung+function+in+chronic+obstructive+pulmonary+disease%3A+results+from+the+TORCH+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study</span></div><div class="casAuthors">Celli Bartolome R; Thomas Nicola E; Anderson Julie A; Ferguson Gary T; Jenkins Christine R; Jones Paul W; Vestbo Jorgen; Knobil Katharine; Yates Julie C; Calverley Peter M A</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">332-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RATIONALE:  Chronic obstructive pulmonary disease (COPD) is characterized by an accelerated decline in lung function.  No drug has been shown conclusively to reduce this decline.  OBJECTIVES:  In a post hoc analysis of the Toward a Revolution in COPD Health (TORCH) study, we investigated the effects of combined salmeterol 50 microg plus fluticasone propionate 500 microg, either component alone or placebo, on the rate of post-bronchodilator FEV(1) decline in patients with moderate or severe COPD.  METHODS:  A randomized, double-blind, placebo-controlled study was conducted from September 2000 to November 2005 in 42 countries.  Of 6,112 patients from the efficacy population, 5,343 were included in this analysis.  MEASUREMENTS AND MAIN RESULTS:  Spirometry was measured every 24 weeks for 3 years.  There were 26,539 on-treatment observations.  The adjusted rate of decline in FEV(1) was 55 ml/year for placebo, 42 ml/year for salmeterol, 42 ml/year for fluticasone propionate, and 39 ml/year for salmeterol plus fluticasone propionate.  Salmeterol plus fluticasone propionate reduced the rate of FEV(1) decline by 16 ml/year compared with placebo (95% confidence interval [CI], 7-25; P < 0.001).  The difference was smaller for fluticasone propionate and salmeterol compared with placebo (13 ml/year; 95% CI, 5-22; P = 0.003).  Rates of decline were similar among the active treatment arms.  FEV(1) declined faster in current smokers and patients with a lower body mass index, and varied between world regions.  Patients who exacerbated more frequently had a faster FEV(1) decline.  CONCLUSIONS:  Pharmacotherapy with salmeterol plus fluticasone propionate, or the components, reduces the rate of decline of FEV(1) in patients with moderate-to-severe COPD, thus slowing disease progression.  Clinical trial (GSK Study Code SCO30003) registered with www.clinicaltrials.gov (NCT00268216).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRFg-vMUBak3EwlCcfExbvbfW6udTcc2eaTLeiJcxg5jrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvpt1Sksg%253D%253D&md5=e52d6a4d1be9ab8c751e2e20b253e76b</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1164%2Frccm.200712-1869OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200712-1869OC%26sid%3Dliteratum%253Aachs%26aulast%3DCelli%26aufirst%3DB.%2BR.%26aulast%3DThomas%26aufirst%3DN.%2BE.%26aulast%3DAnderson%26aufirst%3DJ.%2BA.%26aulast%3DFerguson%26aufirst%3DG.%2BT.%26aulast%3DJenkins%26aufirst%3DC.%2BR.%26aulast%3DJones%26aufirst%3DP.%2BW.%26aulast%3DVestbo%26aufirst%3DJ.%26aulast%3DKnobil%26aufirst%3DK.%26aulast%3DYates%26aufirst%3DJ.%2BC.%26aulast%3DCalverley%26aufirst%3DP.%2BM.%26atitle%3DEffect%2520of%2520pharmacotherapy%2520on%2520rate%2520of%2520decline%2520of%2520lung%2520function%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520results%2520from%2520the%2520TORCH%2520study%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2008%26volume%3D178%26spage%3D332%26epage%3D338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group">Nannini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cates, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasserson, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poole, P.</span><span> </span><span class="NLM_article-title">Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Cochrane Database Syst. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">CD003794</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=CD003794&author=L.+Nanniniauthor=C.+J.+Catesauthor=T.+J.+Lassersonauthor=P.+Poole&title=Combined+corticosteroid+and+long-acting+beta-agonist+in+one+inhaler+versus+placebo+for+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNannini%26aufirst%3DL.%26aulast%3DCates%26aufirst%3DC.%2BJ.%26aulast%3DLasserson%26aufirst%3DT.%2BJ.%26aulast%3DPoole%26aufirst%3DP.%26atitle%3DCombined%2520corticosteroid%2520and%2520long-acting%2520beta-agonist%2520in%2520one%2520inhaler%2520versus%2520placebo%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2007%26volume%3D4%26spage%3DCD003794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Campbell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eliraz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tornling, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nihlén, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bengtsson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabe, K. F.</span><span> </span><span class="NLM_article-title">Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">1511</span><span class="NLM_x">–</span> <span class="NLM_lpage">1520</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2005.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=16199148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BD2MnhsVWhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2005&pages=1511-1520&author=M.+Campbellauthor=A.+Elirazauthor=G.+Johanssonauthor=G.+Tornlingauthor=U.+Nihl%C3%A9nauthor=T.+Bengtssonauthor=K.+F.+Rabe&title=Formoterol+for+maintenance+and+as-needed+treatment+of+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Campbell Malcolm; Eliraz Abraham; Johansson Gunnar; Tornling Goran; Nihlen Ulf; Bengtsson Thomas; Rabe Klaus F</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1511-20</span>
        ISSN:<span class="NLM_cas:issn">0954-6111</span>.
    </div><div class="casAbstract">Formoterol is a long-acting beta2-agonist with a rapid onset of effect in patients with chronic obstructive pulmonary disease (COPD), making it potentially suitable for both maintenance and as-needed bronchodilator treatment.  To evaluate the efficacy and tolerability of maintenance formoterol in patients with COPD and to compare the effects of additional formoterol as needed with terbutaline.  In this 6-month, double-blind study, 657 patients with COPD (40 years, forced expiratory volume in 1s [FEV1] 40-70% predicted normal) were randomized to formoterol 9 microg twice daily (bid) plus terbutaline 0.5 mg as needed (FORM bid), formoterol 9 microg bid plus formoterol 4.5 microg as needed (FORM bid+prn), or placebo bid plus terbutaline 0.5 mg as needed (placebo), all administered via Turbuhaler.  Primary efficacy variables were FEV1 and the sum of breathlessness and chest tightness scores combined symptom score.  Formoterol significantly (P<0.01) increased FEV(1) compared with placebo: FORM bid 6.5% (95% CI: 2.5, 10.7%); FORM bid+prn 11.8% (95% CI: 7.7, 16.2%).  Combined symptom score decreased significantly in both formoterol groups compared with placebo: FORM bid -0.27 (95% CI: -0.49, -0.06; P=0.012); FORM bid+prn -0.32 (95% CI: -0.53, -0.11; P=0.0026).  Similar significant (P<0.05) improvements were seen in both formoterol groups for morning peak expiratory flow, cough and sleep scores, and reliever use.  In this study, formoterol 9 microg bid via Turbuhaler as maintenance therapy, with either formoterol or terbutaline as rescue medication, provided sustained improvements in lung function and COPD symptoms.  Both formoterol regimens were well tolerated with no differences in adverse events or electrocardiogram profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRA_zOkMScMATdblLE_E9PWfW6udTcc2eaTLeiJcxg5jrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnhsVWhsw%253D%253D&md5=8bb1da86e7d852d1266b98859069d0bb</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2005.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2005.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DEliraz%26aufirst%3DA.%26aulast%3DJohansson%26aufirst%3DG.%26aulast%3DTornling%26aufirst%3DG.%26aulast%3DNihl%25C3%25A9n%26aufirst%3DU.%26aulast%3DBengtsson%26aufirst%3DT.%26aulast%3DRabe%26aufirst%3DK.%2BF.%26atitle%3DFormoterol%2520for%2520maintenance%2520and%2520as-needed%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DRespir.%2520Med.%26date%3D2005%26volume%3D99%26spage%3D1511%26epage%3D1520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group">Szafranski, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cukier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramirez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menga, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sansores, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nahabedian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsson, H.</span><span> </span><span class="NLM_article-title">Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">74</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.03.00031402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=12570112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsFahu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=74-81&author=W.+Szafranskiauthor=A.+Cukierauthor=A.+Ramirezauthor=G.+Mengaauthor=R.+Sansoresauthor=S.+Nahabedianauthor=S.+Petersonauthor=H.+Olsson&title=Efficacy+and+safety+of+budesonide%2Fformoterol+in+the+management+of+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Szafranski, W.; Cukier, A.; Ramirez, A.; Menga, G.; Sansores, R.; Nahabedian, S.; Peterson, S.; Olsson, H.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-81</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">The efficacy and safety of budesonide/formoterol in a single inhaler compared with placebo, budesonide and formoterol were evaluated in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).  In a 12-mo, randomized, double-blind, placebo-controlled, parallel-group study in 812 adults (mean age 64 yrs, mean forced expiratory vol. in one second (FEV1) 36% predicted normal), patients received two inhalations twice daily of either budesonide/formoterol (Symbicort) 160/4.5 μg (delivered dose), budesonide 200 μg (metered dose), formoterol 4.5 μg or placebo.  Severe exacerbations and FEV1 (primary variables), peak expiratory flow (PEF), COPD symptoms, health-related quality of life (HRQL), mild exacerbations, use of reliever β2-agonist and safety variables were recorded.  Budesonide/formoterol reduced the mean no. of severe exacerbations per patient per yr by 24% vs. placebo and 23% vs. formoterol.  FEV1 increased by 15% vs. placebo and 9% vs. budesonide.  Morning PEF improved significantly on day 1 vs. placebo and budesonide; after 1 wk, morning PEF was improved vs. placebo, budesonide and formoterol.  Improvements in morning and evening PEF vs. comparators were maintained over 12 mo.  Budesonide/formoterol decreased all symptom scores and use of reliever β2-agonists significantly vs. placebo and budesonide, and improved HRQL vs. placebo.  All treatments were well tolerated.  These results suggest a role for budesonide/formoterol in the long-term management of moderate-to-severe chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlUXMXT1zCKbVg90H21EOLACvtfcHk0liJ5oHg4ZPpLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsFahu7c%253D&md5=dbadf6f2baec75e9323cd622798a4611</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1183%2F09031936.03.00031402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.03.00031402%26sid%3Dliteratum%253Aachs%26aulast%3DSzafranski%26aufirst%3DW.%26aulast%3DCukier%26aufirst%3DA.%26aulast%3DRamirez%26aufirst%3DA.%26aulast%3DMenga%26aufirst%3DG.%26aulast%3DSansores%26aufirst%3DR.%26aulast%3DNahabedian%26aufirst%3DS.%26aulast%3DPeterson%26aufirst%3DS.%26aulast%3DOlsson%26aufirst%3DH.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520budesonide%252Fformoterol%2520in%2520the%2520management%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2003%26volume%3D21%26spage%3D74%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group">Battram, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuenoud, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowling, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairhurst, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fozard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighton-Davies, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEvoy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trifilieff, A.</span><span> </span><span class="NLM_article-title">In vitro and in vivo pharmacological characterization of 5-[(<i>R</i>)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1<i>H</i>-quinolin-2-one (indacaterol), a novel inhaled beta<sub>2</sub> adrenoceptor agonist with a 24-h duration of action</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">317</span><span class="NLM_x">, </span> <span class="NLM_fpage">762</span><span class="NLM_x">–</span> <span class="NLM_lpage">770</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1124%2Fjpet.105.098251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=16434564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD28XktFamu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2006&pages=762-770&author=C.+Battramauthor=S.+J.+Charltonauthor=B.+Cuenoudauthor=M.+R.+Dowlingauthor=R.+A.+Fairhurstauthor=D.+Farrauthor=J.+R.+Fozardauthor=J.+R.+Leighton-Daviesauthor=C.+A.+Lewisauthor=L.+McEvoyauthor=R.+J.+Turnerauthor=A.+Trifilieff&title=In+vitro+and+in+vivo+pharmacological+characterization+of+5-%5B%28R%29-2-%285%2C6-diethyl-indan-2-ylamino%29-1-hydroxy-ethyl%5D-8-hydroxy-1H-quinolin-2-one+%28indacaterol%29%2C+a+novel+inhaled+beta2+adrenoceptor+agonist+with+a+24-h+duration+of+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled β2 adrenoceptor agonist with a 24-h duration of action</span></div><div class="casAuthors">Battram, Cliff; Charlton, Steven J.; Cuenoud, Bernard; Dowling, Mark R.; Fairhurst, Robin A.; Farr, David; Fozard, John R.; Leighton-Davies, Juliet R.; Lewis, Christine A.; McEvoy, Lorraine; Turner, Robert J.; Trifilieff, Alexandre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">762-770</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Here, we describe the preclin. pharmacol. profile of indacaterol, a novel, chirally pure inhaled β2 adrenoceptor agonist, in comparison with marketed drugs.  Indacaterol is close to a full agonist at the human β2 adrenoceptor (Emax = 73±1% of the maximal effect of isoprenaline; pEC50 = 8.06±0.02), whereas salmeterol displays only partial efficacy (38±1%).  The functional selectivity profile of indacaterol over β1 human adrenoceptors is similar to that of formoterol, whereas its β3 adrenoceptor selectivity profile is similar to that of formoterol and salbutamol.  In isolated superfused guinea pig trachea, indacaterol has a fast onset of action (30±4 min) similar to formoterol and salbutamol, and a long duration of action (529±99 min) comparable with salmeterol.  In the conscious guinea pig, when given intratracheally as a dry powder, indacaterol inhibits 5-hydroxytryptamine-induced bronchoconstriction for at least 24 h, whereas salmeterol, formoterol, and salbutamol have durations of action of 12, 4, and 2 h, resp.  When given via nebulization to anesthetized rhesus monkeys, all of the compds. dose-dependently inhibit methacholine-induced bronchoconstriction, although indacaterol produces the most prolonged bronchoprotective effect and induces the lowest increase in heart rate for a similar degree of antibronchoconstrictor activity.  In conclusion, the preclin. profile of indacaterol suggests that this compd. has a superior duration of action compatible with once-daily dosing in human, together with a fast onset of action and an improved cardiovascular safety profile over marketed inhaled β2 adrenoceptor agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNpFkEE8xZvbVg90H21EOLACvtfcHk0liJ5oHg4ZPpLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktFamu70%253D&md5=0ea4e459100f0d3971d8a7f89c5de059</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.098251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.098251%26sid%3Dliteratum%253Aachs%26aulast%3DBattram%26aufirst%3DC.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DCuenoud%26aufirst%3DB.%26aulast%3DDowling%26aufirst%3DM.%2BR.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DFarr%26aufirst%3DD.%26aulast%3DFozard%26aufirst%3DJ.%2BR.%26aulast%3DLeighton-Davies%26aufirst%3DJ.%2BR.%26aulast%3DLewis%26aufirst%3DC.%2BA.%26aulast%3DMcEvoy%26aufirst%3DL.%26aulast%3DTurner%26aufirst%3DR.%2BJ.%26aulast%3DTrifilieff%26aufirst%3DA.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520pharmacological%2520characterization%2520of%25205-%255B%2528R%2529-2-%25285%252C6-diethyl-indan-2-ylamino%2529-1-hydroxy-ethyl%255D-8-hydroxy-1H-quinolin-2-one%2520%2528indacaterol%2529%252C%2520a%2520novel%2520inhaled%2520beta2%2520adrenoceptor%2520agonist%2520with%2520a%252024-h%2520duration%2520of%2520action%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D317%26spage%3D762%26epage%3D770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group">Hawkins, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfeffer, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swedberg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granger, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yusuf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostergren, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michelson, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pocock, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maggioni, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMurray, J. J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">CHARM Investigators and Committees.</span><span> </span><span class="NLM_article-title">Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme</span> <span class="citation_source-journal">Eur. J. Heart Failure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">557</span><span class="NLM_x">–</span> <span class="NLM_lpage">565</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1093%2Feurjhf%2Fhfq040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=20356870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC3czmsFKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=557-565&author=N.+M.+Hawkinsauthor=D.+Wangauthor=M.+Petrieauthor=M.+A.+Pfefferauthor=K.+Swedbergauthor=C.+B.+Grangerauthor=S.+Yusufauthor=S.+D.+Solomonauthor=J.+O.+Ostergrenauthor=E.+L.+Michelsonauthor=S.+J.+Pocockauthor=A.+P.+Maggioniauthor=J.+J.+V.+McMurrayauthor=CHARM+Investigators+and+Committees.&title=Baseline+characteristics+and+outcomes+of+patients+with+heart+failure+receiving+bronchodilators+in+the+CHARM+programme"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme</span></div><div class="casAuthors">Hawkins Nathaniel M; Wang Duolao; Petrie Mark C; Pfeffer Marc A; Swedberg Karl; Granger Christopher B; Yusuf Salim; Solomon Scott D; Ostergren Jan; Michelson Eric L; Pocock Stuart J; Maggioni Aldo P; McMurray John J V</div><div class="citationInfo"><span class="NLM_cas:title">European journal of heart failure</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">557-65</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIMS:  Heart failure (HF) and chronic obstructive pulmonary disease are common partners.  Bronchodilators are associated with adverse cardiovascular outcomes in patients with pulmonary disease.  The outcome of patients with HF prescribed bronchodilators is poorly defined.  METHODS AND RESULTS:  The Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme randomized 7599 patients with symptomatic HF to receive candesartan or placebo.  The relative risk conveyed by bronchodilator therapy was examined using a multivariable Cox proportional hazards model.  The prevalence of bronchodilator therapy was similar in patients with reduced and preserved systolic function (respectively, 8.7 vs. 9.2%, P = 0.46).  Beta-blocker utilization was markedly lower in patients receiving bronchodilators compared with those without (overall 31.9 vs. 57.6%, P < 0.0001).  Bronchodilator use was associated with increased all-cause mortality [HR 1.26 (1.09-1.45), P = 0.0015], cardiovascular death [HR 1.21 (1.03-1.42), P = 0.0216], HF hospitalization [HR 1.49 (1.29-1.72), P < 0.0001], and major adverse cardiovascular events [HR 1.32 (1.17-1.76), P < 0.0001].  The adverse outcomes were consistent in patients with reduced and preserved systolic function.  No significant interaction was observed between bronchodilators and beta-blockade with respect to outcomes.  CONCLUSION:  Bronchodilator use is a powerful independent predictor of worsening HF and increased mortality in a broad spectrum of patients with HF.  Whether this relates to a toxic effect of bronchodilators, underlying pulmonary disease, or both is unclear and warrants further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSojbo8wkBw3XthwrmtH4OBfW6udTcc2eZ8ve0uynrZpLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czmsFKlsQ%253D%253D&md5=fe5e87a1ca9d26a6efbca356bcf9ee20</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1093%2Feurjhf%2Fhfq040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurjhf%252Fhfq040%26sid%3Dliteratum%253Aachs%26aulast%3DHawkins%26aufirst%3DN.%2BM.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DPetrie%26aufirst%3DM.%26aulast%3DPfeffer%26aufirst%3DM.%2BA.%26aulast%3DSwedberg%26aufirst%3DK.%26aulast%3DGranger%26aufirst%3DC.%2BB.%26aulast%3DYusuf%26aufirst%3DS.%26aulast%3DSolomon%26aufirst%3DS.%2BD.%26aulast%3DOstergren%26aufirst%3DJ.%2BO.%26aulast%3DMichelson%26aufirst%3DE.%2BL.%26aulast%3DPocock%26aufirst%3DS.%2BJ.%26aulast%3DMaggioni%26aufirst%3DA.%2BP.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%2BV.%26aulast%3D%26atitle%3DBaseline%2520characteristics%2520and%2520outcomes%2520of%2520patients%2520with%2520heart%2520failure%2520receiving%2520bronchodilators%2520in%2520the%2520CHARM%2520programme%26jtitle%3DEur.%2520J.%2520Heart%2520Failure%26date%3D2010%26volume%3D12%26spage%3D557%26epage%3D565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group">Hanrahan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grogan, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgartner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimetbaum, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morganroth, J.</span><span> </span><span class="NLM_article-title">Arrhythmias in patients with chronic obstructive pulmonary disease (COPD) occurrence frequency and the effect of treatment with the inhaled long-acting beta<sub>2</sub>-agonists arformoterol and salmeterol</span> <span class="citation_source-journal">Medicine (Baltimore)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1097%2FMD.0b013e31818fcc02" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=19011503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BD1cjltFGitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2008&pages=319-328&author=J.+P.+Hanrahanauthor=D.+R.+Groganauthor=R.+A.+Baumgartnerauthor=A.+Wilsonauthor=H.+Chengauthor=P.+J.+Zimetbaumauthor=J.+Morganroth&title=Arrhythmias+in+patients+with+chronic+obstructive+pulmonary+disease+%28COPD%29+occurrence+frequency+and+the+effect+of+treatment+with+the+inhaled+long-acting+beta2-agonists+arformoterol+and+salmeterol"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol</span></div><div class="casAuthors">Hanrahan John P; Grogan Donna R; Baumgartner Rudolf A; Wilson Amy; Cheng Hailong; Zimetbaum Peter J; Morganroth Joel</div><div class="citationInfo"><span class="NLM_cas:title">Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">319-28</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Beta-adrenergic stimulation may increase heart rate and the potential for cardiac arrhythmias.  The effect of inhaled long-acting beta2-agonists (LABAs) on these outcomes was evaluated in patients with chronic obstructive pulmonary disease (COPD) in 2 double-blind randomized clinical trials.  The pretreatment arrhythmia occurrence frequency in these patients was also described.  In this analysis, 24-hour Holter monitoring data were pooled from 2 identically designed Phase III trials.  Patients were randomized to LABA treatment or placebo for 12 weeks: a) nebulized arformoterol 15 microg BID, b) 25 microg BID, or c) 50 microg QD; d) salmeterol metered dose inhaler 42 microg BID; or e) placebo.  The 24-hour Holter monitoring was performed pretreatment and at Weeks 0 (first day of dosing), 6, and 12.  We assessed the proportion of patients with each of 4 arrhythmias: atrial tachycardia, atrial fibrillation/flutter, and "nonsustained"; (4-10 beats) and "sustained"; (>10 beats) ventricular tachycardia.  There were 5226 Holter recordings in 1429 treated patients.  At baseline, there was a low frequency of occurrence of atrial fibrillation/flutter (0.1%), nonsustained ventricular tachycardia (3.1%), and >10 beat ventricular tachycardia (0.3%).  Atrial tachycardia occurred frequently (41.8%).  The proportion of patients with treatment-emergent atrial tachycardia ranged from 27% to 32% and was non-significantly higher, by approximately 2%-5% (p = 0.70), in the LABA groups compared with the placebo group.  The rates of the other more serious arrhythmias did not increase with LABA treatment and were similar to placebo.  All treatment groups (LABA and placebo) had consistent small decreases from baseline in mean 24-hour and maximum hourly heart rate.  In conclusion, in this large cohort of COPD patients with no or stable cardiac comorbidities, a high proportion ( approximately 40%) of patients were observed to have atrial tachycardia before treatment, which increased by 2%-5% with LABA treatment.  More serious arrhythmias were infrequent and did not increase with inhaled LABA therapy.  LABA administration did not increase mean heart rate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQw-TVpH1jTQ825P7XSLhESfW6udTcc2eZTZwF0vOx2fLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjltFGitQ%253D%253D&md5=f243b081a2f6a306e6a8aa8e1149b22d</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1097%2FMD.0b013e31818fcc02&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMD.0b013e31818fcc02%26sid%3Dliteratum%253Aachs%26aulast%3DHanrahan%26aufirst%3DJ.%2BP.%26aulast%3DGrogan%26aufirst%3DD.%2BR.%26aulast%3DBaumgartner%26aufirst%3DR.%2BA.%26aulast%3DWilson%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DZimetbaum%26aufirst%3DP.%2BJ.%26aulast%3DMorganroth%26aufirst%3DJ.%26atitle%3DArrhythmias%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%2520%2528COPD%2529%2520occurrence%2520frequency%2520and%2520the%2520effect%2520of%2520treatment%2520with%2520the%2520inhaled%2520long-acting%2520beta2-agonists%2520arformoterol%2520and%2520salmeterol%26jtitle%3DMedicine%2520%2528Baltimore%2529%26date%3D2008%26volume%3D87%26spage%3D319%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group">Nelson, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleecker, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yancey, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorinsky, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SMART Study Group.</span><span> </span><span class="NLM_article-title">The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2006&pages=15-26&author=H.+S.+Nelsonauthor=S.+T.+Weissauthor=E.+R.+Bleeckerauthor=S.+W.+Yanceyauthor=P.+M.+Dorinskyauthor=SMART+Study+Group.&title=The+Salmeterol+Multicenter+Asthma+Research+Trial%3A+a+comparison+of+usual+pharmacotherapy+for+asthma+or+usual+pharmacotherapy+plus+salmeterol"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DH.%2BS.%26aulast%3DWeiss%26aufirst%3DS.%2BT.%26aulast%3DBleecker%26aufirst%3DE.%2BR.%26aulast%3DYancey%26aufirst%3DS.%2BW.%26aulast%3DDorinsky%26aufirst%3DP.%2BM.%26aulast%3D%26atitle%3DThe%2520Salmeterol%2520Multicenter%2520Asthma%2520Research%2520Trial%253A%2520a%2520comparison%2520of%2520usual%2520pharmacotherapy%2520for%2520asthma%2520or%2520usual%2520pharmacotherapy%2520plus%2520salmeterol%26jtitle%3DChest%26date%3D2006%26volume%3D129%26spage%3D15%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group">Vogelmeier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kardos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gans, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stenglein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thirlwell, J.</span><span> </span><span class="NLM_article-title">Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">1511</span><span class="NLM_x">–</span> <span class="NLM_lpage">1520</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2008.07.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=18804362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BD1cjktFOisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2008&pages=1511-1520&author=C.+Vogelmeierauthor=P.+Kardosauthor=S.+Harariauthor=S.+J.+Gansauthor=S.+Stengleinauthor=J.+Thirlwell&title=Formoterol+mono-+and+combination+therapy+with+tiotropium+in+patients+with+COPD%3A+a+6-month+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study</span></div><div class="casAuthors">Vogelmeier Claus; Kardos Peter; Harari Sergio; Gans Steven J M; Stenglein Stephan; Thirlwell Jackie</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1511-20</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although guidelines recommend combining long-acting bronchodilators in COPD, data are limited.  We examined the clinical efficacy and safety of formoterol, tiotropium and the combination in patients with COPD.  Eight hundred and forty-seven patients with COPD (mean FEV(1) 52% predicted; FEV(1)/FVC 53%) were randomized to receive one of the following four treatments for 24 weeks: formoterol 10 microg b.i.d. plus tiotropium 18 microg o.d.; formoterol 10 microg b.i.d.; tiotropium 18 microg o.d., or placebo.  The study was partially blinded (formoterol and placebo).  For the primary endpoint, FEV(1) 2h post-dose after 24 weeks, there were small differences in favour of the combination therapy versus formoterol (0.07 L, p=0.044) or tiotropium (0.06 L, p=0.066).  All three treatments were superior to placebo (p<0.001).  The combination was statistically superior to monotherapy for: the primary endpoint (p=0.044 vs. formoterol); FEV(1) 5 min after the first dose (p<0.001) and at 12 weeks (p<0.05 vs. tiotropium); and peak expiratory flow averaged over the first 6 weeks (p<0.001 vs. both).  The three active treatments were significantly more effective than placebo for secondary endpoints: COPD-related 'bad days', symptoms, use of rescue medication and peak expiratory flow, and aspects of health-related quality of life.  The overall incidence of adverse events was similar with all active treatments, although COPD-related adverse events were more common with tiotropium.  Combined bronchodilator therapy may be a valuable treatment option for patients with COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQI4mu9SYWimevW160gIxP_fW6udTcc2eZTZwF0vOx2fLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjktFOisQ%253D%253D&md5=9ad0975b9efb39e3043ddbb90302b5c8</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2008.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2008.07.020%26sid%3Dliteratum%253Aachs%26aulast%3DVogelmeier%26aufirst%3DC.%26aulast%3DKardos%26aufirst%3DP.%26aulast%3DHarari%26aufirst%3DS.%26aulast%3DGans%26aufirst%3DS.%2BJ.%26aulast%3DStenglein%26aufirst%3DS.%26aulast%3DThirlwell%26aufirst%3DJ.%26atitle%3DFormoterol%2520mono-%2520and%2520combination%2520therapy%2520with%2520tiotropium%2520in%2520patients%2520with%2520COPD%253A%2520a%25206-month%2520study%26jtitle%3DRespir.%2520Med.%26date%3D2008%26volume%3D102%26spage%3D1511%26epage%3D1520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group">Tashkin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donohue, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahler, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodwin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanrahan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, W. T.</span><span> </span><span class="NLM_article-title">Effects of arformoterol twice daily, tiotropium once daily and their combination in patients with COPD</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">516</span><span class="NLM_x">–</span> <span class="NLM_lpage">524</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2008.12.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=19208459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BD1M7nsVChtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2009&pages=516-524&author=D.+P.+Tashkinauthor=J.+F.+Donohueauthor=D.+A.+Mahlerauthor=H.+Huangauthor=E.+Goodwinauthor=K.+Schaeferauthor=J.+P.+Hanrahanauthor=W.+T.+Andrews&title=Effects+of+arformoterol+twice+daily%2C+tiotropium+once+daily+and+their+combination+in+patients+with+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD</span></div><div class="casAuthors">Tashkin D P; Donohue J F; Mahler D A; Huang H; Goodwin E; Schaefer K; Hanrahan J P; Andrews W T</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">516-24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Current guidelines support using in combination more than one class of long-acting bronchodilator for COPD patients whose symptoms are not controlled by mono-therapy.  This 2-week, multi-center (34 sites), randomized, modified-blind, parallel group study evaluated the efficacy and safety of concomitant treatment with nebulized arformoterol (the formoterol(R,R)-isomer) BID and tiotropium DPI QD.  METHODS:  COPD patients (mean FEV(1) 1.37L, 45.4% predicted) were randomized to receive mono-therapy (either arformoterol 15microg BID [n=76] or tiotropium 18microg QD [n=80]), or combined therapy (sequential dosing of arformoterol 15microg BID and tiotropium 18microg QD [n=78]).  Changes in pulmonary function, dyspnea, and rescue levalbuterol use were evaluated, as were safety outcomes.  RESULTS:  Mean FEV(1)AUC(0-24) (the primary endpoint) improved similarly from baseline for arformoterol (0.10L) and tiotropium (0.08L) treatment groups and greater for the combined therapy group (0.22L; all p-values <0.005).  Peak FEV(1), peak FVC, 24-h trough FEV(1), and inspiratory capacity also improved similarly for the mono-therapies and greatest for the combined therapy.  Dyspnea (mean transition dyspnea index) improved similarly for arformoterol (+2.3) and tiotropium (+1.8) and greatest with combined therapy (+3.1; p-values <0.05).  Levalbuterol use decreased for all treatment groups (range -1.8 to -2.5 actuations/day).  All treatments had similar frequency of adverse events.  CONCLUSION:  In this study, the combination of nebulized arformoterol 15microg BID plus tiotropium 18microg DPI QD was the most effective in improving pulmonary function and disease symptoms.  Mono-therapy improvement with arformoterol or tiotropium was similar.  All three treatments were well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlIXjjeizOy1VwdslNBF-tfW6udTcc2eaUv75MoAPfl7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M7nsVChtA%253D%253D&md5=9ab9999aaefab79fb7d7cc3bebce1f41</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2008.12.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2008.12.014%26sid%3Dliteratum%253Aachs%26aulast%3DTashkin%26aufirst%3DD.%2BP.%26aulast%3DDonohue%26aufirst%3DJ.%2BF.%26aulast%3DMahler%26aufirst%3DD.%2BA.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DGoodwin%26aufirst%3DE.%26aulast%3DSchaefer%26aufirst%3DK.%26aulast%3DHanrahan%26aufirst%3DJ.%2BP.%26aulast%3DAndrews%26aufirst%3DW.%2BT.%26atitle%3DEffects%2520of%2520arformoterol%2520twice%2520daily%252C%2520tiotropium%2520once%2520daily%2520and%2520their%2520combination%2520in%2520patients%2520with%2520COPD%26jtitle%3DRespir.%2520Med.%26date%3D2009%26volume%3D103%26spage%3D516%26epage%3D524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group">Rabe, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timmer, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sagkriotis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viel, K.</span><span> </span><span class="NLM_article-title">Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2008&pages=255-262&author=K.+F.+Rabeauthor=W.+Timmerauthor=A.+Sagkriotisauthor=K.+Viel&title=Comparison+of+a+combination+of+tiotropium+plus+formoterol+to+salmeterol+plus+fluticasone+in+moderate+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRabe%26aufirst%3DK.%2BF.%26aulast%3DTimmer%26aufirst%3DW.%26aulast%3DSagkriotis%26aufirst%3DA.%26aulast%3DViel%26aufirst%3DK.%26atitle%3DComparison%2520of%2520a%2520combination%2520of%2520tiotropium%2520plus%2520formoterol%2520to%2520salmeterol%2520plus%2520fluticasone%2520in%2520moderate%2520COPD%26jtitle%3DChest%26date%3D2008%26volume%3D134%26spage%3D255%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group">Aaron, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandemheen, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fergusson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maltais, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourbeau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIvor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anthony, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowie, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Field, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivington, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Road, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffstein, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marciniuk, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormack, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prins, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleskie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doucette, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayers, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">FitzGerald, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium.</span><span> </span><span class="NLM_article-title">Tiotropium in combination with placebo, salmeterol or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">545</span><span class="NLM_x">–</span> <span class="NLM_lpage">555</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.7326%2F0003-4819-146-8-200704170-00152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=17310045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BD2s3islartQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2007&pages=545-555&author=S.+D.+Aaronauthor=K.+L.+Vandemheenauthor=D.+Fergussonauthor=F.+Maltaisauthor=J.+Bourbeauauthor=R.+Goldsteinauthor=M.+Balterauthor=D.+O%E2%80%99Donnellauthor=A.+McIvorauthor=S.+Sharmaauthor=G.+Bishopauthor=J.+Anthonyauthor=R.+Cowieauthor=S.+Fieldauthor=A.+Hirschauthor=P.+Hernandezauthor=R.+Rivingtonauthor=J.+Roadauthor=V.+Hoffsteinauthor=R.+Hodderauthor=D.+Marciniukauthor=D.+McCormackauthor=G.+Foxauthor=G.+Coxauthor=H.+B.+Prinsauthor=G.+Fordauthor=D.+Bleskieauthor=S.+Doucetteauthor=I.+Mayersauthor=K.+Chapmanauthor=N.+Zamelauthor=M.+FitzGeraldauthor=Canadian+Thoracic+Society%2FCanadian+Respiratory+Clinical+Research+Consortium.&title=Tiotropium+in+combination+with+placebo%2C+salmeterol+or+fluticasone-salmeterol+for+treatment+of+chronic+obstructive+pulmonary+disease%3A+a+randomized+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial</span></div><div class="casAuthors">Aaron Shawn D; Vandemheen Katherine L; Fergusson Dean; Maltais Francois; Bourbeau Jean; Goldstein Roger; Balter Meyer; O'Donnell Denis; McIvor Andrew; Sharma Sat; Bishop Graham; Anthony John; Cowie Robert; Field Stephen; Hirsch Andrew; Hernandez Paul; Rivington Robert; Road Jeremy; Hoffstein Victor; Hodder Richard; Marciniuk Darcy; McCormack David; Fox George; Cox Gerard; Prins Henry B; Ford Gordon; Bleskie Dominique; Doucette Steve; Mayers Irvin; Chapman Kenneth; Zamel Noe; FitzGerald Mark</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">545-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Treatment of moderate or severe chronic obstructive pulmonary disease (COPD) with combinations of inhaled corticosteroids, long-acting beta-agonists, and long-acting anticholinergic bronchodilators is common but unstudied.  OBJECTIVE:  To determine whether combining tiotropium with salmeterol or fluticasone-salmeterol improves clinical outcomes in adults with moderate to severe COPD compared with tiotropium alone.  DESIGN:  Randomized, double-blind, placebo-controlled trial conducted from October 2003 to January 2006.  SETTING:  27 academic and community medical centers in Canada.  PATIENTS:  449 patients with moderate or severe COPD.  INTERVENTION:  1 year of treatment with tiotropium plus placebo, tiotropium plus salmeterol, or tiotropium plus fluticasone-salmeterol.  MEASUREMENTS:  The primary end point was the proportion of patients who experienced an exacerbation of COPD that required treatment with systemic steroids or antibiotics.  RESULTS:  The proportion of patients in the tiotropium plus placebo group who experienced an exacerbation (62.8%) did not differ from that in the tiotropium plus salmeterol group (64.8%; difference, -2.0 percentage points [95% CI, -12.8 to 8.8 percentage points]) or in the tiotropium plus fluticasone-salmeterol group (60.0%; difference, 2.8 percentage points [CI, -8.2 to 13.8 percentage points]).  In sensitivity analyses, the point estimates and 95% confidence bounds shifted in the direction favoring tiotropium plus salmeterol and tiotropium plus fluticasone-salmeterol.  Tiotropium plus fluticasone-salmeterol improved lung function (P = 0.049) and disease-specific quality of life (P = 0.01) and reduced the number of hospitalizations for COPD exacerbation (incidence rate ratio, 0.53 [CI, 0.33 to 0.86]) and all-cause hospitalizations (incidence rate ratio, 0.67 [CI, 0.45 to 0.99]) compared with tiotropium plus placebo.  In contrast, tiotropium plus salmeterol did not statistically improve lung function or hospitalization rates compared with tiotropium plus placebo.  LIMITATIONS:  More than 40% of patients who received tiotropium plus placebo and tiotropium plus salmeterol discontinued therapy prematurely, and many crossed over to treatment with open-label inhaled steroids or long-acting beta-agonists.  CONCLUSIONS:  Addition of fluticasone-salmeterol to tiotropium therapy did not statistically influence rates of COPD exacerbation but did improve lung function, quality of life, and hospitalization rates in patients with moderate to severe COPD.  International Standard Randomised Controlled Trial registration number: ISRCTN29870041.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSN_40o1KWtZ9NTrvPZP1IpfW6udTcc2eaz9AqsMkQIabntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s3islartQ%253D%253D&md5=b189f13e74ad9db756e1299c21913a40</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-146-8-200704170-00152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-146-8-200704170-00152%26sid%3Dliteratum%253Aachs%26aulast%3DAaron%26aufirst%3DS.%2BD.%26aulast%3DVandemheen%26aufirst%3DK.%2BL.%26aulast%3DFergusson%26aufirst%3DD.%26aulast%3DMaltais%26aufirst%3DF.%26aulast%3DBourbeau%26aufirst%3DJ.%26aulast%3DGoldstein%26aufirst%3DR.%26aulast%3DBalter%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DD.%26aulast%3DMcIvor%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DBishop%26aufirst%3DG.%26aulast%3DAnthony%26aufirst%3DJ.%26aulast%3DCowie%26aufirst%3DR.%26aulast%3DField%26aufirst%3DS.%26aulast%3DHirsch%26aufirst%3DA.%26aulast%3DHernandez%26aufirst%3DP.%26aulast%3DRivington%26aufirst%3DR.%26aulast%3DRoad%26aufirst%3DJ.%26aulast%3DHoffstein%26aufirst%3DV.%26aulast%3DHodder%26aufirst%3DR.%26aulast%3DMarciniuk%26aufirst%3DD.%26aulast%3DMcCormack%26aufirst%3DD.%26aulast%3DFox%26aufirst%3DG.%26aulast%3DCox%26aufirst%3DG.%26aulast%3DPrins%26aufirst%3DH.%2BB.%26aulast%3DFord%26aufirst%3DG.%26aulast%3DBleskie%26aufirst%3DD.%26aulast%3DDoucette%26aufirst%3DS.%26aulast%3DMayers%26aufirst%3DI.%26aulast%3DChapman%26aufirst%3DK.%26aulast%3DZamel%26aufirst%3DN.%26aulast%3DFitzGerald%26aufirst%3DM.%26aulast%3D%26atitle%3DTiotropium%2520in%2520combination%2520with%2520placebo%252C%2520salmeterol%2520or%2520fluticasone-salmeterol%2520for%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520randomized%2520trial%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2007%26volume%3D146%26spage%3D545%26epage%3D555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group">Singh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cahn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, B. J.</span><span> </span><span class="NLM_article-title">Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD</span> <span class="citation_source-journal">Thorax</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">592</span><span class="NLM_x">–</span> <span class="NLM_lpage">598</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2008&pages=592-598&author=D.+Singhauthor=J.+Brooksauthor=G.+Haganauthor=A.+Cahnauthor=B.+J.+O%E2%80%99Connor&title=Superiority+of+%E2%80%9Ctriple%E2%80%9D+therapy+with+salmeterol%2Ffluticasone+propionate+and+tiotropium+bromide+versus+individual+components+in+moderate+to+severe+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DBrooks%26aufirst%3DJ.%26aulast%3DHagan%26aufirst%3DG.%26aulast%3DCahn%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DB.%2BJ.%26atitle%3DSuperiority%2520of%2520%25E2%2580%259Ctriple%25E2%2580%259D%2520therapy%2520with%2520salmeterol%252Ffluticasone%2520propionate%2520and%2520tiotropium%2520bromide%2520versus%2520individual%2520components%2520in%2520moderate%2520to%2520severe%2520COPD%26jtitle%3DThorax%26date%3D2008%26volume%3D63%26spage%3D592%26epage%3D598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group">Welte, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miravitlles, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eriksson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polanowski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, R.</span><span> </span><span class="NLM_article-title">Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">180</span><span class="NLM_x">, </span> <span class="NLM_fpage">741</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1164%2Frccm.200904-0492OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=19644045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlGgtbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2009&pages=741-750&author=T.+Welteauthor=M.+Miravitllesauthor=P.+Hernandezauthor=G.+Erikssonauthor=S.+Petersonauthor=T.+Polanowskiauthor=R.+Kessler&title=Efficacy+and+tolerability+of+budesonide%2Fformoterol+added+to+tiotropium+in+patients+with+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease</span></div><div class="casAuthors">Welte, Tobias; Miravitlles, Marc; Hernandez, Paul; Eriksson, Goeran; Peterson, Stefan; Polanowski, Tomasz; Kessler, Romain</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">741-750</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Budesonide/formoterol and tiotropium are commonly used maintenance treatments for patients with chronic obstructive pulmonary disease.  Combining these medications may provide addnl. benefits.  Objectives: To assess the efficacy and tolerability of budesonide/formoterol added to tiotropium in patients eligible for inhaled corticosteroid/long-acting β2-agonist combination therapy.  Methods: In this 12-wk, randomized, double-blind, parallel-group, multicenter study, after a 2-wk run-in, 660 subjects (75% male; mean age, 62 yr; FEV1, 1.1 L; 38% predicted normal), 40 years of age or older, received tiotropium (18 μg once daily) plus either budesonide/formoterol (320/9 μg) (n = 329) or placebo (n = 331) twice daily.  Measurements and Main Results: Clinic predose (primary outcome) and postdose FEV1, predose and postdose forced vital capacity and inspiratory capacity, and health status were measured.  Other outcomes included daily measurements taken at home (pre- and postdose morning FEV1 and peak expiratory flow, morning symptoms and activities, and morning reliever use), severe exacerbations, and tolerability.  Over the treatment period, budesonide/formoterol plus tiotropium significantly increased predose FEV1 by 6% (65 mL) and postdose by 11% (123 and 131 mL at 5 and 60 min postdose, resp.) vs. tiotropium alone (both P < 0.001).  Other outcomes all significantly improved with budesonide/formoterol plus tiotropium vs. tiotropium alone.  The no. of severe exacerbations decreased by 62% (rate ratio, 0.38; 95% confidence interval, 0.25-0.57; P < 0.001).  Both treatments were well tolerated.  Conclusions: In patients with chronic obstructive pulmonary disease, budesonide/formoterol added to tiotropium vs. tiotropium alone provides rapid and sustained improvements in lung function, health status, morning symptoms and activities, and reduces severe exacerbations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIInFGAKucAbVg90H21EOLACvtfcHk0lhDaoCK7SI7RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlGgtbnM&md5=fd32e7085535ca751df8544d1055a07b</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1164%2Frccm.200904-0492OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200904-0492OC%26sid%3Dliteratum%253Aachs%26aulast%3DWelte%26aufirst%3DT.%26aulast%3DMiravitlles%26aufirst%3DM.%26aulast%3DHernandez%26aufirst%3DP.%26aulast%3DEriksson%26aufirst%3DG.%26aulast%3DPeterson%26aufirst%3DS.%26aulast%3DPolanowski%26aufirst%3DT.%26aulast%3DKessler%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520tolerability%2520of%2520budesonide%252Fformoterol%2520added%2520to%2520tiotropium%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2009%26volume%3D180%26spage%3D741%26epage%3D750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group">Salmon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttmann, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeHaas, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotzer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slack, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarau, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palovich, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lainé, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rumsey, W. L.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">345</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1124%2Fjpet.112.202051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23435542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVCgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=2013&pages=260-270&author=M.+Salmonauthor=M.+A.+Luttmannauthor=J.+J.+Foleyauthor=P.+T.+Buckleyauthor=D.+B.+Schmidtauthor=M.+Burmanauthor=E.+F.+Webbauthor=C.+J.+DeHaasauthor=C.+J.+Kotzerauthor=V.+J.+Barrettauthor=R.+J.+Slackauthor=H.+M.+Sarauauthor=M.+R.+Palovichauthor=D.+I.+Lain%C3%A9author=D.+W.+Hayauthor=W.+L.+Rumsey&title=Pharmacological+characterization+of+GSK573719+%28umeclidinium%29%3A+a+novel%2C+long-acting%2C+inhaled+antagonist+of+the+muscarinic+cholinergic+receptors+for+treatment+of+pulmonary+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases</span></div><div class="casAuthors">Salmon, Michael; Luttmann, Mark A.; Foley, James J.; Buckley, Peter T.; Schmidt, Dulcie B.; Burman, Miriam; Webb, Edward F.; DeHaas, Christopher J.; Kotzer, Charles J.; Barrett, Victoria J.; Slack, Robert J.; Sarau, Henry M.; Palovich, Michael R.; Laine, Dramane I.; Hay, Douglas W. P.; Rumsey, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">260-270</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Activation of muscarinic subtype 3 (M3) muscarinic cholinergic receptors (mAChRs) increases airway tone, whereas its blockade improves lung function and quality of life in patients with pulmonary diseases.  The present study evaluated the pharmacol. properties of a novel mAChR antagonist, GSK573719 (4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane; umeclidinium).  The affinity (Ki) of GSK573719 for the cloned human M1-M5 mAChRs ranged from 0.05 to 0.16 nM.  Dissocn. of [3H]GSK573719 from the M3 mAChR was slower than that for the M2 mAChR [half-life (t1/2) values: 82 and 9 min, resp.].  In Chinese hamster ovary cells transfected with recombinant human M3 mAChRs, GSK573719 demonstrated picomolar potency (-log pA2 = 23.9 pM) in an acetylcholine (Ach)-mediated Ca2+ mobilization assay.  Concn.-response curves indicate competitive antagonism with partial reversibility after drug washout.  Using isolated human bronchial strips, GSK573719 was also potent and showed competitive antagonism (-log pA2 = 316 pM) vs. carbachol, and was slowly reversible in a concn.-dependent manner (1-100 nM).  The time to 50% restoration of contraction at 10 nM was about 381 min (vs. 413 min for tiotropium bromide).  In mice, the ED50 value was 0.02 μg/mouse intranasally.  In conscious guinea pigs, intratracheal administration of GSK573719 dose dependently blocked Ach-induced bronchoconstriction with long duration of action, and was comparable to tiotropium; 2.5 μg elicited 50% bronchoprotection for >24 h.  Thus, GSK573719 is a potent anticholinergic agent that demonstrates slow functional reversibility at the human M3 mAChR and long duration of action in animal models.  This pharmacol. profile translated into a 24-h duration of bronchodilation in vivo, which suggested umeclidinium will be a once-daily inhaled treatment of pulmonary diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrepD_oaItRirVg90H21EOLACvtfcHk0lhDaoCK7SI7RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVCgsb0%253D&md5=eceacf0294d1b749e0463c85c8bb8724</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.202051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.202051%26sid%3Dliteratum%253Aachs%26aulast%3DSalmon%26aufirst%3DM.%26aulast%3DLuttmann%26aufirst%3DM.%2BA.%26aulast%3DFoley%26aufirst%3DJ.%2BJ.%26aulast%3DBuckley%26aufirst%3DP.%2BT.%26aulast%3DSchmidt%26aufirst%3DD.%2BB.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DWebb%26aufirst%3DE.%2BF.%26aulast%3DDeHaas%26aufirst%3DC.%2BJ.%26aulast%3DKotzer%26aufirst%3DC.%2BJ.%26aulast%3DBarrett%26aufirst%3DV.%2BJ.%26aulast%3DSlack%26aufirst%3DR.%2BJ.%26aulast%3DSarau%26aufirst%3DH.%2BM.%26aulast%3DPalovich%26aufirst%3DM.%2BR.%26aulast%3DLain%25C3%25A9%26aufirst%3DD.%2BI.%26aulast%3DHay%26aufirst%3DD.%2BW.%26aulast%3DRumsey%26aufirst%3DW.%2BL.%26atitle%3DPharmacological%2520characterization%2520of%2520GSK573719%2520%2528umeclidinium%2529%253A%2520a%2520novel%252C%2520long-acting%252C%2520inhaled%2520antagonist%2520of%2520the%2520muscarinic%2520cholinergic%2520receptors%2520for%2520treatment%2520of%2520pulmonary%2520diseases%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D345%26spage%3D260%26epage%3D270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group">Donohue, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anzueto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crater, G.</span><span> </span><span class="NLM_article-title">A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">970</span><span class="NLM_x">–</span> <span class="NLM_lpage">979</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2012.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=22498110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC38rksFClsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2012&pages=970-979&author=J.+F.+Donohueauthor=A.+Anzuetoauthor=J.+Brooksauthor=R.+Mehtaauthor=C.+Kalbergauthor=G.+Crater&title=A+randomized%2C+double-blind+dose-ranging+study+of+the+novel+LAMA+GSK573719+in+patients+with+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD</span></div><div class="casAuthors">Donohue James F; Anzueto Antonio; Brooks Jean; Mehta Rashmi; Kalberg Christopher; Crater Glenn</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">970-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  This study evaluated the dose-response and dosing interval of the novel long-acting muscarinic receptor antagonist (LAMA) GSK573719 in patients with COPD.  METHODS:  This randomized, double-blind, placebo-controlled, 3-way cross-over, incomplete block study evaluated 5 once-daily doses of GSK573719 (62.5-1000 μg), 3 twice-daily doses (62.5-250 μg), and open-label tiotropium for 14 days in patients (N = 176) with COPD (FEV(1) of 35-70% predicted).  The primary endpoint was morning trough FEV(1) at Day 15.  Secondary endpoints included 0-24 h weighted mean FEV(1) and serial FEV(1) values over 28 h.  Safety measures and pharmacokinetics were assessed.  RESULTS:  All once-daily doses of GSK573719 significantly increased trough FEV(1) at Day 15 with improvements ranging from 95 to 186 mL over placebo (p ≤ 0.006), from 79 to 172 mL with twice-daily dosing (p ≤ 0.03), and 105 mL with tiotropium (p = 0.003).  No clear dose ordering was observed.  Once-daily doses significantly (p < 0.001) increased 0-24 h weighted mean FEV(1) at Day 14 by 131-143 mL over placebo, comparable to increases with the twice-daily doses (120-142 mL) and tiotropium (127 mL).  Significant reductions in rescue albuterol use and improvements in FVC were also observed with once-daily dosing.  Plasma C(max) occurred within 5-15 min of dosing after which the drug was rapidly cleared and eliminated.  GSK573719 was well tolerated, with no apparent treatment-related changes in vital signs, ECG and Holter assessments, or clinical laboratory parameters.  CONCLUSION:  Once-daily dosing with GSK573719 in COPD provides clinically significant and sustained improvement in lung function over 24 h with similar efficacy to twice-daily dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJ3p0V_2egAMKL0FlyGHDofW6udTcc2eav1yp2ZuVuYLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rksFClsw%253D%253D&md5=ac974735ef628d984ff2185ec5a4c55f</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2012.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2012.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DDonohue%26aufirst%3DJ.%2BF.%26aulast%3DAnzueto%26aufirst%3DA.%26aulast%3DBrooks%26aufirst%3DJ.%26aulast%3DMehta%26aufirst%3DR.%26aulast%3DKalberg%26aufirst%3DC.%26aulast%3DCrater%26aufirst%3DG.%26atitle%3DA%2520randomized%252C%2520double-blind%2520dose-ranging%2520study%2520of%2520the%2520novel%2520LAMA%2520GSK573719%2520in%2520patients%2520with%2520COPD%26jtitle%3DRespir.%2520Med.%26date%3D2012%26volume%3D106%26spage%3D970%26epage%3D979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group">Decramer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maltais, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crater, G.</span><span> </span><span class="NLM_article-title">Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients</span> <span class="citation_source-journal">Respir. Physiol. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">185</span><span class="NLM_x">, </span> <span class="NLM_fpage">393</span><span class="NLM_x">–</span> <span class="NLM_lpage">409</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.resp.2012.08.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23026438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2htrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=2013&pages=393-409&author=M.+Decramerauthor=F.+Maltaisauthor=G.+Feldmanauthor=J.+Brooksauthor=S.+Harrisauthor=R.+Mehtaauthor=G.+Crater&title=Bronchodilation+of+umeclidinium%2C+a+new+long-acting+muscarinic+antagonist%2C+in+COPD+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients</span></div><div class="casAuthors">Decramer, Marc; Maltais, Francois; Feldman, Gregory; Brooks, Jean; Harris, Stephanie; Mehta, Rashmi; Crater, Glenn</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory Physiology & Neurobiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">393-399</span>CODEN:
                <span class="NLM_cas:coden">RPNEAV</span>;
        ISSN:<span class="NLM_cas:issn">1569-9048</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This study evaluated the dose-response of the new long-acting muscarinic antagonist umeclidinium (GSK573719) in patients with COPD.This randomized, double-blind, placebo-controlled, parallel-group study evaluated three once-daily doses of umeclidinium (125, 250 and 500 μg) for 28 days in 285 patients with COPD having FEV1 of 35-70% predicted (mean (SD) age = 61.4 (8.41); mean (SD) post-bronchodilator FEV1 = 1.577 (0.450)).  The primary endpoint was morning trough FEV1 at Day 29.  Secondary endpoints included 0-6 h weighted mean FEV1 and serial FEV1 measured over 6 h post-dose and at trough.  Safety and pharmacokinetics were also assessed.All doses of umeclidinium significantly increased trough FEV1 over placebo from 150 to 168 mL (p < 0.001), 0-6 h weighted mean FEV1 from 113 to 211 mL (p < 0.001), and serial FEV1 at each point in time over 24 h.  Redns. in salbutamol use and improvements in FVC were noted for all doses.  Umeclidinium was well tolerated with no apparent treatment-related changes in vital signs.Once-daily umeclidinium provides clin. significant, sustained improvement in lung function and is well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0A6mpnWPriLVg90H21EOLACvtfcHk0liVyyDBkm1PRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2htrfJ&md5=d537a3e997eefbdec4080410f6b944a2</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.resp.2012.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.resp.2012.08.022%26sid%3Dliteratum%253Aachs%26aulast%3DDecramer%26aufirst%3DM.%26aulast%3DMaltais%26aufirst%3DF.%26aulast%3DFeldman%26aufirst%3DG.%26aulast%3DBrooks%26aufirst%3DJ.%26aulast%3DHarris%26aufirst%3DS.%26aulast%3DMehta%26aufirst%3DR.%26aulast%3DCrater%26aufirst%3DG.%26atitle%3DBronchodilation%2520of%2520umeclidinium%252C%2520a%2520new%2520long-acting%2520muscarinic%2520antagonist%252C%2520in%2520COPD%2520patients%26jtitle%3DRespir.%2520Physiol.%2520Neurobiol.%26date%3D2013%26volume%3D185%26spage%3D393%26epage%3D409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group">Tal-Singer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cahn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preece, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crater, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelleher, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pouliquen, I. J.</span><span> </span><span class="NLM_article-title">Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studies</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">701</span><span class="NLM_x">, </span> <span class="NLM_fpage">40</span><span class="NLM_x">–</span> <span class="NLM_lpage">48</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.ejphar.2012.12.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23276660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFCmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=701&publication_year=2013&pages=40-48&author=R.+Tal-Singerauthor=A.+Cahnauthor=R.+Mehtaauthor=A.+Preeceauthor=G.+Craterauthor=D.+Kelleherauthor=I.+J.+Pouliquen&title=Initial+assessment+of+single+and+repeat+doses+of+inhaled+umeclidinium+in+patients+with+chronic+obstructive+pulmonary+disease%3A+two+randomised+studies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: Two randomised studies</span></div><div class="casAuthors">Tal-Singer, Ruth; Cahn, Anthony; Mehta, Rashmi; Preece, Andrew; Crater, Glenn; Kelleher, Dennis; Pouliquen, Isabelle J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">701</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">40-48</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To characterize the safety, tolerability, pharmacodynamics (bronchodilatory effect) and pharmacokinetics of inhaled umeclidinium in patients with chronic obstructive pulmonary disease (COPD).  The first investigation was a single dose, randomized, double-blind, placebo-controlled study (clinicaltrials.gov: NCT00515502) in which ipratropium bromide-sensitive patients received umeclidinium (250 μg, 500 μg, and 1000 μg), tiotropium bromide 18 μg or placebo.  Patients were randomized to receive four out of five possible treatments as an incomplete block four-way cross-over.  A subsequent study (clinicaltrials.gov: NCT700732472) was focused on assessment of safety, tolerability and pharmacokinetics of umeclidinium (250 μg and 1000 μg) administered once-daily for 7 days in a randomized, double-blind, placebo-controlled, parallel-group design.  Of the 24 patients randomized for the single dose study, 20 completed; 31 out of 38 patients completed the repeat dose study.  Most adverse events were mild-to-moderate and transient.  Examn. of heart rate, QTc interval, blood pressure and clin. lab. assessments raised no concern over the safety of umeclidinium.  Evidence of pharmacol. was demonstrated in first study by statistically significant increases in specific airway conductance (sGaw) for up to 24 h for all active treatments compared with placebo.  Increases in forced expiratory vol. in 1 s were also obsd.  Pharmacokinetic anal. demonstrated that max. obsd. plasma umeclidinium concn. (Cmax) was reached rapidly (time to Cmax: ∼5-15 min) after single and repeat doses; 1.5-1.9-fold accumulation was obsd. after repeat-dosing.  Single and repeat doses of umeclidinium were well tolerated and produced clin. relevant lung function improvements over 24 h in patients with COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr77JXR0LYSTLVg90H21EOLACvtfcHk0liVyyDBkm1PRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFCmu7w%253D&md5=916349ac3d5b966d7be88a8e900ddb18</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2012.12.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2012.12.019%26sid%3Dliteratum%253Aachs%26aulast%3DTal-Singer%26aufirst%3DR.%26aulast%3DCahn%26aufirst%3DA.%26aulast%3DMehta%26aufirst%3DR.%26aulast%3DPreece%26aufirst%3DA.%26aulast%3DCrater%26aufirst%3DG.%26aulast%3DKelleher%26aufirst%3DD.%26aulast%3DPouliquen%26aufirst%3DI.%2BJ.%26atitle%3DInitial%2520assessment%2520of%2520single%2520and%2520repeat%2520doses%2520of%2520inhaled%2520umeclidinium%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520two%2520randomised%2520studies%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D701%26spage%3D40%26epage%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group">Bouyssou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casarosa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naline, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pestel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konetzki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devillier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of olodaterol, a novel inhaled beta<sub>2</sub>-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">334</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1124%2Fjpet.110.167007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=20371707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Klt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2010&pages=53-62&author=T.+Bouyssouauthor=P.+Casarosaauthor=E.+Nalineauthor=S.+Pestelauthor=I.+Konetzkiauthor=P.+Devillierauthor=A.+Schnapp&title=Pharmacological+characterization+of+olodaterol%2C+a+novel+inhaled+beta2-adrenoceptor+agonist+exerting+a+24-hour-long+duration+of+action+in+preclinical+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models</span></div><div class="casAuthors">Bouyssou, T.; Casarosa, P.; Naline, E.; Pestel, S.; Konetzki, I.; Devillier, P.; Schnapp, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-62</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The preclin. pharmacol. profile of 6-hydroxy-8-[(1R)-1-hydroxy-2-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]ethyl]-2H-1,4-benzoxazin-3(4H)-one monohydrochloride (olodaterol, previously known as BI 1744 CL), a novel, enantiomeric pure, inhaled human β2-adrenoceptor (hβ2-AR) agonist, was compared with marked drugs, such as salmeterol and formoterol.  In vitro, olodaterol showed a potent, nearly full agonistic response at the hβ2-AR (EC50 = 0.1 nM; intrinsic activity = 88% compared with isoprenaline) and a significant selectivity profile (241- and 2299-fold against the hβ1- and hβ3-ARs, resp.).  Likewise, olodaterol was able to potently reverse contraction induced by different stimuli in isolated human bronchi.  In vivo, antagonistic effects of single doses of olodaterol and formoterol were measured against acetylcholine challenges in anesthetized guinea pigs and dogs for up to 24 h by using the Respimat Soft Mist inhaler.  Heart rate and metabolic parameters (serum potassium, lactate, and glucose) were monitored to evaluate systemic pharmacodynamic effects in the dog model.  In both models, olodaterol provided bronchoprotection over 24 h.  Formoterol applied at an equally ED did not retain efficacy over 24 h.  In both models olodaterol showed a rapid onset of action comparable with formoterol.  Taken together, the preclin. behavior of olodaterol suggests that this novel β2-AR agonist has the profile for once-daily dosing in humans concomitant with a fast onset of action and a favorable systemic pharmacodynamic profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDfOG9fwv5TbVg90H21EOLACvtfcHk0lj-9couyO1UXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Klt78%253D&md5=8e88a0ceea3ede36e4ef29188224a8ab</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.167007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.167007%26sid%3Dliteratum%253Aachs%26aulast%3DBouyssou%26aufirst%3DT.%26aulast%3DCasarosa%26aufirst%3DP.%26aulast%3DNaline%26aufirst%3DE.%26aulast%3DPestel%26aufirst%3DS.%26aulast%3DKonetzki%26aufirst%3DI.%26aulast%3DDevillier%26aufirst%3DP.%26aulast%3DSchnapp%26aufirst%3DA.%26atitle%3DPharmacological%2520characterization%2520of%2520olodaterol%252C%2520a%2520novel%2520inhaled%2520beta2-adrenoceptor%2520agonist%2520exerting%2520a%252024-hour-long%2520duration%2520of%2520action%2520in%2520preclinical%2520models%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D334%26spage%3D53%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group">Lamyel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warnken-Uhlich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seemann, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostenis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmedat, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smit, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gosens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meurs, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller-Larsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Racké, K.</span><span> </span><span class="NLM_article-title">The beta<sub>2</sub>-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts</span> <span class="citation_source-journal">Naunyn-Schmiedeberg’s Arch. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">384</span><span class="NLM_x">, </span> <span class="NLM_fpage">133</span><span class="NLM_x">–</span> <span class="NLM_lpage">145</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1007%2Fs00210-011-0655-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=21603974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFOksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=384&publication_year=2011&pages=133-145&author=F.+Lamyelauthor=M.+Warnken-Uhlichauthor=W.+K.+Seemannauthor=K.+Mohrauthor=E.+Kostenisauthor=A.+S.+Ahmedatauthor=M.+Smitauthor=R.+Gosensauthor=H.+Meursauthor=A.+Miller-Larssonauthor=K.+Rack%C3%A9&title=The+beta2-subtype+of+adrenoceptors+mediates+inhibition+of+pro-fibrotic+events+in+human+lung+fibroblasts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">The β2-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts</span></div><div class="casAuthors">Lamyel, F.; Warnken-Uhlich, M.; Seemann, W. K.; Mohr, K.; Kostenis, E.; Ahmedat, A. S.; Smit, M.; Gosens, R.; Meurs, H.; Miller-Larsson, A.; Racke, Kurt</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">384</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-145</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Fibrosis is part of airway remodelling obsd. in bronchial asthma and COPD.  Pro-fibrotic activity of lung fibroblasts may be suppressed by β-adrenoceptor activation.  We aimed, first, to characterize the expression pattern of β-adrenoceptor subtypes in human lung fibroblasts and, second, to probe β-adrenoceptor signaling with an emphasis on anti-fibrotic actions.  Using reverse transcription PCR, mRNA encoding β2-adrenoceptors was detected in MRC-5, HEL-299 and primary human lung fibroblasts, whereas transcripts for β1- and β3-adrenoceptors were not found.  Real-time measurement of dynamic mass redistribution in MRC-5 cells revealed β-agonist-induced Gs-signaling.  Proliferation of MRC-5 cells (detd. by [3H]-thymidine incorporation) was significantly inhibited by β-agonists including the β2-selective agonist formoterol (-logIC50, 10.2) and olodaterol (-logIC50, 10.6).  Formoterol's effect was insensitive to β1-antagonism (GCP 20712, 3 μM), but sensitive to β2-antagonism (ICI 118,551; apparent, pA 2, 9.6).  Collagen synthesis in MRC-5 cells (detd. by [3H]-proline incorporation) was inhibited by β-agonists including formoterol (-logIC50, 10.0) and olodaterol (-logIC50, 10.3) in a β2-blocker-sensitive manner. α-Smooth muscle actin, a marker of myo-fibroblast differentiation, was down-regulated at the mRNA and the protein level by about 50% following 24 and 48 h exposure to 1 nM formoterol, a maximally active concn.  In conclusion, human lung fibroblasts exclusively express β2-adrenoceptors and these mediate inhibition of various markers of pro-fibrotic cellular activity.  Under clin. conditions, anti-fibrotic actions may accompany the therapeutic effect of long-term β2-agonist treatment of bronchial asthma and COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcrrxy9mSlR7Vg90H21EOLACvtfcHk0lj-9couyO1UXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFOksbc%253D&md5=f72d9809b80589d1a5dc921d1dc09971</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1007%2Fs00210-011-0655-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-011-0655-5%26sid%3Dliteratum%253Aachs%26aulast%3DLamyel%26aufirst%3DF.%26aulast%3DWarnken-Uhlich%26aufirst%3DM.%26aulast%3DSeemann%26aufirst%3DW.%2BK.%26aulast%3DMohr%26aufirst%3DK.%26aulast%3DKostenis%26aufirst%3DE.%26aulast%3DAhmedat%26aufirst%3DA.%2BS.%26aulast%3DSmit%26aufirst%3DM.%26aulast%3DGosens%26aufirst%3DR.%26aulast%3DMeurs%26aufirst%3DH.%26aulast%3DMiller-Larsson%26aufirst%3DA.%26aulast%3DRack%25C3%25A9%26aufirst%3DK.%26atitle%3DThe%2520beta2-subtype%2520of%2520adrenoceptors%2520mediates%2520inhibition%2520of%2520pro-fibrotic%2520events%2520in%2520human%2520lung%2520fibroblasts%26jtitle%3DNaunyn-Schmiedeberg%25E2%2580%2599s%2520Arch.%2520Pharmacol.%26date%3D2011%26volume%3D384%26spage%3D133%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group">Casarosa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kollak, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiechle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostermann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnapp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiesling, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieper, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sieger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gantner, F.</span><span> </span><span class="NLM_article-title">Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">337</span><span class="NLM_x">, </span> <span class="NLM_fpage">600</span><span class="NLM_x">–</span> <span class="NLM_lpage">609</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1124%2Fjpet.111.179259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=21357659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFeitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2011&pages=600-609&author=P.+Casarosaauthor=I.+Kollakauthor=T.+Kiechleauthor=A.+Ostermannauthor=A.+Schnappauthor=R.+Kieslingauthor=M.+Pieperauthor=P.+Siegerauthor=F.+Gantner&title=Functional+and+biochemical+rationales+for+the+24-hour-long+duration+of+action+of+olodaterol"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol</span></div><div class="casAuthors">Casarosa, Paola; Kollak, Ines; Kiechle, Tobias; Ostermann, Angela; Schnapp, Andreas; Kiesling, Ralf; Pieper, Michael; Sieger, Peter; Gantner, Florian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">600-609</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">β2-Adrenoceptor (β2-AR) agonists are powerful bronchodilators and play a pivotal role in the management of pulmonary obstructive diseases, such as asthma and chronic obstructive pulmonary disease.  Although these agents 1st were used many years ago, progress in drug development has resulted in better tolerated, long-acting β2-AR agonists (LABAs), such as formoterol and salmeterol.  Although LABAs were on the market for several years, relatively little is known on the rationale(s) behind their long duration of action.  In this study, we focused on olodaterol (previously known as BI1744CL), a novel inhaled LABA, which provides a bronchodilating effect lasting 24 h and is currently in Phase III clin. trials.  To understand the rationale behind its long duration of action, different aspects of olodaterol were analyzed (i.e., its lipophilicity and propensity to accumulate in the lipid bilayer as well as its tight binding to the β2-AR).  In line with its physicochem. properties, olodaterol assocd. moderately with lipid bilayers.  Instead, kinetic as well as equil. binding studies indicated the presence of a stable [3H]olodaterol/β2-AR complex with a dissocn. half-life of 17.8 h due to ternary complex formation.  The tight binding of olodaterol to the human β2-AR and stabilization of the ternary complex were confirmed in functional expts. monitoring adenylyl cyclase activity after extensive washout.  Taken together, binding, kinetic, and functional data support the existence of a stable complex with the β2-AR that, with a dissocn. half-life >17 h, might indeed be a rationale for the 24-h duration of action of olodaterol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlUqEwPj-SPrVg90H21EOLACvtfcHk0lj-9couyO1UXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFeitb0%253D&md5=a36582775c7a2e91388e33be2c175e59</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.179259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.179259%26sid%3Dliteratum%253Aachs%26aulast%3DCasarosa%26aufirst%3DP.%26aulast%3DKollak%26aufirst%3DI.%26aulast%3DKiechle%26aufirst%3DT.%26aulast%3DOstermann%26aufirst%3DA.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DKiesling%26aufirst%3DR.%26aulast%3DPieper%26aufirst%3DM.%26aulast%3DSieger%26aufirst%3DP.%26aulast%3DGantner%26aufirst%3DF.%26atitle%3DFunctional%2520and%2520biochemical%2520rationales%2520for%2520the%252024-hour-long%2520duration%2520of%2520action%2520of%2520olodaterol%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D337%26spage%3D600%26epage%3D609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group">Aparici, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gómez-Angelats, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vilella, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carcasona, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viñals, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavaldà, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Alba, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gras, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortijo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morcillo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puig, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beleta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralpeix, M.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of abediterol, a novel inhaled β<sub>2</sub>-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">342</span><span class="NLM_x">, </span> <span class="NLM_fpage">497</span><span class="NLM_x">–</span> <span class="NLM_lpage">509</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1124%2Fjpet.112.193284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=22588259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOru7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2012&pages=497-509&author=M.+Apariciauthor=M.+G%C3%B3mez-Angelatsauthor=D.+Vilellaauthor=R.+Otalauthor=C.+Carcasonaauthor=M.+Vi%C3%B1alsauthor=I.+Ramosauthor=A.+Gavald%C3%A0author=J.+De+Albaauthor=J.+Grasauthor=J.+Cortijoauthor=E.+Morcilloauthor=C.+Puigauthor=H.+Ryderauthor=J.+Beletaauthor=M.+Miralpeix&title=Pharmacological+characterization+of+abediterol%2C+a+novel+inhaled+%CE%B22-adrenoceptor+agonist+with+long+duration+of+action+and+a+favorable+safety+profile+in+preclinical+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of abediterol, a novel inhaled β2-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models</span></div><div class="casAuthors">Aparici, Monica; Gomez-Angelats, Mireia; Vilella, Dolors; Otal, Raquel; Carcasona, Carla; Vinals, Marisa; Ramos, Israel; Gavalda, Amadeu; De Alba, Jorge; Gras, Jordi; Cortijo, Julio; Morcillo, Esteban; Puig, Carlos; Ryder, Hamish; Beleta, Jorge; Miralpeix, Montserrat</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">497-509</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Abediterol is a novel potent, long-acting inhaled β2-adrenoceptor agonist in development for the treatment of asthma and chronic obstructive pulmonary disease.  Abediterol shows subnanomolar affinity for the human β2-adrenoceptor and a functional selectivity over β1-adrenoceptors higher than that of formoterol and indacaterol in both a cellular model with overexpressed human receptors and isolated guinea pig tissue.  Abediterol is a full agonist at the human β2-adrenoceptor (Emax = 91 ± 5% of the maximal effect of isoprenaline).  The potency and onset of action that abediterol shows in isolated human bronchi (EC50 = 1.9 ± 0.4 nM; t1/2 onset = 7-10 min) is not significantly different from that of formoterol, but its duration of action (t1/2 ∼ 690 min) is similar to that of indacaterol.  Nebulized abediterol inhibits acetylcholine-induced bronchoconstriction in guinea pigs in a concn.-dependent manner, with higher potency and longer duration of action (t1/2 = 36 h) than salmeterol (t1/2 = 6 h) and formoterol (t1/2 = 4 h) and similar duration of action to indacaterol up to 48 h.  In dogs, the bronchoprotective effect of abediterol is more sustained than that of salmeterol and indacaterol at doses without effects on heart rate, thus showing a greater safety margin (defined as the ratio of dose increasing heart rate by 5% and dose inhibiting bronchospasm by 50%) than salmeterol, formoterol, and indacaterol (5.6 vs. 3.3, 2.2, and 0.3, resp.).  In conclusion, our results suggest that abediterol has a preclin. profile for once-daily dosing in humans together with a fast onset of action and a favorable cardiovascular safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfsT0Jt09WvbVg90H21EOLACvtfcHk0ljj6YEd8eQKJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOru7vK&md5=a102a6455f01c296d2beda412fa527c0</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.193284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.193284%26sid%3Dliteratum%253Aachs%26aulast%3DAparici%26aufirst%3DM.%26aulast%3DG%25C3%25B3mez-Angelats%26aufirst%3DM.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DOtal%26aufirst%3DR.%26aulast%3DCarcasona%26aufirst%3DC.%26aulast%3DVi%25C3%25B1als%26aufirst%3DM.%26aulast%3DRamos%26aufirst%3DI.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DDe%2BAlba%26aufirst%3DJ.%26aulast%3DGras%26aufirst%3DJ.%26aulast%3DCortijo%26aufirst%3DJ.%26aulast%3DMorcillo%26aufirst%3DE.%26aulast%3DPuig%26aufirst%3DC.%26aulast%3DRyder%26aufirst%3DH.%26aulast%3DBeleta%26aufirst%3DJ.%26aulast%3DMiralpeix%26aufirst%3DM.%26atitle%3DPharmacological%2520characterization%2520of%2520abediterol%252C%2520a%2520novel%2520inhaled%2520%25CE%25B22-adrenoceptor%2520agonist%2520with%2520long%2520duration%2520of%2520action%2520and%2520a%2520favorable%2520safety%2520profile%2520in%2520preclinical%2520models%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D342%26spage%3D497%26epage%3D509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group">Timmer, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massana, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimenez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seoane, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Miquel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz, S.</span><span> </span><span class="NLM_article-title">First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long-acting β<sub>2</sub>-agonist</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1347</span><span class="NLM_x">–</span> <span class="NLM_lpage">1353</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1002%2Fjcph.355" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=24989946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFagt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=1347-1353&author=W.+Timmerauthor=E.+Massanaauthor=E.+Jimenezauthor=B.+Seoaneauthor=G.+de+Miquelauthor=S.+Ruiz&title=First-in-human+study+of+the+safety%2C+tolerability%2C+pharmacokinetics+and+pharmacodynamics+of+abediterol+%28LAS100977%29%2C+a+novel+long-acting+%CE%B22-agonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long-acting Β2-agonist</span></div><div class="casAuthors">Timmer, Wolfgang; Massana, Eric; Jimenez, Eulalia; Seoane, Beatriz; de Miquel, Gonzalo; Ruiz, Sandrine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1347-1353</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Here we report the results of a first-in-human study to evaluate the safety, tolerability pharmacokinetics, and pharmacodynamics of abediterol, a new β2-adrenergic agonist.  Forty-eight healthy males aged 18-45 years received abediterol doses of 5, 10, 25, or 50 μg, or placebo.  Safety and tolerability assessments included adverse event reporting, pulse and blood pressure monitoring, 12-lead electrocardiograms, lab. tests, and phys. examn.  Pharmacodynamic assessments included whole body plethysmog. to det. the bronchodilatory effect by means of airway conductance and resistance.  Blood and urine samples were obtained for pharmacokinetic analyses.  Abediterol showed an overall good safety and tolerability profile in the dose range tested, consistent with the expected characteristics of a β2-adrenergic agonist.  A dose-dependent increase of systemic treatment-emergent adverse events was obsd., the most frequent being palpitations, tremor, nausea, and asthenia; most were mild in intensity and resolved without the need for intervention.  Improvements in airway conductance (increase) and resistance (decrease) were greater for all doses of abediterol tested compared with placebo at all time-points up to 36 h.  This first-in-human study suggests a potent, rapid, and sustained bronchodilatory effect of abediterol in healthy male subjects.  Lower doses are currently under investigation in patients with asthma and in patients with COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE8xpmQp8DfLVg90H21EOLACvtfcHk0ljj6YEd8eQKJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFagt7%252FM&md5=1299c729b8dd92206e63c6fe326db666</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1002%2Fjcph.355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.355%26sid%3Dliteratum%253Aachs%26aulast%3DTimmer%26aufirst%3DW.%26aulast%3DMassana%26aufirst%3DE.%26aulast%3DJimenez%26aufirst%3DE.%26aulast%3DSeoane%26aufirst%3DB.%26aulast%3Dde%2BMiquel%26aufirst%3DG.%26aulast%3DRuiz%26aufirst%3DS.%26atitle%3DFirst-in-human%2520study%2520of%2520the%2520safety%252C%2520tolerability%252C%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520abediterol%2520%2528LAS100977%2529%252C%2520a%2520novel%2520long-acting%2520%25CE%25B22-agonist%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2014%26volume%3D54%26spage%3D1347%26epage%3D1353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group">Capacchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipreri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caló, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peveri, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catinella, S.</span><span> </span><span class="NLM_article-title"><sup>1</sup>H NMR discrimination of CHF4226.01 diastereoisomers in DMSO-d6</span> <span class="citation_source-journal">Magn. Reson. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">551</span><span class="NLM_x">–</span> <span class="NLM_lpage">561</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1002%2Fmrc.2427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=19373771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVGltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2009&pages=551-561&author=S.+Capacchiauthor=M.+Lipreriauthor=A.+Rizziauthor=C.+Cal%C3%B3author=T.+Peveriauthor=S.+Catinella&title=1H+NMR+discrimination+of+CHF4226.01+diastereoisomers+in+DMSO-d6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">1H NMR discrimination of CHF4226.01 diastereoisomers in DMSO-d6</span></div><div class="casAuthors">Capacchi, Silvia; Lipreri, Milco; Rizzi, Andrea; Calo, Claudia; Peveri, Tiziana; Catinella, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Magnetic Resonance in Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">551-561</span>CODEN:
                <span class="NLM_cas:coden">MRCHEG</span>;
        ISSN:<span class="NLM_cas:issn">0749-1581</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Two diastereoisomers CHF4226.01 (R, R) and CHF4232.01 (S, R), differing for a chiral center, have been studied to investigate their possible discrimination using NMR. 1D NMR and 2D NMR expts., such as COSY, NOESY and ROESY, were performed on pure isomers and on the assocn. complexes formed in the presence of the chiral reagent (S)-(-)-1-(2-naphthyl)ethylamine (S-NEA).  Moreover, computational studies, concerning conformational anal. and mol. dynamics, were started and supported the NMR results.  Copyright © 2009 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIGr8OLz1Pm7Vg90H21EOLACvtfcHk0liCv-IifVl4GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVGltbg%253D&md5=a998695778865672c2b2d15c2b163dad</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1002%2Fmrc.2427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmrc.2427%26sid%3Dliteratum%253Aachs%26aulast%3DCapacchi%26aufirst%3DS.%26aulast%3DLipreri%26aufirst%3DM.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DCal%25C3%25B3%26aufirst%3DC.%26aulast%3DPeveri%26aufirst%3DT.%26aulast%3DCatinella%26aufirst%3DS.%26atitle%3D1H%2520NMR%2520discrimination%2520of%2520CHF4226.01%2520diastereoisomers%2520in%2520DMSO-d6%26jtitle%3DMagn.%2520Reson.%2520Chem.%26date%3D2009%26volume%3D47%26spage%3D551%26epage%3D561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group">Frampton, J. E.</span><span> </span><span class="NLM_article-title">QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">465</span><span class="NLM_x">–</span> <span class="NLM_lpage">488</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=465-488&author=J.+E.+Frampton&title=QVA149+%28indacaterol%2Fglycopyrronium+fixed-dose+combination%29%3A+a+review+of+its+use+in+patients+with+chronic+obstructive+pulmonary+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFrampton%26aufirst%3DJ.%2BE.%26atitle%3DQVA149%2520%2528indacaterol%252Fglycopyrronium%2520fixed-dose%2520combination%2529%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D465%26epage%3D488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group">Bateman, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, D.</span><span> </span><span class="NLM_article-title">Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1484</span><span class="NLM_x">–</span> <span class="NLM_lpage">1494</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.00200212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23722616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktlahsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2013&pages=1484-1494&author=E.+D.+Batemanauthor=G.+T.+Fergusonauthor=N.+Barnesauthor=N.+Gallagherauthor=Y.+Greenauthor=M.+Henleyauthor=D.+Banerji&title=Dual+bronchodilation+with+QVA149+versus+single+bronchodilator+therapy%3A+the+SHINE+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study</span></div><div class="casAuthors">Bateman, Eric D.; Ferguson, Gary T.; Barnes, Neil; Gallagher, Nicola; Green, Yulia; Henley, Michelle; Banerji, Donald</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1484-1494</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">We investigated the efficacy and safety of dual bronchodilation with QVA149 vs. its monocomponents indacaterol and glycopyrronium, tiotropium and placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).  This was a multicentre, randomized, double-blind, placebo- and active-controlled, 26-wk trial.  Patients (n = 2144) were randomized (2:2:2:2:1) to receive once-daily QVA149 (indacaterol 110 uμg/glycopyrronium 50 μg), indacaterol 150 μg, glycopyrronium 50 μg, open-label tiotropium 18 μg or placebo.  The primary end-point was trough forced expiratory vol. in 1 s (FEV1) at week 26 for QVA149 vs. its monocomponents.  Secondary end-points included dyspnoea, health status, rescue medication use and safety.  Trough FEV1 at week 26 was significantly improved (p<0.001) with QVA149 compared with indacaterol and glycopyrronium (least squares mean (LSM) differences 0.07 L and 0.09 L, resp.), tiotropium and placebo (LSM differences 0.08 L and 0.20 L, resp.); these beneficial effects were sustained throughout the 26-wk study.  QVA149 significantly improved dyspnoea and health status vs. placebo (p<0.001 and p = 0.002, resp.) and tiotropium (p = 0.007 and p = 0.009, resp.) at week 26.  All treatments were well tolerated.  Dual bronchodilation with once-daily QVA149 demonstrated superior and clin. meaningful outcomes vs. placebo and superiority vs. treatment with a single bronchodilator, with a safety and tolerability profile similar to placebo, supporting the concept of fixed-dose long-acting muscarinic antagonist/long-acting β2-agonist combinations for the treatment of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI38gfbCMI37Vg90H21EOLACvtfcHk0liCv-IifVl4GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktlahsg%253D%253D&md5=fa55317191017e1736281011d793ea83</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1183%2F09031936.00200212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00200212%26sid%3Dliteratum%253Aachs%26aulast%3DBateman%26aufirst%3DE.%2BD.%26aulast%3DFerguson%26aufirst%3DG.%2BT.%26aulast%3DBarnes%26aufirst%3DN.%26aulast%3DGallagher%26aufirst%3DN.%26aulast%3DGreen%26aufirst%3DY.%26aulast%3DHenley%26aufirst%3DM.%26aulast%3DBanerji%26aufirst%3DD.%26atitle%3DDual%2520bronchodilation%2520with%2520QVA149%2520versus%2520single%2520bronchodilator%2520therapy%253A%2520the%2520SHINE%2520study%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2013%26volume%3D42%26spage%3D1484%26epage%3D1494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group">Mahler, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decramer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Urzo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worth, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alagappan, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulich, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, D.</span><span> </span><span class="NLM_article-title">Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE study</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1599</span><span class="NLM_x">–</span> <span class="NLM_lpage">1609</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1183%2F09031936.00124013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=24176997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC2c7hsFShsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=1599-1609&author=D.+A.+Mahlerauthor=M.+Decramerauthor=A.+D%E2%80%99Urzoauthor=H.+Worthauthor=T.+Whiteauthor=V.+K.+Alagappanauthor=H.+Chenauthor=N.+Gallagherauthor=K.+Kulichauthor=D.+Banerji&title=Dual+bronchodilation+with+QVA149+reduces+patient-reported+dyspnoea+in+COPD%3A+BLAZE+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study</span></div><div class="casAuthors">Mahler Donald A; Decramer Marc; D'Urzo Anthony; Worth Heinrich; White Tracy; Alagappan Vijay K T; Chen Hungta; Banerji Donald; Gallagher Nicola; Kulich Karoly</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1599-609</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We evaluated the effect of QVA149, a dual bronchodilator combining indacaterol and glycopyrronium, on direct patient-reported dyspnoea in patients with moderate-to-severe chronic obstructive pulmonary disease.  In this multicentre, blinded, double-dummy, three-period crossover study, 247 patients were randomised to once-daily QVA149 110/50 μg, placebo or tiotropium 18 μg.  Superiority of QVA149 versus placebo (primary objective) and tiotropium (secondary objective) was assessed for improvement in dyspnoea via the self-administered computerised (SAC) version of the Baseline and Transition Dyspnoea Index after 6 weeks.  Secondary end-points included lung function, rescue medication use and safety.  After 6 weeks, the SAC Transition Dyspnoea Index total score was significantly higher with QVA149 versus placebo (least squares mean (LSM) treatment difference 1.37, p<0.001) and tiotropium (LSM treatment difference 0.49, p=0.021).  QVA149 provided significant improvements in lung function, with higher forced expiratory volume in 1 s area under the curve from 0-4 h post-dose versus placebo and tiotropium at day 1 and week 6 (all p<0.001).  Rescue medication use was significantly lower with QVA149 versus placebo (p<0.001) and tiotropium (p=0.002).  All treatments were well tolerated.  Once-daily QVA149 provided superior improvements in patient-reported dyspnoea and lung function versus placebo and tiotropium.  These benefits were associated with improvements in other symptoms and reduced use of rescue medication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-C19TuUAlt8jl5L8hwNX0fW6udTcc2ebM4OLIOsxXNbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7hsFShsg%253D%253D&md5=541bf4a7479374424d7c291dd66476ac</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1183%2F09031936.00124013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00124013%26sid%3Dliteratum%253Aachs%26aulast%3DMahler%26aufirst%3DD.%2BA.%26aulast%3DDecramer%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Urzo%26aufirst%3DA.%26aulast%3DWorth%26aufirst%3DH.%26aulast%3DWhite%26aufirst%3DT.%26aulast%3DAlagappan%26aufirst%3DV.%2BK.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DGallagher%26aufirst%3DN.%26aulast%3DKulich%26aufirst%3DK.%26aulast%3DBanerji%26aufirst%3DD.%26atitle%3DDual%2520bronchodilation%2520with%2520QVA149%2520reduces%2520patient-reported%2520dyspnoea%2520in%2520COPD%253A%2520BLAZE%2520study%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2014%26volume%3D43%26spage%3D1599%26epage%3D1609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group">Dahl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kho, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alagappan, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, D.</span><span> </span><span class="NLM_article-title">Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">1558</span><span class="NLM_x">–</span> <span class="NLM_lpage">1567</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2013.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23867808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC3sfitVGqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2013&pages=1558-1567&author=R.+Dahlauthor=K.+R.+Chapmanauthor=M.+Rudolfauthor=R.+Mehtaauthor=P.+Khoauthor=V.+K.+Alagappanauthor=H.+Chenauthor=D.+Banerji&title=Safety+and+efficacy+of+dual+bronchodilation+with+QVA149+in+COPD+patients%3A+the+ENLIGHTEN+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study</span></div><div class="casAuthors">Dahl Ronald; Chapman Kenneth R; Rudolf Michael; Mehta Rajendra; Kho Pearl; Alagappan Vijay K T; Chen Hungta; Banerji Donald</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1558-67</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  QVA149 is an inhaled, once-daily fixed-dose dual bronchodilator combination of the long-acting β2-agonist indacaterol and long-acting muscarinic antagonist glycopyrronium (NVA237) for the treatment of chronic obstructive pulmonary disease (COPD).  We investigated the safety and efficacy of QVA149 over 52 weeks.  METHODS:  This 52-week, multicenter, double-blind, parallel-group, placebo-controlled study randomized (2:1) patients with moderate-to-severe COPD to once-daily QVA149 (110 μg indacaterol/50 μg glycopyrronium) or placebo delivered via the Breezhaler device.  Primary endpoint was safety and tolerability for treatment-emergent adverse events (AEs).  Secondary endpoints included safety based on vital signs, electrocardiograms (ECGs), laboratory evaluations, and pre-dose forced expiratory volume in 1 s (FEV1).  RESULTS:  Of 339 patients randomized, QVA149 [n = 226], placebo [n = 113]; 76.9% male, mean age: 62.6 years, post-bronchodilator FEV1: 57.4% predicted, 83.5% completed study.  A smaller percentage of patients discontinued in the QVA149 group (14.2%) compared with placebo (21.2%).  Overall incidence of AEs was similar in the QVA149 (57.8%) and placebo (56.6%) groups, with most AEs being mild to moderate in severity.  The numerical differences in some AEs observed could be at least in part explained by differences in baseline patient characteristics.  No clinically relevant differences were observed between treatment groups for vital signs or ECG parameters.  The five deaths reported were unrelated to study medication (QVA149, n = 4 [1.8%]; placebo, n = 1 [0.9%]).  QVA149 demonstrated rapid and clinically meaningful bronchodilation sustained over 52 weeks versus placebo.  CONCLUSION:  QVA149 demonstrated a good safety and tolerability profile, providing rapid and sustained bronchodilation over 52 weeks in patients with moderate-to-severe COPD.  ClinicalTrials.gov identifier: NCT01120717.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQwufKv2haYhsKL0FlyGHDofW6udTcc2eZUBmwheaTr9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfitVGqtQ%253D%253D&md5=0daaecfa3575b5f3e1e7dc18b517e778</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2013.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2013.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DChapman%26aufirst%3DK.%2BR.%26aulast%3DRudolf%26aufirst%3DM.%26aulast%3DMehta%26aufirst%3DR.%26aulast%3DKho%26aufirst%3DP.%26aulast%3DAlagappan%26aufirst%3DV.%2BK.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DBanerji%26aufirst%3DD.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520dual%2520bronchodilation%2520with%2520QVA149%2520in%2520COPD%2520patients%253A%2520the%2520ENLIGHTEN%2520study%26jtitle%3DRespir.%2520Med.%26date%3D2013%26volume%3D107%26spage%3D1558%26epage%3D1567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group">Beeh, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jadayel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, D.</span><span> </span><span class="NLM_article-title">Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">584</span><span class="NLM_x">–</span> <span class="NLM_lpage">592</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2014.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=24534204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC2cvlslSmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2014&pages=584-592&author=K.+M.+Beehauthor=S.+Kornauthor=J.+Beierauthor=D.+Jadayelauthor=M.+Henleyauthor=P.+D%E2%80%99Andreaauthor=D.+Banerji&title=Effect+of+QVA149+on+lung+volumes+and+exercise+tolerance+in+COPD+patients%3A+the+BRIGHT+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study</span></div><div class="casAuthors">Beeh Kai-Michael; Korn Stephanie; Beier Jutta; Jadayel Dalal; Henley Michelle; D'Andrea Peter; Banerji Donald</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">584-92</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  QVA149 is a novel, inhaled, once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium (NVA237), for the treatment of chronic obstructive pulmonary disease (COPD).  This study evaluated the effects of QVA149 on exercise tolerance, hyperinflation, lung function and lung volumes versus placebo and tiotropium.  METHODS:  Patients with moderate-to-severe COPD were randomized to QVA149 110/50 μg, placebo or tiotropium 18 μg once daily in a blinded, 3-period crossover study for 3 weeks.  The primary endpoint was exercise endurance time at Day 21 for QVA149 versus placebo.  RESULTS:  Eighty-five patients were randomized; 86% completed the study.  QVA149 significantly improved exercise endurance time at Day 21 compared with placebo (least squares mean treatment difference 60 s [p = 0.006]).  No significant improvements in exercise endurance time at Day 21 between QVA149 and tiotropium were found.  Dynamic inspiratory capacity (IC) at exercise isotime, trough forced expiratory volume in 1 s, residual volume and functional residual capacity showed significant improvements with QVA149 from Day 1 of treatment that were maintained throughout the study.  The safety profiles were similar across groups.  CONCLUSIONS:  In patients with moderate-to-severe COPD, once-daily QVA149 significantly improved exercise endurance time compared with placebo which was associated with sustained reductions of lung hyperinflation as indicated by significant improvement in IC at rest and during exercise.  TRIAL REGISTRATION:  ClinicalTrials.gov NCT01294787.  TAKE HOME MESSAGE:  Dual bronchodilation with QVA149 decreases lung hyperinflation and improves exercise tolerance and lung function in patients with moderate-to-severe COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJNLFWqA5MzinGiHuhFGv8fW6udTcc2eZUBmwheaTr9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvlslSmug%253D%253D&md5=9bc7739335095e26fb429057361eb65a</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2014.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2014.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DBeeh%26aufirst%3DK.%2BM.%26aulast%3DKorn%26aufirst%3DS.%26aulast%3DBeier%26aufirst%3DJ.%26aulast%3DJadayel%26aufirst%3DD.%26aulast%3DHenley%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DP.%26aulast%3DBanerji%26aufirst%3DD.%26atitle%3DEffect%2520of%2520QVA149%2520on%2520lung%2520volumes%2520and%2520exercise%2520tolerance%2520in%2520COPD%2520patients%253A%2520the%2520BRIGHT%2520study%26jtitle%3DRespir.%2520Med.%26date%3D2014%26volume%3D108%26spage%3D584%26epage%3D592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group">Wedzicha, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decramer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficker, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niewoehner, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandström, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrasate, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, D.</span><span> </span><span class="NLM_article-title">Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study</span> <span class="citation_source-journal">Lancet Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">199</span><span class="NLM_x">–</span> <span class="NLM_lpage">209</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2FS2213-2600%2813%2970052-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFCltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=199-209&author=J.+A.+Wedzichaauthor=M.+Decramerauthor=J.+H.+Fickerauthor=D.+E.+Niewoehnerauthor=T.+Sandstr%C3%B6mauthor=A.+F.+Taylorauthor=P.+D%E2%80%99Andreaauthor=C.+Arrasateauthor=H.+Chenauthor=D.+Banerji&title=Analysis+of+chronic+obstructive+pulmonary+disease+exacerbations+with+the+dual+bronchodilator+QVA149+compared+with+glycopyrronium+and+tiotropium+%28SPARK%29%3A+a+randomised%2C+double-blind%2C+parallel-group+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study</span></div><div class="casAuthors">Wedzicha, Jadwiga A.; Decramer, Marc; Ficker, Joachim H.; Niewoehner, Dennis E.; Sandstrom, Thomas; Taylor, Angel Fowler; D'Andrea, Peter; Arrasate, Christie; Chen, Hungta; Banerji, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">199-209</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We evaluated the effect of dual, longacting inhaled bronchodilator treatment on exacerbations in patients with severe and very severe chronic obstructive pulmonary disease (COPD).  In this parallel-group study, 2224 patients (aged ≥40 years, Global Initiative for Chronic Obstructive Lung Disease stages III-IV, and one or more moderate COPD exacerbation in the past year) were randomly assigned (1:1:1; via interactive voice response or web system; stratified for smoking status) to once-daily QVA149 (fixed-dose combination of indacaterol 110 μg and glycopyrronium 50 μg), glycopyrronium 50 μg, or tiotropium 18 μg for 64 wk.  Assignment to QVA149 and glycopyrronium was double-blind; tiotropium was open-label.  Efficacy was assessed in all patients randomly assigned to treatment groups who received at least one dose of study drug; safety was assessed in all patients who received at least one dose whether or not they were assigned to a group.  The primary objective was to show superiority of QVA149 vs. glycopyrronium for rate of moderate to severe COPD exacerbations (defined by worsening symptoms and categorized by treatment requirements) during treatment.  This completed trial is registered at ClinicalTrials.gov, NCT01120691.  Between Apr. 27, 2010, and July 11, 2012, 741 patients were randomly assigned to receive QVA149, 741 to receive glycopyrronium, and 742 to receive tiotropium (729, 739, and 737 patients, resp., analyzed for efficacy).  QVA149 significantly reduced the rate of moderate to severe exacerbations vs. glycopyrronium by 12% (annualized rate of exacerbations 0·84 [95% CI 0·75-0·94] vs 0·95 [0·85-1·06]; rate ratio 0·88, 95% CI 0·77-0·99, p=0·038).  Adverse events (including exacerbations) were reported for 678 (93%) of 729 patients on QVA149, 694 (94%) of 740 on glycopyrronium, and 686 (93%) of 737 on tiotropium.  Incidence of serious adverse events was similar between groups (167 [23%] patients on QVA149, 179 [24%] on glycopyrronium, and 165 [22%] on tiotropium); COPD worsening was the most frequent serious adverse event (107 [15%] patients on QVA149, 116 [16%] on glycopyrronium, 87 [12%] on tiotropium).  The dual bronchodilator QVA149 was superior in preventing moderate to severe COPD exacerbations compared with the single longacting antimuscarinic bronchodilator glycopyrronium, with concomitant improvements in lung function and health status.  These results indicate the potential of dual bronchodilation as a treatment option for patients with severe and very severe COPD.Novartis Pharma AG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh5It-DxP4I7Vg90H21EOLACvtfcHk0lgSE-ynANG6UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFCltL8%253D&md5=5395598ea51ec5290a241a947aef44b9</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2813%2970052-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252813%252970052-3%26sid%3Dliteratum%253Aachs%26aulast%3DWedzicha%26aufirst%3DJ.%2BA.%26aulast%3DDecramer%26aufirst%3DM.%26aulast%3DFicker%26aufirst%3DJ.%2BH.%26aulast%3DNiewoehner%26aufirst%3DD.%2BE.%26aulast%3DSandstr%25C3%25B6m%26aufirst%3DT.%26aulast%3DTaylor%26aufirst%3DA.%2BF.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DP.%26aulast%3DArrasate%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DBanerji%26aufirst%3DD.%26atitle%3DAnalysis%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520exacerbations%2520with%2520the%2520dual%2520bronchodilator%2520QVA149%2520compared%2520with%2520glycopyrronium%2520and%2520tiotropium%2520%2528SPARK%2529%253A%2520a%2520randomised%252C%2520double-blind%252C%2520parallel-group%2520study%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2013%26volume%3D1%26spage%3D199%26epage%3D209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group">Dahl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jadayel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alagappan, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, D.</span><span> </span><span class="NLM_article-title">Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study</span> <span class="citation_source-journal">Int. J. Chronic Obstruct. Pulm. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">501</span><span class="NLM_x">–</span> <span class="NLM_lpage">508</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.2147%2FCOPD.S49615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=24159259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVejt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=501-508&author=R.+Dahlauthor=D.+Jadayelauthor=V.+K.+Alagappanauthor=H.+Chenauthor=D.+Banerji&title=Efficacy+and+safety+of+QVA149+compared+to+the+concurrent+administration+of+its+monocomponents+indacaterol+and+glycopyrronium%3A+the+BEACON+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study</span></div><div class="casAuthors">Dahl, Ronald; Jadayel, Dalal; Alagappan, Vijay K. T.; Chen, Hungta; Banerji, Donald</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Chronic Obstructive Pulmonary Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">501-508, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">IJCOC3</span>;
        ISSN:<span class="NLM_cas:issn">1178-2005</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Introduction: The BEACON study evaluated the efficacy and safety of QVA149, a once-daily dual bronchodilator contg. a fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol and long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237), in development for the treatment of patients with chronic obstructive pulmonary disease (COPD), compared with the free-dose concurrent administration of indacaterol plus glycopyrronium (IND+GLY).  Methods: In this multicenter, double-blind, parallel group study, patients with stage II or stage III COPD (Global initiative for chronic Obstructive Lung Disease [GOLD] 2010) were randomized (1:1) to once-daily QVA149 (110 μg indacaterol/50 μg glycopyrronium) or concurrent administration of indacaterol (150 μg) and glycopyrronium (50 μg) via the Breezhaler device for 4 wk.  The primary endpoint was to evaluate the noninferiority of QVA149 as compared with concurrent administration of IND+GLY, for trough forced expiratory vol. in 1 s (FEV1) after 4 wk of treatment.  The other assessments included FEV1 area under the curve from 0 to 4 h (AUC0-4 h) at day 1 and week 4, symptom scores, rescue medication use, safety and tolerability over the 4 wk study period.  Results: Of 193 patients randomized, 187 (96.9%) completed the study.  Trough FEV1 at week 4 for QVA149 and IND+GLY was 1.46 L ± 0.02 and 1.46 L ± 0.18, resp.  The FEV1 AUC0-4 h at day 1 and week 4 were similar between the two treatment groups.  Both treatment groups had a similar redn. in symptom scores and rescue medication use for the 4 wk treatment period.  Overall, 25.6% of patients in QVA149 group and 25.2% in the IND+GLY group experienced an adverse event, with the majority being mild-to-moderate in severity.  No deaths were reported during the study or during the 30 days follow-up period.  Conclusion: The BEACON study demonstrated that once-daily QVA149 provides an efficacy and safety profile similar to the concurrent administration of its monocomponents indacaterol and glycopyrronium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpRDctxMO58rVg90H21EOLACvtfcHk0lgSE-ynANG6UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVejt7s%253D&md5=65d22196e8b19472e30307a520319e88</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S49615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S49615%26sid%3Dliteratum%253Aachs%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DJadayel%26aufirst%3DD.%26aulast%3DAlagappan%26aufirst%3DV.%2BK.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DBanerji%26aufirst%3DD.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520QVA149%2520compared%2520to%2520the%2520concurrent%2520administration%2520of%2520its%2520monocomponents%2520indacaterol%2520and%2520glycopyrronium%253A%2520the%2520BEACON%2520study%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2013%26volume%3D8%26spage%3D501%26epage%3D508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group">Rodrigo, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plaza, V.</span><span> </span><span class="NLM_article-title">Efficacy and safey of fixed-dose combination of indacaterol and glycopyrronium for the treatment of COPD: a systematic review</span> <span class="citation_source-journal">Chest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2014&pages=309-317&author=G.+J.+Rodrigoauthor=V.+Plaza&title=Efficacy+and+safey+of+fixed-dose+combination+of+indacaterol+and+glycopyrronium+for+the+treatment+of+COPD%3A+a+systematic+review"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigo%26aufirst%3DG.%2BJ.%26aulast%3DPlaza%26aufirst%3DV.%26atitle%3DEfficacy%2520and%2520safey%2520of%2520fixed-dose%2520combination%2520of%2520indacaterol%2520and%2520glycopyrronium%2520for%2520the%2520treatment%2520of%2520COPD%253A%2520a%2520systematic%2520review%26jtitle%3DChest%26date%3D2014%26volume%3D146%26spage%3D309%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group">Rodrigo, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plaza, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro-Rodríguez, J. A.</span><span> </span><span class="NLM_article-title">Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review</span> <span class="citation_source-journal">Pulm. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">40</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.pupt.2011.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=22085775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFOktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=40-47&author=G.+J.+Rodrigoauthor=V.+Plazaauthor=J.+A.+Castro-Rodr%C3%ADguez&title=Comparison+of+three+combined+pharmacological+approaches+with+tiotropium+monotherapy+in+stable+moderate+to+severe+COPD%3A+a+systematic+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: A systematic review</span></div><div class="casAuthors">Rodrigo, Gustavo J.; Plaza, Vicente; Castro-Rodriguez, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-47</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Background: Guidelines recommend the use of inhaled long-acting bronchodilators, inhaled corticosteroids (ICS) and their combinations for maintenance treatment of moderate to severe COPD.  However, there are limited data supporting combination therapy.  Methods: This systematic review assessed the efficacy of three therapeutic approaches: tiotropium plus long-acting beta2-agonist (LABA) ("dual" therapy), LABA/ICS ("combined" therapy), and tiotropium plus LABA/ICS ("triple" therapy), all compared with tiotropium monotherapy.  Randomized controlled trials were identified after a search of different databases of published and unpublished trials.  Results: Twenty trials (6803 participants) were included.  "Dual" therapy showed significant improvements in forced vol. in the first second (FEV1), health-related quality of life (HRQoL), and dyspnea.  However, it failed to reduce the risk of COPD exacerbations.  Compared with tiotropium, "combined" therapy presented modest but significant effects on FEV1, HRQoL, and dyspnea.  Again, there was no significant difference in exacerbations, but it was assocd. with a significant increase of serious adverse effects (SAE) (no. need to treat for harm [NNTH] = 20; 95% CI: 11-119).  Finally, "triple therapy" increased FEV1, improved HRQoL (both benefits exceeded minimal important differences) and decrease COPD exacerbations in anon-significant way. (Odds ratio [OR] = 0.57; 95% CI: 0.24 to 1.37, p = 0.21).  Conclusions: "Dual" and "triple" therapy seem like the most promising for patients with moderate to very severe COPD.  However, data are still scarce and studies too short to generate a strong recommendation.  Future studies should examine long-term efficacy and safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWgACcO1gWMLVg90H21EOLACvtfcHk0lgiVsqiyRmbCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFOktLY%253D&md5=3e2dfda05e640402d31f6c47be86ec19</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2011.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2011.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigo%26aufirst%3DG.%2BJ.%26aulast%3DPlaza%26aufirst%3DV.%26aulast%3DCastro-Rodr%25C3%25ADguez%26aufirst%3DJ.%2BA.%26atitle%3DComparison%2520of%2520three%2520combined%2520pharmacological%2520approaches%2520with%2520tiotropium%2520monotherapy%2520in%2520stable%2520moderate%2520to%2520severe%2520COPD%253A%2520a%2520systematic%2520review%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D25%26spage%3D40%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group">Vogelmeier, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bateman, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallante, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alagappan, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, D.</span><span> </span><span class="NLM_article-title">Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study</span> <span class="citation_source-journal">Lancet Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">51</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2FS2213-2600%2812%2970052-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFCmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=51-60&author=C.+F.+Vogelmeierauthor=E.+D.+Batemanauthor=J.+Pallanteauthor=V.+K.+Alagappanauthor=P.+D%E2%80%99Andreaauthor=H.+Chenauthor=D.+Banerji&title=Efficacy+and+safety+of+once-daily+QVA149+compared+with+twice-daily+salmeterol-fluticasone+in+patients+with+chronic+obstructive+pulmonary+disease+%28ILLUMINATE%29%3A+a+randomised%2C+double-blind%2C+parallel+group+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study</span></div><div class="casAuthors">Vogelmeier, Claus F.; Bateman, Eric D.; Pallante, John; Alagappan, Vijay K. T.; D'Andrea, Peter; Chen, Hungta; Banerji, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-60</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">QVA149 is an inhaled fixed-dose combination therapy under development for the treatment of chronic obstructive pulmonary disease (COPD).  It combines indacaterol (a longacting β2-agonist) with glycopyrronium (a longacting muscarinic antagonist) as a dual bronchodilator.  We aimed to compare the efficacy, safety, and tolerability of QVA149 vs. salmeterol-fluticasone (SFC) over 26 wk in patients with moderate-to-severe COPD.  In this multicentre double-blind, double-dummy, parallel-group study, 523 patients (age 40 years or older, Global Initiative for Chronic Obstructive Lung Disease [GOLD] stages II-III, without exacerbations in the previous year) were randomly assigned (1:1; via automated, interactive response technol. and stratified for smoking status) to once-daily QVA149 110/50 μg or twice-daily SFC 50/500 μg for 26 wk.  Efficacy was assessed in the full anal. set (randomised patients who received at least one dose of study drug); safety was assessed in all patients who received at least one dose of study drug.  The primary endpoint was to demonstrate the superiority of QVA149 compared with SFC for the standardized area under the curve from 0 to 12 h post dose for forced expiratory vol. in 1 s (FEV1 AUC0-12h) after 26 wk of treatment.  This trial was registered at ClinicalTrial.gov, NCT01315249.  Between March 25, 2011, and March 12, 2012, 259 patients were randomly assigned to receive QVA149 and 264 to receive SFC.  At week 26, FEV1 AUC0-12h was significantly higher with QVA149 than with SFC (treatment difference 0·138 L; 95% CI 0·100-0·176; p<0·0001).  Overall incidence of adverse events (including COPD exacerbations) was 55·4% (143 of 258) for the QVA149 group and 60·2% (159 of 264) for the SFC group.  Incidence of serious adverse events was similar between treatment groups (QVA149, 13 of 258 [5·0%]; SFC 14 of 264 [5·3%]); COPD worsening was the most frequent serious adverse event (one of 13 [0·4%] and three of 14 [1·1%], resp.).  Once-daily QVA149 provides significant, sustained, and clin. meaningful improvements in lung function vs. twice-daily SFC, with significant symptomatic benefit.  These results indicate the potential of dual bronchodilation as a treatment option for non-exacerbating symptomatic COPD patients.Novartis Pharma AG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOxmQ6p9ONmbVg90H21EOLACvtfcHk0ljFmyC9AU974Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFCmtr4%253D&md5=c39b6cf8dd09f1165ee0373328493090</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2812%2970052-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252812%252970052-8%26sid%3Dliteratum%253Aachs%26aulast%3DVogelmeier%26aufirst%3DC.%2BF.%26aulast%3DBateman%26aufirst%3DE.%2BD.%26aulast%3DPallante%26aufirst%3DJ.%26aulast%3DAlagappan%26aufirst%3DV.%2BK.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DBanerji%26aufirst%3DD.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520once-daily%2520QVA149%2520compared%2520with%2520twice-daily%2520salmeterol-fluticasone%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%2520%2528ILLUMINATE%2529%253A%2520a%2520randomised%252C%2520double-blind%252C%2520parallel%2520group%2520study%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2013%26volume%3D1%26spage%3D51%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group">Donohue, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maleki-Yazdi, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilbride, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Church, A.</span><span> </span><span class="NLM_article-title">Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD</span> <span class="citation_source-journal">Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">1538</span><span class="NLM_x">–</span> <span class="NLM_lpage">1546</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.rmed.2013.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23830094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A280%3ADC%252BC3sjosVCqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2013&pages=1538-1546&author=J.+F.+Donohueauthor=M.+R.+Maleki-Yazdiauthor=S.+Kilbrideauthor=R.+Mehtaauthor=C.+Kalbergauthor=A.+Church&title=Efficacy+and+safety+of+once-daily+umeclidinium%2Fvilanterol+62.5%2F25+mcg+in+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD</span></div><div class="casAuthors">Donohue J F; Maleki-Yazdi M R; Kilbride S; Mehta R; Kalberg C; Church A</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1538-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">STUDY OBJECTIVE:  To examine the efficacy and safety of the once-daily, inhaled, long-acting muscarinic antagonist/β2-agonist combination umeclidinium/vilanterol (UMEC/VI) compared with UMEC and VI monotherapies in patients with chronic obstructive pulmonary disease (COPD).  METHODS:  In this 24-week, double-blind, placebo-controlled, parallel-group study (ClinicalTrials.gov: NCT01313650) eligible patients were randomised 3:3:3:2 to treatment with UMEC/VI 62.5/25 mcg, UMEC 62.5 mcg, VI 25 mcg or placebo administered once daily via dry powder inhaler (N = 1532; intent-to-treat population).  Primary endpoint was trough forced expiratory volume in one second (FEV1) on Day 169 (23-24 h post-dose).  Additional lung-function, symptomatic, and health-related quality-of-life endpoints were assessed, including 0-6 h weighted-mean FEV1, rescue salbutamol use, Transition Dyspnoea Index (TDI), Shortness Of Breath With Daily Activity (SOBDA) and St.  George's Respiratory Questionnaire (SGRQ) scores.  Safety evaluations included adverse events (AEs), vital signs, 12-lead/24-h Holter electrocardiography parameters and clinical laboratory/haematology measurements.  RESULTS:  All active treatments produced statistically significant improvements in trough FEV1 compared with placebo on Day 169 (0.072-0.167 L, all p < 0.001); increases with UMEC/VI 62.5/25 mcg were significantly greater than monotherapies (0.052-0.095 L, p ≤ 0.004).  Improvements were observed for UMEC/VI 62.5/25 mcg vs placebo for weighted-mean FEV1 on Day 168 (0.242 L, p < 0.001), rescue salbutamol use during Weeks 1-24 (-0.8 puffs/day, p = 0.001), TDI (1.2 units, p < 0.001), SOBDA (-0.17 units, p < 0.001) and SGRQ (-5.51 units, p < 0.001) scores.  No clinically-significant changes in vital signs, electrocardiography, or laboratory parameters were observed.  CONCLUSION:  Once-daily UMEC/VI 62.5/25 mcg was well tolerated and provided clinically-significant improvements in lung function and symptoms in patients with COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQF77nXMFz80xcr74wzj5o5fW6udTcc2eaaPuYy3GMbqbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjosVCqsg%253D%253D&md5=0e36e3b81b44d3617bdc318adddf2b20</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2013.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2013.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DDonohue%26aufirst%3DJ.%2BF.%26aulast%3DMaleki-Yazdi%26aufirst%3DM.%2BR.%26aulast%3DKilbride%26aufirst%3DS.%26aulast%3DMehta%26aufirst%3DR.%26aulast%3DKalberg%26aufirst%3DC.%26aulast%3DChurch%26aufirst%3DA.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520once-daily%2520umeclidinium%252Fvilanterol%252062.5%252F25%2520mcg%2520in%2520COPD%26jtitle%3DRespir.%2520Med.%26date%3D2013%26volume%3D107%26spage%3D1538%26epage%3D1546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group">Celli, B.; Crater, G.; Kilbride, S.; Mehta, R.; Tabberer, M.; Kalberg, C. J.; Church, A.</span><span> </span><span class="NLM_article-title">Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study</span>.  <span class="citation_source-journal">Chest</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1378/chest.13-1579</span> . Published Online: Jan 2,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1378%2Fchest.13-1579" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=B.+Celli&author=G.+Crater&author=S.+Kilbride&author=R.+Mehta&author=M.+Tabberer&author=C.+J.+Kalberg&author=A.+Church&title=Once-daily+umeclidinium%2Fvilanterol+125%2F25+mcg+in+COPD%3A+a+randomized%2C+controlled+study&doi=10.1378%2Fchest.13-1579"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1378%2Fchest.13-1579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.13-1579%26sid%3Dliteratum%253Aachs%26aulast%3DCelli%26aufirst%3DB.%26atitle%3DOnce-daily%2520umeclidinium%252Fvilanterol%2520125%252F25%2520mcg%2520in%2520COPD%253A%2520a%2520randomized%252C%2520controlled%2520study%26jtitle%3DChest%26doi%3D10.1378%2Fchest.13-1579%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group">Decramer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anzueto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerwin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaelin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crater, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabberer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Church, A.</span><span> </span><span class="NLM_article-title">Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials</span> <span class="citation_source-journal">Lancet Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">472</span><span class="NLM_x">–</span> <span class="NLM_lpage">486</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2FS2213-2600%2814%2970065-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVajtrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=472-486&author=M.+Decramerauthor=A.+Anzuetoauthor=E.+Kerwinauthor=T.+Kaelinauthor=N.+Richardauthor=G.+Craterauthor=M.+Tabbererauthor=S.+Harrisauthor=A.+Church&title=Efficacy+and+safety+of+umeclidinium+plus+vilanterol+versus+tiotropium%2C+vilanterol%2C+or+umeclidinium+monotherapies+over+24+weeks+in+patients+with+chronic+obstructive+pulmonary+disease%3A+results+from+two+multicentre%2C+blinded%2C+randomised+controlled+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials</span></div><div class="casAuthors">Decramer, Marc; Anzueto, Antonio; Kerwin, Edward; Kaelin, Thomas; Richard, Nathalie; Crater, Glenn; Tabberer, Maggie; Harris, Stephanie; Church, Alison</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">472-486</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Combination long-acting bronchodilator treatment might be more effective than long-acting bronchodilator monotherapy for the treatment of chronic obstructive pulmonary disease (COPD).  We aimed to compare the efficacy and safety of umeclidinium (UMEC) plus vilanterol (VI) with tiotropium (TIO) monotherapy, UMEC monotherapy, or VI monotherapy in patients with moderate to very severe COPD.  In two multicentre, randomised, blinded, double-dummy, parallel-group, active-controlled trials, eligible patients (current or former smokers aged 40 years or older with an established clin. history of COPD) were randomly assigned in 1:1:1:1 ratio to UMEC 125 μg plus VI 25 μg, UMEC 62·5 μg plus VI 25 μg, TIO 18 μg, and either VI 25 μg (study 1) or UMEC 125 μg (study 2).  All study drugs were used once daily for 24 wk.  TIO was delivered via the HandiHaler inhaler and all other active treatments were delivered via the ELLIPTA dry powder inhaler.  Random assignment (by a validated computer-based system) was done by center and was not stratified.  All patients and physicians were masked to assigned treatment during the studies.  The primary efficacy endpoint of both studies was trough forced expiratory vol. in 1 s (FEV1) on day 169, which was analyzed in the intention-to-treat population.  Both studies are registered with ClinicalTrials.gov, nos. NCT01316900 (study 1) and NCT01316913 (study 2).1141 participants were recruited in study 1, and 1191 in study 2.  For study 1, after exclusions, 208, 209, 214, and 212 patients were included in the intention-to-treat analyses for TIO monotherapy, VI monotherapy, UMEC 125 μg plus VI 25 μg, and UMEC 62·5 μg plus VI 25 μg, resp.  For study 2, 215, 222, 215, and 217 patients were included in the intention-to-treat analyses for TIO monotherapy, UMEC monotherapy, UMEC 125 μg plus VI 25 μg, and UMEC 62·5 μg plus VI 25 μg, resp.  In both studies, we noted improvements in trough FEV1 on day 169 for both doses of UMEC plus VI compared with TIO monotherapy (study 1, UMEC 125 μg plus VI 25 μg: 0·088 L [95% CI 0·036 to 0·140; p=0·0010]; study 1, UMEC 62·5 μg plus VI 25 μg: 0·090 L [0·039 to 0·141; p=0·0006]; study 2, UMEC 125 μg plus VI 25 μg: 0·074 L [0·025 to 0·123; p=0·0031]; study 2, UMEC 62·5 μg plus VI 25 μg: 0·060 L [0·010 to 0·109; nominal p=0·0182]).  Both doses of UMEC plus VI also improved trough FEV1 compared with VI monotherapy (UMEC 125 μg plus VI 25 μg: 0·088 L [0·036 to 0·140; p=0·0010]; UMEC 62·5 μg plus VI 25 μg: 0·090 L [0·039 to 0·142; p=0·0006], but not compared with UMEC 125 μg monotherapy (UMEC 125 μg plus VI 25 μg: 0·037 L [-0·012 to 0·087; p=0·14]; UMEC 62·5 μg plus VI 25 μg: 0·022 L [-0·027 to 0·072; p=0·38]).  All treatments produced improvements in dyspnoea and health-related quality of life; we noted no significant differences in symptoms, health status, or risk of exacerbation between UMEC plus VI and TIO.  The most common on-treatment, severe-intensity adverse event in both studies was acute exacerbation of COPD (1-4 [<1-2%] patients across treatment groups in study 1 and 1-6 [<1-3%] patients in study 2).  We recorded five to 15 (2-7%) on-treatment serious adverse events across treatment groups in study 1, and nine to 22 (4-10%) in study 2.  We noted no substantial changes from baseline in vital signs, clin. lab. findings, or electrocardiog. findings in any of the treatment groups.  Combination treatment with once-daily UMEC plus VI improved lung function compared with VI monotherapy and TIO monotherapy in patients with COPD.  Overall our results suggest that the combination of UMEC plus VI could be beneficial for the treatment of moderate to very severe COPD.GlaxoSmithKline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSMEBX1IMgJrVg90H21EOLACvtfcHk0lhUKu9SDMW8yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVajtrnN&md5=abc15201bb79e9bc20187efd25d83b44</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2814%2970065-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252814%252970065-7%26sid%3Dliteratum%253Aachs%26aulast%3DDecramer%26aufirst%3DM.%26aulast%3DAnzueto%26aufirst%3DA.%26aulast%3DKerwin%26aufirst%3DE.%26aulast%3DKaelin%26aufirst%3DT.%26aulast%3DRichard%26aufirst%3DN.%26aulast%3DCrater%26aufirst%3DG.%26aulast%3DTabberer%26aufirst%3DM.%26aulast%3DHarris%26aufirst%3DS.%26aulast%3DChurch%26aufirst%3DA.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520umeclidinium%2520plus%2520vilanterol%2520versus%2520tiotropium%252C%2520vilanterol%252C%2520or%2520umeclidinium%2520monotherapies%2520over%252024%2520weeks%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520results%2520from%2520two%2520multicentre%252C%2520blinded%252C%2520randomised%2520controlled%2520trials%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2014%26volume%3D2%26spage%3D472%26epage%3D486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group">Hegde, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinfeld, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jasper, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulido-Rios, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mammen, M.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β<sub>2</sub> adrenoceptor agonist properties</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">351</span><span class="NLM_x">, </span> <span class="NLM_fpage">190</span><span class="NLM_x">–</span> <span class="NLM_lpage">199</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1124%2Fjpet.114.216861" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=25100753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yksbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2014&pages=190-199&author=S.+S.+Hegdeauthor=A.+D.+Hughesauthor=Y.+Chenauthor=T.+Steinfeldauthor=J.+R.+Jasperauthor=T.+W.+Leeauthor=A.+McNamaraauthor=W.+J.+Martinauthor=M.+T.+Pulido-Riosauthor=M.+Mammen&title=Pharmacological+characterization+of+GSK-961081+%28TD-5959%29%2C+a+first-in-class+inhaled+bifunctional+bronchodilator+possessing+muscarinic+receptor+antagonist+and+%CE%B22+adrenoceptor+agonist+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2-adrenoceptor agonist properties</span></div><div class="casAuthors">Hegde, Sharath S.; Hughes, Adam D.; Chen, Yan; Steinfeld, Tod; Jasper, Jeffrey R.; Lee, Tae-Weon; McNamara, Alexander; Martin, William J.; Pulido-Rios, M. Teresa; Mammen, Mathai</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">190-199, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The objective of the present studies was to characterize the pharmacol. properties of GSK-961081 [TD-5959; (R)-1-(3-((2-chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl) piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate], a novel first-in-class inhaled bifunctional compd. possessing both muscarinic antagonist (MA) and β2-adrenoceptor agonist (BA) properties (MABA).  In competition radioligand binding studies at human recombinant receptors, GSK-961081 displayed high affinity for hM2 (Ki = 1.4 nM), hM3 muscarinic receptors (Ki = 1.3 nM) and hβ2-adrenoceptors (Ki = 3.7 nM).  GSK-961081 behaved as a potent hβ2-adrenoceptor agonist (EC50 = 0.29 nM for stimulation of cAMP levels) with 440- and 320-fold functional selectivity over hβ1- and hβ3-adrenoceptors, resp.  In guinea pig isolated tracheal tissues, GSK-961081 produced smooth muscle relaxation through MA (EC50 = 50.2 nM), BA (EC50 = 24.6 nM), and MABA (EC50 = 11 nM) mechanisms.  In the guinea pig bronchoprotection assay, inhaled GSK-961081 produced potent, dose-dependent inhibition of bronchoconstrictor responses via MA (ED50 = 33.9 μg/mL), BA (ED50 = 14.1 μg/mL), and MABA (ED50 = 6.4 μg/mL) mechanisms.  Significant bronchoprotective effects of GSK-961081 were evident in guinea pigs via MA, BA, and MABA mechanisms for up to 7 days after dosing.  The lung selectivity index of GSK-961081 in guinea pigs was 55- to 110-fold greater than that of tiotropium with respect to systemic antimuscarinic antisialagogue effects and was 10-fold greater than that of salmeterol with respect to systemic β2-adrenoceptor hypotensive effects.  These preclin. findings studies suggest that GSK-961081 has the potential to be a promising next-generation inhaled lung-selective bronchodilator for the treatment of airway diseases, including chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7s7-fKs3E47Vg90H21EOLACvtfcHk0ljWy_VyTWFa1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yksbfJ&md5=f2b92f897950afedc02c62c056824c17</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.216861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.216861%26sid%3Dliteratum%253Aachs%26aulast%3DHegde%26aufirst%3DS.%2BS.%26aulast%3DHughes%26aufirst%3DA.%2BD.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSteinfeld%26aufirst%3DT.%26aulast%3DJasper%26aufirst%3DJ.%2BR.%26aulast%3DLee%26aufirst%3DT.%2BW.%26aulast%3DMcNamara%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DW.%2BJ.%26aulast%3DPulido-Rios%26aufirst%3DM.%2BT.%26aulast%3DMammen%26aufirst%3DM.%26atitle%3DPharmacological%2520characterization%2520of%2520GSK-961081%2520%2528TD-5959%2529%252C%2520a%2520first-in-class%2520inhaled%2520bifunctional%2520bronchodilator%2520possessing%2520muscarinic%2520receptor%2520antagonist%2520and%2520%25CE%25B22%2520adrenoceptor%2520agonist%2520properties%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D351%26spage%3D190%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group">Bateman, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornmann, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambery, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, V.</span><span> </span><span class="NLM_article-title">Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD</span> <span class="citation_source-journal">Pulm. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">581</span><span class="NLM_x">–</span> <span class="NLM_lpage">587</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Fjm5013227&amp;key=10.1016%2Fj.pupt.2013.03.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Fjm5013227&amp;key=23538170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Fjm5013227&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtValtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=581-587&author=E.+D.+Batemanauthor=O.+Kornmannauthor=C.+Amberyauthor=V.+Norris&title=Pharmacodynamics+of+GSK961081%2C+a+bi-functional+molecule%2C+in+patients+with+COPD"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD</span></div><div class="casAuthors">Bateman, Eric D.; Kornmann, Oliver; Ambery, Claire; Norris, Virginia</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">581-587</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">GSK961081 is an inhaled bi-functional mol. with both muscarinic antagonism and β2-agonism (MABA) properties.This randomised, double-blind, double-dummy, crossover study evaluated 14 days treatment with the MABA GSK961081 400 μg and 1200 μg once daily and tiotropium 18 μg once daily plus salmeterol 50 μg twice daily (TIO + SAL), vs. placebo in 50 patients with moderate COPD.  The primary endpoint was forced expiratory vol. in 1 s (FEV1) at 24 h on Days 1 and 14.MABA 400 (n = 29), MABA 1200 (n = 32) and TIO + SAL (n = 41) resulted in significant increases in FEV1 over 24 h.  Mean (95% CI) 24 h trough FEV1 (L) values relative to placebo (n = 43) were, for Day 1, MABA 400: 0.141 (0.060, 0.222); MABA 1200: 0.184 (0.105, 0.263); TIO + SAL: 0.162 (0.092, 0.231); for Day 14, MABA 400: 0.115 (0.024, 0.205); MABA 1200: 0.168 (0.080, 0.255); TIO + SAL: 0.103 (0.026, 0.180).  Onset of bronchodilation was faster for both MABA doses vs. TIO + SAL.  No clin. relevant systemic pharmacodynamic effects were obsd.  Adverse events were similar across groups; however tremor (n = 2, MABA 1200), dysgeusia (n = 2, MABA 1200; n = 2, MABA 400) and dry mouth (n = 1, MABA 1200) were reported after GSK961081 only.GSK961081 demonstrated sustained bronchodilation similar to TIO + SAL, but with a more rapid onset, and was well tolerated at the tested doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU5q2GJiknn7Vg90H21EOLACvtfcHk0ljWy_VyTWFa1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtValtbo%253D&md5=b23901522cf7dbb18e6bfb07e553f538</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2013.03.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2013.03.015%26sid%3Dliteratum%253Aachs%26aulast%3DBateman%26aufirst%3DE.%2BD.%26aulast%3DKornmann%26aufirst%3DO.%26aulast%3DAmbery%26aufirst%3DC.%26aulast%3DNorris%26aufirst%3DV.%26atitle%3DPharmacodynamics%2520of%2520GSK961081%252C%2520a%2520bi-functional%2520molecule%252C%2520in%2520patients%2520with%2520COPD%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D26%26spage%3D581%26epage%3D587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit182"><span>Anoro Ellipta FDA prescribing information,<span class="NLM_x"> </span><span class="NLM_year">2014</span>. <a href="http://www.rxlist.com/anoro-ellipta-drug.htm" class="extLink">http://www.rxlist.com/anoro-ellipta-drug.htm</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Anoro+Ellipta+FDA+prescribing+information%2C+2014.+http%3A%2F%2Fwww.rxlist.com%2Fanoro-ellipta-drug.htm."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm5013227&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-10%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Fjm5013227%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm5013227" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"667989cf29ba2308","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
